

# Menopause

## Appendices A - G

*Clinical Guideline*

*Methods, evidence and recommendations*

*22 October 2015*

*Final*

*Commissioned by the National Institute for  
Health and Care Excellence*



**Disclaimer**

Healthcare professionals are expected to take NICE clinical guidelines fully into account when exercising their clinical judgement. However, the guidance does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and/or their guardian or carer.

**Copyright**

National Collaborating Centre for Women and Children's Health

**Funding**

Registered charity no. 213280

# Contents

<b>Appendices</b> .....	<b>7</b>
Appendix A: Scope .....	7
Appendix B: Stakeholders.....	22
Appendix C: Declarations of interest .....	29
Appendix D: Review protocols .....	42
D.1 Diagnosis of perimenopause and menopause .....	42
D.2 Classification systems for the diagnosis of menopause .....	43
D.3 Information and advice .....	44
D.4 Managing short-term symptoms .....	45
D.4.1 Management short-term symptoms: network meta-analyses .....	47
D.4.2 Urogenital atrophy.....	49
D.5 Review and referral .....	51
D.6 Starting and stopping HRT .....	52
D.7 Long-terms benefits and risks of HRT.....	53
D.7.1 Venous thromboembolism .....	53
D.7.2 Cardiovascular disease (CVD) .....	54
D.7.3 Development of Type 2 diabetes.....	55
D.7.4 Management of Type 2 diabetes - control of blood sugar.....	55
D.7.5 Breast cancer.....	57
D.7.6 Osteoporosis.....	58
D.7.7 Dementia .....	59
D.7.8 Loss of muscle mass (sarcopenia).....	59
D.8 Premature ovarian insufficiency (POI) .....	61
D.8.1 Diagnosis of premature ovarian insufficiency .....	61
D.8.2 Management of premature ovarian insufficiency .....	62
Appendix E: Search strategies.....	64
E.1 Diagnosis of perimenopause and postmenopause / classification systems for the diagnosis of menopause .....	64
E.2 Information and advice .....	70
E.3 Managing short-term symptoms – clinical evidence.....	73
E.4 Managing short-term symptoms – health economic evidence.....	83
E.4.1 Urogenital atrophy.....	93
E.5 Review and referral .....	99
E.6 Starting and stopping HRT .....	107
E.7 Long-term benefits and risks of HRT .....	110
E.7.1 Venous thromboembolism .....	117
E.7.2 Cardiovascular disease.....	121
E.7.3 Development of type 2 diabetes.....	126

E.7.4 Management of type 2 diabetes – control of blood sugar .....	130
E.7.5 Breast cancer.....	135
E.7.6 Osteoporosis.....	140
E.7.7 Dementia .....	146
E.7.8 Loss of muscle mass (sarcopenia).....	150
E.8 Premature ovarian insufficiency.....	154
E.8.1 Management of premature ovarian insufficiency .....	154
E.8.2 Diagnosis of premature ovarian insufficiency .....	160
Appendix F: Prisma flow charts .....	168
F.1 Diagnosis of perimenopause and postmenopause .....	168
F.2 Classification systems for the diagnosis of menopause .....	168
F.3 Information and advice .....	169
F.4 Managing short-term symptoms .....	169
F.4.1 Urogenital atrophy.....	170
F.5 Review and referral .....	171
F.6 Starting and stopping HRT .....	171
F.7 Long-term benefits and risks of HRT .....	172
F.7.1 Venous thromboembolism .....	172
F.7.2 Cardiovascular disease.....	172
F.7.3 Development of type 2 diabetes.....	173
F.7.4 Management of type 2 diabetes – control of blood sugar .....	173
F.7.5 Breast Cancer.....	174
F.7.6 Osteoporosis.....	174
F.7.7 Dementia .....	175
F.7.8 Loss of muscle mass (sarcopenia).....	175
F.8 Premature ovarian insufficiency.....	176
F.8.1 Diagnosis of premature ovarian insufficiency .....	176
F.8.2 Management of premature ovarian insufficiency .....	176
Appendix G: Excluded studies.....	177
G.1 Diagnosis of perimenopause and menopause.....	177
G.2 Classification systems for the diagnosis of menopause .....	182
G.3 Information and advice .....	186
G.4 Managing short-term symptoms .....	192
G.4.1 Urogenital atrophy.....	231
G.5 Review and referral .....	237
G.6 Starting and stopping HRT .....	237
G.7 Long-term benefits and risks of HRT .....	238
G.7.1 Venous thromboembolism .....	238
G.7.2 Cardiovascular disease.....	240
G.7.3 Development of type 2 diabetes.....	247

G.7.4 Management of type 2 diabetes – control of blood sugar .....	248
G.7.5 Breast cancer.....	249
G.7.6 Osteoporosis.....	258
G.7.7 Dementia .....	263
G.7.8 Loss of muscle mass (sarcopenia).....	285
G.8 Premature ovarian insufficiency.....	287
G.8.1 Diagnosis of premature ovarian insufficiency .....	287
G.8.2 Management of premature ovarian insufficiency .....	289
Appendix H: Evidence tables .....	292
Appendix I: GRADE profiles .....	293
Appendix J: Forest plots.....	294
Appendix K: Network meta-analysis of interventions in the pharmacological and non-pharmacological treatment of short term symptoms for women in menopause.....	295
Appendix L: Health Economics.....	296
Appendix M: Absolute risk references .....	297

# Appendices

## Appendix A: Scope

### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

#### SCOPE

#### 1 Guideline title

Menopause: diagnosis and management of menopause

##### 1.1 *Short title*

Menopause

#### 2 The remit

The Department of Health has asked NICE: 'to produce a clinical guideline on the diagnosis and management of menopause'.

#### 3 Clinical need for the guideline

##### 3.1 *Epidemiology*

- a) Menopause is a biological stage in a woman's life. It occurs when a woman stops menstruating, and it marks the end of her natural reproductive life. The changes associated with menopause occur when the ovaries begin to stop functioning. This includes the cessation of egg (oocyte) maturation and of oestrogen and progesterone secretion.
- b) A woman has a finite number of oocytes at birth, which declines with each menstrual cycle. The menopause is characterised by the eventual depletion of a woman's oocyte store and cessation of menstruation. Menstrual cycle irregularity often occurs before periods stop completely.
- c) Most tissues contain oestrogen receptors through which the hormone exerts its effects. The most immediate changes resulting

from reduced oestrogen levels are evident in the regulation of the menstrual cycle. However, oestrogen depletion associated with the menopause has many other effects on the body – for example, causing vasomotor, musculoskeletal, urogenital and psychological symptoms. It has also been shown to have an impact on the function of other systems in later life, including bone and the cardiovascular system. Oestrogen depletion explains some of the differences in the incidence of osteoporosis between men and women.

- d) Perimenopause, also called the menopausal transition, is the interval in which a woman has irregular cycles of ovulation and menstruation before the menopause.
- e) A woman is defined as postmenopausal from 1 year after her last period. Within the UK population, the mean age of women who have a natural menopause is 51 years, although this can vary depending on different factors, including lifestyle.
- f) Cross-cultural studies have shown that the age of menopause and its impact varies by ethnicity. For example, the US Study of Women's Health Across the Nation reported in 2009 that, on average, African–American women had more hot flushes than white women, and Asian women (Japanese or Chinese) had the fewest hot flushes of all ethnic groups surveyed. The same study reported that early menopause (between 40 and 45 years of age) affected 3.7% of African–American women, 2.9% of white women, 2.2% of Chinese women and 0.8% of Japanese women.
- g) Premature ovarian insufficiency (also known as premature ovarian failure or premature menopause) is usually defined as menopause occurring before the age of 40 years. It can occur naturally or iatrogenically (that is, as a result of treatment). Premature ovarian insufficiency and early perimenopause (menopause between the ages of 40 and 45 years) are associated with an increased risk of



mortality, and with serious morbidity including cardiovascular disease, neurological disease, psychiatric disorders and osteoporosis. Lower socioeconomic status has been associated with premature ovarian insufficiency.

- h) Many of the symptoms of the menopause are short lived and lessen or disappear over time. The most common include vasomotor symptoms (for example hot flushes and sweats), effects on mood (for example low mood) and urogenital symptoms (for example vaginal dryness). Of women responding to a postal survey carried out in Scotland in 2009 about symptoms experienced in the previous month, 47% reported hot flushes, 46% reported night sweats and 26% reported vaginal dryness.
- i) Postmenopausal women are at increased risk of a number of long-term conditions, such as osteoporosis, cardiovascular disease and changes in the vagina and bladder. This is partly a result of oestrogen depletion.
- j) There were more than 11 million women over the age of 45 years in the UK according to the Office of National Statistics 2011 census. This number has been steadily increasing and is forecast to continue to rise. The associated increase in the number of women going through the menopause is expected to result in more new referrals to secondary care – both of women needing short-term symptom control and of women who have associated long-term health issues.

### **3.2 Current practice**

- a) Two landmark studies, the Women's Health Initiative (2002) and the Million Women Study (2003), reported on the risks and benefits associated with the use of hormone replacement therapy (HRT). The publication of these 2 studies was associated with a significant reduction in women's use of HRT in the UK.

- b) A retrospective GP database study (2010) reported that 18% of women aged 45–64 years consulted their GP at least once in 1996 for menopause-related symptoms, but this fell to 10% of women in 2005. Furthermore, a cross-sectional study in 2012 found that more than 60% of women managed their menopausal symptoms without any contact with healthcare professionals, often through social support and obtaining advice from friends, family and the internet.
- c) Variations in consultation patterns for menopausal symptoms depend on many factors, including cultural, ethnic, educational and psychosocial factors, as well as the impact of the symptoms on the women. However, it is currently thought that more than one-third of all women want more support for managing menopausal symptoms from their GP or practice nurse.
- d) The information and support offered to women during and after the menopause is thought to be variable and, for some, inadequate. A UK-based survey published in 2007 indicated that most women would welcome more information about the menopause. To improve the information provided, and to facilitate women being able to make an informed choice, some professional groups have suggested that all women should be invited for a health and lifestyle consultation on their 50th birthday, which would include a discussion of menopausal symptoms and possible long-term sequelae of oestrogen depletion.
- e) Treatments that have been used for menopause-related symptoms include lifestyle advice, HRT, herbal remedies, other complementary (alternative) therapies and antidepressants. In an internet survey (hosted at [www.menopausematters.org.uk](http://www.menopausematters.org.uk) between 2005 and 2006), nearly three-quarters of women reported they did not know enough about HRT to make informed choices, 85% felt they did not know enough to make informed choices about alternative therapies for menopause-related symptoms, and 95% said they would try alternative therapies before HRT in the belief

that they are more 'natural' and because of concern over the health risks of HRT.

- f) There is published evidence that physician speciality is significantly associated with HRT use. For example, in the USA women receiving care from gynaecologists are 2.6 times more likely to use HRT than that women receiving care from family physicians.
- g) The use of HRT in the UK is strongly linked to socioeconomic status, with women of lower socioeconomic status being less likely to use HRT. Inequalities in referral rates have also been associated with geography and age.
- h) The long-term benefits and risks of HRT are not fully agreed. The Women's Health Initiative study found that HRT prevents osteoporotic fractures, but subsequent research suggested that there is an association between prolonged HRT use and increased rates of breast cancer and cardiovascular disease. However, the association between HRT and cardiovascular disease has since been disputed.
- i) In summary, a large number of women in the UK experience menopausal symptoms, which in many cases can significantly affect their quality of life. Not all of these women seek medical treatment, and for those who do there is considerable variation in the help available.

#### **4 The guideline**

The guideline development process is described in detail on the NICE website (see section 6, 'Further information').

This scope defines what the guideline will (and will not) examine, and what the guideline developers will consider. The scope is based on the referral from the Department of Health.

The areas that will be addressed by the guideline are described in the following sections.

## **4.1 Population**

### **4.1.1 Groups that will be covered**

- a) Menopausal women (covering the perimenopause and postmenopause).
- b) Women with premature ovarian insufficiency (irrespective of cause).

### **4.1.2 Groups that will not be covered**

- a) Women who are pregnant.
- b) Women who are breastfeeding.
- c) Men.
- d) Transgender women.

## **4.2 Healthcare setting**

- a) All settings in which NHS care is received or commissioned.

## **4.3 Clinical management**

### **4.3.1 Key clinical issues that will be covered**

- a) Diagnosis and classification of the stages of menopause.
- b) Optimal clinical management of menopause-related symptoms, including:
  - treatments for symptomatic relief (specifically vasomotor, musculoskeletal and psychological symptoms, and altered sexual function), including:
    - hormonal pharmaceutical treatments:
      - ◊ oestrogen combined with progestogen (oral)

- ◇ oestrogen combined with progestogen (transdermal)
- ◇ oestrogen (oral)
- ◇ oestrogen (transdermal)
- ◇ oestrogen (depot)
- ◇ progestogen alone
- ◇ testosterone
- ◇ tibolone
- ◇ bio-identical hormones licensed for use in the UK
- ◇ tissue-selective oestrogen complexes
- ◇ selective oestrogen-receptor modulators
- non-hormonal pharmaceutical treatments:
  - ◇ selective serotonin reuptake inhibitors
  - ◇ serotonin–noradrenaline reuptake inhibitors
  - ◇ gabapentin
  - ◇ clonidine
- non-pharmaceutical treatments:
  - ◇ phytoestrogens
  - ◇ herbal preparations (including black cohosh and red clover)
  - ◇ acupuncture
  - ◇ lifestyle advice
- psychological therapies
  - ◇ cognitive behavioural therapy
- risks and benefits of treatments
- timing of treatment
- monitoring of treatment
- duration of treatment
- treatment withdrawal strategies.

Note that guideline recommendations will normally fall within licensed indications. Exceptionally, and only if clearly supported by evidence, use outside a licensed indication may be recommended. The guideline will assume that prescribers will use a drug's

summary of product characteristics to inform decisions made with individual patients.

- c) Contribution of HRT in preventing long-term sequelae of the menopause (especially osteoporosis and cardiovascular disease).
- d) Diagnosis and management of premature ovarian insufficiency.

#### **4.3.2 Clinical issues that will not be covered**

- a) Contribution of all other agents (excluding HRT) in preventing long-term sequelae of the menopause.
- b) Systemic oestrogen-based hormonal treatment in women who have an increased risk of, or are undergoing treatment for, breast cancer.
- c) Treatment of long-term sequelae of oestrogen depletion caused by menopause (especially osteoporosis and cardiovascular disease).
- d) Premenopausal prevention of menopause-related symptoms (specifically vasomotor, musculoskeletal, urogenital and psychological symptoms and altered sexual function).
- e) Investigation of the cause of premature ovarian insufficiency in women presenting with primary amenorrhea.
- f) Induction of puberty in children and young people.
- g) Cost-effectiveness analysis of methods of contraception during the menopause.

### **4.4 Main outcomes**

#### **4.4.1 Short-term outcomes (up to 5 years of treatment)**

- a) Changes in menopausal symptom scores derived from a combination of menopausal symptoms (for example the Greene Climacteric Scale [GCS]).

- b) Reduction in frequency or intensity of:
  - vasomotor symptoms
  - musculoskeletal symptoms
  - psychological symptoms
  - alterations in sexual function.
- c) Treatment-related adverse effects.
- d) Health-related quality of life.

#### **4.4.2 Long-term outcomes**

- a) Mortality.
- b) Coronary events (myocardial infarction or coronary death).
- c) Stroke (ischaemic or haemorrhagic) or transient ischaemic attack.
- d) Venous thromboembolism (pulmonary embolism or deep vein thrombosis).
- e) Breast cancer.
- f) Osteoporotic fractures (hip and wrist fractures, clinically diagnosed vertebral fractures, total clinically diagnosed fractures).
- g) Cognitive function and dementia (including Alzheimer's disease).
- h) Type 2 diabetes
- i) Health-related quality of life.

#### **4.5 Review questions**

Review questions guide a systematic review of the literature. They address only the key clinical issues covered in the scope, and usually relate to interventions, diagnosis, prognosis, service delivery or patient experience. Please note that these review questions are draft versions and will be finalised with the Guideline Development Group.

#### **4.5.1            Diagnosis and classification of the stage of menopause**

- a)            What is the accuracy of the following in the diagnosis of perimenopause and menopause compared with clinical diagnosis:
- menstrual cycle regularity
  - symptoms (especially vasomotor symptoms)
  - endocrine changes (specifically follicle-stimulating hormone, anti-Müllerian hormone, oestrogen or inhibin B) and total antral follicle count?
- b)            What is the effectiveness of classification systems such as STRAW +10 compared with non-structured classification systems in the diagnosis of menopause?

#### **4.5.2            Optimal clinical management of short-term (up to 5 years) menopause-related symptoms**

- a)            What information about the menopause do women find helpful?
- b)            What is the effectiveness (including risks and benefits) of different therapies compared with placebo and each other for the relief of individual menopause-related vasomotor symptoms, including:
- hormonal pharmaceutical treatments:
    - oestrogen combined with progestogen (oral)
    - oestrogen combined with progestogen (transdermal)
    - oestrogen (oral)
    - oestrogen (transdermal)
    - oestrogen (depot)
    - progestogen alone
    - tissue-selective oestrogen complexes
    - testosterone
    - tibolone
    - bio-identical hormones licensed for use in the UK



- selective oestrogen-receptor modulators
  - non-hormonal pharmaceutical treatments:
    - selective serotonin reuptake inhibitors
    - serotonin–noradrenaline reuptake inhibitors
    - gabapentin
    - clonidine
  - non-pharmaceutical treatments:
    - phytoestrogens
    - herbal preparations (including black cohosh and red clover)
    - acupuncture
    - lifestyle advice
  - psychological therapies
    - cognitive behavioural therapy?
  
- c) What is the effectiveness (including risks and benefits) of different therapies compared with placebo for the relief of individual menopause-related psychological symptoms, musculoskeletal symptoms and altered sexual function, including:
  - hormonal pharmaceutical treatments:
    - oestrogen combined with progestogen (oral)
    - oestrogen combined with progestogen (transdermal)
    - oestrogen (oral)
    - oestrogen (transdermal)
    - oestrogen (depot)
    - progestogen alone
    - tissue-selective oestrogen complexes
    - testosterone
    - tibolone
    - bio-identical hormones licensed for use in the UK
    - selective oestrogen-receptor modulators
  - non-hormonal pharmaceutical treatments:
    - selective serotonin reuptake inhibitors

- serotonin–noradrenaline reuptake inhibitors
  - gabapentin
  - clonidine
  - non-pharmaceutical treatments:
    - phytoestrogens
    - herbal preparations (including black cohosh and red clover)
    - acupuncture
    - lifestyle advice
  - psychological therapies
    - cognitive behavioural therapy?
- d) At what intervals should clinical review be undertaken to assess the effectiveness and safety of treatments and to determine when women need to be referred to secondary care?

If HRT is found to be effective in 4.5.2b and 4.5.2c, the following question will be addressed:

- e) In perimenopausal and postmenopausal women using HRT for symptom relief, what is the effectiveness of an abrupt HRT discontinuation strategy compared with a tapered HRT discontinuation strategy?

**4.5.3 Recognition and amelioration of the long-term sequelae of oestrogen depletion caused by menopause – specifically urogenital atrophy, osteoporosis and cardiovascular disease**

- a) What is the long-term effectiveness of local oestrogens for the treatment of urogenital atrophy?
- b) What are the effects of HRT compared with placebo on the subsequent development of cardiovascular disease (including stroke) in women at different stages of the menopause?
- c) What is the incidence of osteoporosis in:

- postmenopausal women who have used short-term HRT
  - postmenopausal women who have used long-term HRT
  - postmenopausal women who have not used HRT?
- d) What are the effects of HRT administered for menopausal symptoms on the subsequent incidence of breast cancer, venous thromboembolism, early-onset dementia, sarcopenia and type 2 diabetes?

#### **4.5.4          Diagnosis and management of premature ovarian insufficiency**

- a) What is the accuracy of the following in the diagnosis of premature ovarian insufficiency in women under 40 years with up to 12 months' amenorrhoea:
- menstrual cycle regularity
  - symptoms (especially vasomotor symptoms)
  - endocrine changes (specifically follicle-stimulating hormone, anti-Müllerian hormone, oestrogen or inhibin B) and total antral follicle count?
- b) What is the effectiveness of HRT compared with combined oral contraceptives for the management of premature ovarian insufficiency?

#### **4.6          Economic aspects**

Developers will take into account both clinical and cost effectiveness when making recommendations involving a choice between alternative interventions. A review of the economic evidence will be conducted and analyses will be carried out as appropriate. The preferred unit of effectiveness is the quality-adjusted life year (QALY), and the costs considered will usually be only from an NHS and personal social services (PSS) perspective.

Further detail on the methods can be found in 'The guidelines manual' (see 'Further information').

## **4.7 Status**

### **4.7.1 Scope**

This is the final scope.

### **4.7.2 Timing**

The development of the guideline recommendations will begin in August 2013.

## **5 Related NICE guidance**

### **5.1 Published guidance**

#### **5.1.1 Related NICE guidance**

- [Familial breast cancer](#). NICE clinical guideline 164 (2013)
- [Fertility](#). NICE clinical guideline 156 (2013).
- [Osteoporosis](#). NICE clinical guideline 146 (2012).
- [Epilepsy](#). NICE clinical guideline 137 (2012).
- [Patient experience in adult NHS services](#). NICE clinical guideline 138 (2011).
- [Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women \(amended\)](#). NICE technology appraisal 161 (2011).
- [Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women \(amended\)](#). NICE technology appraisal 160 (2011).
- [Chronic heart failure](#). NICE clinical guideline 108 (2010).
- [Denosumab for the prevention of osteoporotic fractures in postmenopausal women](#). NICE technology appraisal 204 (2010).
- [Depression in adults](#). NICE clinical guideline 90 (2009).
- [Advanced breast cancer](#). NICE clinical guideline 81 (2009).
- [Early and locally advanced breast cancer](#). NICE clinical guideline 80 (2009).
- [Heavy menstrual bleeding](#). NICE clinical guideline 44 (2007).

- [Statins for the prevention of cardiovascular events](#). NICE technology appraisal 94 (2006).

## **5.2 Guidance under development**

NICE is currently developing the following related guidance (details available from the NICE website):

- [Urinary incontinence](#). NICE clinical guideline. Publication expected September 2013.
- [Lipid modification \(update\)](#). NICE clinical guideline. Publication expected July 2014.

## **6 Further information**

Information on the guideline development process is provided in the following documents, available from the NICE website:

- [How NICE clinical guidelines are developed: an overview for stakeholders the public and the NHS](#)
- [The guidelines manual](#).

Information on the progress of the guideline will also be available from the [NICE website](#).

## **Appendix B: Stakeholders**

Abbott Healthcare Products Ltd  
Acre Pharma LTD  
Action Cancer - NI  
Allocate Software PLC  
Association of Anaesthetists of Great Britain and Ireland  
Barnsley Hospital NHS Foundation Trust  
Bayer plc  
Beehive Solutions Ltd  
Belfast Health and Social Care Trust  
Besins Healthcare  
Boots  
Brighton and Sussex University Hospital NHS Trust  
British Acupuncture Council  
British Association of Skin Camouflage  
British Medical Association  
British Medical Journal  
British Menopause Society  
British National Formulary  
British Nuclear Cardiology Society  
British Psychological Society  
British Red Cross  
Cambridge University Hospitals NHS Foundation Trust  
Caplond Services  
Capsulation PPS  
Care Quality Commission  
Central London Community Health Care NHS Trust  
Chadderton Health Centre  
Chartered Physiotherapists Promoting Continence  
CLEAR Cannabis Law Reform  
Cornwall Menopause Referral Service  
Croydon Clinical Commissioning Group

Croydon Council  
Croydon Health Services NHS Trust  
Croydon University Hospital  
Cumbria Partnership NHS Foundation Trust  
CWHHE Collaborative CCGs  
Daisy Network  
Department of Health  
Department of Health, Social Services and Public Safety - Northern Ireland  
Derbyshire Community Sexual Health Service  
Diennet Ltd  
Dr Loomba and Partner  
Early Menopause  
East and North Hertfordshire NHS Trust  
East Kent Hospitals University NHS Foundation Trust  
Economic and Social Research Council  
Epilepsy Action  
Ethical Medicines Industry Group  
Faculty of Sexual and Reproductive Healthcare  
FBA and Brook  
Ferring Pharmaceuticals  
Five Boroughs Partnership NHS Trust  
Gedeon Richter UK  
Gedeon Richter Womens Health Division  
GP update / Red Whale  
Gransnet  
Guy's and St Thomas' NHS Foundation Trust  
Health and Care Professions Council  
Health and Social Care Information Centre  
Healthcare Improvement Scotland  
Healthcare Quality Improvement Partnership  
Healthwatch East Sussex  
Herts Valleys Clinical Commissioning Group  
Hockley Medical Practice

Hysterectomy Association  
International Ovarian Tumor Analysis Trial  
King Fahd Military Medical Complex  
King's College Hospital NHS Foundation Trust  
Kingston University and St Georges, University of London  
Leeds North Clinical Commissioning Group  
Liverpool Women's NHS Foundation Trust  
Local Government Association  
London North West Healthcare NHS Trust  
London PMS and Menopause Centre  
Luton and Dunstable Hospital NHS Trust  
Medical Directorate Services  
Medicines and Healthcare Products Regulatory Agency  
Menopause Exchange  
Menopause Matters UK  
Menopause UK  
Merck Sharp & Dohme UK Ltd  
Ministry of Defence  
Monash Health  
MSD Ltd  
Muslim Doctors and Dentists Association  
National Association of Primary Care  
National Clinical Guideline Centre  
National Collaborating Centre for Cancer  
National Collaborating Centre for Mental Health  
National Collaborating Centre for Women's and Children's Health  
National Deaf Children's Society  
National Institute for Health Research  
National Institute for Health Research Health Technology Assessment Programme  
National Osteoporosis Society  
National Patient Safety Agency  
NCRI - Breast CSG Working Group on Symptom Management  
NHS Barnsley Clinical Commissioning Group



NHS Choices

NHS Chorley and South Ribble CCG

NHS Connecting for Health

NHS County Durham and Darlington

NHS Cumbria Clinical Commissioning Group

NHS England

NHS Greater Glasgow and Clyde

NHS Hardwick CCG

NHS Health at Work

NHS Plus

NHS Sheffield

NHS South Cheshire CCG

NHS Southern Derbyshire CCG

NHS Wakefield CCG

NHS Warwickshire North CCG

NHS West Cheshire CCG

NICE - Clinical Guidelines Surveillance

NICE - CPHE

NICE - DAP

NICE - Evidence Services

NICE - Health and Social Care Quality Programme

NICE - Implementation

NICE - Internal Clinical Guidelines Programme

NICE - Interventional Procedures

NICE - Medicines and Prescribing Centre

NICE - MTEP

NICE - PIP

NICE - R&D

NICE - Scientific Advice

NICE - Technology Appraisals

NICE - Topic selection

North and East London Commissioning Support Unit

North of England Commissioning Support

Northern Health and Social Care Trust  
Northwick Park and St Mark's Hospitals  
Nursing and Midwifery Council  
Orion Pharma  
Oxford Health NHS Foundation Trust  
Oxfordshire Clinical Commissioning Group  
Oxleas NHS Foundation Trust  
Pathfinders Specialist and Complex Care  
Pfizer  
Poole Hospital NHS Trust  
PrescQIPP NHS Programme  
Primary Care Pharmacists Association  
Primary Care Women's Health Forum  
Primrose Bank Medical Centre  
Public Health England  
Public Health Wales NHS Trust  
Queen Elizabeth Hospital King's Lynn NHS Trust  
Royal College of Anaesthetists  
Royal College of General Practitioners  
Royal College of General Practitioners in Wales  
Royal College of Midwives  
Royal College of Nursing  
Royal College of Obstetricians and Gynaecologists  
Royal College of Paediatrics and Child Health  
Royal College of Pathologists  
Royal College of Physicians  
Royal College of Psychiatrists  
Royal College of Radiologists  
Royal College of Speech and Language Therapists  
Royal College of Surgeons of England  
Royal Cornwall Hospitals NHS Trust  
Royal Pharmaceutical Society  
Royal Society of Medicine

Royal Wolverhampton Hospitals NHS Trust  
SAGE Publications Limited  
Sandoz Ltd  
Scottish Intercollegiate Guidelines Network  
Self Management UK  
Sheffield Teaching Hospitals NHS Foundation Trust  
Shionogi Limited  
SimplyHormones  
Social Care Institute for Excellence  
Society for the Protection of Unborn Children  
South Chadderton Health Centre  
South Eastern Health and Social Care Trust  
South West Yorkshire Partnership NHS Foundation Trust  
Southern Health & Social Care Trust  
Southport and Ormskirk Hospital NHS Trust  
Staffordshire and Stoke on Trent Partnership NHS Trust  
Stockport Clinical Commissioning Group  
Tayside Sexual and Reproductive Health  
Teva UK  
The Eve Appeal  
The Hysterectomy Centre  
The Institute of Osteopathy  
The Surrey Park Clinic  
UCL/UCLH Institute for Women's Health  
UK Clinical Pharmacy Association  
United Kingdom Council for Psychotherapy  
University College London Hospitals NHS Foundation Trust  
University Hospitals Birmingham  
University of Greenwich  
Victoria Medical Centre  
Welsh Government  
Welsh Scientific Advisory Committee  
Western Health and Social Care Trust

Wigan Borough Clinical Commissioning Group

Women's Support Network

Women's Health Alliance

Worcestershire Acute Hospitals Trust

Yeovil District Hospital NHS Foundation Trust

York Hospitals NHS Foundation Trust

## Appendix C: Declarations of interest

The following members of the Guideline Development Group made declarations of interests. All other members of the group stated that they had no interests to declare. The conflicts of interest policy (2007) was followed until September 2014, when an updated policy was published. The form covered consultancies, fee-paid work, shareholdings, fellowships and support from the healthcare industry. Group members' interests are listed in this section. Where conflicts were identified, group members were asked not to participate in the relevant discussions. Details are available from the group minutes available on the NICE website.

This appendix includes all interests declared between the start of development and submission on 23 March 2015.

**Table 1: Guideline Development Group members' and expert advisers' declarations of interest**

Member	Interest declared	Type of interest	Decision taken
Terry Aspray	Membership of Advisory Board for Lilly Pharmaceuticals	Personal pecuniary	Declare and participate
Terry Aspray	Paid presentation to Sexual and Reproductive Health North East	Non-personal pecuniary	Declare and participate
Terry Aspray	Lecture on Vitamin D in surgery	Specific personal non-financial	Declare and participate
Claire Bowring	Employed by the National Osteoporosis Society as Medical Policy Manager	Specific personal non-financial	Declare and participate
Claire Bowring	Member of the NICE Osteoporosis Guideline Development Group	Specific personal non-financial	Declare and participate
Claire Bowring	Publication: Bowring C, Reid D, Francis R. (2009) Why are physicians reluctant to use estrogens for anything: or do they prefer 'PROFOX'? <i>Menopause Int.</i> 15(3):99	Specific personal non-financial	Declare and participate
Claire Bowring	Bowring CE, Francis RM. (2011) National Osteoporosis Society's Position statement on hormone replacement therapy in the prevention and treatment of osteoporosis. <i>Menopause Int.</i> 17(2):63-5	Specific personal non-financial	Declare and participate
Deborah Holloway	Chaired an RCN women's health conference sponsored by Bayer. Fee was paid directly to the RCN.	Non-personal pecuniary	Declare and participate
Deborah Holloway	Article for menopause exchange newsletter 'Coping with flushes and sweats without HRT'.	Personal pecuniary	Declare and participate
Deborah Holloway	Article for practice nurses 'Post menopause bleeding'.	Personal pecuniary	Declare and participate
Deborah Holloway	Presentation: Bone density changes in POI patients	Personal pecuniary	Declare and participate
Sally Hope	Sits on the women's health board at the MRHA	Personal non-pecuniary	Declare and participate
Sally Hope	Deputy editor of <i>Maturitas</i>	Personal pecuniary	Declare and participate

Member	Interest declared	Type of interest	Decision taken
Sally Hope	Received a lecture fee from Consilient Health to give a workshop to drug representatives on third generation oral contraceptive pills and thrombo-embolic risk following a European medicines statement	Personal pecuniary	Declare and participate
Sally Hope	Received a lecture fee for presentations at two GP conferences speaking on male osteoporosis.	Personal pecuniary	Declare and participate
Sally Hope	Attended a GP Round Table Forum on HRT with a write up in GP magazine.	Personal pecuniary	Declare and participate
Sally Hope	Received lecture fees for non-promotional Educational Lectures for GPs	Personal pecuniary	Declare and participate
Sally Hope	Gave a symposium talk on Vitamin D3 at the National Osteoporosis Conference, Birmingham	Non-specific personal financial	Declare and participate
Sally Hope	Lectured to the Oxfordshire Deanery GP registrar year on Osteoporosis : educational fee paid by Oxfordshire GP Deanery	Personal pecuniary	Declare and participate
Sally Hope	Regular contributor to 'Menopause Matters' magazine: small payment made by subscription of members of the public who take the magazine	Personal pecuniary	Declare and participate
Deborah Keatley	Public Member of NCRI Brain Tumour Clinical Studies Group and member Palliative Care subgroup	Personal non-pecuniary	Declare and participate
Deborah Keatley	Public Member of NIHR HTA Emergency and Elective Specialist Care TIDE Panel	Personal non-pecuniary	Declare and participate
Deborah Keatley	Member of NI Cancer Research Consumer Forum	Personal non-pecuniary	Declare and participate
Deborah Keatley	Member of NI Public Health Research Network	Personal non-pecuniary	Declare and participate
Deborah Keatley	Education level 6 course	Personal specific non-financial	Declare and participate
Deborah Keatley	Presentation on peri/menopause	Personal specific non-financial	Declare and participate
Mary Ann Lumsden	Member of the Medical Advisory Committee of the British Menopause Society (deferred taking up role until guideline's publication)	Specific personal non-financial	Declare and participate
Mary Ann Lumsden	Sits on the women's health board at the MRHA and had recently been appointed as the chair of the NCC-WCH consortium board	Personal non-pecuniary	Declare and participate
Mary Ann Lumsden	Elected as president for the International Menopause Society but will not become president until after the guideline is scheduled to be published.	Personal non-pecuniary	Declare and participate

Member	Interest declared	Type of interest	Decision taken
Mary Ann Lumsden	Presentation: The pace of Guidelines in the Management of Menopausal women Post Reproductive Health Meeting, London.	Personal non-pecuniary	Declare and participate
Mary Ann Lumsden	Presentation: Towards Better Health for Women in Mid-Life and Beyond. The Paul Styra Oration, Delhi.	Personal non-pecuniary	Declare and participate
Mary Ann Lumsden	Presentation: The Role of Guidelines in Evidence Based Health care. FIGO/ Sri Lankhan College of O&G Meeting in Sri Lanka.	Personal non-pecuniary	Declare and participate
Mary Ann Lumsden	Presentation: Clinical Guidance in the Care of menopausal women. Panel discussion at US Endocrine Society Meeting.	Personal non-pecuniary	Declare and participate
Mary Ann Lumsden	Presentation: Managing the Menopause in young and not so young. Presentations to the Obstetrical Societies of Dubai and Kuwait on general menopause management.	Personal non-pecuniary	Declare and participate
Mary Ann Lumsden	Publication: Vascular function and cardiovascular risk factors in women with severe flushing. Sassarini J, Lumsden MA. Maturitas. 2015 Jan 24. pii: S0378-5122(15)00024-9. doi: 10.1016/j.maturitas.2015.01.007. [Epub ahead of print] Review	Personal non-financial	Declare and participate
Mary Ann Lumsden	Publication: Sex hormone replacement in ovarian failure - new treatment concepts. Sassarini J, Lumsden MA, Critchley HO. Best Pract Res Clin Endocrinol Metab. 2015 Jan;29(1):105-14. Doi 10.1016/j.beem.2014.09.010. Epub 2014 Oct 2.	Personal non-financial	Declare and participate
Mary Ann Lumsden	Publication: Prevention of diseases after menopause. Lobo RA, Davis SR, De Villiers TJ, Gompel A, Henderson VW, Hodis HN, Lumsden MA, Mack WJ, Shapiro S, Baber RJ. Climacteric. 2014 Oct;17(5):540-56. doi: 10.3109/13697137.2014.933411. Epub 2014 Jun 27	Personal non-financial	Declare and participate
Mary Ann Lumsden	Presentation to European Menopause and Andropause Society, 'Exercise and the menopause'.	Personal non-pecuniary	Declare and participate
Mary Ann Lumsden	Presentation at British Menopause Society Annual meeting 'Guideline Development'.	Personal non-pecuniary	Declare and participate

Member	Interest declared	Type of interest	Decision taken
Mary Ann Lumsden	Publication: Sassarini, J, Lumsden MA (2015) oestrogen replacement in postmenopausal women. Age Aging 44: 551-8	Specific personal non-financial	Declare and participate
Mary Ann Lumsden	Publication: Sassarini, J, Lumsden, MA (2015) Vascular function and cardiovascular risk factors in women with severe flushing. Maturitas 80: 379-83	Specific personal non-financial	Declare and participate
Sara Moger	Chief executive of the British Menopause Society (BMS)	Personal pecuniary	Declare and participate
Prunella Neale	Applied for sponsorship to Abbott Pharmaceuticals to cover the delegate fee to attend 1 day of the British Menopause Conference, June 2015.	Non-specific personal financial	Declare and participate
Nick Panay	Premature Ovarian Insufficiency lecture	Personal non-pecuniary	Declare and participate
Nick Panay	Genitourinary Syndrome of the Menopause lecture	Personal non-pecuniary	Declare and participate
Nick Panay	Chair of RCOG World congress including 'Premenstrual Syndrome' lecture	Personal non-pecuniary	Declare and participate
Nick Panay	Premenstrual Syndrome lecture	Personal non-pecuniary	Declare and participate
Nick Panay	HRT Update lecture	Personal non-pecuniary	Declare and participate
Nick Panay	Body Identical Hormone Therapy lecture	Personal non-pecuniary	Declare and participate
Nick Panay	Chair of the Vitamin and Mineral Supplement session at the European menopause Society Meeting	Personal non-pecuniary	Declare and participate
Nick Panay	Lectures on Menopause, Natural selection or Modern disease," "Body Identical Hormone Therapy" and Female Androgen Replacement" at Ain Sham's meeting, Cairo	Personal non-pecuniary	Declare and participate
Nick Panay	British Menopause Society Meeting: Chair of the Hysteroscopy / sexual health session and presentation on 'Practical management of menopause'.	Personal non-pecuniary	Declare and participate
Nick Panay	Sat on an advisory board for Pfizer and had attended sponsored conferences. Chaired sessions on OCP and vaginal dryness sponsored by Bayer and Novo-Nordisk	Personal pecuniary	Declare
Nick Panay	Attended advisory board meeting coordinated by Shinogi pharmaceuticals looking at developing a vulvo-vaginal questionnaire	Personal pecuniary	Declare and participate
Nick Panay	Chair Post Reproductive clinical Study Group – RCOG research committee 2010 onwards	Personal non-pecuniary	Declare and participate



Member	Interest declared	Type of interest	Decision taken
Nick Panay	Principal Investigator – POI registry 2013 onwards	Personal non-pecuniary	Declare and participate
Nick Panay	Chaired one session and lectured at IMS meeting: Bayer: Chair – Mirena in peri- and post-menopause Besins: Lecture – Role of body identical hormone therapy Novo Nordisk: Lecture – ultra low dose hormone therapy	Personal non-pecuniary	Declare and participate
Nick Panay	Ongoing menopause advisory work and lecturing for Shionogi, Abbott and Pfizer pharmaceuticals.	Personal non-pecuniary	Declare and participate
Nick Panay	Presentation: International Society of Gynaecological Endocrinology Meeting (ISGE)	Personal non-pecuniary	Declare and participate
Nick Panay	POI Lecture	Personal non-pecuniary	Declare and participate
Nick Panay	Androgen Lecture	Personal non-pecuniary	Declare and participate
Nick Panay	Bio-identical hormone lecture	Personal non-pecuniary	Declare and participate
Nick Panay	Presentation: Menopause: natural selection or modern disease RSM presidential address Presentation: “Premature Ovarian Insufficiency”: Women’s Health Concern RCOG	Personal non-financial	Declare and participate
Nick Panay	Presentation: Premature Ovarian Insufficiency: Irish Menopause Society meeting	Personal non-pecuniary	Declare and participate
Nick Panay	Presentation: HRT: Clarity at Last: Annual Professional Development meeting RCOG	Personal non-pecuniary	Declare and participate
Nick Panay	Presentation: Premature Ovarian Insufficiency: Post-Reproductive Health meeting RCOG	Personal non-pecuniary	Declare and participate
Nick Panay	Presentation: Conference Organiser Post-Reproductive Health meeting RCOG	Personal non-pecuniary	Declare and participate
Nick Panay	Presentation: Premature Ovarian Insufficiency: Abbott Health professional meeting RCOG	Personal non-pecuniary	Declare and participate
Nick Panay	Presentation: Postmenopausal Health meeting: Imperial Staff Postgraduate Forum	Personal non-pecuniary	Declare and participate
Nick Panay	Publication: Panay N, Fenton A. Menopause - natural selection or modern disease? Climacteric. 2015 Feb;18(1):1-2. Doi: 10.3109/13697137.2015.996846. PubMed PMID: 25588545.	Personal non-financial	Declare and participate

Member	Interest declared	Type of interest	Decision taken
Nick Panay	Publication: Panay N, Fenton A. IMS 2014: the Congress 'highlights'. Climacteric. 2014 Dec;17 Suppl 2:1. doi: 10.3109/13697137.2014.974888. PubMed PMID: 25399763.	Personal non-financial	Declare and participate
Nick Panay	Publication: Fenton A, Panay N. Communicating risk and benefit to patients. Climacteric. 2014 Dec;17(6):623-4. doi: 10.3109/13697137.2014.974895. PubMed PMID: 25399700.	Personal non-financial	Declare and participate
Nick Panay	Publication: Nappi RE, Panay N, Bruyniks N, Castelo-Branco C, De Villiers TJ, Simon JA. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric. 2014 Dec 16:1-8. [Epub ahead of print] PubMed PMID: 25335119.	Personal non-financial	Declare and participate
Nick Panay	Publication: Panay N, Fenton A. Perimenopausal hormonal contraception--can we do better? Climacteric. 2014 Oct;17(5):517-9. doi: 10.3109/13697137.2014.955446. PubMed	Personal non-financial	Declare and participate
Nick Panay	Publication: Fenton A, Panay N. (2015) Hormone therapy and cardiovascular disease - are we back to the beginning? Climacteric. 18(4):437-8	Specific personal non-financial	Declare and participate
Nick Panay	Panay N, Fenton A. (2015) Severe PMS/PMDD - is it time for a new approach? Climacteric.18(3):331-2	Specific personal non-financial	Declare and participate
Nick Panay	Cooper NA, Clark TJ, Middleton L, Diwakar L, Smith P, Denny E, Roberts T, Stobert L, Jowett S, Daniels J; (2015) OPT Trial Collaborative Group. Outpatient versus inpatient uterine polyp treatment for abnormal uterine bleeding: randomised controlled non-inferiority study. BMJ. 23;350	Specific personal non-financial	Declare and participate
Nick Panay	Maclaran K, Panay N. (2015) Current concepts in premature ovarian insufficiency. Womens Health (Lond Engl). 11(2):169-82	Specific personal non-financial	Declare and participate
Nick Panay	Fenton A, Panay N. (2015) KEEPS, GSM and much more. Climacteric. 18(2):107	Specific personal non-financial	Declare and participate

Member	Interest declared	Type of interest	Decision taken
Nick Panay	Panay N, Fenton A. (2015) Menopause--natural selection or modern disease? Climacteric.18(1):1-2	Specific personal non-financial	Declare and participate
Nick Panay	Panay N, Fenton A. IMS (2014) the Congress 'highlights'. Climacteric. 17 Suppl 2:1	Specific personal non-financial	Declare and participate
Nick Panay	Fenton A, Panay N. (2014) Communicating risk and benefit to patients. Climacteric. 17(6)	Specific personal non-financial	Declare and participate
Nick Panay	Nappi RE, Panay N, Bruyniks N, Castelo-Branco C, De Villiers TJ, Simon JA. (2015) The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric. 18(2):233-40	Specific personal non-financial	Declare and participate
Nick Panay	Panay N, Fenton A. (2014) Perimenopausal hormonal contraception--can we do better? Climacteric. 17(5):517-9	Specific personal non-financial	Declare and participate
Nick Panay	Fenton A, Panay N. (2014) Menopause and the workplace. Climacteric.17(4):317-8.	Specific personal non-financial	Declare and participate
Nick Panay	Mittal M, Savvas M, Narvekar N, Panay N, Hamoda H. (2014) A cross-sectional national questionnaire survey assessing the clinical attitudes of members of the British Menopause Society to the management of women with premature ovarian insufficiency. Post Reprod Health. 20(3):90-7	Specific personal non-financial	Declare and participate
Nick Panay	Panay N, Fenton A. (2014) The 'window of opportunity'--should we be taking it? Climacteric. 17(3):211-2	Specific personal non-financial	Declare and participate
Nick Panay	Shapiro S, de Villiers TJ, Pines A, Sturdee DW, Baber RJ, Panay N, Stevenson JC, Mueck AO, Burger HG. (2014) Risks and benefits of hormone therapy: has medical dogma now been overturned? Climacteric. 17(3):215-22	Specific personal non-financial	Declare and participate
Nick Panay	Fenton A, Panay N. (2014) Lipid guidelines - are we heading in the right direction? Climacteric. 17(2):107-8	Specific personal non-financial	Declare and participate
Nick Panay	Panay N, Fenton A. (2014) Vulvovaginal atrophy--a tale of neglect. Climacteric. 17(1):1-2.	Specific personal non-financial	Declare and participate

Member	Interest declared	Type of interest	Decision taken
Nick Panay	Shapiro S, deVilliers TJ, Pines A, Sturdee DW, Archer DF, Baber RJ, Panay N, Farmer RD, Stevenson JC, Mueck AO, Burger HG, Gompel A. (2014) Re: Estrogen plus progestin and breast cancer incidence and mortality in the women's health initiative observational study. J Natl Cancer Inst. 106(2)	Specific personal non-financial	Declare and participate
Nick Panay	Ben-Nagi J, Panay N. (2014) Premature ovarian insufficiency: how to improve reproductive outcome? Climacteric. 17(3):242-6	Specific personal non-financial	Declare and participate
Nick Panay	Fenton A, Panay N. (2013) Social media and health. Climacteric. 16(6):609-10	Specific personal non-financial	Declare and participate
Nick Panay	Mittal M, Savvas M, Arya R, McEniery C, Narvekar N, Cardozo L, Panay N, Hamoda H. (2013) A randomised controlled trial comparing the effects of micronized progesterone to medroxyprogesterone acetate on cardiovascular health, lipid metabolism and the coagulation cascade in women with premature ovarian insufficiency: study protocol and review of the literature. Menopause Int. 19(3):127-32	Specific personal non-financial	Declare and participate
Nick Panay	Panay N, Fenton A. (2013) The WHI: have our worst fears come true? Climacteric. 16(5):507-8.	Specific personal non-financial	Declare and participate
Nick Panay	Panay N, Fenton A. (2013) Advances in menopause research-- what does the next decade hold? Climacteric. 16 Suppl 1:3-4.	Specific personal non-financial	Declare and participate
Nick Panay	Fenton A, Panay N. (2013) Menopause--quantifying the cost of symptoms. Climacteric. 16(4):405-6.	Specific personal non-financial	Declare and participate
Nick Panay	Stevenson JC, Panay N, Pexman-Fieth C. (2013) Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety. Maturitas. 76(1):10-21.	Specific personal non-financial	Declare and participate
Nick Panay	Domoney C, Currie H, Panay N, Maamari R, Nappi RE. (2013) The CLOSER survey: impact of postmenopausal vaginal discomfort on women and male partners in the UK. Menopause Int. 19(2):69-76	Specific personal non-financial	Declare and participate

Member	Interest declared	Type of interest	Decision taken
Nick Panay	Panay N, Hamoda H, Arya R, Savvas M; (2013) British Menopause Society and Women's Health Concern. The 2013 British Menopause Society & Women's Health Concern recommendations on hormone replacement therapy. <i>Menopause Int.</i> 19(2):59-68	Specific personal non-financial	Declare and participate
Nick Panay	de Villiers TJ, Pines A, Panay N, Gambacciani M, Archer DF, Baber RJ, Davis, SR, Gompel AA, Henderson VW, Langer R, Lobo RA, Plu-Bureau G, Sturdee DW (2013) International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. <i>Climacteric.</i> 16(3):316-37	Specific personal non-financial	Declare and participate
Nick Panay	Fenton A, Panay N. (2013) DHEA--finding a role for this enigmatic hormone. <i>Climacteric.</i> 16(3):303-4	Specific personal non-financial	Declare and participate
Nick Panay	Nevatte T, O'Brien PM, Bäckström T, Brown C, Dennerstein L, Endicott J, Epperson CN, Eriksson E, Freeman EW, Halbreich U, Ismail K, Panay N, Pearlstein T, Rapkin A, Reid R, Rubinow D, Schmidt P, Steiner M, Studd J, Sundström-Poromaa I, Yonkers K (2013) Consensus Group of the International Society for Premenstrual Disorders. ISPM D consensus on the management of premenstrual disorders. <i>Arch Womens Ment Health.</i> 16(4):279-91	Specific personal non-financial	Declare and participate
Nick Panay	Panay N. (201) 3Does hormone replacement therapy cause breast cancer? Commentary on Shapiro et al. papers, Parts 1-5. <i>J Fam Plann Reprod Health Care.</i> 39(2):72-4.	Specific personal non-financial	Declare and participate
Nick Panay	Panay N, Fenton A. (2013) A global consensus statement on menopause hormone therapy-aims, aspirations and action points. <i>Climacteric.</i> 16(2):201-2	Specific personal non-financial	Declare and participate
Nick Panay	Panay N, Gerval M, Maclaran K. (2013) The safety of postmenopausal testosterone therapy. <i>Climacteric.</i> 16(1):194-5	Specific personal non-financial	Declare and participate

Member	Interest declared	Type of interest	Decision taken
Nick Panay	Stavraka C, Maclaran K, Gabra H, Agarwal R, Ghaem-Maghani S, Taylor A, Dhillo, WS, Panay N, Blagden SP (2013). A study to evaluate the cause of bone demineralization in gynecological cancer survivors. <i>Oncologist</i> .18(4):423-9	Specific personal non-financial	Declare and participate
Nick Panay	Fenton A, Panay N. (2013) Anti-Müllerian hormone - is it a clinically useful test? <i>Climacteric</i> . 16(1):1-2	Specific personal non-financial	Declare and participate
Nick Panay	Ismail KM, Nevatte T, O'Brien S, Paschetta E, Bäckström T, Dennerstein L, Eriksson E, Freeman EW, Panay N, Pearlstein T, Rapkin A, Steiner M, Studd J, Sundström-Poromaa I. (2013) Clinical subtypes of core premenstrual disorders: a Delphi survey. <i>Arch Womens Ment Health</i> . 16(3):197-201.	Specific personal non-financial	Declare and participate
Nick Panay	Panay N, Fenton A. (2012) Good news for HRT--what next? <i>Climacteric</i> . 15(6):511-2.	Specific personal non-financial	Declare and participate
Nick Panay	Fenton A, Panay N. (2012) Hormone replacement therapy prescription: a disconnect between personal and patient prescribing. <i>Climacteric</i> . 15(5):409-10.	Specific personal non-financial	Declare and participate
Nick Panay	Panay N, Fenton A. (2012) Premature ovarian insufficiency: working towards an international database. <i>Climacteric</i> . 15(4):295-6.	Specific personal non-financial	Declare and participate
Nick Panay	Fenton A, Panay N. (2012) The Women's Health Initiative - a decade of progress. <i>Climacteric</i> . 15(3):205	Specific personal non-financial	Declare and participate
Nick Panay	Panay N. (2012) Treatment of premenstrual syndrome: a decision-making algorithm. <i>Menopause Int</i> 18(2):90-2.	Specific personal non-financial	Declare and participate
Nick Panay	Maclaran K, Panay N. (2012) The safety of postmenopausal testosterone therapy. <i>Womens Health</i> . 8(3):263-75	Specific personal non-financial	Declare and participate
Nick Panay	Panay N, Currie H, Morris E. (2012) What really matters is the menopausal woman! <i>J Fam Plann Reprod Health Care</i> . 38(2):136-7.	Specific personal non-financial	Declare and participate

Member	Interest declared	Type of interest	Decision taken
Nick Panay	Panay N, Fenton A. (2012) Does HRT increase the risk of breast cancer? Don't forget the menopausal woman! Climacteric. 15(2):103-4.	Specific personal non-financial	Declare and participate
Nick Panay	Panay N. (2012) Commentary regarding recent Million Women Study critique and subsequent publicity. Menopause Int. 18(1):33-5	Specific personal non-financial	Declare and participate
Nick Panay	Panay N, Maamari R. (2012) Treatment of postmenopausal vaginal atrophy with 10-µg estradiol vaginal tablets. Menopause Int. 18(1):15-9	Specific personal non-financial	Declare and participate
Nick Panay	Mann E, Singer D, Pitkin J, Panay N, Hunter MS. (2012) Psychosocial adjustment in women with premature menopause: a cross-sectional survey. Climacteric. 15(5):481-9	Specific personal non-financial	Declare and participate
Nick Panay	Panay N. (2012) Stopping HRT: were women ill advised? Climacteric. 15(1):99-100	Specific personal non-financial	Declare and participate
Nick Panay	Fenton A, Panay N. (2012) Does routine gynecological surgery contribute to an early menopause? Climacteric.15(1):1-2	Specific personal non-financial	Declare and participate
Anthony Parsons	Attended IMS meeting attendance fee paid by Novo Nordisk.	Personal pecuniary	Declare and participate
Anthony Parsons	Honorarium received from Novo Nordisk for attendance at advisory board meeting. Agenda included items relevant to the guideline but AP did not take part in these discussions.	Personal pecuniary	Declare and participate
Charlotte Coles	No interests declared		
Peter Collins	No interests declared		
Rebecca Hardy	No interests declared		
Adrian Harnett	No interests declared		
Myra Hunter	No interests declared		
Imogen Shaw	No interests declared		
Christine West	No interests declared		

**Table 2: NCC-WCH staff members' declarations of interest**

Member	Interest declared	Type of interest	Decision taken
Melanie Davies	Private medical practice based at the Centre for Reproductive and Genetic Health; occasional patients seen at London Medical	Non-specific personal financial	Declare and participate
Melanie Davies	Education grant received for lectures	Non-specific non-personal	Declare and participate
Melanie Davies	Clinical adviser to Medicines and Healthcare products Regulatory Agency (MHRA)	Non-specific non-financial	Declare and participate

Member	Interest declared	Type of interest	Decision taken
Melanie Davies	Member of European Society for Human Reproduction and Embryology British Menopause Society	Specific non-financial	Declare and participate
Melanie Davies	Medical Adviser, Turner Syndrome Support Society	Specific non-financial	Declare and participate
Melanie Davies	Co-Chair, Guideline Development Group on Premature Ovarian Insufficiency, ESHRE (to December 2014)	Specific personal non-financial	Declare and participate
Melanie Davies	Invited speaker on Premature Ovarian Insufficiency ESHRE meeting	Specific non-personal financial	Declare and participate
Melanie Davies	Registration/accommodation for attendance at IMS meeting (Novo Nordisk)	Specific non-personal financial	Declare and participate
Melanie Davies	Direct payment for medicolegal advice	Non-specific personal financial	Declare and participate
Melanie Davies	Speaker European Paediatric & Adolescent Gynaecology conference	Specific personal non-financial	Declare and participate
Melanie Davies	Speaker patient support group Turner syndrome	Specific personal non-financial	Declare and participate
Melanie Davies	Co-author abstract & oral presentation BMS 'Comparison of efficacy of oral contraceptive pill and hormone replacement therapy for young women with premature ovarian insufficiency'	Specific personal non-financial	Declare and participate
Melanie Davies	Co-author abstract accepted RCOG international congress, Brisbane: treatment for POI	Specific non-financial	Declare and participate
Melanie Davies	Member of the Medical Advisory Committee of the British Menopause Society (deferred taking up role until guideline's publication)	Specific personal non-financial	Declare and participate
Omnia Abdulrazeg	No interests declared		
Sarah Bailey	No interests declared		
Zosia Beckles	No interests declared		
David Bevan	No interests declared		
Fiona Caldwell	No interests declared		
Jiri Chard	No interests declared		
Katherine Cullen	No interests declared		
Hannah Rose Douglas	No interests declared		
Annabel Flint	No interests declared		
Rupert Franklin	No interests declared		
Yelan Guo	No interests declared		
Paul Jacklin	No interests declared		
David James	No interests declared		
Setor Kunutsor	No interests declared		
Sadia Janjua	No interests declared		



Member	Interest declared	Type of interest	Decision taken
Hugh McGuire	No interests declared		
Paul Mitchell	No interests declared		
Hugo Pedder	No interests declared		
Nitara Prasannan	No interests declared		
Sabina Sanghera	No interests declared		
Grammati Sarri	No interests declared		
Amy Wang	No interests declared		
Katie Webster	No interests declared		

## Appendix D: Review protocols

### D.1 Diagnosis of perimenopause and menopause

<b>Question</b>	<p><b>What is the diagnostic accuracy of the following indicators (clinical and biological manifestations) in the diagnosis of perimenopause and menopause:</b></p> <ul style="list-style-type: none"> <li>• age</li> <li>• menopausal symptoms (especially vasomotor symptoms)</li> <li>• endocrine changes (specifically follicle-stimulating hormone, anti-Müllerian hormone, oestrogen or inhibin B)</li> <li>• total antral follicle count</li> </ul>
Objectives	To determine the diagnostic accuracy of specific clinical indicators in diagnosing different stages of menopause
Language	English full text papers
Study design	<ul style="list-style-type: none"> <li>• Diagnostic accuracy studies</li> <li>• Cohort studies – prospective/retrospective</li> </ul>
Population	Women suspected to be menopausal or perimenopausal.
Stratified and subgroup analysis	Stratified analysis will be performed based on the background population of women, for example if women who are suspected to undergoing menopause will be diagnosed from perimenopausal or from postmenopausal or from all women with menopause (pre or postmenopausal)
Clinical indicators (index tests)	<ul style="list-style-type: none"> <li>• Age</li> <li>• menopausal vasomotor symptoms</li> <li>• endocrine features (in blood or urine)</li> <li>• follicle-stimulating hormone (FSH)</li> <li>• anti-Müllerian hormone</li> <li>• oestrogen levels</li> <li>• inhibin A and B</li> <li>• ovarian ultrasound evaluation (including ovarian volume and total antral follicle count)</li> </ul> <p>Note: Any of these features in isolation or in combination will be considered as diagnostic tools of menopause</p> <p>Different levels of the above clinical indicators as reported by the authors will be used as diagnostic tools.</p>
Target condition/reference standard	Menopause defined as 12 or more months of amenorrhoea will be used as the gold standard for diagnostic accuracy tests
Outcomes	<ul style="list-style-type: none"> <li>• Sensitivity / specificity</li> <li>• Likelihood ratio (positive and negative)</li> <li>• Area under the curve (AUC)</li> </ul> <p>Likelihood ratios and sensitivity/specificity will be prioritised.</p> <p>Guideline development Group noted that there are associated risks (particularly psychological) to the individual of both false positive and false negative tests.</p>
Other criteria for inclusion/exclusion of studies	<p>The focus of this review is to investigate the role of clinical features as diagnostic tools of different stages of menopause (pre, peri or post).</p> <p>The Guideline Development Group did not consider including prognostic studies looking at the role of these clinical features to predict the menopause at a certain later time in women's life.</p>

<b>Question</b>	<p><b>What is the diagnostic accuracy of the following indicators (clinical and biological manifestations) in the diagnosis of perimenopause and menopause:</b></p> <ul style="list-style-type: none"> <li>• age</li> <li>• menopausal symptoms (especially vasomotor symptoms)</li> <li>• endocrine changes (specifically follicle-stimulating hormone, anti-Müllerian hormone, oestrogen or inhibin B)</li> <li>• total antral follicle count</li> </ul>
Review strategies	<p>Appraisal of methodological quality:</p> <ul style="list-style-type: none"> <li>• The Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS-2) checklists will be used.</li> </ul> <p>Synthesis of data:</p> <ul style="list-style-type: none"> <li>• Meta-analysis will be conducted where appropriate.</li> </ul>
Equality	Equalities issues will be assessed according to processes described in NICE guidelines manual (2012)

## D.2 Classification systems for the diagnosis of menopause

<b>Question</b>	<p><b>What is the usefulness of formal classification systems compared with non-structured classification systems in the diagnosis of menopause and in guiding further treatment?</b></p>
Objectives	The aim of this question is to determine whether using a formal classification system helps in the diagnosis of menopause and in guiding further investigation and treatment for menopausal symptoms over using a clinical history alone
Language	English
Study design	<p>Only published full text papers</p> <ul style="list-style-type: none"> <li>• Systematic reviews of RCTs</li> <li>• RCTs</li> <li>• Comparative cohort studies (only if RCTs unavailable or limited data to inform decision making)</li> <li>• Non comparative cohort studies</li> </ul>
Population and directness	Women in menopause
Stratified and subgroup analysis	Separate review will be performed for women with POI if data available
Intervention	<p>Any classification scheme of menopause stages including the following;</p> <ul style="list-style-type: none"> <li>• STRAW (Stages of Reproductive Aging Workshop)</li> <li>• STRAW + 10 (update of STRAW by including additional blood tests)</li> <li>• RESTAGE ALGORITHM (5 bleeding criteria for staging menopause)</li> </ul> <p>Note: none of the above classification systems have been validated but are consensus based</p>
Comparator	<ul style="list-style-type: none"> <li>• no classification scheme</li> <li>• clinical history (if retrospective studies)</li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>• Correct diagnosis of menopause</li> <li>• Guidance for further investigation or treatment</li> <li>• Health related quality of life</li> </ul>
Importance of outcomes/critical outcomes	<ul style="list-style-type: none"> <li>• Correct diagnosis of menopause</li> <li>• Guidance for further investigation or treatment</li> </ul>

Question	<b>What is the usefulness of formal classification systems compared with non-structured classification systems in the diagnosis of menopause and in guiding further treatment?</b>
Other criteria for inclusion/exclusion of studies	Studies that looking at diagnostic accuracy of individual clinical indicators (included in classification tools) won't be included for the purposes of this review.
Review strategies	<p>Appraisal of methodological quality</p> <ul style="list-style-type: none"> <li>• The methodological quality of each study will be assessed using NICE checklists along with the quality of the evidence will be assessed by GRADE for each outcome.</li> </ul> <p>Synthesis of data</p> <ul style="list-style-type: none"> <li>• Meta-analysis will be conducted where appropriate.</li> <li>• Default MIDAs will be used: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes.</li> <li>• Record any considerations for continuous data for example if final and change scores will be pooled and if any study reports both, the method used in the majority of studies will be analysed.</li> <li>• If studies only report p-values, this information will be plotted in GRADE tables without an assessment of imprecision possible to be made.</li> </ul>
Equality	Equalities issues will be assessed according to processes described in NICE guidelines manual (2012)

### D.3 Information and advice

Review question for update	<b>What are the information needs for women in menopause?</b>
Objectives	To identify what are the most common areas of information needs for women in menopause and what are the most effective ways of delivering these information.
Language	English full text papers
Study design	<p>For the first part of question: Systematic reviews of qualitative studies, observational studies (ideally large cohorts), qualitative studies (natural history data, patient reported outcomes).</p> <p>For the second part of question: RCTs or comparative cohort studies</p>
Population	<p>Women in menopause (including peri-menopausal and post-menopausal) Information (if available) will be presented separately for the following subgroups:</p> <ul style="list-style-type: none"> <li>• Women with Premature Ovarian Insufficiency (POI) including women with iatrogenic menopause, particularly that due to cancer treatment or at risk of cancer</li> <li>• Women with natural menopause who present for symptom-relief</li> </ul>
Intervention (2nd part of question)	Any format of delivery information including written, oral communication, use of websites regarding menopause
Comparator (2nd part of question)	Delivery of information in different format than the one specified in the intervention.
Clinical outcomes	<p>1st part of question:</p> <ul style="list-style-type: none"> <li>• Areas of information need</li> </ul> <p>2nd part of question:</p> <ul style="list-style-type: none"> <li>• Woman's knowledge about menopause</li> <li>• Number of visits to the health care professionals regarding menopause issues</li> </ul>

Review question for update	What are the information needs for women in menopause?
Other criteria for inclusion/exclusion of studies	Exclusion criteria: <ul style="list-style-type: none"> <li>• studies looking at women's satisfaction with information provision</li> <li>• studies including premenopausal women.</li> </ul>
Review strategies	Appraisal of methodological quality <ul style="list-style-type: none"> <li>• The methodological quality of each study will be assessed using NICE checklists.</li> </ul> Synthesis of data: <ul style="list-style-type: none"> <li>• Narrative summary will be undertaken for the first part of question and quantitatively evidence synthesis for the second part of question.</li> </ul>
Equality	Equalities issues will be assessed according to processes described in NICE guidelines manual (November 2012) but the following subgroups have been identified: <ul style="list-style-type: none"> <li>• Women who have English as a second language,</li> <li>• Women from non UK cultures,</li> <li>• Women with learning disabilities.</li> </ul>
Notes	The Guideline Development Group will consider the evidence on provision of information in relation to existing NHS 5-yearly 'health check' during the menopause.

## D.4 Managing short-term symptoms

Question	What is the most clinical and cost effective treatment for the relief of individual menopause-related symptoms for women in menopause?
Objectives	The aim for this review will be to assess the relative effectiveness of all the main treatments used to treat short term menopause-related symptoms in five clinical categories: <ul style="list-style-type: none"> <li>• vasomotor</li> <li>• psychological</li> <li>• sexual function</li> <li>• musculoskeletal.</li> <li>• Adverse events (discontinuation, bleeding)</li> </ul> Network meta-analysis will be undertaken to allow simultaneous comparison across treatments. If this is not possible then pair-wise comparisons will be provided.
Language	English full text papers
Study design	<ul style="list-style-type: none"> <li>• Systematic reviews of randomised controlled trials (RCTs)</li> <li>• RCTs (parallel and cross over trials)</li> </ul>
Population	Women with symptoms of menopause
Stratified/subgroup analyses	Stratified analysis will be conducted for: <ul style="list-style-type: none"> <li>• Women without a uterus</li> <li>• Women with a uterus</li> <li>• Women at risk of breast cancer including women with hormonally treated breast cancer (e.g. tamoxifen, aromatase inhibitors)</li> </ul> Subgroup analysis will be conducted for if data available: <ul style="list-style-type: none"> <li>• Peri-menopausal women</li> <li>• Post-menopausal women</li> </ul>
Intervention	<ul style="list-style-type: none"> <li>• Hormonal pharmaceutical treatments: <ul style="list-style-type: none"> <li>○ oestrogen combined with progestogen/ progesterone (oral)</li> <li>○ oestrogen combined with progestogen/ progesterone (topical – patch, cream)</li> <li>○ oestrogen (oral)</li> </ul> </li> </ul>

Question	What is the most clinical and cost effective treatment for the relief of individual menopause-related symptoms for women in menopause?
	<ul style="list-style-type: none"> <li>○ oestrogen (topical – patch, cream)</li> <li>○ oestrogen (depot)</li> <li>○ progestogen alone</li> <li>● tissue-selective oestrogen complexes               <ul style="list-style-type: none"> <li>○ testosterone</li> <li>○ tibolone</li> </ul> </li> <li>● bio-identical hormones licensed for use in the UK               <ul style="list-style-type: none"> <li>○ selective oestrogen-receptor modulators (oral)</li> <li>○ selective oestrogen-receptor modulators (topical – patch, cream)</li> </ul> </li> <li>● non-hormonal pharmaceutical treatments:               <ul style="list-style-type: none"> <li>○ selective serotonin reuptake inhibitors</li> <li>○ serotonin–noradrenaline reuptake inhibitors</li> <li>○ gabapentin</li> <li>○ clonidine</li> </ul> </li> <li>● non-pharmaceutical treatments:               <ul style="list-style-type: none"> <li>○ phytoestrogens (including red clover)</li> <li>○ herbal preparations (including black cohosh)</li> <li>○ acupuncture</li> <li>○ lifestyle advice</li> <li>○ Relaxation therapies (including yoga)</li> <li>○ psychological therapies</li> <li>○ cognitive behavioural therapy</li> </ul> </li> </ul>
Comparator	<p>All interventions listed above</p> <ul style="list-style-type: none"> <li>● Placebo</li> <li>● Sham acupuncture</li> <li>● Attention control (sham relaxation)</li> </ul> <p>Usual care/no treatment</p>
Outcomes	<ul style="list-style-type: none"> <li>● Frequency of hot flushes (including night sweats)</li> <li>● Frequency of sexual activity</li> <li>● Psychological symptoms               <ul style="list-style-type: none"> <li>○ Anxiety</li> <li>○ Low mood (not clinical depression)</li> </ul> </li> <li>● Musculoskeletal symptoms</li> <li>● Safety outcomes               <ul style="list-style-type: none"> <li>○ Discontinuation</li> <li>○ Vaginal bleeding</li> </ul> </li> </ul>
Other criteria for inclusion/exclusion of studies	<p>Due to the number of available RCTs (~700) and the time and resource constraint, papers will only be included if the primary inclusion criteria or outcome matches the four areas of effectiveness area – vasomotor, sexual function, musculoskeletal or psychological.</p> <p>For the safety reviews, papers will be included if they report on safety (discontinuation and vaginal bleeding) and they have also been included in the effectiveness reviews (vasomotor, sexual function, psychological &amp; musculoskeletal).</p> <p>Outcomes reported at different time points for treatment and comparator groups will be excluded</p> <p>Data presented in graphical format will not be included.</p>
Review strategies	<p>Appraisal of methodological quality:</p>

Question	What is the most clinical and cost effective treatment for the relief of individual menopause-related symptoms for women in menopause?
	<ul style="list-style-type: none"> <li>The methodological quality of each study will be assessed using NICE checklists along with the quality of the evidence will be assessed by GRADE for each outcome.</li> </ul> <p>Synthesis of data:</p> <ul style="list-style-type: none"> <li>Meta-analysis will be conducted where appropriate.</li> <li>Default MIDAs will be used for imprecision assessment: 0.75 and 1.25 for dichotomous outcomes and ratio of means; 0.5 times SD for continuous outcomes.</li> </ul> <p>Record any considerations for continuous data for example if final and change scores will be pooled and if any study reports both, the method used in the majority of studies will be analysed.</p> <p>If studies only report p-values, this information will be plotted in GRADE tables without an assessment of imprecision possible to be made</p> <p>Specific statistical methods to be considered for the NMA:</p> <p>For the outcome of vasomotor symptoms, we will report the relative effect of the treatments in terms of ratio of mean values (RoM). This decision was made due to the very different way the outcome of vasomotor symptoms has been reported across studies. Since the RoM is unitless, its calculation can be carried out regardless of the specific units used in individual trials. RoM uses the natural logarithm scale to carry out such calculations, similar to statistical procedures for binary effect measures (risk ratio and odds ratio), due to its desirable statistical properties (Friedrich 2008).</p>
Equality	Equalities issues with be assessed according to processes described in NICE guidelines manual (2012)

#### D.4.1 Management short-term symptoms: network meta-analyses

Question	What is the most clinically effective treatment for the relief of individual menopause-related symptoms for women at menopause?
Objective	<p>The aim for this review will be to assess the relative effectiveness of all the main treatments used to treat short term menopause-related symptoms in five clinical categories:</p> <ul style="list-style-type: none"> <li>vasomotor</li> <li>psychological</li> <li>sexual function</li> <li>musculoskeletal</li> <li>adverse events (discontinuation, vaginal bleeding)</li> <li>vasomotor symptoms, discontinuation and vaginal bleeding were selected as the outcomes with the highest priority.</li> </ul>
Population	<p>All women with menopause Exclusion criterion: pre menopause women</p>
Stratified analyses	<ul style="list-style-type: none"> <li>Peri or postmenopause women with uterus</li> <li>Peri or postmenopause women without uterus (hysterectomized)</li> <li>Women with a history or at risk of breast cancer.</li> </ul>
Interventions	<p>Hormonal pharmaceutical treatments:</p> <ul style="list-style-type: none"> <li>oestrogen combined with progestogen/ progesterone (oral)</li> <li>oestrogen combined with progestogen/ progesterone (topical – patch, cream)</li> <li>oestrogen (oral)</li> <li>oestrogen (topical – patch, cream)</li> <li>oestrogen (depot)</li> <li>progestogen alone</li> </ul>

Question	What is the most clinically effective treatment for the relief of individual menopause-related symptoms for women at menopause?
	<p>Tissue-selective oestrogen complexes:</p> <ul style="list-style-type: none"> <li>• testosterone</li> <li>• tibolone bio-identical hormones licensed for use in the UK</li> <li>• selective oestrogen-receptor modulators (oral)</li> <li>• selective oestrogen-receptor modulators (topical – patch, cream)</li> </ul> <p>non-hormonal pharmaceutical treatments:</p> <ul style="list-style-type: none"> <li>• selective serotonin reuptake inhibitors</li> <li>• serotonin–noradrenaline reuptake inhibitors</li> <li>• gabapentin</li> <li>• clonidine</li> </ul> <p>Non-pharmaceutical treatments:</p> <ul style="list-style-type: none"> <li>• phytoestrogens(including red clover)</li> <li>• herbal preparations (including black cohosh)</li> <li>• acupuncture</li> <li>• lifestyle advice</li> <li>• Relaxation therapies (including yoga)</li> <li>• psychological therapies</li> <li>• cognitive behavioural therapy</li> </ul>
Comparisons	<ul style="list-style-type: none"> <li>• All interventions listed above</li> <li>• Placebo</li> <li>• Usual care/no treatment</li> </ul>
Outcomes	<p>The following outcomes at the end of treatment (unless end of treatment is after 26 weeks follow-up) will be included:</p> <ul style="list-style-type: none"> <li>• Frequency of vasomotor symptoms (modelled as a rate). We will not consider severity of symptoms as part of this outcome due to the variation in scores used to measure them.</li> <li>• Hot flushes and night sweats will be included. Where a study reports frequency of both hot flushes and night sweats they will be added together (by treating them as independent outcomes) to give an overall frequency of vasomotor symptoms.</li> <li>• Discontinuation (modelled as OR) – assuming constant probability of discontinuation after 4 weeks of treatment</li> <li>• Vaginal bleeding (modelled as OR) – assuming constant probability of bleeding after 4 weeks of treatment</li> </ul> <p>Special considerations:</p> <ul style="list-style-type: none"> <li>• Only studies which report the number of women with bleeding will be included in the analysis. Studies reporting the total number of bleeds will not be included, as we cannot ascertain the number of bleeds per woman nor the number of women with bleeding.</li> <li>• For HRT study arms we will take the latest time point possible that is longer than 12 weeks and less than 26 weeks follow-up</li> <li>• For non-HRT study arms we will take the latest time point possible that is longer than 4 weeks and less than 26 weeks follow-up</li> </ul>
Study design	<p>Only RCTS will be considered for inclusion. Cross over RCTs will be only considered if provided separated data on the first period or data are reported in a linear mixed model that adjusts for treatment period and reports the coefficient for the effect of treatment vs placebo.</p>



Question	<b>What is the most clinically effective treatment for the relief of individual menopause-related symptoms for women at menopause?</b>
	Exclusion criteria: studies with a duration of less than 4 weeks for non HRT studies and less than 12 weeks for HRT studies, studies including non UK license drugs.
Population size and directness	<p>Studies with indirect populations will be considered under the following assumptions:</p> <ul style="list-style-type: none"> <li>• Mixed population studies: we will only include mixed population studies if more than 2/3 of the sample falls within the pre specified strata.</li> <li>• For the non HRT trials: if population not specified with regards to hysterectomy status we will include studies in NMAs of women with a uterus and women without a uterus because we would assume that the efficacy of different non-HRT interventions would be exchangeable across the two populations</li> <li>• For HRT trials: if trials have not explicitly stated history of breast cancer as an exclusion criterion, but have excluded current breast cancer as an exclusion reason, then we would assume that the trials would have excluded both types of breast cancer.</li> <li>• If a trial does not explicitly state that women with breast cancer, a history of breast cancer, or those who had contraindications to HRT, were included/excluded, we will assume that the authors did not include these patients.</li> <li>• If a trial including breast cancer patients has specified that premenopausal women as assessed before breast cancer diagnosis were included, then this trial would still be included</li> <li>• Within each population, treatment efficacy will be independent of the cause of menopause (i.e. surgical vs natural).</li> </ul>
Review strategy	<p>Synthesis of data</p> <ul style="list-style-type: none"> <li>• Network meta-analysis will be conducted using Winbugs codes (DSU Bristol Unit)</li> <li>• NMA will be based on final scores.</li> </ul> <p>If final scores are not reported, in order to be included in the analysis baseline values should be reported in addition to the change from baseline values.</p> <ul style="list-style-type: none"> <li>• We will use the ratio of means in reporting the frequency of VSM symptoms (95% c.i)</li> <li>• We will use the RRs (95% c.i.) for the report of results of bleeding, discontinuation</li> </ul> <p>Exclusion criteria:</p> <p>We will exclude trials which reported change from baseline as a percentage</p> <p>We will exclude trials which reported outcomes in mean changes without measure of variation (SD, SE, 95% ci)</p>

#### D.4.2 Urogenital atrophy

Question	<b>What is the clinical effectiveness of local oestrogens and ospemifene compared with placebo for menopause-related vaginal/urogenital atrophy?</b>
Objectives	To determine if localised oestrogens and ospemifene are clinically effective and safe in treating vaginal/urogenital atrophy.
Language	English full text papers
Study design	Systematic reviews of RCTs RCTs

Question	<b>What is the clinical effectiveness of local oestrogens and ospemifene compared with placebo for menopause-related vaginal/urogenital atrophy?</b>
Population	Post-menopausal women with vaginal/urogenital atrophy Subgroup analysis (if data available) on: Women at high risk of cancer
Intervention	<ul style="list-style-type: none"> <li>• Local oestrogen (different preparations will be considered)</li> <li>• Ospemifene</li> </ul> Short term duration defined as less than one year. Long term duration defined as 1 year or longer.
Comparator	<ul style="list-style-type: none"> <li>• Placebo (this may include non-hormonal treatment, including moisturisers and lubricants)</li> <li>• No treatment</li> </ul>
Outcomes	Short term outcomes Efficacy outcomes: <ul style="list-style-type: none"> <li>• measurement of vaginal pH,</li> <li>• maturation index (for parabasal, intermediate and superficial cells).</li> <li>• Patient assessment of symptoms improvement (relating to atrophy, dryness, dyspareunia (painful intercourse), itching and discomfort).</li> </ul> Safety outcomes: <ul style="list-style-type: none"> <li>• Assessment of endometrial stimulation measured by the progestagen (progesterone, progestogen) challenge test, ultrasound measurement of endometrial thickness, hysteroscopic appearance, or results from endometrial biopsy (information on endometrial hyperplasia will also be recorded)</li> <li>• Breast pain, which may be considered a surrogate marker (indirect indicator) for systemic absorption, and blood oestradiol levels.</li> <li>• Frequency of adverse events relating to treatment.</li> <li>• Acceptability.</li> <li>• Withdrawal from the study because of adverse events relating to treatment.</li> <li>• Participant adherence to treatment.</li> <li>• Health-related quality of life</li> </ul> Long term outcomes <ul style="list-style-type: none"> <li>• endometrial hyperplasia or cancer confirmed by biopsy (information on endometrial thickness will also be recorded).</li> <li>• Symptom relief</li> <li>• Health-related quality of life</li> </ul>
Other criteria for inclusion/exclusion of studies	Tissue selective oestrogen complexes were removed from the final scope as they are not licensed for any preparation in the UK
Review strategies	Appraisal of methodological quality The methodological quality of each study will be assessed using NICE checklists along with the quality of the evidence will be assessed by GRADE for each outcome. Synthesis of data Meta-analysis will be conducted where appropriate. Default MIDs will be used: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes. Record any considerations for continuous data for example if final and change scores will be pooled and if any study reports both, the method used in the majority of studies will be analysed.

<b>Question</b>	<b>What is the clinical effectiveness of local oestrogens and ospemifene compared with placebo for menopause-related vaginal/urogenital atrophy?</b>
	If studies only report p-values, this information will be plotted in GRADE tables without an assessment of imprecision possible to be made
Equality	Equalities issues with be assessed according to processes described in NICE guidelines manual (2012)

## D.5 Review and referral

<b>Question</b>	<b>At what intervals should clinical review be undertaken to assess the effectiveness and safety of treatments to relieve menopausal symptoms and to determine when women need to be referred to specialist care?</b>
Objectives	This question aims to identify when is the optimum time to review the effectiveness and safety of treatments that were given to women for relief of menopausal symptoms so different management is considered (for example dose alteration, change of intervention, referral to specialist care)
Language	English full text papers
Study design	<ul style="list-style-type: none"> <li>• Randomised controlled trials</li> <li>• Prospective longitudinal studies</li> <li>• Retrospective register studies (if no other data available)</li> </ul>
Population	Women who are taking any one of the interventions for relieve of menopausal symptoms Studies in a UK setting
Intervention	A specific pattern of follow up/clinical review schedule
Comparator	A different pattern of follow up/clinical review schedule Usual care
Outcomes	<ul style="list-style-type: none"> <li>• Number of hospital unscheduled consultations</li> <li>• Continuation with treatment</li> <li>• health related quality of life (using validated measurement scales)</li> <li>• Adverse events</li> </ul>
Other criteria for inclusion/exclusion of studies	Non UK studies will have limited generalibility.
Review strategies	<p>Appraisal of methodological quality</p> <p>The methodological quality of each study will be assessed using NICE checklists along with the quality of the evidence will be assessed by GRADE for each outcome.</p> <p>Synthesis of data</p> <p>Meta-analysis will be conducted where appropriate.</p> <p>Default MID's will be used: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes.</p> <p>Record any considerations for continuous data for example if final and change scores will be pooled and if any study reports both, the method used in the majority of studies will be analysed.</p> <p>If studies only report p-values, this information will be plotted in GRADE tables without an assessment of imprecision possible to be made</p>
Equality	Equalities issues with be assessed according to processes described in NICE guidelines manual (2012)

## D.6 Starting and stopping HRT

<b>Question</b>	<b>In perimenopausal and postmenopausal women using HRT for vasomotor symptom relief, what is the clinical effectiveness of an abrupt HRT discontinuation strategy compared with a tapered HRT discontinuation strategy?</b>
Objectives	To determine the most clinically effective and acceptable strategy for discontinuation to avoid reoccurrence of vasomotor symptoms associated with HRT use.
Language	English full text papers
Study design	<ul style="list-style-type: none"> <li>• Systematic reviews of RCTs</li> <li>• RCTs</li> <li>• Comparative cohort studies</li> </ul>
Population	Women who are discontinuing HRT use for menopausal symptom relief
Intervention	Tapered withdrawal of HRT use Note: The Guideline Development Group want to be more inclusive and consider all possible types of tapered withdrawal.
Comparator	Abrupt withdrawal of HRT use (same regimen as used in intervention arm) The Guideline Development Group wishes to take a more inclusive and consider all possible types of abrupt withdrawal.
Outcomes	<ul style="list-style-type: none"> <li>• Reoccurrence of menopausal symptoms</li> <li>• Health related quality of life</li> <li>• Resumption of HRT treatment</li> <li>• Uptake of alternative treatment</li> <li>• Acceptability of treatment to women (qualitative assessment if scale not available)</li> </ul>
Other criteria for inclusion/exclusion of studies	None
Review strategies	<p>Appraisal of methodological quality</p> <p>The methodological quality of each study will be assessed using NICE checklists along with the quality of the evidence will be assessed by GRADE for each outcome.</p> <p>Synthesis of data</p> <p>Meta-analysis will be conducted where appropriate.</p> <p>Default MIDs will be used: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes.</p> <p>Record any considerations for continuous data for example if final and change scores will be pooled and if any study reports both, the method used in the majority of studies will be analysed.</p> <p>If studies only report p-values, this information will be plotted in GRADE tables without an assessment of imprecision possible to be made.</p>
Equality	Equalities issues with be assessed according to processes described in NICE guidelines manual (2012)

## D.7 Long-terms benefits and risks of HRT

### D.7.1 Venous thromboembolism

Review question for update	What are the effects of HRT administered for menopausal symptoms on the risk of developing venous thromboembolism (VTE)?
Objectives	To investigate if there is any risk associated with VTE for women when HRT is taken for relieving menopausal symptoms
Language	English full text papers
Study design	<ul style="list-style-type: none"> <li>• Systematic reviews of RCTs</li> <li>• Randomised controlled trials,</li> <li>• Comparative cohort studies</li> </ul>
Population	All women on menopause aged 65 years or less
Stratified/subgroup analyses	Subgroup analysis will be conducted if data available: <ul style="list-style-type: none"> <li>• Post-menopausal and perimenopausal women</li> <li>• at different age ranges (under 50, 50-60, 60+)</li> </ul>
Intervention or index test	Hormonal Replacement Treatment <ul style="list-style-type: none"> <li>• by type</li> <li>• by duration</li> <li>• by timing</li> </ul>
Comparator or reference standard	<ul style="list-style-type: none"> <li>• Placebo treatment</li> <li>• No HRT</li> <li>• Different durations of the same HRT (same HRT used in intervention arm)</li> <li>• Different timing since stopping HRT (same HRT used in intervention arm)</li> </ul>
Clinical outcomes	<ul style="list-style-type: none"> <li>• VTE</li> <li>• Mortality (overall or included condition specific mortality)</li> </ul>
Other criteria for inclusion/exclusion of studies	Pre-menopause women
Search strategies	See separate document
Review strategies	Appraisal of methodological quality The methodological quality of each study will be assessed using NICE checklists along with the quality of the evidence will be assessed by GRADE for each outcome. Synthesis of data Meta-analysis will be conducted where appropriate. Default MIDAs will be used: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes. Record any considerations for continuous data for example if final and change scores will be pooled and if any study reports both, the method used in the majority of studies will be analysed. If studies only report p-values, this information will be plotted in GRADE tables without an assessment of imprecision possible to be made
Equality	Equalities issues will be assessed according to processes described in NICE guidelines manual (November 2012)

## D.7.2 Cardiovascular disease (CVD)

Review question for update	What are the effects of HRT administered for menopausal symptoms on the risk of development of cardiovascular disease (including stroke)?
Objectives	To investigate if there is any risk of developing cardiovascular disease in women who received HRT for relief of menopausal symptoms.
Language	English full text papers
Study design	<ul style="list-style-type: none"> <li>• Systematic reviews of RCTs</li> <li>• Randomised controlled trials,</li> <li>• Comparative cohort studies</li> </ul>
Population	All women on menopause aged 65 years or less
Stratified/subgroup analyses	Subgroup analysis will be conducted if data available: <ul style="list-style-type: none"> <li>• Post-menopausal and perimenopausal women</li> <li>• at different age ranges (under 50, 50-60, 60+)</li> </ul>
Intervention or index test	Hormonal Replacement Treatment <ul style="list-style-type: none"> <li>• by type</li> <li>• by duration</li> <li>• by timing</li> </ul>
Comparator or reference standard	<ul style="list-style-type: none"> <li>• Placebo treatment</li> <li>• No HRT</li> <li>• Different durations of the same HRT (same HRT used in intervention arm)</li> <li>• Different timing since stopping HRT (same HRT used in intervention arm)</li> </ul>
Clinical outcomes	<ul style="list-style-type: none"> <li>• Change in blood pressure</li> <li>• Stroke</li> <li>• Myocardial infarction</li> <li>• Cardiac event composite scores</li> <li>• Mortality – cardio related</li> </ul>
Other criteria for inclusion/exclusion of studies	Pre-menopause woman
Review strategies	Appraisal of methodological quality The methodological quality of each study will be assessed using NICE checklists along with the quality of the evidence will be assessed by GRADE for each outcome. Synthesis of data Meta-analysis will be conducted where appropriate. Default MIDAs will be used: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes. Record any considerations for continuous data for example if final and change scores will be pooled and if any study reports both, the method used in the majority of studies will be analysed. If studies only report p-values, this information will be plotted in GRADE tables without an assessment of imprecision possible to be made
Equality	Equalities issues will be assessed according to processes described in NICE guidelines manual (November 2012)

### D.7.3 Development of Type 2 diabetes

<b>Review question for update</b>	<b>What are the effects of HRT administered for menopausal symptoms on the risk of developing type 2 diabetes?</b>
Objectives	What is the risk of developing Type 2 diabetes for women who received HRT for menopausal symptoms?
Language	English full text papers
Study design	Systematic reviews of randomised controlled trials (RCTs) RCTs Comparative cohort studies
Population	All women on menopause aged 65 years or less
Stratified/subgroup analyses	Subgroup analysis will be conducted if data available: <ul style="list-style-type: none"> <li>• Post-menopausal and perimenopausal women</li> <li>• at different age ranges (under 50, 50-60, 60+)</li> </ul>
Intervention or index test	Hormonal Replacement Treatment <ul style="list-style-type: none"> <li>• by type</li> <li>• by duration</li> <li>• by timing</li> </ul>
Comparator or reference standard	<ul style="list-style-type: none"> <li>• Placebo treatment</li> <li>• No HRT</li> <li>• Different durations of the same HRT (same HRT used in intervention arm)</li> <li>• Different timing since stopping HRT (same HRT used in intervention arm)</li> </ul>
Clinical outcomes	<ul style="list-style-type: none"> <li>• Type 2 diabetes</li> <li>• Mortality (overall or included condition specific mortality)</li> </ul>
Other criteria for inclusion/exclusion of studies	Pre-menopause women
Search strategies	See separate document
Review strategies	<p>Appraisal of methodological quality</p> <p>The methodological quality of each study will be assessed using NICE checklists along with the quality of the evidence will be assessed by GRADE for each outcome.</p> <p>Synthesis of data</p> <p>Meta-analysis will be conducted where appropriate.</p> <p>Default MIDs will be used: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes.</p> <p>Record any considerations for continuous data for example if final and change scores will be pooled and if any study reports both, the method used in the majority of studies will be analysed.</p> <p>If studies only report p-values, this information will be plotted in GRADE tables without an assessment of imprecision possible to be made</p>
Equality	Equalities issues with be assessed according to processes described in NICE guidelines manual (November 2012)

### D.7.4 Management of Type 2 diabetes - control of blood sugar

<b>Review question for update</b>	<b>What impact does use of HRT for menopausal symptoms have on control of diabetes/glycaemic levels in those with type 2 diabetes?</b>
Objectives	What is the impact of HRT treatment glucose control in menopausal women with type 2 diabetes:

Review question for update	What impact does use of HRT for menopausal symptoms have on control of diabetes/glycaemic levels in those with type 2 diabetes?
Language	English full text papers
Study design	<ul style="list-style-type: none"> <li>• Systematic reviews of randomised controlled trials (RCTs),</li> <li>• RCTs and</li> <li>• comparative cohort studies</li> </ul>
Status	Published full text articles (no limitation on year of publication)
Population	All perimenopausal and post-menopausal women aged 65 years or less
Stratified and subgroup analysis	Subgroup analysis will be conducted in the presence of heterogeneity for the following factors: <ul style="list-style-type: none"> <li>• Different stages of menopause (post-menopausal and perimenopausal women)</li> <li>• at different age ranges (under 50, 50-60, 60+)</li> </ul>
Intervention	Different type of HRT Subgroup analysis will be performed based on two factors if data available: Duration of HRT use Time since stopping HRT If comparative cohort studies will be including, the following factors are considered important confounders: <ul style="list-style-type: none"> <li>• Age</li> <li>• Ethnicity</li> <li>• Diabetes awareness</li> </ul>
Comparator	<ul style="list-style-type: none"> <li>• Placebo</li> <li>• No HRT</li> </ul>
Clinical outcomes	<ul style="list-style-type: none"> <li>• HbA1c</li> <li>• Hyperglycaemic episodes (self-monitoring, finger prick tests)</li> <li>• Health related quality of life</li> <li>• Mortality (overall or included condition specific mortality)</li> <li>• Adverse effects (complications resulting from diabetes)</li> </ul>
Importance of outcomes/critical outcomes	HbA1c Hyperglycaemic episodes (self-monitoring, finger prick tests) Mortality (overall or included condition specific mortality)
Other criteria for inclusion/exclusion of studies	Pre-menopause women
Review strategies	Appraisal of methodological quality The methodological quality of each study will be assessed using NICE checklists along with the quality of the evidence will be assessed by GRADE for each outcome. Synthesis of data Meta-analysis will be conducted where appropriate. Default MIDs will be used: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes. Record any considerations for continuous data for example if final and change scores will be pooled and if any study reports both, the method used in the majority of studies will be analysed. If studies only report p-values, this information will be plotted in GRADE tables without an assessment of imprecision possible to be made.



Review question for update	What impact does use of HRT for menopausal symptoms have on control of diabetes/glycaemic levels in those with type 2 diabetes?
Equality	Equalities issues with be assessed according to processes described in NICE guidelines manual (November 2012)

### D.7.5 Breast cancer

Review question for update	What are the effects of HRT administered for menopausal symptoms on risk of developing breast cancer?
Objectives	To investigate what is the risk of developing breast cancer for women who had received HRT for menopausal symptoms.
Language	English
Study design	Randomised controlled trials Comparative cohort studies
Status	Published articles (no limitation on year of publication)
Population	All women on menopause aged 65 years or less
Stratified/subgroup analyses	Subgroup analysis will be conducted if data available: <ul style="list-style-type: none"> <li>• Post-menopausal and perimenopausal women</li> <li>• at different age ranges (under 50, 50-60, 60+)</li> </ul>
Intervention or index test	Hormonal Replacement Treatment (HRT) <ul style="list-style-type: none"> <li>• by type (for example oestrogen alone versus oestrogen plus progesterone or by route of administration ((oral vs transdermal)</li> <li>• by duration</li> <li>• by timing</li> </ul>
Comparator or reference standard	<ul style="list-style-type: none"> <li>• Placebo treatment</li> <li>• No HRT</li> <li>• Different durations of the same HRT (same HRT used in intervention arm)</li> <li>• Different timing since stopping HRT (same HRT used in intervention arm)</li> </ul>
Clinical outcomes	<ul style="list-style-type: none"> <li>• Breast cancer</li> <li>• Mortality from breast cancer</li> </ul>
Other criteria for inclusion/exclusion of studies	Pre-menopause women
Review strategies	<p>Appraisal of methodological quality</p> <p>The methodological quality of each study will be assessed using NICE checklists along with the quality of the evidence will be assessed by GRADE for each outcome.</p> <p>Synthesis of data</p> <p>Meta-analysis will be conducted where appropriate.</p> <p>Default MIDs will be used: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes.</p> <p>Record any considerations for continuous data for example if final and change scores will be pooled and if any study reports both, the method used in the majority of studies will be analysed.</p> <p>If studies only report p-values, this information will be plotted in GRADE tables without an assessment of imprecision possible to be made.</p>
Equality	Equalities issues with be assessed according to processes described in NICE guidelines manual (November 2012)

## D.7.6 Osteoporosis

Review question for update	What are the effects of HRT administered for menopausal symptoms on the risk of development of osteoporosis?
Objectives	To investigate what is the risk of development of osteoporosis for women who have received HRT for relief of menopausal related symptoms over variable lengths of time.
Language	English full text papers
Study design	Systematic reviews of RCTs RCTs Comparative cohort studies
Population	All women on menopause aged 65 years or less
Stratified/subgroup analyses	Subgroup analysis will be conducted if data available: <ul style="list-style-type: none"> <li>• Post-menopausal and perimenopausal women</li> <li>• at different age ranges (under 50, 50-60, 60+)</li> </ul>
Intervention or index test	Hormonal Replacement Treatment <ul style="list-style-type: none"> <li>• by type</li> <li>• by duration</li> <li>• by timing</li> </ul>
Comparator or reference standard	<ul style="list-style-type: none"> <li>• Placebo treatment</li> <li>• No HRT</li> <li>• Different durations of the same HRT (same HRT used in intervention arm)</li> <li>• Different timing since stopping HRT (same HRT used in intervention arm)</li> </ul>
Clinical outcomes	Types of fracture: <ul style="list-style-type: none"> <li>• Vertebral</li> <li>• Neck of femur (hip)</li> <li>• Wrist</li> <li>• Any fracture</li> <li>• Non-vertebral fracture</li> <li>• Mortality (fracture related)</li> </ul>
Other criteria for inclusion/exclusion of studies	None
Review strategies	<p>Appraisal of methodological quality</p> <p>The methodological quality of each study will be assessed using NICE checklists along with the quality of the evidence will be assessed by GRADE for each outcome.</p> <p>Synthesis of data</p> <p>Meta-analysis will be conducted where appropriate.</p> <p>Default MIDs will be used: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes.</p> <p>Record any considerations for continuous data for example if final and change scores will be pooled and if any study reports both, the method used in the majority of studies will be analysed.</p> <p>If studies only report p-values, this information will be plotted in GRADE tables without an assessment of imprecision possible to be made</p>
Equality	Equalities issues will be assessed according to processes described in NICE guidelines manual (November 2012)

### D.7.7 Dementia

Review question for update	What are the effects of HRT administered for menopausal symptoms on the risk of dementia?
Objectives	To identify what is the risk of developing dementia for women who received HRT for menopausal symptoms
Language	English full text papers
Study design	<ul style="list-style-type: none"> <li>• Systematic reviews of Randomised controlled trials (RCTs)</li> <li>• RCTs,</li> <li>• Comparative cohort studies</li> </ul>
Population	All menopausal women aged 65 years or less
Stratified/subgroup analyses	Subgroup analysis will be conducted if data available: <ul style="list-style-type: none"> <li>• Post-menopausal and perimenopausal women</li> <li>• at different age ranges (under 50, 50-60, 60+)</li> </ul>
Intervention or index test	Hormonal Replacement Treatment <ul style="list-style-type: none"> <li>• by type</li> <li>• by duration</li> <li>• by timing</li> </ul>
Comparator	<ul style="list-style-type: none"> <li>• Placebo treatment</li> <li>• No HRT</li> <li>• Different durations of the same HRT (same HRT used in intervention arm)</li> <li>• Different timing since stopping HRT (same HRT used in intervention arm)</li> </ul>
Clinical outcomes	<ul style="list-style-type: none"> <li>• Dementia</li> <li>• Mortality (overall or included condition specific mortality)</li> </ul>
Other criteria for inclusion/exclusion of studies	Pre-menopause women
Review strategies	<p>Appraisal of methodological quality</p> <p>The methodological quality of each study will be assessed using NICE checklists along with the quality of the evidence will be assessed by GRADE for each outcome.</p> <p>Synthesis of data</p> <p>Meta-analysis will be conducted where appropriate.</p> <p>Default MIDs will be used: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes.</p> <p>Record any considerations for continuous data for example if final and change scores will be pooled and if any study reports both, the method used in the majority of studies will be analysed.</p> <p>If studies only report p-values, this information will be plotted in GRADE tables without an assessment of imprecision possible to be made.</p>
Equality	Equalities issues with be assessed according to processes described in NICE guidelines manual (November 2012)

### D.7.8 Loss of muscle mass (sarcopenia)

Review question for update	What are the effects of HRT administered for menopausal symptoms on the risk of sarcopenia?
Objectives	To investigate what is the risk of developing sarcopenia for women who received HRT for menopausal symptoms
Language	English
Study design	Systematic reviews of randomised controlled trials (RCTs), RCTs,

Review question for update	What are the effects of HRT administered for menopausal symptoms on the risk of sarcopenia?
	Comparative cohort studies
Status	Published articles (no limitation on year of publication)
Population	All menopausal women aged 65 years or less Subgroup analysis will be conducted if data available: <ul style="list-style-type: none"> <li>• Post-menopausal and perimenopausal women at different age ranges (under 50, 50-60, 60+)</li> </ul>
Intervention or index test	Hormonal Replacement Treatment <ul style="list-style-type: none"> <li>• by type</li> <li>• by duration</li> </ul> by timing
Comparator	<ul style="list-style-type: none"> <li>• Placebo treatment</li> <li>• No HRT</li> <li>• Different durations of the same HRT (same HRT used in intervention arm)</li> </ul> Different timing since stopping HRT (same HRT used in intervention arm)
Clinical outcomes	Sarcopenia
Other criteria for inclusion/exclusion of studies	Pre-menopause women
Review strategies	Appraisal of methodological quality The methodological quality of each study will be assessed using NICE checklists along with the quality of the evidence will be assessed by GRADE for each outcome. Synthesis of data Meta-analysis will be conducted where appropriate. Default MIDs will be used: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes. Record any considerations for continuous data for example if final and change scores will be pooled and if any study reports both, the method used in the majority of studies will be analysed. If studies only report p-values, this information will be plotted in GRADE tables without an assessment of imprecision possible to be made.
Equality	Equalities issues with be assessed according to processes described in NICE guidelines manual (November 2012)

## D.8 Premature ovarian insufficiency (POI)

### D.8.1 Diagnosis of premature ovarian insufficiency

<b>Question</b>	<p><b>What is the diagnostic accuracy of the following indicators (clinical and biological manifestations) in the diagnosis of POI:</b></p> <ul style="list-style-type: none"> <li>• Menstrual irregularity</li> <li>• age</li> <li>• menopausal symptoms (especially vasomotor symptoms)</li> <li>• endocrine changes (specifically follicle-stimulating hormone, anti-Müllerian hormone, oestrogen or inhibin B)</li> <li>• ovarian ultrasound evaluation</li> </ul>
Objectives	To determine the diagnostic accuracy of specific clinical indicators in diagnosing POI
Language	English full text papers
Study design	<ul style="list-style-type: none"> <li>• Diagnostic accuracy studies</li> <li>• Cohort studies – prospective/retrospective</li> </ul>
Population	<p>Women suspected to be POI</p> <p>Subgroup analysis if data available:</p> <ul style="list-style-type: none"> <li>• women with a history of chemotherapy,</li> <li>• women with certain autoimmune diseases,</li> <li>• a family history of POI, and</li> <li>• women with chromosomal abnormalities such as Turner Syndrome</li> </ul>
Stratified and subgroup analysis	Stratified analysis will be performed based on the background population of women, for example if women who are suspected to undergoing menopause will be diagnosed from perimenopausal or from postmenopausal or from all women with menopause (pre or postmenopausal)
Clinical indicators (index tests)	<ul style="list-style-type: none"> <li>• Menstrual irregularity</li> <li>• Age</li> <li>• menopausal vasomotor symptoms</li> <li>• endocrine features (in blood or urine)</li> <li>• follicle-stimulating hormone (FSH)</li> <li>• anti-Müllerian hormone</li> <li>• oestrogen levels</li> <li>• inhibin A and B</li> <li>• ovarian ultrasound evaluation (including ovarian volume and total antral follicle count)</li> </ul> <p>Note: Any of these features in isolation or in combination will be considered as diagnostic tools of menopause</p> <p>Different levels of the above clinical indicators as reported by the authors will be used as diagnostic tools.</p>
Target condition/reference standard	Amenorrhoea
Outcomes	<ul style="list-style-type: none"> <li>• Sensitivity / specificity</li> <li>• Likelihood ratio (positive and negative)</li> <li>• Area under the curve (AUC)</li> </ul> <p>Likelihood ratios and sensitivity/specificity will be prioritised.</p> <p>Guideline Development Group noted that there are associated risks (particularly psychological) to the individual of both false positive and false negative tests.</p>
Other criteria for inclusion/	The focus of this review is to investigate the role of clinical features as diagnostic tools of POI

<b>Question</b>	<p><b>What is the diagnostic accuracy of the following indicators (clinical and biological manifestations) in the diagnosis of POI:</b></p> <ul style="list-style-type: none"> <li>• Menstrual irregularity</li> <li>• age</li> <li>• menopausal symptoms (especially vasomotor symptoms)</li> <li>• endocrine changes (specifically follicle-stimulating hormone, anti-Müllerian hormone, oestrogen or inhibin B)</li> <li>• ovarian ultrasound evaluation</li> </ul>
exclusion of studies	The Guideline Development Group did not consider including prognostic studies looking at the role of these clinical features to predict the POI at a certain later time in women's life.
Review strategies	<p>Appraisal of methodological quality:</p> <ul style="list-style-type: none"> <li>• The Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS-2) checklists will be used.</li> </ul> <p>Synthesis of data:</p> <ul style="list-style-type: none"> <li>• Meta-analysis will be conducted where appropriate.</li> </ul>
Equality	Equalities issues will be assessed according to processes described in NICE guidelines manual (2012)

## D.8.2 Management of premature ovarian insufficiency

<b>Question</b>	<p><b>What is the clinical effectiveness of HRT compared with combined oral contraceptives for the management of premature ovarian insufficiency (POI)?</b></p>
Objectives	To compare the clinical effectiveness of combined oral contraceptives with hormone replacement therapy (HRT) for women with premature ovarian insufficiency (POI)?
Language	English full text papers
Study design	<ul style="list-style-type: none"> <li>• Systematic reviews of RCTs</li> <li>• RCTs</li> <li>• Comparative cohort studies</li> </ul>
Population	<ul style="list-style-type: none"> <li>• Women (&lt; 40 years of age) with POI for any reason.</li> <li>• Women with Turner syndrome (TS) will be included as 90% of TS women have primary amenorrhoea. The Guideline Development Group considered TS as the commonest congenital/genetic condition causing POI.</li> </ul> <p>Note: Premature ovarian insufficiency (also known as premature ovarian failure or premature menopause) is usually defined as menopause occurring before the age of 40 years with a minimum of 6 months of amenorrhoea and raised gonadotrophins (FSH) levels</p>
Intervention	Combined oral contraceptive
Comparator	Hormone replacement therapy (HRT)
Outcomes	<ul style="list-style-type: none"> <li>• Health related quality-of-life</li> <li>• Bone density</li> <li>• Cardio/metabolic risk markers (Insulin resistance/lipids)</li> <li>• Changes in menopausal symptom (including vasomotor and sexual function) scores derived from a combination of menopausal symptoms</li> <li>• Adverse effects (such as DVT, VTE and pulmonary embolism/ Breast tenderness)</li> <li>• Discontinuation rate for any reason</li> </ul>
Other criteria for inclusion/exclusion of studies	Other congenital conditions other than Turner Syndrome.

<b>Question</b>	<b>What is the clinical effectiveness of HRT compared with combined oral contraceptives for the management of premature ovarian insufficiency (POI)?</b>
Review strategies	<p>Appraisal of methodological quality</p> <p>The methodological quality of each study will be assessed using NICE checklists along with the quality of the evidence will be assessed by GRADE for each outcome.</p> <p>Synthesis of data</p> <p>Meta-analysis will be conducted where appropriate.</p> <p>Default MIDs will be used: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes.</p> <p>Record any considerations for continuous data for example if final and change scores will be pooled and if any study reports both, the method used in the majority of studies will be analysed.</p> <p>If studies only report p-values, this information will be plotted in GRADE tables without an assessment of imprecision possible to be made</p>
Equality	Equalities issues with be assessed according to processes described in NICE guidelines manual (2012)

## Appendix E: Search strategies

### E.1 Diagnosis of perimenopause and postmenopause / classification systems for the diagnosis of menopause

#### Database: Medline

#	SEARCH
1	Exp *MENOPAUSE
2	*CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteri\$).ti,ab.
4	"change of life".ti,ab.
5	reproductive ag?ing.ti,ab.
6	*PRIMARY OVARIAN INSUFFICIENCY/
7	((primary or prematur\$ or hypergonadotrop\$) adj1 ovar\$ adj1 (insuffic\$ or fail\$ or incompet\$)).ti,ab.
8	((gonadotrop\$ or resist\$) adj1 ovar\$ adj1 syndrom\$).ti,ab.
9	(POI or POF).ti,ab.
10	or/1-9
11	TERMINOLOGY AS TOPIC/
12	ALGORITHMS/
13	CLASSIFICATION/
14	or/11-13
15	and/10,14
16	exp *MENOPAUSE/ or *CLIMACTERIC/ or *PRIMARY OVARIAN INSUFFICIENCY/
17	SEVERITY OF ILLNESS INDEX/
18	cl.fs.
19	or/17-18
20	and/16,19
21	"Stages of Reproductive Aging Workshop".ti,ab.
22	"Women's Ischemia Syndrome Evaluation".ti,ab.
23	ReSTAGE.ti,ab.
24	"Study of Women's Health Across the Nation".ti,ab.
25	(TREMIM or "Menstrual and Reproductive Health Program" or "MRH Program").ti,ab.
26	"Melbourne Women's Midlife Health Project".ti,ab.
27	"Seattle Midlife Women's Health Study".ti,ab.
28	or/21-27
29	and/16,28
30	((stage? or staging or criteri\$ or classif\$ or algorithm? or taxonom\$ or scale?) adj3 (menopaus\$ or reproductive ag?ing or climacteri\$)).ti,ab.
31	or/15,20,29-30
32	exp "SENSITIVITY AND SPECIFICITY"/
33	(sensitivity or specificity).ti,ab.
34	((pre test or pretest or post test or posttest) adj probability).ti,ab.
35	(predictive value\$ or PPV or NPV).ti,ab.
36	likelihood ratio\$.ti,ab.
37	LIKELIHOOD FUNCTIONS/
38	(ROC curve\$ or AUC).ti,ab.
39	(diagnos* adj2 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.
40	gold standard.ab.
41	or/32-40
42	exp MENSTRUATION DISTURBANCES/
43	((irregular\$ or regular\$ or nonregular\$) adj3 (menstrua\$ or period? or cycle?)).ti,ab.
44	oligomenorr?ea\$.ti,ab.
45	HOT FLASHES/
46	hot fl#sh\$.ti,ab.
47	SWEATING/
48	sweat\$.ti,ab.
49	(vasomotor symptom? or VMS).ti,ab.
50	exp FOLLICLE STIMULATING HORMONE/
51	(follitropin? or follicle stimulating hormone? or FSH).ti,ab.
52	ANTI-MULLERIAN HORMONE/
53	(mu?llerian adj3 (inhibit\$ or regress\$)).ti,ab.
54	((antimu?llerian or anti mu?llerian) adj3 (hormone? or factor?)).ti,ab.
55	exp ESTROGENS/
56	(estrogen\$ or oestrogen\$).ti,ab.
57	exp INHIBINS/



#	SEARCH
58	inhibin b.mp.
59	OVARIAN FOLLICLE/
60	(antral follicle adj3 (count\$ or number\$)).ti,ab.
61	or/42-60
62	and/10,41,61
63	*MENOPAUSE/di or *PRIMARY OVARIAN INSUFFICIENCY/di [Diagnosis]
64	or/62-63
65	or/31,64
66	limit 65 to english language
67	LETTER/
68	EDITORIAL/
69	NEWS/
70	exp HISTORICAL ARTICLE/
71	ANECDOTES AS TOPIC/
72	COMMENT/
73	CASE REPORT/
74	(letter or comment* or abstracts).ti.
75	or/67-74
76	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
77	75 not 76
78	ANIMALS/ not HUMANS/
79	exp ANIMALS, LABORATORY/
80	exp ANIMAL EXPERIMENTATION/
81	exp MODELS, ANIMAL/
82	exp RODENTIA/
83	(rat or rats or mouse or mice).ti.
84	or/77-83
85	66 not 84

### Database: Medline-in-process

#	Searches
1	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteri\$).ti,ab.
2	"change of life".ti,ab.
3	reproductive ag?ing.ti,ab.
4	((primary or prematur\$ or hypergonadotrop\$) adj1 ovar\$ adj1 (insuffic\$ or fail\$ or incompet\$)).ti,ab.
5	((gonadotrop\$ or resist\$) adj1 ovar\$ adj1 syndrom\$).ti,ab.
6	(POI or POF).ti,ab.
7	or/1-6
8	"Stages of Reproductive Aging Workshop".ti,ab.
9	"Women's Ischemia Syndrome Evaluation".ti,ab.
10	ReSTAGE.ti,ab.
11	"Study of Women's Health Across the Nation".ti,ab.
12	(TREM or "Menstrual and Reproductive Health Program" or "MRH Program").ti,ab.
13	"Melbourne Women's Midlife Health Project".ti,ab.
14	"Seattle Midlife Women's Health Study".ti,ab.
15	or/8-14
16	and/7,15
17	((stage? or staging or criteri\$ or classif\$ or algorithm? or taxonom\$ or scale?) adj3 (menopaus\$ or reproductive ag?ing or climacteri\$)).ti,ab.
18	or/16-17
19	(sensitivity or specificity).ti,ab.
20	((pre test or pretest or post test or posttest) adj probability).ti,ab.
21	(predictive value\$ or PPV or NPV).ti,ab.
22	likelihood ratio\$.ti,ab.
23	(ROC curve\$ or AUC).ti,ab.
24	(diagnos* adj2 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.
25	gold standard.ab.
26	or/19-25
27	((irregular\$ or regular\$ or nonregular\$) adj3 (menstrua\$ or period? or cycle?)).ti,ab.
28	oligomenorr?ea\$.ti,ab.
29	hot fl#sh\$.ti,ab.
30	sweat\$.ti,ab.
31	(vasomotor symptom? or VMS).ti,ab.
32	(follitropin? or follicle stimulating hormone? or FSH).ti,ab.
33	(mu?lterian adj3 (inhibit\$ or regress\$)).ti,ab.
34	((antimu?lterian or anti mu?lterian) adj3 (hormone? or factor?)).ti,ab.
35	(estrogen\$ or oestrogen\$).ti,ab.
36	inhibin b.ti,ab.
37	(antral follicle adj3 (count\$ or number\$)).ti,ab.

#	Searches
38	or/27-37
39	and/7,26,38
40	or/18,39

### Database: Cochrane Central Register of Controlled Trials

#	Searches
1	exp *MENOPAUSE/
2	*CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteri\$).ti,ab.
4	"change of life".ti,ab.
5	reproductive ag?ing.ti,ab.
6	*PRIMARY OVARIAN INSUFFICIENCY/
7	((primary or prematur\$ or hypergonadotrop\$) adj1 ovar\$ adj1 (insuffic\$ or fail\$ or incompet\$)).ti,ab.
8	((gonadotrop\$ or resist\$) adj1 ovar\$ adj1 syndrom\$).ti,ab.
9	(POI or POF).ti,ab.
10	or/1-9
11	TERMINOLOGY AS TOPIC/
12	ALGORITHMS/
13	CLASSIFICATION/
14	or/11-13
15	and/10,14
16	exp *MENOPAUSE/ or *CLIMACTERIC/ or *PRIMARY OVARIAN INSUFFICIENCY/
17	SEVERITY OF ILLNESS INDEX/
18	cl.fs.
19	or/17-18
20	and/16,19
21	"Stages of Reproductive Aging Workshop".ti,ab.
22	"Women's Ischemia Syndrome Evaluation".ti,ab.
23	ReSTAGE.ti,ab.
24	"Study of Women's Health Across the Nation".ti,ab.
25	(TREM or "Menstrual and Reproductive Health Program" or "MRH Program").ti,ab.
26	"Melbourne Women's Midlife Health Project".ti,ab.
27	"Seattle Midlife Women's Health Study".ti,ab.
28	or/21-27
29	and/16,28
30	((stage? or staging or criteri\$ or classif\$ or algorithm? or taxonom\$ or scale?) adj3 (menopaus\$ or reproductive ag?ing or climacteri\$)).ti,ab.
31	or/15,20,29-30
32	exp "SENSITIVITY AND SPECIFICITY"/
33	(sensitivity or specificity).ti,ab.
34	((pre test or pretest or post test or posttest) adj probability).ti,ab.
35	(predictive value\$ or PPV or NPV).ti,ab.
36	likelihood ratio\$.ti,ab.
37	LIKELIHOOD FUNCTIONS/
38	(ROC curve\$ or AUC).ti,ab.
39	(diagnos* adj2 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.
40	gold standard.ab.
41	or/32-40
42	exp MENSTRUATION DISTURBANCES/
43	((irregular\$ or regular\$ or nonregular\$) adj3 (menstrua\$ or period? or cycle?)).ti,ab.
44	oligomenorr?ea\$.ti,ab.
45	HOT FLASHES/
46	hot fl#sh\$.ti,ab.
47	SWEATING/
48	sweat\$.ti,ab.
49	(vasomotor symptom? or VMS).ti,ab.
50	exp FOLLICLE STIMULATING HORMONE/
51	(follitropin? or follicle stimulating hormone? or FSH).ti,ab.
52	ANTI-MULLERIAN HORMONE/
53	(mu?llerian adj3 (inhibit\$ or regress\$)).ti,ab.
54	((antimu?llerian or anti mu?llerian) adj3 (hormone? or factor?)).ti,ab.
55	exp ESTROGENS/
56	(estrogen\$ or oestrogen\$).ti,ab.
57	exp INHIBINS/
58	inhibin b.mp.
59	OVARIAN FOLLICLE/
60	(antral follicle adj3 (count\$ or number\$)).ti,ab.
61	or/42-60
62	and/10,41,61

#	Searches
63	*MENOPAUSE/di or *PRIMARY OVARIAN INSUFFICIENCY/di [Diagnosis]
64	or/62-63
65	or/31,64

### Database: Cochrane Database of Systematic Reviews and Database of Abstracts of Reviews of Effects

#	Searches
1	MENOPAUSE.kw.
2	CLIMACTERIC.kw.
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteri\$).tw,tx.
4	"change of life".tw,tx.
5	reproductive ag?ing.tw,tx.
6	PRIMARY OVARIAN INSUFFICIENCY.kw.
7	((primary or prematur\$ or hypergonadotrop\$) adj1 ovar\$ adj1 (insuffic\$ or fail\$ or incompet\$)).tw,tx.
8	((gonadotrop\$ or resist\$) adj1 ovar\$ adj1 syndrom\$).tw,tx.
9	(POI or POF).tw,tx.
10	or/1-9
11	TERMINOLOGY AS TOPIC.kw.
12	ALGORITHMS.kw.
13	CLASSIFICATION.kw.
14	or/11-13
15	and/10,14
16	(MENOPAUSE or CLIMACTERIC or PRIMARY OVARIAN INSUFFICIENCY).kw.
17	SEVERITY OF ILLNESS INDEX.kw.
18	and/16-17
19	"Stages of Reproductive Aging Workshop".tw,tx.
20	"Women's Ischemia Syndrome Evaluation".tw,tx.
21	ReSTAGE.tw,tx.
22	"Study of Women's Health Across the Nation".tw,tx.
23	(TREM or "Menstrual and Reproductive Health Program" or "MRH Program").tw,tx.
24	"Melbourne Women's Midlife Health Project".tw,tx.
25	"Seattle Midlife Women's Health Study".tw,tx.
26	or/19-25
27	and/16,26
28	((stage? or staging or criteri\$ or classif\$ or algorithm? or taxonom\$ or scale?) adj3 (menopaus\$ or reproductive ag?ing or climacteri\$)).tw,tx.
29	or/15,18,27-28
30	"SENSITIVITY AND SPECIFICITY".kw.
31	(sensitivity or specificity).tw,tx.
32	((pre test or pretest or post test or posttest) adj probability).tw,tx.
33	(predictive value\$ or PPV or NPV).tw,tx.
34	likelihood ratio\$.tw,tx.
35	LIKELIHOOD FUNCTIONS.kw.
36	(ROC curve\$ or AUC).tw,tx.
37	(diagnos\$ adj2 (performance\$ or accuracy\$ or utilit\$ or value or efficien\$ or effectiveness)).tw,tx.
38	gold standard.ab.
39	or/30-38
40	MENSTRUATION DISTURBANCES.kw.
41	((irregular\$ or regular\$ or nonregular\$) adj3 (menstrua\$ or period? or cycle?)).tw,tx.
42	oligomenorr?ea\$.tw,tx.
43	HOT FLASHES.kw.
44	hot fl#sh\$.tw,tx.
45	SWEATING.kw.
46	sweat\$.tw,tx.
47	(vasomotor symptom? or VMS).tw,tx.
48	FOLLICLE STIMULATING HORMONE.kw.
49	(follitropin? or follicle stimulating hormone? or FSH).tw,tx.
50	ANTI-MULLERIAN HORMONE.kw.
51	(mu?llerian adj3 (inhibit\$ or regress\$)).tw,tx.
52	((antimu?llerian or anti mu?llerian) adj3 (hormone? or factor?)).tw,tx.
53	ESTROGENS.kw.
54	(estrogen\$ or oestrogen\$).tw,tx.
55	INHIBINS.kw.
56	inhibin b.tw,tx.
57	OVARIAN FOLLICLE.kw.
58	(antral follicle adj3 (count\$ or number\$)).tw,tx.
59	or/40-58
60	and/10,39,59
61	or/29,60

## Database: Heath Technology Assessment

#	Searches
1	exp *MENOPAUSE/
2	*CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteri\$).tw.
4	"change of life".tw.
5	reproductive ag?ing.tw.
6	*PRIMARY OVARIAN INSUFFICIENCY/
7	((primary or prematur\$ or hypergonadotrop\$) adj1 ovar\$ adj1 (insuffic\$ or fail\$ or incompet\$)).tw.
8	((gonadotrop\$ or resist\$) adj1 ovar\$ adj1 syndrom\$).tw.
9	(POI or POF).tw.
10	or/1-9
11	TERMINOLOGY AS TOPIC/
12	ALGORITHMS/
13	CLASSIFICATION/
14	or/11-13
15	and/10,14
16	exp *MENOPAUSE/ or *CLIMACTERIC/ or *PRIMARY OVARIAN INSUFFICIENCY/
17	SEVERITY OF ILLNESS INDEX/
18	cl.fs.
19	or/17-18
20	and/16,19
21	"Stages of Reproductive Aging Workshop".tw.
22	"Women's Ischemia Syndrome Evaluation".tw.
23	ReSTAGE.tw.
24	"Study of Women's Health Across the Nation".tw.
25	(TREMIM or "Menstrual and Reproductive Health Program" or "MRH Program").tw.
26	"Melbourne Women's Midlife Health Project".tw.
27	"Seattle Midlife Women's Health Study".tw.
28	or/21-27
29	and/16,28
30	((stage? or staging or criteri\$ or classif\$ or algorithm? or taxonom\$ or scale?) adj3 (menopaus\$ or reproductive ag?ing or climacteri\$)).tw.
31	or/15,20,29-30
32	exp "SENSITIVITY AND SPECIFICITY"/
33	(sensitivity or specificity).tw.
34	((pre test or pretest or post test or posttest) adj probability).tw.
35	(predictive value\$ or PPV or NPV).tw.
36	likelihood ratio\$.tw.
37	LIKELIHOOD FUNCTIONS/
38	(ROC curve\$ or AUC).tw.
39	(diagnos* adj2 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).tw.
40	gold standard.tw.
41	or/32-40
42	exp MENSTRUATION DISTURBANCES/
43	((irregular\$ or regular\$ or nonregular\$) adj3 (menstrua\$ or period? or cycle?)).tw.
44	oligomenorr?ea\$.tw.
45	HOT FLASHES/
46	hot fl#sh\$.tw.
47	SWEATING/
48	sweat\$.tw.
49	(vasomotor symptom? or VMS).tw.
50	exp FOLLICLE STIMULATING HORMONE/
51	(follitropin? or follicle stimulating hormone? or FSH).tw.
52	ANTI-MULLERIAN HORMONE/
53	(mu?llerian adj3 (inhibit\$ or regress\$)).tw.
54	((antimu?llerian or anti mu?llerian) adj3 (hormone? or factor?)).tw.
55	exp ESTROGENS/
56	(estrogen\$ or oestrogen\$).tw.
57	exp INHIBINS/
58	inhibin b.tw.
59	OVARIAN FOLLICLE/
60	(antral follicle adj3 (count\$ or number\$)).tw.
61	or/42-60
62	and/10,41,61
63	*MENOPAUSE/di or *PRIMARY OVARIAN INSUFFICIENCY/di [Diagnosis]
64	or/62-63
65	or/31,64

**Database: Embase**

#	Searches
1	exp **MENOPAUSE AND CLIMACTERIUM*/
2	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteri\$).ti,ab.
3	"change of life".ti,ab.
4	reproductive ag?ing.ti,ab.
5	*PREMATURE OVARIAN FAILURE/
6	((primary or prematur\$ or hypergonadotrop\$) adj1 ovar\$ adj1 (insuffic\$ or fail\$ or incompet\$)).ti,ab.
7	((gonadotrop\$ or resist\$) adj1 ovar\$ adj1 syndrom\$).ti,ab.
8	(POI or POF).ti,ab.
9	or/1-8
10	CLINICAL CLASSIFICATION/
11	STAGING/
12	NOMENCLATURE/
13	CLASSIFICATION ALGORITHM/
14	or/10-13
15	and/9,14
16	exp **MENOPAUSE AND CLIMACTERIUM*/ or *PREMATURE OVARIAN FAILURE/
17	exp DISEASE CLASSIFICATION/
18	and/16-17
19	"Stages of Reproductive Aging Workshop".ti,ab.
20	"Women's Ischemia Syndrome Evaluation".ti,ab.
21	ReSTAGE.ti,ab.
22	"Study of Women's Health Across the Nation".ti,ab.
23	(TREM or "Menstrual and Reproductive Health Program" or "MRH Program").ti,ab.
24	"Seattle Midlife Women's Health Study".ti,ab.
25	or/19-24
26	and/16,25
27	((stage? or staging or criteri\$ or classif\$ or algorithm? or taxonom\$ or scale?) adj3 (menopaus\$ or reproductive ag?ing or climacteri\$)).ti,ab.
28	or/15,18,26-27
29	"SENSITIVITY AND SPECIFICITY"/
30	(sensitivity or specificity).ti,ab.
31	((pre test or pretest or post test or posttest) adj probability).ti,ab.
32	(predictive value\$ or PPV or NPV).ti,ab.
33	likelihood ratio\$.ti,ab.
34	(ROC curve\$ or AUC).ti,ab.
35	(diagnos* adj2 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.
36	gold standard.ab.
37	*DIAGNOSTIC ACCURACY/ or DIAGNOSTIC TEST ACCURACY STUDY/
38	or/29-37
39	exp MENSTRUATION DISORDER/
40	((irregular\$ or regular\$ or nonregular\$) adj3 (menstrua\$ or period? or cycle?)).ti,ab.
41	oligomenorr?ea\$.ti,ab.
42	HOT FLUSH/
43	hot fl#sh\$.ti,ab.
44	exp SWEATING/
45	sweat\$.ti,ab.
46	VASOMOTOR DISORDER/
47	(vasomotor symptom? or VMS).ti,ab.
48	FOLLITROPIN/
49	(follitropin? or follicle stimulating hormone? or FSH).ti,ab.
50	MULLERIAN INHIBITING FACTOR/
51	(mu?llerian adj3 (inhibit\$ or regress\$)).ti,ab.
52	((antimu?llerian or anti mu?llerian) adj3 (hormone? or factor?)).ti,ab.
53	exp ESTROGEN/
54	(estrogen\$ or oestrogen\$).ti,ab.
55	INHIBIN B/
56	inhibin b.ti,ab.
57	OVARY FOLLICLE/ or exp OVARY FOLLICLE CELL/
58	(antral follicle adj3 (count\$ or number\$)).ti,ab.
59	or/39-58
60	and/9,38,59
61	exp **MENOPAUSE AND CLIMACTERIUM*/di or *PREMATURE OVARIAN FAILURE/di [Diagnosis]
62	or/60-61
63	or/28,62
64	limit 63 to english language
65	conference abstract.pt.
66	letter.pt. or LETTER/
67	note.pt.
68	editorial.pt.

#	Searches
69	CASE REPORT/ or CASE STUDY/
70	(letter or comment* or abstracts).ti.
71	or/65-70
72	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
73	71 not 72
74	ANIMAL/ not HUMAN/
75	NONHUMAN/
76	exp ANIMAL EXPERIMENT/
77	exp EXPERIMENTAL ANIMAL/
78	ANIMAL MODEL/
79	exp RODENT/
80	(rat or rats or mouse or mice).ti.
81	or/73-80
82	64 not 81

## E.2 Information and advice

### Database: Medline

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/ or PREMENOPAUSE/
2	PRIMARY OVARIAN INSUFFICIENCY/
3	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF or POI).ti,ab.
4	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
5	CLIMACTERIC/
6	climacteric.ti,ab.
7	(change adj1 life).ti,ab.
8	or/1-7
9	PATIENT EDUCATION AS TOPIC/
10	HEALTH KNOWLEDGE, ATTITUDES, PRACTICE/
11	HEALTH COMMUNICATION/
12	HEALTH EDUCATION/ or CONSUMER HEALTH INFORMATION/ or HEALTH LITERACY/
13	HEALTH PROMOTION/
14	(inform\$ or advice or advising).ti.
15	((menopaus\$ or patient?) adj3 (inform\$ or advice or advising or knowledge)).ab.
16	(information adj5 need?).ti,ab.
17	or/9-16
18	and/8,17
19	LETTER/
20	EDITORIAL/
21	NEWS/
22	exp HISTORICAL ARTICLE/
23	ANECDOTES AS TOPIC/
24	COMMENT/
25	CASE REPORT/
26	(letter or comment* or abstracts).ti.
27	or/19-26
28	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
29	27 not 28
30	ANIMALS/ not HUMANS/
31	exp ANIMALS, LABORATORY/
32	exp ANIMAL EXPERIMENTATION/
33	exp MODELS, ANIMAL/
34	exp RODENTIA/
35	(rat or rats or mouse or mice).ti.
36	or/29-35
37	18 not 36
38	limit 37 to english language

### Database: Medline-in-process

#	Searches
1	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF or POI).ti,ab.
2	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
3	climacteric.ti,ab.
4	(change adj1 life).ti,ab.
5	or/1-4
6	(health adj3 promot\$).ti,ab.

#	Searches
7	(inform\$ or advice or advising).ti.
8	((menopaus\$ or patient?) adj3 (inform\$ or advice or advising or knowledge or educat\$)).ab.
9	(information adj5 need?).ti,ab.
10	or/6-9
11	and/5,10

### Database: Cochrane Central Register of Controlled Trials

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/ or PREMENOPAUSE/
2	PRIMARY OVARIAN INSUFFICIENCY/
3	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF or POI).ti,ab.
4	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
5	CLIMACTERIC/
6	climacteric.ti,ab.
7	(change adj1 life).ti,ab.
8	or/1-7
9	PATIENT EDUCATION AS TOPIC/
10	HEALTH KNOWLEDGE, ATTITUDES, PRACTICE/
11	HEALTH COMMUNICATION/
12	HEALTH EDUCATION/ or CONSUMER HEALTH INFORMATION/ or HEALTH LITERACY/
13	HEALTH PROMOTION/
14	(inform\$ or advice or advising).ti.
15	((menopaus\$ or patient?) adj3 (inform\$ or advice or advising or knowledge)).ab.
16	(information adj5 need?).ti,ab.
17	or/9-16
18	and/8,17

### Database: Cochrane Database of Systematic Reviews and Database of Abstracts of Reviews of Effects

#	Searches
1	(MENOPAUSE or MENOPAUSE, PREMATURE or PERIMENOPAUSE or POSTMENOPAUSE or PREMENOPAUSE).kw.
2	PRIMARY OVARIAN INSUFFICIENCY.kw.
3	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF or POI).tw,tx.
4	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).tw,tx.
5	CLIMACTERIC.kw.
6	climacteric.tw,tx.
7	(change adj1 life).tw,tx.
8	or/1-7
9	PATIENT EDUCATION AS TOPIC.kw.
10	HEALTH KNOWLEDGE, ATTITUDES, PRACTICE.kw.
11	HEALTH COMMUNICATION.kw.
12	(HEALTH EDUCATION or CONSUMER HEALTH INFORMATION or HEALTH LITERACY).kw.
13	HEALTH PROMOTION.kw.
14	(inform\$ or advice or advising).ti.
15	((menopaus\$ or patient?) adj3 (inform\$ or advice or advising or knowledge)).tw,tx.
16	(information adj5 need?).tw,tx.
17	or/9-16
18	and/8,17

### Database: Health Technology Assessment

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/ or PREMENOPAUSE/
2	PRIMARY OVARIAN INSUFFICIENCY/
3	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF or POI).tw.
4	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).tw.
5	CLIMACTERIC/
6	climacteric.tw.
7	(change adj1 life).tw.
8	or/1-7
9	PATIENT EDUCATION AS TOPIC/
10	HEALTH KNOWLEDGE, ATTITUDES, PRACTICE/
11	HEALTH COMMUNICATION/
12	HEALTH EDUCATION/ or CONSUMER HEALTH INFORMATION/ or HEALTH LITERACY/
13	HEALTH PROMOTION/
14	(inform\$ or advice or advising).ti.

#	Searches
15	((menopaus\$ or patient?) adj3 (inform\$ or advice or advising or knowledge)).tw.
16	(information adj5 need?).tw.
17	or/9-16
18	and/8,17

### Database: Embase

#	Searches
1	"MENOPAUSE AND CLIMACTERIUM"/ or CLIMACTERIUM/ or EARLY MENOPAUSE/ or MENOPAUSE/ or POSTMENOPAUSE/
2	PREMENOPAUSE/
3	PREMATURE OVARIAN FAILURE/
4	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF or POI).ti,ab.
5	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
6	climacteric.ti,ab.
7	(change adj1 life).ti,ab.
8	or/1-7
9	PATIENT EDUCATION/
10	PATIENT INFORMATION/
11	MEDICAL INFORMATION/
12	INFORMATION DISSEMINATION/
13	HEALTH PROMOTION/ or HEALTH EDUCATION/
14	MEDICAL DECISION MAKING/
15	PATIENT DECISION MAKING/
16	INFORMATION SERVICE/
17	(inform\$ or advice or advising).ti.
18	((menopaus\$ or patient?) adj3 (educat\$ or inform\$ or advis\$ or advice or knowledge)).ab.
19	(information adj5 need?).ti,ab.
20	or/9-19
21	and/8,20
22	conference abstract.pt.
23	letter.pt. or LETTER/
24	note.pt.
25	editorial.pt.
26	CASE REPORT/ or CASE STUDY/
27	(letter or comment* or abstracts).ti.
28	or/22-27
29	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
30	28 not 29
31	ANIMAL/ not HUMAN/
32	NONHUMAN/
33	exp ANIMAL EXPERIMENT/
34	exp EXPERIMENTAL ANIMAL/
35	ANIMAL MODEL/
36	exp RODENT/
37	(rat or rats or mouse or mice).ti.
38	or/30-37
39	21 not 38
40	limit 39 to english language

### Database: PsychInfo

#	Searches
1	MENOPAUSE/ or LIFE CHANGES/
2	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF or POI).ti,ab.
3	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
4	climacteric.ti,ab.
5	(change adj1 life).ti,ab.
6	or/1-5
7	information needs.id.
8	INFORMATION/
9	exp NEEDS/
10	and/8-9
11	(inform\$ or advice or advising).ti.
12	((menopaus\$ or patient?) adj3 (inform\$ or advice or advising or knowledge or educat\$)).ab.
13	(information adj5 need?).ti,ab.
14	or/7,10-13
15	and/6,14
16	limit 15 to (human or female)
17	limit 16 to ("0100 journal" or "0110 peer-reviewed journal" or "0500 electronic collection")



## E.3 Managing short-term symptoms – clinical evidence

### Database: Medline

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/ or PREMENOPAUSE/
2	PRIMARY OVARIAN INSUFFICIENCY/
3	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF).ti,ab.
4	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
5	CLIMACTERIC/
6	climacteric.ti,ab.
7	or/1-6
8	exp VASOMOTOR SYSTEM/
9	HOT FLASHES/
10	(hot adj (flash\$ or flush\$)).ti,ab.
11	(vasomotor adj symptom?).ti,ab.
12	SWEATING/
13	sweat\$.ti,ab.
14	HYPERHIDROSIS/
15	(sleep adj3 disturb\$).ti,ab.
16	"SLEEP INITIATION AND MAINTENANCE DISORDERS"/
17	insomnia?.ti,ab.
18	FEMALE UROGENITAL DISEASES/ or exp SEXUAL DYSFUNCTION, PHYSIOLOGICAL/ or VAGINISMUS/ or exp VAGINITIS/ or exp VULVAR DISEASES/
19	VAGINAL DISEASES/
20	VAGINA/
21	ATROPHY/
22	and/20-21
23	DEHYDRATION/
24	((vagin\$ or vulva?) adj3 (atroph\$ or dry\$ or irritat\$)).ti,ab.
25	(discomfort or uncomfortable or pain\$ or dyspareunia).ti,ab.
26	SEXUAL DYSFUNCTION, PSYCHOLOGICAL/
27	SEXUAL BEHAVIOR/
28	LIBIDO/
29	libido.ti,ab.
30	DYSPAREUNIA/
31	((altered or chang? or differ\$) adj3 sexual adj3 (behavio?r\$ or function\$)).ti,ab.
32	MOOD DISORDERS/
33	(mood adj3 (disturbance or disorder)).ti,ab.
34	DEPRESSION/
35	ANXIETY/
36	AFFECTIVE SYMPTOMS/
37	STRESS, PSYCHOLOGICAL/
38	IRRITABLE MOOD/
39	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).ti.
40	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).ab. /freq=2
41	or/8-19,22-40
42	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
43	(hormon\$ adj3 substit\$).ti,ab.
44	(HRT or HT).ti,ab.
45	("menopausal hormone" adj2 therap\$).ti,ab.
46	MHT.ti,ab.
47	exp ESTRIOL/
48	ESTROGENS/ or ESTROGENS, NON-STEROIDAL/
49	ESTRADIOL/ or ESTRAMUSTINE/
50	ETHINYL ESTRADIOL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/
51	(oestrogen? or estrogen? or estradiol?).ti,ab.
52	PROGESTOGENS/
53	progesta\$.ti,ab.
54	MEDROXYPROGESTERONE ACETATE/
55	MPA.ti,ab.
56	exp PROGESTERONE/
57	ETHISTERONE/
58	NORETHINDRONE/ or NORGESTREL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/ or LEVONORGESTREL/ or NORPROGESTERONES/
59	drospirenone.ti,ab.
60	levonorgestrel.ti,ab.
61	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).ti,ab.

#	Searches
62	(angeliq or climagest or climesse or clinorette or femoston or indivina or kiofem or kioavance or novofem or nuvelle or tridestra or trisequens).ti,ab.
63	"cyclo-progynova".ti,ab.
64	(premiq or premak).ti,ab.
65	hormonin.ti,ab.
66	TESTOSTERONE/
67	testosterone.ti,ab.
68	NORPREGENES/
69	(tibolone or livial).ti,ab.
70	exp SELECTIVE ESTROGEN RECEPTOR MODULATORS/
71	SERM?.ti,ab.
72	(bioidentical adj3 hormone adj3 therap\$).ti,ab.
73	(bio identical adj3 hormone adj3 therap\$).ti,ab.
74	BHRT.ti,ab.
75	(natural adj3 hormone therap\$).ti,ab.
76	(estrone or estriol).ti,ab.
77	CLONIDINE/
78	(clonidine or catapres or dixarit).ti,ab.
79	PLANT EXTRACTS/
80	PLANT PREPARATIONS/
81	botanical?.ti,ab.
82	(black adj cohosh?).ti,ab.
83	(cimicifuga or actaea or racemosas or bugbane or ranunculaceae).ti,ab.
84	remifemin.ti,ab.
85	TRIFOLIUM/
86	(red adj clover).ti,ab.
87	(trifolium adj3 (pratense? or repen?)).ti,ab.
88	PHYTOESTROGENS/
89	phyto?estrogen\$.ti,ab.
90	ISOFLAVONES/
91	ESTROGENS, NON-STEROIDAL/
92	SOYBEANS/
93	(soybean or soy or soya).ti,ab.
94	(nonsteroidal adj (estrogen? or estrogen?)).ti,ab.
95	(nonsteroidal adj (estogen? or oestrogen?)).ti,ab.
96	exp SEROTONIN UPTAKE INHIBITORS/
97	(SSRI? or SNRI?).ti,ab.
98	PAROXETINE/
99	FLUOXETINE/
100	CYCLOHEXANOLS/
101	CITALOPRAM/
102	FLUVOXAMINE/
103	(prozac or fluoxetine or sarafem or citalopram or cipramil or venlafaxine or fluvoxamine or faverin or escitalopram or cipralex).ti,ab.
104	GAMMA-AMINOBUTYRIC ACID/
105	(gabapentin or neurotin).ti,ab.
106	exp ACUPUNCTURE THERAPY/
107	(acupuncture or acupressure).ti,ab.
108	(magnetic adj band?).ti,ab.
109	exp LIFE STYLE/
110	((advice or advising) adj3 (drinking or alcohol or smoking or smoke or weight loss or BMI or obese or obesity or exercise or exercising or physical activ\$)).ti,ab.
111	COGNITIVE THERAPY/
112	(cognitive adj3 (therap\$ or psychotherap\$)).ti,ab.
113	or/42-112
114	and/7,41,113
115	META-ANALYSIS/
116	META-ANALYSIS AS TOPIC/
117	(meta analy* or metanaly* or metaanaly*).ti,ab.
118	((systematic* or evidence*) adj2 (review* or overview*)).ti,ab.
119	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
120	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
121	(search* adj4 literature).ab.
122	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
123	cochrane.jw.
124	or/115-123
125	randomized controlled trial.pt.
126	controlled clinical trial.pt.
127	randomi#ed.ab.
128	placebo.ab.

#	Searches
129	randomly.ab.
130	exp CLINICAL TRIALS AS TOPIC/
131	trial.ti.
132	or/125-131
133	or/124,132
134	and/114,133
135	LETTER/
136	EDITORIAL/
137	NEWS/
138	exp HISTORICAL ARTICLE/
139	ANECDOTES AS TOPIC/
140	COMMENT/
141	CASE REPORT/
142	(letter or comment* or abstracts).ti.
143	or/135-142
144	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
145	143 not 144
146	ANIMALS/ not HUMANS/
147	exp ANIMALS, LABORATORY/
148	exp ANIMAL EXPERIMENTATION/
149	exp MODELS, ANIMAL/
150	exp RODENTIA/
151	(rat or rats or mouse or mice).ti.
152	or/145-151
153	134 not 152
154	limit 153 to english language

#### Database: Medline-in-process

#	Searches
1	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF).ti,ab.
2	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
3	climacteric.ti,ab.
4	or/1-3
5	(hot adj (flash\$ or flush\$)).ti,ab.
6	(vasomotor adj symptom?).ti,ab.
7	sweat\$.ti,ab.
8	(sleep adj3 disturb\$).ti,ab.
9	insomnia?.ti,ab.
10	(sexual adj3 (dysfunction or impair\$)).ti,ab.
11	((vagin\$ or vulva?) adj3 (atroph\$ or dry\$ or irritat\$)).ti,ab.
12	(discomfort or uncomfortable or pain\$ or dyspareunia).ti,ab.
13	libido.ti,ab.
14	((altered or chang? or differ\$) adj3 sexual adj3 (behavio?r\$ or function\$)).ti,ab.
15	(mood adj3 (disturbance or disorder)).ti,ab.
16	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).ti.
17	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).ab. /freq=2
18	or/5-17
19	((hormon\$ or estrogen or oestrogen) adj3 therap\$).ti,ab.
20	(hormon\$ adj3 substit\$).ti,ab.
21	(HRT or HT).ti,ab.
22	("menopausal hormone" adj2 therap\$).ti,ab.
23	MHT.ti,ab.
24	(estrogen? or estrogen? or estradiol? or estriol).ti,ab.
25	progest\$.ti,ab.
26	medroxyprogesterone acetate.ti,ab.
27	MPA.ti,ab.
28	ethisterone.ti,ab.
29	(norethindrone or norgestrel or ethinyl estradiol norgestrel combination or levonorgestrel or norprogesterones).ti,ab.
30	drospirenone.ti,ab.
31	levonorgestrel.ti,ab.
32	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynova or progynova or sandrena or zumenon).ti,ab.
33	(angeliq or climagest or climesse or clinorette or femoston or indivina or klioferm or klovance or novofem or nuvelle or tridestra or trisequens).ti,ab.
34	"cyclo-progynova".ti,ab.
35	(premiq or premak).ti,ab.
36	hormonin.ti,ab.
37	testosterone.ti,ab.
38	(tibolone or livial).ti,ab.
39	selective estrogen receptor modulator?.ti,ab.

#	Searches
40	SERM?.ti,ab.
41	(bioidential adj3 hormone adj3 therap\$).ti,ab.
42	(bio identical adj3 hormone adj3 therap\$).ti,ab.
43	BHRT.ti,ab.
44	(natural adj3 hormone therap\$).ti,ab.
45	(estrone or estriol).ti,ab.
46	(clonidine or catapres or dixarit).ti,ab.
47	botanical?.ti,ab.
48	(black adj cohosh?).ti,ab.
49	(cimicifuga or actaea or racemosas or bugbane or ranunculaceae).ti,ab.
50	remifemin.ti,ab.
51	(red adj clover).ti,ab.
52	(trifolium adj3 (pratense? or repen?)).ti,ab.
53	phyto?estrogen\$.ti,ab.
54	isoflavon\$.ti,ab.
55	(nonsteroidal adj3 (estrogen? or oestrogen?)).ti,ab.
56	(non steroidal adj3 (estrogen? or oestrogen?)).ti,ab.
57	(soybean or soy or soya).ti,ab.
58	(nonsteroidal adj (estrogen? or estrogen?)).ti,ab.
59	(nonsteroidal adj (estogen? or oestrogen?)).ti,ab.
60	serotonin reuptake inhibitor?.ti,ab.
61	(SSRI? or SNRI?).ti,ab.
62	(prozac or fluoxetine or sarafem or citalopram or cipramil or venlafaxine or fluvoxamine or faverin or escitalopram or cipralext).ti,ab.
63	(gabapentin or neurotin).ti,ab.
64	(acupuncture or acupressure).ti,ab.
65	(magnetic adj band?).ti,ab.
66	((advice or advising) adj3 (drinking or alcohol or smoking or smoke or weight loss or BMI or obese or obesity or exercise or exercising or physical activ\$)).ti,ab.
67	(cognitive adj3 (therap\$ or psychotherap\$)).ti,ab.
68	or/19-67
69	and/4,18,68

### Database: Cochrane Central Register of Controlled Trials

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/ or PREMENOPAUSE/
2	PRIMARY OVARIAN INSUFFICIENCY/
3	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF).ti,ab.
4	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
5	CLIMACTERIC/
6	climacteric.ti,ab.
7	or/1-6
8	exp VASOMOTOR SYSTEM/
9	HOT FLASHES/
10	(hot adj (flash\$ or flush\$)).ti,ab.
11	(vasomotor adj symptom?).ti,ab.
12	SWEATING/
13	sweat\$.ti,ab.
14	HYPERHIDROSIS/
15	(sleep adj3 disturb\$).ti,ab.
16	"SLEEP INITIATION AND MAINTENANCE DISORDERS"/
17	insomnia?.ti,ab.
18	FEMALE UROGENITAL DISEASES/ or exp SEXUAL DYSFUNCTION, PHYSIOLOGICAL/ or VAGINISMUS/ or exp VAGINITIS/ or exp VULVAR DISEASES/
19	VAGINAL DISEASES/
20	VAGINA/
21	ATROPHY/
22	and/20-21
23	DEHYDRATION/
24	((vagin\$ or vulva?) adj3 (atroph\$ or dry\$ or irritat\$)).ti,ab.
25	(discomfort or uncomfortable or pain\$ or dyspareunia).ti,ab.
26	SEXUAL DYSFUNCTION, PSYCHOLOGICAL/
27	SEXUAL BEHAVIOR/
28	LIBIDO/
29	libido.ti,ab.
30	DYSPAREUNIA/
31	((altered or chang? or differ\$) adj3 sexual adj3 (behavio?r\$ or function\$)).ti,ab.
32	MOOD DISORDERS/
33	(mood adj3 (disturbance or disorder)).ti,ab.

#	Searches
34	DEPRESSION/
35	ANXIETY/
36	AFFECTIVE SYMPTOMS/
37	STRESS, PSYCHOLOGICAL/
38	IRRITABLE MOOD/
39	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).ti.
40	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).ab. /freq=2
41	or/8-19,22-40
42	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
43	(hormon\$ adj3 substit\$).ti,ab.
44	(HRT or HT).ti,ab.
45	("menopausal hormone" adj2 therap\$).ti,ab.
46	MHT.ti,ab.
47	exp ESTRIBOL/
48	ESTROGENS/ or ESTROGENS, NON-STEROIDAL/
49	ESTRADIOL/ or ESTRAMUSTINE/
50	ETHINYL ESTRADIOL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/
51	(oestrogen? or estrogen? or estradiol?).ti,ab.
52	PROGESTOGENS/
53	progesta\$.ti,ab.
54	MEDROXYPROGESTERONE ACETATE/
55	MPA.ti,ab.
56	exp PROGESTERONE/
57	ETHISTERONE/
58	NORETHINDRONE/ or NORGESTREL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/ or LEVONORGESTREL/ or NORPROGESTERONES/
59	drospirenone.ti,ab.
60	levonorgestrel.ti,ab.
61	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).ti,ab.
62	(angeliq or climagest or climesse or clinorette or femoston or indivina or klioferm or klioavance or novofem or nuvelle or tridestra or trisequens).ti,ab.
63	"cyclo-progynova".ti,ab.
64	(premiq or premak).ti,ab.
65	hormonin.ti,ab.
66	TESTOSTERONE/
67	testosterone.ti,ab.
68	NORPREGENES/
69	(tibolone or livial).ti,ab.
70	exp SELECTIVE ESTROGEN RECEPTOR MODULATORS/
71	SERM?.ti,ab.
72	(bioidentical adj3 hormone adj3 therap\$).ti,ab.
73	(bio identical adj3 hormone adj3 therap\$).ti,ab.
74	BHRT.ti,ab.
75	(natural adj3 hormone therap\$).ti,ab.
76	(estrone or estriol).ti,ab.
77	CLONIDINE/
78	(clonidine or catapres or dixarit).ti,ab.
79	PLANT EXTRACTS/
80	PLANT PREPARATIONS/
81	botanical?.ti,ab.
82	(black adj cohosh?).ti,ab.
83	(cimicifuga or actaea or racemosas or bugbane or ranunculaceae).ti,ab.
84	remifemin.ti,ab.
85	TRIFOLIUM/
86	(red adj clover).ti,ab.
87	(trifolium adj3 (pratense? or repen?)).ti,ab.
88	PHYTOESTROGENS/
89	phyto?estrogen\$.ti,ab.
90	ISOFLAVONES/
91	ESTROGENS, NON-STEROIDAL/
92	SOYBEANS/
93	(soybean or soy or soya).ti,ab.
94	(nonsteroidal adj (estrogen? or estrogen?)).ti,ab.
95	(nonsteroidal adj (estogen? or oestrogen?)).ti,ab.
96	exp SEROTONIN UPTAKE INHIBITORS/
97	(SSRI? or SNRI?).ti,ab.
98	PAROXETINE/
99	FLUOXETINE/
100	CYCLOHEXANOLS/

#	Searches
101	CITALOPRAM/
102	FLUVOXAMINE/
103	(prozac or fluoxetine or sarafem or citalopram or cipramil or venlafaxine or fluvoxamine or faverin or escitalopram or cipralext).ti,ab.
104	GAMMA-AMINOBUTYRIC ACID/
105	(gabapentin or neurotin).ti,ab.
106	exp ACUPUNCTURE THERAPY/
107	(acupuncture or acupressure).ti,ab.
108	(magnetic adj band?).ti,ab.
109	exp LIFE STYLE/
110	((advice or advising) adj3 (drinking or alcohol or smoking or smoke or weight loss or BMI or obese or obesity or exercise or exercising or physical activ\$)).ti,ab.
111	COGNITIVE THERAPY/
112	(cognitive adj3 (therap\$ or psychotherap\$)).ti,ab.
113	or/42-112
114	and/7,41,113

### Database: Cochrane Database of Systematic Reviews and Database of Abstracts of Reviews of Effects

#	Searches
1	(MENOPAUSE or MENOPAUSE, PREMATURE or PERIMENOPAUSE or POSTMENOPAUSE or PREMENOPAUSE).kw.
2	PRIMARY OVARIAN INSUFFICIENCY.kw.
3	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF).tw,tx.
4	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).tw,tx.
5	CLIMACTERIC.kw.
6	climacteric.tw,tx.
7	or/1-6
8	VASOMOTOR SYSTEM.kw.
9	HOT FLASHES.kw.
10	(hot adj (flash\$ or flush\$)).tw,tx.
11	(vasomotor adj symptom?).tw,tx.
12	SWEATING.kw.
13	sweat\$.tw,tx.
14	HYPERHIDROSIS.kw.
15	(sleep adj3 disturb\$).tw,tx.
16	"SLEEP INITIATION AND MAINTENANCE DISORDERS".kw.
17	insomnia?.tw,tx.
18	(FEMALE UROGENITAL DISEASES or SEXUAL DYSFUNCTION, PHYSIOLOGICAL or VAGINISMUS or VAGINITIS or VULVAR DISEASES).kw.
19	VAGINAL DISEASES.kw.
20	VAGINA.kw.
21	ATROPHY.kw.
22	and/20-21
23	DEHYDRATION.tw,tx.
24	((vagin\$ or vulva?) adj3 (atroph\$ or dry\$ or irritat\$)).tw,tx.
25	(discomfort or uncomfortable or pain\$ or dyspareunia).tw,tx.
26	SEXUAL DYSFUNCTION, PSYCHOLOGICAL.kw.
27	SEXUAL BEHAVIOR.kw.
28	LIBIDO.kw.
29	libido.tw,tx.
30	DYSPAREUNIA.kw.
31	((altered or chang? or differ\$) adj3 sexual adj3 (behavio?r\$ or function\$)).tw,tx.
32	MOOD DISORDERS.kw.
33	(mood adj3 (disturbance or disorder)).tw,tx.
34	DEPRESSION.kw.
35	ANXIETY.kw.
36	AFFECTIVE SYMPTOMS.kw.
37	STRESS, PSYCHOLOGICAL.kw.
38	IRRITABLE MOOD.kw.
39	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).tw,tx.
40	or/8-19,22-39
41	(HORMONE REPLACEMENT THERAPY or ESTROGEN REPLACEMENT THERAPY).kw.
42	(hormon\$ adj3 substit\$).tw,tx.
43	(HRT or HT).tw,tx.
44	("menopausal hormone" adj2 therap\$).tw,tx.
45	MHT.tw,tx.
46	ESTRIOL.kw.
47	(ESTROGENS or ESTROGENS, NON-STEROIDAL).kw.

#	Searches
48	(ESTRADIOL or ESTRAMUSTINE).kw.
49	(ETHINYL ESTRADIOL or ETHINYL ESTRADIOL-NORGESTREL COMBINATION).kw.
50	(oestrogen? or estrogen? or estradiol?).tw,tx.
51	PROGESTOGENS.kw.
52	progesta\$.tw,tx.
53	MEDROXYPROGESTERONE ACETATE.kw.
54	MPA.tw,tx.
55	PROGESTERONE.kw.
56	ETHISTERONE.kw.
57	(NORETHINDRONE or NORGESTREL or ETHINYL ESTRADIOL-NORGESTREL COMBINATION or LEVONORGESTREL or NORPROGESTERONES).kw.
58	drospirenone.tw,tx.
59	levonorgestrel.tw,tx.
60	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).tw,tx.
61	(angeliq or climagest or climesse or clinorette or femoston or indivina or klioferm or klioavance or novofem or nuvelle or tridestra or trisequens).tw,tx.
62	"cyclo-progynova".tw,tx.
63	(premiq or premak).tw,tx.
64	hormonin.tw,tx.
65	TESTOSTERONE.kw.
66	testosterone.tw,tx.
67	NORPREGENES.kw.
68	(tibolone or livial).tw,tx.
69	SELECTIVE ESTROGEN RECEPTOR MODULATORS.kw.
70	SERM?.tw,tx.
71	(bioidentical adj3 hormone adj3 therap\$).tw,tx.
72	(bio identical adj3 hormone adj3 therap\$).tw,tx.
73	BHRT.tw,tx.
74	(natural adj3 hormone therap\$).tw,tx.
75	(estrone or estriol).tw,tx.
76	CLONIDINE.kw.
77	(clonidine or catapres or dixarit).tw,tx.
78	PLANT EXTRACTS.kw.
79	PLANT PREPARATIONS.kw.
80	botanical?.tw,tx.
81	(black adj cohosh?).tw,tx.
82	(cimicifuga or actaea or racemosas or bugbane or ranunculaceae).tw,tx.
83	remifemin.tw,tx.
84	TRIFOLIUM.kw.
85	(red adj clover).tw,tx.
86	(trifolium adj3 (pratense? or repen?)).tw,tx.
87	PHYTOESTROGENS.kw.
88	phyto?estrogen\$.tw,tx.
89	ISOFLAVONES.kw.
90	ESTROGENS, NON-STEROIDAL.kw.
91	SOYBEANS.kw.
92	(soybean or soy or soya).tw,tx.
93	(nonsteroidal adj (estrogen? or estrogen?)).tw,tx.
94	(nonsteroidal adj (estogen? or oestrogen?)).tw,tx.
95	SEROTONIN UPTAKE INHIBITORS.kw.
96	(SSRI? or SNRI?).tw,tx.
97	PAROXETINE.kw.
98	FLUOXETINE.kw.
99	CYCLOHEXANOLS.kw.
100	CITALOPRAM.kw.
101	FLUVOXAMINE.kw.
102	(prozac or fluoxetine or sarafem or citalopram or cipramil or venlafaxine or fluvoxamine or faverin or escitalopram or cipralex).tw,tx.
103	GAMMA-AMINOBUTYRIC ACID.kw.
104	(gabapentin or neurotin).tw,tx.
105	ACUPUNCTURE THERAPY.kw.
106	(acupuncture or acupressure).tw,tx.
107	(magnetic adj band?).tw,tx.
108	LIFE STYLE.kw.
109	((advice or advising) adj3 (drinking or alcohol or smoking or smoke or weight loss or BMI or obese or obesity or exercise or exercising or physical activ\$)).tw,tx.
110	COGNITIVE THERAPY.kw.
111	(cognitive adj3 (therap\$ or psychotherap\$)).tw,tx.
112	or/41-111
113	and/7,40,112

## Database: Health Technology Assessment

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/ or PREMENOPAUSE/
2	PRIMARY OVARIAN INSUFFICIENCY/
3	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF).tw.
4	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
5	CLIMACTERIC/
6	climacteric.tw.
7	or/1-6
8	exp VASOMOTOR SYSTEM/
9	HOT FLASHES/
10	(hot adj (flash\$ or flush\$)).tw.
11	(vasomotor adj symptom?).tw.
12	SWEATING/
13	sweat\$.tw.
14	HYPERHIDROSIS/
15	(sleep adj3 disturb\$).tw.
16	"SLEEP INITIATION AND MAINTENANCE DISORDERS"/
17	insomnia?.tw.
18	FEMALE UROGENITAL DISEASES/ or exp SEXUAL DYSFUNCTION, PHYSIOLOGICAL/ or VAGINISMUS/ or exp VAGINITIS/ or exp VULVAR DISEASES/
19	VAGINAL DISEASES/
20	VAGINA/
21	ATROPHY/
22	and/20-21
23	DEHYDRATION/
24	((vagin\$ or vulva?) adj3 (atroph\$ or dry\$ or irritat\$)).tw.
25	(discomfort or uncomfortable or pain\$ or dyspareunia).tw.
26	SEXUAL DYSFUNCTION, PSYCHOLOGICAL/
27	SEXUAL BEHAVIOR/
28	LIBIDO/
29	libido.tw.
30	DYSPAREUNIA/
31	((altered or chang? or differ\$) adj3 sexual adj3 (behavio?r\$ or function\$)).tw.
32	MOOD DISORDERS/
33	(mood adj3 (disturbance or disorder)).tw.
34	DEPRESSION/
35	ANXIETY/
36	AFFECTIVE SYMPTOMS/
37	STRESS, PSYCHOLOGICAL/
38	IRRITABLE MOOD/
39	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).tw.
40	or/8-19,22-39
41	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
42	(HRT or HT).tw.
43	(hormon? adj3 substitut\$).tw.
44	("menopausal hormone" adj2 therap\$).tw.
45	MHT.tw.
46	exp ESTRIOL/
47	ESTROGENS/ or ESTROGENS, NON-STEROIDAL/
48	ESTRADIOL/ or ESTRAMUSTINE/
49	ETHINYL ESTRADIOL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/
50	(oestrogen? or estrogen? or estradiol?).tw.
51	PROGESTOGENS/
52	progesta\$.tw.
53	MEDROXYPROGESTERONE ACETATE/
54	MPA.tw.
55	exp PROGESTERONE/
56	ETHISTERONE/
57	NORETHINDRONE/ or NORGESTREL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/ or LEVONORGESTREL/ or NORPROGESTERONES/
58	drospirenone.tw.
59	levonorgestrel.tw.
60	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).tw.
61	(angeliq or climagest or climesse or clinorette or femoston or indivina or klioferm or kliovance or novofem or nuvelle or tridestra or trisequens).tw.
62	"cyclo-progynova".tw.
63	(premiq or premak).tw.
64	hormonin.tw.



#	Searches
65	TESTOSTERONE/
66	testosterone.tw.
67	NORPREGENES/
68	(tibolone or livial).tw.
69	exp SELECTIVE ESTROGEN RECEPTOR MODULATORS/
70	SERM?.tw.
71	(bioidentical adj3 hormone adj3 therap\$).tw.
72	(bio identical adj3 hormone adj3 therap\$).tw.
73	BHRT.tw.
74	(natural adj3 hormone therap\$).tw.
75	(estrone or estriol).tw.
76	CLONIDINE/
77	(clonidine or catapres or dixarit).tw.
78	PLANT EXTRACTS/
79	PLANT PREPARATIONS/
80	botanical?.tw.
81	(black adj cohosh?).tw.
82	(cimicifuga or actaea or racemosas or bugbane or ranunculaceae).tw.
83	remifemin.tw.
84	TRIFOLIUM/
85	(red adj clover).tw.
86	(trifolium adj3 (pratense? or repen?)).tw.
87	PHYTOESTROGENS/
88	phyto?estrogen\$.tw.
89	ISOFLAVONES/
90	ESTROGENS, NON-STEROIDAL/
91	SOYBEANS/
92	(soybean or soy or soya).tw.
93	(nonsteroidal adj (estrogen? or estrogen?)).tw.
94	(nonsteroidal adj (estrogen? or oestrogen?)).tw.
95	exp SEROTONIN UPTAKE INHIBITORS/
96	(SSRI? or SNRI?).tw.
97	PAROXETINE/
98	FLUOXETINE/
99	CYCLOHEXANOLS/
100	CITALOPRAM/
101	FLUVOXAMINE/
102	(prozac or fluoxetine or sarafem or citalopram or cipramil or venlafaxine or fluvoxamine or faverin or escitalopram or cipralextw.).tw.
103	GAMMA-AMINOBTYRIC ACID/
104	(gabapentin or neurotin).tw.
105	exp ACUPUNCTURE THERAPY/
106	(acupuncture or acupressure).tw.
107	(magnetic adj band?).ti,ab.
108	exp LIFE STYLE/
109	((advice or advising) adj3 (drinking or alcohol or smoking or smoke or weight loss or BMI or obese or obesity or exercise or exercising or physical activ\$)).tw.
110	COGNITIVE THERAPY/
111	(cognitive adj3 (therap\$ or psychotherap\$)).tw.
112	or/41-111
113	and/7,40,112

### Database: Embase

#	Searches
1	"MENOPAUSE AND CLIMACTERIUM"/ or CLIMACTERIUM/ or EARLY MENOPAUSE/ or MENOPAUSE/ or POSTMENOPAUSE/
2	PREMENOPAUSE/
3	PREMATURE OVARIAN FAILURE/
4	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF).ti,ab.
5	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
6	climacteric.ti,ab.
7	or/1-6
8	HOT FLUSH/
9	(hot adj (flash\$ or flush\$)).ti,ab.
10	(vasomotor adj symptom?).ti,ab.
11	SWEATING/
12	sweat\$.ti,ab.
13	HYPERHIDROSIS/
14	SLEEP DISORDER/
15	((sleep\$ or mood\$) adj3 disturb\$).ti,ab.

#	Searches
16	insomnia?.ti,ab.
17	UROGENITAL TRACT DISEASE/
18	VAGINA DISEASE/ or VAGINA ATROPHY/ or VAGINAL DISCOMFORT/ or VAGINAL DRYNESS/ or VAGINAL PRURITUS/ or exp VAGINITIS/ or VULVOVAGINAL DISCOMFORT/
19	VAGINAL PAIN/
20	((vagin\$ or vulva?) adj3 (atroph\$ or dry\$ or irritat\$)).ti,ab.
21	(discomfort or uncomfortable or pain\$ or dyspareunia).ti,ab.
22	exp FEMALE SEXUAL DYSFUNCTION/
23	LIBIDO DISORDER/
24	((altered or chang? or differ\$) adj3 sexual adj3 (behavio?r\$ or function\$)).ti,ab.
25	MOOD DISORDER/
26	DEPRESSION/
27	ANXIETY/
28	EMOTIONAL DISORDER/
29	MENTAL STRESS/
30	IRRITABILITY/
31	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).ti.
32	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).ab. /freq=2
33	or/8-32
34	exp HORMONE SUBSTITUTION/ or ESTROGEN THERAPY/
35	(HRT or HT).ti,ab.
36	("menopausal hormone" adj2 therap\$).ti,ab.
37	MHT.ti,ab.
38	ESTRIOL/
39	exp ESTROGEN/
40	(oestrogen? or estrogen? or estradiol?).ti,ab.
41	exp GESTAGEN/
42	progest\$.ti,ab.
43	drospirenone.ti,ab.
44	levonorgestrel.ti,ab.
45	MPA.ti,ab.
46	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).ti,ab.
47	(angeliq or climagest or climesse or clinorette or femoston or indivina or kiofem or kioavance or novofem or nuvelle or tridestra or trisequens).ti,ab.
48	"cyclo-progynova".ti,ab.
49	(premiq or premak).ti,ab.
50	hormonin.ti,ab.
51	TESTOSTERONE/
52	testosterone.ti,ab.
53	TIBOLONE/
54	(tibolone or livial).ti,ab.
55	SELECTIVE ESTROGEN RECEPTOR MODULATOR/
56	SERM?.ti,ab.
57	(bioidentical adj3 hormone adj3 therap\$).ti,ab.
58	(bio identical adj3 hormone adj3 therap\$).ti,ab.
59	(natural adj3 hormone therap\$).ti,ab.
60	BHRT.ti,ab.
61	ESTRONE/
62	CLONIDINE/
63	(clonidine or catapres or dixarit).ti,ab.
64	GABAPENTINE/
65	(gabapentin or neurontin).ti,ab.
66	PHYTOESTROGEN/
67	(phytoestrogen or phyto estrogen or phyto oestrogen).ti,ab.
68	SOYBEAN/
69	(soybean or soy or soya).ti,ab.
70	ISOFLAVONE/
71	ISOFLAVONE DERIVATIVE/
72	PLANT EXTRACT/
73	MEDICINAL PLANT/
74	ACTAEA RACEMOSA/
75	(black adj cohosh).ti,ab.
76	(cimicifuga or actaea or racemosas or bugbane or ranunculaceae).ti,ab.
77	remifemin.ti,ab.
78	RED CLOVER/
79	(red clover or trifolium).ti,ab.
80	ANTIESTROGEN/
81	(nonsteroidal adj (oestrogen\$ or estrogen\$)).ti,ab.
82	(non steroidal adj (oestrogen\$ or estrogen\$)).ti,ab.

#	Searches
83	SEROTONIN UPTAKE INHIBITOR/
84	(prozac or fluoxetine or sarafem or citalopram or cipramil or venlafaxine or fluvoxamine or faverin or escitalopram or cipralext).ti,ab.
85	ACUPUNCTURE/
86	(acupuncture or acupressure).ti,ab.
87	(magnetic adj band?).ti,ab.
88	LIFESTYLE MODIFICATION/
89	((advice or advising) adj3 (drinking or alcohol or smoking or smoke or weight loss or BMI or obese or obesity or exercise or exercising or physical activ\$)).ti,ab.
90	COGNITIVE THERAPY/
91	(cognitive adj3 therap\$).ti,ab.
92	CBT.ti,ab.
93	or/34-92
94	and/7,33,93
95	SYSTEMATIC REVIEW/
96	META-ANALYSIS/
97	(meta analy* or metanaly* or metaanaly*).ti,ab.
98	((systematic or evidence) adj2 (review* or overview*)).ti,ab.
99	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
100	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
101	(search* adj4 literature).ab.
102	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
103	((pool* or combined) adj2 (data or trials or studies or results)).ab.
104	cochrane.jw.
105	or/95-104
106	random*.ti,ab.
107	factorial*.ti,ab.
108	(crossover* or cross over*).ti,ab.
109	((doubl* or singl*) adj blind*).ti,ab.
110	(assign* or allocat* or volunteer* or placebo*).ti,ab.
111	CROSSOVER PROCEDURE/
112	SINGLE BLIND PROCEDURE/
113	RANDOMIZED CONTROLLED TRIAL/
114	DOUBLE BLIND PROCEDURE/
115	or/106-114
116	or/105,115
117	and/94,116
118	conference abstract.pt.
119	letter.pt. or LETTER/
120	note.pt.
121	editorial.pt.
122	CASE REPORT/ or CASE STUDY/
123	(letter or comment* or abstracts).ti.
124	or/118-123
125	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
126	124 not 125
127	ANIMAL/ not HUMAN/
128	NONHUMAN/
129	exp ANIMAL EXPERIMENT/
130	exp EXPERIMENTAL ANIMAL/
131	ANIMAL MODEL/
132	exp RODENT/
133	(rat or rats or mouse or mice).ti.
134	or/126-133
135	117 not 134
136	limit 135 to english language

## E.4 Managing short-term symptoms – health economic evidence

### Database: Medline

#	Searches
1	ECONOMICS/
2	VALUE OF LIFE/
3	exp "COSTS AND COST ANALYSIS"/
4	exp ECONOMICS, HOSPITAL/

#	Searches
5	exp ECONOMICS, MEDICAL/
6	exp RESOURCE ALLOCATION/
7	ECONOMICS, NURSING/
8	ECONOMICS, PHARMACEUTICAL/
9	exp "FEES AND CHARGES"/
10	exp BUDGETS/
11	budget*.ti,ab.
12	cost*.ti,ab.
13	(economic* or pharmaco?economic*).ti,ab.
14	(price* or pricing*).ti,ab.
15	(financ* or fee or fees or expenditure* or saving*).ti,ab.
16	(value adj2 (money or monetary)).ti,ab.
17	resourc* allocat*.ti,ab.
18	(fund or funds or funding* or funded).ti,ab.
19	(ration or rations or rationing* or rationed).ti,ab.
20	ec.fs.
21	or/1-20
22	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/ or PREMENOPAUSE/
23	PRIMARY OVARIAN INSUFFICIENCY/
24	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF).ti,ab.
25	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
26	CLIMACTERIC/
27	climacteric.ti,ab.
28	or/22-27
29	exp VASOMOTOR SYSTEM/
30	HOT FLASHES/
31	(hot adj (flash\$ or flush\$)).ti,ab.
32	(vasomotor adj symptom?).ti,ab.
33	SWEATING/
34	sweat\$.ti,ab.
35	HYPERHIDROSIS/
36	(sleep adj3 disturb\$).ti,ab.
37	"SLEEP INITIATION AND MAINTENANCE DISORDERS"/
38	insomnia?.ti,ab.
39	FEMALE UROGENITAL DISEASES/ or exp SEXUAL DYSFUNCTION, PHYSIOLOGICAL/ or VAGINISMUS/ or exp VAGINITIS/ or exp VULVAR DISEASES/
40	VAGINAL DISEASES/
41	VAGINA/
42	ATROPHY/
43	and/41-42
44	DEHYDRATION/
45	((vagin\$ or vulva?) adj3 (atroph\$ or dry\$ or irritat\$)).ti,ab.
46	(discomfort or uncomfortable or pain\$ or dyspareunia).ti,ab.
47	SEXUAL DYSFUNCTION, PSYCHOLOGICAL/
48	SEXUAL BEHAVIOR/
49	LIBIDO/
50	libido.ti,ab.
51	DYSPAREUNIA/
52	((altered or chang? or differ\$) adj3 sexual adj3 (behavio?r\$ or function\$)).ti,ab.
53	MOOD DISORDERS/
54	(mood adj3 (disturbance or disorder)).ti,ab.
55	DEPRESSION/
56	ANXIETY/
57	AFFECTIVE SYMPTOMS/
58	STRESS, PSYCHOLOGICAL/
59	IRRITABLE MOOD/
60	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).ti.
61	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).ab. /freq=2
62	or/29-40,43-61
63	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
64	(hormon\$ adj3 substit\$).ti,ab.
65	(HRT or HT).ti,ab.
66	("menopausal hormone" adj2 therap\$).ti,ab.
67	MHT.ti,ab.
68	exp ESTRIOL/
69	ESTROGENS/ or ESTROGENS, NON-STEROIDAL/
70	ESTRADIOL/ or ESTRAMUSTINE/
71	ETHINYL ESTRADIOL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/
72	(oestrogen? or estrogen? or estradiol?).ti,ab.

#	Searches
73	PROGESTOGENS/
74	progesta\$.ti,ab.
75	MEDROXYPROGESTERONE ACETATE/
76	MPA.ti,ab.
77	exp PROGESTERONE/
78	ETHISTERONE/
79	NORETHINDRONE/ or NORGESTREL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/ or LEVONORGESTREL/ or NORPROGESTERONES/
80	drospirenone.ti,ab.
81	levonorgestrel.ti,ab.
82	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).ti,ab.
83	(angeliq or climagest or climesse or clinorette or femoston or indivina or klioferm or kliovance or novofem or nuvelle or tridestra or trisequens).ti,ab.
84	"cyclo-progynova".ti,ab.
85	(premiq or premak).ti,ab.
86	hormonin.ti,ab.
87	TESTOSTERONE/
88	testosterone.ti,ab.
89	NORPREGENES/
90	(tibolone or livial).ti,ab.
91	exp SELECTIVE ESTROGEN RECEPTOR MODULATORS/
92	SERM?.ti,ab.
93	(bioidentical adj3 hormone adj3 therap\$).ti,ab.
94	(bio identical adj3 hormone adj3 therap\$).ti,ab.
95	BHRT.ti,ab.
96	(natural adj3 hormone therap\$).ti,ab.
97	(estrone or estriol).ti,ab.
98	CLONIDINE/
99	(clonidine or catapres or dixarit).ti,ab.
100	PLANT EXTRACTS/
101	PLANT PREPARATIONS/
102	botanical?.ti,ab.
103	(black adj cohosh?).ti,ab.
104	(cimicifuga or actaea or racemosas or bugbane or ranunculaceae).ti,ab.
105	remifemin.ti,ab.
106	TRIFOLIUM/
107	(red adj clover).ti,ab.
108	(trifolium adj3 (pratense? or repen?)).ti,ab.
109	PHYTOESTROGENS/
110	phyto?estrogen\$.ti,ab.
111	ISOFLAVONES/
112	ESTROGENS, NON-STEROIDAL/
113	SOYBEANS/
114	(soybean or soy or soya).ti,ab.
115	(nonsteroidal adj (estrogen? or estrogen?)).ti,ab.
116	(nonsteroidal adj (estogen? or oestrogen?)).ti,ab.
117	exp SEROTONIN UPTAKE INHIBITORS/
118	(SSRI? or SNRI?).ti,ab.
119	PAROXETINE/
120	FLUOXETINE/
121	CYCLOHEXANOLS/
122	CITALOPRAM/
123	FLUVOXAMINE/
124	(prozac or fluoxetine or sarafem or citalopram or cipramil or venlafaxine or fluvoxamine or faverin or escitalopram or cipralax).ti,ab.
125	GAMMA-AMINOBTYRIC ACID/
126	(gabapentin or neurotin).ti,ab.
127	exp ACUPUNCTURE THERAPY/
128	(acupuncture or acupressure).ti,ab.
129	(magnetic adj band?).ti,ab.
130	exp LIFE STYLE/
131	((advice or advising) adj3 (drinking or alcohol or smoking or smoke or weight loss or BMI or obese or obesity or exercise or exercising or physical activ\$)).ti,ab.
132	COGNITIVE THERAPY/
133	(cognitive adj3 (therap\$ or psychotherap\$)).ti,ab.
134	or/63-133
135	and/28,62,134
136	and/21,135
137	LETTER/
138	EDITORIAL/

#	Searches
139	NEWS/
140	exp HISTORICAL ARTICLE/
141	ANECDOTES AS TOPIC/
142	COMMENT/
143	CASE REPORT/
144	(letter or comment* or abstracts).ti.
145	or/137-144
146	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
147	145 not 146
148	ANIMALS/ not HUMANS/
149	exp ANIMALS, LABORATORY/
150	exp ANIMAL EXPERIMENTATION/
151	exp MODELS, ANIMAL/
152	exp RODENTIA/
153	(rat or rats or mouse or mice).ti.
154	or/147-153
155	136 not 154
156	limit 155 to english language

### Database: Cochrane Central Register of Controlled Trials

#	Searches
1	ECONOMICS/
2	VALUE OF LIFE/
3	exp "COSTS AND COST ANALYSIS"/
4	exp ECONOMICS, HOSPITAL/
5	exp ECONOMICS, MEDICAL/
6	exp RESOURCE ALLOCATION/
7	ECONOMICS, NURSING/
8	ECONOMICS, PHARMACEUTICAL/
9	exp "FEES AND CHARGES"/
10	exp BUDGETS/
11	budget*.ti,ab.
12	cost*.ti,ab.
13	(economic* or pharmaco?economic*).ti,ab.
14	(price* or pricing*).ti,ab.
15	(financ* or fee or fees or expenditure* or saving*).ti,ab.
16	(value adj2 (money or monetary)).ti,ab.
17	resourc* allocat*.ti,ab.
18	(fund or funds or funding* or funded).ti,ab.
19	(ration or rations or rationing* or rationed).ti,ab.
20	ec.fs.
21	or/1-20
22	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/ or PREMENOPAUSE/
23	PRIMARY OVARIAN INSUFFICIENCY/
24	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF).ti,ab.
25	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
26	CLIMACTERIC/
27	climacteric.ti,ab.
28	or/22-27
29	exp VASOMOTOR SYSTEM/
30	HOT FLASHES/
31	(hot adj (flash\$ or flush\$)).ti,ab.
32	(vasomotor adj symptom?).ti,ab.
33	SWEATING/
34	sweat\$.ti,ab.
35	HYPERHIDROSIS/
36	(sleep adj3 disturb\$).ti,ab.
37	"SLEEP INITIATION AND MAINTENANCE DISORDERS"/
38	insomnia?.ti,ab.
39	FEMALE UROGENITAL DISEASES/ or exp SEXUAL DYSFUNCTION, PHYSIOLOGICAL/ or VAGINISMUS/ or exp VAGINITIS/ or exp VULVAR DISEASES/
40	VAGINAL DISEASES/
41	VAGINA/
42	ATROPHY/
43	and/41-42
44	DEHYDRATION/
45	((vagin\$ or vulva?) adj3 (atroph\$ or dry\$ or irritat\$)).ti,ab.
46	(discomfort or uncomfortable or pain\$ or dyspareunia).ti,ab.
47	SEXUAL DYSFUNCTION, PSYCHOLOGICAL/

#	Searches
48	SEXUAL BEHAVIOR/
49	LIBIDO/
50	libido.ti,ab.
51	DYSPAREUNIA/
52	((altered or chang? or differ\$) adj3 sexual adj3 (behavio?r\$ or function\$)).ti,ab.
53	MOOD DISORDERS/
54	(mood adj3 (disturbance or disorder)).ti,ab.
55	DEPRESSION/
56	ANXIETY/
57	AFFECTIVE SYMPTOMS/
58	STRESS, PSYCHOLOGICAL/
59	IRRITABLE MOOD/
60	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).ti.
61	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).ab. /freq=2
62	or/29-40,43-61
63	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
64	(hormon\$ adj3 substit\$).ti,ab.
65	(HRT or HT).ti,ab.
66	("menopausal hormone" adj2 therap\$).ti,ab.
67	MHT.ti,ab.
68	exp ESTRIOL/
69	ESTROGENS/ or ESTROGENS, NON-STEROIDAL/
70	ESTRADIOL/ or ESTRAMUSTINE/
71	ETHINYL ESTRADIOL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/
72	(oestrogen? or estrogen? or estradiol?).ti,ab.
73	PROGESTOGENS/
74	progesta\$.ti,ab.
75	MEDROXYPROGESTERONE ACETATE/
76	MPA.ti,ab.
77	exp PROGESTERONE/
78	ETHISTERONE/
79	NORETHINDRONE/ or NORGESTREL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/ or LEVONORGESTREL/ or NORPROGESTERONES/
80	drospirenone.ti,ab.
81	levonorgestrel.ti,ab.
82	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).ti,ab.
83	(angeliq or climagest or climesse or clinorette or femoston or indivina or klioferm or klioavance or novofem or nuvelle or tridestra or trisequens).ti,ab.
84	"cyclo-progynova".ti,ab.
85	(premiq or premak).ti,ab.
86	hormonin.ti,ab.
87	TESTOSTERONE/
88	testosterone.ti,ab.
89	NORPREGENES/
90	(tibolone or livial).ti,ab.
91	exp SELECTIVE ESTROGEN RECEPTOR MODULATORS/
92	SERM?.ti,ab.
93	(bioidentical adj3 hormone adj3 therap\$).ti,ab.
94	(bio identical adj3 hormone adj3 therap\$).ti,ab.
95	BHRT.ti,ab.
96	(natural adj3 hormone therap\$).ti,ab.
97	(estrone or estriol).ti,ab.
98	CLONIDINE/
99	(clonidine or catapres or dixarit).ti,ab.
100	PLANT EXTRACTS/
101	PLANT PREPARATIONS/
102	botanical?.ti,ab.
103	(black adj cohosh?).ti,ab.
104	(cimicifuga or actaea or racemosas or bugbane or ranunculaceae).ti,ab.
105	remifemin.ti,ab.
106	TRIFOLIUM/
107	(red adj clover).ti,ab.
108	(trifolium adj3 (pratense? or repen?)).ti,ab.
109	PHYTOESTROGENS/
110	phyto?estrogen\$.ti,ab.
111	ISOFLAVONES/
112	ESTROGENS, NON-STEROIDAL/
113	SOYBEANS/
114	(soybean or soy or soya).ti,ab.

#	Searches
115	(nonsteroidal adj (estrogen? or estrogen?)).ti,ab.
116	(nonsteroidal adj (estogen? or oestrogen?)).ti,ab.
117	exp SEROTONIN UPTAKE INHIBITORS/
118	(SSRI? or SNRI?).ti,ab.
119	PAROXETINE/
120	FLUOXETINE/
121	CYCLOHEXANOLS/
122	CITALOPRAM/
123	FLUVOXAMINE/
124	(prozac or fluoxetine or sarafem or citalopram or cipramil or venlafaxine or fluvoxamine or faverin or escitalopram or cipralext).ti,ab.
125	GAMMA-AMINOBTYRIC ACID/
126	(gabapentin or neurotin).ti,ab.
127	exp ACUPUNCTURE THERAPY/
128	(acupuncture or acupressure).ti,ab.
129	(magnetic adj band?).ti,ab.
130	exp LIFE STYLE/
131	((advice or advising) adj3 (drinking or alcohol or smoking or smoke or weight loss or BMI or obese or obesity or exercise or exercising or physical activ\$)).ti,ab.
132	COGNITIVE THERAPY/
133	(cognitive adj3 (therap\$ or psychotherap\$)).ti,ab.
134	or/63-133
135	and/28,62,134
136	and/21,135
137	limit 136 to english language

#### Database: Health Technology Assessment

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/ or PREMENOPAUSE/
2	PRIMARY OVARIAN INSUFFICIENCY/
3	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF).tw.
4	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
5	CLIMACTERIC/
6	climacteric.tw.
7	or/1-6
8	exp VASOMOTOR SYSTEM/
9	HOT FLASHES/
10	(hot adj (flash\$ or flush\$)).tw.
11	(vasomotor adj symptom?).tw.
12	SWEATING/
13	sweat\$.tw.
14	HYPERHIDROSIS/
15	(sleep adj3 disturb\$).tw.
16	"SLEEP INITIATION AND MAINTENANCE DISORDERS"/
17	insomnia?.tw.
18	FEMALE UROGENITAL DISEASES/ or exp SEXUAL DYSFUNCTION, PHYSIOLOGICAL/ or VAGINISMUS/ or exp VAGINITIS/ or exp VULVAR DISEASES/
19	VAGINAL DISEASES/
20	VAGINA/
21	ATROPHY/
22	and/20-21
23	DEHYDRATION/
24	((vagin\$ or vulva?) adj3 (atroph\$ or dry\$ or irritat\$)).tw.
25	(discomfort or uncomfortable or pain\$ or dyspareunia).tw.
26	SEXUAL DYSFUNCTION, PSYCHOLOGICAL/
27	SEXUAL BEHAVIOR/
28	LIBIDO/
29	libido.tw.
30	DYSPAREUNIA/
31	((altered or chang? or differ\$) adj3 sexual adj3 (behavio?r\$ or function\$)).tw.
32	MOOD DISORDERS/
33	(mood adj3 (disturbance or disorder)).tw.
34	DEPRESSION/
35	ANXIETY/
36	AFFECTIVE SYMPTOMS/
37	STRESS, PSYCHOLOGICAL/
38	IRRITABLE MOOD/
39	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).tw.
40	or/8-19,22-39



#	Searches
41	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
42	(HRT or HT).tw.
43	(hormon? adj3 substitut\$).tw.
44	("menopausal hormone" adj2 therap\$).tw.
45	MHT.tw.
46	exp ESTRADIOL/
47	ESTROGENS/ or ESTROGENS, NON-STEROIDAL/
48	ESTRADIOL/ or ESTRAMUSTINE/
49	ETHINYL ESTRADIOL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/
50	(oestrogen? or estrogen? or estradiol?).tw.
51	PROGESTOGENS/
52	progesta\$.tw.
53	MEDROXYPROGESTERONE ACETATE/
54	MPA.tw.
55	exp PROGESTERONE/
56	ETHISTERONE/
57	NORETHINDRONE/ or NORGESTREL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/ or LEVONORGESTREL/ or NORPROGESTERONES/
58	drospirenone.tw.
59	levonorgestrel.tw.
60	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).tw.
61	(angeliq or climagest or climesse or clinorette or femoston or indivina or kiofem or kioavance or novofem or nuvelle or tridestra or trisequens).tw.
62	"cyclo-progynova".tw.
63	(premiq or premak).tw.
64	hormonin.tw.
65	TESTOSTERONE/
66	testosterone.tw.
67	NORPREGENES/
68	(tibolone or livial).tw.
69	exp SELECTIVE ESTROGEN RECEPTOR MODULATORS/
70	SERM?.tw.
71	(bioidentical adj3 hormone adj3 therap\$).tw.
72	(bio identical adj3 hormone adj3 therap\$).tw.
73	BHRT.tw.
74	(natural adj3 hormone therap\$).tw.
75	(estrone or estriol).tw.
76	CLONIDINE/
77	(clonidine or catapres or dixarit).tw.
78	PLANT EXTRACTS/
79	PLANT PREPARATIONS/
80	botanical?.tw.
81	(black adj cohosh?).tw.
82	(cimicifuga or actaea or racemosas or bugbane or ranunculaceae).tw.
83	remifemin.tw.
84	TRIFOLIUM/
85	(red adj clover).tw.
86	(trifolium adj3 (pratense? or repen?)).tw.
87	PHYTOESTROGENS/
88	phyto?estrogen\$.tw.
89	ISOFLAVONES/
90	ESTROGENS, NON-STEROIDAL/
91	SOYBEANS/
92	(soybean or soy or soya).tw.
93	(nonsteroidal adj (estrogen? or estrogen?)).tw.
94	(nonsteroidal adj (estogen? or oestrogen?)).tw.
95	exp SEROTONIN UPTAKE INHIBITORS/
96	(SSRI? or SNRI?).tw.
97	PAROXETINE/
98	FLUOXETINE/
99	CYCLOHEXANOLS/
100	CITALOPRAM/
101	FLUVOXAMINE/
102	(prozac or fluoxetine or sarafem or citalopram or cipramil or venlafaxine or fluvoxamine or faverin or escitalopram or cipralax).tw.
103	GAMMA-AMINOBUTYRIC ACID/
104	(gabapentin or neurotin).tw.
105	exp ACUPUNCTURE THERAPY/
106	(acupuncture or acupressure).tw.
107	(magnetic adj band?).ti.ab.

#	Searches
108	exp LIFE STYLE/
109	((advice or advising) adj3 (drinking or alcohol or smoking or smoke or weight loss or BMI or obese or obesity or exercise or exercising or physical activ\$)).tw.
110	COGNITIVE THERAPY/
111	(cognitive adj3 (therap\$ or psychotherap\$)).tw.
112	or/41-111
113	and/7,40,112

### Database: NHS Economic Evaluation Database

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/ or PREMENOPAUSE/
2	PRIMARY OVARIAN INSUFFICIENCY/
3	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF).tw.
4	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
5	CLIMACTERIC/
6	climacteric.tw.
7	or/1-6
8	exp VASOMOTOR SYSTEM/
9	HOT FLASHES/
10	(hot adj (flash\$ or flush\$)).tw.
11	(vasomotor adj symptom?).tw.
12	SWEATING/
13	sweat\$.tw.
14	HYPERHIDROSIS/
15	(sleep adj3 disturb\$).tw.
16	"SLEEP INITIATION AND MAINTENANCE DISORDERS"/
17	insomnia?.tw.
18	FEMALE UROGENITAL DISEASES/ or exp SEXUAL DYSFUNCTION, PHYSIOLOGICAL/ or VAGINISMUS/ or exp VAGINITIS/ or exp VULVAR DISEASES/
19	VAGINAL DISEASES/
20	VAGINA/
21	ATROPHY/
22	and/20-21
23	DEHYDRATION/
24	((vagin\$ or vulva?) adj3 (atroph\$ or dry\$ or irritat\$)).tw.
25	(discomfort or uncomfortable or pain\$ or dyspareunia).tw.
26	SEXUAL DYSFUNCTION, PSYCHOLOGICAL/
27	SEXUAL BEHAVIOR/
28	LIBIDO/
29	libido.tw.
30	DYSPAREUNIA/
31	((altered or chang? or differ\$) adj3 sexual adj3 (behavio?r\$ or function\$)).tw.
32	MOOD DISORDERS/
33	(mood adj3 (disturbance or disorder)).tw.
34	DEPRESSION/
35	ANXIETY/
36	AFFECTIVE SYMPTOMS/
37	STRESS, PSYCHOLOGICAL/
38	IRRITABLE MOOD/
39	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).tw.
40	or/8-19,22-39
41	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
42	(HRT or HT).tw.
43	(hormon? adj3 substitut\$).tw.
44	("menopausal hormone" adj2 therap\$).tw.
45	MHT.tw.
46	exp ESTRIOL/
47	ESTROGENS/ or ESTROGENS, NON-STEROIDAL/
48	ESTRADIOL/ or ESTRAMUSTINE/
49	ETHINYL ESTRADIOL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/
50	(oestrogen? or estrogen? or estradiol?).tw.
51	PROGESTOGENS/
52	progesta\$.tw.
53	MEDROXYPROGESTERONE ACETATE/
54	MPA.tw.
55	exp PROGESTERONE/
56	ETHISTERONE/
57	NORETHINDRONE/ or NORGESTREL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/ or LEVONORGESTREL/ or NORPROGESTERONES/

#	Searches
58	drospirenone.tw.
59	levonorgestrel.tw.
60	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).tw.
61	(angeliq or climagest or climesse or clinorette or femoston or indivina or kiofem or kioavance or novofem or nuvelle or tridestra or trisequens).tw.
62	"cyclo-progynova".tw.
63	(premiq or premak).tw.
64	hormonin.tw.
65	TESTOSTERONE/
66	testosterone.tw.
67	NORPREGENES/
68	(tibolone or livial).tw.
69	exp SELECTIVE ESTROGEN RECEPTOR MODULATORS/
70	SERM?.tw.
71	(bioidentical adj3 hormone adj3 therap\$).tw.
72	(bio identical adj3 hormone adj3 therap\$).tw.
73	BHRT.tw.
74	(natural adj3 hormone therap\$).tw.
75	(estrone or estriol).tw.
76	CLONIDINE/
77	(clonidine or catapres or dixarit).tw.
78	PLANT EXTRACTS/
79	PLANT PREPARATIONS/
80	botanical?.tw.
81	(black adj cohosh?).tw.
82	(cimicifuga or actaea or racemosas or bugbane or ranunculaceae).tw.
83	remifemin.tw.
84	TRIFOLIUM/
85	(red adj clover).tw.
86	(trifolium adj3 (pratense? or repen?)).tw.
87	PHYTOESTROGENS/
88	phyto?estrogen\$.tw.
89	ISOFLAVONES/
90	ESTROGENS, NON-STEROIDAL/
91	SOYBEANS/
92	(soybean or soy or soya).tw.
93	(nonsteroidal adj (estrogen? or estrogen?)).tw.
94	(nonsteroidal adj (estogen? or oestrogen?)).tw.
95	exp SEROTONIN UPTAKE INHIBITORS/
96	(SSRI? or SNRI?).tw.
97	PAROXETINE/
98	FLUOXETINE/
99	CYCLOHEXANOLS/
100	CITALOPRAM/
101	FLUVOXAMINE/
102	(prozac or fluoxetine or sarafem or citalopram or cipramil or venlafaxine or fluvoxamine or faverin or escitalopram or cipralext).tw.
103	GAMMA-AMINO BUTYRIC ACID/
104	(gabapentin or neurotin).tw.
105	exp ACUPUNCTURE THERAPY/
106	(acupuncture or acupressure).tw.
107	(magnetic adj band?).ti,ab.
108	exp LIFE STYLE/
109	((advice or advising) adj3 (drinking or alcohol or smoking or smoke or weight loss or BMI or obese or obesity or exercise or exercising or physical activ\$)).tw.
110	COGNITIVE THERAPY/
111	(cognitive adj3 (therap\$ or psychotherap\$)).tw.
112	or/41-111
113	and/7,40,112

### Database: Embase

#	Searches
1	HEALTH ECONOMICS/
2	exp ECONOMIC EVALUATION/
3	exp HEALTH CARE COST/
4	exp FEE/
5	BUDGET/
6	FUNDING/
7	RESOURCE ALLOCATION/

#	Searches
8	budget*.ti,ab.
9	cost*.ti,ab.
10	(economic* or pharmaco?economic*).ti,ab.
11	(price* or pricing*).ti,ab.
12	(financ* or fee or fees or expenditure* or saving*).ti,ab.
13	(value adj2 (money or monetary)).ti,ab.
14	resourc* allocat*.ti,ab.
15	(fund or funds or funding* or funded).ti,ab.
16	(ration or rations or rationing* or rationed).ti,ab.
17	or/1-16
18	"MENOPAUSE AND CLIMACTERIUM"/ or CLIMACTERIUM/ or EARLY MENOPAUSE/ or MENOPAUSE/ or POSTMENOPAUSE/
19	PREMENOPAUSE/
20	PREMATURE OVARIAN FAILURE/
21	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF).ti,ab.
22	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
23	climacteric.ti,ab.
24	or/18-23
25	HOT FLUSH/
26	(hot adj (flash\$ or flush\$)).ti,ab.
27	(vasomotor adj symptom?).ti,ab.
28	SWEATING/
29	sweat\$.ti,ab.
30	HYPERHIDROSIS/
31	SLEEP DISORDER/
32	((sleep\$ or mood\$) adj3 disturb\$).ti,ab.
33	insomnia?.ti,ab.
34	UROGENITAL TRACT DISEASE/
35	VAGINA DISEASE/ or VAGINA ATROPHY/ or VAGINAL DISCOMFORT/ or VAGINAL DRYNESS/ or VAGINAL PRURITUS/ or exp VAGINITIS/ or VULVOVAGINAL DISCOMFORT/
36	VAGINAL PAIN/
37	((vagin\$ or vulva?) adj3 (atroph\$ or dry\$ or irritat\$)).ti,ab.
38	(discomfort or uncomfortable or pain\$ or dyspareunia).ti,ab.
39	exp FEMALE SEXUAL DYSFUNCTION/
40	LIBIDO DISORDER/
41	((altered or chang? or differ\$) adj3 sexual adj3 (behavio?r\$ or function\$)).ti,ab.
42	MOOD DISORDER/
43	DEPRESSION/
44	ANXIETY/
45	EMOTIONAL DISORDER/
46	MENTAL STRESS/
47	IRRITABILITY/
48	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).ti.
49	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).ab. /freq=2
50	or/25-49
51	exp HORMONE SUBSTITUTION/ or ESTROGEN THERAPY/
52	(HRT or HT).ti,ab.
53	("menopausal hormone" adj2 therap\$).ti,ab.
54	MHT.ti,ab.
55	ESTRIOL/
56	exp ESTROGEN/
57	(oestrogen? or estrogen? or estradiol?).ti,ab.
58	exp GESTAGEN/
59	progest\$.ti,ab.
60	drospirenone.ti,ab.
61	levonorgestrel.ti,ab.
62	MPA.ti,ab.
63	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).ti,ab.
64	(angeliq or climagest or climesse or clinorette or femoston or indivina or klioferm or klovance or novofem or nuvelle or tridestra or trisequens).ti,ab.
65	"cyclo-progynova".ti,ab.
66	(premiq or premak).ti,ab.
67	hormonin.ti,ab.
68	TESTOSTERONE/
69	testosterone.ti,ab.
70	TIBOLONE/
71	(tibolone or livial).ti,ab.
72	SELECTIVE ESTROGEN RECEPTOR MODULATOR/
73	SERM?.ti,ab.
74	(bioidentical adj3 hormone adj3 therap\$).ti,ab.

#	Searches
75	(bio identical adj3 hormone adj3 therap\$).ti,ab.
76	(natural adj3 hormone therap\$).ti,ab.
77	BHRT.ti,ab.
78	ESTRONE/
79	CLONIDINE/
80	(clonidine or catapres or dixarit).ti,ab.
81	GABAPENTINE/
82	(gabapentin or neurontin).ti,ab.
83	PHYTOESTROGEN/
84	(phytoestrogen or phyto estrogen or phyto oestrogen).ti,ab.
85	SOYBEAN/
86	(soybean or soy or soya).ti,ab.
87	ISOFLAVONE/
88	ISOFLAVONE DERIVATIVE/
89	PLANT EXTRACT/
90	MEDICINAL PLANT/
91	ACTAEA RACEMOSA/
92	(black adj cohosh).ti,ab.
93	(cimicifuga or actaea or racemosas or bugbane or ranunculaceae).ti,ab.
94	remifemin.ti,ab.
95	RED CLOVER/
96	(red clover or trifolium).ti,ab.
97	ANTIESTROGEN/
98	(nonsteroidal adj (oestrogen\$ or estrogen\$)).ti,ab.
99	(non steroidal adj (oestrogen\$ or estrogen\$)).ti,ab.
100	SEROTONIN UPTAKE INHIBITOR/
101	(prozac or fluoxetine or sarafem or citalopram or cipramil or venlafaxine or fluvoxamine or faverin or escitalopram or cipralext).ti,ab.
102	ACUPUNCTURE/
103	(acupuncture or acupressure).ti,ab.
104	(magnetic adj band?).ti,ab.
105	LIFESTYLE MODIFICATION/
106	((advice or advising) adj3 (drinking or alcohol or smoking or smoke or weight loss or BMI or obese or obesity or exercise or exercising or physical activ\$)).ti,ab.
107	COGNITIVE THERAPY/
108	(cognitive adj3 therap\$).ti,ab.
109	CBT.ti,ab.
110	or/51-109
111	and/24,50,110
112	and/17,111
113	conference abstract.pt.
114	letter.pt. or LETTER/
115	note.pt.
116	editorial.pt.
117	CASE REPORT/ or CASE STUDY/
118	(letter or comment* or abstracts).ti.
119	or/113-118
120	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
121	119 not 120
122	ANIMAL/ not HUMAN/
123	NONHUMAN/
124	exp ANIMAL EXPERIMENT/
125	exp EXPERIMENTAL ANIMAL/
126	ANIMAL MODEL/
127	exp RODENT/
128	(rat or rats or mouse or mice).ti.
129	or/121-128
130	112 not 129
131	limit 130 to english language

## E.4.1 Urogenital atrophy

### Database: Medline

#	Searches
1	CLIMACTERIC/ or MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	menopaus\$.ti,ab.
3	postmenopaus\$.ti,ab.
4	post menopaus\$.ti,ab.
5	perimenopaus\$.ti,ab.

#	Searches
6	peri menopaus\$.ti,ab.
7	climacteric.ti,ab.
8	"the change of life".ti,ab.
9	or/1-8
10	VAGINA/ or VULVA/
11	ATROPHY/
12	PRURITUS/ or PRURITUS VULVAE/
13	DYSPAREUNIA/
14	or/11-13
15	and/10,14
16	and/9,15
17	VULVOVAGINITIS/
18	vulvovagini\$.ti,ab.
19	((vagina? or vulvovaginal or urogenital or genitourinary) adj5 (atroph\$ or dry\$ or pruritis or sore\$ or irrita\$ or itch\$ or pain\$ or dyspar?euni? or dysuri? or discharge? or discomfort\$ or erosion)).ti,ab.
20	(vaginitis adj5 atroph\$).ti,ab.
21	or/17-20
22	and/9,21
23	exp FEMALE UROGENITAL DISEASES/
24	urogenital.ti,ab.
25	or/23-24
26	and/9,25
27	VAGINA/de, pa [Drug Effects, Pathology]
28	VULVA/de, pa [Drug Effects, Pathology]
29	or/27-28
30	and/9,29
31	or/16,22,26,30
32	ESTROGEN REPLACEMENT THERAPY/
33	((estrogen or oestrogen) adj3 replac\$).ti,ab.
34	ESTRADIOL/
35	ESTRIOL/
36	(estradiol or estriol or oestradiol or oestriol).ti,ab.
37	"ESTROGENS, CONJUGATED (USP)"/
38	exp SELECTIVE ESTROGEN RECEPTOR MODULATOR/
39	(selective adj estrogen adj receptor? adj modulator?).ti,ab.
40	(selective adj oestrogen adj receptor? modulator?).ti,ab.
41	SERM?.ti,ab.
42	or/32-41
43	ADMINISTRATION, INTRAVAGINAL/
44	"VAGINAL CREAMS, FOAMS, AND JELLIES"/
45	((local\$ or topical\$ or intravaginal\$ or intra vaginal\$) adj5 (oestrogen? or estrogen? or administration)).ti,ab.
46	(gynest or ovestin or vagifem or estring or vaginal ring).ti,ab.
47	PESSARIES/
48	(vaginal\$ adj5 (cream? or gel? or pessar\$ or ring? or tablet?)).ti,ab.
49	or/43-48
50	and/42,49
51	DIENESTROL/
52	(dienestrol or synestrol or dienestrol or oestrasid).ti,ab.
53	(ospemifene or ospheña or ophena).ti,ab.
54	"ortho-gynest".ti,ab.
55	(gynest or ovestin or vagifem or estring).ti,ab.
56	or/51-55
57	or/50,56
58	and/9,31,57
59	LETTER/
60	EDITORIAL/
61	NEWS/
62	exp HISTORICAL ARTICLE/
63	ANECDOTES AS TOPIC/
64	COMMENT/
65	CASE REPORT/
66	(letter or comment* or abstracts).ti.
67	or/59-66
68	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
69	67 not 68
70	ANIMALS/ not HUMANS/
71	exp ANIMALS, LABORATORY/
72	exp ANIMAL EXPERIMENTATION/
73	exp MODELS, ANIMAL/
74	exp RODENTIA/

#	Searches
75	(rat or rats or mouse or mice).ti.
76	or/69-75
77	58 not 76

### Database: Medline-in-progress

#	Searches
1	menopaus\$.ti,ab.
2	postmenopaus\$.ti,ab.
3	post menopaus\$.ti,ab.
4	perimenopaus\$.ti,ab.
5	peri menopaus\$.ti,ab.
6	climacteric.ti,ab.
7	"the change of life".ti,ab.
8	or/1-7
9	(vaginitis adj5 atroph\$).ti,ab.
10	vulvovagini\$.ti,ab.
11	((vagina? or vulva? or vulvovaginal or urogenital\$ or genitourinary) adj5 (atroph\$ or dry\$ or pruritis or sore\$ or irrita\$ or itch\$ or pain\$ or dyspar?euni? or dysuri? or discharge? or discomfort\$ or erosion)).ti,ab.
12	urogenital.ti,ab.
13	or/9-12
14	((estrogen or oestrogen) adj3 replac\$).ti,ab.
15	(estradiol or estriol or oestradiol or oestriol).ti,ab.
16	(selective adj estrogen adj receptor? adj modulator?).ti,ab.
17	(selective adj oestrogen adj receptor? modulator?).ti,ab.
18	SERM?.ti,ab.
19	or/14-18
20	((local\$ or topical\$ or intravaginal\$ or intra vaginal\$) adj5 (oestrogen? or estrogen? or administration)).ti,ab.
21	(gynest or ovestin or vagifem or estring or vaginal ring).ti,ab.
22	(vaginal\$ adj5 (cream? or gel? or ring? or tablet?)).ti,ab.
23	pessar\$.ti,ab.
24	or/20-23
25	and/19,24
26	(dienestrol or synestrol or dienoestrol or oestrasid).ti,ab.
27	(ospemifene or ospheña or ophena).ti,ab.
28	"ortho-gynest".ti,ab.
29	(gynest or ovestin or vagifem or estring).ti,ab.
30	or/26-29
31	or/25,30
32	and/8,13,31

### Database: Cochrane Central Register of Controlled Trials

#	Searches
1	CLIMACTERIC/ or MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	menopaus\$.ti,ab.
3	postmenopaus\$.ti,ab.
4	post menopaus\$.ti,ab.
5	perimenopaus\$.ti,ab.
6	peri menopaus\$.ti,ab.
7	climacteric.ti,ab.
8	"the change of life".ti,ab.
9	or/1-8
10	VAGINA/ or VULVA/
11	ATROPHY/
12	PRURITUS/ or PRURITUS VULVAE/
13	DYSPAREUNIA/
14	or/11-13
15	and/10,14
16	and/9,15
17	VULVOVAGINITIS/
18	vulvovagini\$.ti,ab.
19	((vagina? or vulvovaginal or urogenital or genitourinary) adj5 (atroph\$ or dry\$ or pruritis or sore\$ or irrita\$ or itch\$ or pain\$ or dyspar?euni? or dysuri? or discharge? or discomfort\$ or erosion)).ti,ab.
20	(vaginitis adj5 atroph\$).ti,ab.
21	or/17-20
22	and/9,21
23	exp FEMALE UROGENITAL DISEASES/
24	urogenital.ti,ab.
25	or/23-24
26	and/9,25

#	Searches
27	VAGINA/de, pa
28	VULVA/de, pa
29	or/27-28
30	and/9,29
31	or/16,22,26,30
32	ESTROGEN REPLACEMENT THERAPY/
33	((estrogen or oestrogen) adj3 replac\$).ti,ab.
34	ESTRADIOL/
35	ESTRIOL/
36	(estradiol or estriol or oestradiol or oestriol).ti,ab.
37	"ESTROGENS, CONJUGATED (USP)"/
38	exp SELECTIVE ESTROGEN RECEPTOR MODULATOR/
39	(selective adj estrogen adj receptor? adj modulator?).ti,ab.
40	(selective adj oestrogen adj receptor? modulator?).ti,ab.
41	SERM?.ti,ab.
42	or/32-41
43	ADMINISTRATION, INTRAVAGINAL/
44	"VAGINAL CREAMS, FOAMS, AND JELLIES"/
45	((local\$ or topical\$ or intravaginal\$ or intra vaginal\$) adj5 (oestrogen? or estrogen? or administration)).ti,ab.
46	(gynest or ovestin or vagifem or estring or vaginal ring).ti,ab.
47	PESSARIES/
48	(vaginal\$ adj5 (cream? or gel? or pessar\$ or ring? or tablet?)).ti,ab.
49	or/43-48
50	and/42,49
51	DIENESTROL/
52	(dienestrol or synestrol or dienestrol or oestrasid).ti,ab.
53	(ospemifene or ospheña or ophena).ti,ab.
54	"ortho-gynest".ti,ab.
55	(gynest or ovestin or vagifem or estring).ti,ab.
56	or/51-55
57	or/50,56
58	and/9,31,57

### Database: Cochrane Database of Systematic Reviews and Database of Abstracts of Reviews of Effects

#	Searches
1	(CLIMACTERIC or MENOPAUSE or MENOPAUSE, PREMATURE or PERIMENOPAUSE or POSTMENOPAUSE).kw.
2	menopaus\$.tw,tx.
3	postmenopaus\$.tw,tx.
4	post menopaus\$.tw,tx.
5	perimenopaus\$.tw,tx.
6	peri menopaus\$.tw,tx.
7	climacteric.tw,tx.
8	"the change of life".tw,tx.
9	or/1-8
10	(VAGINA or VULVA).kw.
11	ATROPHY.kw.
12	(PRURITUS or PRURITUS VULVAE).kw.
13	DYSPAREUNIA.kw.
14	or/11-13
15	and/10,14
16	and/9,15
17	VULVOVAGINITIS.kw.
18	vulvovagini\$.tw,tx.
19	((vagina? or vulvovaginal or urogenital or genitourinary) adj5 (atroph\$ or dry\$ or pruritis or sore\$ or irrita\$ or itch\$ or pain\$ or dyspar?euni? or dysuri? or discharge? or discomfort\$ or erosion)).tw,tx.
20	(vaginitis adj5 atroph\$).tw,tx.
21	or/17-20
22	and/9,21
23	FEMALE UROGENITAL DISEASES.kw.
24	urogenital.tw,tx.
25	or/23-24
26	and/9,25
27	VAGINA.kw.
28	VULVA.kw.
29	or/27-28
30	and/9,29
31	or/16,22,26,30
32	ESTROGEN REPLACEMENT THERAPY.kw.



#	Searches
33	((estrogen or oestrogen) adj3 replac\$).tw,tx.
34	ESTRADIOL.kw.
35	ESTRIOL.kw.
36	(estradiol or estriol or oestradiol or oestriol).tw,tx.
37	"ESTROGENS, CONJUGATED (USP)".kw.
38	SELECTIVE ESTROGEN RECEPTOR MODULATOR.kw.
39	(selective adj estrogen adj receptor? adj modulator?).tw,tx.
40	(selective adj oestrogen adj receptor? adj modulator?).tw,tx.
41	SERM?.tw,tx.
42	or/32-41
43	ADMINISTRATION, INTRAVAGINAL.kw.
44	"VAGINAL CREAMS, FOAMS, AND JELLIES".kw.
45	((local\$ or topical\$ or intravaginal\$ or intra vaginal\$) adj5 (oestrogen? or estrogen? or administration)).tw,tx.
46	(gynest or ovestin or vagifem or estring or vaginal ring).tw,tx.
47	PESSARIES.kw.
48	(vaginal\$ adj5 (cream? or gel? or pessar\$ or ring? or tablet?)).tw,tx.
49	or/43-48
50	and/42,49
51	DIENESTROL.kw.
52	(dienestrol or synestrol or dienestrol or oestrasid).tw,tx.
53	(ospemifene or ospheña or ophena).tw,tx.
54	"ortho-gynest".tw,tx.
55	(gynest or ovestin or vagifem or estring).tw,tx.
56	or/51-55
57	or/50,56
58	and/9,31,57

#### Database: Health Technology Assessment

#	Searches
1	CLIMACTERIC/ or MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	menopaus\$.tw.
3	postmenopaus\$.tw.
4	post menopaus\$.tw.
5	perimenopaus\$.tw.
6	peri menopaus\$.tw.
7	climacteric.tw.
8	"the change of life".tw.
9	or/1-8
10	VAGINA/ or VULVA/
11	ATROPHY/
12	PRURITUS/ or PRURITUS VULVAE/
13	DYSPAREUNIA/
14	or/11-13
15	and/10,14
16	and/9,15
17	VULVOVAGINITIS/
18	vulvovagini\$.tw.
19	((vagina? or vulvovaginal or urogenital or genitourinary) adj5 (atroph\$ or dry\$ or pruritis or sore\$ or irrita\$ or itch\$ or pain\$ or dyspar?euni? or dysuri? or discharge? or discomfort\$ or erosion)).tw.
20	(vaginitis adj5 atroph\$).tw.
21	or/17-20
22	and/9,21
23	exp FEMALE UROGENITAL DISEASES/
24	urogenital.tw.
25	or/23-24
26	and/9,25
27	VAGINA/de, pa
28	VULVA/de, pa
29	or/27-28
30	and/9,29
31	or/16,22,26,30
32	ESTROGEN REPLACEMENT THERAPY/
33	((estrogen or oestrogen) adj3 replac\$).tw.
34	ESTRADIOL/
35	ESTRIOL/
36	(estradiol or estriol or oestradiol or oestriol).tw.
37	"ESTROGENS, CONJUGATED (USP)"/
38	exp SELECTIVE ESTROGEN RECEPTOR MODULATOR/
39	(selective adj estrogen adj receptor? adj modulator?).tw.

#	Searches
40	(selective adj oestrogen adj receptor? adj modulator?).tw.
41	SERM?.tw.
42	or/32-41
43	ADMINISTRATION, INTRAVAGINAL/
44	"VAGINAL CREAMS, FOAMS, AND JELLIES"/
45	((local\$ or topical\$ or intravaginal\$ or intra vaginal\$) adj5 (oestrogen? or estrogen? or administration)).tw.
46	(gynest or ovestin or vagifem or estring or vaginal ring).tw.
47	PESSARIES/
48	(vaginal\$ adj5 (cream? or gel? or pessar\$ or ring? or tablet?)).tw.
49	or/43-48
50	and/42,49
51	DIENESTROL/
52	(dienestrol or synestrol or dionoestrol or oestrasid).tw.
53	(ospemifene or ospheña or ophena).tw.
54	"ortho-gynest".tw.
55	(gynest or ovestin or vagifem or estring).tw.
56	or/51-55
57	or/50,56
58	and/9,31,57

### Database: Embase

#	Searches
1	"MENOPAUSE AND CLIMACTERIUM"/ or CLIMACTERIUM/ or EARLY MENOPAUSE/ or MENOPAUSE/ or POSTMENOPAUSE/
2	menopaus\$.ti,ab.
3	postmenopaus\$.ti,ab.
4	post menopaus\$.ti,ab.
5	perimenopaus\$.ti,ab.
6	peri menopaus\$.ti,ab.
7	climacteric.ti,ab.
8	"the change of life".ti,ab.
9	or/1-8
10	VAGINAL ATROPHY/
11	((vagina? or vulvovaginal or urogenital or genitourinary) adj5 (atroph\$ or dry\$ or pruritis or sore\$ or irrita\$ or itch\$ or pain\$ or dyspar?euni? or dysuri? or discharge? or erosion or eroded)).ti,ab.
12	(vaginitis adj5 atroph\$).ti,ab.
13	VULVA PRURITUS/ or VAGINAL PRURITUS/
14	or/10-13
15	exp VAGINA/
16	DYSPAREUNIA/
17	and/15-16
18	VULVOVAGINITIS/
19	vulvovagini\$.ti,ab.
20	((wom#n or female?) adj5 urogenital).ti,ab.
21	GENITAL SYSTEM DISEASE/ or GENITAL BLEEDING/ or GENITAL EDEMA/ or GENITAL ERYTHEMA/ or GENITAL INJURY/ or GENITAL PAIN/ or GENITAL PRURITUS/ or GENITAL TRACT INFECTION/ or GENITAL TRACT INFLAMMATION/
22	MENOPAUSE RELATED DISORDER/ or MENOPAUSAL SYNDROME/
23	or/18-22
24	or/14,17,23
25	and/9,24
26	ESTROGEN THERAPY/
27	((estrogen or oestrogen) adj3 replac\$).ti,ab.
28	ESTRADIOL/
29	ESTRIOL/
30	(estradiol or estriol or oestradiol or oestriol).ti,ab.
31	CONJUGATED ESTROGEN/
32	SELECTIVE ESTROGEN RECEPTOR MODULATOR/
33	(selective adj estrogen adj receptor? adj modulator?).ti,ab.
34	(selective adj oestrogen adj receptor? adj modulator?).ti,ab.
35	SERM?.ti,ab.
36	or/26-35
37	INTRAVAGINAL DRUG ADMINISTRATION/
38	VAGINAL RING/
39	VAGINAL PESSARY/
40	(vaginal\$ adj5 (cream? or gel? or pessar\$ or ring? or tablet?)).ti,ab.
41	((local\$ or topical or intravaginal\$ or intra vaginal\$) adj5 (oestrogen? or estrogen? or administration)).ti,ab.
42	or/37-41
43	and/36,42
44	DIENESTROL/

#	Searches
45	(dienestrol or synestrol or dienoeestrol or oestrasid).ti,ab.
46	(ospemifene or ospheña or ophena).ti,ab.
47	"ortho-gynest".ti,ab.
48	(gynest or ovestin or vagifem or estring).ti,ab.
49	or/44-48
50	or/43,49
51	and/25,50
52	conference abstract.pt.
53	letter.pt. or LETTER/
54	note.pt.
55	editorial.pt.
56	CASE REPORT/ or CASE STUDY/
57	(letter or comment* or abstracts).ti.
58	or/52-57
59	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
60	58 not 59
61	ANIMAL/ not HUMAN/
62	NONHUMAN/
63	exp ANIMAL EXPERIMENT/
64	exp EXPERIMENTAL ANIMAL/
65	ANIMAL MODEL/
66	exp RODENT/
67	(rat or rats or mouse or mice).ti.
68	or/60-67
69	51 not 68
70	limit 69 to english language

## E.5 Review and referral

### Database: Medline

#	Searches
1	((timing or time or assess\$) adj3 (clinical or treatment or therap\$) adj3 review\$).ti,ab.
2	(assess\$ adj5 interval?).ti,ab.
3	((frequen\$ or regular\$ or timing or time or schedul\$) adj3 (review or check up or follow up or assessment or evaluat\$)).ti,ab.
4	((review or follow up) adj2 (assess\$ or consultation?)).ti,ab.
5	or/1-4
6	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/ or PREMENOPAUSE/
7	PRIMARY OVARIAN INSUFFICIENCY/
8	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF or POI).ti,ab.
9	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
10	CLIMACTERIC/
11	climacteric.ti,ab.
12	(change adj1 life).ti,ab.
13	or/6-12
14	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
15	(hormon\$ adj3 substit\$).ti,ab.
16	(HRT or HT).ti,ab.
17	("menopausal hormone" adj2 therap\$).ti,ab.
18	MHT.ti,ab.
19	exp ESTRADIOL/
20	ESTROGENS/ or ESTROGENS, NON-STEROIDAL/
21	ESTRADIOL/ or ESTRAMUSTINE/
22	ETHINYL ESTRADIOL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/
23	(oestrogen? or estrogen? or estradiol?).ti,ab.
24	PROGESTOGENS/
25	progesta\$.ti,ab.
26	MEDROXYPROGESTERONE ACETATE/
27	MPA.ti,ab.
28	exp PROGESTERONE/
29	ETHISTERONE/
30	NORETHINDRONE/ or NORGESTREL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/ or LEVONORGESTREL/ or NORPROGESTERONES/
31	drospirenone.ti,ab.
32	levonorgestrel.ti,ab.
33	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).ti,ab.

#	Searches
34	(angeliq or climagest or climesse or clinorette or femoston or indivina or kiofem or kioavance or novofem or nuvelle or tridestra or trisequens).ti,ab.
35	"cyclo-progynova".ti,ab.
36	(premiq or premak).ti,ab.
37	hormonin.ti,ab.
38	TESTOSTERONE/
39	testosterone.ti,ab.
40	NORPREGENES/
41	(tibolone or livial).ti,ab.
42	exp SELECTIVE ESTROGEN RECEPTOR MODULATORS/
43	SERM?.ti,ab.
44	(bioidentical adj3 hormone adj3 therap\$).ti,ab.
45	(bio identical adj3 hormone adj3 therap\$).ti,ab.
46	BHRT.ti,ab.
47	(natural adj3 hormone therap\$).ti,ab.
48	(estrone or estriol).ti,ab.
49	CLONIDINE/
50	(clonidine or catapres or dixarit).ti,ab.
51	PLANT EXTRACTS/
52	PLANT PREPARATIONS/
53	botanical?.ti,ab.
54	(black adj cohosh?).ti,ab.
55	(cimicifuga or actaea or racemosas or bugbane or ranunculaceae).ti,ab.
56	remifemin.ti,ab.
57	TRIFOLIUM/
58	(red adj clover).ti,ab.
59	(trifolium adj3 (pratense? or repen?)).ti,ab.
60	PHYTOESTROGENS/
61	phyto?estrogen\$.ti,ab.
62	ISOFLAVONES/
63	ESTROGENS, NON-STEROIDAL/
64	SOYBEANS/
65	(soybean or soy or soya).ti,ab.
66	(nonsteroidal adj (estrogen? or estrogen?)).ti,ab.
67	(nonsteroidal adj (estogen? or oestrogen?)).ti,ab.
68	exp SEROTONIN UPTAKE INHIBITORS/
69	(SSRI? or SNRI?).ti,ab.
70	PAROXETINE/
71	FLUOXETINE/
72	CYCLOHEXANOLS/
73	CITALOPRAM/
74	FLUVOXAMINE/
75	(prozac or fluoxetine or sarafem or citalopram or cipramil or venlafaxine or fluvoxamine or faverin or escitalopram or cipralex).ti,ab.
76	GAMMA-AMINOBUTYRIC ACID/
77	(gabapentin or neurotin).ti,ab.
78	exp ACUPUNCTURE THERAPY/
79	(acupuncture or acupressure).ti,ab.
80	(magnetic adj band?).ti,ab.
81	exp LIFE STYLE/
82	((advice or advising) adj3 (drinking or alcohol or smoking or smoke or weight loss or BMI or obese or obesity or exercise or exercising or physical activ\$)).ti,ab.
83	COGNITIVE THERAPY/
84	(cognitive adj3 (therap\$ or psychotherap\$)).ti,ab.
85	or/14-84
86	and/5,13,85
87	LETTER/
88	EDITORIAL/
89	NEWS/
90	exp HISTORICAL ARTICLE/
91	ANECDOTES AS TOPIC/
92	COMMENT/
93	CASE REPORT/
94	(letter or comment* or abstracts).ti.
95	or/87-94
96	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
97	95 not 96
98	ANIMALS/ not HUMANS/
99	exp ANIMALS, LABORATORY/
100	exp ANIMAL EXPERIMENTATION/

#	Searches
101	exp MODELS, ANIMAL/
102	exp RODENTIA/
103	(rat or rats or mouse or mice).ti.
104	or/97-103
105	86 not 104
106	limit 105 to english language

### Database: Medline In-Process

#	Searches
1	((timing or time or assess\$) adj3 (clinical or treatment or therap\$) adj3 review\$).tw,tx.
2	(assess\$ adj5 interval?).tw,tx.
3	((frequen\$ or regular\$ or timing or time or schedul\$) adj3 (review or check up or follow up or assessment or evaluat\$)).tw,tx.
4	((review or follow up) adj2 (assess\$ or consultation?)).tw,tx.
5	or/1-4
6	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF or POI).ti,ab.
7	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
8	climacteric.ti,ab.
9	(change adj1 life).ti,ab.
10	or/6-9
11	((hormon\$ or estrogen or oestrogen) adj3 therap\$).ti,ab.
12	(hormon\$ adj3 substit\$).ti,ab.
13	(HRT or HT).ti,ab.
14	("menopausal hormone" adj2 therap\$).ti,ab.
15	MHT.ti,ab.
16	(oestrogen? or estrogen? or estradiol? or estriol).ti,ab.
17	progest\$.ti,ab.
18	medroxyprogesterone acetate.ti,ab.
19	MPA.ti,ab.
20	ethisterone.ti,ab.
21	(norethindrone or norgestrel or ethinyl estradiol norgestrel combination or levonorgestrel or norprogesterones).ti,ab.
22	drospirenone.ti,ab.
23	levonorgestrel.ti,ab.
24	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).ti,ab.
25	(angeliq or climagest or climesse or clinorette or femoston or indivina or kiofem or kioavance or novofem or nuvelle or tridestra or trisequens).ti,ab.
26	"cyclo-progynova".ti,ab.
27	(premiq or premak).ti,ab.
28	hormonin.ti,ab.
29	testosterone.ti,ab.
30	(tibolone or livial).ti,ab.
31	selective estrogen receptor modulator?.ti,ab.
32	SERM?.ti,ab.
33	(bioidentical adj3 hormone adj3 therap\$).ti,ab.
34	(bio identical adj3 hormone adj3 therap\$).ti,ab.
35	BHRT.ti,ab.
36	(natural adj3 hormone therap\$).ti,ab.
37	(estrone or estriol).ti,ab.
38	(clonidine or catapres or dixarit).ti,ab.
39	botanical?.ti,ab.
40	(black adj cohosh?).ti,ab.
41	(cimicifuga or actaea or racemosas or bugbane or ranunculaceae).ti,ab.
42	remifemin.ti,ab.
43	(red adj clover).ti,ab.
44	(trifolium adj3 (pratense? or repen?)).ti,ab.
45	phyto?estrogen\$.ti,ab.
46	isoflavon\$.ti,ab.
47	(nonsteroidal adj3 (estrogen? or oestrogen?)).ti,ab.
48	(non steroidal adj3 (estrogen? or oestrogen?)).ti,ab.
49	(soybean or soy or soya).ti,ab.
50	(nonsteroidal adj (estrogen? or estrogen?)).ti,ab.
51	(nonsteroidal adj (estogen? or oestrogen?)).ti,ab.
52	serotonin reuptake inhibitor?.ti,ab.
53	(SSRI? or SNRI?).ti,ab.
54	(prozac or fluoxetine or sarafem or citalopram or cipramil or venlafaxine or fluvoxamine or faverin or escitalopram or cipralax).ti,ab.
55	(gabapentin or neurotin).ti,ab.
56	(acupuncture or acupressure).ti,ab.
57	(magnetic adj band?).ti,ab.

#	Searches
58	((advice or advising) adj3 (drinking or alcohol or smoking or smoke or weight loss or BMI or obese or obesity or exercise or exercising or physical activ\$)).ti,ab.
59	(cognitive adj3 (therap\$ or psychotherap\$)).ti,ab.
60	or/11-59
61	and/5,10,60

### Database: Cochrane Central Register of Controlled Trials

#	Searches
1	((timing or time or assess\$) adj3 (clinical or treatment or therap\$) adj3 review\$).ti,ab.
2	(assess\$ adj5 interval?).ti,ab.
3	((frequen\$ or regular\$ or timing or time or schedul\$) adj3 (review or check up or follow up or assessment or evaluat\$)).ti,ab.
4	((review or follow up) adj2 (assess\$ or consultation?)).ti,ab.
5	or/1-4
6	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/ or PREMENOPAUSE/
7	PRIMARY OVARIAN INSUFFICIENCY/
8	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF or POI).ti,ab.
9	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
10	CLIMACTERIC/
11	climacteric.ti,ab.
12	(change adj1 life).ti,ab.
13	or/6-12
14	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
15	(hormon\$ adj3 substit\$).ti,ab.
16	(HRT or HT).ti,ab.
17	("menopausal hormone" adj2 therap\$).ti,ab.
18	MHT.ti,ab.
19	exp ESTRIOL/
20	ESTROGENS/ or ESTROGENS, NON-STEROIDAL/
21	ESTRADIOL/ or ESTRAMUSTINE/
22	ETHINYL ESTRADIOL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/
23	(oestrogen? or estrogen? or estradiol?).ti,ab.
24	PROGESTOGENS/
25	progesta\$.ti,ab.
26	MEDROXYPROGESTERONE ACETATE/
27	MPA.ti,ab.
28	exp PROGESTERONE/
29	ETHISTERONE/
30	NORETHINDRONE/ or NORGESTREL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/ or LEVONORGESTREL/ or NORPROGESTERONES/
31	drospirenone.ti,ab.
32	levonorgestrel.ti,ab.
33	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynova or progynova or sandrena or zumenon).ti,ab.
34	(angeliq or climagest or climesse or clinorette or femoston or indivina or kiofem or kioavance or novofem or nuvelle or tridestra or trisequens).ti,ab.
35	"cyclo-progynova".ti,ab.
36	(premiq or premak).ti,ab.
37	hormonin.ti,ab.
38	TESTOSTERONE/
39	testosterone.ti,ab.
40	NORPREGENES/
41	(tibolone or livial).ti,ab.
42	exp SELECTIVE ESTROGEN RECEPTOR MODULATORS/
43	SERM?.ti,ab.
44	(bioidentical adj3 hormone adj3 therap\$).ti,ab.
45	(bio identical adj3 hormone adj3 therap\$).ti,ab.
46	BHRT.ti,ab.
47	(natural adj3 hormone therap\$).ti,ab.
48	(estrone or estriol).ti,ab.
49	CLONIDINE/
50	(clonidine or catapres or dixarit).ti,ab.
51	PLANT EXTRACTS/
52	PLANT PREPARATIONS/
53	botanical?.ti,ab.
54	(black adj cohosh?).ti,ab.
55	(cimicifuga or actaea or racemosas or bugbane or ranunculaceae).ti,ab.
56	remifemin.ti,ab.
57	TRIFOLIUM/

#	Searches
58	(red adj clover).ti,ab.
59	(trifolium adj3 (pratense? or repen?)).ti,ab.
60	PHYTOESTROGENS/
61	phyto?estrogen\$.ti,ab.
62	ISOFLAVONES/
63	ESTROGENS, NON-STEROIDAL/
64	SOYBEANS/
65	(soybean or soy or soya).ti,ab.
66	(nonsteroidal adj (estrogen? or estrogen?)).ti,ab.
67	(nonsteroidal adj (estogen? or oestrogen?)).ti,ab.
68	exp SEROTONIN UPTAKE INHIBITORS/
69	(SSRI? or SNRI?).ti,ab.
70	PAROXETINE/
71	FLUOXETINE/
72	CYCLOHEXANOLS/
73	CITALOPRAM/
74	FLUVOXAMINE/
75	(prozac or fluoxetine or sarafem or citalopram or cipramil or venlafaxine or fluvoxamine or faverin or escitalopram or cipralex).ti,ab.
76	GAMMA-AMINO BUTYRIC ACID/
77	(gabapentin or neurotin).ti,ab.
78	exp ACUPUNCTURE THERAPY/
79	(acupuncture or acupressure).ti,ab.
80	(magnetic adj band?).ti,ab.
81	exp LIFE STYLE/
82	((advice or advising) adj3 (drinking or alcohol or smoking or smoke or weight loss or BMI or obese or obesity or exercise or exercising or physical activ\$)).ti,ab.
83	COGNITIVE THERAPY/
84	(cognitive adj3 (therap\$ or psychotherap\$)).ti,ab.
85	or/14-84
86	and/5,13,85

### Database: Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects

#	Searches
1	((timing or time or assess\$) adj3 (clinical or treatment or therap\$) adj3 review\$).tw,tx.
2	(assess\$ adj5 interval?).tw,tx.
3	((frequen\$ or regular\$ or timing or time or schedul\$) adj3 (review or check up or follow up or assessment or evaluat\$)).tw,tx.
4	((review or follow up) adj2 (assess\$ or consultation?)).tw,tx.
5	or/1-4
6	(MENOPAUSE or MENOPAUSE, PREMATURE or PERIMENOPAUSE or POSTMENOPAUSE or PREMENOPAUSE).kw.
7	PRIMARY OVARIAN INSUFFICIENCY.kw.
8	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF or POI).tw,tx.
9	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).tw,tx.
10	CLIMACTERIC.kw.
11	climacteric.tw,tx.
12	(change adj1 life).tw,tx.
13	or/6-12
14	(HORMONE REPLACEMENT THERAPY or ESTROGEN REPLACEMENT THERAPY).kw.
15	(hormon\$ adj3 substit\$).tw,tx.
16	(HRT or HT).tw.
17	("menopausal hormone" adj2 therap\$).tw,tx.
18	MHT.tw,tx.
19	ESTRIOL.kw.
20	(ESTROGENS or ESTROGENS, NON-STEROIDAL).kw.
21	(ESTRADIOL or ESTRAMUSTINE).kw.
22	(ETHINYL ESTRADIOL or ETHINYL ESTRADIOL-NORGESTREL COMBINATION).kw.
23	(oestrogen? or estrogen? or estradiol?).tw,tx.
24	PROGESTOGENS.kw.
25	progesta\$.tw,tx.
26	MEDROXYPROGESTERONE ACETATE.kw.
27	MPA.tw,tx.
28	PROGESTERONE.kw.
29	ETHISTERONE.kw.
30	(NORETHINDRONE or NORGESTREL or ETHINYL ESTRADIOL-NORGESTREL COMBINATION or LEVONORGESTREL or NORPROGESTERONES).kw.
31	drospirenone.tw,tx.

#	Searches
32	levonorgestrel.tw,tx.
33	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).tw,tx.
34	(angeliq or climagest or climesse or clinorette or femoston or indivina or kiofem or kioavance or novofem or nuvelle or tridestra or trisequens).tw,tx.
35	"cyclo-progynova".tw,tx.
36	(premiq or premak).tw,tx.
37	hormonin.tw,tx.
38	TESTOSTERONE.kw.
39	testosterone.tw,tx.
40	NORPREGENES.kw.
41	(tibolone or livial).tw,tx.
42	SELECTIVE ESTROGEN RECEPTOR MODULATORS.kw.
43	SERM?.tw,tx.
44	(bioidentical adj3 hormone adj3 therap\$).tw,tx.
45	(bio identical adj3 hormone adj3 therap\$).tw,tx.
46	BHRT.tw,tx.
47	(natural adj3 hormone therap\$).tw,tx.
48	(estrone or estriol).tw,tx.
49	CLONIDINE.kw.
50	(clonidine or catapres or dixarit).tw,tx.
51	PLANT EXTRACTS.kw.
52	PLANT PREPARATIONS.kw.
53	botanical?.tw,tx.
54	(black adj cohosh?).tw,tx.
55	(cimicifuga or actaea or racemosas or bugbane or ranunculaceae).tw,tx.
56	remifemin.tw,tx.
57	TRIFOLIUM.kw.
58	(red adj clover).tw,tx.
59	(trifolium adj3 (pratense? or repen?)).tw,tx.
60	PHYTOESTROGENS.kw.
61	phyto?estrogen\$.tw,tx.
62	ISOFLAVONES.kw.
63	ESTROGENS, NON-STEROIDAL.kw.
64	SOYBEANS.kw.
65	(soybean or soy or soya).tw,tx.
66	(nonsteroidal adj (estrogen? or estrogen?)).tw,tx.
67	(nonsteroidal adj (estogen? or oestrogen?)).tw,tx.
68	SEROTONIN UPTAKE INHIBITORS.kw.
69	(SSRI? or SNRI?).tw,tx.
70	PAROXETINE.kw.
71	FLUOXETINE.kw.
72	CYCLOHEXANOLS.kw.
73	CITALOPRAM.kw.
74	FLUVOXAMINE.kw.
75	(prozac or fluoxetine or sarafem or citalopram or cipramil or venlafaxine or fluvoxamine or faverin or escitalopram or cipralax).tw,tx.
76	GAMMA-AMINOBTYRIC ACID.kw.
77	(gabapentin or neurotin).tw,tx.
78	ACUPUNCTURE THERAPY.kw.
79	(acupuncture or acupressure).tw,tx.
80	(magnetic adj band?).tw,tx.
81	LIFE STYLE.kw.
82	((advice or advising) adj3 (drinking or alcohol or smoking or smoke or weight loss or BMI or obese or obesity or exercise or exercising or physical activ\$)).tw,tx.
83	COGNITIVE THERAPY.kw.
84	(cognitive adj3 (therap\$ or psychotherap\$)).tw,tx.
85	or/14-84
86	and/5,13,85

### Database: Health Technology Assessment

#	Searches
1	((timing or time or assess\$) adj3 (clinical or treatment or therap\$) adj3 review\$).tw.
2	(assess\$ adj5 interval?).tw.
3	((frequen\$ or regular\$ or timing or time or schedul\$) adj3 (review or check up or follow up or assessment or evaluat\$)).tw.
4	((review or follow up) adj2 (assess\$ or consultation?)).tw.
5	or/1-4
6	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/ or PREMENOPAUSE/



#	Searches
7	PRIMARY OVARIAN INSUFFICIENCY/
8	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF or POI).tw.
9	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).tw.
10	CLIMACTERIC/
11	climacteric.tw.
12	(change adj1 life).tw.
13	or/6-12
14	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
15	(hormon\$ adj3 substit\$).tw.
16	(HRT or HT).tw.
17	("menopausal hormone" adj2 therap\$).tw.
18	MHT.tw.
19	exp ESTRIOL/
20	ESTROGENS/ or ESTROGENS, NON-STEROIDAL/
21	ESTRADIOL/ or ESTRAMUSTINE/
22	ETHINYL ESTRADIOL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/
23	(oestrogen? or estrogen? or estradiol?).tw.
24	PROGESTOGENS/
25	progesta\$.tw.
26	MEDROXYPROGESTERONE ACETATE/
27	MPA.tw.
28	exp PROGESTERONE/
29	ETHISTERONE/
30	NORETHINDRONE/ or NORGESTREL/ or ETHINYL ESTRADIOL-NORGESTREL COMBINATION/ or LEVONORGESTREL/ or NORPROGESTERONES/
31	drospirenone.tw.
32	levonorgestrel.tw.
33	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).tw.
34	(angeliq or climagest or climesse or clinorette or femoston or indivina or klioferm or klovance or novofem or nuvelle or tridestra or trisequens).tw.
35	"cyclo-progynova".tw.
36	(premiq or premak).tw.
37	hormonin.tw.
38	TESTOSTERONE/
39	testosterone.tw.
40	NORPREGENES/
41	(tibolone or livial).tw.
42	exp SELECTIVE ESTROGEN RECEPTOR MODULATORS/
43	SERM?.tw.
44	(bioidentical adj3 hormone adj3 therap\$).tw.
45	(bio identical adj3 hormone adj3 therap\$).tw.
46	BHRT.tw.
47	(natural adj3 hormone therap\$).tw.
48	(estrone or estriol).tw.
49	CLONIDINE/
50	(clonidine or catapres or dixarit).tw.
51	PLANT EXTRACTS/
52	PLANT PREPARATIONS/
53	botanical?.tw.
54	(black adj cohosh?).tw.
55	(cimicifuga or actaea or racemosas or bugbane or ranunculaceae).tw.
56	remifemin.tw.
57	TRIFOLIUM/
58	(red adj clover).tw.
59	(trifolium adj3 (pratense? or repen?)).tw.
60	PHYTOESTROGENS/
61	phyto?estrogen\$.tw.
62	ISOFLAVONES/
63	ESTROGENS, NON-STEROIDAL/
64	SOYBEANS/
65	(soybean or soy or soya).tw.
66	(nonsteroidal adj (estrogen? or estrogen?)).tw.
67	(nonsteroidal adj (estogen? or oestrogen?)).tw.
68	exp SEROTONIN UPTAKE INHIBITORS/
69	(SSRI? or SNRI?).tw.
70	PAROXETINE/
71	FLUOXETINE/
72	CYCLOHEXANOLS/
73	CITALOPRAM/

#	Searches
74	FLUVOXAMINE/
75	(prozac or fluoxetine or sarafem or citalopram or cipramil or venlafaxine or fluvoxamine or faverin or escitalopram or cipralextw).tw.
76	GAMMA-AMINOBTYRIC ACID/
77	(gabapentin or neurotin).tw.
78	exp ACUPUNCTURE THERAPY/
79	(acupuncture or acupressure).tw.
80	(magnetic adj band?).tw.
81	exp LIFE STYLE/
82	((advice or advising) adj3 (drinking or alcohol or smoking or smoke or weight loss or BMI or obese or obesity or exercise or exercising or physical activ\$)).tw.
83	COGNITIVE THERAPY/
84	(cognitive adj3 (therap\$ or psychotherap\$)).tw.
85	or/14-84
86	and/5,13,85

### Database: Embase

#	Searches
1	((timing or time or assess\$) adj3 (clinical or treatment or therap\$) adj3 review\$).ti,ab.
2	(assess\$ adj5 interval?).ti,ab.
3	((frequen\$ or regular\$ or timing or time or schedul\$) adj3 (review or check up or follow up or assessment or evaluat\$)).ti,ab.
4	((review or follow up) adj2 (assess\$ or consultation?)).ti,ab.
5	treatment planning/
6	or/1-5
7	"MENOPAUSE AND CLIMACTERIUM"/ or CLIMACTERIUM/ or EARLY MENOPAUSE/ or MENOPAUSE/ or POSTMENOPAUSE/
8	PREMENOPAUSE/
9	PREMATURE OVARIAN FAILURE/
10	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF).ti,ab.
11	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
12	climacteric.ti,ab.
13	(change adj1 life).ti,ab.
14	or/7-13
15	exp HORMONE SUBSTITUTION/ or ESTROGEN THERAPY/
16	(HRT or HT).ti,ab.
17	("menopausal hormone" adj2 therap\$).ti,ab.
18	MHT.ti,ab.
19	ESTRIOL/
20	exp ESTROGEN/
21	(oestrogen? or estrogen? or estradiol?).ti,ab.
22	exp GESTAGEN/
23	progest\$.ti,ab.
24	drospirenone.ti,ab.
25	levonorgestrel.ti,ab.
26	MPA.ti,ab.
27	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).ti,ab.
28	(angeliq or climagest or climesse or clinorette or femoston or indivina or kiofem or kioavance or novofem or nuvelle or tridestra or trisequens).ti,ab.
29	"cyclo-progynova".ti,ab.
30	(premiq or premak).ti,ab.
31	hormonin.ti,ab.
32	TESTOSTERONE/
33	testosterone.ti,ab.
34	TIBOLONE/
35	(tibolone or livial).ti,ab.
36	SELECTIVE ESTROGEN RECEPTOR MODULATOR/
37	SERM?.ti,ab.
38	(bioidentical adj3 hormone adj3 therap\$).ti,ab.
39	(bio identical adj3 hormone adj3 therap\$).ti,ab.
40	(natural adj3 hormone therap\$).ti,ab.
41	BHRT.ti,ab.
42	ESTRONE/
43	CLONIDINE/
44	(clonidine or catapres or dixarit).ti,ab.
45	GABAPENTINE/
46	(gabapentin or neurontin).ti,ab.
47	PHYTOESTROGEN/
48	(phytoestrogen or phyto estrogen or phyto oestrogen).ti,ab.

#	Searches
49	SOYBEAN/
50	(soybean or soy or soya).ti,ab.
51	ISOFLAVONE/
52	ISOFLAVONE DERIVATIVE/
53	PLANT EXTRACT/
54	MEDICINAL PLANT/
55	ACTAEA RACEMOSA/
56	(black adj cohosh).ti,ab.
57	(cimicifuga or actaea or racemosas or bugbane or ranunculaceae).ti,ab.
58	remifemin.ti,ab.
59	RED CLOVER/
60	(red clover or trifolium).ti,ab.
61	ANTIESTROGEN/
62	(nonsteroidal adj (oestrogen\$ or estrogen\$)).ti,ab.
63	(non steroidal adj (oestrogen\$ or estrogen\$)).ti,ab.
64	SEROTONIN UPTAKE INHIBITOR/
65	(prozac or fluoxetine or sarafem or citalopram or cipramil or venlafaxine or fluvoxamine or faverin or escitalopram or cipralext).ti,ab.
66	ACUPUNCTURE/
67	(acupuncture or acupressure).ti,ab.
68	(magnetic adj band?).ti,ab.
69	LIFESTYLE MODIFICATION/
70	((advice or advising) adj3 (drinking or alcohol or smoking or smoke or weight loss or BMI or obese or obesity or exercise or exercising or physical activ\$)).ti,ab.
71	COGNITIVE THERAPY/
72	(cognitive adj3 therap\$).ti,ab.
73	CBT.ti,ab.
74	or/15-73
75	and/6,14,74
76	conference abstract.pt.
77	letter.pt. or LETTER/
78	note.pt.
79	editorial.pt.
80	CASE REPORT/ or CASE STUDY/
81	(letter or comment* or abstracts).ti.
82	or/76-81
83	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
84	82 not 83
85	ANIMAL/ not HUMAN/
86	NONHUMAN/
87	exp ANIMAL EXPERIMENT/
88	exp EXPERIMENTAL ANIMAL/
89	ANIMAL MODEL/
90	exp RODENT/
91	(rat or rats or mouse or mice).ti.
92	or/84-91
93	75 not 92
94	limit 93 to english language

## E.6 Starting and stopping HRT

### Database: Medline

#	Searches
1	exp MENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
4	"change of life".ti,ab.
5	PRIMARY OVARIAN INSUFFICIENCY/
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
7	(POI or POF).ti,ab.
8	or/1-7
9	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
10	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
11	(HRT or HT).ti,ab.
12	("menopausal hormone" adj2 therap\$).ti,ab.
13	MHT.ti,ab.
14	or/9-13

#	Searches
15	and/8,14
16	DRUG ADMINISTRATION SCHEDULE/
17	WITHHOLDING TREATMENT/
18	or/16-17
19	(discontin\$ or immediate\$ or stop\$ or ceas\$ or abrupt\$ or sudden\$).ti,ab.
20	"cold turkey".ti,ab.
21	or/19-20
22	(taper\$ or decreas\$ or often or frequen\$).ti,ab.
23	((dose or dosage) adj5 (lower\$ or reduc\$)).ti,ab.
24	or/22-23
25	and/21,24
26	15 and (18 or 25)
27	LETTER/
28	EDITORIAL/
29	NEWS/
30	exp HISTORICAL ARTICLE/
31	ANECDOTES AS TOPIC/
32	COMMENT/
33	CASE REPORT/
34	(letter or comment* or abstracts).ti.
35	or/27-34
36	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
37	35 not 36
38	ANIMALS/ not HUMANS/
39	exp ANIMALS, LABORATORY/
40	exp ANIMAL EXPERIMENTATION/
41	exp MODELS, ANIMAL/
42	exp RODENTIA/
43	(rat or rats or mouse or mice).ti.
44	or/37-43
45	26 not 44
46	limit 45 to english language

#### Database: Medline-in-progress

#	Searches
1	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
2	"change of life".ti,ab.
3	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
4	(POI or POF).ti,ab.
5	or/1-4
6	((hormon\$ or oestrogen or estrogen) adj3 (therap\$ or substitut\$)).ti,ab.
7	(HRT or HT).ti,ab.
8	("menopausal hormone" adj2 therap\$).ti,ab.
9	MHT.ti,ab.
10	or/6-9
11	and/5,10
12	(discontin\$ or immediate\$ or stop\$ or ceas\$ or abrupt\$ or sudden\$).ti,ab.
13	"cold turkey".ti,ab.
14	or/12-13
15	(taper\$ or decreas\$ or often or frequen\$).ti,ab.
16	((dose or dosage) adj5 (lower\$ or reduc\$)).ti,ab.
17	or/15-16
18	and/14,17
19	and/11,18

#### Database: Cochrane Central Register of Controlled Trials

#	Searches
1	exp MENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
4	"change of life".ti,ab.
5	PRIMARY OVARIAN INSUFFICIENCY/
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
7	(POI or POF).ti,ab.
8	or/1-7
9	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
10	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.

#	Searches
11	(HRT or HT).ti,ab.
12	("menopausal hormone" adj2 therap\$).ti,ab.
13	MHT.ti,ab.
14	or/9-13
15	and/8,14
16	DRUG ADMINISTRATION SCHEDULE/
17	WITHHOLDING TREATMENT/
18	or/16-17
19	(discontin\$ or immediate\$ or stop\$ or ceas\$ or abrupt\$ or sudden\$).ti,ab.
20	"cold turkey".ti,ab.
21	or/19-20
22	(taper\$ or decreas\$ or often or frequen\$).ti,ab.
23	((dose or dosage) adj5 (lower\$ or reduc\$)).ti,ab.
24	or/22-23
25	and/21,24
26	15 and (18 or 25)

### Database: Cochrane Database of Systematic Reviews and Database of Abstracts of Reviews of Effects

#	Searches
1	MENOPAUSE.kw.
2	CLIMACTERIC.kw.
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw,tx.
4	"change of life".tw,tx.
5	PRIMARY OVARIAN INSUFFICIENCY.kw.
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw,tx.
7	(POI or POF).tw,tx.
8	or/1-7
9	(HORMONE REPLACEMENT THERAPY or ESTROGEN REPLACEMENT THERAPY).kw.
10	(hormon\$ adj3 (therap\$ or substitut\$)).tw,tx.
11	(HRT or HT).tw,tx.
12	("menopausal hormone" adj2 therap\$).tw,tx.
13	MHT.tw,tx.
14	or/9-13
15	and/8,14
16	DRUG ADMINISTRATION SCHEDULE.kw.
17	WITHHOLDING TREATMENT.kw.
18	or/16-17
19	(discontin\$ or immediate\$ or stop\$ or ceas\$ or abrupt\$ or sudden\$).tw,tx.
20	"cold turkey".tw,tx.
21	or/19-20
22	(taper\$ or decreas\$ or often or frequen\$).tw,tx.
23	((dose or dosage) adj5 (lower\$ or reduc\$)).tw,tx.
24	or/22-23
25	and/21,24
26	15 and (18 or 25)

### Database: Health Technology Assessment

#	Searches
1	exp MENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw.
4	"change of life".tw.
5	PRIMARY OVARIAN INSUFFICIENCY/
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw.
7	(POI or POF).tw.
8	or/1-7
9	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
10	(hormon\$ adj3 (therap\$ or substitut\$)).tw.
11	(HRT or HT).tw.
12	("menopausal hormone" adj2 therap\$).tw.
13	MHT.tw.
14	or/9-13
15	and/8,14
16	DRUG ADMINISTRATION SCHEDULE/
17	WITHHOLDING TREATMENT/

#	Searches
18	or/16-17
19	(discontin\$ or immediate\$ or stop\$ or ceas\$ or abrupt\$ or sudden\$).tw.
20	"cold turkey".tw.
21	or/19-20
22	(taper\$ or decreas\$ or often or frequen\$).tw.
23	((dose or dosage) adj5 (lower\$ or reduc\$)).tw.
24	or/22-23
25	and/21,24
26	15 and (18 or 25)

### Database: Embase

#	Searches
1	exp **"MENOPAUSE AND CLIMACTERIUM"/
2	MENOPAUSAL SYNDROME/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteri\$).ti,ab.
4	"change of life".ti,ab.
5	reproductive ag?ing.ti,ab.
6	*PREMATURE OVARIAN FAILURE/
7	((primary or prematur\$ or hypergonadotrop\$) adj1 ovar\$ adj1 (insuffic\$ or fail\$ or incompet\$)).ti,ab.
8	((gonadotrop\$ or resist\$) adj1 ovar\$ adj1 syndrom\$).ti,ab.
9	(POI or POF).ti,ab.
10	or/1-9
11	exp HORMONE SUBSTITUTION/ or ESTROGEN THERAPY/
12	(HRT or HT).ti,ab.
13	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
14	MHT.ti,ab.
15	or/11-14
16	and/10,15
17	drug withdrawal/
18	drug dose reduction/
19	treatment withdrawal/
20	or/17-19
21	(discontin\$ or immediate\$ or stop\$ or ceas\$ or abrupt\$ or sudden\$).ti,ab.
22	"cold turkey".ti,ab.
23	or/21-22
24	(taper\$ or decreas\$ or often or frequen\$).ti,ab.
25	((dose or dosage) adj5 (lower\$ or reduc\$)).ti,ab.
26	or/24-25
27	and/23,26
28	16 and (20 or 27)
29	conference abstract.pt.
30	letter.pt. or LETTER/
31	note.pt.
32	editorial.pt.
33	CASE REPORT/ or CASE STUDY/
34	(letter or comment* or abstracts).ti.
35	or/29-34
36	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
37	35 not 36
38	ANIMAL/ not HUMAN/
39	NONHUMAN/
40	exp ANIMAL EXPERIMENT/
41	exp EXPERIMENTAL ANIMAL/
42	ANIMAL MODEL/
43	exp RODENT/
44	(rat or rats or mouse or mice).ti.
45	or/37-44
46	28 not 45
47	limit 46 to english language

## E.7 Long-term benefits and risks of HRT

### Database: Medline

#	Searches
1	ECONOMICS/
2	VALUE OF LIFE/
3	exp "COSTS AND COST ANALYSIS"/

#	Searches
4	exp ECONOMICS, HOSPITAL/
5	exp ECONOMICS, MEDICAL/
6	exp RESOURCE ALLOCATION/
7	ECONOMICS, NURSING/
8	ECONOMICS, PHARMACEUTICAL/
9	exp "FEES AND CHARGES"/
10	exp BUDGETS/
11	budget*.ti,ab.
12	cost*.ti,ab.
13	(economic* or pharmaco?economic*).ti,ab.
14	(price* or pricing*).ti,ab.
15	(financ* or fee or fees or expenditure* or saving*).ti,ab.
16	(value adj2 (money or monetary)).ti,ab.
17	resourc* allocat*.ti,ab.
18	(fund or funds or funding* or funded).ti,ab.
19	(ration or rations or rationing* or rationed).ti,ab.
20	ec.fs.
21	or/1-20
22	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
23	CLIMACTERIC/
24	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
25	"change of life".ti,ab.
26	PRIMARY OVARIAN INSUFFICIENCY/
27	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
28	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
29	(POI or POF).ti,ab.
30	or/22-29
31	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
32	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
33	(HRT or HT).ti,ab.
34	("menopausal hormone" adj2 therap\$).ti,ab.
35	MHT.ti,ab.
36	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
37	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
38	MPA.ti,ab.
39	or/31-38
40	BREAST NEOPLASMS/ or CARCINOMA, DUCTAL, BREAST/ or "HEREDITARY BREAST AND OVARIAN CANCER SYNDROME"/ or INFLAMMATORY BREAST NEOPLASMS/ or TRIPLE NEGATIVE BREAST NEOPLASMS/
41	(breast adj5 (cancer? or carcinoma? or tumo?r?)).ti,ab.
42	or/40-41
43	INTESTINAL NEOPLASMS/ or CECAL NEOPLASMS/ or COLORECTAL NEOPLASMS/ or ADENOMATOUS POLYPOSIS COLI/ or exp COLONIC NEOPLASMS/
44	((bowel or colorectal or colon\$ or intestin\$) adj5 (cancer? or carcinoma? or tumo?r?)).ti,ab.
45	or/43-44
46	exp LUNG NEOPLASMS/
47	((lung? or pulmonary) adj5 (cancer? or carcinoma? or tumo?r?)).ti,ab.
48	or/46-47
49	exp OVARIAN NEOPLASMS/
50	((ovary or ovaries or ovarian) adj5 (cancer? or carcinoma? or tumo?r?)).ti,ab.
51	or/49-50
52	exp DIABETES MELLITUS, TYPE 2/
53	(diabet\$ adj5 ("type two" or "type 2" or "type II" or T2 or TII or matur\$ or adult\$ or slow or late or stable or ketosis resistant or keto resist\$ or keto?resist\$ or non keto\$ or non?keto\$)).ti,ab.
54	(diabet\$ adj5 ((non insulin or non?insulin) adj2 depend\$)).ti,ab.
55	(NIDDM or T2D or TIID or DM2 or DMII).ti,ab.
56	MUSCULAR ATROPHY/ or SARCOOPENIA/
57	sarcopen\$.ti,ab.
58	(muscle? adj (mass or function or strenght\$)).ti,ab.
59	PULMONARY EMBOLISM/ or PULMONARY INFARCTION/ or THROMBOEMBOLISM/ or VENOUS THROMBOEMBOLISM/
60	(VTE or DVT or PE).ti,ab.
61	(deep vein adj2 thrombosis).ti,ab.
62	((pulmonary or lung?) adj3 emboli\$).ti,ab.
63	DEMENCIA/ or ALZHEIMER DISEASE/ or exp DEMENTIA, VASCULAR/ or exp FRONTOTEMPORAL LOBAR DEGENERATION/ or LEWY BODY DISEASE/
64	(amentia? or dementia? or alzheimer\$ or lewy body).ti,ab.
65	((memory or remember\$ or cognitiv\$) adj3 (loss\$ or declin\$)).ti,ab.
66	or/52-65
67	or/42,45,48,51,66
68	INCIDENCE/

#	Searches
69	inciden\$.ti.
70	RISK/
71	risk.ti.
72	RISK ASSESSMENT/
73	RISK FACTORS/
74	PREVALENCE/
75	(inciden\$ or risk\$ or prevalen\$).ab. /freq=2
76	or/68-75
77	and/30,39,67,76
78	and/21,77
79	LETTER/
80	EDITORIAL/
81	NEWS/
82	exp HISTORICAL ARTICLE/
83	ANECDOTES AS TOPIC/
84	COMMENT/
85	CASE REPORT/
86	(letter or comment* or abstracts).ti.
87	or/79-86
88	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
89	87 not 88
90	ANIMALS/ not HUMANS/
91	exp ANIMALS, LABORATORY/
92	exp ANIMAL EXPERIMENTATION/
93	exp MODELS, ANIMAL/
94	exp RODENTIA/
95	(rat or rats or mouse or mice).ti.
96	or/89-95
97	78 not 96
98	limit 97 to english language

### Database: Cochrane Central Register of Controlled Trials

#	Searches
1	ECONOMICS/
2	VALUE OF LIFE/
3	exp "COSTS AND COST ANALYSIS"/
4	exp ECONOMICS, HOSPITAL/
5	exp ECONOMICS, MEDICAL/
6	exp RESOURCE ALLOCATION/
7	ECONOMICS, NURSING/
8	ECONOMICS, PHARMACEUTICAL/
9	exp "FEES AND CHARGES"/
10	exp BUDGETS/
11	budget*.ti,ab.
12	cost*.ti,ab.
13	(economic* or pharmaco?economic*).ti,ab.
14	(price* or pricing*).ti,ab.
15	(financ* or fee or fees or expenditure* or saving*).ti,ab.
16	(value adj2 (money or monetary)).ti,ab.
17	resourc* allocat*.ti,ab.
18	(fund or funds or funding* or funded).ti,ab.
19	(ration or rations or rationing* or rationed).ti,ab.
20	ec.fs.
21	or/1-20
22	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
23	CLIMACTERIC/
24	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
25	"change of life".ti,ab.
26	PRIMARY OVARIAN INSUFFICIENCY/
27	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
28	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
29	(POI or POF).ti,ab.
30	or/22-29
31	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
32	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
33	(HRT or HT).ti,ab.
34	("menopausal hormone" adj2 therap\$).ti,ab.
35	MHT.ti,ab.



#	Searches
36	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
37	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
38	MPA.ti,ab.
39	or/31-38
40	BREAST NEOPLASMS/ or CARCINOMA, DUCTAL, BREAST/ or "HEREDITARY BREAST AND OVARIAN CANCER SYNDROME"/ or INFLAMMATORY BREAST NEOPLASMS/ or TRIPLE NEGATIVE BREAST NEOPLASMS/
41	(breast adj5 (cancer? or carcinoma? or tumor?r?)).ti,ab.
42	or/40-41
43	INTESTINAL NEOPLASMS/ or CECAL NEOPLASMS/ or COLORECTAL NEOPLASMS/ or ADENOMATOUS POLYPOSIS COLI/ or exp COLONIC NEOPLASMS/
44	((bowel or colorectal or colon\$ or intestin\$) adj5 (cancer? or carcinoma? or tumor?r?)).ti,ab.
45	or/43-44
46	exp LUNG NEOPLASMS/
47	((lung? or pulmonary) adj5 (cancer? or carcinoma? or tumor?r?)).ti,ab.
48	or/46-47
49	exp OVARIAN NEOPLASMS/
50	((ovary or ovaries or ovarian) adj5 (cancer? or carcinoma? or tumor?r?)).ti,ab.
51	or/49-50
52	exp DIABETES MELLITUS, TYPE 2/
53	(diabet\$ adj5 ("type two" or "type 2" or "type II" or T2 or TII or matur\$ or adult\$ or slow or late or stable or ketosis resistant or keto resist\$ or keto?resist\$ or non keto\$ or non?keto\$)).ti,ab.
54	(diabet\$ adj5 ((non insulin or non?insulin) adj2 depend\$)).ti,ab.
55	(NIDDM or T2D or TIID or DM2 or DMII).ti,ab.
56	MUSCULAR ATROPHY/ or SARCOPENIA/
57	sarcopen\$.ti,ab.
58	(muscle? adj (mass or function or strenght\$)).ti,ab.
59	PULMONARY EMBOLISM/ or PULMONARY INFARCTION/ or THROMBOEMBOLISM/ or VENOUS THROMBOEMBOLISM/
60	(VTE or DVT or PE).ti,ab.
61	(deep vein adj2 thrombosis).ti,ab.
62	((pulmonary or lung?) adj3 emboli\$).ti,ab.
63	DEMENTIA/ or ALZHEIMER DISEASE/ or exp DEMENTIA, VASCULAR/ or exp FRONTOTEMPORAL LOBAR DEGENERATION/ or LEWY BODY DISEASE/
64	(amentia? or dementia? or alzheimer\$ or lewy body).ti,ab.
65	((memory or remember\$ or cognitiv\$) adj3 (loss\$ or declin\$)).ti,ab.
66	or/52-65
67	or/42,45,48,51,66
68	INCIDENCE/
69	inciden\$.ti.
70	RISK/
71	risk.ti.
72	RISK ASSESSMENT/
73	RISK FACTORS/
74	PREVALENCE/
75	(inciden\$ or risk\$ or prevalen\$).ab. /freq=2
76	or/68-75
77	and/30,39,67,76
78	and/21,77
79	LETTER/
80	EDITORIAL/
81	NEWS/
82	exp HISTORICAL ARTICLE/
83	ANECDOTES AS TOPIC/
84	COMMENT/
85	CASE REPORT/
86	(letter or comment* or abstracts).ti.
87	or/79-86
88	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
89	87 not 88
90	ANIMALS/ not HUMANS/
91	exp ANIMALS, LABORATORY/
92	exp ANIMAL EXPERIMENTATION/
93	exp MODELS, ANIMAL/
94	exp RODENTIA/
95	(rat or rats or mouse or mice).ti.
96	or/89-95
97	78 not 96
98	limit 97 to english language

## Database: Health Technology Assessment

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw.
4	"change of life".tw.
5	PRIMARY OVARIAN INSUFFICIENCY/
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw.
7	((earl\$ or prematur\$) adj3 menopaus\$).tw.
8	(POI or POF).tw.
9	or/1-8
10	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
11	(hormon\$ adj3 (therap\$ or substitut\$)).tw.
12	(HRT or HT).tw.
13	("menopausal hormone" adj2 therap\$).tw.
14	MHT.tw.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).tw.
16	MPA.tw.
17	or/10-16
18	BREAST NEOPLASMS/ or CARCINOMA, DUCTAL, BREAST/ or "HEREDITARY BREAST AND OVARIAN CANCER SYNDROME"/ or INFLAMMATORY BREAST NEOPLASMS/ or TRIPLE NEGATIVE BREAST NEOPLASMS/
19	(breast adj5 (cancer? or carcinoma? or tumo?r?)).tw.
20	or/18-19
21	INTESTINAL NEOPLASMS/ or CECAL NEOPLASMS/ or COLORECTAL NEOPLASMS/ or ADENOMATOUS POLYPOSIS COLI/ or exp COLONIC NEOPLASMS/
22	((bowel or colorectal or colon\$ or intestin\$) adj5 (cancer? or carcinoma? or tumo?r?)).tw.
23	or/21-22
24	exp LUNG NEOPLASMS/
25	((lung? or pulmonary) adj5 (cancer? or carcinoma? or tumo?r?)).tw.
26	or/24-25
27	exp OVARIAN NEOPLASMS/
28	((ovary or ovaries or ovarian) adj5 (cancer? or carcinoma? or tumo?r?)).tw.
29	or/27-28
30	exp DIABETES MELLITUS, TYPE 2/
31	(diabet\$ adj5 ("type two" or "type 2" or "type II" or T2 or TII or matur\$ or adult\$ or slow or late or stable or ketosis resistant or keto resist\$ or keto?resist\$ or non keto\$ or non?keto\$)).tw.
32	(diabet\$ adj5 ((non insulin or non?insulin) adj2 depend\$)).tw.
33	(NIDDM or T2D or TIID or DM2 or DMII).tw.
34	MUSCULAR ATROPHY/ or SARCOPENIA/
35	sarcopen\$.tw.
36	(muscle? adj (mass or function or strenght\$)).tw.
37	PULMONARY EMBOLISM/ or PULMONARY INFARCTION/ or THROMBOEMBOLISM/ or VENOUS THROMBOEMBOLISM/
38	(VTE or DVT or PE).tw.
39	(deep vein adj2 thrombosis).tw.
40	((pulmonary or lung?) adj3 emboli\$).tw.
41	DEMENTIA/ or ALZHEIMER DISEASE/ or exp DEMENTIA, VASCULAR/ or exp Dementia/ or LEWY BODY DISEASE/
42	(amentia? or dementia? or alzheimer\$ or lewy body).tw.
43	((memory or remember\$ or cognitiv\$) adj3 (loss\$ or declin\$)).tw.
44	or/30-43
45	or/20,23,26,29,44
46	INCIDENCE/
47	RISK/
48	RISK ASSESSMENT/
49	RISK FACTORS/
50	PREVALENCE/
51	(inciden\$ or risk\$ or prevalen\$).tw.
52	or/46,51
53	and/9,17,45,52

## Database: NHS Economic Evaluation Database

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw.
4	"change of life".tw.
5	PRIMARY OVARIAN INSUFFICIENCY/
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw.
7	((earl\$ or prematur\$) adj3 menopaus\$).tw.

#	Searches
8	(POI or POF).tw.
9	or/1-8
10	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
11	(hormon\$ adj3 (therap\$ or substitut\$)).tw.
12	(HRT or HT).tw.
13	("menopausal hormone" adj2 therap\$).tw.
14	MHT.tw.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).tw.
16	MPA.tw.
17	or/10-16
18	BREAST NEOPLASMS/ or CARCINOMA, DUCTAL, BREAST/ or "HEREDITARY BREAST AND OVARIAN CANCER SYNDROME"/ or INFLAMMATORY BREAST NEOPLASMS/ or TRIPLE NEGATIVE BREAST NEOPLASMS/
19	(breast adj5 (cancer? or carcinoma? or tumo?r?)).tw.
20	or/18-19
21	INTESTINAL NEOPLASMS/ or CECAL NEOPLASMS/ or COLORECTAL NEOPLASMS/ or ADENOMATOUS POLYPOSIS COLI/ or exp COLONIC NEOPLASMS/
22	((bowel or colorectal or colon\$ or intestin\$) adj5 (cancer? or carcinoma? or tumo?r?)).tw.
23	or/21-22
24	exp LUNG NEOPLASMS/
25	((lung? or pulmonary) adj5 (cancer? or carcinoma? or tumo?r?)).tw.
26	or/24-25
27	exp OVARIAN NEOPLASMS/
28	((ovary or ovaries or ovarian) adj5 (cancer? or carcinoma? or tumo?r?)).tw.
29	or/27-28
30	exp DIABETES MELLITUS, TYPE 2/
31	(diabet\$ adj5 ("type two" or "type 2" or "type II" or T2 or TII or matur\$ or adult\$ or slow or late or stable or ketosis resistant or keto resist\$ or keto?resist\$ or non keto\$ or non?keto\$)).tw.
32	(diabet\$ adj5 ((non insulin or non?insulin) adj2 depend\$)).tw.
33	(NIDDM or T2D or TIID or DM2 or DMII).tw.
34	MUSCULAR ATROPHY/ or SARCOPENIA/
35	sarcopen\$.tw.
36	(muscle? adj (mass or function or strenght\$)).tw.
37	PULMONARY EMBOLISM/ or PULMONARY INFARCTION/ or THROMBOEMBOLISM/ or VENOUS THROMBOEMBOLISM/
38	(VTE or DVT or PE).tw.
39	(deep vein adj2 thrombosis).tw.
40	((pulmonary or lung?) adj3 emboli\$).tw.
41	DEMENTIA/ or ALZHEIMER DISEASE/ or exp DEMENTIA, VASCULAR/ or exp Dementia/ or LEWY BODY DISEASE/
42	(amentia? or dementia? or alzheimer\$ or lewy body).tw.
43	((memory or remember\$ or cognitiv\$) adj3 (loss\$ or declin\$)).tw.
44	or/30-43
45	or/20,23,26,29,44
46	INCIDENCE/
47	RISK/
48	RISK ASSESSMENT/
49	RISK FACTORS/
50	PREVALENCE/
51	(inciden\$ or risk\$ or prevalen\$).tw.
52	or/46,51
53	and/9,17,45,52

### Database: Embase

#	Searches
1	HEALTH ECONOMICS/
2	exp ECONOMIC EVALUATION/
3	exp HEALTH CARE COST/
4	exp FEE/
5	BUDGET/
6	FUNDING/
7	RESOURCE ALLOCATION/
8	budget*.ti,ab.
9	cost*.ti,ab.
10	(economic* or pharmaco?economic*).ti,ab.
11	(price* or pricing*).ti,ab.
12	(financ* or fee or fees or expenditure* or saving*).ti,ab.
13	(value adj2 (money or monetary)).ti,ab.
14	resourc* allocat*.ti,ab.
15	(fund or funds or funding* or funded).ti,ab.
16	(ration or rations or rationing* or rationed).ti,ab.
17	or/1-16

#	Searches
18	exp HORMONE SUBSTITUTION/ or ESTROGEN THERAPY/
19	(HRT or HT).ti,ab.
20	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
21	MHT.ti,ab.
22	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
23	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
24	MPA.ti,ab.
25	or/18-24
26	exp BREAST CANCER/ or BREAST TUMOR/
27	(breast adj5 (cancer? or carcinoma? or tumo#r?)).ti,ab.
28	or/26-27
29	INTESTINE CANCER/ or exp INTESTINE TUMOR/ or exp LARGE INTESTINE CANCER/ or exp SMALL INTESTINE CANCER/
30	((bowel or colorectal or colon or intestin\$) adj5 (cancer? or carcinoma? or tumo#r?)).ti,ab.
31	or/29-30
32	LUNG TUMOR/ or RESPIRATORY TRACT TUMOR/ or LUNG ADENOMA/ or exp LUNG CANCER/ or LUNG GRANULOMATOSIS/ or PULMONARY SCLEROSING HEMANGIOMA/
33	((lung? or pulmonary) adj5 (cancer? or carcinoma? or tumo#r?)).ti,ab.
34	or/32-33
35	OVARY TUMOR/ or BRENNER TUMOR/ or LUTEOMA/ or MEIGS SYNDROME/ or exp OVARY CANCER/ or OVARY TERATOMA/ or THECOMA/
36	((ovary or ovaries or ovarian) adj5 (cancer? or carcinoma? or tumo#r?)).ti,ab.
37	or/35-36
38	or/28,31,34,37
39	NON INSULIN DEPENDENT DIABETES MELLITUS/
40	(diabet\$ adj5 ("type two" or "type 2" or "type II" or T2 or TII or matur\$ or adult\$ or slow or late or stable or ketosis resistant or keto resist\$ or keto?resist\$ or non keto\$ or non?keto\$)).ti,ab.
41	(diabet\$ adj5 ((non insulin or non?insulin) adj2 depend\$)).ti,ab.
42	(NIDDM or T2D or TIID or DM2 or DMII).ti,ab.
43	or/39-42
44	MUSCLE ATROPHY/ or SARCOPENIA/
45	MUSCLE WEAKNESS/
46	sarcopen\$.ti,ab.
47	(muscle? adj (mass or function or strenght\$)).ti,ab.
48	or/44-47
49	VENOUS THROMBOEMBOLISM/ or DEEP VEIN THROMBOSIS/ or LOWER EXTREMITY DEEP VEIN THROMBOSIS/ or LUNG EMBOLISM/ or UPPER EXTREMITY DEEP VEIN THROMBOSIS/
50	(VTE or DVT or PE).ti,ab.
51	(deep vein adj thrombosis).ti,ab.
52	((pulmonary or lung?) adj3 emboli\$).ti,ab.
53	or/49-52
54	DEMENTIA/ or ALZHEIMER DISEASE/ or DIFFUSE LEWY BODY DISEASE/ or exp FRONTOTEMPORAL DEMENTIA/ or MULTIINFARCT DEMENTIA/ or PICK PRESENILE DEMENTIA/ or PRESENILE DEMENTIA/ or PRION DISEASE/ or exp SENILE DEMENTIA/
55	(amentia? or dementia? or alzheimer\$ or lewy body).ti,ab.
56	((memory or remember\$ or cognitiv\$) adj3 (loss\$ or declin\$)).ti,ab.
57	or/54-56
58	or/38,43,48,53,57
59	INCIDENCE/
60	RISK/
61	RISK FACTOR/
62	RISK ASSESSMENT/
63	risk\$.ti.
64	PREVALENCE/
65	(inciden\$ or risk\$ or prevalen\$).ab. /freq=2
66	(inciden\$ or risk\$ or prevalen\$).ti.
67	or/59-66
68	and/25,58,67
69	and/17,68
70	conference abstract.pt.
71	letter.pt. or LETTER/
72	note.pt.
73	editorial.pt.
74	CASE REPORT/ or CASE STUDY/
75	(letter or comment* or abstracts).ti.
76	or/70-75
77	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
78	76 not 77
79	ANIMAL/ not HUMAN/
80	NONHUMAN/
81	exp ANIMAL EXPERIMENT/

#	Searches
82	exp EXPERIMENTAL ANIMAL/
83	ANIMAL MODEL/
84	exp RODENT/
85	(rat or rats or mouse or mice).ti.
86	or/78-85
87	69 not 86
88	limit 87 to english language
89	female/
90	and/88-89

## E.7.1 Venous thromboembolism

### Database: Medline

#	Searches
1	randomized controlled trial.pt.
2	controlled clinical trial.pt.
3	DOUBLE BLIND METHOD/
4	SINGLE BLIND METHOD/
5	RANDOM ALLOCATION/
6	or/1-5
7	((single or double or triple or treble) adj5 (blind\$ or mask\$)).tw,sh.
8	clinical trial.pt.
9	exp CLINICAL TRIAL/
10	exp CLINICAL TRIALS AS TOPIC/
11	(clinic\$ adj5 trial\$).tw,sh.
12	PLACEBOS/
13	placebo\$.tw,sh.
14	random\$.tw,sh.
15	or/7-14
16	or/6-15
17	META ANALYSIS/
18	META ANALYSIS AS TOPIC/
19	meta analysis.pt.
20	(metaanaly\$ or meta-analy\$ or (meta adj analy\$)).tw,sh.
21	(systematic\$ adj5 (review\$ or overview\$)).tw,sh.
22	(methodologic\$ adj5 (review\$ or overview\$)).tw,sh.
23	or/17-22
24	review\$.pt.
25	(medline or medlars or embase or cinahl or cochrane or psycinfo or psychinfo or psychlit or psyclit or "web of science" or "science citation" or scisearch).tw.
26	((hand or manual\$) adj2 search\$).tw.
27	(electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw,sh.
28	(pooling or pooled or mantel haenszel).tw,sh.
29	(peto or dersimonian or der simonian or fixed effect).tw,sh.
30	or/25-29
31	and/24,30
32	exp CASE-CONTROL STUDIES/
33	(case\$ adj2 control\$).tw.
34	exp COHORT STUDIES/
35	cohort\$.tw.
36	or/32-35
37	or/16,23,31,36
38	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
39	CLIMACTERIC/
40	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
41	"change of life".ti,ab.
42	PRIMARY OVARIAN INSUFFICIENCY/
43	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
44	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
45	(POI or POF).ti,ab.
46	or/38-45
47	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
48	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
49	(HRT or HT).ti,ab.
50	("menopausal hormone" adj2 therap\$).ti,ab.
51	MHT.ti,ab.
52	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
53	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2

#	Searches
54	MPA.ti,ab.
55	or/47-54
56	PULMONARY EMBOLISM/ or PULMONARY INFARCTION/ or THROMBOEMBOLISM/ or VENOUS THROMBOEMBOLISM/
57	(VTE or DVT or PE).ti,ab.
58	(deep vein adj2 thrombosis).ti,ab.
59	((vein or venous) adj2 thrombo\$).ti,ab.
60	((pulmonary or lung?) adj3 emboli\$).ti,ab.
61	or/56-60
62	and/37,46,55,61
63	LETTER/
64	EDITORIAL/
65	NEWS/
66	exp HISTORICAL ARTICLE/
67	ANECDOTES AS TOPIC/
68	COMMENT/
69	CASE REPORT/
70	(letter or comment* or abstracts).ti.
71	or/63-70
72	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
73	71 not 72
74	ANIMALS/ not HUMANS/
75	exp ANIMALS, LABORATORY/
76	exp ANIMAL EXPERIMENTATION/
77	exp MODELS, ANIMAL/
78	exp RODENTIA/
79	(rat or rats or mouse or mice).ti.
80	or/73-79
81	62 not 80
82	limit 81 to english language

#### Database: Medline In-Process

#	Searches
1	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
2	"change of life".ti,ab.
3	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
4	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
5	(POI or POF).ti,ab.
6	or/1-5
7	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
8	(HRT or HT).ti,ab.
9	("menopausal hormone" adj2 therap\$).ti,ab.
10	MHT.ti,ab.
11	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
12	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
13	MPA.ti,ab.
14	or/7-13
15	(VTE or DVT or PE).ti,ab.
16	(deep vein adj2 thrombosis).ti,ab.
17	((vein or venous) adj2 thrombo\$).ti,ab.
18	((pulmonary or lung?) adj3 emboli\$ of infarct\$).ti,ab.
19	thromboembol\$.ti,ab.
20	or/15-19
21	and/6,14,20

#### Database: Cochrane Central Register of Controlled Trials

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
4	"change of life".ti,ab.
5	PRIMARY OVARIAN INSUFFICIENCY/
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
7	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
8	(POI or POF).ti,ab.
9	or/1-8
10	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/

#	Searches
11	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
12	(HRT or HT).ti,ab.
13	("menopausal hormone" adj2 therap\$).ti,ab.
14	MHT.ti,ab.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
16	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
17	MPA.ti,ab.
18	or/10-17
19	PULMONARY EMBOLISM/ or PULMONARY INFARCTION/ or THROMBOEMBOLISM/ or VENOUS THROMBOEMBOLISM/
20	(VTE or DVT or PE).ti,ab.
21	(deep vein adj2 thrombosis).ti,ab.
22	((vein or venous) adj2 thrombo\$).ti,ab.
23	((pulmonary or lung?) adj3 emboli\$).ti,ab.
24	or/19-23
25	and/9,18,24

### Database: Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects

#	Searches
1	(MENOPAUSE or MENOPAUSE, PREMATURE or PERIMENOPAUSE or POSTMENOPAUSE).kw.
2	CLIMACTERIC.kw.
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw,tx.
4	"change of life".tw,tx.
5	PRIMARY OVARIAN INSUFFICIENCY.kw.
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw,tx.
7	((earl\$ or prematur\$) adj3 menopaus\$).tw,tx.
8	(POI or POF).tw,tx.
9	or/1-8
10	(HORMONE REPLACEMENT THERAPY or ESTROGEN REPLACEMENT THERAPY).kw.
11	(hormon\$ adj3 (therap\$ or substitut\$)).tw,tx.
12	(HRT or HT).tw,tx.
13	("menopausal hormone" adj2 therap\$).tw,tx.
14	MHT.tw,tx.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).tw,tx.
16	MPA.tw,tx.
17	or/10-16
18	(PULMONARY EMBOLISM or PULMONARY INFARCTION or THROMBOEMBOLISM or VENOUS THROMBOEMBOLISM).kw.
19	(VTE or DVT or PE).tw,tx.
20	(deep vein adj2 thrombosis).tw,tx.
21	((vein or venous) adj2 thrombo\$).tw,tx.
22	((pulmonary or lung?) adj3 emboli\$).tw,tx.
23	or/18-22
24	and/9,17,23

### Database: Health Technology Assessment

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw.
4	"change of life".tw.
5	PRIMARY OVARIAN INSUFFICIENCY/
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw.
7	((earl\$ or prematur\$) adj3 menopaus\$).tw.
8	(POI or POF).tw.
9	or/1-8
10	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
11	(hormon\$ adj3 (therap\$ or substitut\$)).tw.
12	(HRT or HT).tw.
13	("menopausal hormone" adj2 therap\$).tw.
14	MHT.tw.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).tw.
16	MPA.tw.
17	or/10-16
18	PULMONARY EMBOLISM/ or PULMONARY INFARCTION/ or THROMBOEMBOLISM/ or VENOUS THROMBOEMBOLISM/

#	Searches
19	(VTE or DVT or PE).tw.
20	(deep vein adj2 thrombosis).tw.
21	((vein or venous) adj2 thrombo\$).tw.
22	((pulmonary or lung?) adj3 emboli\$).tw.
23	or/18-22
24	and/9,17,23

### Database: Embase

#	Searches
1	CLINICAL TRIAL/ or "CLINICAL TRIAL (TOPIC)"/
2	(clinic\$ adj5 trial\$).tw,sh.
3	SINGLE BLIND PROCEDURE/
4	DOUBLE BLIND PROCEDURE/
5	RANDOM ALLOCATION/
6	CROSSOVER PROCEDURE/
7	PLACEBO/
8	placebo\$.tw,sh.
9	random\$.tw,sh.
10	RANDOMIZED CONTROLLED TRIAL/ or "RANDOMIZED CONTROLLED TRIAL (TOPIC)"/
11	((single or double or triple or treble) adj (blind\$ or mask\$)).tw,sh.
12	randomi?ed control\$ trial\$.tw.
13	or/1-12
14	META ANALYSIS/
15	((meta adj analy\$) or metaanalys\$ or meta-analy\$).tw,sh.
16	(systematic\$ adj5 (review\$ or overview\$)).tw,sh.
17	(methodologic\$ adj5 (review\$ or overview\$)).tw,sh.
18	or/14-17
19	review.pt.
20	(medline or medlars or embase).ab.
21	(scisearch or science citation index).ab.
22	(psychlit or psychlit or psychinfo or psycinfo or cinahl or cochrane).ab.
23	((hand or manual\$) adj2 search\$).tw.
24	(electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw.
25	(pooling or pooled or mantel haenszel).tw.
26	(peto or dersimonian or "der simonian" or fixed effect).tw.
27	or/20-26
28	and/19,27
29	exp CASE CONTROL STUDY/
30	RETROSPECTIVE STUDY/
31	(case\$ adj2 control\$).tw.
32	COHORT ANALYSIS/
33	LONGITUDINAL STUDY/
34	FOLLOW UP/
35	PROSPECTIVE STUDY/
36	cohort\$.tw.
37	or/29-36
38	or/13,18,28,37
39	(book or conference paper or editorial or letter or note or proceeding or short survey).pt.
40	38 not 39
41	"MENOPAUSE AND CLIMACTERIUM"/ or CLIMACTERIUM/ or EARLY MENOPAUSE/ or MENOPAUSE/ or POSTMENOPAUSE/
42	PREMENOPAUSE/
43	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
44	PREMATURE OVARIAN FAILURE/
45	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF or POI).ti,ab.
46	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
47	climacteric.ti,ab.
48	(change adj1 life).ti,ab.
49	or/41-48
50	exp HORMONE SUBSTITUTION/ or ESTROGEN THERAPY/
51	(HRT or HT).ti,ab.
52	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
53	MHT.ti,ab.
54	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
55	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
56	MPA.ti,ab.
57	or/50-56
58	VENOUS THROMBOEMBOLISM/ or DEEP VEIN THROMBOSIS/ or LOWER EXTREMITY DEEP VEIN THROMBOSIS/ or LUNG EMBOLISM/ or UPPER EXTREMITY DEEP VEIN THROMBOSIS/
59	(VTE or DVT or PE).ti,ab.



#	Searches
60	(deep vein adj thrombosis).ti,ab.
61	((vein or venous) adj2 thrombo\$).ti,ab.
62	((pulmonary or lung?) adj3 emboli\$).ti,ab.
63	or/58-62
64	and/40,49,57,63
65	conference abstract.pt.
66	letter.pt. or LETTER/
67	note.pt.
68	editorial.pt.
69	CASE REPORT/ or CASE STUDY/
70	(letter or comment* or abstracts).ti.
71	or/65-70
72	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
73	71 not 72
74	ANIMAL/ not HUMAN/
75	NONHUMAN/
76	exp ANIMAL EXPERIMENT/
77	exp EXPERIMENTAL ANIMAL/
78	ANIMAL MODEL/
79	exp RODENT/
80	(rat or rats or mouse or mice).ti.
81	or/73-80
82	64 not 81
83	limit 82 to english language
84	limit 83 to female

## E.7.2 Cardiovascular disease

### Database: Medline

#	Searches
1	randomized controlled trial.pt.
2	controlled clinical trial.pt.
3	DOUBLE BLIND METHOD/
4	SINGLE BLIND METHOD/
5	RANDOM ALLOCATION/
6	or/1-5
7	((single or double or triple or treble) adj5 (blind\$ or mask\$)).tw,sh.
8	clinical trial.pt.
9	exp CLINICAL TRIAL/
10	exp CLINICAL TRIALS AS TOPIC/
11	(clinic\$ adj5 trial\$).tw,sh.
12	PLACEBOS/
13	placebo\$.tw,sh.
14	random\$.tw,sh.
15	or/7-14
16	or/6,15
17	META ANALYSIS/
18	META ANALYSIS AS TOPIC/
19	meta analysis.pt.
20	(metaanaly\$ or meta-analy\$ or (meta adj analy\$)).tw,sh.
21	(systematic\$ adj5 (review\$ or overview\$)).tw,sh.
22	(methodologic\$ adj5 (review\$ or overview\$)).tw,sh.
23	or/17-22
24	review\$.pt.
25	(medline or medlars or embase or cinahl or cochrane or psycinfo or psychinfo or psychlit or psyclit or "web of science" or "science citation" or scisearch).tw.
26	((hand or manual\$) adj2 search\$).tw.
27	(electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw,sh.
28	(pooling or pooled or mantel haenszel).tw,sh.
29	(peto or dersimonian or der simonian or fixed effect).tw,sh.
30	or/25-29
31	and/24,30
32	exp COHORT STUDIES/
33	cohort\$.tw.
34	or/32-33
35	or/16,23,31,34
36	letter.pt.
37	comment.pt.
38	editorial.pt.

#	Searches
39	historical article.pt.
40	or/36-39
41	35 not 40
42	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
43	CLIMACTERIC/
44	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
45	"change of life".ti,ab.
46	or/42-45
47	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
48	exp ESTROGENS/tu or ESTRADIOL/tu [Therapeutic Use]
49	(hormon\$ adj3 (therap\$ or substitut\$ or replacement or exogenous)).ti,ab.
50	(HRT or HT or MHT).ti,ab.
51	((oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone or progest\$ or medroxyprogest\$) adj3 (therap\$ or substitut\$ or replacement or exogenous)).ti,ab.
52	or/47-51
53	exp CARDIOVASCULAR DISEASES/
54	(cardio\$ or cardia\$ or heart\$ or coronary\$ or angina\$ or ventric\$ or myocard\$ or pericard\$ or isch?em\$ or emboli\$ or arrhythmi\$ or thrombo\$ or atrial fibrillat\$ or tachycardi\$ or endocardi\$).ti,ab.
55	(sick adj sinus).ti,ab.
56	exp STROKE/
57	(stroke or stokes).ti,ab.
58	(cerebrovasc\$ or cerebral vascular or apoplexy).ti,ab.
59	(brain adj2 accident\$).ti,ab.
60	((brain\$ or cerebral or lacunar) adj2 infarct\$).ti,ab.
61	exp HYPERTENSION/
62	(hypertensi\$ or peripheral arter\$ disease\$).ti,ab.
63	((high or increased or elevated) adj2 blood pressure).ti,ab.
64	or/53-63
65	PREVALENCE/
66	INCIDENCE/
67	exp RISK/
68	(prevalen\$ or incidence? or risk\$ or rate?).ti.
69	CHEMOPREVENTION/
70	(prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$).ti.
71	or/65-70
72	and/46,52,64,71
73	*HORMONE REPLACEMENT THERAPY/ or *ESTROGEN REPLACEMENT THERAPY/
74	((hormon\$ or oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone or progest\$ or medroxyprogest\$) adj3 (therap\$ or substitut\$ or replacement or exogenous)).ti.
75	or/73-74
76	exp *CARDIOVASCULAR DISEASES/ or exp *STROKE/ or exp *HYPERTENSION/
77	(ae or pc).fs. [Adverse Effects or Prevention & Control]
78	46 or FEMALE/
79	and/75-78
80	or/72,79
81	limit 80 to english language
82	LETTER/
83	EDITORIAL/
84	NEWS/
85	exp HISTORICAL ARTICLE/
86	ANECDOTES AS TOPIC/
87	COMMENT/
88	CASE REPORT/
89	(letter or comment* or abstracts).ti.
90	or/82-89
91	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
92	90 not 91
93	ANIMALS/ not HUMANS/
94	exp ANIMALS, LABORATORY/
95	exp ANIMAL EXPERIMENTATION/
96	exp MODELS, ANIMAL/
97	exp RODENTIA/
98	(rat or rats or mouse or mice).ti.
99	or/92-98
100	81 not 99
101	and/41,100

#### Database: Medline In-Process

#	Searches
1	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.

#	Searches
2	"change of life".ti,ab.
3	or/1-2
4	(hormon\$ adj3 (therap\$ or substitut\$ or replacement or exogenous)).ti,ab.
5	(HRT or HT or MHT).ti,ab.
6	((oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone or progest\$ or medroxyprogest\$) adj3 (therap\$ or substitut\$ or replacement or exogenous)).ti,ab.
7	or/4-6
8	(cardio\$ or cardia\$ or heart\$ or coronary\$ or angina\$ or ventric\$ or myocard\$ or pericard\$ or isch?em\$ or emboli\$ or arrhythmi\$ or thrombo\$ or atrial fibrillat\$ or tachycardi\$ or endocardi\$).ti,ab.
9	(sick adj sinus).ti,ab.
10	(stroke or stokes).ti,ab.
11	(cerebrovasc\$ or cerebral vascular or apoplexy).ti,ab.
12	(brain adj2 accident\$).ti,ab.
13	((brain\$ or cerebral or lacunar) adj2 infarct\$).ti,ab.
14	(hypertensi\$ or peripheral arter\$ disease\$).ti,ab.
15	((high or increased or elevated) adj2 blood pressure).ti,ab.
16	or/8-15
17	(prevalen\$ or incidence? or risk\$ or rate?).ti.
18	(prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$).ti.
19	or/17-18
20	and/3,7,16,19

### Database: Cochrane Central Register of Controlled Trials

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
4	"change of life".ti,ab.
5	or/1-4
6	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
7	exp ESTROGENS/tu or ESTRADIOL/tu [Therapeutic Use]
8	(hormon\$ adj3 (therap\$ or substitut\$ or replacement or exogenous)).ti,ab.
9	(HRT or HT or MHT).ti,ab.
10	((oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone or progest\$ or medroxyprogest\$) adj3 (therap\$ or substitut\$ or replacement or exogenous)).ti,ab.
11	or/6-10
12	exp CARDIOVASCULAR DISEASES/
13	(cardio\$ or cardia\$ or heart\$ or coronary\$ or angina\$ or ventric\$ or myocard\$ or pericard\$ or isch?em\$ or emboli\$ or arrhythmi\$ or thrombo\$ or atrial fibrillat\$ or tachycardi\$ or endocardi\$).ti,ab.
14	(sick adj sinus).ti,ab.
15	exp STROKE/
16	(stroke or stokes).ti,ab.
17	(cerebrovasc\$ or cerebral vascular or apoplexy).ti,ab.
18	(brain adj2 accident\$).ti,ab.
19	((brain\$ or cerebral or lacunar) adj2 infarct\$).ti,ab.
20	exp HYPERTENSION/
21	(hypertensi\$ or peripheral arter\$ disease\$).ti,ab.
22	((high or increased or elevated) adj2 blood pressure).ti,ab.
23	or/12-22
24	PREVALENCE/
25	INCIDENCE/
26	exp RISK/
27	(prevalen\$ or incidence? or risk\$ or rate?).ti.
28	CHEMOPREVENTION/
29	(prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$).ti.
30	or/24-29
31	and/5,11,23,30
32	*HORMONE REPLACEMENT THERAPY/ or *ESTROGEN REPLACEMENT THERAPY/
33	((hormon\$ or oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone or progest\$ or medroxyprogest\$) adj3 (therap\$ or substitut\$ or replacement or exogenous)).ti.
34	or/32-33
35	exp *CARDIOVASCULAR DISEASES/ or exp *STROKE/ or exp *HYPERTENSION/
36	(ae or pc).fs. [Adverse Effects or Prevention & Control]
37	5 or FEMALE/
38	and/34-37
39	or/31,38

### Database: Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects

#	Searches
1	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw,tx,kw.
2	"change of life".tw,tx.
3	or/1-2
4	(hormon\$ adj3 (therap\$ or substitut\$ or replacement or exogenous)).tw,tx,kw.
5	(HRT or HT or MHT).tw,tx.
6	((oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone or progest\$ or medroxyprogest\$) adj3 (therap\$ or substitut\$ or replacement or exogenous)).tw,tx,kw.
7	or/4-6
8	CARDIOVASCULAR DISEASE?.kw.
9	(cardio\$ or cardia\$ or heart\$ or coronary\$ or angina\$ or ventric\$ or myocard\$ or pericard\$ or isch?em\$ or emboli\$ or arrhythmi\$ or thrombo\$ or atrial fibrillat\$ or tachycardi\$ or endocardi\$).tw,tx.
10	(sick adj sinus).tw,tx.
11	(stroke or stokes).tw,tx,kw.
12	(cerebrovasc\$ or cerebral vascular or apoplexy).tw,tx,kw.
13	(brain adj2 accident\$).tw,tx.
14	((brain\$ or cerebral or lacunar) adj2 infarct\$).tw,tx.
15	(hypertensi\$ or peripheral arter\$ disease\$).tw,tx,kw.
16	((high or increased or elevated) adj2 blood pressure).tw,tx.
17	or/8-16
18	(prevalen\$ or incidence? or risk\$ or rate?).tw,tx,kw.
19	(prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$).tw,tx,kw.
20	or/18-19
21	and/3,7,17,20

### Database: Health Technology Assessment

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw.
4	"change of life".tw.
5	or/1-4
6	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
7	(hormon\$ adj3 (therap\$ or substitut\$ or replacement or exogenous)).tw.
8	(HRT or HT or MHT).tw.
9	((oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone or progest\$ or medroxyprogest\$) adj3 (therap\$ or substitut\$ or replacement or exogenous)).tw.
10	or/6-9
11	exp CARDIOVASCULAR DISEASES/
12	(cardio\$ or cardia\$ or heart\$ or coronary\$ or angina\$ or ventric\$ or myocard\$ or pericard\$ or isch?em\$ or emboli\$ or arrhythmi\$ or thrombo\$ or atrial fibrillat\$ or tachycardi\$ or endocardi\$).tw.
13	(sick adj sinus).tw.
14	exp STROKE/
15	(stroke or stokes).tw.
16	(cerebrovasc\$ or cerebral vascular or apoplexy).tw.
17	(brain adj2 accident\$).tw.
18	((brain\$ or cerebral or lacunar) adj2 infarct\$).tw.
19	exp HYPERTENSION/
20	(hypertensi\$ or peripheral arter\$ disease\$).tw.
21	((high or increased or elevated) adj2 blood pressure).tw.
22	or/11-21
23	PREVALENCE/
24	INCIDENCE/
25	exp RISK/
26	(prevalen\$ or incidence? or risk\$ or rate?).ti.
27	CHEMOPREVENTION/
28	(prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$).ti.
29	or/23-28
30	and/5,10,22,29

### Database: Embase

#	Searches
1	CLINICAL TRIAL/ or "CLINICAL TRIAL (TOPIC)"/
2	(clinic\$ adj5 trial\$).tw,sh.
3	SINGLE BLIND PROCEDURE/
4	DOUBLE BLIND PROCEDURE/
5	RANDOM ALLOCATION/

#	Searches
6	CROSSOVER PROCEDURE/
7	PLACEBO/
8	placebo\$.tw,sh.
9	random\$.tw,sh.
10	RANDOMIZED CONTROLLED TRIAL/ or "RANDOMIZED CONTROLLED TRIAL (TOPIC)"/
11	((single or double or triple or treble) adj (blind\$ or mask\$)).tw,sh.
12	randomi?ed control\$ trial\$.tw.
13	or/1-12
14	META ANALYSIS/
15	((meta adj analy\$) or metaanalys\$ or meta-analy\$).tw,sh.
16	(systematic\$ adj5 (review\$ or overview\$)).tw,sh.
17	(methodologic\$ adj5 (review\$ or overview\$)).tw,sh.
18	or/14-17
19	review.pt.
20	(medline or medlars or embase).ab.
21	(scisearch or science citation index).ab.
22	(psychlit or psyclit or psychinfo or psycinfo or cinahl or cochrane).ab.
23	((hand or manual\$) adj2 search\$).tw.
24	(electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw.
25	(pooling or pooled or mantel haenszel).tw.
26	(peto or dersimonian or "der simonian" or fixed effect).tw.
27	or/20-26
28	and/19,27
29	COHORT ANALYSIS/
30	LONGITUDINAL STUDY/
31	FOLLOW UP/
32	PROSPECTIVE STUDY/
33	cohort\$.tw.
34	or/29-33
35	or/13,18,28,34
36	(book or conference paper or editorial or letter or note or proceeding or short survey).pt.
37	35 not 36
38	"MENOPAUSE AND CLIMACTERIUM"/ or CLIMACTERIUM/ or EARLY MENOPAUSE/ or MENOPAUSE/ or POSTMENOPAUSE/
39	MENOPAUSAL SYNDROME/
40	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
41	"change of life".ti,ab.
42	or/38-41
43	HORMONE SUBSTITUTION/ or ESTROGEN THERAPY/
44	exp ESTROGEN/dt [Drug Therapy]
45	(hormon\$ adj3 (therap\$ or substitut\$ or replacement or exogenous)).ti,ab.
46	(HRT or HT or MHT).ti,ab.
47	((oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone or progest\$ or medroxyprogest\$) adj3 (therap\$ or substitut\$ or replacement or exogenous)).ti,ab.
48	or/43-47
49	exp CARDIOVASCULAR DISEASE/
50	(cardio\$ or cardia\$ or heart\$ or coronary\$ or angina\$ or ventric\$ or myocard\$ or pericard\$ or isch?em\$ or emboli\$ or arrhythmi\$ or thrombo\$ or atrial fibrillat\$ or tachycardi\$ or endocardi\$).ti,ab.
51	(sick adj sinus).ti,ab.
52	exp CEREBROVASCULAR ACCIDENT/
53	(stroke or stokes).ti,ab.
54	(cerebrovasc\$ or cerebral vascular or apoplexy).ti,ab.
55	(brain adj2 accident\$).ti,ab.
56	((brain\$ or cerebral or lacunar) adj2 infarct\$).ti,ab.
57	exp HYPERTENSION/
58	(hypertensi\$ or peripheral arter\$ disease\$).ti,ab.
59	((high or increased or elevated) adj2 blood pressure).ti,ab.
60	or/49-59
61	PREVALENCE/
62	INCIDENCE/
63	exp CARDIOVASCULAR RISK/
64	(prevalen\$ or incidence? or risk\$ or rate?).ti.
65	PROPHYLAXIS/
66	CHEMOPROPHYLAXIS/
67	(prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$).ti.
68	or/61-67
69	and/42,48,60,68
70	*HORMONE SUBSTITUTION/ or *ESTROGEN THERAPY/
71	((hormon\$ or oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone or progest\$ or medroxyprogest\$) adj3 (therap\$ or substitut\$ or replacement or exogenous)).ti.
72	or/70-71

#	Searches
73	(ae or pc or si).fs. [Adverse Drug Reaction or Prevention or Side Effect]
74	exp *CARDIOVASCULAR DISEASE/ or exp *CEREBROVASCULAR ACCIDENT/ or exp *HYPERTENSION/
75	42 or FEMALE/
76	and/72-75
77	or/69,76
78	limit 77 to english language
79	conference abstract.pt.
80	letter.pt. or LETTER/
81	note.pt.
82	editorial.pt.
83	CASE REPORT/ or CASE STUDY/
84	(letter or comment* or abstracts).ti.
85	or/79-84
86	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
87	85 not 86
88	ANIMAL/ not HUMAN/
89	NONHUMAN/
90	exp ANIMAL EXPERIMENT/
91	exp EXPERIMENTAL ANIMAL/
92	ANIMAL MODEL/
93	exp RODENT/
94	(rat or rats or mouse or mice).ti.
95	or/87-94
96	78 not 95
97	and/37,96

### E.7.3 Development of type 2 diabetes

#### Database: Medline

#	Searches
1	randomized controlled trial.pt.
2	controlled clinical trial.pt.
3	DOUBLE BLIND METHOD/
4	SINGLE BLIND METHOD/
5	RANDOM ALLOCATION/
6	or/1-5
7	((single or double or triple or treble) adj5 (blind\$ or mask\$)).tw,sh.
8	clinical trial.pt.
9	exp CLINICAL TRIAL/
10	exp CLINICAL TRIALS AS TOPIC/
11	(clinic\$ adj5 trial\$).tw,sh.
12	PLACEBOS/
13	placebo\$.tw,sh.
14	random\$.tw,sh.
15	or/7-14
16	or/6-15
17	META ANALYSIS/
18	META ANALYSIS AS TOPIC/
19	meta analysis.pt.
20	(metaanaly\$ or meta-analy\$ or (meta adj analy\$)).tw,sh.
21	(systematic\$ adj5 (review\$ or overview\$)).tw,sh.
22	(methodologic\$ adj5 (review\$ or overview\$)).tw,sh.
23	or/17-22
24	review\$.pt.
25	(medline or medlars or embase or cinahl or cochrane or psycinfo or psychinfo or psychlit or psyclit or "web of science" or "science citation" or scisearch).tw.
26	((hand or manual\$) adj2 search\$).tw.
27	(electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw,sh.
28	(pooling or pooled or mantel haenszel).tw,sh.
29	(peto or dersimonian or der simonian or fixed effect).tw,sh.
30	or/25-29
31	and/24,30
32	exp CASE-CONTROL STUDIES/
33	(case\$ adj2 control\$).tw.
34	exp COHORT STUDIES/
35	cohort\$.tw.
36	or/32-35
37	or/16,23,31,36
38	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/

#	Searches
39	CLIMACTERIC/
40	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
41	"change of life".ti,ab.
42	PRIMARY OVARIAN INSUFFICIENCY/
43	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
44	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
45	(POI or POF).ti,ab.
46	or/38-45
47	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
48	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
49	(HRT or HT).ti,ab.
50	("menopausal hormone" adj2 therap\$).ti,ab.
51	MHT.ti,ab.
52	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
53	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
54	MPA.ti,ab.
55	or/47-54
56	exp DIABETES MELLITUS, TYPE 2/
57	(diabet\$ adj5 ("type two" or "type 2" or "type II" or T2 or TII or matur\$ or adult\$ or slow or late or stable or ketosis resistant or keto resist\$ or keto?resist\$ or non keto\$ or non?keto\$)).ti,ab.
58	(diabet\$ adj5 ((non insulin or non?insulin) adj2 depend\$)).ti,ab.
59	(NIDDM or T2D or TIID or DM2 or DMII).ti,ab.
60	METABOLIC SYNDROME X/
61	((metabolic or insulin or reaven) adj3 syndrome).ti,ab.
62	or/56-61
63	and/37,46,55,62
64	LETTER/
65	EDITORIAL/
66	NEWS/
67	exp HISTORICAL ARTICLE/
68	ANECDOTES AS TOPIC/
69	COMMENT/
70	CASE REPORT/
71	(letter or comment* or abstracts).ti.
72	or/64-71
73	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
74	72 not 73
75	ANIMALS/ not HUMANS/
76	exp ANIMALS, LABORATORY/
77	exp ANIMAL EXPERIMENTATION/
78	exp MODELS, ANIMAL/
79	exp RODENTIA/
80	(rat or rats or mouse or mice).ti.
81	or/74-80
82	63 not 81
83	limit 82 to english language

### Database: Medline In-Process

#	Searches
1	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
2	"change of life".ti,ab.
3	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
4	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
5	(POI or POF).ti,ab.
6	or/1-5
7	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
8	(HRT or HT).ti,ab.
9	("menopausal hormone" adj2 therap\$).ti,ab.
10	MHT.ti,ab.
11	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
12	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
13	MPA.ti,ab.
14	or/7-13
15	(diabet\$ adj5 ("type two" or "type 2" or "type II" or T2 or TII or matur\$ or adult\$ or slow or late or stable or ketosis resistant or keto resist\$ or keto?resist\$ or non keto\$ or non?keto\$)).ti,ab.
16	(diabet\$ adj5 ((non insulin or non?insulin) adj2 depend\$)).ti,ab.
17	(NIDDM or T2D or TIID or DM2 or DMII).ti,ab.
18	((metabolic or insulin or reaven) adj3 syndrome).ti,ab.

#	Searches
19	or/15-18
20	and/6,14,19

### Database: Cochrane Central Register of Controlled Trials

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
4	"change of life".ti,ab.
5	PRIMARY OVARIAN INSUFFICIENCY/
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
7	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
8	(POI or POF).ti,ab.
9	or/1-8
10	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
11	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
12	(HRT or HT).ti,ab.
13	("menopausal hormone" adj2 therap\$).ti,ab.
14	MHT.ti,ab.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
16	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
17	MPA.ti,ab.
18	or/10-17
19	exp DIABETES MELLITUS, TYPE 2/
20	(diabet\$ adj5 ("type two" or "type 2" or "type II" or T2 or TII or matur\$ or adult\$ or slow or late or stable or ketosis resistant or keto resist\$ or keto?resist\$ or non keto\$ or non?keto\$)).ti,ab.
21	(diabet\$ adj5 ((non insulin or non?insulin) adj2 depend\$)).ti,ab.
22	(NIDDM or T2D or TIID or DM2 or DMII).ti,ab.
23	METABOLIC SYNDROME X/
24	((metabolic or insulin or reaven) adj3 syndrome).ti,ab.
25	or/19-24
26	and/9,18,25

### Database: Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects

#	Searches
1	(MENOPAUSE or MENOPAUSE, PREMATURE or PERIMENOPAUSE or POSTMENOPAUSE).kw.
2	CLIMACTERIC.kw.
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw,tx.
4	"change of life".tw,tx.
5	PRIMARY OVARIAN INSUFFICIENCY.kw.
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw,tx.
7	((earl\$ or prematur\$) adj3 menopaus\$).tw,tx.
8	(POI or POF).tw,tx.
9	or/1-8
10	(HORMONE REPLACEMENT THERAPY or ESTROGEN REPLACEMENT THERAPY).kw.
11	(hormon\$ adj3 (therap\$ or substitut\$)).tw,tx.
12	(HRT or HT).tw,tx.
13	("menopausal hormone" adj2 therap\$).tw,tx.
14	MHT.tw,tx.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).tw,tx.
16	MPA.tw,tx.
17	or/10-16
18	DIABETES MELLITUS, TYPE 2.kw.
19	(diabet\$ adj5 ("type two" or "type 2" or "type II" or T2 or TII or matur\$ or adult\$ or slow or late or stable or ketosis resistant or keto resist\$ or keto?resist\$ or non keto\$ or non?keto\$)).tw,tx.
20	(diabet\$ adj5 ((non insulin or non?insulin) adj2 depend\$)).tw,tx.
21	(NIDDM or T2D or TIID or DM2 or DMII).tw,tx.
22	METABOLIC SYNDROME X.kw.
23	((metabolic or insulin or reaven) adj3 syndrome).tw,tx.
24	or/18-23
25	and/9,17,24

### Database: Health Technology Assessment

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/



#	Searches
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw.
4	"change of life".tw.
5	PRIMARY OVARIAN INSUFFICIENCY/
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw.
7	((earl\$ or prematur\$) adj3 menopaus\$).tw.
8	(POI or POF).tw.
9	or/1-8
10	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
11	(hormon\$ adj3 (therap\$ or substitut\$)).tw.
12	(HRT or HT).tw.
13	("menopausal hormone" adj2 therap\$).tw.
14	MHT.tw.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).tw.
16	MPA.tw.
17	or/10-16
18	exp DIABETES MELLITUS, TYPE 2/
19	(diabet\$ adj5 ("type two" or "type 2" or "type II" or T2 or TII or matur\$ or adult\$ or slow or late or stable or ketosis resistant or keto resist\$ or keto?resist\$ or non keto\$ or non?keto\$)).tw.
20	(diabet\$ adj5 ((non insulin or non?insulin) adj2 depend\$)).tw.
21	(NIDDM or T2D or TIID or DM2 or DMII).tw.
22	METABOLIC SYNDROME X/
23	((metabolic or insulin or reaven) adj3 syndrome).tw.
24	or/18-23
25	and/9,17,24

#### Database: Embase

#	Searches
1	CLINICAL TRIAL/ or "CLINICAL TRIAL (TOPIC)"/
2	(clinic\$ adj5 trial\$).tw,sh.
3	SINGLE BLIND PROCEDURE/
4	DOUBLE BLIND PROCEDURE/
5	RANDOM ALLOCATION/
6	CROSSOVER PROCEDURE/
7	PLACEBO/
8	placebo\$.tw,sh.
9	random\$.tw,sh.
10	RANDOMIZED CONTROLLED TRIAL/ or "RANDOMIZED CONTROLLED TRIAL (TOPIC)"/
11	((single or double or triple or treble) adj (blind\$ or mask\$)).tw,sh.
12	randomi?ed control\$ trial\$.tw.
13	or/1-12
14	META ANALYSIS/
15	((meta adj analy\$) or metaanalys\$ or meta-analy\$).tw,sh.
16	(systematic\$ adj5 (review\$ or overview\$)).tw,sh.
17	(methodologic\$ adj5 (review\$ or overview\$)).tw,sh.
18	or/14-17
19	review.pt.
20	(medline or medlars or embase).ab.
21	(scisearch or science citation index).ab.
22	(psychlit or psyclit or psychinfo or psycinfo or cinahl or cochrane).ab.
23	((hand or manual\$) adj2 search\$).tw.
24	(electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw.
25	(pooling or pooled or mantel haenszel).tw.
26	(peto or dersimonian or "der simonian" or fixed effect).tw.
27	or/20-26
28	and/19,27
29	exp CASE CONTROL STUDY/
30	RETROSPECTIVE STUDY/
31	(case\$ adj2 control\$).tw.
32	COHORT ANALYSIS/
33	LONGITUDINAL STUDY/
34	FOLLOW UP/
35	PROSPECTIVE STUDY/
36	cohort\$.tw.
37	or/29-36
38	or/13,18,28,37
39	(book or conference paper or editorial or letter or note or proceeding or short survey).pt.
40	38 not 39

#	Searches
41	"MENOPAUSE AND CLIMACTERIUM"/ or CLIMACTERIUM/ or EARLY MENOPAUSE/ or MENOPAUSE/ or POSTMENOPAUSE/
42	PREMENOPAUSE/
43	PREMATURE OVARIAN FAILURE/
44	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF or POI).ti,ab.
45	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
46	climacteric.ti,ab.
47	(change adj1 life).ti,ab.
48	or/41-47
49	exp HORMONE SUBSTITUTION/ or ESTROGEN THERAPY/
50	(HRT or HT).ti,ab.
51	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
52	MHT.ti,ab.
53	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
54	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
55	MPA.ti,ab.
56	or/49-55
57	NON INSULIN DEPENDENT DIABETES MELLITUS/
58	(diabet\$ adj5 ("type two" or "type 2" or "type II" or T2 or TII or matur\$ or adult\$ or slow or late or stable or ketosis resistant or keto resist\$ or keto?resist\$ or non keto\$ or non?keto\$)).ti,ab.
59	(diabet\$ adj5 ((non insulin or non?insulin) adj2 depend\$)).ti,ab.
60	(NIDDM or T2D or TIID or DM2 or DMII).ti,ab.
61	METABOLIC SYNDROME X/
62	((metabolic or insulin or reaven) adj3 syndrome).ti,ab.
63	or/57-62
64	and/40,48,56,63
65	conference abstract.pt.
66	letter.pt. or LETTER/
67	note.pt.
68	editorial.pt.
69	CASE REPORT/ or CASE STUDY/
70	(letter or comment* or abstracts).ti.
71	or/65-70
72	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
73	71 not 72
74	ANIMAL/ not HUMAN/
75	NONHUMAN/
76	exp ANIMAL EXPERIMENT/
77	exp EXPERIMENTAL ANIMAL/
78	ANIMAL MODEL/
79	exp RODENT/
80	(rat or rats or mouse or mice).ti.
81	or/73-80
82	64 not 81
83	limit 82 to english language
84	female/
85	and/83-84

## E.7.4 Management of type 2 diabetes – control of blood sugar

### Database: Medline

#	Searches
1	randomized controlled trial.pt.
2	controlled clinical trial.pt.
3	DOUBLE BLIND METHOD/
4	SINGLE BLIND METHOD/
5	RANDOM ALLOCATION/
6	or/1-5
7	((single or double or triple or treble) adj5 (blind\$ or mask\$)).tw,sh.
8	clinical trial.pt.
9	exp CLINICAL TRIAL/
10	exp CLINICAL TRIALS AS TOPIC/
11	(clinic\$ adj5 trial\$).tw,sh.
12	PLACEBOS/
13	placebo\$.tw,sh.
14	random\$.tw,sh.
15	or/7-14
16	or/6-15
17	META ANALYSIS/

#	Searches
18	META ANALYSIS AS TOPIC/
19	meta analysis.pt.
20	(metaanaly\$ or meta-analy\$ or (meta adj analy\$)).tw,sh.
21	(systematic\$ adj5 (review\$ or overview\$)).tw,sh.
22	(methodologic\$ adj5 (review\$ or overview\$)).tw,sh.
23	or/17-22
24	review\$.pt.
25	(medline or medlars or embase or cinahl or cochrane or psycinfo or psychinfo or psychlit or psyclit or "web of science" or "science citation" or scisearch).tw.
26	((hand or manual\$) adj2 search\$).tw.
27	(electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw,sh.
28	(pooling or pooled or mantel haenszel).tw,sh.
29	(peto or dersimonian or der simonian or fixed effect).tw,sh.
30	or/25-29
31	and/24,30
32	exp CASE-CONTROL STUDIES/
33	(case\$ adj2 control\$).tw.
34	exp COHORT STUDIES/
35	cohort\$.tw.
36	or/32-35
37	or/16,23,31,36
38	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
39	CLIMACTERIC/
40	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
41	"change of life".ti,ab.
42	PRIMARY OVARIAN INSUFFICIENCY/
43	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
44	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
45	(POI or POF).ti,ab.
46	or/38-45
47	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
48	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
49	(HRT or HT).ti,ab.
50	("menopausal hormone" adj2 therap\$).ti,ab.
51	MHT.ti,ab.
52	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti,ab.
53	MPA.ti,ab.
54	or/47-53
55	BLOOD GLUCOSE/
56	(blood adj3 (glucose or sugar?)).ti,ab.
57	BLOOD GLUCOSE SELF-MONITORING/
58	BGSM.ti,ab.
59	(home glucose adj (test\$ or monitor\$)).ti,ab.
60	(self adj (test\$ or monitor\$)).ti,ab.
61	GLUCOSE TOLERANCE TEST/
62	(glucose adj (toleran\$ or test\$ or load\$)).ti,ab.
63	OGTT.ti,ab.
64	(fasting adj plasma adj glucose).ti,ab.
65	FPG.ti,ab.
66	HEMOGLOBIN A, GLYCOSYLATED/
67	HbA1c.ti,ab.
68	(h?emoglobin? adj3 glycosylat\$).ti,ab.
69	(glycated adj3 h?emoglobin?).ti,ab.
70	or/55-69
71	and/37,46,54,70
72	LETTER/
73	EDITORIAL/
74	NEWS/
75	exp HISTORICAL ARTICLE/
76	ANECDOTES AS TOPIC/
77	COMMENT/
78	CASE REPORT/
79	(letter or comment* or abstracts).ti.
80	or/72-79
81	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
82	80 not 81
83	ANIMALS/ not HUMANS/
84	exp ANIMALS, LABORATORY/
85	exp ANIMAL EXPERIMENTATION/

#	Searches
86	exp MODELS, ANIMAL/
87	exp RODENTIA/
88	(rat or rats or mouse or mice).ti.
89	or/82-88
90	71 not 89
91	limit 90 to english language

### Database: Medline In-Process

#	Searches
1	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
2	"change of life".ti,ab.
3	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
4	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
5	(POI or POF).ti,ab.
6	or/1-5
7	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
8	(HRT or HT).ti,ab.
9	("menopausal hormone" adj2 therap\$).ti,ab.
10	MHT.ti,ab.
11	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti,ab.
12	MPA.ti,ab.
13	or/7-12
14	(blood adj3 (glucose or sugar?)).ti,ab.
15	BGSM.ti,ab.
16	(home glucose adj (test\$ or monitor\$)).ti,ab.
17	(self adj (test\$ or monitor\$)).ti,ab.
18	(glucose adj (toleran\$ or test\$ or load\$)).ti,ab.
19	OGTT.ti,ab.
20	(fasting adj plasma adj glucose).ti,ab.
21	FPG.ti,ab.
22	HbA1c.ti,ab.
23	(h?emoglobin? adj3 glycosylat\$).ti,ab.
24	(glycated adj3 h?emoglobin?).ti,ab.
25	or/14-24
26	and/6,13,25

### Database: Cochrane Central Register of Controlled Trials

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
4	"change of life".ti,ab.
5	PRIMARY OVARIAN INSUFFICIENCY/
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
7	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
8	(POI or POF).ti,ab.
9	or/1-8
10	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
11	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
12	(HRT or HT).ti,ab.
13	("menopausal hormone" adj2 therap\$).ti,ab.
14	MHT.ti,ab.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti,ab.
16	MPA.ti,ab.
17	or/10-16
18	BLOOD GLUCOSE/
19	(blood adj3 (glucose or sugar?)).ti,ab.
20	BLOOD GLUCOSE SELF-MONITORING/
21	BGSM.ti,ab.
22	(home glucose adj (test\$ or monitor\$)).ti,ab.
23	(self adj (test\$ or monitor\$)).ti,ab.
24	GLUCOSE TOLERANCE TEST/
25	(glucose adj (toleran\$ or test\$ or load\$)).ti,ab.
26	OGTT.ti,ab.
27	(fasting adj plasma adj glucose).ti,ab.
28	FPG.ti,ab.
29	HEMOGLOBIN A, GLYCOSYLATED/

#	Searches
30	HbA1c.ti,ab.
31	(h?emoglobin? adj3 glycosylat\$.ti,ab.
32	(glycated adj3 h?emoglobin?).ti,ab.
33	or/18-32
34	and/9,17,33

### Database: Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects

#	Searches
1	(MENOPAUSE or MENOPAUSE, PREMATURE or PERIMENOPAUSE or POSTMENOPAUSE).kw.
2	CLIMACTERIC.kw.
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw,tx.
4	"change of life".tw,tx.
5	PRIMARY OVARIAN INSUFFICIENCY.kw.
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw,tx.
7	((earl\$ or prematur\$) adj3 menopaus\$).tw,tx.
8	(POI or POF).tw,tx.
9	or/1-8
10	(HORMONE REPLACEMENT THERAPY or ESTROGEN REPLACEMENT THERAPY).kw.
11	(hormon\$ adj3 (therap\$ or substitut\$)).tw,tx.
12	(HRT or HT).tw.
13	("menopausal hormone" adj2 therap\$).tw,tx.
14	MHT.tw.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).tw,tx.
16	MPA.tw.
17	or/10-16
18	BLOOD GLUCOSE.kw.
19	(blood adj3 (glucose or sugar?)).tw,tx.
20	BLOOD GLUCOSE SELF-MONITORING.kw.
21	BGSM.tw,tx.
22	(home glucose adj (test\$ or monitor\$)).tw,tx.
23	(self adj (test\$ or monitor\$)).tw,tx.
24	GLUCOSE TOLERANCE TEST.kw.
25	(glucose adj (toleran\$ or test\$ or load\$)).tw,tx.
26	OGTT.tw.
27	(fasting adj plasma adj glucose).tw,tx.
28	FPG.tw.
29	HEMOGLOBIN A, GLYCOSYLATED.kw.
30	HbA1c.tw,tx.
31	(h?emoglobin? adj3 glycosylat\$).tw,tx.
32	(glycated adj3 h?emoglobin?).tw,tx.
33	or/18-32
34	and/9,17,33

### Database: Health Technology Assessment

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw.
4	"change of life".tw.
5	PRIMARY OVARIAN INSUFFICIENCY/
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw.
7	((earl\$ or prematur\$) adj3 menopaus\$).tw.
8	(POI or POF).tw.
9	or/1-8
10	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
11	(hormon\$ adj3 (therap\$ or substitut\$)).tw.
12	(HRT or HT).tw.
13	("menopausal hormone" adj2 therap\$).tw.
14	MHT.tw.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).tw.
16	MPA.tw.
17	or/10-16
18	BLOOD GLUCOSE/
19	(blood adj3 (glucose or sugar?)).tw.
20	BLOOD GLUCOSE SELF-MONITORING/

#	Searches
21	BGSM.ti,ab.
22	(home glucose adj (test\$ or monitor\$)).tw.
23	(self adj (test\$ or monitor\$)).tw.
24	GLUCOSE TOLERANCE TEST/
25	(glucose adj (toleran\$ or test\$ or load\$)).tw.
26	OGTT.tw.
27	(fasting adj plasma adj glucose).tw.
28	FPG.tw.
29	HEMOGLOBIN A, GLYCOSYLATED/
30	HbA1c.tw.
31	(h?emoglobin? adj3 glycosylat\$).tw.
32	(glycated adj3 h?emoglobin?).tw.
33	or/18-32
34	and/9,17,33

### Database: Embase

#	Searches
1	CLINICAL TRIAL/ or "CLINICAL TRIAL (TOPIC)"/
2	(clinic\$ adj5 trial\$).tw,sh.
3	SINGLE BLIND PROCEDURE/
4	DOUBLE BLIND PROCEDURE/
5	RANDOM ALLOCATION/
6	CROSSOVER PROCEDURE/
7	PLACEBO/
8	placebo\$.tw,sh.
9	random\$.tw,sh.
10	RANDOMIZED CONTROLLED TRIAL/ or "RANDOMIZED CONTROLLED TRIAL (TOPIC)"/
11	((single or double or triple or treble) adj (blind\$ or mask\$)).tw,sh.
12	randomi?ed control\$ trial\$.tw.
13	or/1-12
14	META ANALYSIS/
15	((meta adj analy\$) or metaanalys\$ or meta-analy\$).tw,sh.
16	(systematic\$ adj5 (review\$ or overview\$)).tw,sh.
17	(methodologic\$ adj5 (review\$ or overview\$)).tw,sh.
18	or/14-17
19	review.pt.
20	(medline or medlars or embase).ab.
21	(scisearch or science citation index).ab.
22	(psychlit or psychlit or psychinfo or psycinfo or cinahl or cochrane).ab.
23	((hand or manual\$) adj2 search\$).tw.
24	(electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw.
25	(pooling or pooled or mantel haenszel).tw.
26	(peto or dersimonian or "der simonian" or fixed effect).tw.
27	or/20-26
28	and/19,27
29	exp CASE CONTROL STUDY/
30	RETROSPECTIVE STUDY/
31	(case\$ adj2 control\$).tw.
32	COHORT ANALYSIS/
33	LONGITUDINAL STUDY/
34	FOLLOW UP/
35	PROSPECTIVE STUDY/
36	cohort\$.tw.
37	or/29-36
38	or/13,18,28,37
39	(book or conference paper or editorial or letter or note or proceeding or short survey).pt.
40	38 not 39
41	"MENOPAUSE AND CLIMACTERIUM"/ or CLIMACTERIUM/ or EARLY MENOPAUSE/ or MENOPAUSE/ or POSTMENOPAUSE/
42	PREMENOPAUSE/
43	PREMATURE OVARIAN FAILURE/
44	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF or POI).ti,ab.
45	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
46	climacteric.ti,ab.
47	(change adj1 life).ti,ab.
48	or/41-47
49	exp HORMONE SUBSTITUTION/ or ESTROGEN THERAPY/
50	(HRT or HT).ti,ab.
51	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.

#	Searches
52	MHT.ti,ab.
53	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti,ab.
54	MPA.ti,ab.
55	or/49-54
56	GLUCOSE BLOOD LEVEL/
57	(blood adj3 (glucose or sugar?)).ti,ab.
58	BLOOD GLUCOSE MONITORING/
59	BGSM.ti,ab.
60	(home glucose adj (test\$ or monitor\$)).ti,ab.
61	(self adj (test\$ or monitor\$)).ti,ab.
62	GLUCOSE TOLERANCE TEST/
63	(glucose adj (toleran\$ or test\$ or load\$)).ti,ab.
64	ORAL GLUCOSE TOLERANCE TEST/
65	OGTT.ti,ab.
66	(fasting adj plasma adj glucose).ti,ab.
67	FPG.ti,ab.
68	HEMOGLOBIN A1c/
69	HbA1c.ti,ab.
70	(h?emoglobin adj3 glycosylat\$).ti,ab.
71	(glycated adj3 h?emoglobin?).ti,ab.
72	or/56-71
73	and/40,48,55,72
74	conference abstract.pt.
75	letter.pt. or LETTER/
76	note.pt.
77	editorial.pt.
78	CASE REPORT/ or CASE STUDY/
79	(letter or comment* or abstracts).ti.
80	or/74-79
81	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
82	80 not 81
83	ANIMAL/ not HUMAN/
84	NONHUMAN/
85	exp ANIMAL EXPERIMENT/
86	exp EXPERIMENTAL ANIMAL/
87	ANIMAL MODEL/
88	exp RODENT/
89	(rat or rats or mouse or mice).ti.
90	or/82-89
91	73 not 90
92	FEMALE/
93	and/91-92
94	limit 93 to english language

## E.7.5 Breast cancer

### Database: Medline

#	Searches
1	randomized controlled trial.pt.
2	controlled clinical trial.pt.
3	DOUBLE BLIND METHOD/
4	SINGLE BLIND METHOD/
5	RANDOM ALLOCATION/
6	or/1-5
7	((single or double or triple or treble) adj5 (blind\$ or mask\$)).tw,sh.
8	clinical trial.pt.
9	exp CLINICAL TRIAL/
10	exp CLINICAL TRIALS AS TOPIC/
11	(clinic\$ adj5 trial\$).tw,sh.
12	PLACEBOS/
13	placebo\$.tw,sh.
14	random\$.tw,sh.
15	or/7-14
16	or/6-15
17	META ANALYSIS/
18	META ANALYSIS AS TOPIC/
19	meta analysis.pt.
20	(metaanaly\$ or meta-analy\$ or (meta adj analy\$)).tw,sh.

#	Searches
21	(systematic\$ adj5 (review\$ or overview\$)).tw,sh.
22	(methodologic\$ adj5 (review\$ or overview\$)).tw,sh.
23	or/17-22
24	review\$.pt.
25	(medline or medlars or embase or cinahl or cochrane or psycinfo or psychinfo or psychlit or psyclit or "web of science" or "science citation" or scisearch).tw.
26	((hand or manual\$) adj2 search\$).tw.
27	(electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw,sh.
28	(pooling or pooled or mantel haenszel).tw,sh.
29	(peto or dersimonian or der simonian or fixed effect).tw,sh.
30	or/25-29
31	and/24,30
32	exp CASE-CONTROL STUDIES/
33	(case\$ adj2 control\$).tw.
34	exp COHORT STUDIES/
35	cohort\$.tw.
36	or/32-35
37	or/16,23,31,36
38	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
39	CLIMACTERIC/
40	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
41	"change of life".ti,ab.
42	PRIMARY OVARIAN INSUFFICIENCY/
43	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
44	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
45	(POI or POF).ti,ab.
46	or/38-45
47	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
48	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
49	(HRT or HT).ti,ab.
50	("menopausal hormone" adj2 therap\$).ti,ab.
51	MHT.ti,ab.
52	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
53	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
54	MPA.ti,ab.
55	or/47-54
56	BREAST NEOPLASMS/ or CARCINOMA, DUCTAL, BREAST/ or "HEREDITARY BREAST AND OVARIAN CANCER SYNDROME"/ or INFLAMMATORY BREAST NEOPLASMS/ or TRIPLE NEGATIVE BREAST NEOPLASMS/
57	(breast adj5 (cancer? or carcinoma? or tumo?r?)).ti,ab.
58	or/56-57
59	PREVALENCE/
60	INCIDENCE/
61	exp RISK/
62	(prevalen\$ or incidence? or risk\$ or rate?).ti.
63	CHEMOPREVENTION/
64	(prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$).ti.
65	or/59-64
66	and/46,55,58,65
67	*HORMONE REPLACEMENT THERAPY/ or *ESTROGEN REPLACEMENT THERAPY/
68	((hormon\$ or oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone or progest\$ or medroxyprogest\$) adj3 (therap\$ or substitut\$ or replacement or exogenous)).ti.
69	or/67-68
70	*BREAST NEOPLASMS/ or *CARCINOMA, DUCTAL, BREAST/ or **HEREDITARY BREAST AND OVARIAN CANCER SYNDROME"/ or *INFLAMMATORY BREAST NEOPLASMS/ or *TRIPLE NEGATIVE BREAST NEOPLASMS/
71	(ae or pc).fs.
72	and/69-71
73	and/46,72
74	or/66,73
75	FEMALE/
76	and/74-75
77	and/37,76
78	LETTER/
79	EDITORIAL/
80	NEWS/
81	exp HISTORICAL ARTICLE/
82	ANECDOTES AS TOPIC/
83	COMMENT/
84	CASE REPORT/
85	(letter or comment* or abstracts).ti.



#	Searches
86	or/78-85
87	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
88	86 not 87
89	ANIMALS/ not HUMANS/
90	exp ANIMALS, LABORATORY/
91	exp ANIMAL EXPERIMENTATION/
92	exp MODELS, ANIMAL/
93	exp RODENTIA/
94	(rat or rats or mouse or mice).ti.
95	or/88-94
96	77 not 95
97	limit 96 to english language

### Database: Medline-in-process

#	Searches
1	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
2	"change of life".ti,ab.
3	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
4	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
5	(POI or POF).ti,ab.
6	or/1-5
7	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
8	(HRT or HT).ti,ab.
9	("menopausal hormone" adj2 therap\$).ti,ab.
10	MHT.ti,ab.
11	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
12	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
13	MPA.ti,ab.
14	or/7-13
15	(breast adj5 (cancer? or carcinoma? or tumo?r?)).ti,ab.
16	and/6,14-15
17	(prevalen\$ or incidence? or risk\$ or rate?).ti.
18	(prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$).ti.
19	or/17-18
20	and/16,19

### Database: Cochrane Central Register of Controlled Trials

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
4	"change of life".ti,ab.
5	PRIMARY OVARIAN INSUFFICIENCY/
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
7	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
8	(POI or POF).ti,ab.
9	or/1-8
10	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
11	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
12	(HRT or HT).ti,ab.
13	("menopausal hormone" adj2 therap\$).ti,ab.
14	MHT.ti,ab.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
16	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
17	MPA.ti,ab.
18	or/10-17
19	BREAST NEOPLASMS/ or CARCINOMA, DUCTAL, BREAST/ or "HEREDITARY BREAST AND OVARIAN CANCER SYNDROME"/ or INFLAMMATORY BREAST NEOPLASMS/ or TRIPLE NEGATIVE BREAST NEOPLASMS/
20	(breast adj5 (cancer? or carcinoma? or tumo?r?)).ti,ab.
21	or/19-20
22	PREVALENCE/
23	INCIDENCE/
24	exp RISK/
25	(prevalen\$ or incidence? or risk\$ or rate?).ti.
26	CHEMOPREVENTION/
27	(prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$).ti.
28	or/22-27

#	Searches
29	and/9,18,21,28
30	*HORMONE REPLACEMENT THERAPY/ or *ESTROGEN REPLACEMENT THERAPY/
31	((hormon\$ or oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone or progest\$ or medroxyprogest\$) adj3 (therap\$ or substitut\$ or replacement or exogenous)).ti.
32	or/30-31
33	BREAST NEOPLASMS/ or CARCINOMA, DUCTAL, BREAST/ or "HEREDITARY BREAST AND OVARIAN CANCER SYNDROME"/ or INFLAMMATORY BREAST NEOPLASMS/ or TRIPLE NEGATIVE BREAST NEOPLASMS/
34	(ae or pc).fs.
35	9 and FEMALE/
36	and/32-35
37	or/29,36

### Database: Cochrane Database of Systematic Reviews and Database of Abstracts of Reviews of Effects

#	Searches
1	(MENOPAUSE or MENOPAUSE, PREMATURE or PERIMENOPAUSE or POSTMENOPAUSE).kw.
2	CLIMACTERIC.kw.
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw,tx.
4	"change of life".tw,tx.
5	PRIMARY OVARIAN INSUFFICIENCY.kw.
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw,tx.
7	((earl\$ or prematur\$) adj3 menopaus\$).tw.
8	(POI or POF).tw,tx.
9	or/1-8
10	(HORMONE REPLACEMENT THERAPY or ESTROGEN REPLACEMENT THERAPY).kw.
11	(hormon\$ adj3 (therap\$ or substitut\$)).tw,tx.
12	(HRT or HT).tw,tx.
13	("menopausal hormone" adj2 therap\$).tw,tx.
14	MHT.tw,tx.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).tw,tx.
16	MPA.tw,tx.
17	or/10-16
18	(BREAST NEOPLASMS or CARCINOMA, DUCTAL, BREAST or "HEREDITARY BREAST AND OVARIAN CANCER SYNDROME" or INFLAMMATORY BREAST NEOPLASMS or TRIPLE NEGATIVE BREAST NEOPLASMS).kw.
19	(breast adj5 (cancer? or carcinoma? or tumo?r?)).tw,tx.
20	or/18-19
21	and/9,17,20
22	(prevalen\$ or incidence? or risk\$ or rate?).tw,tx,kw.
23	(prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$).tw,tx,kw.
24	or/22-23
25	and/21,24

### Database: Health Technology Assessment

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw.
4	"change of life".tw.
5	PRIMARY OVARIAN INSUFFICIENCY/
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw.
7	((earl\$ or prematur\$) adj3 menopaus\$).tw.
8	(POI or POF).tw.
9	or/1-8
10	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
11	(hormon\$ adj3 (therap\$ or substitut\$)).tw.
12	(HRT or HT).tw.
13	("menopausal hormone" adj2 therap\$).tw.
14	MHT.tw.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).tw.
16	MPA.tw.
17	or/10-16
18	BREAST NEOPLASMS/ or CARCINOMA, DUCTAL, BREAST/ or "HEREDITARY BREAST AND OVARIAN CANCER SYNDROME"/ or INFLAMMATORY BREAST NEOPLASMS/ or TRIPLE NEGATIVE BREAST NEOPLASMS/
19	(breast adj5 (cancer? or carcinoma? or tumo?r?)).tw.
20	or/18-19
21	and/9,17,20

**Database: Embase**

#	Searches
1	CLINICAL TRIAL/ or "CLINICAL TRIAL (TOPIC)"/
2	(clinic\$ adj5 trial\$.tw,sh.
3	SINGLE BLIND PROCEDURE/
4	DOUBLE BLIND PROCEDURE/
5	RANDOM ALLOCATION/
6	CROSSOVER PROCEDURE/
7	PLACEBO/
8	placebo\$.tw,sh.
9	random\$.tw,sh.
10	RANDOMIZED CONTROLLED TRIAL/ or "RANDOMIZED CONTROLLED TRIAL (TOPIC)"/
11	((single or double or triple or treble) adj (blind\$ or mask\$)).tw,sh.
12	randomi?ed control\$ trial\$.tw.
13	or/1-12
14	META ANALYSIS/
15	((meta adj analys\$) or metaanalys\$ or meta-analy\$).tw,sh.
16	(systematic\$ adj5 (review\$ or overview\$)).tw,sh.
17	(methodologic\$ adj5 (review\$ or overview\$)).tw,sh.
18	or/14-17
19	review.pt.
20	(medline or medlars or embase).ab.
21	(scisearch or science citation index).ab.
22	(psychlit or psyclit or psychinfo or psycinfo or cinahl or cochrane).ab.
23	((hand or manual\$) adj2 search\$.tw.
24	(electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw.
25	(pooling or pooled or mantel haenszel).tw.
26	(peto or dersimonian or "der simonian" or fixed effect).tw.
27	or/20-26
28	and/19,27
29	exp CASE CONTROL STUDY/
30	RETROSPECTIVE STUDY/
31	(case\$ adj2 control\$.tw.
32	COHORT ANALYSIS/
33	LONGITUDINAL STUDY/
34	FOLLOW UP/
35	PROSPECTIVE STUDY/
36	cohort\$.tw.
37	or/29-36
38	or/13,18,28,37
39	(book or conference paper or editorial or letter or note or proceeding or short survey).pt.
40	38 not 39
41	"MENOPAUSE AND CLIMACTERIUM"/ or CLIMACTERIUM/ or EARLY MENOPAUSE/ or MENOPAUSE/ or POSTMENOPAUSE/
42	PREMENOPAUSE/
43	PREMATURE OVARIAN FAILURE/
44	(menopaus\$ or perimenopaus\$ or peri menopaus\$ or postmenopaus\$ or post menopaus\$ or POF or POI or climacteric).ti,ab.
45	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
46	(change adj1 life).ti,ab.
47	or/41-46
48	exp HORMONE SUBSTITUTION/ or ESTROGEN THERAPY/
49	(HRT or HT).ti,ab.
50	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
51	MHT.ti,ab.
52	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
53	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
54	MPA.ti,ab.
55	or/48-54
56	exp BREAST CANCER/ or BREAST TUMOR/
57	(breast adj5 (cancer? or carcinoma? or tumo#r?)).ti,ab.
58	or/56-57
59	INCIDENCE/
60	CANCER RISK/
61	RISK FACTOR/
62	PREVALENCE/
63	(inciden\$ or risk\$ or prevalen\$).ti.
64	PROPHYLAXIS/
65	CHEMOPROPHYLAXIS/
66	(prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$).ti.
67	or/59-66

#	Searches
68	and/47,55,58,67
69	*HORMONE SUBSTITUTION/ or *ESTROGEN THERAPY/
70	((hormon\$ or oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone or progest\$ or medroxyprogest\$) adj3 (therap\$ or substitut\$ or replacement or exogenous)).ti.
71	or/69-70
72	(ae or pc or si).fs. [Adverse Drug Reaction or Prevention or Side Effect]
73	exp *BREAST CANCER/ or *BREAST TUMOR/
74	and/71-73
75	and/47,74
76	or/68,75
77	and/40,76
78	FEMALE/
79	and/77-78
80	conference abstract.pt.
81	letter.pt. or LETTER/
82	note.pt.
83	editorial.pt.
84	CASE REPORT/ or CASE STUDY/
85	(letter or comment* or abstracts).ti.
86	or/80-85
87	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
88	86 not 87
89	ANIMAL/ not HUMAN/
90	NONHUMAN/
91	exp ANIMAL EXPERIMENT/
92	exp EXPERIMENTAL ANIMAL/
93	ANIMAL MODEL/
94	exp RODENT/
95	(rat or rats or mouse or mice).ti.
96	or/88-95
97	79 not 96

## E.7.6 Osteoporosis

### Database: Medline

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
4	(post menopaus\$ or peri menopaus\$).ti,ab.
5	"change of life".ti,ab.
6	PRIMARY OVARIAN INSUFFICIENCY/
7	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
8	(POI or POF).ti,ab.
9	((early or earlier) adj3 menopaus\$).ti,ab.
10	or/1-9
11	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
12	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
13	(HRT or HT).ti,ab.
14	("menopausal hormone" adj2 therap\$).ti,ab.
15	MHT.ti,ab.
16	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
17	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
18	MPA.ti,ab.
19	or/11-18
20	OSTEOPOROSIS/
21	FEMALE/ and HUMANS/
22	and/20-21
23	*FRACTURES, BONE/ or OSTEOPOROTIC FRACTURES/ or SPINAL FRACTURES/ or RADIUS FRACTURES/
24	(bone? adj5 (fractur\$ or turnover or density or break\$)).ti.
25	(bone? adj5 (fractur\$ or turnover or density or break\$)).ab.
26	fracture?.ti.
27	(fracture? adj3 (vertebra? or wrist or radial or radius or femur? or hip? or lumbar)).ab.
28	fracture?.ab. /freq=2
29	exp BONE REMODELING/
30	BONE DENSITY/
31	or/23-30
32	or/22,31

#	Searches
33	PREVALENCE/ or INCIDENCE/
34	exp RISK/
35	CHEMOPREVENTION/
36	(prevalen\$ or incidence? or risk\$ or rate?).ti.
37	(prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$).ti.
38	or/33-37
39	and/10,19,32,38
40	((osteoporos\$ or osteopen\$) adj3 (rate? or event? or inciden\$ or prevalen\$ or frequen\$ or risk? or prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$)).ti.
41	and/10,19,40
42	or/39,41
43	OSTEOPOROSIS, POSTMENOPAUSAL/
44	(co or ep or pc).fs.
45	and/43-44
46	and/10,19,45
47	or/42,46
48	LETTER/
49	EDITORIAL/
50	NEWS/
51	exp HISTORICAL ARTICLE/
52	ANECDOTES AS TOPIC/
53	COMMENT/
54	CASE REPORT/
55	(letter or comment* or abstracts).ti.
56	or/48-55
57	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
58	56 not 57
59	ANIMALS/ not HUMANS/
60	exp ANIMALS, LABORATORY/
61	exp ANIMAL EXPERIMENTATION/
62	exp MODELS, ANIMAL/
63	exp RODENTIA/
64	(rat or rats or mouse or mice).ti.
65	or/58-64
66	47 not 65
67	limit 66 to english language
68	2014\$.ed,yr.
69	and/67-68
70	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
71	CLIMACTERIC/
72	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
73	(post menopaus\$ or peri menopaus\$).ti,ab.
74	"change of life".ti,ab.
75	PRIMARY OVARIAN INSUFFICIENCY/
76	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
77	(POI or POF).ti,ab.
78	((early or earlier) adj3 menopaus\$).ti,ab.
79	or/70-78
80	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
81	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
82	(HRT or HT).ti,ab.
83	("menopausal hormone" adj2 therap\$).ti,ab.
84	MHT.ti,ab.
85	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
86	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
87	MPA.ti,ab.
88	or/80-87
89	OSTEOPOROSIS/
90	FEMALE/ and HUMANS/
91	and/89-90
92	*FRACTURES, BONE/ or OSTEOPOROTIC FRACTURES/ or SPINAL FRACTURES/ or RADIUS FRACTURES/
93	(bone? adj5 (fractur\$ or turnover or density or break\$)).ti.
94	(bone? adj5 (fractur\$ or turnover or density or break\$)).ab.
95	fracture?.ti.
96	(fracture? adj3 (vertebra? or wrist or radial or radius or femur? or hip? or lumbar)).ab.
97	fracture?.ab. /freq=2
98	exp BONE REMODELING/
99	BONE DENSITY/
100	or/92-99

#	Searches
101	or/91,100
102	PREVALENCE/ or INCIDENCE/
103	exp RISK/
104	CHEMOPREVENTION/
105	(prevalen\$ or incidence? or risk\$ or rate?).ti.
106	(prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$).ti.
107	or/102-106
108	and/79,88,101,107
109	((osteopor\$ or osteopen\$) adj3 (rate? or event? or inciden\$ or prevalen\$ or frequen\$ or risk? or prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$)).ti.
110	and/79,88,109
111	or/108,110
112	OSTEOPOROSIS, POSTMENOPAUSAL/
113	(co or ep or pc).fs.
114	and/112-113
115	and/79,88,114
116	or/111,115
117	LETTER/
118	EDITORIAL/
119	NEWS/
120	exp HISTORICAL ARTICLE/
121	ANECDOTES AS TOPIC/
122	COMMENT/
123	CASE REPORT/
124	(letter or comment* or abstracts).ti.
125	or/117-124
126	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
127	125 not 126
128	ANIMALS/ not HUMANS/
129	exp ANIMALS, LABORATORY/
130	exp ANIMAL EXPERIMENTATION/
131	exp MODELS, ANIMAL/
132	exp RODENTIA/
133	(rat or rats or mouse or mice).ti.
134	or/127-133
135	116 not 134
136	limit 135 to english language

### Database: Medline In-Process

#	Searches
1	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
2	(post menopaus\$ or peri menopaus\$).ti,ab.
3	"change of life".ti,ab.
4	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
5	(POI or POF).ti,ab.
6	((early or earlier) adj3 menopaus\$).ti,ab.
7	or/1-6
8	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
9	(HRT or HT).ti,ab.
10	("menopausal hormone" adj2 therap\$).ti,ab.
11	MHT.ti,ab.
12	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
13	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
14	MPA.ti,ab.
15	or/8-14
16	(bone? adj5 (fractur\$ or turnover or density or break\$ or remodel\$)).ti,ab.
17	fracture?.ti.
18	(fracture? adj3 (vertebra? or wrist or radial or radius or femur? or hip? or lumbar)).ab.
19	fracture?.ab. /freq=2
20	or/16-19
21	(prevalen\$ or incidence? or risk\$ or rate?).ti.
22	(prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$).ti.
23	((osteopor\$ or osteopen\$) adj3 (rate? or event? or inciden\$ or prevalen\$ or frequen\$ or risk? or prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$)).ti.
24	or/21-23
25	and/7,15,20,24

### Database: Cochrane Central Register of Controlled Trials

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
4	(post menopaus\$ or peri menopaus\$).ti,ab.
5	"change of life".ti,ab.
6	PRIMARY OVARIAN INSUFFICIENCY/
7	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
8	(POI or POF).ti,ab.
9	((early or earlier) adj3 menopaus\$).ti,ab.
10	or/1-9
11	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
12	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
13	(HRT or HT).ti,ab.
14	("menopausal hormone" adj2 therap\$).ti,ab.
15	MHT.ti,ab.
16	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
17	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
18	MPA.ti,ab.
19	or/11-18
20	OSTEOPOROSIS/
21	FEMALE/ and HUMANS/
22	and/20-21
23	*FRACTURES, BONE/ or OSTEOPOROTIC FRACTURES/ or SPINAL FRACTURES/ or RADIUS FRACTURES/
24	(bone? adj5 (fractur\$ or turnover or density or break\$)).ti.
25	(bone? adj5 (fractur\$ or turnover or density or break\$)).ab.
26	fracture?.ti.
27	(fracture? adj3 (vertebra? or wrist or radial or radius or femur? or hip? or lumbar)).ab.
28	fracture?.ab. /freq=2
29	exp BONE REMODELING/
30	BONE DENSITY/
31	or/23-30
32	or/22,31
33	PREVALENCE/ or INCIDENCE/
34	exp RISK/
35	CHEMOPREVENTION/
36	(prevalen\$ or incidence? or risk\$ or rate?).ti.
37	(prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$).ti.
38	or/33-37
39	and/10,19,32,38
40	((osteoporos\$ or osteopen\$) adj3 (rate? or event? or inciden\$ or prevalen\$ or frequen\$ or risk? or prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$)).ti.
41	and/10,19,40
42	or/39,41
43	OSTEOPOROSIS, POSTMENOPAUSAL/
44	(co or ep or pc).fs.
45	and/43-44
46	and/10,19,45
47	or/42,46

### Database: Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects

#	Searches
1	(MENOPAUSE or MENOPAUSE, PREMATURE or PERIMENOPAUSE or POSTMENOPAUSE).kw.
2	CLIMACTERIC.kw.
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw,tx.
4	(post menopaus\$ or peri menopaus\$).tw,tx.
5	"change of life".tw,tx.
6	PRIMARY OVARIAN INSUFFICIENCY.kw.
7	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw,tx.
8	(POI or POF).tw,tx.
9	((early or earlier) adj3 menopaus\$).tw,tx.
10	or/1-9
11	(HORMONE REPLACEMENT THERAPY or ESTROGEN REPLACEMENT THERAPY).kw.
12	(hormon\$ adj3 (therap\$ or substitut\$)).tw,tx.
13	(HRT or HT).ti,ab.
14	("menopausal hormone" adj2 therap\$).tw,tx.

#	Searches
15	MHT.tw.tx.
16	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).tw.tx.
17	MPA.tw.tx.
18	or/11-17
19	OSTEOPOROSIS.kw.
20	(FEMALE and HUMANS).kw.
21	and/19-20
22	(FRACTURES, BONE or OSTEOPOROTIC FRACTURES or SPINAL FRACTURES or RADIUS FRACTURES).kw.
23	(bone? adj5 (fractur\$ or turnover or density or break\$)).tw.tx.
24	fracture?.ti.
25	(fracture? adj3 (vertebra? or wrist or radial or radius or femur? or hip? or lumbar)).tw.tx.
26	BONE REMODELING.kw.
27	BONE DENSITY.kw.
28	or/22-27
29	or/21,28
30	(PREVALENCE or INCIDENCE).kw.
31	RISK.kw.
32	CHEMOPREVENTION.kw.
33	(prevalen\$ or incidence? or risk\$ or rate?).ti.
34	(prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$).ti.
35	or/30-34
36	and/10,18,29,35
37	((osteoporos\$ or osteopen\$) adj3 (rate? or event? or inciden\$ or prevalen\$ or frequen\$ or risk? or prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$)).ti.
38	[OSTEOPOROSIS, POSTMENOPAUSAL/]
39	(co or ep or pc).fs.
40	and/38-39
41	or/37,40
42	or/36,41

### Database: Health Technology Assessment

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw.
4	(post menopaus\$ or peri menopaus\$).tw.
5	"change of life".tw.
6	PRIMARY OVARIAN INSUFFICIENCY/
7	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw.
8	(POI or POF).tw.
9	((early or earlier) adj3 menopaus\$).tw.
10	or/1-9
11	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
12	(hormon\$ adj3 (therap\$ or substitut\$)).tw.
13	(HRT or HT).ti,ab.
14	("menopausal hormone" adj2 therap\$).tw.
15	MHT.tw.
16	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).tw.
17	MPA.ti,ab.
18	or/11-17
19	OSTEOPOROSIS/
20	FEMALE/ and HUMANS/
21	and/19-20
22	*FRACTURES, BONE/ or OSTEOPOROTIC FRACTURES/ or SPINAL FRACTURES/ or RADIUS FRACTURES/
23	(bone? adj5 (fractur\$ or turnover or density or break\$)).tw.
24	fracture?.ti.
25	(fracture? adj3 (vertebra? or wrist or radial or radius or femur? or hip? or lumbar)).tw.
26	exp BONE REMODELING/
27	BONE DENSITY/
28	or/22-27
29	or/21,28
30	PREVALENCE/ or INCIDENCE/
31	exp RISK/
32	CHEMOPREVENTION/
33	(prevalen\$ or incidence? or risk\$ or rate?).ti.
34	(prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$).ti.
35	or/30-34
36	and/10,18,29,35



#	Searches
37	((osteoporos\$ or osteopen\$) adj3 (rate? or event? or inciden\$ or prevalen\$ or frequen\$ or risk? or prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$)).ti.
38	OSTEOPOROSIS, POSTMENOPAUSAL/
39	(co or ep or pc).fs.
40	and/38-39
41	or/37,40
42	or/36,41

### Database: Embase

#	Searches
1	"MENOPAUSE AND CLIMACTERIUM"/ or CLIMACTERIUM/ or EARLY MENOPAUSE/ or MENOPAUSE/ or POSTMENOPAUSE/
2	MENOPAUSAL SYNDROME/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteri\$).ti,ab.
4	"change of life".ti,ab.
5	reproductive ag?ing.ti,ab.
6	*PREMATURE OVARIAN FAILURE/
7	((primary or prematur\$ or hypergonadotrop\$) adj1 ovar\$ adj1 (insuffic\$ or fail\$ or incompet\$)).ti,ab.
8	((gonadotrop\$ or resist\$) adj1 ovar\$ adj1 syndrom\$).ti,ab.
9	(POI or POF).ti,ab.
10	or/1-9
11	exp HORMONE SUBSTITUTION/ or ESTROGEN THERAPY/
12	(HRT or HT).ti,ab.
13	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
14	MHT.ti,ab.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
16	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
17	MPA.ti,ab.
18	or/11-17
19	and/10,18
20	((osteoporos\$ or osteopen\$) adj3 (rate? or event? or inciden\$ or prevalen\$ or frequen\$ or risk? or prophyla\$ or chemoprophyla\$ or chemoprevent\$)).ti.
21	POSTMENOPAUSE OSTEOPOROSIS/
22	FRACTURE/
23	SPINE FRACTURE/
24	WRIST FRACTURE/
25	FRAGILITY FRACTURE/
26	(bone? adj5 (fractur\$ or turnover or density or break\$)).ti.
27	(bone? adj5 (fractur\$ or turnover or density or break\$)).ab.
28	fracture?.ti.
29	fracture?.ab. /freq=2
30	(fracture? adj3 (vertebra? or wrist or radial or radius or femur? or hip? or lumbar)).ab.
31	BONE REMODELING/
32	BONE DENSITY/
33	or/21-32
34	PREVALENCE/ or INCIDENCE/
35	(rate? or event? or inciden\$ or prevalen\$ or frequen\$ or risk?).ti,ab.
36	exp RISK/
37	CHEMOPROPHYLAXIS/
38	(prevalen\$ or incidence? or risk\$ or rate?).ti.
39	(prevent\$ or prophyla\$ or chemoprophyla\$ or chemoprevent\$).ti.
40	or/34-39
41	and/33,40
42	or/20,41
43	and/19,42
44	*POSTMENOPAUSE OSTEOPOROSIS/ep, pc
45	and/19,44
46	or/43,45
47	conference abstract.pt.
48	letter.pt. or LETTER/
49	note.pt.
50	editorial.pt.
51	CASE REPORT/ or CASE STUDY/
52	(letter or comment* or abstracts).ti.
53	or/47-52
54	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
55	53 not 54
56	ANIMAL/ not HUMAN/
57	NONHUMAN/
58	exp ANIMAL EXPERIMENT/

#	Searches
59	exp EXPERIMENTAL ANIMAL/
60	ANIMAL MODEL/
61	exp RODENT/
62	(rat or rats or mouse or mice).ti.
63	or/55-62
64	46 not 63
65	FEMALE/
66	and/64-65
67	limit 66 to english language

## E.7.7 Dementia

### Database: Medline

#	Searches
1	randomized controlled trial.pt.
2	controlled clinical trial.pt.
3	DOUBLE BLIND METHOD/
4	SINGLE BLIND METHOD/
5	RANDOM ALLOCATION/
6	or/1-5
7	((single or double or triple or treble) adj5 (blind\$ or mask\$)).tw,sh.
8	clinical trial.pt.
9	exp CLINICAL TRIAL/
10	exp CLINICAL TRIALS AS TOPIC/
11	(clinic\$ adj5 trial\$).tw,sh.
12	PLACEBOS/
13	placebo\$.tw,sh.
14	random\$.tw,sh.
15	or/7-14
16	or/6-15
17	META ANALYSIS/
18	META ANALYSIS AS TOPIC/
19	meta analysis.pt.
20	(metaanaly\$ or meta-analy\$ or (meta adj analy\$)).tw,sh.
21	(systematic\$ adj5 (review\$ or overview\$)).tw,sh.
22	(methodologic\$ adj5 (review\$ or overview\$)).tw,sh.
23	or/17-22
24	review\$.pt.
25	(medline or medlars or embase or cinahl or cochrane or psycinfo or psychinfo or psychlit or psyclit or "web of science" or "science citation" or scisearch).tw.
26	((hand or manual\$) adj2 search\$).tw.
27	(electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw,sh.
28	(pooling or pooled or mantel haenszel).tw,sh.
29	(peto or dersimonian or der simonian or fixed effect).tw,sh.
30	or/25-29
31	and/24,30
32	exp CASE-CONTROL STUDIES/
33	(case\$ adj2 control\$).tw.
34	exp COHORT STUDIES/
35	cohort\$.tw.
36	or/32-35
37	or/16,23,31,36
38	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
39	CLIMACTERIC/
40	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
41	"change of life".ti,ab.
42	PRIMARY OVARIAN INSUFFICIENCY/
43	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
44	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
45	(POI or POF).ti,ab.
46	or/38-45
47	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
48	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
49	(HRT or HT).ti,ab.
50	("menopausal hormone" adj2 therap\$).ti,ab.
51	MHT.ti,ab.
52	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
53	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2

#	Searches
54	MPA.ti,ab.
55	or/47-54
56	DEMENTIA/ or ALZHEIMER DISEASE/ or exp DEMENTIA, VASCULAR/ or exp FRONTOTEMPORAL LOBAR DEGENERATION/ or LEWY BODY DISEASE/
57	(amentia? or dementia? or alzheimer\$ or lewy body).ti,ab.
58	((memory or remember\$ or cognitiv\$ or brain? or hippocamp\$) adj3 (loss\$ or declin\$ or function\$ or atroph\$)).ti,ab.
59	COGNITION/
60	COGNITION DISORDERS/ or MILD COGNITIVE IMPAIRMENT/
61	BRAIN/
62	HIPPOCAMPUS/
63	or/56-62
64	and/37,46,55,63
65	LETTER/
66	EDITORIAL/
67	NEWS/
68	exp HISTORICAL ARTICLE/
69	ANECDOTES AS TOPIC/
70	COMMENT/
71	CASE REPORT/
72	(letter or comment* or abstracts).ti.
73	or/65-72
74	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
75	73 not 74
76	ANIMALS/ not HUMANS/
77	exp ANIMALS, LABORATORY/
78	exp ANIMAL EXPERIMENTATION/
79	exp MODELS, ANIMAL/
80	exp RODENTIA/
81	(rat or rats or mouse or mice).ti.
82	or/75-81
83	64 not 82
84	limit 83 to english language

#### Database: Medline-in-progress

#	Searches
1	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
2	"change of life".ti,ab.
3	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
4	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
5	(POI or POF).ti,ab.
6	or/1-5
7	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
8	(HRT or HT).ti,ab.
9	("menopausal hormone" adj2 therap\$).ti,ab.
10	MHT.ti,ab.
11	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
12	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
13	MPA.ti,ab.
14	or/7-13
15	(amentia? or dementia? or alzheimer\$ or lewy body).ti,ab.
16	((memory or remember\$ or cognitiv\$ or brain? or hippocamp\$) adj5 (loss\$ or declin\$ or function\$ or atroph\$)).ti,ab.
17	or/15-16
18	and/6,14,17

#### Database: Cochrane Central Register of Controlled Trials

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
4	"change of life".ti,ab.
5	PRIMARY OVARIAN INSUFFICIENCY/
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
7	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
8	(POI or POF).ti,ab.
9	or/1-8
10	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
11	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.

#	Searches
12	(HRT or HT).ti,ab.
13	("menopausal hormone" adj2 therap\$).ti,ab.
14	MHT.ti,ab.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
16	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
17	MPA.ti,ab.
18	or/10-17
19	DEMENTIA/ or ALZHEIMER DISEASE/ or exp DEMENTIA, VASCULAR/ or exp FRONTOTEMPORAL LOBAR DEGENERATION/ or LEWY BODY DISEASE/
20	(amentia? or dementia? or alzheimer\$ or lewy body).ti,ab.
21	((memory or remember\$ or cognitiv\$ or brain? or hippocamp\$) adj3 (loss\$ or declin\$ or function\$ or atroph\$)).ti,ab.
22	COGNITION/
23	COGNITION DISORDERS/ or MILD COGNITIVE IMPAIRMENT/
24	BRAIN/
25	HIPPOCAMPUS/
26	or/19-25
27	and/9,18,26
28	limit 27 to english language

### Database: Cochrane Database of Systematic Reviews and Database of Abstracts of Reviews of Effects

#	Searches
1	(MENOPAUSE or MENOPAUSE, PREMATURE or PERIMENOPAUSE or POSTMENOPAUSE).kw.
2	CLIMACTERIC.kw.
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw,tx.
4	"change of life".tw,tx.
5	PRIMARY OVARIAN INSUFFICIENCY.kw.
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw,tx.
7	((earl\$ or prematur\$) adj3 menopaus\$).tw,tx.
8	(POI or POF).tw,tx.
9	or/1-8
10	(HORMONE REPLACEMENT THERAPY or ESTROGEN REPLACEMENT THERAPY).kw.
11	(hormon\$ adj3 (therap\$ or substitut\$)).tw,tx.
12	(HRT or HT).tw,tx.
13	("menopausal hormone" adj2 therap\$).tw,tx.
14	MHT.tw,tx.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).tw,tx.
16	MPA.tw,tx.
17	or/10-16
18	(DEMENTIA or ALZHEIMER DISEASE or DEMENTIA, VASCULAR or FRONTOTEMPORAL LOBAR DEGENERATION or LEWY BODY DISEASE).kw.
19	(amentia? or dementia? or alzheimer\$ or lewy body).tw,tx.
20	((memory or remember\$ or cognitiv\$ or brain? or hippocamp\$) adj3 (loss\$ or declin\$ or function\$ or atroph\$)).tw,tx.
21	COGNITION.kw.
22	(COGNITION DISORDERS or MILD COGNITIVE IMPAIRMENT).kw.
23	BRAIN.kw.
24	HIPPOCAMPUS.kw.
25	or/18-24
26	and/9,17,25

### Database: Health Technology Assessment

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw.
4	"change of life".tw.
5	PRIMARY OVARIAN INSUFFICIENCY/
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw.
7	((earl\$ or prematur\$) adj3 menopaus\$).tw.
8	(POI or POF).tw.
9	or/1-8
10	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
11	(hormon\$ adj3 (therap\$ or substitut\$)).tw.
12	(HRT or HT).tw.
13	("menopausal hormone" adj2 therap\$).tw.
14	MHT.tw.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).tw.

#	Searches
16	MPA.tw.
17	or/10-16
18	DEMENTIA/ or ALZHEIMER DISEASE/ or exp DEMENTIA, VASCULAR/ or exp FRONTOTEMPORAL LOBAR DEGENERATION/ or LEWY BODY DISEASE/
19	(amentia? or dementia? or alzheimer\$ or lewy body).tw.
20	((memory or remember\$ or cognitiv\$ or brain? or hippocamp\$) adj3 (loss\$ or declin\$ or function\$ or atroph\$)).tw.
21	COGNITION/
22	COGNITION DISORDERS/ or MILD COGNITIVE IMPAIRMENT/
23	BRAIN/
24	HIPPOCAMPUS/
25	or/18-24
26	and/9,17,25

### Database: Embase

#	Searches
1	CLINICAL TRIAL/ or "CLINICAL TRIAL (TOPIC)"/
2	(clinic\$ adj5 trial\$).tw,sh.
3	SINGLE BLIND PROCEDURE/
4	DOUBLE BLIND PROCEDURE/
5	RANDOM ALLOCATION/
6	CROSSOVER PROCEDURE/
7	PLACEBO/
8	placebo\$.tw,sh.
9	random\$.tw,sh.
10	RANDOMIZED CONTROLLED TRIAL/ or "RANDOMIZED CONTROLLED TRIAL (TOPIC)"/
11	((single or double or triple or treble) adj (blind\$ or mask\$)).tw,sh.
12	randomi?ed control\$ trial\$.tw.
13	or/1-12
14	META ANALYSIS/
15	((meta adj analys\$) or metaanalys\$ or meta-analy\$).tw,sh.
16	(systematic\$ adj5 (review\$ or overview\$)).tw,sh.
17	(methodologic\$ adj5 (review\$ or overview\$)).tw,sh.
18	or/14-17
19	review.pt.
20	(medline or medlars or embase).ab.
21	(scisearch or science citation index).ab.
22	(psychlit or psyclit or psychinfo or psycinfo or cinahl or cochrane).ab.
23	((hand or manual\$) adj2 search\$).tw.
24	(electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw.
25	(pooling or pooled or mantel haenszel).tw.
26	(peto or dersimonian or "der simonian" or fixed effect).tw.
27	or/20-26
28	and/19,27
29	exp CASE CONTROL STUDY/
30	RETROSPECTIVE STUDY/
31	(case\$ adj2 control\$).tw.
32	COHORT ANALYSIS/
33	LONGITUDINAL STUDY/
34	FOLLOW UP/
35	PROSPECTIVE STUDY/
36	cohort\$.tw.
37	or/29-36
38	or/13,18,28,37
39	(book or conference paper or editorial or letter or note or proceeding or short survey).pt.
40	38 not 39
41	"MENOPAUSE AND CLIMACTERIUM"/ or CLIMACTERIUM/ or EARLY MENOPAUSE/ or MENOPAUSE/ or POSTMENOPAUSE/
42	PREMENOPAUSE/
43	(menopaus\$ or postmenopaus\$ or post menopaus\$ or perimenopaus\$ or peri menopaus\$ or climacteric or POI or POF).ti,ab.
44	PREMATURE OVARIAN FAILURE/
45	((premature or primary) adj3 ovar\$ adj3 (insuffici\$ or failure?)).ti,ab.
46	climacteric.ti,ab.
47	(change adj1 life).ti,ab.
48	or/41-47
49	exp HORMONE SUBSTITUTION/ or ESTROGEN THERAPY/
50	(HRT or HT).ti,ab.
51	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
52	MHT.ti,ab.
53	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.

#	Searches
54	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
55	MPA.ti,ab.
56	or/49-55
57	DEMENTIA/ or ALZHEIMER DISEASE/ or DIFFUSE LEWY BODY DISEASE/ or exp FRONTOTEMPORAL DEMENTIA/ or MULTIINFARCT DEMENTIA/ or PICK PRESENILE DEMENTIA/ or PRESENILE DEMENTIA/ or PRION DISEASE/ or exp SENILE DEMENTIA/
58	(amnesia? or dementia? or alzheimer\$ or lewy body).ti,ab.
59	((memory or remember\$ or cognitiv\$ or brain? or hippocamp\$) adj3 (loss\$ or declin\$ or function\$ or atroph\$)).ti,ab.
60	COGNITION/
61	COGNITIVE DEFECT/
62	or/57-61
63	and/40,48,56,62
64	conference abstract.pt.
65	letter.pt. or LETTER/
66	note.pt.
67	editorial.pt.
68	CASE REPORT/ or CASE STUDY/
69	(letter or comment* or abstracts).ti.
70	or/64-69
71	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
72	70 not 71
73	ANIMAL/ not HUMAN/
74	NONHUMAN/
75	exp ANIMAL EXPERIMENT/
76	exp EXPERIMENTAL ANIMAL/
77	ANIMAL MODEL/
78	exp RODENT/
79	(rat or rats or mouse or mice).ti.
80	or/72-79
81	63 not 80
82	limit 81 to english language
83	FEMALE/
84	and/82-83

## E.7.8 Loss of muscle mass (sarcopenia)

### Database: Medline

#	Searches
1	randomized controlled trial.pt.
2	controlled clinical trial.pt.
3	DOUBLE BLIND METHOD/
4	SINGLE BLIND METHOD/
5	RANDOM ALLOCATION/
6	or/1-5
7	((single or double or triple or treble) adj5 (blind\$ or mask\$)).tw,sh.
8	clinical trial.pt.
9	exp CLINICAL TRIAL/
10	exp CLINICAL TRIALS AS TOPIC/
11	(clinic\$ adj5 trial\$).tw,sh.
12	PLACEBOS/
13	placebo\$.tw,sh.
14	random\$.tw,sh.
15	or/7-14
16	or/6-15
17	META ANALYSIS/
18	META ANALYSIS AS TOPIC/
19	meta analysis.pt.
20	(metaanaly\$ or meta-analy\$ or (meta adj analy\$)).tw,sh.
21	(systematic\$ adj5 (review\$ or overview\$)).tw,sh.
22	(methodologic\$ adj5 (review\$ or overview\$)).tw,sh.
23	or/17-22
24	review\$.pt.
25	(medline or medlars or embase or cinahl or cochrane or psycinfo or psychinfo or psychlit or psyclit or "web of science" or "science citation" or scisearch).tw.
26	((hand or manual\$) adj2 search\$).tw.
27	(electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw,sh.
28	(pooling or pooled or mantel haenszel).tw,sh.
29	(peto or dersimonian or der simonian or fixed effect).tw,sh.
30	or/25-29

#	Searches
31	and/24,30
32	exp CASE-CONTROL STUDIES/
33	(case\$ adj2 control\$).tw.
34	exp COHORT STUDIES/
35	cohort\$.tw.
36	or/32-35
37	or/16,23,31,36
38	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
39	CLIMACTERIC/
40	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
41	"change of life".ti,ab.
42	PRIMARY OVARIAN INSUFFICIENCY/
43	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
44	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
45	(POI or POF).ti,ab.
46	or/38-45
47	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
48	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
49	(HRT or HT).ti,ab.
50	("menopausal hormone" adj2 therap\$).ti,ab.
51	MHT.ti,ab.
52	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
53	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
54	MPA.ti,ab.
55	or/47-54
56	exp MUSCLE STRENGTH/
57	MUSCLE CONTRACTION/
58	MUSCULAR ATROPHY/ or SARCOPENIA/
59	(sarcopen\$ or dynapen?).ti,ab.
60	MUSCLE,SKELETAL/
61	((muscle? or muscular\$) adj (mass or function or strength\$ or loss or lost or declin\$ or atroph\$)).ti,ab.
62	or/56-61
63	and/37,46,55,62
64	LETTER/
65	EDITORIAL/
66	NEWS/
67	exp HISTORICAL ARTICLE/
68	ANECDOTES AS TOPIC/
69	COMMENT/
70	CASE REPORT/
71	(letter or comment* or abstracts).ti.
72	or/64-71
73	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
74	72 not 73
75	ANIMALS/ not HUMANS/
76	exp ANIMALS, LABORATORY/
77	exp ANIMAL EXPERIMENTATION/
78	exp MODELS, ANIMAL/
79	exp RODENTIA/
80	(rat or rats or mouse or mice).ti.
81	or/74-80
82	63 not 81
83	limit 82 to english language

### Database: Medline-in-progress

#	Searches
1	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
2	"change of life".ti,ab.
3	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
4	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
5	(POI or POF).ti,ab.
6	or/1-5
7	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
8	(HRT or HT).ti,ab.
9	("menopausal hormone" adj2 therap\$).ti,ab.
10	MHT.ti,ab.
11	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
12	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2

#	Searches
13	MPA.ti,ab.
14	or/7-13
15	(sarcopen\$ or dynapeni?).ti,ab.
16	((muscle? or muscular\$) adj (skeletal or mass or function\$ or strength\$ or loss or lost or declin\$ or atroph\$ or contract\$)).ti,ab.
17	or/15-16
18	and/6,14,17

### Database: Cochrane Central Register of Controlled Trials

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).ti,ab.
4	"change of life".ti,ab.
5	PRIMARY OVARIAN INSUFFICIENCY/
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
7	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
8	(POI or POF).ti,ab.
9	or/1-8
10	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
11	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
12	(HRT or HT).ti,ab.
13	("menopausal hormone" adj2 therap\$).ti,ab.
14	MHT.ti,ab.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
16	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
17	MPA.ti,ab.
18	or/10-17
19	exp MUSCLE STRENGTH/
20	MUSCLE CONTRACTION/
21	MUSCULAR ATROPHY/ or SARCOPENIA/
22	(sarcopen\$ or dynapeni?).ti,ab.
23	MUSCLE,SKELETAL/
24	((muscle? or muscular\$) adj (mass or function or strength\$ or loss or lost or declin\$ or atroph\$)).ti,ab.
25	or/19-24
26	and/9,18,25
27	limit 26 to english language

### Database: Cochrane Database of Systematic Reviews and Database of Abstracts of Reviews of Effects

#	Searches
1	(MENOPAUSE or MENOPAUSE, PREMATURE or PERIMENOPAUSE or POSTMENOPAUSE).kw.
2	CLIMACTERIC.kw.
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw,tx.
4	"change of life".tw,tx.
5	PRIMARY OVARIAN INSUFFICIENCY.kw.
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw,tx.
7	((earl\$ or prematur\$) adj3 menopaus\$).tw,tx.
8	(POI or POF).tw,tx.
9	or/1-8
10	(HORMONE REPLACEMENT THERAPY or ESTROGEN REPLACEMENT THERAPY).kw.
11	(hormon\$ adj3 (therap\$ or substitut\$)).tw,tx.
12	(HRT or HT).tw,tx.
13	("menopausal hormone" adj2 therap\$).tw,tx.
14	MHT.tw,tx.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).tw,tx.
16	MPA.tw,tx.
17	or/10-16
18	MUSCLE STRENGTH.kw.
19	MUSCLE CONTRACTION.kw.
20	(MUSCULAR ATROPHY or SARCOPENIA).kw.
21	(sarcopen\$ or dynapeni?).tw,tx.
22	MUSCLE,SKELETAL.kw.
23	((muscle? or muscular\$) adj (mass or function or strength\$ or loss or lost or declin\$ or atroph\$)).tw,tx.
24	or/18-23
25	and/9,17,24



### Database: Health Technology Assessment

#	Searches
1	MENOPAUSE/ or MENOPAUSE, PREMATURE/ or PERIMENOPAUSE/ or POSTMENOPAUSE/
2	CLIMACTERIC/
3	(menopaus\$ or postmenopaus\$ or perimenopaus\$ or climacteric).tw.
4	"change of life".tw.
5	PRIMARY OVARIAN INSUFFICIENCY/
6	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw.
7	((earl\$ or prematur\$) adj3 menopaus\$).tw.
8	(POI or POF).tw.
9	or/1-8
10	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
11	(hormon\$ adj3 (therap\$ or substitut\$)).tw.
12	(HRT or HT).tw.
13	("menopausal hormone" adj2 therap\$).tw.
14	MHT.tw.
15	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).tw.
16	MPA.tw.
17	or/10-16
18	exp MUSCLE STRENGTH/
19	MUSCLE CONTRACTION/
20	MUSCULAR ATROPHY/ or SARCOPENIA/
21	(sarcopen\$ or dynapeni?).tw.
22	MUSCLE,SKELETAL/
23	((muscle? or muscular\$) adj (mass or function or strength\$ or loss or lost or declin\$ or atroph\$)).tw.
24	or/18-23
25	and/9,17,24

### Database: Embase

#	Searches
1	CLINICAL TRIAL/ or "CLINICAL TRIAL (TOPIC)"/
2	(clinic\$ adj5 trial\$).tw,sh.
3	SINGLE BLIND PROCEDURE/
4	DOUBLE BLIND PROCEDURE/
5	RANDOM ALLOCATION/
6	CROSSOVER PROCEDURE/
7	PLACEBO/
8	placebo\$.tw,sh.
9	random\$.tw,sh.
10	RANDOMIZED CONTROLLED TRIAL/ or "RANDOMIZED CONTROLLED TRIAL (TOPIC)"/
11	((single or double or triple or treble) adj (blind\$ or mask\$)).tw,sh.
12	randomi?ed control\$ trial\$.tw.
13	or/1-12
14	META ANALYSIS/
15	((meta adj analy\$) or metaanalys\$ or meta-analy\$).tw,sh.
16	(systematic\$ adj5 (review\$ or overview\$)).tw,sh.
17	(methodologic\$ adj5 (review\$ or overview\$)).tw,sh.
18	or/14-17
19	review.pt.
20	(medline or medlars or embase).ab.
21	(scisearch or science citation index).ab.
22	(psychlit or psychlit or psychinfo or psycinfo or cinahl or cochrane).ab.
23	((hand or manual\$) adj2 search\$).tw.
24	(electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw.
25	(pooling or pooled or mantel haenszel).tw.
26	(peto or dersimonian or "der simonian" or fixed effect).tw.
27	or/20-26
28	and/19,27
29	exp CASE CONTROL STUDY/
30	RETROSPECTIVE STUDY/
31	(case\$ adj2 control\$).tw.
32	COHORT ANALYSIS/
33	LONGITUDINAL STUDY/
34	FOLLOW UP/
35	PROSPECTIVE STUDY/
36	cohort\$.tw.
37	or/29-36
38	or/13,18,28,37
39	(book or conference paper or editorial or letter or note or proceeding or short survey).pt.

#	Searches
40	38 not 39
41	exp HORMONE SUBSTITUTION/ or ESTROGEN THERAPY/
42	(HRT or HT).ti,ab.
43	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
44	MHT.ti,ab.
45	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ti.
46	(oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone).ab. /freq=2
47	MPA.ti,ab.
48	or/41-47
49	MUSCLE STRENGTH/
50	exp MUSCLE CONTRACTION/
51	MUSCLE ATROPHY/ or SARCOPENIA/
52	MUSCLE WEAKNESS/
53	MUSCLE MASS/
54	SKELETAL MUSCLE/
55	(sarcopen\$ or dynapeni?).ti,ab.
56	((muscle? or muscular\$) adj (mass or function or strength\$ or loss or lost or declin\$ or atroph\$)).ti,ab.
57	or/49-56
58	and/40,48,57
59	conference abstract.pt.
60	letter.pt. or LETTER/
61	note.pt.
62	editorial.pt.
63	CASE REPORT/ or CASE STUDY/
64	(letter or comment* or abstracts).ti.
65	or/59-64
66	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
67	65 not 66
68	ANIMAL/ not HUMAN/
69	NONHUMAN/
70	exp ANIMAL EXPERIMENT/
71	exp EXPERIMENTAL ANIMAL/
72	ANIMAL MODEL/
73	exp RODENT/
74	(rat or rats or mouse or mice).ti.
75	or/67-74
76	58 not 75
77	FEMALE/
78	and/76-77

## E.8 Premature ovarian insufficiency

### E.8.1 Management of premature ovarian insufficiency

#### Database: Medline

#	Searches
1	randomized controlled trial.pt.
2	controlled clinical trial.pt.
3	DOUBLE BLIND METHOD/
4	SINGLE BLIND METHOD/
5	RANDOM ALLOCATION/
6	RANDOMIZED CONTROLLED TRIALS AS TOPIC/
7	or/1-6
8	((single or double or triple or treble) adj5 (blind\$ or mask\$)).tw,sh.
9	clinical trial.pt.
10	exp CLINICAL TRIAL/
11	exp CLINICAL TRIALS AS TOPIC/
12	(clinic\$ adj5 trial\$).tw,sh.
13	PLACEBOS/
14	placebo\$.tw,sh.
15	random\$.tw,sh.
16	or/8-15
17	or/7,16
18	META ANALYSIS/
19	META ANALYSIS AS TOPIC/
20	meta analysis.pt.
21	(metaanaly\$ or meta-analy\$ or (meta adj analy\$)).tw,sh.

#	Searches
22	(systematic\$ adj5 (review\$ or overview\$)).tw,sh.
23	(methodologic\$ adj5 (review\$ or overview\$)).tw,sh.
24	or/18-23
25	review\$.pt.
26	(medline or medlars or embase or cinahl or cochrane or psycinfo or psychinfo or psychlit or psyclit or "web of science" or "science citation" or scisearch).tw.
27	((hand or manual\$) adj2 search\$).tw.
28	(electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw,sh.
29	(pooling or pooled or mantel haenszel).tw,sh.
30	(peto or dersimonian or der simonian or fixed effect).tw,sh.
31	or/26-30
32	and/25,31
33	exp CASE-CONTROL STUDIES/
34	(case\$ adj2 control\$).tw.
35	exp COHORT STUDIES/
36	cohort\$.tw.
37	or/33-36
38	or/17,24,32,37
39	letter.pt.
40	comment.pt.
41	editorial.pt.
42	historical article.pt.
43	or/39-42
44	38 not 43
45	PRIMARY OVARIAN INSUFFICIENCY/
46	PREMATURE MENOPAUSE/
47	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
48	((early or premature) adj menopaus\$).ti,ab.
49	(POI or POF).ti,ab.
50	TURNER SYNDROME/
51	((Turner? or Ullrich\$ or Bonnevie\$) adj2 (syndrome or mosaic\$ or status)).ti,ab.
52	(gonadal dysgenesis or monosomy x).ti,ab.
53	or/45-52
54	ESTROGENS/ or EPIMESTROL/ or ESTRADIOL/ or ESTROGENIC STEROIDS, ALKYLATED/ or "ESTROGENS, CONJUGATED (USP)"/ or "ESTROGENS, ESTERIFIED (USP)"/ or ESTRONE/ or ETHINYL ESTRADIOL/ or MESTRANOL/ or QUINESTROL/
55	((oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone) adj3 (replace\$ or therap\$ or substitut\$)).ti,ab.
56	PROGESTOGENS/
57	progesta\$.ti,ab.
58	MEDROXYPROGESTERONE ACETATE/
59	MPA.ti,ab.
60	exp PROGESTERONE/
61	ETHISTERONE/
62	NORETHINDRONE/ or NORGESTREL/ or LEVONORGESTREL/ or NORPROGESTERONES/
63	exp NORPREGNENES/
64	(tibolone or livial).ti,ab.
65	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
66	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
67	(HRT or HT).ti,ab.
68	("menopausal hormone" adj2 therap\$).ti,ab.
69	MHT.ti,ab.
70	drospirenone.ti,ab.
71	levonorgestrel.ti,ab.
72	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).ti,ab.
73	(angeliq or climagest or climesse or clinorette or femoston or indivina or klioferm or kliovance or novofem or nuvelle or tridestra or trisequens).ti,ab.
74	"cyclo-progynova".ti,ab.
75	(premiq or premak).ti,ab.
76	hormonin.ti,ab.
77	TESTOSTERONE/
78	(testosterone adj3 (replace\$ or therap\$ or substitut\$)).ti,ab.
79	exp CONTRACEPTIVES, ORAL/
80	(combined adj oral adj3 contraceptive?).ti,ab.
81	COCP.ti,ab.
82	(loestrin or mercilon or gedarel or femodette or sunya or millinette or elevin or levest or logynon or microgynon or ovranelle or rigevidon or triregol or binovum or brevinor or loestrin or norimin or ovysmen or synphase or trinovum or marvelon or yasmin or femodene or katya or triadene or norinyl or qlaira).ti,ab.
83	or/54-82

#	Searches
84	and/53,83
85	and/44,84
86	LETTER/
87	EDITORIAL/
88	NEWS/
89	exp HISTORICAL ARTICLE/
90	ANECDOTES AS TOPIC/
91	COMMENT/
92	CASE REPORT/
93	(letter or comment* or abstracts).ti.
94	or/86-93
95	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
96	94 not 95
97	ANIMALS/ not HUMANS/
98	exp ANIMALS, LABORATORY/
99	exp ANIMAL EXPERIMENTATION/
100	exp MODELS, ANIMAL/
101	exp RODENTIA/
102	(rat or rats or mouse or mice).ti.
103	or/96-102
104	85 not 103
105	limit 104 to english language

### Database: Medline-in-progress

#	Searches
1	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$).ti,ab.
2	(POI or POF).ti,ab.
3	((early or premature) adj menopaus\$).ti,ab.
4	((Turner? or Ullrich\$ or Bonnevie\$) adj2 (syndrome or mosaic\$ or status)).ti,ab.
5	(gonadal dysgenesis or monosomy x).ti,ab.
6	or/1-5
7	((oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone) adj3 (replace\$ or therap\$ or substitut\$)).ti,ab.
8	(mestranol or quinestrol).ti,ab.
9	(progesta\$ or progestogen?).ti,ab.
10	"medroxyprogesterone acetate".ti,ab.
11	MPA.ti,ab.
12	ethisterone.ti,ab.
13	(norethindrone or norgestrel or levonorgestrel or norprogesterone?).ti,ab.
14	norpregnes.ti,ab.
15	(tibolone or livial).ti,ab.
16	((hormon\$ or oestrogen\$ or estrogen\$) adj3 (therap\$ or substitut\$)).ti,ab.
17	(HRT or HT).ti,ab.
18	("menopausal hormone" adj2 therap\$).ti,ab.
19	MHT.ti,ab.
20	drospirenone.ti,ab.
21	levonorgestrel.ti,ab.
22	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).ti,ab.
23	(angeliq or climagest or climesse or clinorette or femoston or indivina or klioferm or klovance or novofem or nuvelle or tridestra or trisequens).ti,ab.
24	"cyclo-progynova".ti,ab.
25	(premiq or premak).ti,ab.
26	hormonin.ti,ab.
27	(testosterone adj3 (replace\$ or therap\$ or substitut\$)).ti,ab.
28	(combined adj oral adj3 contraceptive?).ti,ab.
29	COCP.ti,ab.
30	(loestrin or mercilon or gedarel or femodette or sunya or millinette or elevin or levest or logynon or microgynon or ovranelle or rigevidon or triregol or binovum or brevinor or loestrin or norimin or ovysmen or synphase or trinovum or marvelon or yasmin or femodene or katya or triadene or norinyl or qlaira).ti,ab.
31	or/7-30
32	and/6,31

### Database: Cochrane Central Register of Controlled Trials

#	Searches
1	PRIMARY OVARIAN INSUFFICIENCY/
2	PREMATURE MENOPAUSE/

#	Searches
3	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
4	(POI or POF).ti,ab.
5	((early or premature) adj menopaus\$).ti,ab.
6	TURNER SYNDROME/
7	((Turner? or Ullrich\$ or Bonnevie\$) adj2 (syndrome or mosaic\$ or status)).ti,ab.
8	(gonadal dysgenesis or monosomy x).ti,ab.
9	or/1-8
10	ESTROGENS/ or EPIMESTROL/ or ESTRADIOL/ or ESTROGENIC STEROIDS, ALKYLATED/ or "ESTROGENS, CONJUGATED (USP)" or "ESTROGENS, ESTERIFIED (USP)" or ESTRONE/ or ETHINYL ESTRADIOL/ or MESTRANOL/ or QUINESTROL/
11	((oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone) adj3 (replace\$ or therap\$ or substitut\$)).ti,ab.
12	PROGESTOGENS/
13	progesta\$.ti,ab.
14	MEDROXYPROGESTERONE ACETATE/
15	MPA.ti,ab.
16	exp PROGESTERONE/
17	ETHISTERONE/
18	NORETHINDRONE/ or NORGESTREL/ or LEVONORGESTREL/ or NORPROGESTERONES/
19	exp NORPREGNENES/
20	(tibolone or livial).ti,ab.
21	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
22	(hormon\$ adj3 (therap\$ or substitut\$)).ti,ab.
23	(HRT or HT).ti,ab.
24	("menopausal hormone" adj2 therap\$).ti,ab.
25	MHT.ti,ab.
26	drospirenone.ti,ab.
27	levonorgestrel.ti,ab.
28	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).ti,ab.
29	(angeliq or climagest or climesse or clinorette or femoston or indivina or kiofem or kioavance or novofem or nuvelle or tridestra or trisequens).ti,ab.
30	"cyclo-progynova".ti,ab.
31	(premiq or premak).ti,ab.
32	hormonin.ti,ab.
33	TESTOSTERONE/
34	(testosterone adj3 (replace\$ or therap\$ or substitut\$)).ti,ab.
35	exp CONTRACEPTIVES, ORAL/
36	(combined adj oral adj3 contraceptive?).ti,ab.
37	COCP.ti,ab.
38	(loestrin or mercilon or gedarel or femodette or sunya or millinette or elevin or levest or logynon or microgynon or ovrnette or rigevidon or triregol or binovum or brevinor or loestrin or norimin or ovysmen or synphase or trinovum or marvelon or yasmin or femodene or katya or triadene or norinyl or qlaira).ti,ab.
39	or/10-38
40	and/9,39

### Database: Cochrane Database of Systematic Reviews and Database of Abstracts of Reviews of Effects

#	Searches
1	PRIMARY OVARIAN INSUFFICIENCY.kw.
2	PREMATURE MENOPAUSE.kw.
3	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw,tx.
4	(POI or POF).tw,tx.
5	((early or premature) adj menopaus\$).tw,tx.
6	TURNER SYNDROME.kw.
7	((Turner? or Ullrich\$ or Bonnevie\$) adj2 (syndrome or mosaic\$ or status)).tw,tx.
8	(gonadal dysgenesis or monosomy x).tw,tx.
9	or/1-8
10	(ESTROGENS or EPIMESTROL or ESTRADIOL or ESTROGENIC STEROIDS, ALKYLATED or "ESTROGENS, CONJUGATED (USP)" or "ESTROGENS, ESTERIFIED (USP)" or ESTRONE or ETHINYL ESTRADIOL or MESTRANOL or QUINESTROL).kw.
11	((oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone) adj3 (replace\$ or therap\$ or substitut\$)).tw,tx.
12	PROGESTOGENS.kw.
13	progesta\$.tw.
14	MEDROXYPROGESTERONE ACETATE.kw.
15	MPA.tw,tx.
16	PROGESTERONE.kw.

#	Searches
17	ETHISTERONE.kw.
18	(NORETHINDRONE or NORGESTREL or LEVONORGESTREL or NORPROGESTERONES).kw.
19	NORPREGNENES.kw.
20	(tibolone or livial).tw,tx.
21	(HORMONE REPLACEMENT THERAPY or ESTROGEN REPLACEMENT THERAPY).kw.
22	(hormon\$ adj3 (therap\$ or substitut\$)).tw,tx.
23	(HRT or HT).tw,tx.
24	("menopausal hormone" adj2 therap\$).tw,tx.
25	MHT.tw,tx.
26	drospirenone.tw,tx.
27	levonorgestrel.tw,tx.
28	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).tw,tx.
29	(angeliq or climagest or climesse or clinorette or femoston or indivina or kiofem or kioavance or novofem or nuvelle or tridestra or trisequens).tw,tx.
30	"cyclo-progynova".tw,tx.
31	(premiq or premak).tw,tx.
32	hormonin.tw,tx.
33	TESTOSTERONE.kw.
34	(testosterone adj3 (replace\$ or therap\$ or substitut\$)).tw,tx.
35	CONTRACEPTIVES, ORAL.kw.
36	(combined adj oral adj3 contraceptive?).tw,tx.
37	COCP.tw,tx.
38	(loestrin or mercilon or gedarel or femodette or sunya or millinette or elevin or levest or logynon or microgynon or ovanette or rigevidon or triregol or binovum or brevinor or loestrin or norimin or ovysmen or synphase or trinovum or marvelon or yasmin or femodene or katya or triadene or norinyl or qlaira).tw,tx.
39	or/10-38
40	and/9,39

### Database: Health Technology Assessment

#	Searches
1	PRIMARY OVARIAN INSUFFICIENCY/
2	PREMATURE MENOPAUSE/
3	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw.
4	(POI or POF).tw.
5	((early or premature) adj menopaus\$).tw.
6	TURNER SYNDROME/
7	((Turner? or Ullrich\$ or Bonnevie\$) adj2 (syndrome or mosaic\$ or status)).tw.
8	(gonadal dysgenesis or monosomy x).tw.
9	or/1-8
10	ESTROGENS/ or EPIMESTROL/ or ESTRADIOL/ or ESTROGENIC STEROIDS, ALKYLATED/ or "ESTROGENS, CONJUGATED (USP)" or "ESTROGENS, ESTERIFIED (USP)" or ESTRONE/ or ETHINYL ESTRADIOL/ or MESTRANOL/ or QUINESTROL/
11	((oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone) adj3 (replace\$ or therap\$ or substitut\$)).tw.
12	PROGESTOGENS/
13	progesta\$.tw.
14	MEDROXYPROGESTERONE ACETATE/
15	MPA.tw.
16	exp PROGESTERONE/
17	ETHISTERONE/
18	NORETHINDRONE/ or NORGESTREL/ or LEVONORGESTREL/ or NORPROGESTERONES/
19	exp NORPREGNENES/
20	(tibolone or livial).tw.
21	HORMONE REPLACEMENT THERAPY/ or ESTROGEN REPLACEMENT THERAPY/
22	(hormon\$ adj3 (therap\$ or substitut\$)).tw.
23	(HRT or HT).tw.
24	("menopausal hormone" adj2 therap\$).tw.
25	MHT.tw.
26	drospirenone.tw.
27	levonorgestrel.tw.
28	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).tw.
29	(angeliq or climagest or climesse or clinorette or femoston or indivina or kiofem or kioavance or novofem or nuvelle or tridestra or trisequens).tw.
30	"cyclo-progynova".tw.
31	(premiq or premak).tw.
32	hormonin.tw.
33	TESTOSTERONE/
34	(testosterone adj3 (replace\$ or therap\$ or substitut\$)).tw.

#	Searches
35	exp CONTRACEPTIVES, ORAL/
36	(combined adj oral adj3 contraceptive?).tw.
37	COCP.tw.
38	(loestrin or mercilon or gedarel or femodette or sunya or millinette or elevin or levest or logynon or microgynon or ovranelle or rigevidon or triregol or binovum or brevinor or loestrin or norimin or ovysmen or synphase or trinovum or marvelon or yasmin or femodene or katya or triadene or norinyl or qlaira).tw.
39	or/10-38
40	and/9,39

### Database: Embase

#	Searches
1	CLINICAL TRIAL/ or "CLINICAL TRIAL (TOPIC)"/
2	(clinic\$ adj5 trial\$).tw,sh.
3	SINGLE BLIND PROCEDURE/
4	DOUBLE BLIND PROCEDURE/
5	RANDOM ALLOCATION/
6	CROSSOVER PROCEDURE/
7	PLACEBO/
8	placebo\$.tw,sh.
9	random\$.tw,sh.
10	RANDOMIZED CONTROLLED TRIAL/ or "RANDOMIZED CONTROLLED TRIAL (TOPIC)"/
11	((single or double or triple or treble) adj (blind\$ or mask\$)).tw,sh.
12	randomi?ed control\$ trial\$.tw.
13	or/1-12
14	META ANALYSIS/
15	((meta adj analy\$) or metaanalys\$ or meta-analy\$).tw,sh.
16	(systematic\$ adj5 (review\$ or overview\$)).tw,sh.
17	(methodologic\$ adj5 (review\$ or overview\$)).tw,sh.
18	or/14-17
19	review.pt.
20	(medline or medlars or embase).ab.
21	(scisearch or science citation index).ab.
22	(psychlit or psyclit or psychinfo or psycinfo or cinahl or cochrane).ab.
23	((hand or manual\$) adj2 search\$).tw.
24	(electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw.
25	(pooling or pooled or mantel haenszel).tw.
26	(peto or dersimonian or "der simonian" or fixed effect).tw.
27	or/20-26
28	and/19,27
29	exp CASE CONTROL STUDY/
30	RETROSPECTIVE STUDY/
31	(case\$ adj2 control\$).tw.
32	COHORT ANALYSIS/
33	LONGITUDINAL STUDY/
34	FOLLOW UP/
35	PROSPECTIVE STUDY/
36	cohort\$.tw.
37	or/29-36
38	or/13,18,28,37
39	(book or conference paper or editorial or letter or note or proceeding or short survey).pt.
40	38 not 39
41	PREMATURE OVARIAN FAILURE/
42	EARLY MENOPAUSE/
43	((early or premature) adj menopaus\$).ti,ab.
44	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
45	(POI or POF).ti,ab.
46	TURNER SYNDROME/
47	((Turner? or Ullrich\$ or Bonnevie\$) adj2 (syndrome or mosaic\$ or status\$)).ti,ab.
48	(gonadal dysgenesis or monosomy x).ti,ab.
49	or/41-48
50	exp ESTROGEN/
51	((oestrogen\$ or estrogen\$ or oestradiol or estradiol or estrone or oestrone) adj3 (replace\$ or therap\$ or substitut\$)).ti,ab.
52	exp GESTAGEN/
53	progest\$.ti,ab.
54	MPA.ti,ab.
55	(bedol or climaval or elleste or estraderm or estradot or evorel or femseven or oestrogel or progynoval or prognova or sandrena or zumenon).ti,ab.

#	Searches
56	(angeliq or climagest or climesse or clinorette or femoston or indivina or klioferm or klovance or novofem or nuvelle or tridestra or trisequens).ti,ab.
57	"cyclo-progynova".ti,ab.
58	(premiq or premak).ti,ab.
59	hormonin.ti,ab.
60	TESTOSTERONE/
61	testosterone.ti,ab.
62	TIBOLONE/
63	(tibolone or livial).ti,ab.
64	exp oral contraceptive agent/
65	(combined adj oral adj3 contraceptive?).ti,ab.
66	COCP.ti,ab.
67	(loestrin or mercilon or gedarel or femodette or sunya or millinette or elevin or levest or logynon or microgynon or ovrnette or rigevidon or triregol or binovum or brevinor or loestrin or norimin or ovysmen or synphase or trinovum or marvelon or yasmin or femodene or katya or triadene or norinyl or qlaira).ti,ab.
68	or/50-67
69	and/49,68
70	and/40,69
71	conference abstract.pt.
72	letter.pt. or LETTER/
73	note.pt.
74	editorial.pt.
75	CASE REPORT/ or CASE STUDY/
76	(letter or comment* or abstracts).ti.
77	or/71-76
78	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
79	77 not 78
80	ANIMAL/ not HUMAN/
81	NONHUMAN/
82	exp ANIMAL EXPERIMENT/
83	exp EXPERIMENTAL ANIMAL/
84	ANIMAL MODEL/
85	exp RODENT/
86	(rat or rats or mouse or mice).ti.
87	or/79-86
88	70 not 87
89	limit 88 to english language

## E.8.2 Diagnosis of premature ovarian insufficiency

### Database: Medline

#	Searches
1	PRIMARY OVARIAN INSUFFICIENCY/
2	PREMATURE MENOPAUSE/
3	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
4	((earl\$ or prematur\$) adj3 menopaus\$).ti,ab.
5	(POI or POF).ti,ab.
6	or/1-5
7	exp MENSTRUAL CYCLE/
8	((ovar\$ or endometri\$ or menstru\$) adj3 cycle?).ti,ab.
9	((period? or cycle? or menses or menstru?) adj3 (irregular\$ or regular\$ or nonregular or lenght\$ or short\$ or skip\$ or flow\$)).ti,ab.
10	MENSTRUATION DISTURBANCES/
11	AMENORRHEA/ or OLIGOMENORRHEA/
12	(amenorrh\$ or oligomenorr\$).ti,ab.
13	exp VASOMOTOR SYSTEM/
14	HOT FLASHES/
15	(hot adj (flash\$ or flush\$)).ti,ab.
16	(vasomotor adj symptom?).ti,ab.
17	SWEATING/
18	sweat\$.ti,ab.
19	HYPERHIDROSIS/
20	(sleep adj3 disturb\$).ti,ab.
21	"SLEEP INITIATION AND MAINTENANCE DISORDERS"/
22	insomnia?.ti,ab.
23	FEMALE UROGENITAL DISEASES/ or exp SEXUAL DYSFUNCTION, PHYSIOLOGICAL/ or VAGINISMUS/ or exp VAGINITIS/ or exp VULVAR DISEASES/
24	VAGINAL DISEASES/



#	Searches
25	VAGINA/
26	ATROPHY/
27	and/25-26
28	DEHYDRATION/
29	((vagin\$ or vulva?) adj3 (atroph\$ or dry\$ or irritat\$)).ti,ab.
30	(discomfort or uncomfortable or pain\$ or dyspareunia).ti,ab.
31	SEXUAL DYSFUNCTION, PSYCHOLOGICAL/
32	SEXUAL BEHAVIOR/
33	LIBIDO/
34	libido.ti,ab.
35	DYSPAREUNIA/
36	((altered or chang? or differ\$) adj3 sexual adj3 (behavio?r\$ or function\$)).ti,ab.
37	MOOD DISORDERS/
38	(mood adj3 (disturbance or disorder)).ti,ab.
39	DEPRESSION/
40	ANXIETY/
41	AFFECTIVE SYMPTOMS/
42	STRESS, PSYCHOLOGICAL/
43	IRRITABLE MOOD/
44	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).ti.
45	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).ab. /freq=2
46	FOLLICLE STIMULATING HORMONE/ or FOLLICLE STIMULATING HORMONE, BETA SUBUNIT/ or GLYCOPROTEIN HORMONES, ALPHA SUBUNIT/ or LUTEINIZING HORMONE/ or LUTEINIZING HORMONE, BETA SUBUNIT/
47	(FSH or LH).ti,ab.
48	((follicule stimulat or lutein\$) adj hormone?).ti,ab.
49	follitropin.ti,ab.
50	(interstitial cell stimulating adj4 hormone).ti,ab.
51	ANTI-MULLERIAN HORMONE/
52	(mullerian adj3 (factor? or substance? or hormone?)).ti,ab.
53	AMH.ti,ab.
54	(antral follicle? adj3 count\$).ti,ab.
55	AFC.ti,ab.
56	exp INHIBINS/
57	inhibin\$.ti,ab.
58	ESTROGENS/ or ESTRADIOL/
59	(oestogen? or estrogen\$ or estradiol or oestradiol).ti,ab.
60	exp OVARY/
61	ORGAN SIZE/
62	and/60-61
63	(ovar\$ adj3 (volume or size)).ti,ab.
64	or/62-63
65	or/7-24,27-59,64
66	exp "SENSITIVITY AND SPECIFICITY"/
67	(sensitivity or specificity).ti,ab.
68	((pre test or pretest or post test or posttest) adj probability).ti,ab.
69	(predictive value\$ or PPV or NPV).ti,ab.
70	likelihood ratio\$.ti,ab.
71	LIKELIHOOD FUNCTIONS/
72	(ROC curve\$ or AUC).ti,ab.
73	(diagnos* adj2 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.
74	gold standard.ti,ab.
75	or/66-74
76	and/6,65,75
77	PRIMARY OVARIAN INSUFFICIENCY/ or PREMATURE MENOPAUSE/
78	di.fs.
79	77 and 78
80	or/76,79
81	LETTER/
82	EDITORIAL/
83	NEWS/
84	exp HISTORICAL ARTICLE/
85	ANECDOTES AS TOPIC/
86	COMMENT/
87	CASE REPORT/
88	(letter or comment* or abstracts).ti.
89	or/81-88
90	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
91	89 not 90
92	ANIMALS/ not HUMANS/

#	Searches
93	exp ANIMALS, LABORATORY/
94	exp ANIMAL EXPERIMENTATION/
95	exp MODELS, ANIMAL/
96	exp RODENTIA/
97	(rat or rats or mouse or mice).ti.
98	or/91-97
99	80 not 98
100	limit 99 to english language

### Database: Medline In-Process

#	Searches
1	((primary or matur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
2	hypoestrogen\$.ti,ab.
3	((earl\$ or matur\$) adj3 menopaus\$).ti,ab.
4	(POI or POF).ti,ab.
5	or/1-4
6	((ovar\$ or endometri\$ or menstru\$) adj3 cycle?).ti,ab.
7	((period? or cycle? or menses or menstru?) adj3 (irregular\$ or regular\$ or nonregular or lenght\$ or short\$ or skip\$ or flow\$ or disturb\$)).ti,ab.
8	(amenorrh\$ or oligomenorr\$).ti,ab.
9	(hot adj (flash\$ or flush\$)).ti,ab.
10	(vasomotor adj symptom?).ti,ab.
11	(sweat\$ or hyperhidrosis).ti,ab.
12	sleep\$.ti,ab.
13	insomnia?.ti,ab.
14	urogenital.ti,ab.
15	(sexual\$ adj3 (dysfunction? or problem?)).ti,ab.
16	(vaginismus or vaginal atrophy).ti,ab.
17	((vagin\$ or vulva?) adj3 (atroph\$ or dry\$ or irritat\$)).ti,ab.
18	(discomfort or uncomfortable or pain\$ or dyspareunia).ti,ab.
19	libido.ti,ab.
20	((altered or chang? or differ\$) adj3 sexual adj3 (behavio?r\$ or function\$)).ti,ab.
21	(mood adj3 (disturbance or disorder)).ti,ab.
22	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$ or affective).ti.
23	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$ or affective).ab. /freq=2
24	((follitropin or follicle stimulating or lutein\$) adj3 hormone?).ti,ab.
25	(FSH or LH).ti,ab.
26	((follicule stimulat or lutein\$) adj hormone?).ti,ab.
27	follitropin.ti,ab.
28	(interstitial cell stimulating adj4 hormone).ti,ab.
29	(mullerian adj3 (factor? or substance? or hormone?)).ti,ab.
30	AMH.ti,ab.
31	(antral follicle? adj3 count\$).ti,ab.
32	AFC.ti,ab.
33	inhibin\$.ti,ab.
34	(oestogen? or estrogen\$ or estradiol or oestradiol).ti,ab.
35	(ovar\$ adj3 (volume or size)).ti,ab.
36	or/6-35
37	(sensitivity or specificity).ti,ab.
38	((pre test or pretest or post test or posttest) adj probability).ti,ab.
39	(predictive value\$ or PPV or NPV).ti,ab.
40	(likelihood adj3 (ratio? or function?)).ti,ab.
41	(ROC curve\$ or AUC).ti,ab.
42	(diagnos* adj2 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.
43	gold standard.ti,ab.
44	or/37-43
45	and/5,36,44

### Database: Cochrane Central Register of Controlled Trials

#	Searches
1	PRIMARY OVARIAN INSUFFICIENCY/
2	PREMATURE MENOPAUSE/
3	((primary or matur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
4	((earl\$ or matur\$) adj3 menopaus\$).ti,ab.
5	(POI or POF).ti,ab.
6	or/1-5
7	exp MENSTRUAL CYCLE/

#	Searches
8	((ovar\$ or endometri\$ or menstru\$) adj3 cycle?).ti,ab.
9	((period? or cycle? or menses or menstru?) adj3 (irregular\$ or regular\$ or nonregular or lenght\$ or short\$ or skip\$ or flow\$)).ti,ab.
10	MENSTRUATION DISTURBANCES/
11	AMENORRHEA/ or OLIGOMENORRHEA/
12	(amenorrh\$ or oligomenorr\$).ti,ab.
13	exp VASOMOTOR SYSTEM/
14	HOT FLASHES/
15	(hot adj (flash\$ or flush\$)).ti,ab.
16	(vasomotor adj symptom?).ti,ab.
17	SWEATING/
18	sweat\$.ti,ab.
19	HYPERHIDROSIS/
20	(sleep adj3 disturb\$).ti,ab.
21	"SLEEP INITIATION AND MAINTENANCE DISORDERS"/
22	insomnia?.ti,ab.
23	FEMALE UROGENITAL DISEASES/ or exp SEXUAL DYSFUNCTION, PHYSIOLOGICAL/ or VAGINISMUS/ or exp VAGINITIS/ or exp VULVAR DISEASES/
24	VAGINAL DISEASES/
25	VAGINA/
26	ATROPHY/
27	and/25-26
28	DEHYDRATION/
29	((vagin\$ or vulva?) adj3 (atroph\$ or dry\$ or irritat\$)).ti,ab.
30	(discomfort or uncomfortable or pain\$ or dyspareunia).ti,ab.
31	SEXUAL DYSFUNCTION, PSYCHOLOGICAL/
32	SEXUAL BEHAVIOR/
33	LIBIDO/
34	libido.ti,ab.
35	DYSPAREUNIA/
36	((altered or chang\$ or differ\$) adj3 sexual adj3 (behavio?r\$ or function\$)).ti,ab.
37	MOOD DISORDERS/
38	(mood adj3 (disturbance or disorder)).ti,ab.
39	DEPRESSION/
40	ANXIETY/
41	AFFECTIVE SYMPTOMS/
42	STRESS, PSYCHOLOGICAL/
43	IRRITABLE MOOD/
44	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).ti.
45	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).ab. /freq=2
46	FOLLICLE STIMULATING HORMONE/ or FOLLICLE STIMULATING HORMONE, BETA SUBUNIT/ or GLYCOPROTEIN HORMONES, ALPHA SUBUNIT/ or LUTEINIZING HORMONE/ or LUTEINIZING HORMONE, BETA SUBUNIT/
47	(FSH or LH).ti,ab.
48	((follicule stimulat or lutein\$) adj hormone?).ti,ab.
49	follitropin.ti,ab.
50	(interstitial cell stimulating adj4 hormone).ti,ab.
51	ANTI-MULLERIAN HORMONE/
52	(mullerian adj3 (factor? or substance? or hormone?)).ti,ab.
53	AMH.ti,ab.
54	(antral follicle? adj3 count\$).ti,ab.
55	AFC.ti,ab.
56	exp INHIBINS/
57	inhibin\$.ti,ab.
58	ESTROGENS/ or ESTRADIOL/
59	(oestogen? or estrogen\$ or estradiol or oestradiol).ti,ab.
60	exp OVARY/
61	ORGAN SIZE/
62	and/60-61
63	(ovar\$ adj3 (volume or size)).ti,ab.
64	or/62-63
65	or/7-24,27-59,64
66	exp "SENSITIVITY AND SPECIFICITY"/
67	(sensitivity or specificity).ti,ab.
68	((pre test or pretest or post test or posttest) adj probability).ti,ab.
69	(predictive value\$ or PPV or NPV).ti,ab.
70	likelihood ratio\$.ti,ab.
71	LIKELIHOOD FUNCTIONS/
72	(ROC curve\$ or AUC).ti,ab.
73	(diagnos* adj2 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.
74	gold standard.ti,ab.

#	Searches
75	or/66-74
76	and/6,65,75
77	PRIMARY OVARIAN INSUFFICIENCY/ or PREMATURE MENOPAUSE/
78	di.fs.
79	77 and 78
80	or/76,79

### Database: Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects

#	Searches
1	PRIMARY OVARIAN INSUFFICIENCY.kw.
2	PREMATURE MENOPAUSE.kw.
3	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw,tx.
4	((earl\$ or prematur\$) adj3 menopaus\$).tw,tx.
5	(POI or POF).tw.
6	or/1-5
7	MENSTRUAL CYCLE.kw.
8	((ovar\$ or endometri\$ or menstru\$) adj3 cycle?).tw,tx.
9	((period? or cycle? or menses or menstru?) adj3 (irregular\$ or regular\$ or nonregular or lenght\$ or short\$ or skip\$ or flow\$)).tw,tx.
10	MENSTRUATION DISTURBANCES.kw.
11	(AMENORRHEA or OLIGOMENORRHEA).kw.
12	(amenorrh\$ or oligomenorrh\$).tw,tx.
13	VASOMOTOR SYSTEM.kw.
14	HOT FLASHES.kw.
15	(hot adj (flash\$ or flush\$)).tw,tx.
16	(vasomotor adj symptom?).tw,tx.
17	SWEATING.kw.
18	sweat\$.tw,tx.
19	HYPERHIDROSIS.kw.
20	(sleep adj3 disturb\$).tw,tx.
21	"SLEEP INITIATION AND MAINTENANCE DISORDERS".kw.
22	insomnia?.tw,tx.
23	(FEMALE UROGENITAL DISEASES or SEXUAL DYSFUNCTION, PHYSIOLOGICAL or VAGINISMUS or VAGINITIS or VULVAR DISEASES).kw.
24	VAGINAL DISEASES.kw.
25	VAGINA.kw.
26	ATROPHY.kw.
27	and/25-26
28	DEHYDRATION.kw.
29	((vagin\$ or vulva?) adj3 (atroph\$ or dry\$ or irritat\$)).tw,tx.
30	(discomfort or uncomfortable or pain\$ or dyspareunia).tw,tx.
31	SEXUAL DYSFUNCTION, PSYCHOLOGICAL.kw.
32	SEXUAL BEHAVIOR.kw.
33	LIBIDO.kw.
34	libido.tw,tx.
35	DYSPAREUNIA.kw.
36	((altered or chang? or differ\$) adj3 sexual adj3 (behavio?r\$ or function\$)).tw,tx.
37	MOOD DISORDERS.kw.
38	(mood adj3 (disturbance or disorder)).tw,tx.
39	DEPRESSION.kw.
40	ANXIETY.kw.
41	AFFECTIVE SYMPTOMS.kw.
42	STRESS, PSYCHOLOGICAL.kw.
43	IRRITABLE MOOD.kw.
44	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$).tw,tx.
45	(FOLLICLE STIMULATING HORMONE or FOLLICLE STIMULATING HORMONE, BETA SUBUNIT or GLYCOPROTEIN HORMONES, ALPHA SUBUNIT or LUTEINIZING HORMONE or LUTEINIZING HORMONE, BETA SUBUNIT).kw.
46	(FSH or LH).tw,tx.
47	((follicule stimulat or lutein\$) adj hormone?).tw,tx.
48	follitropin.tw,tx.
49	(interstitial cell stimulating adj4 hormone).tw,tx.
50	ANTI-MULLERIAN HORMONE.kw.
51	(mullerian adj3 (factor? or substance? or hormone?)).tw,tx.
52	AMH.tw,tx.
53	(antral follicle? adj3 count\$).tw,tx.
54	AFC.tw,tx.

#	Searches
55	INHIBINS.kw.
56	inhibin\$.tw,tx.
57	(ESTROGENS or ESTRADIOL).kw.
58	(oestrogen? or estrogen\$ or estradiol or oestradiol).tw,tx.
59	OVARY.kw.
60	ORGAN SIZE.kw.
61	and/59-60
62	(ovar\$ adj3 (volume or size)).tw,tx.
63	or/61-62
64	or/7-24,27-58,63
65	"SENSITIVITY AND SPECIFICITY".kw.
66	(sensitivity or specificity).tw,tx.
67	((pre test or pretest or post test or posttest) adj probability).tw,tx.
68	(predictive value\$ or PPV or NPV).tw,tx.
69	likelihood ratio\$.tw,tx.
70	LIKELIHOOD FUNCTIONS.kw.
71	(ROC curve\$ or AUC).tw,tx.
72	(diagnos* adj2 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).tw,tx.
73	gold standard.tw,tx.
74	or/65-73
75	and/6,64,74

### Database: Health Technology Assessment

#	Searches
1	PRIMARY OVARIAN INSUFFICIENCY/
2	PREMATURE MENOPAUSE/
3	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).tw.
4	((earl\$ or prematur\$) adj3 menopaus\$).tw.
5	(POI or POF).tw.
6	or/1-5
7	exp MENSTRUAL CYCLE/
8	((ovar\$ or endometri\$ or menstru\$) adj3 cycle?).tw.
9	((period? or cycle? or menses or menstru?) adj3 (irregular\$ or regular\$ or nonregular or lenght\$ or short\$ or skip\$ or flow\$)).tw.
10	MENSTRUATION DISTURBANCES/
11	AMENORRHEA/ or OLIGOMENORRHEA/
12	(amenorrh\$ or oligomenorr\$).tw.
13	exp VASOMOTOR SYSTEM/
14	HOT FLASHES/
15	(hot adj (flash\$ or flush\$)).tw.
16	(vasomotor adj symptom?).tw.
17	SWEATING/
18	sweat\$.tw.
19	HYPERHIDROSIS/
20	(sleep adj3 disturb\$).tw.
21	"SLEEP INITIATION AND MAINTENANCE DISORDERS"/
22	insomnia?.tw.
23	FEMALE UROGENITAL DISEASES/ or exp SEXUAL DYSFUNCTION, PHYSIOLOGICAL/ or VAGINISMUS/ or exp VAGINITIS/ or exp VULVAR DISEASES/
24	VAGINAL DISEASES/
25	VAGINA/
26	ATROPHY/
27	and/25-26
28	DEHYDRATION/
29	((vagin\$ or vulva?) adj3 (atroph\$ or dry\$ or irritat\$)).tw.
30	(discomfort or uncomfotable or pain\$ or dyspareunia).tw.
31	SEXUAL DYSFUNCTION, PSYCHOLOGICAL/
32	SEXUAL BEHAVIOR/
33	LIBIDO/
34	libido.tw.
35	DYSPAREUNIA/
36	((altered or chang? or differ\$) adj3 sexual adj3 (behavio?r\$ or function\$)).tw.
37	MOOD DISORDERS/
38	(mood adj3 (disturbance or disorder)).tw.
39	DEPRESSION/
40	ANXIETY/
41	AFFECTIVE SYMPTOMS/
42	STRESS, PSYCHOLOGICAL/
43	IRRITABLE MOOD/

#	Searches
44	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$.)tw.
45	FOLLICLE STIMULATING HORMONE/ or FOLLICLE STIMULATING HORMONE, BETA SUBUNIT/ or GLYCOPROTEIN HORMONES, ALPHA SUBUNIT/ or LUTEINIZING HORMONE/ or LUTEINIZING HORMONE, BETA SUBUNIT/
46	(FSH or LH).tw.
47	((follicle stimulat or lutein\$) adj hormone?).tw.
48	follitropin.tw.
49	(interstitial cell stimulating adj4 hormone).tw.
50	ANTI-MULLERIAN HORMONE/
51	(mullerian adj3 (factor? or substance? or hormone?)).tw.
52	AMH.tw.
53	(antral follicle? adj3 count\$.)tw.
54	AFC.tw.
55	exp INHIBINS/
56	inhibin\$.tw.
57	ESTROGENS/ or ESTRADIOL/
58	(oestogen? or estrogen\$ or estradiol or oestradiol).tw.
59	exp OVARY/
60	ORGAN SIZE/
61	and/59-60
62	(ovar\$ adj3 (volume or size)).tw.
63	or/61-62
64	or/7-24,27-58,63
65	exp "SENSITIVITY AND SPECIFICITY"/
66	(sensitivity or specificity).tw.
67	((pre test or pretest or post test or posttest) adj probability).tw.
68	(predictive value\$ or PPV or NPV).tw.
69	likelihood ratio\$.tw.
70	LIKELIHOOD FUNCTIONS/
71	(ROC curve\$ or AUC).tw.
72	(diagnos* adj2 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).tw.
73	gold standard.tw.
74	or/65-73
75	and/6,64,74
76	PRIMARY OVARIAN INSUFFICIENCY/ or PREMATURE MENOPAUSE/
77	di.fs.
78	76 and 77
79	or/75,78


### Database: Embase

#	Searches
1	PREMATURE OVARIAN FAILURE/
2	EARLY MENOPAUSE/
3	((premature or earl\$) adj3 menopaus\$.)ti,ab.
4	((primary or prematur\$ or gonadotrop\$ or hypergonadotrop\$ or resist\$) adj3 ovar\$ adj3 (insuffic\$ or fail\$ or incompet\$ or syndrom\$)).ti,ab.
5	(POI or POF).ti,ab.
6	or/1-5
7	exp MENSTRUATION DISORDER/
8	((irregular\$ or regular\$ or nonregular\$) adj3 (menstrua\$ or period? or cycle?)).ti,ab.
9	oligomenorr?ea\$.ti,ab.
10	HOT FLUSH/
11	hot fl#sh\$.ti,ab.
12	exp SWEATING/
13	sweat\$.ti,ab.
14	VASOMOTOR DISORDER/
15	(vasomotor symptom? or VMS).ti,ab.
16	MOOD DISORDER/
17	DEPRESSION/
18	ANXIETY/
19	EMOTIONAL DISORDER/
20	MENTAL STRESS/
21	IRRITABILITY/
22	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$ or affective).ti.
23	(stress\$ or emotion\$ or depress\$ or anxiety or anxious\$ or affective).ab. /freq=2
24	FOLLITROPIN/
25	(follitropin? or follicle stimulating hormone? or FSH).ti,ab.
26	LUTEINIZING HORMONE/
27	(lutropin or lutein\$ or LH).ti,ab.
28	(interstitial cell stimulating adj4 hormone).ti,ab.


#	Searches
29	MULLERIAN INHIBITING FACTOR/
30	(mu?llerian adj3 (inhibit\$ or regress\$)).ti,ab.
31	((antimu?llerian or anti mu?llerian) adj3 (hormone? or factor?)).ti,ab.
32	exp ESTROGEN/
33	(estrogen\$ or oestrogen\$ or estradiol or oestradiol).ti,ab.
34	INHIBIN A/
35	INHIBIN B/
36	inhibin\$.ti,ab.
37	OVARY FOLLICLE/ or exp OVARY FOLLICLE CELL/
38	(antral follicle adj3 (count\$ or number\$)).ti,ab.
39	exp OVARY/
40	ORGAN SIZE/
41	and/39-40
42	or/7-38,41
43	"SENSITIVITY AND SPECIFICITY"/
44	(sensitivity or specificity).ti,ab.
45	((pre test or pretest or post test or posttest) adj probability).ti,ab.
46	(predictive value\$ or PPV or NPV).ti,ab.
47	likelihood ratio\$.ti,ab.
48	(ROC curve\$ or AUC).ti,ab.
49	(diagnos* adj2 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab.
50	gold standard.ti,ab.
51	DIAGNOSTIC ACCURACY/ or DIAGNOSTIC TEST ACCURACY STUDY/
52	or/43-51
53	and/6,42,52
54	PREMATURE OVARIAN FAILURE/
55	EARLY MENOPAUSE/
56	or/54-55
57	di.fs.
58	and/56-57
59	or/53,58
60	conference abstract.pt.
61	letter.pt. or LETTER/
62	note.pt.
63	editorial.pt.
64	CASE REPORT/ or CASE STUDY/
65	(letter or comment* or abstracts).ti.
66	or/60-65
67	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
68	66 not 67
69	ANIMAL/ not HUMAN/
70	NONHUMAN/
71	exp ANIMAL EXPERIMENT/
72	exp EXPERIMENTAL ANIMAL/
73	ANIMAL MODEL/
74	exp RODENT/
75	(rat or rats or mouse or mice).ti.
76	or/68-75
77	59 not 76
78	limit 77 to english language

## Appendix F: Prisma flow charts

### F.1 Diagnosis of perimenopause and postmenopause




### F.2 Classification systems for the diagnosis of menopause






### F.3 Information and advice




### F.4 Managing short-term symptoms




## F.4.1 Urogenital atrophy


### F.4.1.1 Short-term




### F.4.1.2 Long-term



## F.5 Review and referral




## F.6 Starting and stopping HRT




## F.7 Long-term benefits and risks of HRT


### F.7.1 Venous thromboembolism




### F.7.2 Cardiovascular disease




### F.7.3 Development of type 2 diabetes




### F.7.4 Management of type 2 diabetes – control of blood sugar




### F.7.5 Breast Cancer




### F.7.6 Osteoporosis



### F.7.7 Dementia




### F.7.8 Loss of muscle mass (sarcopenia)




## F.8 Premature ovarian insufficiency

### F.8.1 Diagnosis of premature ovarian insufficiency



### F.8.2 Management of premature ovarian insufficiency





## Appendix G: Excluded studies

### G.1 Diagnosis of perimenopause and menopause

Study	Reason for exclusion
Abdelrahman,R.Y., Abushaikha,L.A., al-Motlaq,M.A., Predictors of psychological well-being and stress among Jordanian menopausal women.[Erratum appears in Qual Life Res. 2014 May;23(4):1407], Quality of Life Research, 23, 167-173, 2014	No data could be extracted to construct 2 x 2 table.
Abe,N., Takeuchi,H., Kikuchi,I., Kinoshita,K., Effectiveness of microlaparoscopy in the diagnosis of premature ovarian failure, Journal of Obstetrics and Gynaecology Research, 32, 224-229, 2006	Includes women with POI only.
Ahmed,EbbiaryN, Lenton,E.A., Salt,C., Ward,A.M., Cooke,I.D., The significance of elevated basal follicle stimulating hormone in regularly menstruating infertile women, Human Reproduction, 9, 245-252, 1994	No data reported to allow construction of 2 x 2 table for diagnostic accuracy. Focus on fertility, not menopause.
Akahoshi,M., Soda,M., Nakashima,E., Tominaga,T., Ichimaru,S., Seto,S., Yano,K., The effects of body mass index on age at menopause, International Journal of Obesity, 26, 961-968, 2002	No relevant outcomes of interest.
Alquaiz,J.M., Siddiqui,A.R., Tayel,S.A., Habib,F.A., Determinants of severity of menopausal symptoms among Saudi women in Riyadh city, Climacteric, 17, 71-78, 2014	Symptoms examined in the study were from the Somato-Vegetative domain of MRC-II scale, which included hot flushes, heart discomfort, sleep problems, joint and muscle discomfort.
Arrigo,T., Bertelloni,S., Carcione,L., De,LucaF, De,SanctisC, Einaudi,S., Pirazzoli,P., Segni,M., Urso,L., Wasniewska,M., Characterization of early presentation idiopathic ovarian failure in girls and adolescents, Journal of Pediatric Endocrinology and Metabolism, 16, 835-842, 2003	No relevant outcomes. Includes women with POI only.
Ashrafi,M., Fallahian,M., Eshrati,B., Yazdi,R.S., The presence of anti thyroid and anti ovarian auto-antibodies in familial premature ovarian failure, International Journal of Fertility and Sterility, 1, 171-174, 2008	No outcomes of interest. Women with POI only.
Backer,L.C., Rubin,C.S., Marcus,M., Kieszak,S.M., Schober,S.E., Serum follicle-stimulating hormone and luteinizing hormone levels in women aged 35-60 in the U.S. population: the Third National Health and Nutrition Examination Survey (NHANES III, 1988-1994), Menopause, 6, 29-35, 1999	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Barentsen,R., van de Weijer,P.H., van,Gend S., Foekema,H., Climacteric symptoms in a representative Dutch population sample as measured with the Greene Climacteric Scale, Maturitas, 38, 123-128, 2001	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Bastian,L.A., Couchman,G.M., Rimer,B.K., McBride,C.M., Feaganes,J.R., Siegler,I.C., Perceptions of menopausal stage and patterns of hormone replacement therapy use, Journal of Women's Health, 6, 467-475, 1997	No relevant outcomes. No comparison of objectively defined pre, peri or postmenopausal groups of women.
Bastian,L.A., Smith,C.M., Nanda,K., Is this woman perimenopausal?, JAMA, 289, 895-902, 2003	Systematic review
Bentzen,J.G., Forman,J.L., Johannsen,T.H., Pinborg,A., Larsen,E.C., Andersen,A.N., Ovarian antral follicle subclasses and anti-mullerian hormone during normal reproductive aging, Journal of Clinical Endocrinology and Metabolism, 98, 1602-1611, 2013	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Blumel, J. E., Chedraui, P., Aedo, S., Fica, J., Mezones-Holguin, E., Baron, G., Bencosme, A., Benitez, Z., Bravo, L. M., Calle, A., Flores, D., Espinoza, M. T., Gomez, G., Hernandez-Bueno, J. A., Laribezcoa, F., Martino, M., Lima, S., Monterrosa, A., Mostajo, D., Ojeda, E., Onatra, W., Sanchez, H., Tserotas, K., Vallejo, M. S., Witis, S., Zuniga, M. C., Obesity and its relation to depressive symptoms and sedentary lifestyle in middle-aged women, Maturitas, 80, 100-5, 2015	No data could be extracted to construct 2 x 2 table;
Blumel,J.E., Chedraui,P., Baron,G., Belzares,E., Bencosme,A., Calle,A., Danckers,L., Espinoza,M.T., Flores,D., Gomez,G., Hernandez-Bueno,J.A., Izaguirre,H., Leon-Leon,P., Lima,S., Mezones-Holguin,E., Monterrosa,A., Mostajo,D., Navarro,D., Ojeda,E., Onatra,W., Royer,M., Soto,E., Tserotas,K., Vallejo,S., Collaborative Group for Research of the Climacteric in Latin America (REDLINC), A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women, Menopause, 18, 778-785, 2011	Data already included from Blumel 2012
Brambilla,D.J., McKinlay,S.M., Johannes,C.B., Defining the perimenopause for application in epidemiologic investigations, American Journal of Epidemiology, 140, 1091-1095, 1994	No relevant outcomes. Predictive testing.
Broekmans,F.J., Faddy,M.J., Scheffer,G., Te Velde,E.R., Antral follicle counts are related to age at natural fertility loss and age at menopause, Menopause, 11, 607-614, 2004	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Broer,S.L., Eijkemans,M.J., Scheffer,G.J., van,Rooij,I., de,Vet A., Themmen,A.P., Laven,J.S., de Jong,F.H., Te Velde,E.R., Fauser,B.C., Broekmans,F.J., Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women, Journal of Clinical Endocrinology and Metabolism, 96, 2532-2539, 2011	Predictive testing only. No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Burger,H., The menopausal transition--endocrinology. [20 refs], Journal of Sexual Medicine, 5, 2266-2273, 2008	Review article.

Study	Reason for exclusion
Burger,H., Woods,N.F., Dennerstein,L., Alexander,J.L., Kotz,K., Richardson,G., Nomenclature and endocrinology of menopause and perimenopause, Expert Review of Neurotherapeutics, 7, S35-S43, 2007	Review article.
Burger,H.G., The menopause: When it is all over or is it?, Australian and New Zealand Journal of Obstetrics and Gynaecology, 34, 293-295, 1994	Review article.
Burger,H.G., Physiology and endocrinology of the menopause, Medicine, 34, 27-30, 2006	Review article
Burger,H.G., Dudley,E.C., Cui,J., Dennerstein,L., Hopper,J.L., A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition, Journal of Clinical Endocrinology and Metabolism, 85, 2832-2838, 2000	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Burger,H.G., Hale,G.E., Robertson,D.M., Dennerstein,L., A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project. [57 refs], Human Reproduction Update, 13, 559-565, 2007	Review article
Campbell,I.G., Bromberger,J.T., Buysse,D.J., Hall,M.H., Hardin,K.A., Kravitz,H.M., Matthews,K.A., Rasor,M.O., Utts,J., Gold,E., Evaluation of the association of menopausal status with delta and beta EEG activity during sleep, Sleep, 34, 1561-1568, 2011	No outcomes of interest. No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Cervellati,C., Pansini,F.S., Bonaccorsi,G., Bergamini,C.M., Patella,A., Casali,F., Fantini,G.F., Pascale,G., Castaldini,C., Ferrazzini,S., Ridolfi,F., Cervellati,G., Cremonini,E., Christodoulou,P., Bagni,B., 17-estradiol levels and oxidative balance in a population of pre-, peri-, and post-menopausal women, Gynecological Endocrinology, 27, 1028-1032, 2011	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Chakravarti,S., Collins,W.P., Forecast,J.D., Hormonal profiles after the menopause, British Medical Journal, 2, 784-787, 1976	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Chao,K.C., Ho,C.H., Shyong,W.Y., Huang,C.Y., Tsai,S.C., Cheng,H.Y., Chou,L.C., Lin,C.H., Li,H.Y., Anti-Mullerian hormone serum level as a predictive marker of ovarian function in Taiwanese women, Journal of the Chinese Medical Association, 75, 70-74, 2012	Predictive testing. No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Chedraui,P., Perez-Lopez,F.R., Sanchez,H., Sanchez,P., Miranda,O., Quispe,P., Madero-Trelles,T., Hidalgo,L., Arboleda,D., Lopez,G., Quintero,J.C., Application of the 10-item Cervantes Scale among mid-aged Ecuadorian women for the assessment of menopausal symptoms, Maturitas, 79, 100-105, 2014	No data could be extracted to construct 2 x 2 table;
Conway,G.S., Kaltsas,G., Patel,A., Davies,M.C., Jacobs,H.S., Characterization of idiopathic premature ovarian failure, Fertility and Sterility, 65, 337-341, 1996	Women with POI only.
Crawford,S.L., Avis,N.E., Gold,E., Johnston,J., Kelsey,J., Santoro,N., Sowers,M., Sternfeld,B., Sensitivity and specificity of recalled vasomotor symptoms in a multiethnic cohort, American Journal of Epidemiology, 168, 1452-1459, 2008	Assesses concordance between recalled and daily self reporting of symptoms only.
Cray,L.A., Woods,N.F., Mitchell,E.S., Identifying symptom clusters during the menopausal transition: observations from the Seattle Midlife Women's Health Study, Climacteric, 16, 539-549, 2013	No data could be extracted to construct 2 x 2 table;
da Silva, A. R., d'Andretta Tanaka, A. C., Factors associated with menopausal symptom severity in middle-aged Brazilian women from the Brazilian Western Amazon, Maturitas, 76, 64-9, 2013	No data could be extracted to construct 2 x 2 table;
Dennerstein,L., Dudley,E.C., Hopper,J.L., Guthrie,J.R., Burger,H.G., A prospective population-based study of menopausal symptoms, Obstetrics and Gynecology, 96, 351-358, 2000	Longitudinal follow up data from another included study (Dennerstein 1993)
Dennerstein,L., Leher,P., Burger,H.G., Guthrie,J.R., New findings from non-linear longitudinal modelling of menopausal hormone changes, Human Reproduction Update, 13, 551-557, 2007	No data reported to allow construction of 2 x 2 table for diagnostic accuracy
Dennerstein,L., Smith,A.M., Morse,C.A., Burger,H.G., Sexuality and the menopause, Journal of Psychosomatic Obstetrics and Gynecology, 15, 59-66, 1994	No relevant outcomes.
Ding,T., Luo,A., Jiang,J., Du,X., Yang,S., Lai,Z., Shen,W., Lu,Y., Ma,D., Wang,S., Changes of endocrine and ultrasound markers as ovarian aging in modifying the Stages of Reproductive Aging Workshop (STRAW) staging system with subclassification of mid reproductive age stage, Gynecological Endocrinology, 29, 6-9, 2013	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Dolleman, M., Depmann, M., Eijkemans, M. J., Heimensem, J., Broer, S. L., van der Stroom, E. M., Laven, J. S., Van Rooij, I. A., Scheffer, G. J., Peeters, P. H., van der Schouw, Y. T., Lambalk, C. B., Broekmans, F. J., Anti-Mullerian hormone is a more accurate predictor of individual time to menopause than mother's age at menopause, Human Reproduction, 29, 584-91, 2014	No data could be extracted to construct 2 x 2 table.
Dutta, R., Dcruze, L., Anuradha, R., Rao, S., Rashmi, M. R., A population based study on the menopausal symptoms in a rural area of Tamil Nadu, India, Journal of Clinical and Diagnostic Research, 6, 597-601, 2012	No data could be extracted to construct 2 x 2 table.
Farquhar,C.M., Sadler,L., Harvey,S.A., Stewart,A.W., The association of hysterectomy and menopause: a prospective cohort study, BJOG: An International Journal of Obstetrics and Gynaecology, 112, 956-962, 2005	Predictive testing. No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Fenichel,P., Sosset,C., Barbarino-Monnier,P., Gobert,B., Hieronimus,S., Bene,M.C., Harter,M., Prevalence, specificity and significance of ovarian antibodies during spontaneous premature ovarian failure, Human Reproduction, 12, 2623-2628, 1997	Women had POI.

Study	Reason for exclusion
Fentiman,I.S., Allen,D., Wheeler,M., Rymer,J., The influence of premenopausal hormones on severity of climacteric symptoms and use of HRT, <i>Climacteric</i> , 9, 135-145, 2006	Prevalence of symptoms not presented in association with menopausal status.
Flaws,J.A., Langenberg,P., Babus,J.K., Hirshfield,A.N., Sharara,F.I., Ovarian volume and antral follicle counts as indicators of menopausal status, <i>Menopause</i> , 8, 175-180, 2001	Definition of menopause does not fit inclusion criteria - defined as 6 months of amenorrhoea.
Freeman,E.W., Sammel,M.D., Gracia,C.R., Kapoor,S., Lin,H., Liu,L., Nelson,D.B., Follicular phase hormone levels and menstrual bleeding status in the approach to menopause, <i>Fertility and Sterility</i> , 83, 383-392, 2005	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Freeman,E.W., Sammel,M.D., Lin,H., Gracia,C.R., Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women, <i>Journal of Clinical Endocrinology and Metabolism</i> , 97, 1673-1680, 2012	All women perimenopausal. Looks only at predictive testing, not diagnostic.
Freeman,E.W., Sammel,M.D., Lin,H., Gracia,C.R., Pien,G.W., Nelson,D.B., Sheng,L., Symptoms associated with menopausal transition and reproductive hormones in midlife women, <i>Obstetrics and Gynecology</i> , 110, 230-240, 2007	Unable to construct 2x2 grid for diagnostic accuracy - although percentage of subjects with symptoms is presented (graphically) the number of subjects at each stage of menopausal transition cannot be determined due to number of drop-outs (unable to determine at what stage the participants dropped out)
Garamszegi,C., Dennerstein,L., Dudley,E., Guthrie,J.R., Ryan,M., Burger,H., Menopausal status: subjectively and objectively defined, <i>Journal of Psychosomatic Obstetrics and Gynecology</i> , 19, 165-173, 1998	Longitudinal follow up data from another included study (Dennerstein 1993)
Gracia-Closas,M., Herrero,R., Bratti,C., Hildesheim,A., Sherman,M.E., Morera,L.A., Schiffman,M., Epidemiologic determinants of vaginal pH, <i>American Journal of Obstetrics and Gynecology</i> <i>Am J Obstet Gynecol</i> , 180, 1060-1066, 1999	No relevant outcomes.
Gold,E.B., Bromberger,J., Crawford,S., Samuels,S., Greendale,G.A., Harlow,S.D., Skurnick,J., Factors associated with age at natural menopause in a multiethnic sample of midlife women, <i>American Journal of Epidemiology</i> , 153, 865-874, 2001	No relevant outcomes.
Gracia,C.R., Sammel,M.D., Freeman,E.W., Lin,H., Langan,E., Kapoor,S., Nelson,D.B., Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition, <i>Menopause</i> , 12, 128-135, 2005	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Gronowski,A.M., Fantz,C.R., Parvin,C.A., Sokoll,L.J., Wiley,C.L., Wener,M.H., Grenache,D.G., Use of serum FSH to identify perimenopausal women with pituitary hCG, <i>Clinical Chemistry</i> , 54, 652-656, 2008	No relevant outcomes. All women perimenopausal.
Hagen,C.P., Aksglaede,L., Sorensen,K., Main,K.M., Boas,M., Cleemann,L., Holm,K., Gravholt,C.H., Andersson,A.M., Pedersen,A.T., Petersen,J.H., Linneberg,A., Kjaergaard,S., Juul,A., Serum levels of anti-Mullerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients, <i>Journal of Clinical Endocrinology and Metabolism</i> , 95, 5003-5010, 2010	No outcomes of interest. Diagnostic testing for POI.
Haimov-Kochman,R., Constantini,N., Brzezinski,A., Hochner-Celnikier,D., Regular exercise is the most significant lifestyle parameter associated with the severity of climacteric symptoms: a cross sectional study, <i>European Journal of Obstetrics, Gynecology, and Reproductive Biology</i> , 170, 229-234, 2013	No data could be extracted to construct 2 x 2 table.
Hale,G.E., Burger,H.G., Hormonal changes and biomarkers in late reproductive age, menopausal transition and menopause, <i>Best Practice and Research: Clinical Obstetrics and Gynaecology</i> , 23, 7-23, 2009	Review article.
Hale,G.E., Hughes,C.L., Burger,H.G., Robertson,D.M., Fraser,I.S., Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition, <i>Menopause</i> , 16, 50-59, 2009	No outcomes of interest.
Harlow,S.D., Crawford,S.L., Sommer,B., Greendale,G.A., Self-defined menopausal status in a multi-ethnic sample of midlife women, <i>Maturitas</i> , 36, 93-112, 2000	No outcomes of interest.
Hinrichsen, G., Wernecke, K. D., Schalinski, A., Borde, T., David, M., Menopausal symptoms in an intercultural context: a comparison between German women, Chinese women and migrant Chinese women using the Menopause Rating Scale (MRS II), <i>Archives of Gynecology &amp; Obstetrics</i> , 290, 963-71, 2014	Symptoms examined in the study were from the Somato-Vegetative domain of MRC-II scale, which included hot flushes, heart discomfort, sleep problems, joint and muscle discomfort.
Huerta,R., Mena,A., Malacara,J.M., de Leon,J.D., Symptoms at the menopausal and premenopausal years: their relationship with insulin, glucose, cortisol, FSH, prolactin, obesity and attitudes towards sexuality, <i>Psychoneuroendocrinology</i> , 20, 851-864, 1995	No relevant outcomes.
Jara,D., Fuenzalida,A., Figueroa,R., delPrado M., Flores,D., Blumel,J.E., Chedraui,P., Is the Menopause Rating Scale accurate for diagnosing sexual dysfunction among climacteric women?, <i>Maturitas</i> , 62, 321-323, 2009	PICO not met - no information on whether women were pre or post menopausal
Johnston,J.M., Colvin,A., Johnson,B.D., Santoro,N., Harlow,S.D., Bairey Merz,C.N., Sutton-Tyrrell,K., Comparison of SWAN and WISE menopausal status classification algorithms, <i>Journal of Women's Health</i> , 15, 1184-1194, 2006	Secondary analysis of data from another included study (Gold 2000)
Kaori,I., Ayako,T., Kazuhiro,A., Ryosuke,T., Tsuyoshi,H., Ippei,T., Hideki,M., Role of antimullerian hormone as a biomarker of the menopausal transition, <i>Menopause</i> , 20, 218-222, 2013	Longitudinal study of women through the menopause transition. Data presented for the same women at several time point, therefore unable to

Study	Reason for exclusion
	construct 2 x 2 table for diagnostic accuracy.
Kuh,D., Cardozo,L., Hardy,R., Urinary incontinence in middle aged women: childhood enuresis and other lifetime risk factors in a British prospective cohort, <i>Journal of Epidemiology and Community Health</i> , 53, 453-458, 1999	No relevant outcomes.
Legorreta, D., Montano, J. A., Hernandez, I., Salinas, C., Hernandez-Bueno, J. A., Amec Research Committee, Age at menopause, motives for consultation and symptoms reported by 40-59-year-old Mexican women, <i>Climacteric</i> , 16, 417-25, 2013	Included women on HRT treatment or not was not reported.
Li,H.W., Anderson,R.A., Yeung,W.S., Ho,P.C., Ng,E.H., Evaluation of serum antimullerian hormone and inhibin B concentrations in the differential diagnosis of secondary oligoamenorrhea, <i>Fertility and Sterility</i> , 96, 774-779, 2011	No relevant outcomes - assesses secondary amenorrhoea, but not menopause/perimenopause.
Mangweth-Matzek,B., Hoek,H.W., Rupp,C.I., Kemmler,G., Pope,H.G.,Jr., Kinzl,J., The menopausal transition--a possible window of vulnerability for eating pathology, <i>International Journal of Eating Disorders</i> , 46, 609-616, 2013	Indicators used were somatic-vegetative symptoms of MRS scale, which included muscle discomfort.
Meduri,G., Massin,N., Guibourdenche,J., Bachelot,A., Fiori,O., Kuttenn,F., Misrahi,M., Touraine,P., Serum anti-Mullerian hormone expression in women with premature ovarian failure, <i>Human Reproduction</i> , 22, 117-123, 2007	Women with POI only.
Metintas,S., Arykan,I., Kalyoncu,C., Ozalp,S., Menopause Rating Scale as a screening tool in rural Turkey, <i>Rural and Remote Health</i> , 10, 1230-1Mar, 2010	No data reported to allow construction of 2 x 2 table for diagnostic accuracy. No breakdown of prevalence of symptoms according to menopausal status.
Moilanen,J., Aalto,A.M., Hemminki,E., Aro,A.R., Raitanen,J., Luoto,R., Prevalence of menopause symptoms and their association with lifestyle among Finnish middle-aged women, <i>Maturitas</i> , 67, 368-374, 2010	About 40% of participants were on HRT treatment.
Muttukrishna,T., Child,G.M., Lockwood,N.P., Groome,D.H., Barlow,W.L., Ledger, Serum concentrations of dimeric inhibins, activin A, gonadotrophins and ovarian steroids during the menstrual cycle in older women, <i>Human Reproduction</i> , 15, 549-556, 2000	No relevant outcomes. No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Nusrat,U., Tabassum,R., Shukar-ud-din,S., Perception and experience of menopause and its management among the women attending out patient department at Dow University Hospital, <i>Internet Journal of Gynecology and Obstetrics</i> , 17, -, 2013	No data could be extracted to construct 2 x 2 table.
Oge,T., Hassa,H., Aydin,Y., Yalcin,O.T., Colak,E., The relationship between urogenital symptoms and climacteric complaints, <i>Climacteric</i> , 16, 646-652, 2013	No data could be extracted to construct 2 x 2 table;
Oi,N., Ohi,K., The relationship between psychosocial problems including depression and behavioural trends among middle-aged menopausal women in a cohort study, <i>International Journal of Cosmetic Science</i> , 35, 581-587, 2013	No data could be extracted to construct 2 x 2 table.
Olaolorun,F.M., Lawoyin,T.O., Experience of menopausal symptoms by women in an urban community in Ibadan, Nigeria, <i>Menopause</i> , 16, 822-830, 2009	The study did not report in/exclusion criteria of recruitment, unclear whether women on HRT treatment were included or not.
Ornat,L., Martinez-Deearth,R., Chedraui,P., Perez-Lopez,F.R., Assessment of subjective sleep disturbance and related factors during female mid-life with the Jenkins Sleep Scale, <i>Maturitas</i> , 77, 344-350, 2014	No relevant clinical indicators examined.
Overlie,I., Morkrid,L., Andersson,A.M., Skakkebaek,N.E., Moen,M.H., Holte,A., Inhibin A and B as markers of menopause: a five-year prospective longitudinal study of hormonal changes during the menopausal transition, <i>Acta Obstetrica et Gynecologica Scandinavica</i> , 84, 281-285, 2005	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Paramsothy, P., Harlow, S. D., Greendale, G. A., Gold, E. B., Crawford, S. L., Elliott, M. R., Lisabeth, L. D., Randolph, J. F., Jr., Bleeding patterns during the menopausal transition in the multi-ethnic Study of Women's Health Across the Nation (SWAN): a prospective cohort study, <i>BJOG: An International Journal of Obstetrics &amp; Gynaecology</i> , 121, 1564-73, 2014	The focus of the study was bleeding during menopausal transition, no relevant clinical indicator of interest was examined.
Paramsothy,P., Harlow,S.D., Elliott,M.R., Lisabeth,L.D., Crawford,S.L., Randolph,J.F.,Jr., Classifying menopause stage by menstrual calendars and annual interviews: need for improved questionnaires, <i>Menopause</i> , 20, 727-735, 2013	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Park,Y.J., Kim,H.S., Ku,P.S., Kang,H.C., Chun,S.H., A survey on the climacteric symptoms in Korean women, <i>Women and Health</i> , 34, 17-28, 2001	Included women were on HRT treatment or not was not reported.
Pimenta,F., Leal,I., Maroco,J., Ramos,C., Menopause Symptoms' Severity Inventory (MSSI-38): assessing the frequency and intensity of symptoms, <i>Climacteric</i> , 15, 143-152, 2012	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Rabiee, M., Akbari, H., Davati, A., Moghadamnia, M., Investigating the influence of mood-changes and effective elements of peri menopause on patients' companions referred to hospitals related to Shahed University, <i>Iranian Journal of Obstetrics, Gynecology and Infertility</i> , 15, 8-15, 2012	Publication in Arabic language.
Randolph,J.F.,Jr., Crawford,S., Dennerstein,L., Cain,K., Harlow,S.D., Little,R., Mitchell,E.S., Nan,B., Taffe,J., Yosef,M., The value of follicle-stimulating hormone concentration and clinical findings as markers of the late menopausal transition, <i>Journal of Clinical Endocrinology and Metabolism</i> , 91, 3034-3040, 2006	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Randolph,J.F.,Jr., Sowers,M., Bondarenko,I., Gold,E.B., Greendale,G.A., Bromberger,J.T., Brockwell,S.E., Matthews,K.A., The relationship of longitudinal	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.

Study	Reason for exclusion
change in reproductive hormones and vasomotor symptoms during the menopausal transition, <i>Journal of Clinical Endocrinology and Metabolism</i> , 90, 6106-6112, 2005	
Randolph, J.F., Jr., Sowers, M., Bondarenko, I.V., Harlow, S.D., Luborsky, J.L., Little, R.J., Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age, <i>Journal of Clinical Endocrinology and Metabolism</i> , 89, 1555-1561, 2004	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Randolph, J.F., Jr., Zheng, H., Sowers, M.R., Crandall, C., Crawford, S., Gold, E.B., Vuga, M., Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period, <i>Journal of Clinical Endocrinology and Metabolism</i> , 96, 746-754, 2011	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Roy, S., Caillouette, J.C., Roy, T., Faden, J.S., Vaginal pH is similar to follicle-stimulating hormone for menopause diagnosis, <i>American Journal of Obstetrics and Gynecology</i> , 190, 1272-1277, 2004	Use estradiol level to define menopause.
Santoro, N., Crawford, S.L., Allsworth, J.E., Gold, E.B., Greendale, G.A., Korenman, S., Lasley, B.L., McConnell, D., McGaffigan, P., Midgely, R., Schocken, M., Sowers, M., Weiss, G., Assessing menstrual cycles with urinary hormone assays, <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 284, E521-E530, 2003	No outcomes of interest. Considers timing of ovulation in perimenopausal women.
Santoro, N., Crawford, S.L., Lasley, W.L., Luborsky, J.L., Matthews, K.A., McConnell, D., Randolph, J.F., Jr., Gold, E.B., Greendale, G.A., Korenman, S.G., Powell, L., Sowers, M.F., Weiss, G., Factors related to declining luteal function in women during the menopausal transition, <i>Journal of Clinical Endocrinology and Metabolism</i> , 93, 1711-1721, 2008	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Santoro, N., Sutton-Tyrrell, K., The SWAN song: Study of Women's Health Across the Nation's recurring themes, <i>Obstetrics and Gynecology Clinics of North America</i> , 38, 417-423, 2011	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Schneider, H.P., Rosemeier, H.P., Schnitker, J., Gerbsch, S., Turck, R., Application and factor analysis of the menopause rating scale [MRS] in a post-marketing surveillance study of Climen, <i>Maturitas</i> , 37, 113-124, 2000	PICO not met - no analysis of diagnostic accuracy for menopause
Sherburn, M., Guthrie, J.R., Dudley, E.C., O'Connell, H.E., Dennerstein, L., Is incontinence associated with menopause?, <i>Obstetrics and Gynecology</i> , 98, 628-633, 2001	No relevant outcomes.
Siefert, L.L., Begum, K., Sharmeen, T., Murphy, L., Muttukrishna, S., Chowdhury, O., Bentley, G.R., Estimating ovarian reserve: The contribution of one-time hormonal measurements and STRAW stages, <i>Menopause</i> , 18, 1376-, 2011	Conference abstract
Skurnick, J.H., Weiss, G., Goldsmith, L.T., Santoro, N., Crawford, S., Longitudinal changes in hypothalamic and ovarian function in perimenopausal women with anovulatory cycles: relationship with vasomotor symptoms, <i>Fertility and Sterility</i> , 91, 1127-1134, 2009	Secondary analysis of data from another included study (Gold 2000)
Smith-DiJulio, K., Mitchell, E.S., Woods, N.F., Concordance of retrospective and prospective reporting of menstrual irregularity by women in the menopausal transition, <i>Climacteric</i> , 8, 390-397, 2005	No relevant outcomes - paper assesses concordance of reporting only.
Smith-DiJulio, K., Percival, D.B., Woods, N.F., Tao, E.Y., Mitchell, E.S., Hot flash severity in hormone therapy users/nonusers across the menopausal transition, <i>Maturitas</i> , 58, 191-200, 2007	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Sowers, M.R., Eyvazzadeh, A.D., McConnell, D., Yosef, M., Jannausch, M.L., Zhang, D., Harlow, S., Randolph, J.F., Jr., Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition, <i>Journal of Clinical Endocrinology and Metabolism</i> , 93, 3478-3483, 2008	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Sowers, M.R., Zheng, H., McConnell, D., Nan, B., Harlow, S., Randolph, J.F., Jr., Follicle stimulating hormone and its rate of change in defining menopause transition stages, <i>Journal of Clinical Endocrinology and Metabolism</i> , 93, 3958-3964, 2008	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Sun, N., Lin, S.Q., Lin, H.J., He, Z., Wang, Y.H., Zhang, Y., Chen, F.L., Jiang, Y., Comparison of follicle-stimulating hormone, estradiol, ovarian volume, and antral follicle count, based on the Stages of Reproductive Aging Workshop system, among community-based women in China, <i>Menopause</i> , 20, 736-741, 2013	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Tan, M.N., Kartal, M., Guldal, D., The effect of physical activity and body mass index on menopausal symptoms in Turkish women: a cross-sectional study in primary care, <i>BMC Women's Health</i> , 14, 38-, 2014	No data could be extracted to construct 2 x 2 table;
Tehrani, F.R., Shakeri, N., Soleymani-Dodaran, M., Azizi, F., Predicting age at menopause from serum antimullerian hormone concentration, <i>Menopause</i> , 18, 766-770, 2011	Predictive testing. No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Tehrani, F.R., Soleymani-Dodaran, M., Azizi, F., A single test of antimullerian hormone in late reproductive-aged women is a good predictor of menopause, <i>Menopause</i> , 16, 797-802, 2009	Predictive testing. No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Tehrani, F.R., Soleymani-Dodaran, M., Tohidi, M., Gohari, M.R., Azizi, F., Modeling age at menopause using serum concentration of anti-mullerian hormone. [Erratum appears in <i>J Clin Endocrinol Metab.</i> 2013 Apr;98(4):1766], <i>Journal of Clinical Endocrinology and Metabolism</i> , 98, 729-735, 2013	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Tepper, P.G., Randolph, J.F., Jr., McConnell, D.S., Crawford, S.L., El, Khoudary, Sr., Joffe, H., Gold, E.B., Zheng, H., Bromberger, J.T., Sutton-Tyrrell, K., Trajectory clustering of estradiol and follicle-stimulating hormone during the menopausal	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.

Study	Reason for exclusion
transition among women in the Study of Women's Health across the Nation (SWAN), Journal of Clinical Endocrinology and Metabolism, 97, 2872-2880, 2012	
Terauchi,M., Hiramitsu,S., Akiyoshi,M., Owa,Y., Kato,K., Obayashi,S., Matsushima,E., Kubota,T., Associations among depression, anxiety and somatic symptoms in peri- and postmenopausal women, Journal of Obstetrics and Gynaecology Research, 39, 1007-1013, 2013	No data could be extracted to construct 2 x 2 table.
Travers,C., O'Neill,S.M., King,R., Battistutta,D., Khoo,S.K., Greene Climacteric Scale: norms in an Australian population in relation to age and menopausal status, Climacteric, 8, 56-62, 2005	Just median scores for VSM symptoms measured by the Greene Climacteric Scale were reported for each menopausal transitional group. No data could be extracted to construct 2 x 2 table;
Tufan,E., Elter,K., Durmusoglu,F., Assessment of reproductive ageing patterns by hormonal and ultrasonographic ovarian reserve tests, Human Reproduction, 19, 2484-2489, 2004	No relevant outcomes.
Vahidoodsari,F., Ayati,S., Yousefi,Z., Saeed,S., Comparing Serum Follicle-Stimulating Hormone (FSH) Level with Vaginal PH in Women with Menopausal Symptoms, Oman Medical Journal, 25, 13-16, 2010	All women included were postmenopausal.
van,Rooij,I., Broekmans,F.J., Scheffer,G.J., Looman,C.W., Habbema,J.D., de Jong,F.H., Fauser,B.J., Themmen,A.P., Te Velde,E.R., Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study, Fertility and Sterility, 83, 979-987, 2005	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Van,Rooij,I., Den,Tonkelaar,I., Broekmans,F.J.M., Looman,C.W.N., Scheffer,G.J., de,JongF, Themmen,A.P.N., Te,VeldeE, Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition, Menopause, 11, 601-606, 2004	Predictive testing. No data reported to allow construction of 2 x 2 table for diagnostic accuracy.
Waidyasekera,H., Wijewardena,K., Lindmark,G., Naessen,T., Menopausal symptoms and quality of life during the menopausal transition in Sri Lankan women, Menopause, 16, 164-170, 2009	Included women were on HRT treatment or not was not reported.
Whiteley,J., DiBonaventura,Md, Wagner,J.S., Alvir,J., Shah,S., The impact of menopausal symptoms on quality of life, productivity, and economic outcomes, Journal of Women's Health, 22, 983-990, 2013	No data could be extracted to construct 2 x 2 table.
Woods,N.F., Cray,L., Mitchell,E.S., Herting,J.R., Endocrine biomarkers and symptom clusters during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study, Menopause, 21, 646-652, 2014	No data could be extracted to construct 2 x 2 table.
Yang,Y.S., Hur,M.H., Kim,S.Y., Young,K., Correlation between sonographic and endocrine markers of ovarian aging as predictors for late menopausal transition, Menopause, 18, 138-145, 2011	No data reported to allow construction of 2 x 2 table for diagnostic accuracy.

## G.2 Classification systems for the diagnosis of menopause

Study	Reason for exclusion
AlQuaiz,A.M., Tayel,S.A., Habiba,F.A., Assessment of symptoms of menopause and their severity among Saudi women in Riyadh, Annals of Saudi Medicine, 33, 63-67, 2013	Describes symptoms, does not classify stages of the menopause
Bell,R.J., Lijovic,M., Fradkin,P., Davis,S.R., A pragmatic approach to the classification of menopausal status for community-based research, Menopause, 15, 978-983, 2008	Develops system to classify women with breast cancer as pre, peri or postmenopausal. No consideration of clinical relevance of system, or other protocol outcomes.
Berecki-Gisolf,J., Begum,N., Dobson,A.J., Symptoms reported by women in midlife: menopausal transition or aging?, Menopause, 16, 1021-1029, 2009	Evaluate symptoms, do not classify stages of the menopause
Blumel,J.E., Chedraui,P., Baron,G., Belzares,E., Bencosme,A., Calle,A., Danckers,L., Espinoza,M.T., Flores,D., Gomez,G., Hernandez-Bueno,J.A., Izaguirre,H., Leon-Leon,P., Lima,S., Mezones-Holguin,E., Monterrosa,A., Mostajo,D., Navarro,D., Ojeda,E., Onatra,W., Royer,M., Soto,E., Tserotas,K., Vallejo,M.S., Collaborative Group for Research of the Climacteric in Latin America (REDLINC), Menopausal symptoms appear before the menopause and persist 5 years beyond: a detailed analysis of a multinational study, Climacteric, 15, 542-551, 2012	MRS and symptom prevalence reported according to menopausal stages
Brown,W.J., Mishra,G.D., Dobson,A., Changes in physical symptoms during the menopause transition, International Journal of Behavioral Medicine, 9, 53-67, 2002	Evaluate symptoms, not a classification system
Burger,H.G., The stages of reproductive aging as proposed by workshops held in 2001 and 2010 (STRAW and STRAW + 10): a commentary, Climacteric, 16 Suppl 1, 5-7, 2013	Commentary only.
Burger,H.G., Cahir,N., Robertson,D.M., Groome,N.P., Dudley,E., Green,A., Dennerstein,L., Serum inhibins A and B fall differentially as FSH rises in perimenopausal women, Clinical Endocrinology, 48, 809-813, 1998	Not a classification system
Burleson,M.H., Todd,M., Trevathan,W.R., Daily vasomotor symptoms, sleep problems, and mood: using daily data to evaluate the domino hypothesis in middle-aged women, Menopause, 17, 87-95, 2010	Does not classify stages of the menopause

Study	Reason for exclusion
Carranza-Lira,S., Reyes Razo,B.P., Chan,Verdugo R., SUMEVA, a new system of climacteric symptom evaluation, and its correlation with FSH and estradiol levels, International Journal of Fertility and Womens Medicine, 51, 140-144, 2006	Does not classify stages of the menopause, all women perimenopausal
Chuni,N., Sreeramareddy,C.T., Frequency of symptoms, determinants of severe symptoms, validity of and cut-off score for Menopause Rating Scale (MRS) as a screening tool: a cross-sectional survey among midlife Nepalese women, BMC Women's Health, 11, 30-, 2011	No relevant protocol outcomes
Col,N.F., Guthrie,J.R., Politi,M., Dennerstein,L., Duration of vasomotor symptoms in middle-aged women: a longitudinal study, Menopause, 16, 453-457, 2009	Does not classify stages of the menopause
Cooper,G.S., Baird,D.D., The use of questionnaire data to classify peri- and premenopausal status, Epidemiology, 6, 625-628, 1995	Only classify pre and perimenopausal women
Cooper,G.S., Baird,D.D., Darden,F.R., Measures of menopausal status in relation to demographic, reproductive, and behavioral characteristics in a population-based study of women aged 35-49 years, American Journal of Epidemiology, 153, 1159-1165, 2001	Report associations, not a classification system
Dennerstein,L., Dudley,E., Burger,H., Well-being and the menopausal transition, Journal of Psychosomatic Obstetrics and Gynecology, 18, 95-101, 1997	Does not classify stages of the menopause
Ding,T., Luo,A., Jiang,J., Du,X., Yang,S., Lai,Z., Shen,W., Lu,Y., Ma,D., Wang,S., Changes of endocrine and ultrasound markers as ovarian aging in modifying the Stages of Reproductive Aging Workshop (STRAW) staging system with subclassification of mid reproductive age stage, Gynecological Endocrinology, 29, 6-9, 2013	Evaluate ovary aging markers according to STRAW groups. No assessment of clinical relevance/other outcomes of interest.
Dudley,E.C., Hopper,J.L., Taffe,J., Guthrie,J.R., Burger,H.G., Dennerstein,L., Using longitudinal data to define the perimenopause by menstrual cycle characteristics, Climacteric, 1, 18-25, 1998	Predict time to postmenopause, do not classify stages
El,Shafie K., Al,Farsi Y., Al,Zadjali N., Al,Adawi S., Al,Busaidi Z., Al,Shafae M., Menopausal symptoms among healthy, middle-aged Omani women as assessed with the Menopause Rating Scale, Menopause, 18, 1113-1119, 2011	Association of symptoms, not a classification system
Ensrud,K.E., Stone,K.L., Blackwell,T.L., Sawaya,G.F., Tagliaferri,M., Diem,S.J., Grady,D., Frequency and severity of hot flashes and sleep disturbance in postmenopausal women with hot flashes, Menopause, 16, 286-292, 2009	All women postmenopausal, do not classify stages of the menopause
Eskin,B.A., Tank,J., Montgomery,O., Sell,C., Use of a quality of life (QOL) menopause rating scale (MRS) to define hormone and aging symptoms during the menopause and post-menopause (geripause), Endocrine Reviews, 33, -, 2012	Conference paper
Garcia-Closas,M., Herrero,R., Bratti,C., Hildesheim,A., Sherman,M.E., Morera,L.A., Schiffman,M., Epidemiologic determinants of vaginal pH, American Journal of Obstetrics and GynecologyAm J Obstet Gynecol, 180, 1060-1066, 1999	Wvaluate the relationship between vaginal pH and factors related to cervical cancer
Gharraibeh,M., Al-Obeisat,S., Hattab,J., Severity of menopausal symptoms of Jordanian women, Climacteric, 13, 385-394, 2010	Evaluate symptom severity, do not classify stages of the menopause
Giacobbe,M., Mendes Pinto-Neto,A., Simoes Costa-Paiva,L.H., Martinez,E.Z., The usefulness of ovarian volume, antral follicle count and age as predictors of menopausal status, Climacteric, 7, 255-260, 2004	Compare pre and post, not a classification system
Gold,E.B., Bromberger,J., Crawford,S., Samuels,S., Greendale,G.A., Harlow,S.D., Skurnick,J., Factors associated with age at natural menopause in a multiethnic sample of midlife women, American Journal of Epidemiology, 153, 865-874, 2001	Evaluate age at natural menopause, do not classify stages of the menopause
Gold,E.B., Sternfeld,B., Kelsey,J.L., Brown,C., Mouton,C., Reame,N., Salamone,L., Stellato,R., Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age, American Journal of Epidemiology, 152, 463-473, 2000	Do not classify stages of the menopause
Gracia,C.R., Sammel,M.D., Freeman,E.W., Lin,H., Langan,E., Kapoor,S., Nelson,D.B., Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition, Menopause, 12, 128-135, 2005	compares classification system but no assessment of the clinical relevance or other outcomes.
Greendale,G.A., Ishii,S., Huang,M.H., Karlamangla,A.S., Predicting the timeline to the final menstrual period: the study of women's health across the nation, Journal of Clinical Endocrinology and Metabolism, 98, 1483-1491, 2013	Predict the final menstrual period
Grigoriou,V., Augoulea,A., Armeni,E., Rizos,D., Alexandrou,A., Dendrinou,S., Panoulis,K., Lambrinouadaki,I., Prevalence of vasomotor, psychological, psychosomatic and sexual symptoms in perimenopausal and recently postmenopausal Greek women: association with demographic, life-style and hormonal factors, Gynecological Endocrinology, 29, 125-128, 2013	Evaluate symptoms and association, not a classification system
Gronowski,A.M., Fantz,C.R., Parvin,C.A., Sokoll,L.J., Wiley,C.L., Wener,M.H., Grenache,D.G., Use of serum FSH to identify perimenopausal women with pituitary hCG, Clinical Chemistry, 54, 652-656, 2008	Evaluate human chorionic gonadotropin in perimenopausal women
Guthrie,J.R., Dennerstein,L., Taffe,J.R., Lehert,P., Burger,H.G., Hot flushes during the menopause transition: a longitudinal study in Australian-born women, Menopause, 12, 460-467, 2005	Evaluate association, not a classification system
Guthrie,J.R., Dennerstein,L., Taffe,J.R., Lehert,P., Burger,H.G., The menopausal transition: a 9-year prospective population-based study. The Melbourne Women's Midlife Health Project, Climacteric, 7, 375-389, 2004	Evaluate associations, not a classification system
Hagen,C.P., Aksglaede,L., Sorensen,K., Main,K.M., Boas,M., Cleemann,L., Holm,K., Gravholt,C.H., Andersson,A.M., Pedersen,A.T., Petersen,J.H., Linneberg,A., Kjaergaard,S., Juul,A., Serum levels of anti-Mullerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in	Evaluate ovarian function

Study	Reason for exclusion
172 Turner syndrome patients, Journal of Clinical Endocrinology and Metabolism, 95, 5003-5010, 2010	
Hale,G.E., Burger,H.G., Hormonal changes and biomarkers in late reproductive age, menopausal transition and menopause, Best Practice and Research: Clinical Obstetrics and Gynaecology, 23, 7-23, 2009	Only discuss STRAW system, not a RCT or observational study
Hale,G.E., Hughes,C.L., Burger,H.G., Robertson,D.M., Fraser,I.S., Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition, Menopause, 16, 50-59, 2009	No relevant protocol outcomes, compare biphasic ovulatory cycles between STRAW groups
Hale,G.E., Zhao,X., Hughes,C.L., Burger,H.G., Robertson,D.M., Fraser,I.S., Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system, Journal of Clinical Endocrinology and Metabolism, 92, 3060-3067, 2007	Description of features at different STRAW stages, no assessment of utility of classification scheme.
Hansen,K.R., Craig,L.B., Zavy,M.T., Klein,N.A., Soules,M.R., Ovarian primordial and nongrowing follicle counts according to the Stages of Reproductive Aging Workshop (STRAW) staging system, Menopause, 19, 164-171, 2012	Validate STRAW system, no assessment of diagnostic utility/clinical relevance, or other outcomes of interest.
Harlow,S.D., Cain,K., Crawford,S., Dennerstein,L., Little,R., Mitchell,E.S., Nan,B., Randolph,J.F.,Jr., Taffe,J., Yosef,M., Evaluation of four proposed bleeding criteria for the onset of late menopausal transition, Journal of Clinical Endocrinology and Metabolism, 91, 3432-3438, 2006	Determine final menstrual period
Harlow,S.D., Crawford,S., Dennerstein,L., Burger,H.G., Mitchell,E.S., Sowers,M.F., ReSTAGE,Collaboration, Recommendations from a multi-study evaluation of proposed criteria for staging reproductive aging. [27 refs], Climacteric, 10, 112-119, 2007	Proposed changes to STRAW system. No assessment of clinical relevance/diagnostic utility or other outcomes of interest.
Harlow,S.D., Crawford,S.L., Sommer,B., Greendale,G.A., Self-defined menopausal status in a multi-ethnic sample of midlife women, Maturitas, 36, 93-112, 2000	Not a classification system
Harlow,S.D., Gass,M., Hall,J.E., Lobo,R., Maki,P., Rebar,R.W., Sherman,S., Sluss,P.M., de Villiers,T.J., Collaborative Group., Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging, Journal of Clinical Endocrinology and Metabolism, 97, 1159-1168, 2012	Summary of STRAW 10 criteria, no assessment of diagnostic utility/clinical relevance or other outcomes of interest.
Harlow,S.D., Mitchell,E.S., Crawford,S., Nan,B., Little,R., Taffe,J., ReSTAGE,Collaboration, The ReSTAGE Collaboration: defining optimal bleeding criteria for onset of early menopausal transition, Fertility and Sterility, 89, 129-140, 2008	Do not classify stages of the menopause
Heinemann,K., Ruebig,A., Potthoff,P., Schneider,H.P., Strelow,F., Heinemann,L.A., Do,M.T., The Menopause Rating Scale (MRS) scale: a methodological review, Health and Quality of Life Outcomes, 2, 45-, 2004	Evaluate the MRS, do not classify stages of the menopause
Heinemann,L.A., DoMinh,T., Strelow,F., Gerbsch,S., Schnitker,J., Schneider,H.P., The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study, Health and Quality of Life Outcomes, 2, 67-, 2004	Do not classify stages of the menopause, evaluate symptom complaints from the MRS
Henrich,J.B., Hughes,J.P., Kaufman,S.C., Brody,D.J., Curtin,L.R., Limitations of follicle-stimulating hormone in assessing menopause status: findings from the National Health and Nutrition Examination Survey (NHANES 1999-2000)*, Menopause, 13, 171-177, 2006	Report FSH cutoff points, not a classification system
Huang,X., Harlow,S.D., Elliott,M.R., Distinguishing 6 population subgroups by timing and characteristics of the menopausal transition, American Journal of Epidemiology, 175, 74-83, 2012	Develop an algorithm to classify stages, no relevant outcomes
Huerta,R., Mena,A., Malacara,J.M., de Leon,J.D., Symptoms at the menopausal and premenopausal years: their relationship with insulin, glucose, cortisol, FSH, prolactin, obesity and attitudes towards sexuality, Psychoneuroendocrinology, 20, 851-864, 1995	Determine association, not a classification system
Jaff, N. G., Snyman, T., Norris, S. A., Crowther, N. J., Staging reproductive aging using Stages of Reproductive Aging Workshop + 10 in black urban African women in the Study of Women Entering and in Endocrine Transition, Menopause, 21, 1225-33, 2014	Population did not fit UK setting, no comparator group reported in study
Jaff,N.G., Snyman,T., Norris,S.A., Crowther,N.J., Staging reproductive aging using STRAW+10 in urban African women in the study of women entering and in endocrine transition (sweet), Menopause, 20, 1325-, 2013	Conference abstract. Publication of study in 2014
Jara,D., Fuenzalida,A., Figueroa,R., delPrado M., Flores,D., Blumel,J.E., Chedraui,P., Is the Menopause Rating Scale accurate for diagnosing sexual dysfunction among climacteric women?, Maturitas, 62, 321-323, 2009	Diagnose sexual dysfunction
Johnson,B.D., Merz,C.N., Braunstein,G.D., Berga,S.L., Bittner,V., Hodgson,T.K., Gierach,G.L., Reis,S.E., Vido,D.A., Sharaf,B.L., Smith,K.M., Sopko,G., Kelsey,S.F., Determination of menopausal status in women: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) Study, Journal of Women's Health, 13, 872-887, 2004	Compares the accuracy of 2 algorithms for defining menopausal status, but no assessment of clinical relevance.
Johnston,J.M., Colvin,A., Johnson,B.D., Santoro,N., Harlow,S.D., Bairey Merz,C.N., Sutton-Tyrrell,K., Comparison of SWAN and WISE menopausal status classification algorithms, Journal of Women's Health, 15, 1184-1194, 2006	Compares 2 classification systems. No assessment of clinical relevance/diagnostic utility or other outcomes of interest



Study	Reason for exclusion
Kahwati,L.C., Haigler,L., Rideout,S., What is the best way to diagnose menopause?, Journal of Family Practice, 54, 1000-1002, 2005	Diagnose the menopause, do not classify stages
Kaori,I., Ayako,T., Kazuhiro,A., Ryosuke,T., Tsuyoshi,H., Ippei,T., Hideki,M., Role of antimullerian hormone as a biomarker of the menopausal transition, Menopause, 20, 218-222, 2013	Determine if AMH can predict the onset of menopause
Kapur,P., Sinha,B., Pereira,B.M., Measuring climacteric symptoms and age at natural menopause in an Indian population using the Greene Climacteric Scale, Menopause, 16, 378-384, 2009	Evaluate symptoms and association, do not classify stages of the menopause
Kasuga,M., Makita,K., Ishitani,K., Takamatsu,K., Watanabe,K., Plotnikoff,G.A., Horiguchi,F., Nozawa,S., Relation between climacteric symptoms and ovarian hypofunction in middle-aged and older Japanese women, Menopause, 11, 631-638, 2004	Determine associations, not a classification system
Legorreta,D., Montano,J.A., Hernandez,I., Salinas,C., Hernandez-Bueno,J.A., Amec Research Committee., Age at menopause, motives for consultation and symptoms reported by 40-59-year-old Mexican women, Climacteric, 16, 417-425, 2013	Does not classify stages of the menopause
Li,H.W., Anderson,R.A., Yeung,W.S., Ho,P.C., Ng,E.H., Evaluation of serum antimullerian hormone and inhibin B concentrations in the differential diagnosis of secondary oligoamenorrhea, Fertility and Sterility, 96, 774-779, 2011	Diagnose secondary oligoamenorrhea
Lisabeth,L.D., Harlow,S.D., Gillespie,B., Lin,X., Sowers,M.F., Staging reproductive aging: a comparison of proposed bleeding criteria for the menopausal transition, Menopause, 11, 186-197, 2004	Focus on bleeding criteria, not a classification system
Mansfield,P.K., Carey,M., Anderson,A., Barsom,S.H., Koch,P.B., Staging the menopausal transition: data from the TREMIN Research Program on Women's Health, Women's Health Issues, 14, 220-226, 2004	Validate STRAW using self reported menstrual cycles to assess movement across the stages
Meduri,G., Massin,N., Guibourdenche,J., Bachelot,A., Fiori,O., Kuttenn,F., Misrahi,M., Touraine,P., Serum anti-Mullerian hormone expression in women with premature ovarian failure, Human Reproduction, 22, 117-123, 2007	Diagnose premature ovarian failure
Metintas,S., Arykan,I., Kalyoncu,C., Ozalp,S., Menopause Rating Scale as a screening tool in rural Turkey, Rural and Remote Health, 10, 1230-1Mar, 2010	Evaluate severity of symptoms, do not classify stages of the menopause
Miro,F., Parker,S.W., Aspinall,L.J., Coley,J., Pery,P.W., Ellis,J.E., Sequential classification of endocrine stages during reproductive aging in women: the FREEDOM study, Menopause, 12, 281-290, 2005	Develops a classification system but no assessment of clinical relevance of the system.
Mishra,G.D., Kuh,D., Health symptoms during midlife in relation to menopausal transition: British prospective cohort study, BMJ, 344, e402-, 2012	Evaluate symptom association, not a classification system
Mitchell,E.S., Woods,N.F., Mariella,A., Three stages of the menopausal transition from the Seattle Midlife Women's Health Study: toward a more precise definition, Menopause, 7, 334-349, 2000	Develop a classification system, no relevant protocol outcomes.
Moilanen,J., Aalto,A.M., Hemminki,E., Aro,A.R., Raitanen,J., Luoto,R., Prevalence of menopause symptoms and their association with lifestyle among Finnish middle-aged women, Maturitas, 67, 368-374, 2010	Evaluate symptom severity and association, not a classification system
Moradan,S., Ghorbani,R., Nasiri,Z., Can vaginal pH predict menopause?, Saudi Medical Journal, 31, 253-256, 2010	Focus on vaginal pH, not a classification system
Muttukrishna,T., Child,G.M., Lockwood,N.P., Groome,D.H., Barlow,W.L., Ledger, Serum concentrations of dimeric inhibins, activin A, gonadotrophins and ovarian steroids during the menstrual cycle in older women, Human Reproduction, 15, 549-556, 2000	Do not classify stages of the menopause
Olaolun,F.M., Lawoyin,T.O., Experience of menopausal symptoms by women in an urban community in Ibadan, Nigeria, Menopause, 16, 822-830, 2009	Evaluate symptoms, do not classify stages of the menopause
Park,Y.J., Kim,H.S., Ku,P.S., Kang,H.C., Chun,S.H., A survey on the climacteric symptoms in Korean women, Women and Health, 34, 17-28, 2001	Evaluate symptoms, not a classification system
Practice Committee of American Society for Reproductive Medicine., The menopausal transition. [47 refs], Fertility and Sterility, 90, S61-S65, 2008	Describe STRAW, not a RCT or observational study
Robertson,D.M., Hale,G.E., Fraser,I.S., Hughes,C.L., Burger,H.G., A proposed classification system for menstrual cycles in the menopause transition based on changes in serum hormone profiles, Menopause, 15, 1139-1144, 2008	Do not classify stages of the menopause
Sammel,M.D., Freeman,E.W., Liu,Z., Lin,H., Guo,W., Factors that influence entry into stages of the menopausal transition, Menopause, 16, 1218-1227, 2009	Association of covariates with transition to STRAW stages.
Santoro,N., Brockwell,S., Johnston,J., Crawford,S.L., Gold,E.B., Harlow,S.D., Matthews,K.A., Sutton-Tyrrell,K., Helping midlife women predict the onset of the final menses: SWAN, the Study of Women's Health Across the Nation, Menopause, 14, 415-424, 2007	Predict time to the final menstrual period
Santoro,N., Randolph,J.F., Jr., Reproductive hormones and the menopause transition, Obstetrics and Gynecology Clinics of North America, 38, 455-466, 2011	Discuss methods for evaluating the transition, not a RCT or observational study
Schneider,H.P., Rosemeier,H.P., Schnitker,J., Gerbsch,S., Turck,R., Application and factor analysis of the menopause rating scale [MRS] in a post-marketing surveillance study of Climen, Maturitas, 37, 113-124, 2000	Effect of HRT use on the MRS
Schneider,H.P.G., Heinemann,L.A.J., Rosemeier,H.P., Potthoff,P., Behre,H.M., The menopause rating scale (MRS): Comparison with Kupperman index and quality-of-life scale SF-36, Climacteric, 3, 50-58, 2000	Not a classification system
Shea,J.L., Chinese women's symptoms: Relation to menopause, age and related attitudes, Climacteric, 9, 30-39, 2006	Evaluate symptoms, do not classify stages of the menopause

Study	Reason for exclusion
Shin,S.Y., Lee,J.R., Noh,G.W., Kim,H.J., Kang,W.J., Kim,S.H., Chung,J.K., Analysis of serum levels of anti-Mullerian hormone, inhibin B, insulin-like growth factor-I, insulin-like growth factor binding protein-3, and follicle-stimulating hormone with respect to age and menopausal status, Journal of Korean Medical Science, 23, 104-110, 2008	Do not classify stages of the menopause
Shiwaku,K., Yamane,Y., Sugimura,I., Hayashi,M., Nojiri,M., Matsushima,S., Koyama,W., Vasomotor and other menopausal symptoms influenced by menopausal stage and psychosocial factors in Japanese middle-aged women, Journal of Occupational Health, 43, 356-364, 2001	Evaluate symptoms, do not classify symptoms of the menopause
Sierra,B., Hidalgo,L.A., Chedraui,P.A., Measuring climacteric symptoms in an Ecuadorian population with the Greene Climacteric Scale, Maturitas, 51, 236-245, 2005	Evaluate association, do not classify stages of the menopause
Soules,M.R., Sherman,S., Parrott,E., Rebar,R., Santoro,N., Utian,W., Woods,N., Executive summary: Stages of Reproductive Aging Workshop (STRAW), Climacteric, 4, 267-272, 2001	Describe STRAW system
Soules,M.R., Sherman,S., Parrott,E., Rebar,R., Santoro,N., Utian,W., Woods,N., Executive summary: Stages of Reproductive Aging Workshop (STRAW) Park City, Utah, July, 2001, Menopause, 8, 402-407, 2001	Describe STRAW system, no relevant outcomes
Soules,M.R., Sherman,S., Parrott,E., Rebar,R., Santoro,N., Utian,W., Woods,N., Stages of Reproductive Aging Workshop (STRAW), Journal of women's health and gender-based medicine, 10, 843-848, 2001	Describe STRAW system, no protocol outcomes
Sun,N., Lin,S.Q., Lin,H.J., He,Z., Wang,Y.H., Zhang,Y., Chen,F.L., Jiang,Y., Comparison of follicle-stimulating hormone, estradiol, ovarian volume, and antral follicle count, based on the Stages of Reproductive Aging Workshop system, among community-based women in China, Menopause, 20, 736-741, 2013	Analyses hormone levels at different STRAW stages, no assessment of clinical relevance or diagnostic utility.
Taffe,J.R., Cain,K.C., Mitchell,E.S., Woods,N.F., Crawford,S.L., Harlow,S.D., "Persistence" improves the 60-day amenorrhea marker of entry to late-stage menopausal transition for women aged 40 to 44 years, Menopause, 17, 191-193, 2010	Do not classify stages of the menopause
Taylor,S.M., Kinney,A.M., Kline,J.K., Menopausal transition: predicting time to menopause for women 44 years or older from simple questions on menstrual variability, Menopause, 11, 40-48, 2004	Predict time to menopause, do not classify stages of the menopause
Travers,C., O'Neill,S.M., King,R., Battistutta,D., Khoo,S.K., Greene Climacteric Scale: norms in an Australian population in relation to age and menopausal status, Climacteric, 8, 56-62, 2005	Evaluate symptoms, do not classify stages of the menopause
Van Voorhis,B.J., Santoro,N., Harlow,S., Crawford,S.L., Randolph,J., The relationship of bleeding patterns to daily reproductive hormones in women approaching menopause, Obstetrics and Gynecology, 112, 101-108, 2008	Evaluate associations, do not classify stages of the menopause
Waidyasekera,H., Wijewardena,K., Lindmark,G., Naessen,T., Menopausal symptoms and quality of life during the menopausal transition in Sri Lankan women, Menopause, 16, 164-170, 2009	Evaluate symptoms and associations, do not classify stages of the menopause
Whitham,H.K., Macle hose,R.F., Harlow,B.L., Wellons,M.F., Schreiner,P.J., Assessing the utility of methods for menopausal transition classification in a population-based cohort: the CARDIA Study, Maturitas, 75, 289-293, 2013	Considers ability to predict menopause 5 years after classifying as perimenopausal.
Williams,R.E., Kalilani,L., DiBenedetti,D.B., Zhou,X., Granger,A.L., Fehnel,S.E., Levine,K.B., Jordan,J., Clark,R.V., Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States, Climacteric, 11, 32-43, 2008	Evaluate symptoms and associations, do not classify stages of the menopause
Woods,N.F., Mitchell,E.S., Staging reproductive aging: contemporary research applications of Staging Reproductive Aging Workshop and Staging Reproductive Aging Workshop + 10, Menopause, 20, 717-718, 2013	Editorial comment.
Woods,N.F., Smith-Dijulio,K., Percival,D.B., Tao,E.Y., Taylor,H.J., Mitchell,E.S., Symptoms during the menopausal transition and early postmenopause and their relation to endocrine levels over time: observations from the Seattle Midlife Women's Health Study.[Erratum appears in J Womens Health (Larchmt). 2007 Nov;16(9):1379], Journal of Women's Health, 16, 667-677, 2007	Evaluate associations, do not classify stages of the menopause

### G.3 Information and advice

Study	Reason for exclusion
Hormone replacement therapy: Patient education crucial, Drugs and Therapy Perspectives, 13, 9-11, 1999	Editorial article, not a study.
Patient information. Understanding menopause, Advance for Nurse Practitioners, 10, 58-, 2002	This is a fact sheet not a study
Abernethy,K., Practice nurse survey 2013 - A survey of smear-taking nurses in regard to menopause advice, Menopause International, 19, 110-111, 2013	Abstract
Abernethy,K., The menopause: preparing women for what to expect, Professional Care of Mother and Child, 8, 67-70, 1998	This is an information leaflet, not a study.
Appling,S.E., Allen,J.K., Van,Zandt S., Olsen,S., Brager,R., Hallerdin,J., Knowledge of menopause and hormone replacement therapy use in low-income urban women, Journal of Womens Health and Gender-Based Medicine, 9, 57-64, 2000	Outcome is demographic variance of women with and without knowledge.

Study	Reason for exclusion
Ayres,J., Bridgeman,L., James,S., Leaney,A., Ann,L.S., The development and implementation of patient advice literature for patients attending the menopause clinics at St James' University Hospital, Leeds, Menopause International, 19, 111-, 2013	Abstract
Babio,G.O., Marquez-Calderon,S., Garca-Gutierrez,J.F., Bermudez-Tamayo,C., Plazaola-Castano,J., Ruiz-Perez,I., Women's autonomy and the evaluation of the information available on the Internet on hormone therapy after menopause, CIN: Computers, Informatics, Nursing, 24, 226-234, 2006	This is an evaluation of websites, not women's opinions.
Balabanovic,J., Ayers,B., Hunter,M.S., Women's experiences of Group Cognitive Behaviour Therapy for hot flushes and night sweats following breast cancer treatment: an interpretative phenomenological analysis, Maturitas, 72, 236-242, 2012	Not an information-provision intervention. CBT not specific to menopause.
Barriga,J., Castelo-Branco,C., Chedraui,P., Hidalgo,L., Veas,P., Educational and organizational interventions used to improve the knowledge of metabolic syndrome among postmenopausal women, Fertility and Sterility, 90, 444-446, 2008	This is too specific to metabolic syndrome sufferers.
Bastian,L.A., McBride,C.M., Fish,L., Lyna,P., Farrell,D., Lipkus,I.M., Rimer,B.K., Siegler,I.C., Evaluating participants' use of a hormone replacement therapy decision-making intervention, Patient Education and Counseling, 48, 283-291, 2002	Decisional conflict Results compare 'optimal users' with 'sub-optimal users'.
Bertero,C., What do women think about menopause? A qualitative study of women's expectations, apprehensions and knowledge about the climacteric period, International Nursing Review, 50, 109-118, 2003	This assessed women's knowledge, but not where they got the knowledge from.
Bhavnani,V., Clarke,A., Women awaiting hysterectomy: a qualitative study of issues involved in decisions about oophorectomy, BJOG: An International Journal of Obstetrics and Gynaecology, 110, 168-174, 2003	Although this was airogenic menopause, it didn't cover information sources.
Blettner,M., Hadji,P., Harbeck,N., Jackisch,C., Luck,H.J., Zaun,S., Windemuth-Kieselbach,C., Haidinger,R., Rexrodt,VonFircksA., Kreienberg,R., Final results from PACT (Patient's Anastrozole Compliance to Therapy Programme), a non-interventional study evaluating the influence of a standardized information service on compliance in postmenopausal women with early breast cancer, Journal of Cancer Research and Clinical Oncology, 138, 64-, 2012	Abstract only
Buchanan,M.C., Villagran,M.M., Ragan,S.L., Women, menopause, and (Ms.)information: communication about the climacteric, Health Communication, 14, 99-119, 2002	Not a study. Check references to other studies though
Burki,R., Climacteric commentaries. Where do women get their information about hormone therapy--and whom do/should they trust?, Climacteric, 15, 202-203, 2012	Abstract only
Carmody,J.F., Crawford,S., Salmoirago-Blotcher,E., Leung,K., Churchill,L., Olendzki,N., Mindfulness training for coping with hot flashes: Results of a randomized trial, Menopause, 18, 611-620, 2011	Classes did not include menopause education
Carpenter,J.S., Studts,J.L., Byrne,M.M., A systematic review of menopausal symptom management decision aid trials, Maturitas, 69, 11-21, 2011	Literature search
Centre for Reviews and Dissemination., Health and patient practitioner interactions: a systematic review (Structured abstract), Database of Abstracts of Reviews of Effects, -, 2014	This does not include any details of women's views.
Charbonneau,D.H., An analysis of benefits and risk information on pharmaceutical web sites for the treatment of menopause, Health Information and Libraries Journal, 30, 212-219, 2013	This is a literature review of information-websites.
Chioti,A., Neven,P., Markopoulos,C.I., Tanner,M., Kreienberg,R., Atkins,L., Marty,M., The cariatide study: Evaluation of the impact of educational material on the compliance and persistence rates to adjuvant aromatase inhibitor medication in postmenopausal breast cancer patients, European Journal of Cancer, Supplement, 7, 300-, 2009	Abstract only
Christofi,N., Hextall,A., An evidence-based approach to lifestyle interventions in urogynaecology. [46 refs], Menopause International, 13, 154-158, 2007	Not a study
Clark,H.D., O'Connor,A.M., Graham,I.D., Wells,G.A., What factors are associated with a woman's decision to take hormone replacement therapy? Evaluated in the context of a decision aid, Health Expectations, 6, 110-117, 2003	Outcome is HRT uptake.
Cobb,J.O., Reassuring the woman facing menopause: strategies and resources. [29 refs], Patient Education and Counseling, 33, 281-288, 1998	Not a study
Cohen,D., Longo,M.F., Hood,K., Edwards,A., Elwyn,G., Resource effects of training general practitioners in risk communication skills and shared decision making competences, Journal of Evaluation in Clinical Practice, 10, 439-445, 2004	Outcome is referrals.
Cohn,J.K., HRT: A difficult choice for post- menopausal women, Cardiology Review, 18, 34-37, 2001	This is an editorial article
Col,N.F., Using Internet technologies to improve and simplify counseling about menopause: the WISDOM website, Maturitas, 57, 95-99, 2007	This paper does not contain the details or data from the RCT it refers to.
Col,N.F., Ngo,L., Fortin,J.M., Goldberg,R.J., O'Connor,A.M., Can computerized decision support help patients make complex treatment decisions? A randomized controlled trial of an individualized menopause decision aid, Medical Decision Making, 27, 585-598, 2007	No views on mode or content of information reported.
Connelly,M.T., Rusinak,D., Livingston,W., Raeke,L., Inui,T.S., Patient knowledge about hormone replacement therapy: implications for treatment, Menopause, 7, 266-272, 2000	Wrong outcome

Study	Reason for exclusion
Coope,J., Marsh,J., Can we improve compliance with long-term HRT?, <i>Maturitas</i> , 15, 151-158, 1992	Does not include women's views
Coulter,A., Patient-centered decision making: Empowering women to make informed choices, <i>Women's Health Issues</i> , 11, 325-330, 2001	Not from women's perspective.
Crowe,M., Burrell,B., Whitehead,L., Lifestyle risk management--a qualitative analysis of women's descriptions of taking hormone therapy following surgically induced menopause, <i>Journal of Advanced Nursing</i> , 68, 1814-1823, 2012	Wrong outcome
Cumming,G.P., Currie,H., The internet and the menopause consultation: Menopause management in the third millennium, <i>Journal of the British Menopause Society</i> , 11, 103-108, 2005	Not a study
Cumming,G.P., Currie,H.D., Panay,N., Moncur,R., Lee,A.J., Stopping hormone replacement therapy: were women ill advised?, <i>Menopause International</i> , 17, 82-87, 2011	No usefulness data
Cumming,G.P., Herald,J., Moncur,R., Currie,H., Lee,A.J., Women's attitudes to hormone replacement therapy, alternative therapy and sexual health: a web-based survey, <i>Menopause International</i> , 13, 79-83, 2007	No usefulness data
Daghio,M.M., Ciardullo,A.V., Fattori,G., Borsari,S., Ferrante,M., Lupo,S., Picco,P., Vezzani,M.D., Masellis,G., Evaluation of a health literacy intervention: Readability and understanding of an information tool on menopause written with the help of women, <i>Gazzetta Medica Italiana Archivio per le Scienze Mediche</i> , 164, 59-63, 2005	The outcome is not necessarily useful for life-quality.
Dancer,T.W., Cummins,D., Approaches to estrogen replacement therapy: Therapeutic options for the menopausal woman, <i>Drug Topics</i> , 142, 102-111, 1998	An information sheet, not a study.
Daoust,J.L., Mercer,L.C., Duncan,A.M., Prevalence of natural health product use in healthy postmenopausal women, <i>Menopause</i> , 13, 241-250, 2006	Information given applied to natural health products only
Daugherty,J.E., Treatment strategies for premenstrual syndrome. [47 refs], <i>American Family Physician</i> , 58, 183-192, 1998	Paper requested in error (premenstrual symptoms)
David,M., Borde,T., Kentenich,H., Knowledge among German and Turkish women about specifically female bodily functions, contraception, preventative medical examinations and menopause, <i>Ethnicity and Health</i> , 5, 101-112, 2000	Does not report information sources.
David,P., Buckworth,J., Pennell,M.L., Katz,M.L., DeGraffinreid,C.R., Paskett,E.D., A walking intervention for postmenopausal women using mobile phones and Interactive Voice Response, <i>Journal of Telemedicine and Telecare</i> , 18, 20-25, 2012	No information on menopausal symptoms imparted to women
Davies,P.H., Barnett,A.H., Hormone replacement therapy in women with diabetes mellitus: A survey of knowledge of risks and benefits, <i>Practical Diabetes International</i> , 15, 78-81, 1998	No outcomes for individual sources of information.
Dayspring,T., Pokrywka,G., Pharmacotherapeutic decisions in menopausal women with cardiovascular risk, <i>Future Lipidology</i> , 2, 197-210, 2007	This paper does not discuss advice that led to women's decisions.
Deeks,A., Zoungas,S., Teede,H., Risk perception in women: a focus on menopause, <i>Menopause</i> , 15, 304-309, 2008	No information intervention
Deeks,A.A., Psychological aspects of menopause management, <i>Bailliere's Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 17, 17-31, 2003	Does not include information-related research
Deeks,A.A., Gibson-Helm,M., Teede,H., Vincent,A., Premature menopause: a comprehensive understanding of psychosocial aspects, <i>Climacteric</i> , 14, 565-572, 2011	Reasons for preferences or quality of life outcomes not reported.
DiSaia,P.J., Brewster,W.R., Hormone replacement therapy for survivors of breast and endometrial cancer. [37 refs], <i>Current Oncology Reports</i> , 4, 152-158, 2002	Not a study
Donati,S., Cotichini,R., Mosconi,P., Satolli,R., Colombo,C., Liberati,A., Mele,E.A., Menopause: knowledge, attitude and practice among Italian women, <i>Maturitas</i> , 63, 246-252, 2009	The outcome is uptake of HRT rather than quality of life or usefulness of information.
Donati,S., Satolli,R., Colombo,C., Senatore,S., Cotichini,R., Da,Cas R., Spila,Alegiani S., Mosconi,P., Informing women on menopause and hormone therapy: Know The Menopause a multidisciplinary project involving local healthcare system, <i>PLoS ONE [Electronic Resource]</i> , 8, e85121-, 2013	Usefulness of information not reported
Doren,M., Urogenital aging - Creation of improved awareness, <i>American Journal of Obstetrics and Gynecology</i> , 178, S254-S256, 1998	This is an editorial article rather than a study.
Dormire,S., Becker,H., Menopause health decision support for women with physical disabilities. [44 refs], <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 36, 97-104, 2007	Not a study
Drennan,V., McGeeney,S., Menopausal support, <i>Nursing Mirror</i> , 160, 27-28, 1985	Wrong outcome
Drew,S.V., Rowe,R., Panay,N., Studd,J.W., A general practice pilot audit study to assess advice and treatment offered to women following hysterectomy, <i>Climacteric</i> , 2, 212-217, 1999	The outcome is uptake of HRT, with no measurements of women's quality of life or information choices.
Dumbrell Laundry,M.J., A positive approach to menopause, <i>Canadian Nurse</i> , 91, 47-48, 1995	This is an editorial article, not a study.
Edwards,A., Elwyn,G., Hood,K., Atwell,C., Robling,M., Houston,H., Kinnersley,P., Russell,I., Patient-based outcome results from a cluster randomized trial of shared decision making skill development and use of risk communication aids in general practice, <i>Family Practice</i> , 21, 347-354, 2004	Wrong outcomes
Elwyn,G., Edwards,A., Hood,K., Robling,M., Atwell,C., Russell,I., Wensing,M., Grol,R., Study Steering Group., Achieving involvement: process outcomes from a cluster randomized trial of shared decision making skill development and use of risk communication aids in general practice, <i>Family Practice</i> , 21, 337-346, 2004	Includes prostatism

Study	Reason for exclusion
Esposito,Sorpreso,I, Laprano Vieira,L.H., Longoni,Calio C., Abi,Haidar M., Baracat,E.C., Soares,J.M.,Jr., Health education intervention in early and late postmenopausal Brazilian women, <i>Climacteric</i> , 15, 573-580, 2012	Outcomes do not include women's evaluation of the information or quality of life outcomes.
Ettinger,B., Grady,D., Tosteson,A.N., Pressman,A., Macer,J.L., Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy, <i>Obstetrics and Gynecology</i> , 102, 1225-1232, 2003	Outcome is HRT decision
Ettinger,B., Woods,N.F., Barrett-Connor,E., Pressman,A., The North American Menopause Society 1998 menopause survey: Part II. Counseling about hormone replacement therapy: Association with socioeconomic status and access to medical care, <i>Menopause</i> , 7, 143-148, 2000	Information-intervention not consistent or described in paper.
Fallowfield,L., Fleissig,A., Barrett,J., Menon,U., Jacobs,I., Kilkerr,J., Farewell,V., UKTOCS,Trialists, Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey of 21,715 women participating in the UK Collaborative Trial of Ovarian Cancer Screening, <i>British Journal of Cancer</i> , 103, 454-461, 2010	Wrong population: cancer
Fistonic,I., Srecko,C., Marina,F., Ivan,S., Menopause in Croatia. Socio-demographic characteristics, women's attitudes and source of information, compliance with HRT, <i>Maturitas</i> , 47, 91-98, 2004	No reporting of information content of counselling.
Fox-Young,S., Sheehan,M., O'Connor,V., Cragg,C., Del,Mar C., Women's knowledge about the physical and emotional changes associated with menopause, <i>Women and Health</i> , 29, 37-51, 1999	There are no advice-sources in the outcomes.
Franic,D., Verdenik,I., Meden-Vrtovec,H., Effect of counseling on adherence to perimenopausal hormone therapy in Slovenia, <i>International Journal of Gynaecology and Obstetrics</i> , 111, 260-263, 2010	The outcome was adherence to HRT
Franic,D., Verdenik,I., Meden-Vrtovec,H., Svab,I., Continuation of hormone replacement therapy in Slovenia: a prospective, randomized, controlled trial--1-year follow-up, <i>Maturitas</i> , 54, 110-118, 2006	Continuation of HRT is the only outcome.
Gallagher,T.C., Geling,O., FitzGibbons,J., Aforismo,J., Comite,F., Are women being counseled about estrogen replacement therapy?, <i>Medical Care Research and Review</i> , 57 Suppl 2, 72-92, 2000	No reporting of which aspects of advice were helpful.
Gallant,N.R., Corbin,M., Bencivenga,M.M., Farnan,M., Wiker,N., Bressler,A., Camacho,F., Lengerich,E.J., Adaptation of an evidence-based intervention for Appalachian women: new STEPS (Strength Through Education, Physical fitness and Support) for breast health, <i>Journal of Cancer Education</i> , 28, 275-281, 2013	Not a study
Ganesan,K., Teklehaimanot,S., Norris,K., Estrogen replacement therapy use in minority postmenopausal women, <i>Ethnicity and Disease</i> , 10, 257-261, 2000	No data on advice or info
Gannon,L., Stevens,J., Portraits of menopause in the mass media, <i>Women and Health</i> , 27, 1-15, 1998	This is a frequency analysis of mass media. Not women's views.
Garcia,C.L., Gomez-Calcerrada,S.G., Cognitive-behavioral intervention among women with slight menopausal symptoms: A pilot study, <i>Spanish Journal of Psychology</i> , 14, 344-355, 2011	Ambiguous as intervention is half information and half CBT
Gardiner,P., Stargrove,M.B., Low,DogT, Concomitant use of prescription medications and dietary supplements in menopausal women: An approach to provider preparedness, <i>Maturitas</i> , 68, 251-255, 2011	Not a study
Giguere,Anik, Legare,France, Grimshaw,Jeremy, Turcotte,Stephane, Fiander,Michelle, Grudniewicz,Agnes, MakossoKallyth,Sun, Wolf,Fredric M., Farmer,Anna P., Gagnon,MariePierre, Printed educational materials: effects on professional practice and healthcare outcomes, <i>Cochrane Database of Systematic Reviews</i> , -, 2013	Wrong population: Physicians were researched, not women.
Grady,D., Cummings,S.R., Petitti,D., Rubin,S.M., Audet,A.M., Gold,P.M., Huth,E.J., Mazzaferri,E.L., Mulley,Jr, Thibault,G.E., Cleaveland,C.R., Cassel,C.K., Gullen,D.J., Sox,Jr, Young,Q.D., Berenson,R.A., Eisenberg,J.M., Myers,Jr, Guidelines for counseling postmenopausal women about preventive hormone therapy, <i>Annals of Internal Medicine</i> , 117, 1038-1041, 1992	Not a study
Graziottin,A., Strategies for effectively addressing women's concerns about the menopause and HRT, <i>Maturitas</i> , 33 Suppl 1, S15-S23, 1999	Not a study
Grisso,J.A., Freeman,E.W., Maurin,E., Garcia-Espana,B., Berlin,J.A., Racial differences in menopause information and the experience of hot flashes, <i>Journal of General Internal Medicine</i> , 14, 98-103, 1999	No detail of what advice from doctors was.
Guilera,M., Fuentes,M., Grifols,M., Ferrer,J., Badia,X., OPTIMA,study investigators, Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study, <i>Osteoporosis International</i> , 17, 664-671, 2006	Osteoporosis specific
Hampson,S.E., Hibbard,J.H., Cross-talk about the menopause: enhancing provider-patient interactions about the menopause and hormone therapy. [44 refs], <i>Patient Education and Counseling</i> , 27, 177-184, 1996	This is a text book review
Harrison,T., Becker,H., A qualitative study of menopause among women with disabilities, <i>Advances in Nursing Science</i> , 30, 123-138, 2007	The outcomes and intervention do not fit our criteria.
Hee,P., Compliance to estrogen treatment one to three years after hysterectomy and bilateral salpingoophorectomy. The cohort's lifestyle, knowledge of ERT, benefits etc, <i>Acta Obstetrica et Gynecologica Scandinavica</i> , 78, 534-539, 1999	Wrong outcome: compliance
Hertz,R., Evaluation of current information concerning the relationship between hormonal usage and cancer, <i>Clinical Obstetrics and Gynecology</i> , 20, 165-175, 1977	The population is not women.

Study	Reason for exclusion
Hill-Sakurai,L.E., Muller,J., Thom,D.H., Complementary and alternative medicine for menopause: a qualitative analysis of women's decision making, <i>Journal of General Internal Medicine</i> , 23, 619-622, 2008	Does not address the outcome
Holmes-Rovner,M., Kroll,J., Rovner,D.R., Schmitt,N., Rothert,M., Padonu,G., Talarczyk,G., Patient decision support intervention: increased consistency with decision analytic models, <i>Medical Care</i> , 37, 270-284, 1999	Outcome was likelihood of treatment which is not the right outcome.
Hunnskaar,S., Backe,B., Attitudes towards and level of information on perimenopausal and postmenopausal hormone replacement therapy among Norwegian women, <i>Maturitas</i> , 15, 183-194, 1992	Outcome is knowledge of menopause - not usefulness.
Hunter,M., O'Dea,I., An evaluation of a health education intervention for mid-aged women: five year follow-up of effects upon knowledge, impact of menopause and health, <i>Patient Education and Counseling</i> , 38, 249-255, 1999	Not a RCT
Huston,S.A., Bagozzi,R.P., Kirking,D.M., Decision-making about the use of hormone therapy among perimenopausal women, <i>British Journal of Health Psychology</i> , 15, 231-251, 2010	This is a study of the relationship between intention and action.
Huston,S.A., Jackowski,R.M., Kirking,D.M., Women's trust in and use of information sources in the treatment of menopausal symptoms, <i>Women's Health Issues</i> , 19, 144-153, 2009	Outcomes look at trustworthiness of healthcare professionals, rather than usefulness of information.
Johnson,S.R., The clinical decision regarding hormone replacement therapy, <i>Endocrinology and Metabolism Clinics of North America</i> , 26, 413-435, 1997	Not a study
Jones,J.B., Hormone replacement therapy: women's decision-making process, <i>Social Work in Health Care</i> , 28, 95-111, 1999	There is not enough data on the role of information in decision making.
Karimi,L., Afshari,P., Sadeghi,S., Women's knowledge towards hormone replacement therapy, <i>Maturitas</i> , 63, S75-, 2009	Abstract
Kolip,P., Hoefling-Engels,N., Schmacke,N., Attitudes toward postmenopausal long-term hormone therapy, <i>Qualitative Health Research</i> , 19, 207-215, 2009	Not enough data on specific advice.
Kuller,L.H., Kriska,A.M., Kinzel,L.S., Simkin-Silverman,L.R., Sutton-Tyrrell,K., Johnson,B.D., Conroy,M.B., The clinical trial of Women On the Move through Activity and Nutrition (WOMAN) study, <i>Contemporary Clinical Trials</i> , 28, 370-381, 2007	This is an exercise intervention
La,ValleurJ, Counseling the perimenopausal woman, <i>Obstetrics and Gynecology Clinics of North America</i> , 29, 541-553, 2002	Not a study
LaRocco,S.A., Polit,D.F., Women's knowledge about the menopause, <i>Nursing Research</i> , 29, 10-13, 1980	Information and advice is not discussed in this paper.
Liao,K., Hunter,M.S., White,P., Beliefs about menopause of general practitioners and mid-aged women, <i>Family Practice</i> , 11, 408-412, 1994	The outcome is knowledge without reference to health.
Liaw,T., Lawrence,M., Rendell,J., The effect of a computer-generated patient-held medical record summary and/or a written personal health record on patients' attitudes, knowledge and behaviour concerning health promotion, <i>Family Practice</i> , 13, 289-293, 1996	This is about patient access to their records rather than interventions.
Liu,J., Eden,J., Experience and attitudes toward menopause in Chinese women living in Sydney--a cross sectional survey, <i>Maturitas</i> , 58, 359-365, 2007	No data on information sources and content
Mansfield,P.K., Voda,A.M., Woman-centered information on menopause for health care providers: findings from the Midlife Women's Health Survey. [47 refs], <i>Health Care for Women International</i> , 18, 55-72, 1997	Not a study
Matloff,E.T., Moyer,A., Shannon,K.M., Niendorf,K.B., Col,N.F., Healthy women with a family history of breast cancer: impact of a tailored genetic counseling intervention on risk perception, knowledge, and menopausal therapy decision making, <i>Journal of Women's Health</i> , 15, 843-856, 2006	No reporting of information content
Mayer,D.K., Linscott,E., Information for women: management of menopausal symptoms, <i>Oncology Nursing Forum</i> , 22, 1567-1570, 1995	Not a study
McVeigh,C., Menopause and healthy aging: a pilot project, <i>Australian and New Zealand Journal of Public Health</i> , 20, 95-96, 1996	Results are too restricted and too general to be of use.
Molenaar,S., Interpretive Review: Feasibility and effects of decision aids, <i>Medical Decision Making</i> , 20, 112-127, 2000	Not a study
Murtagh,M.J., Hepworth,J., Menopause as a long-term risk to health: implications of general practitioner accounts of prevention for women's choice and decision-making, <i>Sociology of Health and Illness</i> , 25, 185-207, 2003	Wrong outcome
O'Connor,A.M., Tugwell,P., Wells,G.A., Elmslie,T., Jolly,E., Hollingworth,G., McPherson,R., Drake,E., Hopman,W., Mackenzie,T., Randomized trial of a portable, self-administered decision aid for postmenopausal women considering long-term preventive hormone therapy, <i>Medical Decision Making</i> , 18, 295-303, 1998	Outcome is HRT choice rather than usefulness or quality of life.
Okumus,M., Ceceli,E., Tasbas,O., Kocaoglu,S., Akdogan,S., Borman,P., Educational status and knowledge level of pre- and postmenopausal women about osteoporosis and risk factors: a cross-sectional study in a group of Turkish female subjects, <i>Journal of Back and Musculoskeletal Rehabilitation</i> , 26, 337-343, 2013	Too specific to osteoporosis.
Palacios,S., Sanchez-Borrego,R., Neyro,J.L., Quereda,F., Vazquez,F., Perez,M., Perez,M., Knowledge and compliance from patients with postmenopausal osteoporosis treatment, <i>Menopause International</i> , 15, 113-119, 2009	Osteoporosis only
Perez-Lopez,F.R., An evaluation of the contents and quality of menopause information on the World Wide Web, <i>Maturitas</i> , 49, 276-282, 2004	Website evaluation without consultation with women.

Study	Reason for exclusion
Perez-Lopez,F.R., Perez Roncero,G.R., Assessing the content and quality of information on the treatment of postmenopausal osteoporosis on the World Wide Web, <i>Gynecological Endocrinology</i> , 22, 669-675, 2006	Does not include women's assessments of information-quality on websites.
Polonijo,Andrea N., Carpiano,Richard M., "Women's trust in and use of information sources in the treatment of menopausal symptoms": Erratum, <i>Women's Health Issues</i> , 19, 157-158, 2009	This is an Erratum only
Rabin,D.S., Cipparrone,N., Linn,E.S., Moen,M., Why menopausal women do not want to take hormone replacement therapy, <i>Menopause</i> , 6, 61-67, 1999	No detail of what info was useful
Reed,M., Anderson,C., Evaluation of patient information Internet web sites about menopause and hormone replacement therapy, <i>Maturitas</i> , 43, 135-154, 2002	Literature review of websites with no women reviewers.
Roberge,N.J., Osteoporosis education strategies, <i>Orthopaedic Physical Therapy Clinics of North America</i> , 7, 251-292, 1998	Too specific to osteoporosis
Rolnick,S.J., Kopher,R., Jackson,J., Fischer,L.R., Compo,R., What is the impact of osteoporosis education and bone mineral density testing for postmenopausal women in a managed care setting?, <i>Menopause</i> , 8, 141-148, 2001	This is osteoporosis-specific
Rotem,M., Kushnir,T., Levine,R., Ehrenfeld,M., A psycho-educational program for improving women's attitudes and coping with menopause symptoms, <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 34, 233-240, 2005	No outcomes for how programme influenced women's knowledge or decisional conflict.
Rotherth,M., Padonu,G., Holmes-Rovner,M., Kroll,J., Talarczyk,G., Rovner,D., Schmitt,N., Breer,L., Menopausal women as decision makers in health care, <i>Experimental Gerontology</i> , 29, 463-468, 1994	Not a study
Rotherth,M., Rovner,D., Holmes,M., Schmitt,N., Talarczyk,G., Kroll,J., Gogate,J., Women's use of information regarding hormone replacement therapy, <i>Research in Nursing and Health</i> , 13, 355-366, 1990	The outcomes of this study are reasons for decisions.
Ruggiero,R.J., Patient communication and counseling on contraception and hormone replacement therapy, <i>American Journal of Managed Care</i> , 7, S580-S585, 2001	The population was doctors, not women.
Sahin,N.H., Bal,M.D., Boga,N.M., Gokdemirel,S., Taspinar,A., Women's perception of the menopause and hormone treatment: barriers against hormone therapy, <i>Climacteric</i> , 14, 152-156, 2011	Quality of advice is not reported
Saw,S.M., Hong,C.Y., Lee,J., Wong,M.L., Chan,M.F., Cheng,A., Leong,K.H., Awareness and health beliefs of women towards osteoporosis, <i>Osteoporosis International</i> , 14, 595-601, 2003	Only looks at osteoporosis
Schonberg,M.A., Wee,C.C., Menopausal symptom management and prevention counseling after the Women's Health Initiative among women seen in an internal medicine practice, <i>Journal of Women's Health</i> , 14, 507-514, 2005	No data on what was useful
Schousboe,J.T., DeBold,R.C., Kuno,L.S., Weiss,T.W., Chen,Y.T., Abbott,I.I.I.T., Education and phone follow-up in postmenopausal women at risk for osteoporosis: Effects on calcium intake, exercise frequency, and medication use, <i>Disease Management and Health Outcomes</i> , 13, 395-404, 2005	This is too specific to osteoporosis as an outcome.
Schulman,J.E., Williams,S., Khera,O., Sahba,T., Michelson,J., Fine,K., Effective osteoporosis education in the outpatient orthopaedic setting, <i>Journal of Bone and Joint Surgery - American Volume</i> , 89, 301-306, 2007	This is an osteoporosis population
Senba,N., Matsuo,H., Effect of a health education program on climacteric women, <i>Climacteric</i> , 13, 561-569, 2010	Health information provision of intervention not specific enough to menopause. Intervention is recorded as general health management skills such as relaxation etc.
Sethi,K., Pitkin,J., British-Asian women's views on and attitudes towards menopause and hormone replacement therapy, <i>Climacteric</i> , 3, 248-253, 2000	Not enough reporting of specific advice-needs.
Silverman,S.L., Greenwald,M., Klein,R.A., Drinkwater,B.L., Effect of bone density information on decisions about hormone replacement therapy: A randomized trial, <i>Obstetrics and Gynecology</i> , 89, 321-325, 1997	The data is confusing because information-giving is combined with bone-density testing.
Smith,P.E., Menopause assessment, treatment, and patient education, <i>The Nurse practitioner</i> , 30, 32-43, 2005	This is an information pamphlet, not a study.
Stephens,C., Budge,R.C., Carryer,J., What is this thing called hormone replacement therapy? Discursive construction of medication in situated practice, <i>Qualitative Health Research</i> , 12, 347-359, 2002	No outcomes on knowledge sources
Stirtzinger,R., Robinson,G.E., Crawford,B., Educational Approach to Menopausal Distress: Pilot study of patient workshops, <i>Canadian Family Physician</i> , 38, 285-291, 1992	This does not refer to specific information needs.
Sturdee,D.W., The importance of patient education in improving compliance. [33 refs], <i>Climacteric</i> , 3 Suppl 2, 9-13, 2000	Does not quite fir the criteria of the review.
Swiers,D., Women's knowledge of HRT and the prevention of osteoporosis, <i>Nursing standard (Royal College of Nursing (Great Britain) : ; 1987)</i> , 10, 35-37, 1996	Not enough information about trial.
Tao,M., Teng,Y., Shao,H., Wu,P., Mills,E.J., Knowledge, perceptions and information about hormone therapy (HT) among menopausal women: a systematic review and meta-synthesis, <i>PLoS ONE [Electronic Resource]</i> , 6, e24661-, 2011	5 studies in this meta-analysis have been weeded out. 1 has been requested. 2 are not on STAR, but do not look relevant enough to request.
Tao,M., Teng,Y., Shao,H., Wu,P., Mills,E.J., Knowledge, perceptions and information about hormone therapy (HT) among menopausal women: a systematic review and meta-synthesis, <i>PLoS ONE</i> , 6, 1-10, 2011	Individual studies which have the right outcome are being individually reviewed.

Study	Reason for exclusion
Thomas,L.G., Corwin,E.J., The readability of printed education materials regarding hormone replacement therapy, <i>Journal of the American Academy of Nurse Practitioners</i> , 10, 447-452, 1998	Women's opinions have not been incorporated into this study.
Toiviainen,H., Hemminki,E., Finnish physicians' attitudes towards preconsultation information: Menopausal treatment practices as an example, <i>Patient Education and Counseling</i> , 35, 101-109, 1998	No women's views included.
Trudeau,K.J., Ainscough,J.L., Trant,M., Starker,J., Cousineau,T.M., Identifying the educational needs of menopausal women: a feasibility study, <i>Womens Health Issues</i> , 21, 145-152, 2011	Results of the focus group are not appropriately reported.
Tsao,L.I., Huang,K.E., Effectiveness of a perimenopausal health education intervention for mid-life women in northern Taiwan (#MS03-21-LW), <i>Patient Education and Counseling</i> , 54, 321-328, 2004	2 reasons for exclusion: The intervention was peri-menopause information ONLY, and women were not RELIABLY reported as menopausal/pre-menopausal.
US Congress, Office of Technology Assessment., Public information about osteoporosis: what's available, what's needed?, Background Paper, OTA-BP-H-131, -, 1994	Specifically osteoporosis.
Yazdkhasti,M., Keshavarz,M., Khoei,E.M., Hosseini,A., Esmailzadeh,S., Pebdani,M.A., Jafarzadeh,H., The Effect of Support Group Method on Quality of Life in Post-menopausal Women, <i>Iranian Journal of Public Health</i> , 41, 78-84, 2012	Study not culturally transferable due to deprivation of geographical area (semi-rural Iranian).
Yazdkhasti,M., Keshavarz,M., Mahmoodi,Z., Hosseini,A.F., Self-directed Learning and Its Impact on Menopausal Symptoms, <i>Iranian Red Crescent Medical Journal</i> , 16, e13259-, 2014	Study not culturally transferable due to deprivation of geographical area (semi-rural Iranian).

## G.4 Managing short-term symptoms

Study	Reason for exclusion
Megestrol prevents hot flashes, <i>Hospital Practice</i> , 29, 22-, 1994	Commentary
Clonidine, gabapentin, and some SSRIs effective for hot flashes, <i>Journal of Family Practice</i> , 55, 662-, 2006	Not a study
Clonidine in treatment of menopausal flushing, <i>Acta Obstetrica et Gynecologica Scandinavica - Supplement</i> , 132, 1-35, 1985	This is not a study (an article only)
A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group, <i>International Journal of Fertility and Menopausal Studies</i> , 38, 5-11, 1993	Comparison of 2 makes of patch (not relevant to protocol).
Conjugated equine estradiol and 17beta-estradiol effectively relieve hot flashes in menopausal women, <i>Evidence-Based Healthcare and Public Health</i> , 8, 310-311, 2004	Abstract only
High-dose gabapentin = estrogen for hot flashes, <i>Journal of Family Practice</i> , 55, 846-, 2006	Summary of a randomised controlled trial
Abdali,K., Khajehei,M., Tabatabaee,H.R., Effect of St John's wort on severity, frequency, and duration of hot flashes in premenopausal, perimenopausal and postmenopausal women: a randomized, double-blind, placebo-controlled study, <i>Menopause</i> , 17, 326-331, 2010	Subjects include premenopausal women and no subgroup analysis done
Adamson,D.L., Webb,C.M., Collins,P., Esterified estrogens combined with methyltestosterone improve emotional well-being in postmenopausal women with chest pain and normal coronary angiograms, <i>Menopause</i> , 8, 233-238, 2001	Interventions not of interest
Aedo,S., Cavada,G., Campodonico,I., Porcile,A., Irribarra,C., Sertraline improves the somatic and psychological symptoms of the climacteric syndrome, <i>Climacteric</i> , 14, 590-595, 2011	Results not calculable due to composite score scales
Agosta,C., Atlante,M., Benvenuti,C., Randomized controlled study on clinical efficacy of isoflavones plus <i>Lactobacillus sporogenes</i> , associated or not with a natural anxiolytic agent in menopause, <i>Minerva Ginecologica</i> , 63, 11-17, 2011	Study reports on reduction in severity of flushes not frequency
Aiello,E.J., Yasui,Y., Tworoger,S.S., Ulrich,C.M., Irwin,M.L., Bowen,D., Schwartz,R.S., Kumai,C., Potter,J.D., McTiernan,A., Effect of a yearlong, moderate-intensity exercise intervention on the occurrence and severity of menopause symptoms in postmenopausal women, <i>Menopause</i> , 11, 382-388, 2004	Wrong type of results-reporting
Akhila,V., Pratakumar., A comparison of transdermal and oral HRT for menopausal symptom control, <i>International Journal of Fertility and Womens Medicine</i> , 51, 64-69, 2006	Study does not examine frequency of vasomotor symptoms but symptomatic improvement (complete/partial and no improvement in a particular symptom)
Al-Azzawi,F., Buckler,H.M., United Kingdom Vaginal Ring Investigator Group., Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms, <i>Climacteric</i> , 6, 118-127, 2003	Combination therapy (placebo oestrogen) is not of interest
Al-Azzawi,F., Lees,B., Thompson,J., Stevenson,J.C., Bone mineral density in postmenopausal women treated with a vaginal ring delivering systemic doses of estradiol acetate, <i>Menopause</i> , 12, 331-339, 2005	Wrong outcome
Al-Azzawi,F., Wahab,M., Thompson,J., Pornel,B., Hirvonen,E., Ylikorkala,O., van der Mooren,M.J., Dillon,J., Magaril,C., Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical	Wrong outcome



Study	Reason for exclusion
sequential combinations of trimegestone or norethisterone acetate, <i>Climacteric</i> , 4, 343-354, 2001	
Albertazzi,P., Natale,V., Barbolini,C., Teglio,L., Di,Micco R., The effect of tibolone versus continuous combined norethisterone acetate and oestradiol on memory, libido and mood of postmenopausal women: a pilot study, <i>Maturitas</i> , 36, 223-229, 2000	PICO not met - Outcomes of interest not reported
Albertazzi,P., Pansini,F., Bottazzi,M., Bonaccorsi,G., de,Aloysio D., Morton,M.S., Dietary soy supplementation and phytoestrogen levels, <i>Obstetrics and Gynecology</i> , 94, 229-231, 1999	Secondary publication of 255376
Albertazzi,P., Steel,S.A., Bottazzi,M., Effect of pure genistein on bone markers and hot flushes, <i>Climacteric</i> , 8, 371-379, 2005	Frequency of VMS not reported.
Alcoff,J.M., Campbell,D., Tribble,D., Oldfield,B., Cruess,D., Double-blind, placebo-controlled, crossover trial of propranolol as treatment for menopausal vasomotor symptoms, <i>Clinical Therapeutics</i> , 3, 356-364, 1981	PICO not met - Intervention (Propranolol) not of interest
Alder,J., Eymann,Besken K., Armbruster,U., Decio,R., Gairing,A., Kang,A., Bitzer,J., Cognitive-behavioural group intervention for climacteric syndrome, <i>Psychotherapy and Psychosomatics</i> , 75, 298-303, 2006	Not an RCT
Aldrighi,J.M., Quail,D.C., Levy-Frebault,J., Aguas,F., Kosian,K., Garrido,L., Bosio-Le,Goux B., Sarachaga,M., Graebe,A., Nino,A.J., Nickelsen,T., Predictors of hot flushes in postmenopausal women who receive raloxifene therapy, <i>American Journal of Obstetrics and Gynecology</i> , 191, 1979-1988, 2004	Secondary publication of 232662
Almendral,C., Casper,F., Distler,W., Frick,J., Herold,J., Huenges,P., Hussong,R., Methfessel,H.D., Muller,M., Petri,E., Retzke,U., Santellani,M., Weise,W., Wilhelm,H., Wortmann,M., Zimber,P., Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: A comparative and a placebo-controlled multicenter study, <i>International Urogynecology Journal and Pelvic Floor Dysfunction</i> , 10, 171-176, 1999	PICO not met - Symptom profile (vaginal atrophy) not of interest
Alraek,T., Malterud,K., Acupuncture for menopausal hot flashes: a qualitative study about patient experiences, <i>Journal of Alternative and Complementary Medicine</i> , 15, 153-158, 2009	Secondary publication of 227668. Also a qualitative study.
Aly,M., Use of black cohosh ( <i>Cimicifuga racemosa</i> ) in postmenopausal women: A randomized controlled study, <i>International Journal of Gynecology and Obstetrics</i> , 107, S646-, 2009	Conference abstract
Anarte,M.T., Cuadros,J.L., Herrera,J., Hormonal and psychological treatment: therapeutic alternative for menopausal women?, <i>Maturitas</i> , 29, 203-213, 1998	Intervention not of interest (psychological treatment combined with HRT)
Anderer,P., Saletu,B., Saletu-Zyhlarz,G., Gruber,D., Metka,M., Huber,J., Pascual-Marqui,R.D., Brain regions activated during an auditory discrimination task in insomniac postmenopausal patients before and after hormone replacement therapy: low-resolution brain electromagnetic tomography applied to event-related potentials, <i>Neuropsychobiology</i> , 49, 134-153, 2004	Study aimed to study the effects of estrogen and combined estrogen-progestogen replacement on event-related brain potentials
Anderer,P., Semlitsch,H.V., Saletu,B., Saletu-Zyhlarz,G., Gruber,D., Metka,M., Huber,J., Graser,T., Oettel,M., Effects of hormone replacement therapy on perceptual and cognitive event-related potentials in menopausal insomnia, <i>Psychoneuroendocrinology</i> , 28, 419-445, 2003	No outcomes of interest reported.
Andersen,J., Kamby,C., Ejlersen,B., Cold,S., Ewertz,M., Jacobsen,E.H., Philip,P., Moller,K.A., Jensen,D., Moller,S., Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C), <i>Acta Oncologica</i> , 47, 718-724, 2008	PICO not met - Intervention (Tamoxifen) not of interest
Andersson,T.L., Stehle,B., Davidsson,B., Hoglund,P., Bioavailability of estradiol from two matrix transdermal delivery systems: Menorest and Climara, <i>Maturitas</i> , 34, 57-64, 2000	No outcomes of interest.
Andreen,L., Bixo,M., Nyberg,S., Sundstrom-Poromaa,I., Backstrom,T., Progesterone effects during sequential hormone replacement therapy, <i>European Journal of Endocrinology</i> , 148, 571-577, 2003	Wrong outcome
Andreen,L., Sundstrom-Poromaa,I., Bixo,M., Andersson,A., Nyberg,S., Backstrom,T., Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone, <i>Psychoneuroendocrinology</i> , 30, 212-224, 2005	PICO not met - Outcomes of interest not reported
Andreen,L., Sundstrom-Poromaa,I., Bixo,M., Nyberg,S., Backstrom,T., Allopregnanolone concentration and mood-a bimodal association in postmenopausal women treated with oral progesterone, <i>Psychopharmacology</i> , 187, 209-221, 2006	Composite result
Andrikoula,M., Baker,D., Nestic,J., Liao,L.M., Duka,T., Prelevic,G.M., The effects of micronutrient supplementation on vasomotor symptoms in postmenopausal women, <i>Climacteric</i> , 14, 544-550, 2011	Intervention not as specified in protocol (micronutrient supplement)
Appling,S., Paez,K., Allen,J., Ethnicity and vasomotor symptoms in postmenopausal women, <i>Journal of Women's Health</i> , 16, 1130-1138, 2007	Secondary publication
Archer,D.F., Dupont,C.M., Constantine,G.D., Pickar,J.H., Olivier,S., Study 319 Investigators., Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety, <i>American Journal of Obstetrics and Gynecology</i> , 200, 238-238, 2009	Outcome estimates not of interest.

Study	Reason for exclusion
Archer,D.F., Furst,K., Tipping,D., Dain,M.P., VandePol,C., A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group, <i>Obstetrics and Gynecology</i> , 94, 498-503, 1999	Frequency of hot flushes per day is presented in graph format without accompanying numbers for each group
Archer,D.F., Pickar,J.H., MacAllister,D.C., Warren,M.P., Transdermal estradiol gel for the treatment of symptomatic postmenopausal women, <i>Menopause</i> , 19, 622-629, 2012	No variation per treatment group
Archer,D.F., Seidman,L., Constantine,G.D., Pickar,J.H., Olivier,S., A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause, <i>American Journal of Obstetrics and Gynecology</i> , 200, 172-10, 2009	Outcome estimates not of interest.
Archer,D.F., Thorneycroft,I.H., Foegh,M., Hanes,V., Glant,M.D., Bitterman,P., Kempson,R.L., Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial, <i>Menopause</i> , 12, 716-727, 2005	No relevant outcomes
Argyroudis,E.M., Iatrakis,G., Kourkoubas,A., Georgoulis,N., Kourounis,G., Tsionis,C., Prapa,Z., Karamanos,K., Diakakis,I., Giannikos,L., Ladopoulos,J., Tibolone in the treatment of psychosomatic symptoms in menopause, <i>Clinical and Experimental Obstetrics and Gynecology</i> , 24, 167-168, 1997	Results reported as N, not frequency
Aslaksen,K., Frankendal,B., Effect of oral medroxyprogesterone acetate on menopausal symptoms in patients with endometrial carcinoma, <i>Acta Obstetrica et Gynecologica Scandinavica</i> , 61, 423-428, 1982	Outcome = plasma viscosity
Aso,T., Uchiyama,S., Matsumura,Y., Taguchi,M., Nozaki,M., Takamatsu,K., Ishizuka,B., Kubota,T., Mizunuma,H., Ohta,H., A natural S-equol supplement alleviates hot flushes and other menopausal symptoms in equol nonproducing postmenopausal Japanese women, <i>Journal of Women's Health</i> , 21, 92-100, 2012	Not relevant to UK and an unlicensed preparation.
Atkinson,C., Warren,R.M., Sala,E., Dowsett,M., Dunning,A.M., Healey,C.S., Runswick,S., Day,N.E., Bingham,S.A., Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165], <i>Breast Cancer Research</i> , 6, R170-R179, 2004	Includes pre-menopausal women
Atteritano,M., Mazzaferro,S., Bitto,A., Cannata,M.L., D'Anna,R., Squadrito,F., Macri,I., Frisina,A., Frisina,N., Bagnato,G., Genistein effects on quality of life and depression symptoms in osteopenic postmenopausal women: a 2-year randomized, double-blind, controlled study, <i>Osteoporosis International</i> , 25, 1123-1129, 2014	Study was 2 year trial
Auerbach,L., Rakus,J., Bauer,C., Gerner,C., Ullmann,R., Wimmer,H., Huber,J., Pomegranate seed oil in women with menopausal symptoms: a prospective randomized, placebo-controlled, double-blinded trial, <i>Menopause</i> , 19, 426-432, 2012	Combination therapy not of interest (pomegranate seed oil phytoestrogen)
Avis,N.E., Legault,C., Coeytaux,R.R., Pian-Smith,M., Shifren,J.L., Chen,W., Valaskatgis,P., A randomized, controlled pilot study of acupuncture treatment for menopausal hot flashes, <i>Menopause</i> , 15, 1070-1078, 2008	Data presented in graphical format with approximation of results given (no exact figures for results)
Ayers,B., Mann,E., Hunter,M.S., A randomised controlled trial of cognitive-behavioural therapy for women with problematic menopausal hot flushes: MENOS 2 trial protocol, <i>BMJ Open</i> , 1, e000047-, 2011	Protocol only
Aylward,M., Holly,F., Parker,R.J., An evaluation of clinical response to piperazine oestrone sulphate ('Harmogen') in menopause patients, <i>Current Medical Research and Opinion</i> , 2, 417-423, 1974	PICO not met - Intervention given for less than 12 weeks. Outcomes not of interest.
Ayton,R.A., Darling,G.M., Murkies,A.L., Farrell,E.A., Weisberg,E., Selinus,I., Fraser,I.D., A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy, <i>British Journal of Obstetrics and Gynaecology</i> , 103, 351-358, 1996	This is an atrophy study
Azizi,H., Feng,Liu Y., Du,L., Hua,Wang C., Bahrami-Taghanaki,H., Ollah,Esmaily H., Azizi,H., Ou,Xue,X, Menopause-related symptoms: traditional Chinese medicine vs hormone therapy, <i>Alternative Therapies in Health and Medicine</i> , 17, 48-53, 2011	Study does not report on frequency of flushes but number of Kupperman Index symptoms in general
Bacchi-Modena,A., Bolis,P., Campagnoli,C., De,Cicco F., Meschia,M., Pansini,F., Pisati,R., Huls,G., Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch, <i>Maturitas</i> , 27, 285-292, 1997	No variation in change score per treatment group
Bachmann,G., Bobula,J., Mirkin,S., Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy, <i>Climacteric</i> , 13, 132-140, 2010	Secondary publication of 226742
Bachmann,G., Lobo,R.A., Gut,R., Nachtigall,L., Notelovitz,M., Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial, <i>Obstetrics and Gynecology</i> , 111, 67-76, 2008	This is an Atrophy study.
Bachmann,G.A., Komi,J.O., Ospemifene Study Group., Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study, <i>Menopause</i> , 17, 480-486, 2010	No relevant outcomes
Bachmann,G.A., Schaefer,M., Uddin,A., Utian,W.H., Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women, <i>Menopause</i> , 16, 877-882, 2009	No relevant outcomes
Baerug,U., Winge,T., Nordland,G., Faber-Swensson,E., Heldaas,K., Norling,B., Larsen,S., Arce,J.C., Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms?, <i>Climacteric</i> , 1, 219-228, 1998	Results on graph

Study	Reason for exclusion
Bai,W., Henneicke-von Zepelin,H.H., Wang,S., Zheng,S., Liu,J., Zhang,Z., Geng,L., Hu,L., Jiao,C., Liske,E., Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone, <i>Maturitas</i> , 58, 31-41, 2007	Outcome expressed as composite KI score
Bain,C.A., Walters,M.R., Lees,K.R., Lumsden,M.A., The effect of HRT on cerebral haemodynamics and cerebral vasomotor reactivity in post-menopausal women, <i>Human Reproduction</i> , 19, 2411-2414, 2004	PICO not met - Outcomes of interest not reported
Baker,L.D., Asthana,S., Cholerton,B.A., Wilkinson,C.W., Plymate,S.R., Green,P.S., Merriam,G.R., Fishel,M.A., Watson,G.S., Cherrier,M.M., Kletke,M.L., Mehta,P.D., Craft,S., Cognitive response to estradiol in postmenopausal women is modified by high cortisol, <i>Neurobiology of Aging</i> , 33, 829-20, 2012	PICO not met - Age of participants 56 to 84 years, therefore likely to be more than 5 years from FMP.
Baksu,A., Ayas,B., Citak,S., Kalan,A., Baksu,B., Goker,N., Efficacy of tibolone and transdermal estrogen therapy on psychological symptoms in women following surgical menopause, <i>International Journal of Gynaecology and Obstetrics</i> , 91, 58-62, 2005	Study excluded women with depression and did not report menopause symptoms
Baksu,B., Baksu,A., Goker,N., Citak,S., Do different delivery systems of hormone therapy have different effects on psychological symptoms in surgically menopausal women? A randomized controlled trial, <i>Maturitas</i> , 62, 140-145, 2009	Study excluded women with depression and did not report menopause symptoms
Balabanovic,J., Ayers,B., Hunter,M.S., Women's experiences of Group Cognitive Behaviour Therapy for hot flushes and night sweats following breast cancer treatment: an interpretative phenomenological analysis, <i>Maturitas</i> , 72, 236-242, 2012	Secondary publication of 256621
Balk,J.L., Whiteside,D.A., Naus,G., DeFerrari,E., Roberts,J.M., A pilot study of the effects of phytoestrogen supplementation on postmenopausal endometrium, <i>Journal of the Society for Gynecologic Investigation</i> , 9, 238-242, 2002	Vasomotor outcome reported in severity scores not frequency
Bao,T., Cai,L., Giles,J.T., Gould,J., Tarpinian,K., Betts,K., Medeiros,M., Jeter,S., Tait,N., Chumsri,S., Armstrong,D.K., Tan,M., Folked,E., Dowsett,M., Singh,H., Tkaczuk,K., Stearns,V., A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors, <i>Breast Cancer Research and Treatment</i> , 138, 167-174, 2013	Outcomes of interest not reported
Baracat,E., Aguiar,L.F., Barbosa,I.C., Campos,A.A., Haidar,M., Leal,J.W.B., An open, randomized assessment of the efficacy and safety of two transdermal estradiol patches for relief of climacteric symptoms, <i>Jornal Brasileiro De Ginecologia</i> , 106, 281-289, 1996	Non-English language paper
Baracat,E.C., Barbosa,I.C., Giordano,M.G., Haidar,M.A., Marinho,R.M., Menegocci,J.C., Morais,K.M., Tomaz,G., Wehba,S., A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.[Erratum appears in <i>Climacteric</i> 2002 Jun;5(2):vi], <i>Climacteric</i> , 5, 60-69, 2002	Results on graph
Barati,M., Moramezi,F., Masihi,S., Moghadam,S.N., Comparison of effectiveness of two different premarin dose in hot flash treatment, <i>Pakistan Journal of Medical Sciences</i> , 24, 406-409, 2008	Intensity of hot flushes is combined with the frequency of hot flushes in the outcome measure
Barentsen,R., van de Weijer,P.H., Schram,J.H., Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy, <i>European Journal of Obstetrics, Gynecology, and Reproductive Biology</i> , 71, 73-80, 1997	Vaginal atrophy study
Barnabei,V.M., Cochrane,B.B., Aragaki,A.K., Nygaard,I., Williams,R.S., McGovern,P.G., Young,R.L., Wells,E.C., O'Sullivan,M.J., Chen,B., Schenken,R., Johnson,S.R., Women's Health Initiative Investigators., Menopausal symptoms and treatment-related effects of estrogen and progestogen in the Women's Health Initiative, <i>Obstetrics and Gynecology</i> , 105, 1063-1073, 2005	Assessed severity of VMS.
Barnabei,V.M., Grady,D., Stovall,D.W., Cauley,J.A., Lin,F., Stuenkel,C.A., Stefanick,M.L., Pickar,J.H., Menopausal symptoms in older women and the effects of treatment with hormone therapy.[Erratum appears in <i>Obstet Gynecol.</i> 2003 Mar;101(3):619], <i>Obstetrics and Gynecology</i> , 100, 1209-1218, 2002	Frequency of hot flushes not reported
Barnhart,K.T., Freeman,E., Grisso,J.A., Rader,D.J., Sammel,M., Kapoor,S., Nestler,J.E., The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life, <i>Journal of Clinical Endocrinology and Metabolism</i> , 84, 3896-3902, 1999	No relevant outcomes
Barrett-Connor,E., Young,R., Notelovitz,M., Sullivan,J., Wiita,B., Yang,H.M., Nolan,J., A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles, <i>Journal of Reproductive Medicine</i> , 44, 1012-1020, 1999	Abstract only
Barton,D., La,Vasseur B., Loprinzi,C., Novotny,P., Wilwerding,M.B., Sloan,J., Venlafaxine for the control of hot flashes: results of a longitudinal continuation study, <i>Oncology Nursing Forum</i> , 29, 33-40, 2002	Secondary publication of 256569
Barton,D., Loprinzi,C., Wahner-Roedler,D., Hot flashes: aetiology and management. [85 refs], <i>Drugs and Aging</i> , 18, 597-606, 2001	Overview of hot flushes from aetiology to management options

Study	Reason for exclusion
Barton,D.L., Wender,D.B., Sloan,J.A., Dalton,R.J., Balcueva,E.P., Atherton,P.J., Bernath,A.M., Jr., DeKrey,W.L., Larson,T., Bearden,J.D., III, Carpenter,P.C., Loprinzi,C.L., Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3, <i>Journal of the National Cancer Institute</i> , 99, 672-679, 2007	Outcome not relevant
Basaria,S., Nguyen,T., Rosenson,R.S., Dobs,A.S., Effect of methyl testosterone administration on plasma viscosity in postmenopausal women, <i>Clinical Endocrinology</i> , 57, 209-214, 2002	No relevant outcomes
Battaglia,C., Cianciosi,A., Mancini,F., Fabbri,R., Busacchi,P., Nappi,R.E., Venturoli,S., Genistein supplements might not induce clitoral modifications in postmenopausal women: a prospective, pilot study, <i>Journal of Sexual Medicine</i> , 6, 3132-3138, 2009	Subjects not randomly assigned to treatment groups
Baumgardner,S.B., Condrea,H., Daane,T.A., Dorsey,J.H., Jurow,H.N., Shively,J.P., Wachsmann,M., Wharton,L.R., Jr., Zibel,M.J., Replacement estrogen therapy for menopausal vasomotor flushes. Comparison of quinestrol and conjugated estrogens, <i>Obstetrics and Gynecology</i> , 51, 445-452, 1978	Quantified severity of VMS. Results reported in graphical format.
Beavers,K.M., Serra,M.C., Beavers,D.P., Cooke,M.B., Willoughby,D.S., Soy milk supplementation does not alter plasma markers of inflammation and oxidative stress in postmenopausal women, <i>Nutrition Research</i> , 29, 616-622, 2009	Not an efficacy study
Bech,P., Munk-Jensen,N., Obel,E.B., Ulrich,L.G., Eiken,P., Nielsen,S.P., Combined versus sequential hormonal replacement therapy: a double-blind, placebo-controlled study on quality of life-related outcome measures, <i>Psychotherapy and Psychosomatics</i> , 67, 259-265, 1998	Results = composite KI score
Ben-Chetrit,A., Hochner-Celnikier,D., Lindenberg,T., Zacut,D., Shimonovitz,S., Gelber,H., Spitz,I.M., Vaginal ring delivering estradiol and progesterone: a possible alternative to relieve climacteric symptoms, <i>Israel Medical Association Journal: Imaj</i> , 7, 302-306, 2005	Data in graph format
Benedek-Jaszmann,L.J., Long-term placebo-controlled efficacy and safety study of Org OD 14 in climacteric women, <i>Maturitas</i> , , 25-33, 1987	PICO not met - Intervention (ORG OD 14) not of interest
Benster,B., Carey,A., Wadsworth,F., Vashisht,A., Domoney,C., Studd,J., A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women, <i>Menopause International</i> , 15, 63-69, 2009	The study does not report hot flushes as frequency
Bergstrom,I., Landgren,B.M., Pyykko,I., Training or EPT in perimenopause on balance and flushes, <i>Acta Obstetrica et Gynecologica Scandinavica</i> , 86, 467-472, 2007	Evaluated the effect of estrogen plus progesterone therapy or aerobic training on balance. Outcome estimates were also not adequately reported.
Berhan,Y., Berhan,A., Is Desvenlafaxine Effective and Safe in the Treatment of Menopausal Vasomotor Symptoms? A Meta-analysis and Meta-regression of Randomized Double-blind Controlled Studies, <i>Ethiopian Journal of Health Sciences</i> , 24, 209-218, 2014	Meta-analysis of individual studies that have been excluded or included in the review
Berlanga,C., Mendieta,D., Alva,G., del Carmen,Lara M., Failure of tibolone to potentiate the pharmacological effect of fluoxetine in postmenopausal major depression, <i>Journal of Women's Health</i> , 12, 33-39, 2003	PICO not met - Intervention (Fluoxetine with Tibolone) not of interest
Berman,J.R., Berman,L.A., Toler,S.M., Gill,J., Haughie,S., Sildenafil Study Group., Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study, <i>Journal of Urology</i> , 170, 2333-2338, 2003	PICO not met - Intervention (Sildenafil) not of interest
Bertone-Johnson,E.R., Powers,S.I., Spangler,L., Brunner,R.L., Michael,Y.L., Larson,J.C., Millen,A.E., Bueche,M.N., Salmoirago-Blotcher,E., Liu,S., Wassertheil-Smoller,S., Ockene,J.K., Ockene,I., Manson,J.E., Vitamin D intake from foods and supplements and depressive symptoms in a diverse population of older women, <i>American Journal of Clinical Nutrition</i> , 94, 1104-1112, 2011	Not a RCT
Biglia,N., Peano,E., Sgandurra,P., Moggio,G., Panuccio,E., Migliardi,M., Ravarino,N., Ponzone,R., Sismondi,P., Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study, <i>Gynecological Endocrinology</i> , 26, 404-412, 2010	Outcome not of interest (urogenital atrophy)
Biglia,N., Sgandurra,P., Peano,E., Marengo,D., Moggio,G., Bounous,V., Tomasi,Cont N., Ponzone,R., Sismondi,P., Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E, <i>Climacteric</i> , 12, 310-318, 2009	Active treatment is Vitamin E, which is not a treatment specified by the protocol
Binder,E.F., Schechtman,K.B., Birge,S.J., Williams,D.B., Kohrt,W.M., Effects of hormone replacement therapy on cognitive performance in elderly women, <i>Maturitas</i> , 38, 137-146, 2001	Does not meet PICO-patients did not have menopausal symptoms
Bitto,A., Granese,R., Triolo,O., Villari,D., Maisano,D., Giordano,D., Altavilla,D., Marini,H., Adamo,E.B., Nicotina,P.A., D'Anna,R., Squadrito,F., Genistein aglycone: A new therapeutic approach to reduce endometrial hyperplasia, <i>Phytomedicine</i> , 17, 844-850, 2010	PICO not met - Population included only pre-menopausal women. Outcomes not of interest.
Bjorn,I., Bixo,M., Nojd,K.S., Collberg,P., Nyberg,S., Sundstrom-Poromaa,I., Backstrom,T., The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy, <i>Gynecological Endocrinology</i> , 16, 1-8, 2002	Outcomes reported graphically.
Bjorn,I., Sundstrom-Poromaa,I., Bixo,M., Nyberg,S., Backstrom,G., Backstrom,T., Increase of estrogen dose deteriorates mood during progestogen phase in	PICO not met - Outcomes of interest not reported.

Study	Reason for exclusion
sequential hormonal therapy, Journal of Clinical Endocrinology and Metabolism, 88, 2026-2030, 2003	
Blumel, J.E., Castelo-Branco, C., Binfa, L., Aparicio, R., Mamani, L., A scheme of combined oral contraceptives for women more than 40 years old, Menopause, 8, 286-289, 2001	Contraceptive study
Blumel, J.E., Del Pino M., Aprikian, D., Vallejo, S., Sarra, S., Castelo-Branco, C., Effect of androgens combined with hormone therapy on quality of life in postmenopausal women with sexual dysfunction, Gynecological Endocrinology, 24, 691-695, 2008	Does not meet PICO (interventions not of interest)
Bokmand, S., Flyger, H., Acupuncture relieves menopausal discomfort in breast cancer patients: A prospective, double blinded, randomized study, Breast, 22, 320-323, 2013	Outcome estimates not relevant
Bolanos, R., Del Castillo A., Francia, J., Soy isoflavones versus placebo in the treatment of climacteric vasomotor symptoms: systematic review and meta-analysis. [19 refs], Menopause, 17, 660-666, 2010	Systematic review
Bolanos-Diaz, R., Zavala-Gonzales, J.C., Mezones-Holguin, E., Francia-Romero, J., Soy extracts versus hormone therapy for reduction of menopausal hot flushes: indirect comparison, Menopause, 18, 825-829, 2011	Systematic review
Booji, A., Biewenga-Booji, C.M., Huber-Bruning, O., Cornelis, C., Jacobs, J.W., Bijlsma, J.W., Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, 55, 811-815, 1996	Only reports musculoskeletal outcomes in women with known rheumatoid arthritis.
Boraz, M.A., Simkin-Silverman, L.R., Wing, R.R., Meilahn, E.N., Kuller, L.H., Hormone replacement therapy use and menopausal symptoms among women participating in a behavioral lifestyle intervention, Preventive Medicine, 33, 108-114, 2001	PICO not met - Population included only premenopausal women
Bordeleau, L., Pritchard, K.I., Loprinzi, C.L., Ennis, M., Jugovic, O., Warr, D., Haq, R., Goodwin, P.J., Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors, Journal of Clinical Oncology, 28, 5147-5152, 2010	Frequency of hot flashes during treatment not reported
Borrelli, F., Ernst, E., Black cohosh (Cimicifuga racemosa) for menopausal symptoms: a systematic review of its efficacy. [95 refs], Pharmacological Research, 58, 8-14, 2008	Systematic review
Borud, E.K., Alraek, T., White, A., Fonnebo, V., Eggen, A.E., Hammar, M., Astrand, L.L., Theodorsson, E., Grimsgaard, S., The Acupuncture on Hot Flashes Among Menopausal Women (ACUFLASH) study, a randomized controlled trial, Menopause, 16, 484-493, 2009	No outcomes of interest
Borud, E.K., Alraek, T., White, A., Fonnebo, V., Grimsgaard, S., The effect of TCM acupuncture on hot flushes among menopausal women (ACUFLASH) study: a study protocol of an ongoing multi-centre randomised controlled clinical trial, BMC Complementary and Alternative Medicine, Vol.7, pp.6, 2007., -, -32676	Study protocol
Borud, E.K., Alraek, T., White, A., Fonnebo, V., Grimsgaard, S., The effect of TCM acupuncture on hot flushes among menopausal women (ACUFLASH) study: a study protocol of an ongoing multi-centre randomised controlled clinical trial, BMC Complementary and Alternative Medicine, 7, 6-, 2007	Study protocol
Borud, E.K., Alraek, T., White, A., Grimsgaard, S., The Acupuncture on Hot Flashes Among Menopausal Women study: observational follow-up results at 6 and 12 months, Menopause, 17, 262-268, 2010	Not an RCT
Borud, E.K., Alraek, T., White, A., Grimsgaard, S., The acupuncture treatment for postmenopausal hot flushes (Acufash) study: traditional Chinese medicine diagnoses and acupuncture points used, and their relation to the treatment response, Acupuncture in Medicine, 27, 101-108, 2009	No frequency data
Borud, E.K., Martinussen, M., Eggen, A.E., Grimsgaard, S., The Women's Health Questionnaire (WHQ): a psychometric evaluation of the 36-item Norwegian version, Scandinavian Journal of Psychology, 50, 183-189, 2009	Not a RCT. No interventions
Bouchard, P., Panay, N., de Villiers, T.J., Vincendon, P., Bao, W., Cheng, R.J., Constantine, G., Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms, Climacteric, 15, 12-20, 2012	No frequency data
Braunstein, G.D., Sundwall, D.A., Katz, M., Shifren, J.L., Buster, J.E., Simon, J.A., Bachman, G., Aguirre, O.A., Lucas, J.D., Rodenberg, C., Buch, A., Watts, N.B., Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial, Archives of Internal Medicine, 165, 1582-1589, 2005	Outcome estimates not of interest
Brennan, J.J., Lu, Z., Whitman, M., Stafiniak, P., van der Hoop, R.G., Serum concentrations of 17beta-estradiol and estrone after multiple-dose administration of percutaneous estradiol gel in symptomatic menopausal women, Therapeutic Drug Monitoring, 23, 134-138, 2001	Outcome serum concentrations of 17beta-estradiol (E2) and unconjugated estrone (E1) not of interest
Brooks, N.A., Wilcox, G., Walker, K.Z., Ashton, J.F., Cox, M.B., Stojanovska, L., Beneficial effects of Lepidium meyenii (Maca) on psychological symptoms and measures of sexual dysfunction in postmenopausal women are not related to estrogen or androgen content, Menopause, 15, 1157-1162, 2008	Outcome estimates not retrievable
Brown, J.S., Vittinghoff, E., Kanaya, A.M., Agarwal, S.K., Hulley, S., Foxman, B., Heart and Estrogen/Progestogen Replacement Study Research Group., Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors, Obstetrics and Gynecology, 98, 1045-1052, 2001	Secondary publication

Study	Reason for exclusion
Bruhat,M., Rudolf,K., Vaheri,R., Kainulainen,P., Timonen,U., Viitanen,A., Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy: a randomized comparative dose-ranging study, <i>Maturitas</i> , 40, 259-271, 2001	No frequency data
Brunner,R.L., Gass,M., Aragaki,A., Hays,J., Granek,I., Woods,N., Mason,E., Brzyski,R., Ockene,J., Assaf,A., LaCroix,A., Matthews,K., Wallace,R., Women's Health Initiative Investigators., Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial, <i>Archives of Internal Medicine</i> , 165, 1976-1986, 2005	Secondary publication
Buijs,C., Mom,C.H., Willemsse,P.H., Marike,Boezen H., Maurer,J.M., Wymenga,A.N., de Jong,R.S., Nieboer,P., de Vries,E.G., Mourits,M.J., Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study, <i>Breast Cancer Research and Treatment</i> , 115, 573-580, 2009	Results data presented as graph
Bukulmez,O., Al,A., Gurdal,H., Yarali,H., Ulug,B., Gurgan,T., Short-term effects of three continuous hormone replacement therapy regimens on platelet tritiated imipramine binding and mood scores: a prospective randomized trial, <i>Fertility and Sterility</i> , 75, 737-743, 2001	No outcomes of interest
Bullock,J.L., Massey,F.M., Gambrell,R.D.,Jr., Use of medroxyprogesterone acetate to prevent menopausal symptoms, <i>Obstetrics and Gynecology</i> , 46, 165-168, 1975	No VMS frequency data
Bunyaratavej,N., Songpatanasilp,T., Application of Gabapentin in Thai women with menopausal syndrome, <i>Journal of the Medical Association of Thailand</i> , 88 Suppl 5, S21-S23, 2005	PICO not met - Comparator used was not as specified in the protocol
Burger,H., Hailes,J., Nelson,J., Menelaus,M., Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women, <i>British Medical Journal Clinical Research Ed.</i> , 294, 936-937, 1987	Abstract and outcome estimates not relevant.
Bushmakina,A.G., Abraham,L., Pinkerton,J.V., Cappelleri,J.C., Mirkin,S., Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogens, <i>Menopause</i> , 21, 815-822, 2014	Outcomes not of interest
Buster,J.E., Kingsberg,S.A., Aguirre,O., Brown,C., Breaux,J.G., Buch,A., Rodenberg,C.A., Wekselman,K., Casson,P., Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial, <i>Obstetrics and Gynecology</i> , 105, 944-952, 2005	Outcomes not relevant
Buster,J.E., Koltun,W.D., Pascual,M.L., Day,W.W., Peterson,C., Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial, <i>Obstetrics and Gynecology</i> , 111, 1343-1351, 2008	Baseline values not reported
Butt,D.A., Deng,L.Y., Lewis,J.E., Lock,M., Minimal decrease in hot flashes desired by postmenopausal women in family practice, <i>Menopause</i> , 14, 203-207, 2007	Not a RCT.
Butt,D.A., Lock,M., Lewis,J.E., Ross,S., Moineddin,R., Effectiveness of Gabapentin for the treatment of hot flashes in postmenopausal women: a randomized controlled trial, <i>Menopause</i> , 13, 985, 2006-2006	Conference abstract
Bygdeman,M., Swahn,M.L., Replens versus dienoeestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women, <i>Maturitas</i> , 23, 259-263, 1996	Atrophy study
Byrjalsen,I., Alexandersen,P., Christiansen,C., Piperazine oestrone sulphate and interrupted norethisterone: Effects on the postmenopausal endometrium, <i>British Journal of Obstetrics and Gynaecology</i> , 107, 347-355, 2000	Does not meet PICO (outcome not of interest)
Cagnacci,A., Arangino,S., Baldassari,F., Alessandrini,C., Landi,S., Volpe,A., A comparison of the central effects of different progestogens used in hormone replacement therapy, <i>Maturitas</i> , 48, 456-462, 2004	Study does not mention patients have menopause symptoms
Cagnacci,A., Arangino,S., Renzi,A., Zanni,A.L., Malmusi,S., Volpe,A., Kava-Kava administration reduces anxiety in perimenopausal women, <i>Maturitas</i> , 44, 103-109, 2003	Interventions not of interest
Cagnacci,A., Melis,G.B., Soldani,R., Paoletti,A.M., Gambacciani,M., Spinetti,A., Fioretti,P., Neuroendocrine and clinical effects of transdermal 17 beta-estradiol in postmenopausal women, <i>Maturitas</i> , 13, 283-296, 1991	No VSM frequency data
Cameron,P.F., Clark-Wilson,L.J., Dickinson,J.A., Oestrogens in the treatment of depression occurring at the menopause. A report from the General Practitioner Research Group, <i>Journal of Pharmacotherapy</i> , 1, 70-77, 1978	Interventions not of interest (amitriptyline oestrogen)
Cameron,S.T., Glasier,A.F., Gebbie,A., Dewart,H., Baird,D.T., Comparison of a transdermal continuous combined and an interrupted progestogen HRT, <i>Maturitas</i> , 53, 19-26, 2006	Estimates for VMS not reported.
Campbell, S., Whitehead, M., Oestrogen therapy and the menopausal syndrome, <i>Clinics in Obstetrics and Gynaecology</i> , 4, 31-47, 1977	No measure of uncertainty/variance reported
Campagnoli,C., Abba,C., Ambroggio,S., Peris,C., Perona,M., Sanseverino,P., Polyunsaturated fatty acids (PUFAs) might reduce hot flashes: an indication from two controlled trials on soy isoflavones alone and with a PUFA supplement, <i>Maturitas</i> , 51, 127-134, 2005	Pooled analysis of two RCT'S
Campisi,R., Camilletti,J., Mele,A., Erriest,J., Pedroni,P., Guiglionni,A., Tibolone improves myocardial perfusion in postmenopausal women with ischemic heart disease: an open-label exploratory pilot study, <i>Journal of the American College of Cardiology</i> , 47, 559-564, 2006	PICO not met - Outcomes of interest not reported

Study	Reason for exclusion
Capobianco,G., Donolo,E., Borghero,G., Dessole,F., Cherchi,P.L., Dessole,S., Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women, Archives of Gynecology and Obstetrics, 285, 397-403, 2012	PICO not met - Intervention (Pelvic floor exercises) not of interest
Carmignani,L.O., Pedro,A.O., Costa-Paiva,L.H., Pinto-Neto,A.M., The effect of dietary soy supplementation compared to estrogen and placebo on menopausal symptoms: a randomized controlled trial, Maturitas, 67, 262-269, 2010	Data presented in graphical format without accompanying numbers
Carpenter,J.S., Guthrie,K.A., Larson,J.C., Freeman,E.W., Joffe,H., Reed,S.D., Ensrud,K.E., Lacroix,A.Z., Effect of escitalopram on hot flash interference: a randomized, controlled trial, Fertility and Sterility, 97, 1399-1404, 2012	Results data presented as composite score
Carranza-Lira,S., Gooch,A.L., Saldivar,N., Osterwalder,M.S., Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses, International Journal of Fertility and Womens Medicine, 52, 93-96, 2007	Used a severity/intensity score to quantify outcome of hot flushes
Carranza-Lira,S., Gooch,A.L., Velasco-Diaz,G., Solano,J., rzola-Paniagua,A., Low and ultra low-dose estrogen therapy for climacteric symptom control--preliminary report, International Journal of Fertility and Womens Medicine, 51, 171-175, 2006	Evaluated symptom intensity using an analog visual scale of 10 cm length, in which 0 was symptom absence and 10 the maximum intensity of the symptom.
Carranza-Lira,S., Gregor-Gooch,A.L., Sarachaga-Osterwalder,M., Mood modifications with raloxifene and continuous combined estrogen plus progesterone hormone therapy, International Journal of Fertility and Womens Medicine, 49, 120-122, 2004	Study does not mention patients have menopause symptoms
Carranza-Lira,S., Valentino-Figueroa,M.L., Estrogen therapy for depression in postmenopausal women, International Journal of Gynaecology and Obstetrics, 65, 35-38, 1999	Population not relevant to protocol
Carter,J., Goldfrank,D., Schover,L.R., Simple strategies for vaginal health promotion in cancer survivors, Journal of Sexual Medicine, 8, 549-559, 2011	Not a RCT
Caserta,R., Gargiulo,L., Battinelli,W., Tartaglia,E., Guerriero,V., Caserta,L., Nesti,E., Panariello,S., Efficacy and safety of a week transdermal estradiol drug delivery system: A pharmacokinetic comparison of two different dosage of formulations, Giornale Italiano di Ostetricia e Ginecologia, 22, 279-283, 2000	Article in Italian.
Casini,M.L., Marelli,G., Papaleo,E., Ferrari,A., D'Ambrosio,F., Unfer,V., Psychological assessment of the effects of treatment with phytoestrogens on postmenopausal women: A randomized, double-blind, crossover, placebo-controlled study, Fertility and Sterility, 85, 972-978, 2006	No mention of menopause symptoms
Casper,F., Petri,E., Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group, International Urogynecology Journal, 10, 171-176, 1999	PICO not met - Symptom profile (vaginal atrophy) not of interest
Castelo,BrancoDeLucaA, Maggio,DaFonsecaA, Carvalho,LopesC, Bagnoli,V.R., Soares,Jr, Baracat,E.C., Acupuncture-ameliorated menopausal symptoms: Single-blind, placebo-controlled, randomized trial, Climacteric, 14, 140-145, 2011	Results reported as composite score (KI)so not calculable.
Caufriez,A., Leproult,R., L'Hermite-Baleriaux,M., Kerkhofs,M., Copinschi,G., Progesterone prevents sleep disturbances and modulates GH, TSH, and melatonin secretion in postmenopausal women, Journal of Clinical Endocrinology and Metabolism, 96, E614-E623, 2011	PICO not met - Intervention given for less than 12 weeks.Outcome estimates not extractable
Cayan,F., Dilek,U., Pata,O., Dilek,S., Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women, Journal of Sexual Medicine, 5, 132-138, 2008	Not a randomised control trial. Outcome not relevant.
Chandeying,V., Lamlerkittikul,S., Challenges in the conduct of Thai herbal scientific study: efficacy and safety of phytoestrogen, pueraria mirifica (Kwao Keur Kao), phase I, in the alleviation of climacteric symptoms in perimenopausal women, Journal of the Medical Association of Thailand, 90, 1274-1280, 2007	The study did not report hot flushes as frequency
Chandeying,V., Sangthawan,M., Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study, Journal of the Medical Association of Thailand, 90, 1720-1726, 2007	The study does not report frequency of vasomotor symptoms, and no other outcomes reported
Chang,A., Kwak,B.Y., Yi,K., Kim,J.S., The effect of herbal extract (EstroG-100) on pre-, peri- and post-menopausal women: a randomized double-blind, placebo-controlled study, Phytotherapy Research, 26, 510-516, 2012	Results reported as KI score, so not calculable.
Chang,S.P., Yang,W.S., Lee,S.K., Min,W.K., Park,J.S., Kim,S.B., Effects of hormonal replacement therapy on oxidative stress and total antioxidant capacity in postmenopausal hemodialysis patients, Renal Failure, 24, 49-57, 2002	No relevant data
Chao,H.T., Kuo,C.D., Su,Y.J., Chuang,S.S., Fang,Y.J., Ho,L.T., Short-term effect of transdermal estrogen on autonomic nervous modulation in postmenopausal women, Fertility and Sterility, 84, 1477-1483, 2005	PICO not met - Outcomes of interest not reported
Chattha,R., Nagarathna,R., Padmalatha,V., Nagendra,H.R., Effect of yoga on cognitive functions in climacteric syndrome: a randomised control study, BJOG: An International Journal of Obstetrics and Gynaecology, 115, 991-1000, 2008	Does not meet PICO (no mention of menopausal symptoms of interest)
Cheema,D., Coomarasamy,A., El-Toukhy,T., Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review. [72 refs], Archives of Gynecology and Obstetrics, 276, 463-469, 2007	Not primary data

Study	Reason for exclusion
Chen,G.Z., Xu,Y.X., Zhang,J.W., Liu,S.H., Guo,Z.Y., Effect of acupoint catgut-embedding on the quality of life, reproductive endocrine and bone metabolism of postmenopausal women, Chinese Journal of Integrative Medicine, 16, 498-503, 2010	Interventions not of interest
Cheng,G., Butler,R., Warner,M., Gustafsson,J.A., Wilczek,B., Landgren,B.M., Effects of short-term estradiol and norethindrone acetate treatment on the breasts of normal postmenopausal women, Menopause, 20, 496-503, 2013	Composite score of hot flush frequency and severity
Cheng,G., Wilczek,B., Warner,M., Gustafsson,J.A., Landgren,B.M., Isoflavone treatment for acute menopausal symptoms, Menopause, 14, 468-473, 2007	Study does not report on frequency of hot flushes but a hot flush score (It seems this score is not based on frequency alone but other measures such as severity too)
Cheng,R.J., Dupont,C., Archer,D.F., Bao,W., Racketta,J., Constantine,G., Pickar,J.H., Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms, Climacteric, 16, 17-27, 2013	Outcomes stratified by mood disturbance level at baseline
Chiechi,L.M., Putignano,G., Guerra,V., Schiavelli,M.P., Cisternino,A.M., Carriero,C., The effect of a soy rich diet on the vaginal epithelium in postmenopause: a randomized double blind trial, Maturitas, 45, 241-246, 2003	Vaginal epithelium outcome not of interest
Chien,L.W., Liu,S.J., Chang,Y., Liu,C.F., Local thermal therapy effects on menopausal symptoms and bone mineral density, Journal of Alternative and Complementary Medicine, 17, 1133-1140, 2011	PICO not met - Intervention (Local thermal therapy) not of interest
Chilcot,J., Norton,S., Hunter,M.S., Cognitive behaviour therapy for menopausal symptoms following breast cancer treatment: Who benefits and how does it work?, Maturitas, 78, 56-61, 2014	Outcomes not reported
Chlebowski,R.T., Cirillo,D.J., Eaton,C.B., Stefanick,M.L., Pettinger,M., Carbone,L.D., Johnson,K.C., Simon,M.S., Woods,N.F., Wactawski-Wende,J., Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial, Menopause, 20, 600-608, 2013	Outcomes reported at 1 year, 3 years and 6 years
Cho,S.H., Whang,W.W., Acupuncture for vasomotor menopausal symptoms: a systematic review. [61 refs], Menopause, 16, 1065-1073, 2009	Systematic review
Choi,S.Y., Kang,P., Lee,H.S., Seol,G.H., Effects of Inhalation of Essential Oil of Citrus aurantium L. var. amara on Menopausal Symptoms, Stress, and Estrogen in Postmenopausal Women: A Randomized Controlled Trial, Evidence-Based Complementary and Alternative Medicine: eCAM, 2014, 796518-, 2014	Intervention not of interest
Chompootaweep,S., Nunthapisud,P., Trivijitsilp,P., Sentrakul,P., Dusitsin,N., The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study, Clinical Pharmacology and Therapeutics, 64, 204-210, 1998	PICO not met - Intervention (CEE) given for less than 12 weeks. Outcome not of interest.
Chung,D.J., Kim,H.Y., Park,K.H., Jeong,K.A., Lee,S.K., Lee,Y.I., Hur,S.E., Cho,M.S., Lee,B.S., Bai,S.W., Kim,C.M., Cho,S.H., Hwang,J.Y., Park,J.H., Black cohosh and St. John's wort (GYNO-Plus) for climacteric symptoms, Yonsei Medical Journal, 48, 289-294, 2007	Study reports on hot flush score which is not based on frequency alone
Cianci,A., Cicero,A.F., Colacurci,N., Matarazzo,M.G., De,Leo,V, Activity of isoflavones and berberine on vasomotor symptoms and lipid profile in menopausal women, Gynecological Endocrinology, 28, 699-702, 2012	Isoquinoline is not an intervention required by protocol
Cieraad,D., Conradt,C., Jesinger,D., Bakowski,M., Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms, Archives of Gynecology and Obstetrics, 274, 74-80, 2006	Statistical significance or insignificance not reported
Civelli,M., Preti,A.P., Cenacchi,V., Rondelli,I., Guastalla,D., Tarral,A., Dostert,P., Guillevic,Y., Homery,M.C., Single and multiple ascending dose studies of a novel tissue-selective oestrogen receptor modulator, CHF 4227, in healthy postmenopausal women, British Journal of Clinical Pharmacology, 64, 304-316, 2007	PICO not met - Outcomes of interest not reported. Hot flushes presented as percentage of subjects with at least a hot flush.
Clayton,A.H., Kornstein,S.G., Dunlop,B.W., Focht,K., Musgnung,J., Ramey,T., Bao,W., Ninan,P.T., Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder, Journal of Clinical Psychiatry, 74, 1010-1017, 2013	Population: women with major depressive disorder who have no symptoms
Clemons,M., Clamp,A., Anderson,B., Management of the menopause in cancer survivors. [143 refs], Cancer Treatment Reviews, 28, 321-333, 2002	Not primary data
Cohen,S.M., Rousseau,M.E., Carey,B.L., Can acupuncture ease the symptoms of menopause?, Holistic Nursing Practice, 17, 295-299, 2003	VMS symptom results reported as composite severity score
Colacurci,N., Zarcone,R., Borrelli,A., De,Franciscis P., Fortunato,N., Cirillo,M., Fornaro,F., Effects of soy isoflavones on menopausal neurovegetative symptoms, Minerva Ginecologica, 56, 407-412, 2004	Results not calculable due to KI format of reporting.
Colau,J.C., Vincent,S., Marijnen,P., Allaert,F.A., Efficacy of a non-hormonal treatment, BRN-01, on menopausal hot flashes: a multicenter, randomized, double-blind, placebo-controlled trial, Drugs in R and D, 12, 107-119, 2012	The vasomotor outcome was measured by a product of daily frequency and intensity of all hot flashes experienced, rather than frequency alone. We cannot use



Study	Reason for exclusion
	measures that include severity of vasomotor symptoms for the NMA. Not a RCT
Colli,M.C., Bracht,A., Soares,A.A., de Oliveira,A.L., Boer,C.G., de Souza,C.G., Peralta,R.M., Evaluation of the efficacy of flaxseed meal and flaxseed extract in reducing menopausal symptoms, <i>Journal of Medicinal Food</i> , 15, 840-845, 2012	
Conard,J., Basdevant,A., Thomas,J.L., Ochsenbein,E., Denis,C., Guyene,T.T., Degrelle,H., Cardiovascular risk factors and combined estrogen-progestogen replacement therapy: A placebo-controlled study with nomegestrol acetate and estradiol, <i>Fertility and Sterility</i> , 64, 957-962, 1995	Outcome not relevant. Compared the effect of HRT and placebo on cardiovascular risk factors.
Coope,J., Is oestrogen therapy effective in the treatment of menopausal depression?, <i>Journal of the Royal College of General Practitioners</i> , 31, 134-140, 1981	PICO not met - Unable to calculate numerical outcomes
Coope,J., Thomson,J.M., Poller,L., Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting, <i>British Medical Journal</i> , 4, 139-143, 1975	Data presented in graphical format without accompanying numbers
Corbelli, J., Shaikh, N., Wessel, C., Hess, R., Low-dose transdermal estradiol for vasomotor symptoms: a systematic review, <i>Menopause</i> , 22, 114-21, 2015	Systematic review-individual studies have been excluded or included in the review
Coutinho,W., Appolinario,J.C., Povoia,L.C., Meirelles,R., Hormonal therapy and the psychiatric symptoms in menopause. Part 2 - Double-blind study on the effects of natural progesterone on the affective symptoms in menopause, <i>Jornal Brasileiro De Psiquiatria</i> , 44, 223-229, 1995	Non-English language
Cowles,V.E., Gordi,T., Hou,S.Y., Steady-state pharmacokinetics of gabapentin after administration of a novel gastroretentive extended-release formulation in postmenopausal women with vasomotor symptoms, <i>Clinical Drug Investigation</i> , 32, 593-601, 2012	No relevant data
Crandall,C.J., Karlamangla,A., Huang,M.H., Ursin,G., Guan,M., Greendale,G.A., Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy.[Erratum appears in <i>Arch Intern Med</i> . 2006 Nov 13;166(20):2176], <i>Archives of Internal Medicine</i> , 166, 1578-1584, 2006	This is a breast pain study
Crandall,C.J., Markovic,D., Huang,M.H., Greendale,G.A., Predictors of breast discomfort among women initiating menopausal hormone therapy, <i>Menopause</i> , 17, 462-470, 2010	Secondary publication. Outcomes not of interest.
Crawford,S.L., Jackson,E.A., Churchill,L., Lampe,J.W., Leung,K., Ockene,J.K., Impact of dose, frequency of administration, and equal production on efficacy of isoflavones for menopausal hot flashes: a pilot randomized trial, <i>Menopause</i> , 20, 936-945, 2013	Study did not report individual treatment groups
Crist,B.L., Alekel,D.L., Ritland,L.M., Hanson,L.N., Genschel,U., Reddy,M.B., Association of oxidative stress, iron, and centralized fat mass in healthy postmenopausal women, <i>Journal of Women's Health</i> , 18, 795-801, 2009	No relevant outcomes.
Cummings,J.A., Brizendine,L., Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women, <i>Menopause</i> , 9, 253-263, 2002	PICO not met - Intervention (combined HRT) given for less than 12 weeks
Cunha,E.P., Azevedo,L.H., Pompei,L.M., Strufaldi,R., Steiner,M.L., Ferreira,J.A., Peixoto,S., Fernandes,C.E., Effect of abrupt discontinuation versus gradual dose reduction of postmenopausal hormone therapy on hot flashes, <i>Climacteric</i> , 13, 362-367, 2010	This is a withdrawal study
Cuzick,J., Sestak,I., Cella,D., Fallowfield,L., ATAC Trialists' Group., Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial, <i>Lancet Oncology</i> , 9, 1143-1148, 2008	No relevant interventions or outcomes.
Dalais,F.S., Rice,G.E., Wahlqvist,M.L., Grehan,M., Murkies,A.L., Medley,G., Ayton,R., Strauss,B.J., Effects of dietary phytoestrogens in postmenopausal women, <i>Climacteric</i> , 1, 124-129, 1998	Outcome not of interest (hot flush rate and not enough information to determine how hot flush rate was calculated)
Daley,A.J., Stokes-Lampard,H., Thomas,A., Rees,M., Coleman,S., Roalfe,A., Hunter,M.S., MacArthur,C., Aerobic exercise as a treatment for vasomotor menopausal symptoms: randomised controlled trial protocol, <i>Maturitas</i> , 76, 350-356, 2013	Protocol
David,A., Don,R., Tajchner,G., Weissglas,L., Verapride: alternative antidopaminergic treatment for menopausal symptoms, <i>American Journal of Obstetrics and Gynecology</i> , 158, 1107-1115, 1988	Intervention not listed on protocol
Davidson,M.H., Maki,K.C., Marx,P., Maki,A.C., Cyrowski,M.S., Nanavati,N., Arce,J.C., Effects of continuous estrogen and estrogen-progestogen replacement regimens on cardiovascular risk markers in postmenopausal women, <i>Archives of Internal Medicine</i> , 160, 3315-3325, 2000	This is a cardio-vascular study
Davis,S., Papalia,M.A., Norman,R.J., O'Neill,S., Redelman,M., Williamson,M., Stuckey,B.G., Wlodarczyk,J., Gardner,K., Humberstone,A., Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial, <i>Annals of Internal Medicine</i> , 148, 569-577, 2008	PICO not met - Population include only pre-menopausal women
Davis,S.R., Davison,S.L., Wilson,S., Shepherd,J., Lawton,B., Intranasal versus transdermal matrix oestrogen replacement in Australasian women, <i>Maturitas</i> , 51, 163-171, 2005	Outcome reported in graphical format

Study	Reason for exclusion
Davis, S.R., Goldstat, R., Papalia, M.A., Shah, S., Kulkarni, J., Donath, S., Bell, R.J., Effects of aromatase inhibition on sexual function and well-being in postmenopausal women treated with testosterone: a randomized, placebo-controlled trial, <i>Menopause</i> , 13, 37-45, 2006	Intervention not of interest
Davis, S.R., Hirschberg, A.L., Wagner, L.K., Lodhi, I., von, Schoultz B., The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy, <i>Journal of Clinical Endocrinology and Metabolism</i> , 94, 4907-4913, 2009	Secondary publication of 255862. Evaluated the effects of testosterone therapy on mammographic density.
Davis, S.R., McCloud, P., Strauss, B.J., Burger, H., Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. [Reprint of <i>Maturitas</i> . 1995 Apr;21(3):227-36; PMID: 7616872], <i>Maturitas</i> , 61, 17-26, 2008	Results reported graphically.
Davis, S.R., Moreau, M., Kroll, R., Bouchard, C., Panay, N., Gass, M., Braunstein, G.D., Hirschberg, A.L., Rodenberg, C., Pack, S., Koch, H., Moufarege, A., Studd, J., Testosterone for low libido in postmenopausal women not taking estrogen: A phase iii research study of female sexual dysfunction in women on testosterone patch without estrogen (APHRODITE), <i>Obstetrical and Gynecological Survey</i> , 64, 170-172, 2009	Population and outcomes not of interest.
Davis, S.R., O'Neill, S.M., Eden, J., Baber, R., Ekangaki, A., Stocks, J.M., Thiebaud, D., Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study, <i>Menopause</i> , 11, 167-175, 2004	PICO not met - Combination of interventions investigated in 4 phases
Davis, S.R., van der Mooren, M.J., van Lunsen, R.H., Lopes, P., Ribot, C., Rees, M., Moufarege, A., Rodenberg, C., Buch, A., Purdie, D.W., Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. [Erratum appears in <i>Menopause</i> . 2006 Sep-Oct;13(5):850 Note: Ribot, Jean [corrected to Ribot, Claude]], <i>Menopause</i> , 13, 387-396, 2006	Results incalculable due to method of reporting.
de Luca, A.C., da Fonseca, A.M., Lopes, C.M., Bagnoli, V.R., Soares, J.M., Baracat, E.C., Acupuncture-ameliorated menopausal symptoms: single-blind, placebo-controlled, randomized trial, <i>Climacteric</i> , 14, 140-145, 2011	Results incalculable due to KI score
De Meersman, R.E., Zion, A.S., Giardina, E.G., Weir, J.P., Lieberman, J.S., Downey, J.A., Estrogen replacement, vascular distensibility, and blood pressures in postmenopausal women, <i>American Journal of Physiology</i> , 274, H1539-H1544, 1998	Outcome not relevant. Assessed the effects of estrogen on vascular distensibility and blood pressure.
de Paula, F.J., Soares, J.M., Jr., Haidar, M.A., de Lima, G.R., Baracat, E.C., The benefits of androgens combined with hormone replacement therapy regarding to patients with postmenopausal sexual symptoms, <i>Maturitas</i> , 56, 69-77, 2007	PICO not met - Combination of interventions investigated. All women already receiving HRT
de, Aloysio D., Rovati, L.C., Giacobelli, G., Setnikar, I., Bottiglioni, F., Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study, <i>Arzneimittel-Forschung</i> , 50, 293-300, 2000	No VMS frequency outcome
De, Aloysio D., Fabiani, A.G., Mauloni, M., Bottiglioni, F., Use of Org OD 14 for the treatment of climacteric complaints, <i>Maturitas</i> , 1, 49-65, 1987	PICO not met - Intervention (ORG OD 14) not of interest
De, Aloysio D., Rovati, L.C., Giacobelli, G., Setnikar, I., Bottiglioni, F., Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches / A randomized, double-blind placebo-controlled study, <i>Arzneimittel-Forschung/Drug Research</i> , 50, 293-300, 2000	Study reports change from baseline in percentages
De, Franciscis P., Cobellis, L., Fornaro, F., Sepe, E., Torella, M., Colacurci, N., Low-dose hormone therapy in the perimenopause, <i>International Journal of Gynaecology and Obstetrics</i> , 98, 138-142, 2007	Mean number of hot flashes was reported in a graphical format
De, Leo, V., la, Marca A., Morgante, G., Lanzetta, D., Florio, P., Petraglia, F., Evaluation of combining kava extract with hormone replacement therapy in the treatment of postmenopausal anxiety, <i>Maturitas</i> , 39, 185-188, 2001	PICO not met - Combination of interventions investigated
del, Giorno C., Fonseca, A.M., Bagnoli, V.R., Assis, J.S., Soares, J.M., Jr., Baracat, E.C., Effects of <i>Trifolium pratense</i> on the climacteric and sexual symptoms in postmenopause women, <i>Revista Da Associacao Medica Brasileira</i> , 56, 558-562, 2010	This study reports results as KI, not VMS frequency, and sexual satisfaction not coital frequency
Demetrio, F.N., Renno, J., Jr., Gianfaldoni, A., Goncalves, M., Halbe, H.W., Filho, A.H., Gorenstein, C., Effect of estrogen replacement therapy on symptoms of depression and anxiety in non-depressive menopausal women: a randomized double-blind, controlled study, <i>Archives of Women's Mental Health</i> , 14, 479-486, 2011	Does not match our review protocol
Dennerstein, L., Burrows, G.D., Hyman, G., Wood, C., Menopausal hot flashes: a double blind comparison of placebo, ethinyl oestradiol and norgestrel, <i>British Journal of Obstetrics and Gynaecology</i> , 85, 852-856, 1978	The study did not report hot flashes as frequency
Dennerstein, L., Burrows, G.D., Hyman, G.J., Sharpe, K., Hormone therapy and affect, <i>Maturitas</i> , 1, 247-259, 1979	Crossover study with no wash-out period mentioned
Dessole, S., Rubattu, G., Ambrosini, G., Gallo, O., Capobianco, G., Cherchi, P.L., Marci, R., Cosmi, E., Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women, <i>Menopause</i> , 11, 49-56, 2004	This is an atrophy study
Dew, T.P., Williamson, G., Controlled flax interventions for the improvement of menopausal symptoms and postmenopausal bone health: a systematic review, <i>Menopause</i> , 20, 1207-1215, 2013	Systematic review-individual studies have been excluded or included in the review

Study	Reason for exclusion
Dias,R., Kerr,Correa F., Moreno,R.A., Trinca,L., Pontes,A., Dalben,I., Halbe,H.W., Hrt with androgen as a strategy to treat postmenopausal depression: preliminary results, International Journal of Neuropsychopharmacology, 5, 86, 2002-, 2002	Conference abstract only.
Dias,R.S., Kerr-Correa,F., Moreno,R.A., Trinca,L.A., Pontes,A., Halbe,H.W., Gianfaldoni,A., Dalben,I.S., Efficacy of hormone therapy with and without methyltestosterone augmentation of venlafaxine in the treatment of postmenopausal depression: a double-blind controlled pilot study, Menopause, 13, 202-211, 2006	Combination interventions not of interest
Dickerson,J., Bressler,R., Christian,C.D., Hermann,H.W., Efficacy of estradiol vaginal cream in postmenopausal women, Clinical Pharmacology and Therapeutics, 26, 502-507, 1979	Outcome = blood chemistry
Diem,S., Grady,D., Quan,J., Vittinghoff,E., Wallace,R., Hanes,V., Ensrud,K., Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years, Menopause, 13, 130-138, 2006	Results reported as n% with flushes, not VSM frequency.
Ditkoff,E.C., Crary,W.G., Cristo,M., Lobo,R.A., Estrogen improves psychological function in asymptomatic postmenopausal women, Obstetrics and Gynecology, 78, 991-995, 1991	Conference abstract
Dobs,A.S., Nguyen,T., Pace,C., Roberts,C.P., Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women, Journal of Clinical Endocrinology and Metabolism, 87, 1509-1516, 2002	Outcomes not of interest.
Dodin,S., Asselin,G., Blanchet,C., Thiebaut,C., Gravel,K., Marc,I., Maunsell,E., Ernst,E., Wu,T., Acupuncture for menopausal hot flushes, Cochrane Database of Systematic Reviews, 2008. Article Number, -, 2008	Secondary data
Dodin,Sylvie, Blanchet,Claudine, Marc,Isabelle, Ernst,Edzard, Wu,Taixiang, Vaillancourt,Caroline, Paquette,Joalee, Maunsell,Elizabeth, Acupuncture for menopausal hot flushes, Cochrane Database of Systematic Reviews, -, 2013	Individual studies checked for inclusion criteria and checked in STAR for interventions and outcomes
Dormaaenen,A., Heimdal,M.R., Wang,C.E., Grimsgaard,A.S., Depression in postmenopause: a study on a subsample of the Acupuncture on Hot Flushes Among Menopausal Women (ACUFLASH) study, Menopause, 18, 525-530, 2011	Secondary publication of 227668
Dow,M.G., Hart,D.M., Forrest,C.A., Hormonal treatments of sexual unresponsiveness in postmenopausal women: a comparative study, British Journal of Obstetrics and Gynaecology, 90, 361-366, 1983	Secondary data
Draper,M.W., Flowers,D.E., Huster,W.J., Neild,J.A., Harper,K.D., Arnaud,C., A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women, Journal of Bone and Mineral Research, 11, 835-842, 1996	Bone turnover
Dugal,R., Hesla,K., Sordal,T., Aase,K.H., Lilleidet,O., Wickstrom,E., Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy, Acta Obstetrica et Gynecologica Scandinavica, 79, 293-297, 2000	Outcome not relevant
Duijts,S.F., Oldenburg,H.S., van,Beurden M., Aaronson,N.K., Cognitive behavioral therapy and physical exercise for climacteric symptoms in breast cancer patients experiencing treatment-induced menopause: design of a multicenter trial, BMC Women's Health, Vol.9, pp.15, 2009., -, -32676	Study protocol
Duijts,S.F., van,Beurden M., Oldenburg,H.S., Hunter,M.S., Kieffer,J.M., Stuiver,M.M., Gerritsma,M.A., Menke-Pluymers,M.B., Plaisier,P.W., Rijna,H., Lopes Cardozo,A.M., Timmers,G., van der,Meij S., van,der,V., Bijker,N., de Widt-Levert,L.M., Geenen,M.M., Heuff,G., van Dulken,E.J., Boven,E., Aaronson,N.K., Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial, Journal of Clinical Oncology, 30, 4124-4133, 2012	No VMS symptom frequency reported
Dumas,J.A., Albert,K.M., Naylor,M.R., Sites,C.K., Benkelfat,C., Newhouse,P.A., The effects of age and estrogen on stress responsivity in older women, American Journal of Geriatric Psychiatry, 20, 734-743, 2012	Does not mention if patients have menopausal symptoms
Edington,R.F., Chagnon,J.P., Steinberg,W.M., Clonidine (Dixarit) for menopausal flushing, Canadian Medical Association Journal, 123, 23-26, 1980	Neither the time point or washout period is clear
Edlefsen,K.L., Jackson,R.D., Prentice,R.L., Janssen,I., Rajkovic,A., O'Sullivan,M.J., Anderson,G., The effects of postmenopausal hormone therapy on serum estrogen, progesterone, and sex hormone-binding globulin levels in healthy postmenopausal women, Menopause, 17, 622-629, 2010	Secondary publication
Egarter,C., Huber,J., Leikmoser,R., Haidbauer,R., Pusch,H., Fischl,F., Putz,M., Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints, Maturitas, 23, 55-62, 1996	Results data presented irrelevantly
Ekblad,S., Lonnberg,B., Berg,G., Odkvist,L., Ledin,T., Hammar,M., Estrogen effects on postural balance in postmenopausal women without vasomotor symptoms: a randomized masked trial, Obstetrics and Gynecology, 95, 278-283, 2000	Frequency not calculable
El-Hage,G., Eden,J.A., Manga,R.Z., A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder, Climacteric, 10, 335-343, 2007	Outcome not of interest
Elkins,G.R., Fisher,W.I., Johnson,A.K., Hypnosis for hot flashes among postmenopausal women study: a study protocol of an ongoing randomized clinical	Study protocol

Study	Reason for exclusion
trial, BMC Complementary and Alternative Medicine, Vol.11, pp.92, 2011., -, - 32676	
Elkins,G.R., Fisher,W.I., Johnson,A.K., Hypnosis for hot flashes among postmenopausal women study: a study protocol of an ongoing randomized clinical trial, BMC Complementary and Alternative Medicine, 11, 92-, 2011	Study protocol
Engelman,H.M., Alekel,D.L., Hanson,L.N., Kanthasamy,A.G., Reddy,M.B., Blood lipid and oxidative stress responses to soy protein with isoflavones and phytic acid in postmenopausal women, American Journal of Clinical Nutrition, 81, 590-596, 2005	Wrong outcome and no outcomes reported
Ensrud,K.E., Joffe,H., Guthrie,K.A., Larson,J.C., Reed,S.D., Newton,K.M., Sternfeld,B., Lacroix,A.Z., Landis,C.A., Woods,N.F., Freeman,E.W., Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial, Menopause, 19, 848-855, 2012	Uses old PSQI global score (Buysse 1989)
Eriksen,B., A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women, American Journal of Obstetrics and Gynecology, 180, 1072-1079, 1999	No outcomes of interest
Eriksen,P.S., Rasmussen,H., Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study, European Journal of Obstetrics, Gynecology, and Reproductive Biology, 44, 137-144, 1992	This is an atrophy study
Erkkola,R., Vervarcke,S., Vansteelandt,S., Rompotti,P., De,Keukeleire D., Heyerick,A., A randomized, double-blind, placebo-controlled, cross-over pilot study on the use of a standardized hop extract to alleviate menopausal discomforts, Phytomedicine, 17, 389-396, 2010	Results KI only not frequency
Estrella,R.E., Landa,A.I., Lafuente,J.V., Gargiulo,P.A., Effects of antidepressants and soybean association in depressive menopausal women, Acta Poloniae Pharmaceutica, 71, 323-327, 2014	Data was not extractable
Evans,M.L., Pritts,E., Vittinghoff,E., McClish,K., Morgan,K.S., Jaffe,R.B., Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial, Obstetrics and Gynecology, 105, 161-166, 2005	Frequency not calculable
Fahraeus,L., Wallentin,L., High density lipoprotein subfractions during oral and cutaneous administration of 17 beta-estradiol to menopausal women, Journal of Clinical Endocrinology and Metabolism, 56, 797-801, 1983	Outcome not of interest
Farag,N.H., Barshop,B.A., Mills,P.J., Effects of estrogen and psychological stress on plasma homocysteine levels, Fertility and Sterility, 79, 256-260, 2003	No outcomes
Farag,N.H., Nelesen,R.A., Parry,B.L., Loreda,J.S., Dimsdale,J.E., Mills,P.J., Autonomic and cardiovascular function in postmenopausal women: the effects of estrogen versus combination therapy, American Journal of Obstetrics and Gynecology, 186, 954-961, 2002	No outcomes of interest
Fernandes,C.E., Pompei,L.M., Machado,R.B., Ferreira,J.A.S., Melo,N.R., Peixoto,S., Effects of estradiol and norethisterone on lipids, insulin resistance and carotid flow, Maturitas, 59, 249-258, 2008	No outcomes of interest
Ferrero,S., Gerbaldo,D., Fulcheri,E., Cristoforoni,P., Vaginal micronized progesterone in continuous hormone replacement therapy. A prospective randomized study, Minerva Ginecologica, 54, 519-530, 2002	Women were already taking HRT
Foidart,J.M., Beliard,A., Hedon,B., Ochsenein,E., Bernard,A.M., Bergeron,C., Thomas,J.L., Impact of percutaneous oestradiol gels in postmenopausal hormone replacement therapy on clinical symptoms and endometrium, British Journal of Obstetrics and Gynaecology, 104, 305-310, 1997	Wrong population
Foidart,J.M., Vervliet,J., Buytaert,P., Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints, Maturitas, 13, 99-107, 1991	Results - KI only for VMS outcomes, and atrophy measures
Fonseca,A.M., Bagnoli,V.R., Penteado,S.R., Paixao,J.S., Cavalcanti,A.L., Pinotti,J.A., Monophasic estrogen-progestogen therapy and sexuality in postmenopausal women, Clinical Drug Investigation, 27, 131-137, 2007	Outcomes not of interest
Foster,G.V., Zacur,H.A., Rock,J.A., Hot flashes in postmenopausal women ameliorated by danazol, Fertility and Sterility, 43, 401-404, 1985	Population and outcomes not relevant.
Franke,H.R., Snaaijer,F.F., Houben,P.W., van der Mooren,M.J., Treatment of dysfunctional uterine bleeding in the perimenopause: the effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment--a randomized, placebo-controlled, double-blind trial, Gynecological Endocrinology, 22, 692-697, 2006	PICO not met - Intervention (Goserelin) not of interest. Outcomes not relevant.
Freedman,R.R., Blacker,C.M., Estrogen raises the sweating threshold in postmenopausal women with hot flashes, Fertility and Sterility, 77, 487-490, 2002	No outcomes of interest
Frei-Kleiner,S., Schaffner,W., Rahlfs,V.W., Bodmer,Ch, Birkhauser,M., Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial, Maturitas, 51, 397-404, 2005	VSM outcome score rated, not frequency
Friebely,J.S., Shifren,J.L., Schiff,I., Regestein,Q.R., Preliminary observations on differing psychological effects of conjugated and esterified estrogen treatments, Journal of Womens Health and Gender-Based Medicine, 10, 181-187, 2001	Secondary publication
Frisk,J., Carlhall,S., Kallstrom,A.C., Lindh-Astrand,L., Malmstrom,A., Hammar,M., Long-term follow-up of acupuncture and hormone therapy on hot flushes in women	Older study of 256049

Study	Reason for exclusion
with breast cancer: a prospective, randomized, controlled multicenter trial, <i>Climacteric</i> , 11, 166-174, 2008	
Furuhjelm,M., Karlgren,E., Carlstrom,K., The effect of estrogen therapy on somatic and psychical symptoms in postmenopausal women, <i>Acta Obstetricia et Gynecologica Scandinavica</i> , 63, 655-661, 1984	Not a RCT
Galesanu,C., Lisnic,N., Moisii,L., Galesanu,R.G., Onofriescu,M., Effect of hormone replacement therapy on sexual dysfunction in postmenopausal women, <i>Gineco.ro</i> , 6, 186-191, 2010	Results data not reported as frequency
Galhardo,C.L., Soares,J.M.,Jr., Simoes,R.S., Haidar,M.A., Rodrigues de,Lima G., Baracat,E.C., Estrogen effects on the vaginal pH, flora and cytology in late postmenopause after a long period without hormone therapy, <i>Clinical and Experimental Obstetrics and Gynecology</i> , 33, 85-89, 2006	PICO not met - Symptom profile (vaginal atrophy) not of interest
Gallagher,J.C., Strzinek,R.A., Cheng,R.F., Ausmanas,M.K., Astl,D., Seljan,P., The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause, <i>Journal of Women's Health</i> , 21, 188-198, 2012	PICO not met. Outcome not of interest.
Gam,F., Helles,A., Andersen,B., Hormonal treatment of menopausal complaints. A controlled trial of two oestrogen gestagen sequential preparations, <i>UGESKR-LAEG</i> , 139, 2808-2812, 1977	Non English paper
Gambacciani,M., Ciaponi,M., Cappagli,B., Monteleone,P., Benussi,C., Bevilacqua,G., Genazzani,A.R., Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women, <i>Maturitas</i> , 44, 157-163, 2003	Outcomes not of interest and reported graphically.
Gambacciani,M., Ciaponi,M., Cappagli,B., Monteleone,P., Benussi,C., Bevilacqua,G., Genazzani,A.R., Postmenopausal femur bone loss: effects of a low dose hormone replacement therapy, <i>Maturitas</i> , 45, 175-183, 2003	outcome of interest not reported
Gambacciani,M., Ciaponi,M., Cappagli,B., Monteleone,P., Benussi,C., Bevilacqua,G., Vacca,F., Genazzani,A.R., Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women, <i>Maturitas</i> , 50, 91-97, 2005	Data in graphical format only
Gambacciani,M., Rosano,G., Cappagli,B., Pepe,A., Vitale,C., Genazzani,A.R., Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study, <i>Climacteric</i> , 14, 18-24, 2011	No outcomes of interest
Gambacciani,M., Spielmann,D., Genazzani,A.R., Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17beta-estradiol and trimegestone versus two regimens combining 1 or 2 mg 17beta-estradiol and norethisterone acetate, <i>Gynecological Endocrinology</i> , 21, 65-73, 2005	Climacteric symptoms in general
Ganz,P.A., Greendale,G.A., Petersen,L., Zibecchi,L., Kahn,B., Belin,T.R., Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial, <i>Journal of the National Cancer Institute</i> , 92, 1054-1064, 2000	PICO not met - Not all women had vasomotor symptoms. Outcome not relevant.
Gartoulla,P., Han,M.M., Red clover extract for alleviating hot flushes in postmenopausal women: a meta-analysis, <i>Maturitas</i> , 79, 58-64, 2014	Individual studies checked for inclusion criteria for interventions and outcomes of interest and checked in STAR
Gass,M.S., Rebar,R.W., Cuffie-Jackson,C., Cedars,M.I., Lobo,R.A., Shoupe,D., Judd,H.L., Buyalos,R.P., Clisham,P.R., A short study in the treatment of hot flushes with buccal administration of 17-beta estradiol, <i>Maturitas</i> , 49, 140-147, 2004	PICO not met - Intervention (Buccal estradiol) not of interest
Gast,M.J., Freedman,M.A., Vieweg,A.J., De Melo,N.R., Girao,M.J., Zinaman,M.J., Dyspareunia Study Group., A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women, <i>Menopause</i> , 16, 247-256, 2009	Results in graph only
Gelfand,M.M., Moreau,M., Ayotte,N.J., Hilditch,J.R., Wong,B.A., Lau,C.Y., Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: a placebo-controlled study, <i>Menopause</i> , 10, 29-36, 2003	Results data reported on graph
Gennari,C., Agnusdei,D., Crepaldi,G., Isaia,G., Mazzuoli,G., Ortolani,S., Bufalino,L., Passeri,M., Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause, <i>Menopause</i> , 5, 9-15, 1998	PICO not met - Intervention (Ipriflavone) not of interest. Outcomes not relevant.
George,C.W., Utian,W.H., Beumont,P.J.V., Beardwood,C.J., Effect of exogenous oestrogens on minor psychiatric symptoms in postmenopausal women, <i>South African Medical Journal</i> , 47, 2387-2388, 1973	Abstract
Gerdes,L.C., Sonnendecker,E.W., Polakow,E.S., Psychological changes effected by estrogen-progestogen and clonidine treatment in climacteric women, <i>American Journal of Obstetrics and Gynecology</i> , 142, 98-104, 1982	Secondary publication of 227276
Gerlinger,C., Gude,K., Hiemeyer,F., Schmelter,T., Schafers,M., An empirically validated responder definition for the reduction of moderate to severe hot flushes in postmenopausal women, <i>Menopause</i> , 19, 799-803, 2012	Article focuses on definition of treatment responders for the reduction of moderate to severe hot flushes in postmenopausal women
Gigliotti,B., Multinu,A., Lai,V.R., Role of pivagabine in the treatment of climacteric syndrome, <i>Arzneimittel-Forschung</i> , 47, 1317-1321, 1997	PICO not met - Intervention (Pivagabine) not of interest
Girdler,S.S., Hinderliter,A.L., Wells,E.C., Sherwood,A., Grewen,K.M., Light,K.C., Transdermal versus oral estrogen therapy in postmenopausal smokers:	Outcome = hemodynamic and endothelial effects.

Study	Reason for exclusion
hemodynamic and endothelial effects, <i>Obstetrics and Gynecology</i> , 103, 169-180, 2004	
Girdler,S.S., Hinderliter,A.L., West,S.G., Grewen,K., Steege,J., Light,K.C., Postmenopausal smokers show reduced hemodynamic benefit from oral hormone replacement, <i>American Journal of Cardiology</i> , 86, 590-592, 2000	PICO not met-Outcomes of interest not reported
Girdler,S.S., O'Briant,C., Steege,J., Grewen,K., Light,K.C., A comparison of the effect of estrogen with or without progesterone on mood and physical symptoms in postmenopausal women, <i>Journal of Womens Health and Gender-Based Medicine</i> , 8, 637-646, 1999	No outcomes of interest
Gol,M., Akan,P., Dogan,E., Karas,C., Saygili,U., Posaci,C., Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels, <i>Maturitas</i> , 53, 252-259, 2006	Wrong outcome: blood chemistry
Good,W.R., John,V.A., Ramirez,M., Higgins,J.E., Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Alora Study Group, <i>Climacteric</i> , 2, 29-36, 1999	Results reported as graph so cannot be quantified.
Goodwin,J.W., Green,S.J., Moinpour,C.M., Bearden,J.D.,III, Giguere,J.K., Jiang,C.S., Lippman,S.M., Martino,S., Albain,K.S., Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626, <i>Journal of Clinical Oncology</i> , 26, 1650-1656, 2008	Exclude for populations: Not all women with breast cancer were hormonally treated for breast cancer
Gordon,S., Walsh,B.W., Ciaccia,A.V., Siddhanti,S., Rosen,A.S., Plouffe,L.,Jr., Transition from estrogen-progesterone to raloxifene in postmenopausal women: effect on vasomotor symptoms, <i>Obstetrics and Gynecology</i> , 103, 267-273, 2004	Design not relevant to review question.
Gordon,S.F., Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy, <i>American Journal of Obstetrics and Gynecology</i> , 173, 998-1004, 1995	No primary data
Gossell-Williams,M., Hyde,C., Hunter,T., Simms-Stewart,D., Fletcher,H., McGrowder,D., Walters,C.A., Improvement in HDL cholesterol in postmenopausal women supplemented with pumpkin seed oil: pilot study, <i>Climacteric</i> , 14, 558-564, 2011	Secondary publication of 226591
Grady,D., Macer,J., Kristof,M., Shen,H., Tagliaferri,M., Creasman,J., Is a shorter hot flash diary just as good as a 7-day diary?, <i>Menopause</i> , 16, 932-936, 2009	Does not meet protocol
Grady,D., Sawaya,G.F., Johnson,K.C., Koltun,W., Hess,R., Vittinghoff,E., Kristof,M., Tagliaferri,M., Cohen,I., Ensrud,K.E., MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flashes: a phase II clinical trial, <i>Menopause</i> , 16, 458-465, 2009	Results data reported graphically
Granot,M., Yarnitsky,D., Itskovitz-Eldor,J., Granovsky,Y., Peer,E., Zimmer,E.Z., Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin2A receptor binding, <i>Obstetrics and Gynecology</i> , 98, 450-457, 2001	Outcome = platelets
Graser,T., Romer,T., Wiedey,K.D., Janaud,A., Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints, <i>Climacteric</i> , 4, 332-342, 2001	Not RCT
Greendale,G.A., Petersen,L., Zibecchi,L., Ganz,P.A., Factors related to sexual function in postmenopausal women with a history of breast cancer, <i>Menopause</i> , 8, 111-119, 2001	Secondary publication of 226536. Cross-sectional analyses of baseline trial data
Greendale,G.A., Reboussin,B.A., Hogan,P., Barnabei,V.M., Shumaker,S., Johnson,S., Barrett-Connor,E., Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestogen Interventions Trial, <i>Obstetrics and Gynecology</i> , 92, 982-988, 1998	No outcomes of interest
Greene,R.A., Estrogen and cerebral blood flow: a mechanism to explain the impact of estrogen on the incidence and treatment of Alzheimer's disease, <i>International Journal of Fertility and Womens Medicine</i> , 45, 253-257, 2000	Outcome not of interest
Guichard,J.P., Sauron,R., Jones,A.B., Comparison of the pharmacokinetics of 17 beta-estradiol after a single 4-day application of Oesclim 50, Oesclim 100, and Vivelle 0.05 (Menorest 50) transdermal delivery systems, <i>Journal of Clinical Pharmacology</i> , 39, 811-816, 1999	No outcomes of interest reported
Gupta,B., Mittal,P., Khuteta,R., Bhargava,A., A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause, <i>Journal of obstetrics and gynaecology of India</i> , 63, 194-198, 2013	Wrong outcome
Gupta,P., Ozel,B., Stanczyk,F.Z., Felix,J.C., Mishell,D.R.,Jr., The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status, <i>Menopause</i> , 15, 94-97, 2008	PICO not met - Population (vaginal atrophy) not of interest
Guttuso,Jr, McDermott,M.P., Ng,P., Kiebertz,K., Effect of L-methionine on hot flashes in postmenopausal women: A randomized controlled trial, <i>Menopause</i> , 16, 1004-1008, 2009	Methionine: intervention not of interest
Guttuso,T.,Jr., McDermott,M.P., Ng,P., Kiebertz,K., Effect of L-methionine on hot flashes in postmenopausal women: a randomized controlled trial, <i>Menopause</i> , 16, 1004-1008, 2009	Methionine: intervention not of interest
Haas,S., Walsh,B., Evans,S., Krache,M., Ravnkar,V., Schiff,I., The effect of transdermal estradiol on hormone and metabolic dynamics over a six-week period, <i>Obstetrics and Gynecology</i> , 71, 671-676, 1988	Baseline estimates were presented graphically.

Study	Reason for exclusion
Hachul,H., Garcia,T.K., Maciel,A.L., Yagihara,F., Tufik,S., Bittencourt,L., Acupuncture improves sleep in postmenopause in a randomized, double-blind, placebo-controlled study, <i>Climacteric</i> , 16, 36-40, 2013	Does not report sample size per treatment group
Hackman,B.W., Galbraith,D., Six month pilot study of oestrogen replacement therapy with piperazine oestrone sulphate and its effect on memory, <i>Current Medical Research and Opinion</i> , 4, 21-28, 1977	Not all patients have menopausal symptoms
Hagen,C., Christensen,M.S., Christiansen,C., Stocklund,K.E., Transbol,I., Effects of two years' estrogen-gestagen replacement on climacteric symptoms and gonadotropins in the early postmenopausal period, <i>Acta Obstetrica et Gynecologica Scandinavica</i> , 61, 237-241, 1982	KI composite score
Hailes,J.D., Nelson,J.B., Schneider,M., Conjugated equine estrogen versus placebo in the management of menopausal symptoms, <i>Medical Journal of Australia</i> , 2, 340-342, 1981	No relevant data
Haimov-Kochman,R., Barak-Glantz,E., Arbel,R., Leefsma,M., Brzezinski,A., Milwidsky,A., Hochner-Celnikier,D., Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study, <i>Menopause</i> , 13, 370-376, 2006	Results not calculable
Haines,C.J., Xing,S.M., Park,K.H., Holinka,C.F., Ausmanas,M.K., Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study, <i>Maturitas</i> , 52, 264-276, 2005	Secondary publication
Haines,C.J., Yim,S.F., Chung,T.K., Lam,C.W., Lau,E.W., Ng,M.H., Chin,R., Lee,D.T., A prospective, randomized, placebo-controlled study of the dose effect of oral oestradiol on menopausal symptoms, psychological well being, and quality of life in postmenopausal Chinese women, <i>Maturitas</i> , 44, 207-214, 2003	Results reported as KI score
Haines,C.J., Yim,S.F., Chung,T.K.H., Lam,C.W.K., Lau,E.W.C., Ng,M.H.L., Chin,R., Lee,D.T.S., A prospective, randomized, placebo-controlled study of the dose effect of oral estradiol on bone mineral density in postmenopausal Chinese women, <i>Maturitas</i> , 45, 169-173, 2003	Bone density paper
Hall,G.M., Daniels,M., Huskisson,E.C., Spector,T.D., A randomised controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis, <i>Annals of the Rheumatic Diseases</i> , 53, 112-116, 1994	Disease activity study
Hamada,A.L., Maruo,T., Samoto,T., Yoshida,S., Nash,H., Spitz,I.M., Johansson,E., Estradiol/progesterone-releasing vaginal rings for hormone replacement therapy in postmenopausal women, <i>Gynecological Endocrinology</i> , 17, 247-254, 2003	Outcome estimates presented graphically.
Hammar,M., Christau,S., Nathorst-Boos,J., Rud,T., Garre,K., A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms, <i>British Journal of Obstetrics and Gynaecology</i> , 105, 904-911, 1998	Hot flush scoring used
Hammar,M., Ekblad,S., Lonnberg,B., Berg,G., Lindgren,R., Wyon,Y., Postmenopausal women without previous or current vasomotor symptoms do not flush after abruptly abandoning estrogen replacement therapy, <i>Maturitas</i> , 31, 117-122, 1999	PICO not met - Women were asymptomatic
Hammes,M., Acupuncture and auricular acupressure in relieving menopausal hot flashes of bilaterally ovariectomized Chinese women: A randomized controlled trial, <i>Deutsche Zeitschrift fur Akupunktur</i> , 52, 35-36, 2009	Non-English language
Hartley,D.E., Elsabagh,S., File,S.E., Gincosan (a combination of Ginkgo biloba and Panax ginseng): the effects on mood and cognition of 6 and 12 weeks' treatment in post-menopausal women, <i>Nutritional Neuroscience</i> , 7, 325-333, 2004	Does not indicate if women had menopausal symptoms
Harvey,A.T., Silkey,B.S., Kornstein,S.G., Clary,C.M., Acute worsening of chronic depression during a double-blind, randomized clinical trial of antidepressant efficacy: differences by sex and menopausal status, <i>Journal of Clinical Psychiatry</i> , 68, 951-958, 2007	Intervention (imipramine, a tricyclic antidepressant) not of interest
Haskell,S.G., Richardson,E.D., The effect of raloxifene on cognitive function in postmenopausal women: a randomized clinical trial, <i>Connecticut Medicine</i> , 68, 355-358, 2004	Study excluded women with potential menopausal symptoms (received oestrogen treatment within last 6 months)
Hassa,H., Tanir,H.M., Oge,T., Is placebo as effective as estrogen regimens on vasomotor symptoms in women with surgical menopause?, <i>Clinical and Experimental Obstetrics and Gynecology</i> , 37, 135-137, 2010	The study reported outcomes at 6 months
Hautamaki,H., Haapalahti,P., Piirila,P., Tuomikoski,P., Sovijarvi,A., Ylikorkala,O., Mikkola,T.S., Effect of hot flushes on cardiovascular autonomic responsiveness: a randomized controlled trial on hormone therapy, <i>Maturitas</i> , 72, 243-248, 2012	Outcome not relevant
Hayes,L.P., Carroll,D.G., Kelley,K.W., Use of gabapentin for the management of natural or surgical menopausal hot flashes, <i>Annals of Pharmacotherapy</i> , 45, 388-394, 2011	Review
Hays,J., Ockene,J.K., Brunner,R.L., Kotchen,J.M., Manson,J.E., Patterson,R.E., Aragaki,A.K., Shumaker,S.A., Brzyski,R.G., LaCroix,A.Z., Granek,I.A., Valanis,B.G., Women's Health Initiative Investigators., Effects of estrogen plus progestogen on health-related quality of life, <i>New England Journal of Medicine</i> , 348, 1839-1854, 2003	Secondary publication

Study	Reason for exclusion
Heger,M., Ventskovskiy,B.M., Borzenko,I., Kneis,K.C., Rettenberger,R., Kaszkin-Bettag,M., Heger,P.W., Efficacy and safety of a special extract of <i>Rheum rhaponticum</i> (ERr 731) in perimenopausal women with climacteric complaints: a 12-week randomized, double-blind, placebo-controlled trial.[Erratum appears in <i>Menopause</i> . 2007 Mar-Apr;14(2):339], <i>Menopause</i> , 13, 744-759, 2006	MRS score
Heikkinen,J., Vaheri,R., Timonen,U., Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomised comparison of low and standard doses.[Erratum appears in <i>J Br Menopause Soc</i> . 2004 Dec;10(4):168], <i>Journal of the British Menopause Society</i> , 10, 95-102, 2004	Secondary publication
Heikkinen,J., Vaheri,R., Timonen,U., A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: Update of safety and quality-of-life findings.[Erratum appears in <i>J Br Menopause Soc</i> . 2006 Dec;12(4):174], <i>Journal of the British Menopause Society</i> , 12, 115-125, 2006	Secondary publication
Heimer,G.M., Englund,D.E., Effects of vaginally-administered oestril on postmenopausal urogenital disorders: a cyto hormonal study, <i>Maturitas</i> , 14, 171-179, 1992	PICO not met - Symptom profile (vaginal atrophy) not of interest
Heinrich,A.B., Wolf,O.T., Investigating the effects of estradiol or estradiol/progesterone treatment on mood, depressive symptoms, menopausal symptoms and subjective sleep quality in older healthy hysterectomized women: a questionnaire study, <i>Neuropsychobiology</i> , 52, 17-23, 2005	Trial groups have not been randomised.
Heitmann,C., Greiser,E., Doren,M., The impact of the Women's Health Initiative Randomized Controlled Trial 2002 on perceived risk communication and use of postmenopausal hormone therapy in Germany, <i>Menopause</i> , 12, 405-411, 2005	No outcomes of interest
Hemminki,E., Veerus,P., Pisarev,H., Hovi,S.L., Topo,P., Karro,H., The effects of postmenopausal hormone therapy on social activity, partner relationship, and sexual life - experience from the EPHT trial, <i>BMC Women's Health</i> , Vol.9, pp.16, 2009., -, -32676	Secondary publication
Hermenegildo,C., Oviedo,P.J., Laguna,A., Garcia-Perez,M.A., Tarin,J.J., Cano,A., Transdermal estradiol reduces F2alpha-isoprostane levels in postmenopausal women, <i>Menopause</i> , 15, 714-717, 2008	PICO not met - Intervention given for less than 12 weeks. Outcomes not of relevance.
Hernandez,MunozG, Pluchino,S., <i>Cimicifuga racemosa</i> for the treatment of hot flashes in women surviving breast cancer, <i>Maturitas</i> , 44, S59-S65, 2003	Combination therapy (tamoxifen herbal) is not of interest
Heyerick,A., Vervarcke,S., Depypere,H., Bracke,M., De,Keukeleire D., A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts, <i>Maturitas</i> , 54, 164-175, 2006	Outcome not of interest.
Hickok,L.R., Toomey,C., Speroff,L., A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women, <i>Obstetrics and Gynecology</i> , 82, 919-924, 1993	Histology study
Hidalgo,L.A., Chedraui,P.A., Morocho,N., Ross,S., San,MiguelG, The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: A randomized, double-blind, placebo-controlled study, <i>Gynecological Endocrinology</i> , 21, 257-264, 2005	KI results
Hilditch,J.R., Lewis,J., Ross,A.H., Peter,A., van,Maris B., Franssen,E., Charles,J., Norton,P., Dunn,E.V., A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestogen on quality of life in postmenopausal women, <i>Maturitas</i> , 24, 177-184, 1996	Results not calculable
Hirata,J.D., Swiersz,L.M., Zell,B., Small,R., Ettinger,B., Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial, <i>Fertility and Sterility</i> , 68, 981-986, 1997	Outcome = endometrial cell changes.
Hirvonen,E., Cacciatore,B., Wahlstrom,T., Rita,H., Wilen-Rosenqvist,G., Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch, <i>British Journal of Obstetrics and Gynaecology</i> , 104 Suppl 16, 26-31, 1997	No outcomes of interest
Hirvonen,E., Crona,N., Wahlstrom,T., Backstrom,A.C., Effect of an estradiol gel with monthly or quarterly progestogen on menopausal symptoms and bleeding, <i>Climacteric</i> , 3, 262-270, 2000	Not RCT
Hirvonen,E., Lamberg-Allardt,C., Lankinen,K.S., Geurts,P., Wilen-Rosenqvist,G., Transdermal oestradiol gel in the treatment of the climacterium: a comparison with oral therapy, <i>British Journal of Obstetrics and Gynaecology</i> , 104 Suppl 16, 19-25, 1997	No outcomes of interest
Hitchcock,C.L., Elliott,T.G., Norman,E.G., Stajic,V., Teede,H., Prior,J.C., Hot flashes and night sweats differ in associations with cardiovascular markers in healthy early postmenopausal women, <i>Menopause</i> , 19, 1208-1214, 2012	No relevant data
Hlatky,M.A., Boothroyd,D., Vittinghoff,E., Sharp,P., Whooley,M.A., Heart and Estrogen/Progestogen Replacement Study (HERS) Research Group., Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestogen Replacement Study (HERS) trial, <i>JAMA</i> , 287, 591-597, 2002	Secondary publication
Holdright,D.R., Sullivan,A.K., Wright,C.A., Sparrow,J.L., Cunningham,D., Fox,K.M., Acute effect of oestrogen replacement therapy on treadmill performance in postmenopausal women with coronary artery disease, <i>European Heart Journal</i> , 16, 1566-1570, 1995	PICO not met - Intervention (Transdermal estradiol) given for less than 12 weeks



Study	Reason for exclusion
Howes,L.G., Howes,J.B., Knight,D.C., Isoflavone therapy for menopausal flushes: a systematic review and meta-analysis, <i>Maturitas</i> , 55, 203-211, 2006	Systematic review
Hsu,C.C., Kuo,H.C., Chang,S.Y., Wu,T.C., Huang,K.E., The assessment of efficacy of <i>Dioscorea alata</i> for menopausal symptom treatment in Taiwanese women, <i>Climacteric</i> , 14, 132-139, 2011	Composite Greene score
Huang,A., Yaffe,K., Vittinghoff,E., Kuppermann,M., Addis,I., Hanes,V., Quan,J., Grady,D., The effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women, <i>American Journal of Obstetrics and Gynecology</i> , 198, 265-267, 2008	Results not calculable
Huang,A.J., Sawaya,G.F., Vittinghoff,E., Lin,F., Grady,D., Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women, <i>Menopause</i> , 16, 639-643, 2009	No relevant data
Huang,M.I., Nir,Y., Chen,B., Schnyer,R., Manber,R., A randomized controlled pilot study of acupuncture for postmenopausal hot flashes: effect on nocturnal hot flashes and sleep quality, <i>Fertility and Sterility</i> , 86, 700-710, 2006	Results reported as graphs
Hudita,D., Posea,C., Ceausu,I., Rusu,M., Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women, <i>European Review for Medical and Pharmacological Sciences</i> , 7, 117-125, 2003	Scoring of VSM results
Hunter, M., Liao K., Evaluation of a four-session cognitive-behavioural intervention for menopause hot flushes, <i>British Journal of Health Psychology</i> , 1, 113-125, 1996	Randomly allocated groups in trial (CBT vs waiting list) too small for inclusion (n=12). Other comparisons were not randomised.
Huntley,A.L., Ernst,E., Soy for the treatment of perimenopausal symptoms--a systematic review. [35 refs], <i>Maturitas</i> , 47, 1-9, 2004	Systematic review
Huntley,L., Ernst,E., A systematic review of herbal medicinal products for the treatment of menopausal symptoms, <i>Menopause</i> , 10, 465-76, 2003	Secondary data
Inan,I., Kelekci,S., Yilmaz,B., Psychological effects of tibolone and sequential estrogen-progestogen therapy in perimenopausal women, <i>Gynecological Endocrinology</i> , 20, 64-67, 2005	Populations do not have menopausal symptoms of interest
Ishiwata,N., Melby,M.K., Mizuno,S., Watanabe,S., New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women, <i>Menopause</i> , 16, 141-148, 2009	Reported as composite Green scale
Ito,T.Y., Polan,M.L., Whipple,B., Trant,A.S., The enhancement of female sexual function with ArginMax, a nutritional supplement, among women differing in menopausal status, <i>Journal of Sex and Marital Therapy</i> , 32, 369-378, 2006	PICO not met - Population include a majority of pre-menopausal women
Jackson,S., James,M., Abrams,P., The effect of oestradiol on vaginal collagen metabolism in postmenopausal women with genuine stress incontinence, <i>BJOG: An International Journal of Obstetrics and Gynaecology</i> , 109, 339-344, 2002	PICO not met - Population only included women with stress urinary incontinence
Jackson,S., Shepherd,A., Brookes,S., Abrams,P., The effect of oestrogen supplementation on post-menopausal urinary stress incontinence: a double-blind placebo-controlled trial, <i>British Journal of Obstetrics and Gynaecology</i> , 106, 711-718, 1999	Incontinence
Jacobs,A., Wegewitz,U., Sommerfeld,C., Grossklaus,R., Lampen,A., Efficacy of isoflavones in relieving vasomotor menopausal symptoms - A systematic review. [75 refs], <i>Molecular Nutrition and Food Research</i> , 53, 1084-1097, 2009	Not primary data
Jacobson,J.S., Troxel,A.B., Evans,J., Klaus,L., Vahdat,L., Kinne,D., Lo,K.M., Moore,A., Rosenman,P.J., Kaufman,E.L., Neugut,A.I., Grann,V.R., Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer, <i>Journal of Clinical Oncology</i> , 19, 2739-2745, 2001	Hot flush frequency presented in graphical format only
Jarkova,N.B., Martenyi,F., Masanauskaitė,D., Walls,E.L., Smetnik,V.P., Pavo,I., Mood effect of raloxifene in postmenopausal women, <i>Maturitas</i> , 42, 71-75, 2002	Population does not include women with post-menopausal symptoms
Jarvinen,P.A., Kokkonen,J., Ryhanen,P., Oestriol succinate in the treatment of climacteric women (a double-blind trial), <i>Acta Obstetrica et Gynecologica Scandinavica - Supplement</i> , 9, Suppl-, 1971	Outcome not of interest.
Jenks,B.H., Iwashita,S., Nakagawa,Y., Ragland,K., Lee,J., Carson,W.H., Ueno,T., Uchiyama,S., A pilot study on the effects of S-equol compared to soy isoflavones on menopausal hot flash frequency, <i>Journal of Women's Health</i> , 21, 674-682, 2012	Combination therapy (phytoestrogen treatments combined with placebo)
Jensen,J., Christiansen,C., Dose-response and withdrawal effects on climacteric symptoms after hormonal replacement therapy. A placebo-controlled therapeutic trial, <i>Maturitas</i> , 5, 125-133, 1983	Outcome is withdrawal effects from HRT
Jensen,P.B., Jensen,J., Riis,B.J., Rodbro,P., Strom,V., Christiansen,C., Climacteric symptoms after oral and percutaneous hormone replacement therapy, <i>Maturitas</i> , 9, 207-215, 1987	Outcome estimate expressed in terms of Kupperman index and graphically.
Jirapinyo,M., Theppisai,U., Manonai,J., Suchartwatnachai,C., Jorgensen,L.N., Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naive Thai women, <i>Acta Obstetrica et Gynecologica Scandinavica</i> , 82, 857-866, 2003	Histology
Joffe,H., Guthrie,K.A., Larson,J., Cohen,L.S., Carpenter,J.S., Lacroix,A.Z., Freeman,E.W., Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network, <i>Menopause</i> , 20, 261-268, 2013	Outcome not of interest
Joffe,H., Hall,J.E., Gruber,S., Sarmiento,I.A., Cohen,L.S., Yurgelun-Todd,D., Martin,K.A., Estrogen therapy selectively enhances prefrontal cognitive processes:	Outcome not of interest

Study	Reason for exclusion
a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women, <i>Menopause</i> , 13, 411-422, 2006	
Joffe,H., Partridge,A., Giobbie-Hurder,A., Li,X., Habin,K., Goss,P., Winer,E., Garber,J., Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: A randomized, double-blind, placebo-controlled trial, <i>Menopause</i> , 17, 908-916, 2010	Intervention not of interest (zolpidem)
Joffe,H., Petrillo,L.F., Koukopoulos,A., Viguera,A.C., Hirschberg,A., Nonacs,R., Somley,B., Pasciullo,E., White,D.P., Hall,J.E., Cohen,L.S., Increased estradiol and improved sleep, but not hot flashes, predict enhanced mood during the menopausal transition, <i>Journal of Clinical Endocrinology and Metabolism</i> , 96, E1044-E1054, 2011	PICO not met - Intervention (zolpidem) not of interest
Johnson,S.R., Ettinger,B., Macer,J.L., Ensrud,K.E., Quan,J., Grady,D., Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol, <i>Obstetrics and Gynecology</i> , 105, 779-787, 2005	Secondary publication
Johnston,C.C., Bjarnason,N.H., Cohen,F.J., Shah,A., Lindsay,R., Mitlak,B.H., Huster,W., Draper,M.W., Harper,K.D., Heath,H., Gennari,C., Christiansen,C., Arnaud,C.D., Delmas,P.D., Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials, <i>Archives of Internal Medicine</i> , 160, 3444-3450, 2000	Pooled analysis of 2 RCT's
Jou,H.J., Wu,S.C., Chang,F.W., Ling,P.Y., Chu,K.S., Wu,W.H., Effect of intestinal production of equol on menopausal symptoms in women treated with soy isoflavones, <i>International Journal of Gynaecology and Obstetrics</i> , 102, 44-49, 2008	Results of interest not calculable
Kagan,R., Williams,R.S., Pan,K., Mirkin,S., Pickar,J.H., A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women, <i>Menopause</i> , 17, 281-289, 2010	Atrophy outcome
Kalogirou,D., Antoniou,G., Karakitsos,P., Kalogirou,O., Antoniou,D., Giannikos,L., A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response, <i>International Journal of Fertility and Menopausal Studies</i> , 41, 522-527, 1996	Atrophy outcome
Kalyan,S., Hitchcock,C.L., Sirrs,S., Pudek,M., Prior,J.C., Cardiovascular and metabolic effects of medroxyprogesterone acetate versus conjugated equine estrogen after premenopausal hysterectomy with bilateral ovariectomy, <i>Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy</i> , 30, 442-452, 2010	Secondary publication of 227180. Outcomes not of interest
Kao,C.L., Chen,C.H., Lin,W.Y., Chiao,Y.C., Hsieh,C.L., Effect of auricular acupuncture on peri- and early postmenopausal women with anxiety: a double-blinded, randomized, and controlled pilot study, <i>Evidence-Based Complementary and Alternative Medicine: eCAM</i> , 2012, 567639-, 2012	Intervention not of interest
Karsidag,A.Y., Karsidag,C., Buyukbayrak,E.E., Kars,B., Pirimoglu,M., Unal,O., Turan,M.C., Raloxifene: is it really effective on mood changes in postmenopausal osteopenic women?, <i>Journal of Psychosomatic Obstetrics and Gynecology</i> , 31, 273-278, 2010	Population do not include women with menopausal symptoms
Kaszkin-Bettag,M., Ventskovskiy,B.M., Kravchenko,A., Rettenberger,R., Richardson,A., Heger,P.W., Heger,M., The special extract ERr 731 of the roots of <i>Rheum raphaniticum</i> decreases anxiety and improves health state and general well-being in perimenopausal women, <i>Menopause</i> , 14, 270-283, 2007	Secondary publication of 227749
Kaszkin-Bettag,M., Ventskovskiy,B.M., Solskyy,S., Beck,S., Hasper,I., Kravchenko,A., Rettenberger,R., Richardson,A., Heger,P.W., Confirmation of the efficacy of ERr 731 in perimenopausal women with menopausal symptoms, <i>Alternative Therapies in Health and Medicine</i> , 15, 24-34, 2009	Results = MRS score
Katz,D.L., Evans,M.A., Njike,V.Y., Hoxley,M.L., Nawaz,H., Comerford,B.P., Sarrel,P.M., Raloxifene, soy phytoestrogens and endothelial function in postmenopausal women, <i>Climacteric</i> , 10, 500-507, 2007	Outcome not relevant. Compared the effects of raloxifene and soy phytoestrogens on endothelial function.
Kawano,H., Yasue,H., Hirai,N., Yoshida,T., Fukushima,H., Miyamoto,S., Kojima,S., Hokamaki,J., Nakamura,H., Yodoi,J., Ogawa,H., Effects of transdermal and oral estrogen supplementation on endothelial function, inflammation and cellular redox state, <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 41, 346-353, 2003	PICO not met - Outcomes of interest not reported
Keefer,L., Blanchard,E.B., A behavioral group treatment program for menopausal hot flashes: results of a pilot study, <i>Applied Psychophysiology and Biofeedback</i> , 30, 21-30, 2005	Outcome estimates reported not relevant
Kenemans,P., Bundred,N.J., Foidart,J.M., Kubista,E., von,Schultz B., Sismondi,P., Vassilopoulou-Sellin,R., Yip,C.H., Egberts,J., Mol-Arts,M., Mulder,R., van,Os S., Beckmann,M.W., LIBERATE Study Group., Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial, <i>Lancet Oncology</i> , 10, 135-146, 2009	Outcome not of interest (breast cancer recurrence)
Kerwin,J.P., Gordon,P.R., Senf,J.H., The variable response of women with menopausal hot flashes when treated with sertraline, <i>Menopause</i> , 14, 841-845, 2007	Secondary publication of 227739

Study	Reason for exclusion
Kessel,B., Nachtigall,L., Plouffe,L., Siddhanti,S., Rosen,A., Parsons,A., Effect of raloxifene on sexual function in postmenopausal women, <i>Climacteric</i> , 6, 248-256, 2003	Scoring used for frequency of sexual intercourse/activity and treatments not of interest (selective oestrogen-receptor modulator/oestrogen)
Khoo,S.K., Coglan,M., Battistutta,D., Tippett,V., Raphael,B., Hormonal treatment and psychological function during the menopausal transition: an evaluation of the effects of conjugated estrogens/cyclic medroxyprogesterone acetate, <i>Climacteric</i> , 1, 55-62, 1998	Unclear which psychological scale used in results
Kicovic,P.M., Cortes-Prieto,J., Luisi,M., Placebo-controlled cross-over study of effects of Org OD 14 in menopausal women, <i>Reproduccion</i> , 6, 81-91, 1982	Results of interest not calculable due to composite scoring
Kim,H.Y., Lee,B.I., The effects of black cohosh root extract on the vasomotor symptom and bone metabolism of menopausal women, <i>Maturitas</i> , Vol.54S, pp.s71, 2006., -	Abstract
Kim,K.-H., Kang,K.-K., Jung,H.-J., Park,J.-E., Jung,S.-Y., Choi,J.-Y., Choi,S.-M., Study protocol: effects of acupuncture on hot flushes in perimenopausal and postmenopausal women - a multicenter randomized clinical trial, <i>Trials</i> , Vol.9, pp.70TN: ISRCTN49335612/ISRCTN, 2008., ISRCTN49335612/ISRCTN-, 2008	Study protocol
Kim,S.Y., Seo,S.K., Choi,Y.M., Jeon,Y.E., Lim,K.J., Cho,S., Choi,Y.S., Lee,B.S., Effects of red ginseng supplementation on menopausal symptoms and cardiovascular risk factors in postmenopausal women: a double-blind randomized controlled trial, <i>Menopause</i> , 19, 461-466, 2012	No outcomes of interest
Kingsberg,S., Shifren,J., Wekselman,K., Rodenberg,C., Koochaki,P., Derogatis,L., Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder, <i>Journal of Sexual Medicine</i> , 4, 1001-1008, 2007	Pooled analysis of two RCT's
Kirkham,C., Hahn,P.M., Van,VugtD, Carmichael,J.A., Reid,R.L., A randomized, double-blind, placebo-controlled, cross-over trial to assess the side effects of medroxyprogesterone acetate in hormone replacement therapy, <i>Obstetrics and Gynecology</i> , 78, 93-97, 1991	No outcomes of interest
Klaiber,E.L., Broverman,D.M., Vogel,W., Kobayashi,Y., Estrogen therapy for severe persistent depressions in women, <i>Archives of General Psychiatry</i> , 36, 550-554, 1979	Includes pre-menopausal women
Kobata,S.A., Girao,M.J., Baracat,E.C., Kajikawa,M., Di,Bella V., Jr., Sartori,M.G., Jarmy-Di Bella,Z.I., Estrogen therapy influence on periurethral vessels in postmenopausal incontinent women using Dopplervelocimetry analysis, <i>Maturitas</i> , 61, 243-247, 2008	PICO not met - Population only included women with urinary incontinence. Outcomes also not of interest.
Koh,K.K., Cardillo,C., Bui,M.N., Hathaway,L., Csako,G., Waclawiw,M.A., Panza,J.A., Cannon,R.O., III, Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women, <i>Circulation</i> , 99, 354-360, 1999	PICO not met - Women were asymptomatic
Kohama,T., Negami,M., Effect of low-dose French maritime pine bark extract on climacteric syndrome in 170 perimenopausal women: a randomized, double-blind, placebo-controlled trial, <i>Journal of Reproductive Medicine</i> , 58, 39-46, 2013	Results of interest not calculable due to composite scoring
Koike,K., Ohno,S., Takahashi,N., Suzuki,N., Nozaki,N., Murakami,K., Sugiura,K., Yamada,K., Inoue,M., Efficacy of the herbal medicine Unkei-to as an adjunctive treatment to hormone replacement therapy for postmenopausal women with depressive symptoms, <i>Clinical Neuropharmacology</i> , 27, 157-162, 2004	PICO not met - Population consisted of treatment-resistant women
Kok,L., Kreijkamp-Kaspers,S., Grobbee,D.E., Lampe,J.W., van der Schouw,Y.T., A randomized, placebo-controlled trial on the effects of soy protein containing isoflavones on quality of life in postmenopausal women, <i>Menopause</i> , 12, 56-62, 2005	Women did not have major menopausal complaints and no mention of menopausal symptoms
Kokcu,A., Cetinkaya,M.B., Yanik,F., Alper,T., Malatyalioglu,E., The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women, <i>Maturitas</i> , 36, 75-80, 2000	Coital frequency scores
Komesaroff,P.A., Black,C.V., Cable,V., Sudhir,K., Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women, <i>Climacteric</i> , 4, 144-150, 2001	Outcome estimates based on symptom scores
Komesaroff,P.A., Esler,M.D., Sudhir,K., Estrogen supplementation attenuates glucocorticoid and catecholamine responses to mental stress in perimenopausal women, <i>Journal of Clinical Endocrinology and Metabolism</i> , 84, 606-610, 1999	PICO not met - Women were asymptomatic
Kornafel,K.L., March,C.M., Estradiol gel in the treatment of menopausal symptoms: a placebo-controlled double-blind case study of efficacy and safety, <i>Southern Medical Journal</i> , 85, 270-273, 1992	Outcome estimates reported not of relevance
Kornstein,S.G., Jiang,Q., Reddy,S., Musgnung,J.J., Guico-Pabia,C.J., Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder, <i>Journal of Clinical Psychiatry</i> , 71, 1088-1096, 2010	PICO not met - Intervention (Desvenlafaxine) not of interest. Population not of interest.
Kotsopoulos,D., Dalais,F.S., Liang,Y.L., McGrath,B.P., Teede,H.J., The effects of soy protein containing phytoestrogens on menopausal symptoms in postmenopausal women, <i>Climacteric</i> , 3, 161-167, 2000	VMS reported based on symptom scores.
Kroenke,C.H., Caan,B.J., Stefanick,M.L., Anderson,G., Brzyski,R., Johnson,K.C., LeBlanc,E., Lee,C., La Croix,A.Z., Park,H.L., Sims,S.T., Vitolins,M., Wallace,R., Effects of a dietary intervention and weight change on vasomotor symptoms in the Women's Health Initiative, <i>Menopause</i> , 19, 980-988, 2012	Intervention and outcome not of interest

Study	Reason for exclusion
Kronenberg,F., Fugh-Berman,A., Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. [58 refs], <i>Annals of Internal Medicine</i> , 137, 805-813, 2002	Not primary data
Kulasingam,S., Moineddin,R., Lewis,J.E., Tierney,M.C., The validity of the Menopause Specific Quality of Life Questionnaire in older women, <i>Maturitas</i> , 60, 239-243, 2008	Focuses on validity of measure
Kumru,S., Yildiz,F.M., Godekmerdan,A., Kutlu,S., Yilmaz,B., Gurates,B., Effects of raloxifene and hormone replacement therapy on serum Th2 and Th3 type cytokine concentrations in healthy postmenopausal women: A randomised controlled trial, <i>Archives of Gynecology and Obstetrics</i> , 277, 489-493, 2008	No outcomes of interest
Kwee,S.H., Tan,H.H., Marsman,A., Wauters,C., The effect of Chinese herbal medicines (CHM) on menopausal symptoms compared to hormone replacement therapy (HRT) and placebo, <i>Maturitas</i> , 58, 83-90, 2007	Outcome estimates reported graphically.
Kyllonen,E.S., Vaananen,H.K., Vanharanta,J.H., Heikkinen,J.E., Influence of estrogen-progestogen treatment on back pain and disability among slim premenopausal women with low lumbar spine bone mineral density. A 2-year placebo-controlled randomized trial, <i>Spine</i> , 24, 704-708, 1999	PICO not met - Study only included premenopausal women. Outcomes not relevant.
Laan,E., van Lunsen,R.H., Everaerd,W., The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women, <i>Climacteric</i> , 4, 28-41, 2001	Does not meet PICO (patients not of interest--subjects were not selected on the basis of sexual function or dysfunction and those treated for sexual desire or response were excluded)
Labrie,F., Archer,D., Bouchard,C., Fortier,M., Cusan,L., Gomez,J.L., Girard,G., Baron,M., Ayotte,N., Moreau,M., Dube,R., Cote,I., Labrie,C., Lavoie,L., Berger,L., Gilbert,L., Martel,C., Balsler,J., Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women, <i>Menopause</i> , 16, 923-931, 2009	PICO not met - Intervention (Dehydroepiandrosterone) not of interest. Outcome also not of interest.
Labrie,F., Archer,D., Bouchard,C., Fortier,M., Cusan,L., Gomez,J.L., Girard,G., Baron,M., Ayotte,N., Moreau,M., Dube,R., Cote,I., Labrie,C., Lavoie,L., Berube,R., Belanger,P., Berger,L., Gilbert,L., Martel,C., Balsler,J., Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration, <i>Menopause</i> , 16, 897-906, 2009	PICO not met - Intervention (Dehydroepiandrosterone) not of interest. Outcomes also not of interest.
Labrie,F., Archer,D.F., Bouchard,C., Fortier,M., Cusan,L., Gomez,J.L., Girard,G., Baron,M., Ayotte,N., Moreau,M., Dube,R., Cote,I., Labrie,C., Lavoie,L., Berger,L., Gilbert,L., Martel,C., Balsler,J., Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia, <i>Climacteric</i> , 14, 282-288, 2011	PICO not met - Intervention (Dehydroepiandrosterone) not of interest. Outcome also not of interest.
Labrie,F., Cusan,L., Gomez,J.L., Cote,I., Berube,R., Belanger,P., Martel,C., Labrie,C., Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women.[Erratum appears in <i>J Steroid Biochem Mol Biol</i> . 2008 Nov;112(1-3):169], <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 111, 178-194, 2008	PICO not met - Intervention (Dehydroepiandrosterone) not of interest. Outcomes not of interest.
Lacroix,A.Z., Freeman,E.W., Larson,J., Carpenter,J.S., Joffe,H., Reed,S.D., Newton,K.M., Seguin,R.A., Sternfeld,B., Cohen,L., Ensrud,K.E., Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial, <i>Maturitas</i> , 73, 361-368, 2012	Secondary publication of 226516
Lacut,K., Oger,E., Le,GalG, Blouch,M.T., Abgrall,J.F., Kerlan,V., Scarabin,P.Y., Mottier,D., Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein, Thrombosis and Haemostasis, 90, 124-131, 2003	Blood chemistry outcomes
Lagrelus,A., Fredricsson,B., Hirt,M., Weintraub,L., Clinical experience with a low-dose combination of estradiol valerate and levonorgestrel. Double-blind comparative study between SH D 386 F and Cyclabil. Effects on symptoms, lipids and endometrial condition, <i>Acta Obstetrica et Gynecologica Scandinavica - Supplement</i> , 134, 97-101, 1986	Frequency of VMS not reported.
Laidlaw,M., Cockerline,C.A., Sepkovic,D.W., Effects of a breast-health herbal formula supplement on estrogen metabolism in pre- and post-menopausal women not taking hormonal contraceptives or supplements: A randomized controlled trial, <i>Breast Cancer: Basic and Clinical Research</i> , 4, 85-95, 2010	PICO not met - women were asymptomatic. Relevant outcomes not assessed.
Lam,P.M., Cheung,G.W., Shek,D.T., Lee,D.T., Haines,C.J., Chung,T.K., A randomized, placebo-controlled, crossover study of tibolone (Livial) on menopause symptoms, psychological well-being, and dyadic relationship of postmenopausal Chinese women and their spouses, <i>Menopause</i> , 11, 416-422, 2004	Results of interest not calculable due to composite scoring
Lamlerkittikul,S., Chandeying,V., Efficacy and safety of Pueraria mirifica (Kwao Kruea Khao) for the treatment of vasomotor symptoms in perimenopausal women: Phase II Study, <i>Journal of the Medical Association of Thailand</i> , 87, 33-40, 2004	Outcome estimates not of interest
Landgren,M.B., Bennink,H.J., Helmond,F.A., Engelen,S., Dose-response analysis of effects of tibolone on climacteric symptoms, <i>BJOG: An International Journal of Obstetrics and Gynaecology</i> , 109, 1109-1114, 2002	outcomes of interest reported in graphical format without accompanying numbers
Lantto,H., Haapalahti,P., Tuomikoski,P., Viitasalo,M., Vaananen,H., Sovijarvi,A.R., Ylikorkala,O., Mikkola,T.S., Vasomotor hot flashes and heart rate variability: a placebo-controlled trial of postmenopausal hormone therapy, <i>Menopause</i> , 19, 82-88, 2012	Outcomes not of interest

Study	Reason for exclusion
Le,Donne M., Caruso,C., Mancuso,A., Costa,G., lemno,R., Pizzimenti,G., Cavallari,V., The effect of vaginally administered genistein in comparison with hyaluronic acid on atrophic epithelium in postmenopause, Archives of Gynecology and Obstetrics, 283, 1319-1323, 2011	Results of interest not calculable due to composite scoring
LeBlanc,E.S., Neiss,M.B., Carello,P.E., Samuels,M.H., Janowsky,J.S., Hot flashes and estrogen therapy do not influence cognition in early menopausal women, Menopause, 14, 191-202, 2007	Results of interest not calculable due to composite scoring
Leder,B.Z., Leblanc,K.M., Longcope,C., Lee,H., Catlin,D.H., Finkelstein,J.S., Effects of oral androstenedione administration on serum testosterone and estradiol levels in postmenopausal women, Journal of Clinical Endocrinology and Metabolism, 87, 5449-5454, 2002	PICO not met - Outcomes of interest not reported
Lee,J., Kim,K.W., Kim,H.K., Chae,S.W., Jung,J.C., Kwon,S.H., Rhee,C.H., The effect of Rexflavone (Sophorae fructus extract) on menopausal symptoms in postmenopausal women: a randomized double-blind placebo controlled clinical trial, Archives of Pharmacal Research, 33, 523-530, 2010	KMS scale
Lee,M.S., Shin,B.C., Ernst,E., Acupuncture for treating menopausal hot flushes: a systematic review. [47 refs], Climacteric, 12, 16-25, 2009	Secondary data
Leonetti,H.B., Longo,S., Anasti,J.N., Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss, Obstetrics and Gynecology, 94, 225-228, 1999	outcome reported improvement or resolution of VSM symptoms
Lethaby,Anne, Marjoribanks,Jane, Kronenberg,Fredi, Roberts,Helen, Eden,John, Brown,Julie, Phytoestrogens for menopausal vasomotor symptoms, Cochrane Database of Systematic Reviews, -, 2013	Individual studies checked for inclusion criteria and checked in STAR for interventions and outcomes of interest
Levine,D.W., Dailey,M.E., Rockhill,B., Tipping,D., Naughton,M.J., Shumaker,S.A., Validation of the Women's Health Initiative Insomnia Rating Scale in a multicenter controlled clinical trial, Psychosomatic Medicine, 67, 98-104, 2005	Does not meet PICO-evaluation of construct validity of insomnia rating scale not of interest
Levis,S., Strickman-Stein,N., Doerge,D.R., Krischer,J., Design and baseline characteristics of the soy phytoestrogens as replacement estrogen (SPARE) study- a clinical trial of the effects of soy isoflavones in menopausal women, Contemporary Clinical Trials, 31, 293-302, 2010	Protocol and baseline characteristics for RCT. No outcome data.
Levis,S., Strickman-Stein,N., Ganjei-Azar,P., Xu,P., Doerge,D.R., Krischer,J., Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial, Archives of Internal Medicine, 171, 1363-1369, 2011	menopausal symptoms are not the primary outcome of the study
Lewiecki,E.M., Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: A randomized trial, Southern Medical Journal, 101, 2-, 2008	Outcome (bone metabolism) not relevant
Lewis,J.E., Nickell,L.A., Thompson,L.U., Szalai,J.P., Kiss,A., Hilditch,J.R., A randomized controlled trial of the effect of dietary soy and flaxseed muffins on quality of life and hot flashes during menopause, Menopause, 13, 631-642, 2006	Results of interest not calculable due to scoring method.
Light,K.C., Grewen,K.M., Amico,J.A., Brownley,K.A., West,S.G., Hinderliter,A.L., Girdler,S.S., Oxytocinergic activity is linked to lower blood pressure and vascular resistance during stress in postmenopausal women on estrogen replacement, Hormones and Behavior, 47, 540-548, 2005	Secondary publication
Limouzin-Lamothe,M.A., Mairon,N., Joyce,C.R., Le,Gal M., Quality of life after the menopause: influence of hormonal replacement therapy, American Journal of Obstetrics and Gynecology, 170, 618-624, 1994	Comparator not of interest (verapipride)
Lind,T., Cameron,E.C., Hunter,W.M., Leon,C., Moran,P.F., Oxley,A., Gerrard,J., Lind,U.C., A prospective, controlled trial of six forms of hormone replacement therapy given to postmenopausal women, British Journal of Obstetrics and Gynaecology, 86 Suppl 3, 1-29, 1979	PICO not met as there are no comparison groups--all six HRT interventions were combined together
Lindsay,R., Gallagher,J.C., Kleerekoper,M., Pickar,J.H., Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women, JAMA, 287, 2668-2676, 2002	Secondary data
Lindsay,R., Hart,D.M., Failure of response of menopausal vasomotor symptoms to clonidine, Maturitas, 1, 21-25, 1978	results reported as composite scores
Lindsay,R., Hart,D.M., Kraszewski,A., Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis, British Medical Journal, 280, 1207-1209, 1980	PICO not met - Outcomes of interest not reported
Linzmayr,L., Semlitsch,H.V., Saletu,B., Bock,G., Saletu-Zyhlarz,G., Zoghiami,A., Gruber,D., Metka,M., Huber,J., Oettel,M., Graser,T., Grunberger,J., Double-blind, placebo-controlled psychometric studies on the effects of a combined estrogen-progestogen regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients, Arzneimittel-Forschung, 51, 238-245, 2001	PICO not met - Outcomes of interest not reported
Lipovac,M., Chedraui,P., Gruenhut,C., Gocan,A., Kurz,C., Neuber,B., Imhof,M., Effect of Red Clover Isoflavones over Skin, Appendages, and Mucosal Status in Postmenopausal Women, Obstetrics and Gynecology International, 2011, 949302-, 2011	Outcomes not relevant.
Lipovac,M., Chedraui,P., Gruenhut,C., Gocan,A., Stammler,M., Imhof,M., Improvement of postmenopausal depressive and anxiety symptoms after treatment with isoflavones derived from red clover extracts, Maturitas, 65, 258-261, 2010	Secondary publication

Study	Reason for exclusion
Liske,E., Hanggi,W., Henneicke-von,ZepelinH, Boblitz,N., Wustenberg,P., Rahlfs,V.W., Physiological investigation of a unique extract of black cohosh ( <i>Cimicifugae racemosae rhizoma</i> ): A 6-month clinical study demonstrates no systemic estrogenic effect, <i>Journal of Women's Health</i> , 11, 163-174, 2002	No outcomes of interest
Liu,J., Does Dang Gui Buxue Tang improve moderate to severe menopausal symptoms and quality of life in post-menopausal women?, <i>Focus on Alternative and Complementary Therapies</i> , 18, 140-141, 2013	Abstract only
Liu,J., Allgood,A., Derogatis,L.R., Swanson,S., O'Mahony,M., Nedoss,B., Soper,H., Zbella,E., Prokofieva,S.V., Zipfel,L., Guo,C.Y., Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study, <i>Fertility and Sterility</i> , 95, 366-368, 2011	Data presented in graph format without accompanying numbers
Liu,J.H., Reape,K.Z., Hait,H.I., Synthetic conjugated estrogens-B and postmenopausal nocturnal vasomotor symptoms: a randomized controlled trial, <i>Obstetrics and Gynecology</i> , 119, 78-84, 2012	Outcome: awakenings, not flushes
Liu,P., He,F.F., Bai,W.P., Yu,Q., Shi,W., Wu,Y.Y., He,D.J., Xiao,J.H., Zheng,Y., Liao,Q.P., Menopausal depression: comparison of hormone replacement therapy and hormone replacement therapy plus fluoxetine, <i>Chinese Medical Journal</i> , 117, 189-194, 2004	Comparator (SSRI plus HRT) not of interest
Lloyd,G., McGing,E., Cooper,A., Patel,N., Lumb,P.J., Wierzbicki,A.S., Jackson,G., A randomised placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women, <i>Journal of Human Hypertension</i> , 14, 99-104, 2000	Populations not of interest (women with hypertension)
Lobo,R.A., McCormick,W., Singer,F., Roy,S., Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women, <i>Obstetrics and Gynecology</i> , 63, 1-5, 1984	number of daily vasomotor symptoms presented in graphical format
Lobo,R.A., Pinkerton,J.V., Gass,M.L., Dorin,M.H., Ronkin,S., Pickar,J.H., Constantine,G., Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile, <i>Fertility and Sterility</i> , 92, 1025-1038, 2009	outcome of interest (frequency of hot flashes) reported in graphical format without accompanying numbers
Lobo,R.A., Rosen,R.C., Yang,H.M., Block,B., Van Der Hoop,R.G., Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire, <i>Fertility and Sterility</i> , 79, 1341-1352, 2003	Results of interest not calculable due to composite scoring
Loh,F.H., Chen,L.H., Yu,S.L., Jorgensen,L.N., The efficacy of two dosages of a continuous combined hormone replacement regimen, <i>Maturitas</i> , 41, 123-131, 2002	Results of interest not calculable due to composite scoring
Long,C.Y., Liu,C.M., Hsu,S.C., Chen,Y.H., Wu,C.H., Tsai,E.M., A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women, <i>Fertility and Sterility</i> , 85, 155-160, 2006	Outcomes not of interest.
Long,C.Y., Liu,C.M., Hsu,S.C., Wu,C.H., Wang,C.L., Tsai,E.M., A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women, <i>Menopause</i> , 13, 737-743, 2006	No comparator
Lopes,P., Merkus,H.M., Nauman,J., Bruschi,F., Foidart,J.M., Calaf,J., Randomized comparison of intranasal and transdermal estradiol, <i>Obstetrics and Gynecology</i> , 96, 906-912, 2000	PICO not met - Intervention (Intranasal Estradiol) not of interest
Lopes,P., Rozenberg,S., Graaf,J., Fernandez-Villoria,E., Marianowski,L., Aerodiol versus the transdermal route: perspectives for patient preference, <i>Maturitas</i> , 38 Suppl 1, S31-S39, 2001	Outcome estimates not relevant.
Loprinzi,C.L., Diekmann,B., Novotny,P.J., Stearns,V., Sloan,J.A., Newer antidepressants and gabapentin for hot flashes: A discussion of trial duration, <i>Menopause</i> , 16, 883-887, 2009	Secondary data
Loprinzi,C.L., Goldberg,R.M., O'Fallon,J.R., Quella,S.K., Miser,A.W., Mynderse,L.A., Brown,L.D., Tschetter,L.K., Wilwerding,M.B., Dose,M., Transdermal clonidine for ameliorating post-orchietomy hot flashes, <i>Journal of Urology</i> , 151, 634-636, 1994	PICO not met - Population (post-orchietomy hot flashes) not of interest
Loprinzi,C.L., Levitt,R., Barton,D., Sloan,J.A., Dakhil,S.R., Nikcevich,D.A., Bearden,J.D.,III, Mailliard,J.A., Tschetter,L.K., Fitch,T.R., Kugler,J.W., Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7, <i>Journal of Clinical Oncology</i> , 24, 1409-1414, 2006	Hot flush scores (composite of frequency and severity)
Loprinzi,C.L., Qin,R., Balcueva,E.P., Flynn,K.A., Rowland,K.M.,Jr., Graham,D.L., Erwin,N.K., Dakhil,S.R., Jurgens,D.J., Burger,K.N., Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1.[Erratum appears in <i>J Clin Oncol</i> . 2010 Apr 1;28(10):1808 Note: Baclueva, Ernie P [corrected to Balcueva, Ernie P]], <i>Journal of Clinical Oncology</i> , 28, 641-647, 2010	Baseline values not reported
Lose,G., Englev,E., Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms, <i>BJOG: An International Journal of Obstetrics &amp; Gynaecology</i> , 107, 1029-1034, 2000	no outcome of interest
Luoto,R., Moilanen,J., Heinonen,R., Mikkola,T., Raitanen,J., Tomas,E., Ojala,K., Mansikkamaki,K., Nygard,C.H., Effect of aerobic training on hot flushes and quality of life--a randomized controlled trial, <i>Annals of Medicine</i> , 44, 616-626, 2012	Comparator not defined

Study	Reason for exclusion
MacGregor,C.A., Canney,P.A., Patterson,G., McDonald,R., Paul,J., A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer, <i>European Journal of Cancer</i> , 41, 708-714, 2005	Results of interest not calculable due to composite scoring
Maffei,S., Mercuri,A., Prontera,C., Zucchelli,G.C., Vassalle,C., Vasoactive biomarkers and oxidative stress in healthy recently postmenopausal women treated with hormone replacement therapy, <i>Climacteric</i> , 9, 452-458, 2006	The outcomes are bio-markers.
Maheux,R., Naud,F., Rioux,M., Grenier,R., Lemay,A., Guy,J., Langevin,M., A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness, <i>American Journal of Obstetrics and Gynecology</i> , 170, 642-649, 1994	No relevant data
Mainini,G., Torella,M., Di Donna,M.C., Esposito,E., Ercolano,S., Correa,R., Cucinella,G., Stradella,L., Luisi,A., Basso,A., Cerreto,F.V., Cicatiello,R., Matteo,M., De,Franciscis P., Nonhormonal management of postmenopausal women: effects of a red clover based isoflavones supplementation on climacteric syndrome and cardiovascular risk serum profile, <i>Clinical and Experimental Obstetrics and Gynecology</i> , 40, 337-341, 2013	Insufficient data
Maki,P.M., Gast,M.J., Vieweg,A.J., Burriss,S.W., Yaffe,K., Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial, <i>Neurology</i> , 69, 1322-1330, 2007	No outcomes of interest
Maki,P.M., Rubin,L.H., Fornelli,D., Drogos,L., Banuvar,S., Shulman,L.P., Geller,S.E., Effects of botanicals and combined hormone therapy on cognition in postmenopausal women, <i>Menopause</i> , 16, 1167-1177, 2009	Secondary publication of 226557
Mangione,C.M., A randomized trial of alternative medicines for vasomotor symptoms of menopause, <i>Annals of Internal Medicine</i> , 145, 924-925, 2006	Is an editorial and not a study
Mann,E., Smith,M., Hellier,J., Hunter,M.S., A randomised controlled trial of a cognitive behavioural intervention for women who have menopausal symptoms following breast cancer treatment (MENOS 1): trial protocol, <i>BMC Cancer</i> , Vol.11, pp.44, 2011., -, -32676	Trial protocol
Manonai,J., Chittacharoen,A., Theppisai,U., Transvaginal color Doppler sonographic assessment of uterus and ovaries in postmenopausal women: The effect of local estrogen treatment, <i>European Journal of Obstetrics Gynecology and Reproductive Biology</i> , 127, 222-226, 2006	This is a uterus/ovary study
Manonai,J., Chittacharoen,A., Theppisai,U., Theppisai,H., Effect of Pueraria mirifica on vaginal health, <i>Menopause</i> , 14, 919-924, 2007	No outcomes of interest
Manonai,J., Songchitsomboon,S., Chanda,K., Hong,J.H., Komindr,S., The effect of a soy-rich diet on urogenital atrophy: a randomized, cross-over trial, <i>Maturitas</i> , 54, 135-140, 2006	PICO not met - symptom profile (vaginal atrophy) not of interest
Manonai,J., Theppisai,U., Suthutvoravut,S., Udomsubpayakul,U., Chittacharoen,A., The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study, <i>Journal of Obstetrics and Gynaecology Research</i> , 27, 255-260, 2001	Urogenital outcomes.
Mansikkamaki,K., Raitanen,J., Nygard,C.H., Heinonen,R., Mikkola,T., EijaTomas, Luoto,R., Sleep quality and aerobic training among menopausal women--a randomized controlled trial, <i>Maturitas</i> , 72, 339-345, 2012	Comparator not defined
Marchesoni,D., Mozzanega,B., Maggino,T., Nardelli,G.B., Postmenopausal hot flashes: Endocrine correlations and progestogenic treatment. Double blind crossed clinical trial using MPA versus placebo, <i>Journal of Gynaecological Endocrinology</i> , 1, 63-69, 1985	VSM frequency reported on a composite score with severity
Marinho,R.M., Soares,J.M.,Jr., Santiago,R.C., Maganhin,C.C., Machado,F., de Miranda Cota,A.M., Baracat,E.C., Effects of estradiol on the cognitive function of postmenopausal women, <i>Maturitas</i> , 60, 230-234, 2008	No outcomes of interest
Marsden,J., Baum,M., A'Hern,R., West,A., Fallowfield,L., Whitehead,M., Sacks,N., The impact of hormone replacement therapy on breast cancer patients' quality of life and sexuality: A pilot study, <i>Journal of the British Menopause Society</i> , 7, 85-91, 2001	Results not reported separately for each intervention type (combined results for both oestradiol valerate and oestrogen plus levonorgestrel)
Marsden,J., Baum,M., Whitehead,M.I., Crook,D., Sacks,N.P.M., A randomised trial of HRT in women with a history of breast cancer - A feasibility study, <i>Acta Obstetrica et Gynecologica Scandinavica - Supplement</i> , 76, 22, 1997-, 1997	Conference abstract
Marsden,J., Sacks,N.P.M., Worthington,M., Crook,D., Serum lipids and lipoproteins in women in early stage breast cancer: effects of HRT and tamoxifen, <i>British Journal of Cancer</i> , 76, 24, 1997-, 1997	Conference abstract
Marsden,J., Whitehead,M., A'Hern,R., Baum,M., Sacks,N., Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible?, <i>Fertility and Sterility</i> , 73, 292-299, 2000	No outcomes of interest
Marslew,U., Overgaard,K., Riis,B.J., Christiansen,C., Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding, <i>Obstetrics and Gynecology</i> , 79, 202-210, 1992	Secondary publication of 226935
Marslew,U., Riis,B., Christiansen,C., Progestogens: therapeutic and adverse effects in early post-menopausal women, <i>Maturitas</i> , 13, 7-16, 1991	Results of interest not calculable due to composite scoring
Marslew,U., Riis,B.J., Christiansen,C., Desogestrel in hormone replacement therapy: long-term effects on bone, calcium and lipid metabolism, climacteric	Secondary publication of 226935

Study	Reason for exclusion
symptoms, and bleeding, European Journal of Clinical Investigation, 21, 601-607, 1991	
Martin,P.L., Burnier,A.M., Segre,E.J., Huix,F.J., Graded sequential therapy in the menopause: a double-blind study, American Journal of Obstetrics and Gynecology, 111, 178-186, 1971	The outcome is a VMS severity score (not frequency)
Marx,P., Schade,G., Wilbourn,S., Blank,S., Moyer,D.L., Nett,R., Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis, Maturitas, 47, 47-54, 2004	Urogenital outcomes only
Mattsson,L.A., Christiansen,C., Colau,J.C., Palacios,S., Kenemans,P., Bergeron,C., Chevallier,O., von,Holst T., Gangar,K., Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms, American Journal of Obstetrics and Gynecology, 182, 545-552, 2000	KI score
Mattsson,L.A., Cullberg,G., Eriksson,O., Knutsson,F., Vaginal administration of low-dose oestradiol--effects on the endometrium and vaginal cytology, Maturitas, 11, 217-222, 1989	PICO not met - Symptom profile (Urogenital atrophy) not of interest
Mattsson,L.A., Skouby,S., Rees,M., Heikkinen,J., Kudela,M., Stadnicki-Kolendo,A., Mattila,L., Salminen,K., Vuorela,A., Mustonen,M., Study Group., Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women, Menopause International, 13, 124-131, 2007	Outcomes presented in graphical format
Mattsson,L.A., Skouby,S.O., Heikkinen,J., Vaheri,R., Maenpaa,J., Timonen,U., A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional-dose regimen, Climacteric, 7, 59-69, 2004	Results reported on graph.
Meeuwse,I.B., Samson,M.M., Duursma,S.A., Verhaar,H.J., The influence of tibolone on quality of life in postmenopausal women, Maturitas, 41, 35-43, 2002	Not all women are symptomatic
Meissner,H.O., Kapczynski,W., Mscisz,A., Lutomski,J., Use of gelatinized maca (lepidium peruvianum) in early postmenopausal women, International Journal of Biomedical Science, 1, 33-45, 2005	Outcome estimates not of interest
Meissner,H.O., Mscisz,A., Reich-Bilinska,H., Kapczynski,W., Mrozikiewicz,P., Bobkiewicz-Kozlowska,T., Kedzia,B., Lowicka,A., Barchia,I., Hormone-Balancing Effect of Pre-Gelatinized Organic Maca (Lepidium peruvianum Chacon): (II) Physiological and Symptomatic Responses of Early-Postmenopausal Women to Standardized doses of Maca in Double Blind, Randomized, Placebo-Controlled, Multi-Centre Clinical Study, International Journal of Biomedical Science, 2, 360-374, 2006	PICO not met - Intervention (Lepidium peruvianum Chacon) not of interest
Melis,G.B., Gambacciani,M., Cagnacci,A., Paoletti,A.M., Mais,V., Fioretti,P., Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women, Obstetrics and Gynecology, 72, 688-692, 1988	PICO not met - Intervention (Veralipride) not of interest. Outcomes not relevant.
Mendoza,N., Suarez,A.M., Alamo,F., Bartual,E., Vergara,F., Herruzo,A., Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17 beta-estradiol for hormonal replacement therapy in women with surgical menopause.[Erratum appears in Maturitas 2001 Nov 30;40(2):191], Maturitas, 37, 37-43, 2000	Outcome was lipids related
Meyer,W.R., Costello,N., Straneva,P., West,S., Copeland,K., Girdler,S., Effect of low-dose estrogen on hemodynamic response to stress, Fertility and Sterility, 75, 394-399, 2001	Haemodynamics study
Michael,Y.L., Gold,R., Manson,J.E., Keast,E.M., Cochrane,B.B., Woods,N.F., Brzyski,R.G., McNeely,S.G., Wallace,R.B., Hormone therapy and physical function change among older women in the Women's Health Initiative: A randomized controlled trial, Menopause, 17, 295-302, 2010	Secondary publication of WHI
MINAGUCHI,Hiroshi, FUJIMOTO,Seiichiro, Kazuo,S.A.T.O., TAKETANI,Yuji, ASOU,Takeshi, OKADA,Hiroji, OHAMA,Kousou, AONO,Toshihiro, NAGATA,Yukihiro, Phase II Clinical Study of RG83933 Transdermal Estradiol Delivery System -Dose finding study-, Rinsho Hyoka (Clinical Evaluation), 25, 23-42, 1997	Non-English language
Mittal,N., Hota,D., Dutta,P., Bhansali,A., Suri,V., Aggarwal,N., Marwah,R.K., Chakrabarti,A., Evaluation of effect of isoflavone on thyroid economy & autoimmunity in oophorectomised women: A randomised, double-blind, placebo-controlled trial, Indian Journal of Medical Research, 133, 633-640, 2011	Outcome is thyroid related
Mizunuma,H., Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms, Climacteric, 14, 581-589, 2011	No outcomes of interest
Modelska,K., Cummings,S., Female sexual dysfunction in postmenopausal women: systematic review of placebo-controlled trials. [87 refs], American Journal of Obstetrics and Gynecology, 188, 286-293, 2003	Systematic review: only p values reported
Molander,U., Milsom,I., Ekelund,P., Mellstrom,D., Eriksson,O., Effect of oral oestriol on vaginal flora and cytology and urogenital symptoms in the post-menopause, Maturitas, 12, 113-120, 1990	PICO not met - Polulation (urohenital symptoms) not of interest
Montgomery,J.C., Treatment of Decreased Libido in Climacteric Women: Effects of Oestradiol Implants Alone and in Combination with Testosterone, Journal of Obstetrics and Gynaecology, 11, 302, 1991-, 1991	Abstract only



Study	Reason for exclusion
Montgomery,J.C., Appleby,L., Brincat,M., Versi,E., Tapp,A., Fenwick,P.B., Studd,J.W., Effect of oestrogen and testosterone implants on psychological disorders in the climacteric, <i>Lancet</i> , 1, 297-299, 1987	Comparator not of interest (placebo plus norethisterone)
Morabito,N., Crisafulli,A., Vergara,C., Gaudio,A., Lasco,A., Frisina,N., D'Anna,R., Corrado,F., Pizzoleo,M.A., Cincotta,M., Altavilla,D., Ientile,R., Squadrito,F., Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study, <i>Journal of Bone and Mineral Research</i> , 17, 1904-1912, 2002	No outcomes of interest
Morais-Socorro,M., Cavalcanti,M.A., Martins,R., Neto,Francisco P., Rezende,A., Azevedo,G., Almeida,M., Safety and efficacy of tibolone and menopausal transition: a randomized, double-blind placebo-controlled trial, <i>Gynecological Endocrinology</i> , 28, 483-487, 2012	No outcomes of interest
Morgan,M.L., Cook,I.A., Rapkin,A.J., Leuchter,A.F., Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study, <i>Journal of Clinical Psychiatry</i> , 66, 774-780, 2005	Outcomes in graphical format without complete accompanying numbers
Morgan,M.L., Rapkin,A.J., Biggio,G., Serra,M., Pisu,M.G., Rasgon,N., Neuroactive steroids after estrogen exposure in depressed postmenopausal women treated with sertraline and asymptomatic postmenopausal women, <i>Archives of Women's Mental Health</i> , 13, 91-98, 2010	Population asymptomatic
Morgante,G., Farina,M., Cianci,A., La,Marca A., Petraglia,F., De,Leo,V, Verapiride administered in combination with raloxifene decreases hot flushes and improves bone density in early postmenopausal women, <i>Gynecological Endocrinology</i> , 18, 194-198, 2004	PICO not met - Intervention (Raloxifene veraliride) not of interest. Outcomes presented graphically.
Moriyama,C.K., Oneda,B., Bernardo,F.R., Cardoso,C.G.,Jr., Forjaz,C.L., Abrahao,S.B., Mion,D.,Jr., Fonseca,A.M., Tinucci,T., A randomized, placebo-controlled trial of the effects of physical exercises and estrogen therapy on health-related quality of life in postmenopausal women, <i>Menopause</i> , 15, 613-618, 2008	Combination therapies not of interest (exercise HRT)
Murkies,A.L., Lombard,C., Strauss,B.J., Wilcox,G., Burger,H.G., Morton,M.S., Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat.[Reprint in <i>Maturitas</i> . 2008 Sep-Oct;61(1-2):27-33; PMID: 19434877], <i>Maturitas</i> , 21, 189-195, 1995	Older version of article 256772
Murkies,A.L., Lombard,C., Strauss,B.J., Wilcox,G., Burger,H.G., Morton,M.S., Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat.[Reprint of <i>Maturitas</i> . 1995 Apr;21(3):189-95; PMID: 7616867], <i>Maturitas</i> , 61, 27-33, 2008	Treatment is a food supplement which does not have a controlled isoflavone dose.
Mustonen,M., Writing Group for the Indivina, Low dose HRT sufficient for severe hot flushes in early postmenopausal women, <i>Maturitas</i> , Vol.54S, pp.s83, 2006., -	Abstract
Nachtigall,L., Casson,P., Lucas,J., Schofield,V., Melson,C., Simon,J.A., Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen, <i>Gynecological Endocrinology</i> , 27, 39-48, 2011	Secondary publication of 254964
Nachtigall,L.E., Clinical trial of the estradiol vaginal ring in the U.S, <i>Maturitas</i> , 22 Suppl, S43-S47, 1995	PICO not met - Population (vaginal atrophy) not of interest
Nachtigall,L.E., Comparative study: Replens versus local estrogen in menopausal women, <i>Fertility and Sterility</i> , 61, 178-180, 1994	Atrophy outcomes. Not of interest
Naessen,T., Lindmark,B., Lagerstrom,C., Larsen,H.C., Persson,I., Early postmenopausal hormone therapy improves postural balance, <i>Menopause</i> , 14, 14-19, 2007	Outcomes of interest not reported
Nagata,H., Nozaki,M., Nakano,H., Short-term combinational therapy of low-dose estrogen with selective serotonin re-uptake inhibitor (fluvoxamine) for oophorectomized women with hot flashes and depressive tendencies, <i>Journal of Obstetrics and Gynaecology Research</i> , 31, 107-114, 2005	Comparator not of interest (SSRI CEE)
Nahidi,F., Kariman,N., Simbar,M., Mojab,F., The study on the effects of Pimpinella anisum on relief and recurrence of menopausal hot flashes, <i>Iranian journal of pharmaceutical research</i> , 11, 1079-1085, 2012	abstract result not the same as the result table-week 4 hot flash frequency didn't match up, abstract presented frequency of hot flashes in %, whereas result table didn't.
Nand,S.L., Webster,M.A., Baber,R., Heller,G.Z., Menopausal symptom control and side-effects on continuous estrone sulfate and three doses of medroxyprogesterone acetate. Ogen/Provera Study Group, <i>Climacteric</i> , 1, 211-218, 1998	Outcomes not of interest
Nappi,C., Petraglia,F., de Chiara,B.M., Genazzani,A.D., Montemagno,R., Genazzani,A.R., Montemagno,U., The effect of various drugs with neuroendocrine activity and transdermal estradiol on plasma gonadotropin concentrations after ovariectomy in reproductive-aged women, <i>Acta Obstetrica et Gynecologica Scandinavica</i> , 70, 435-439, 1991	No outcome
Nappi,R.E., Ferdeghini,F., Sampaolo,P., Vaccaro,P., De,Leonardis C., Albani,F., Salonia,A., Polatti,F., Clitoral circulation in postmenopausal women with sexual dysfunction: a pilot randomized study with hormone therapy, <i>Maturitas</i> , 55, 288-295, 2006	Sexual function study (clitoral circulation)
Nappi,R.E., Malavasi,B., Brundu,B., Facchinetti,F., Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol, <i>Gynecological Endocrinology</i> , 20, 30-35, 2005	Results reported on graph.

Study	Reason for exclusion
Nash,H.A., varez-Sanchez,F., Mishell,D.R.,Jr., Fraser,I.S., Maruo,T., Harmon,T.M., Estradiol-delivering vaginal rings for hormone replacement therapy, American Journal of Obstetrics and Gynecology, 181, 1400-1406, 1999	Results reported as graph
Nathorst-Boos,J., Hammar,M., Effect on sexual life--a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen, Maturitas, 26, 15-20, 1997	McCoy sex scale has its own scoring system
Nathorst-Boos,J., Wiklund,I., Mattsson,L.A., Sandin,K., von,Schoultz B., Is sexual life influenced by transdermal estrogen therapy? A double blind placebo controlled study in postmenopausal women, Acta Obstetrica et Gynecologica Scandinavica, 72, 656-660, 1993	Results of interest not calculable due to composite scoring
Nedrow,A., Miller,J., Walker,M., Nygren,P., Huffman,L.H., Nelson,H.D., Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review. [98 refs], Archives of Internal Medicine, 166, 1453-1465, 2006	Systematic review
Nedstrand,E., Wijma,K., Wyon,Y., Hammar,M., Applied relaxation and oral estradiol treatment of vasomotor symptoms in postmenopausal women, Maturitas, 51, 154-162, 2005	Secondary publication of 227586
Neff,M.J., NAMS releases position statement on the treatment of vasomotor symptoms associated with menopause, American Family Physician, 70, 393-394, 396	Results of interest not calculable due to composite scoring
Nelson,H.D., Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. [53 refs], JAMA, 291, 1610-1620, 2004	Systematic review
Nelson,H.D., Vesco,K.K., Haney,E., Fu,R., Nedrow,A., Miller,J., Nicolaidis,C., Walker,M., Humphrey,L., Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. [74 refs], JAMA, 295, 2057-2071, 2006	Systematic review
Nesheim,B.I., Saetre,T., Reduction of menopausal hot flashes by methyl dopa. A double blind crossover trial, European Journal of Clinical Pharmacology, 20, 413-416, 1981	PICO not met - Intervention (methyl dopa) not of interest
Nevinny,StickelJ, Double-blind cross-over study with Org OD 14 and placebo in postmenopausal patients, Archives of Gynecology, 234, 27-31, 1983	Results of interest not calculable due to scoring
Newton,K.M., Isoflavones hold limited promise for the treatment of menopausal vasomotor symptoms, Evidence Based Medicine, 19, 178-, 2014	Commentary, no data provided
Newton,K.M., Reed,S.D., Grothaus,L., Ehrlich,K., Guiltinan,J., Ludman,E., LaCroix,A.Z., The Herbal Alternatives for Menopause (HALT) Study: background and study design.[Reprint in Maturitas. 2008 Sep-Oct;61(1-2):181-93; PMID: 19434890], Maturitas, 52, 134-146, 2005	Study protocol
Newton,K.M., Reed,S.D., LaCroix,A.Z., Grothaus,L.C., Ehrlich,K., Guiltinan,J., Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial.[Summary for patients in Ann Intern Med. 2006 Dec 19;145(12):125; PMID: 17179054], Annals of Internal Medicine, 145, 869-879, 2006	Secondary publication of 227210
Nguyen-Pascal,M.L., Thomas,J.L., Bergougnot,L., Garnero,P., Drapier-Faure,E., Delmas,P.D., Norgestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in menopausal women after a 12-week treatment period, Climacteric, 8, 136-145, 2005	Outcomes reported not of interest
Nijland,E.A., Nathorst-Boos,J., Palacios,S., van de Weijer,P.W., Davis,S., Stathopoulos,V.M., Birkhaeuser,M.H., von,Mauw E., Mulder,R.J., Schultz,W.C., LISA study investigators group., Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction, Climacteric, 12, 114-121, 2009	Results of interest not calculable due to composite scoring and outcomes not of interest
Nikander,E., Metsa-Heikkila,M., Ylikorkala,O., Tiitinen,A., Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer, Journal of Clinical Endocrinology and Metabolism, 89, 1207-1212, 2004	Bone turnover not an outcome of interest.
Nikander,E., Rutanen,E.M., Nieminen,P., Wahlstrom,T., Ylikorkala,O., Tiitinen,A., Lack of effect of isoflavonoids on the vagina and endometrium in postmenopausal women, Fertility and Sterility, 83, 137-142, 2005	Cytology outcome not of interest
Nilsson,K., Heimer,G., Low-dose oestradiol in the treatment of urogenital oestrogen deficiency--a pharmacokinetic and pharmacodynamic study, Maturitas, 15, 121-127, 1992	Histology outcome not of interest
Noe,G., Sitruk-Ware,R., Zegers-Hochschild,F., Variano,B., Montero,J.C., Arriagada,P., Li,A., Stanczyk,F.Z., Felix,J.C., Mishell,Jr, Croxatto,H.B., Endometrial effect of progesterone delivered by vaginal rings in estrogen-treated postmenopausal women, Climacteric, 13, 433-441, 2010	Endometrial outcome not of interest
Nordin,B.E., Jones,M.M., Crilly,R.G., Marshall,D.H., Brooke,R., A placebo-controlled trial of ethinyl oestradiol and norethisterone in climacteric women, Maturitas, 2, 247-251, 1980	Results of interest not calculable due to scoring method.
Notelovitz,M., Funk,S., Nanavati,N., Mazzeo,M., Estradiol absorption from vaginal tablets in postmenopausal women, Obstetrics and Gynecology, 99, 556-562, 2002	No outcomes of interest - considers only vaginal maturation indices. Only compares 2 different doses of intravaginal estradiol.
Odabasi,A.R., Yuksel,H., Demircan,S.S., Kacar,D.F., Culhaci,N., Ozkara,E.E., A prospective randomized comparative study of the effects of intranasal and transdermal 17 beta-estradiol on postmenopausal symptoms and vaginal cytology, Journal of Postgraduate Medicine, 53, 221-227, 2007	Hot flush scores used

Study	Reason for exclusion
Odmark,I.S., Backstrom,T., Jonsson,B., Bixo,M., Long-term effects of two different continuous combined regimens of hormone replacement therapy on well-being, <i>Gynecological Endocrinology</i> , 18, 305-317, 2004	Type of outcome estimates not relevant
Oh,K.J., Chae,M.J., Lee,H.S., Hong,H.D., Park,K., Effects of Korean red ginseng on sexual arousal in menopausal women: placebo-controlled, double-blind crossover clinical study, <i>Journal of Sexual Medicine</i> , 7, 1469-1477, 2010	Wrong outcome: sexual arousal and scoring used
Oktem,M., Eroglu,D., Karahan,H.B., Taskintuna,N., Kuscu,E., Zeyneloglu,H.B., Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial, <i>Advances in Therapy</i> , 24, 448-461, 2007	Data inconsistent
Onalan,G., Onalan,R., Selam,B., Akar,M., Gunenc,Z., Topcuoglu,A., Mood scores in relation to hormone replacement therapies during menopause: a prospective randomized trial, <i>Tohoku Journal of Experimental Medicine</i> , 207, 223-231, 2005	Results reported in graph only
Osmanagaoglu,M.A., Atasaral,T., Baltaci,D., Bozkaya,H., Effect of different preparations of hormone therapy on sexual dysfunction in naturally postmenopausal women, <i>Climacteric</i> , 9, 464-472, 2006	Results of interest not calculable due to scoring method.
Osmer,R., Friede,M., Liske,E., Schnitker,J., Freudenstein,J., Henneicke-von Zepelin,H.H., Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms.[Erratum appears in <i>Obstet Gynecol.</i> 2005 Sep;106(3):644], <i>Obstetrics and Gynecology</i> , 105, 1074-1083, 2005	Results of interest not calculable due to scoring method.
Padwick,M.L., Siddle,N.C., Lane,G., Endacott,J.A., Cooper,H., Pryse-Davies,J., Whitehead,M.I., Oestriol with oestradiol versus oestradiol alone: a comparison of endometrial, symptomatic and psychological effects, <i>British Journal of Obstetrics and Gynaecology</i> , 93, 606-612, 1986	histology outcomes not of interest
Palacios,S., Castelo-Branco,C., Cancelo,M.J., Vazquez,F., Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy, <i>Maturitas</i> , 50, 98-104, 2005	Atrophy not of interest
Palacios,S., Menendez,C., Jurado,A.R., Castano,R., Vargas,J.C., Changes in sex behaviour after menopause: effects of tibolone, <i>Maturitas</i> , 22, 155-161, 1995	Outcomes (sexual desire) reported not of interest
Panahi,Y., Beiraghdar,F., Kashani,N., Javan,N.B., Dadjo,Y., Comparison of piascledine (Avocado and Soybean oil) and hormone replacement therapy in menopausal-induced hot flashing, <i>Iranian journal of pharmaceutical research</i> , 10, 941-951, 2011	Reported outcomes not of interest
Panay,N., Al-Azzawi,F., Bouchard,C., Davis,S.R., Eden,J., Lodhi,I., Rees,M., Rodenberg,C.A., Rymer,J., Schwenkhagen,A., Sturdee,D.W., Testosterone treatment of HSDD in naturally menopausal women: the ADORE study, <i>Climacteric</i> , 13, 121-131, 2010	Reported outcomes not of interest
Panay,N., Pritsch,M., Alt,J., Cyclical dydrogesterone in secondary amenorrhea: Results of a double-blind, placebo-controlled, randomized study, <i>Gynecological Endocrinology</i> , 23, 611-618, 2007	Bleeding not of interest
Panay, N., Ylikorkala, O., Archer, D.F., Gut, R., Lang, E., Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief, 10, 120-131, 2007	Study did not report uncertainty/variances of estimates
Panay,N., Toth,K., Pelissier,C., Studd,J., Dose-ranging studies of a novel intranasal estrogen replacement therapy, <i>Maturitas</i> , 38 Suppl 1, S15-S22, 2001	Outcome estimates not relevant.
Panjari,M., Bell,R.J., Jane,F., Adams,J., Morrow,C., Davis,S.R., The safety of 52 weeks of oral DHEA therapy for postmenopausal women, <i>Maturitas</i> , 63, 240-245, 2009	Intervention not of interest
Panjari,M., Bell,R.J., Jane,F., Wolfe,R., Adams,J., Morrow,C., Davis,S.R., A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido, <i>Journal of Sexual Medicine</i> , 6, 2579-2590, 2009	Intervention not of interest
Paoletti,A.M., Floris,S., Mannias,M., Orru,M., Crippa,D., Orlandi,R., Del Zompo,M.M., Melis,G.B., Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause, <i>Journal of Clinical Endocrinology and Metabolism</i> , 86, 608-612, 2001	PICO not met - Outcomes of interest not reported
Park,J.E., Lee,M.S., Jung,S., Kim,A., Kang,K., Choi,J., Park,J., Choi,S.M., Moxibustion for treating menopausal hot flashes: a randomized clinical trial, <i>Menopause</i> , 16, 660-665, 2009	data presented in graphical format without accompanying numbers
Parry,B.L., Meliska,C.J., Martinez,L.F., Basavaraj,N., Zirpoli,G.G., Sorenson,D., Maurer,E.L., Lopez,A., Markova,K., Gamst,A., Wolfson,T., Hauger,R., Kripke,D.F., Menopause: neuroendocrine changes and hormone replacement therapy, <i>Journal of the American Medical Womens Association</i> , 59, 135-145, 2004	Compares normal control patients to depressed patients so not all patients have depressive symptoms. Interventions are different for control group versus depressed group.
Parsons,A., Merritt,D., Rosen,A., Heath,H.III, Siddhanti,S., Plouffe,L., Jr., Study Groups on the Effects of Raloxifene HCl With Low-Dose Premarin Vaginal Cream., Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy, <i>Obstetrics and Gynecology</i> , 101, 346-352, 2003	Atrophy outcomes not of interest
Paterson,M.E., A randomized double-blind cross-over trial into the effect of norethisterone on climacteric symptoms and biochemical profiles, <i>British Journal of Obstetrics and Gynaecology</i> , 89, 464-472, 1982	Results of interest not calculable due to scoring method.

Study	Reason for exclusion
Paterson, M.E., A randomised, double-blind, cross-over study into the effect of sequential mestranol and norethisterone on climacteric symptoms and biochemical parameters, <i>Maturitas</i> , 4, 83-94, 1982	Unclear data (no clear labels nor information on how to interpret the data).
Pearce, J., Hawton, K., Blake, F., Barlow, D., Rees, M., Fagg, J., Keenan, J., Psychological effects of continuation versus discontinuation of hormone replacement therapy by estrogen implants: a placebo-controlled study, <i>Journal of Psychosomatic Research</i> , 42, 177-186, 1997	No comparison of methods of discontinuation - only compares women who discontinue treatment with those who continue.
Pefanco, M.A., Kenny, A.M., Kaplan, R.F., Kuchel, G., Walsh, S., Kleppinger, A., Prestwood, K., The effect of 3-year treatment with 0.25 mg/day of micronized 17beta-estradiol on cognitive function in older postmenopausal women, <i>Journal of the American Geriatrics Society</i> , 55, 426-431, 2007	Study does not indicate if patients have menopausal symptoms
Pelissier, C., Maroni, M., Yaneva, H., Brin, S., Peltier-Pujol, F., Jondet, M., Chlormadinone acetate versus micronized progesterone in the sequential combined hormone replacement therapy of the menopause, <i>Maturitas</i> , 40, 85-94, 2001	Results of interest not calculable due to scoring method.
Penotti, M., Sironi, L., Cannata, L., Vigano, P., Casini, A., Gabrielli, L., Vignali, M., Effects of androgen supplementation of hormone replacement therapy on the vascular reactivity of cerebral arteries, <i>Fertility and Sterility</i> , 76, 235-240, 2001	Reported outcomes not of relevance
Penteado, S.R., Fonseca, A.M., Bagnoli, V.R., Abdo, C.H., Junior, J.M., Baracat, E.C., Effects of the addition of methyltestosterone to combined hormone therapy with estrogens and progestogens on sexual energy and on orgasm in postmenopausal women, <i>Climacteric</i> , 11, 17-25, 2008	Interventions not of interest
Petri, Nahas E., Nahas, Neto J., De, Luca L., Traiman, P., Pontes, A., Dalben, I., Benefits of soy germ isoflavones in postmenopausal women with contraindication for conventional hormone replacement therapy, <i>Maturitas</i> , 48, 372-380, 2004	Results of interest not calculable due to scoring method.
Pinkerton, J.V., Harvey, J.A., Pan, K., Thompson, J.R., Ryan, K.A., Chines, A.A., Mirkin, S., Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial, <i>Obstetrics and Gynecology</i> , 121, 959-968, 2013	Reported outcome not relevant to protocol
Pinkerton, J.V., Utian, W.H., Constantine, G.D., Olivier, S., Pickar, J.H., Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial, <i>Menopause</i> , 16, 1116-1124, 2009	No variation per treatment group
Pitkin, J., Smetnik, V.P., Vadasz, P., Mustonen, M., Salminen, K., Ylikangas, S., Study Group., Continuous combined hormone replacement therapy relieves climacteric symptoms and improves health-related quality of life in early postmenopausal women, <i>Menopause International</i> , 13, 116-123, 2007	Results of interest not calculable due to graphs.
Place, V.A., Powers, M., Darley, P.E., Schenkel, L., Good, W.R., A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms, <i>American Journal of Obstetrics and Gynecology</i> , 152, 1092-1099, 1985	No baseline values provided and combination interventions not of interest (placebo combined with conjugated equine oestrogens)
Plouffe, L., Jr., Trott, E.A., Largoza, M., Hansen, K.A., An open trial of sertraline for menopausal hot flashes: potential involvement of serotonin in vasomotor instability. [Erratum appears in <i>Del Med J</i> 1998 Feb;70(2):93], <i>Delaware Medical Journal</i> , 69, 481-482, 1997	Bleeding outcome not relevant
Pockaj, B.A., Gallagher, J.G., Loprinzi, C.L., Stella, P.J., Barton, D.L., Sloan, J.A., LaVasseur, B.I., Rao, R.M., Fitch, T.R., Rowland, K.M., Novotny, P.J., Flynn, P.J., Richelson, E., Fauq, A.H., Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1, <i>Journal of Clinical Oncology</i> , 24, 2836-2841, 2006	Results of interest not calculable due to scoring method.
Pockaj, B.A., Loprinzi, C.L., Sloan, J.A., Novotny, P.J., Barton, D.L., Hagenmaier, A., Zhang, H., Lambert, G.H., Reeser, K.A., Wisbey, J.A., Pilot evaluation of black cohosh for the treatment of hot flashes in women, <i>Cancer Investigation</i> , 22, 515-521, 2004	Not a randomised controlled trial
Poller, L., Thomson, J.M., Coope, J., A double-blind cross-over study of piperazine oestrone sulphate and placebo with coagulation studies, <i>British Journal of Obstetrics and Gynaecology</i> , 87, 718-725, 1980	Sodium estrone sulfate is not an intervention required by protocol
Polo-Kantola, P., Erkkola, R., Helenius, H., Irjala, K., Polo, O., When does estrogen replacement therapy improve sleep quality?, <i>American Journal of Obstetrics and Gynecology</i> , 178, 1002-1009, 1998	Population not of interest and outcomes reported graphically.
Polo-Kantola, P., Erkkola, R., Irjala, K., Pullinen, S., Virtanen, I., Polo, O., Effect of short-term transdermal estrogen replacement therapy on sleep: a randomized, double-blind crossover trial in postmenopausal women, <i>Fertility and Sterility</i> , 71, 873-880, 1999	No usable data on outcomes (VSM, discontinuation, bleeding)
Pornel, B., Efficacy and safety of Menorest in two positive-controlled studies, <i>European Journal of Obstetrics, Gynecology, and Reproductive Biology</i> , 64 Suppl, S35-S37, 1996	Secondary report of Stud 1996
Pornel, B., Genazzani, A.R., Costes, D., Dain, M.P., Lelann, L., VandePol, C., Efficacy and tolerability of Menorest registered trade mark 50 compared with estraderm registered trade mark TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study, <i>Maturitas</i> , 22, 207-218, 1995	duplicate of article 227167
Pornel, B., Spielmann, D., A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17beta-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and	Baseline estimates illustrated with a figure.

Study	Reason for exclusion
norethisterone over a two-year period, <i>Gynecological Endocrinology</i> , 21, 74-81, 2005	
Portman,D.J., Bachmann,G.A., Simon,J.A., Ospemifene Study Group., Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy, <i>Menopause</i> , 20, 623-630, 2013	outcome not of interest (dyspareunia and vulvar/vaginal atrophy)
Portman,D.J., Symons,J.P., Wilborn,W., Kempfert,N.J., A randomized, double-blind, placebo-controlled, multicenter study that assessed the endometrial effects of norethindrone acetate plus ethinyl estradiol versus ethinyl estradiol alone, <i>American Journal of Obstetrics and Gynecology</i> , 188, 334-342, 2003	Secondary publication of 227348. Outcomes not of interest.
Post,M.S., Thomassen,M.C.L.G., Van,DerMoorenM, Van,BaalW, Rosing,J., Kenemans,P., Stehouwer,C.D.A., Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: A randomized, placebo-controlled study in postmenopausal women, <i>Arteriosclerosis, thrombosis, and vascular biology</i> , 23, 1116-1121, 2003	Results of interest not calculable due to scoring method.
Prior,J.C., Hitchcock,C.L., Progesterone for hot flush and night sweat treatment--effectiveness for severe vasomotor symptoms and lack of withdrawal rebound, <i>Gynecological Endocrinology</i> , 28 Suppl 2, 7-11, 2012	Results of interest not calculable due to scoring method.
Prior,J.C., Nielsen,J.D., Hitchcock,C.L., Williams,L.A., Vigna,Y.M., Dean,C.B., Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy, <i>Clinical Science</i> , 112, 517-525, 2007	Vasomotor rates used
Pruthi,S., Qin,R., Terstreip,S.A., Liu,H., Loprinzi,C.L., Shah,T.R.C., Tucker,K.F., Dakhil,S.R., Bury,M.J., Carolla,R.L., Steen,P.D., Vuky,J., Barton,D.L., A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North central cancer treatment group N08C7, <i>Menopause</i> , 19, 48-53, 2012	Frequency is in graph format only and accompanying text is unclear on the time point.
Punnonen,R., Rauramo,L., Effect of estrogen therapy on climacteric symptoms and tissue changes, <i>Acta Obstetrica et Gynecologica Scandinavica</i> , 53, 267-269, 1974	Outcomes not of interest
Qian,L.Q., Wang,B., Niu,J.Y., Gao,S., Zhao,D.Y., Assessment of the clinical effect of Chinese medicine therapy combined with psychological intervention for treatment of patients of peri-menopausal syndrome complicated with hyperlipidemia, <i>Chinese Journal of Integrative Medicine</i> , 16, 124-130, 2010	Outcomes not of interest
Qu,F., Zhou,J., Sang,X., Wang,X., Nan,R., Acupuncture and auricular acupressure in relieving menopausal hot flashes of bilaterally ovariectomized Chinese women: A randomized controlled trial, <i>Evidence-based Complementary and Alternative Medicine</i> , 2011 , 2011. Article Number, -, 2011	Results of interest not calculable due to scoring method.
Raghunandan,C., Agrawal,S., Dubey,P., Choudhury,M., Jain,A., A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women, <i>Journal of Sexual Medicine</i> , 7, 1284-1290, 2010	sexuality score reported, not frequency
Rakesh,M., Mittal,N., Hota,D., Ahluwalia,J., Suri,V., Aggarwal,N., Chakrabarti,A., A randomised, double blind, placebo controlled study to evaluate the effect of isoflavones on ADP and epinephrine induced platelet aggregation in oophorectomised women, <i>Pharmacologyonline</i> , 1, 458-468, 2010	ADP and platelet aggregate study. Not relevant.
Rasgon,N.L., Dunkin,J., Fairbanks,L., Altshuler,L.L., Troung,C., Elman,S., Wroolie,T.E., Brunhuber,M.V., Rapkin,A., Estrogen and response to sertraline in postmenopausal women with major depressive disorder: a pilot study, <i>Journal of Psychiatric Research</i> , 41, 338-343, 2007	Interventions not of interest (SSRI plus oestrogen or placebo)
Raus,K., Brucker,C., Gorkow,C., Wuttke,W., First-time proof of endometrial safety of the special black cohosh extract ( <i>Actaea</i> or <i>Cimicifuga racemosa</i> extract) CR BNO 1055, <i>Menopause</i> , 13, 678-691, 2006	Not a RCT
Raymundo,N., Yu-cheng,B., Zi-yan,H., Lai,C.H., Leung,K., Subramaniam,R., Bin-rong,C., Ling,Y.S., Nasri,N., Calimon,N., Treatment of atrophic vaginitis with topical conjugated equine estrogens in postmenopausal Asian women, <i>Climacteric</i> , 7, 312-318, 2004	Atrophy study. Not relevant.
Raynaud,J.P., Levrier,M., Calaf,J., Laur,C., Pelissier,C., Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch 40 and Estrapatch 60) with a twice week system, <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 93, 309-318, 2005	Outcome estimates reported not relevant
Rebar,R.W., Trabal,J., Mortola,J., Low-dose esterified estrogens (0.3 mg/day): long-term and short-term effects on menopausal symptoms and quality of life in postmenopausal women, <i>Climacteric</i> , 3, 176-182, 2000	Outcome estimates reported graphically.
Reddy,S.Y., Warner,H., Guttuso,T.,Jr., Messing,S., DiGrazio,W., Thornburg,L., Guzick,D.S., Gabapentin, estrogen, and placebo for treating hot flashes: a randomized controlled trial, <i>Obstetrics and Gynecology</i> , 108, 41-48, 2006	Hot flush composite scores used and results presented graphically.
Reed,S.D., Newton,K.M., LaCroix,A.Z., Grothaus,L.C., Grieco,V.S., Ehrlich,K., Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study, <i>Menopause</i> , 15, 51-58, 2008	Secondary publication of 277058
Rees,M.C., Kuhl,H., Engelstein,M., Mattila,L., Maenpaa,J., Mustonen,M., Study Group, Endometrial safety and tolerability of triphasic sequential hormone	Relevant outcome estimates reported graphically.

Study	Reason for exclusion
replacement estradiol valerate/medroxyprogesterone acetate therapy regimen, <i>Climacteric</i> , 7, 23-32, 2004	
Ribom,E.L., Svensson,P., Van,OsS, Larsson,M., Naessen,T., Low-dose tibolone (1.25 mg/d) does not affect muscle strength in older women, <i>Menopause</i> , 18, 194-197, 2011	Study does not indicate if patients have menopausal symptoms
Riesco,E., Choquette,S., Audet,M., Tessier,D., Dionne,I.J., Effect of exercise combined with phytoestrogens on quality of life in postmenopausal women, <i>Climacteric</i> , 14, 573-580, 2011	VMS: Results not calculable due to composite score scales.
Rigano,A., Rigano,M., Cancellieri,F., Pulle,C., Sexually and well-being in early menopause. Effect of transdermal estradiol therapy, <i>Panminerva Medica</i> , 43, 115-118, 2001	Outcome estimates reported not relevant.
Rioux,J.E., Devlin,C., Gelfand,M.M., Steinberg,W.M., Hepburn,D.S., 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis, <i>Menopause</i> , 7, 156-161, 2000	Atrophy study: wrong outcome.
Roberts,H., Lethaby,A., Phytoestrogens for menopausal vasomotor symptoms: a Cochrane review summary, <i>Maturitas</i> , 78, 79-81, 2014	Editorial of Cochrane review, summary
Ronkin,S., Northington,R., Baracat,E., Nunes,M.G., Archer,D.F., Constantine,G., Pickar,J.H., Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women, <i>Obstetrics and Gynecology</i> , 105, 1397-1404, 2005	Endometrial histology study (wrong outcome)
Rosano,G.M., Peters,N.S., Lefroy,D., Lindsay,D.C., Sarrel,P.M., Collins,P., Poole-Wilson,P.A., 17-beta-Estradiol therapy lessens angina in postmenopausal women with syndrome X, <i>Journal of the American College of Cardiology</i> , 28, 1500-1505, 1996	An angina study: wrong outcome
Ross,S.M., Menopause: a standardized isopropanolic black cohosh extract (remifemin) is found to be safe and effective for menopausal symptoms, <i>Holistic Nursing Practice</i> , 26, 58-61, 2012	Results not calculable due to graphical reporting.
Rovati,L.C., Schmid,K., Giacobelli,G., Bonn,M., Setnikar,I., Wolff,F., Genazzani,A.R., Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies, <i>Arzneimittel-Forschung</i> , 49, 933-943, 1999	Outcome estimates not relevant.
Rozenbaum,H., Chevallier,O., Moyal,M., Durand,G., Perineau,M., This,P., Aerodiol study group., Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women, <i>Climacteric</i> , 5, 249-258, 2002	Study tests oestrogen alone on women with a uterus
Rozenberg,S., Caubel,P., Lim,P.C., Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms, <i>International Journal of Gynaecology and Obstetrics</i> , 72, 235-243, 2001	Outcome estimates reported not relevant.
Rozenberg,S., Ylikorkala,O., Arrenbrecht,S., Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids, <i>International Journal of Fertility and Womens Medicine</i> , 42 Suppl 2, 376-387, 1997	Results not calculable due to graphical reporting.
Rubio-Auriales,E., Lopez,M., Lipezker,M., Lara,C., Ramirez,A., Rampazzo,C., Hurtado de Mendoza,M.T., Lowrey,F., Loehr,L.A., Lammers,P., Phentolamine mesylate in postmenopausal women with female sexual arousal disorder: a psychophysiological study, <i>Journal of Sex and Marital Therapy</i> , 28 Suppl 1, 205-215, 2002	(Phentolamine) not of interest
Russo,R., Corosu,R., The clinical use of a preparation based on phyto-oestrogens in the treatment of menopausal disorders, <i>Acta Bio-Medica de l'Ateneo Parmense</i> , 74, 137-143, 2003	Results not calculable due to inconsistent reporting.
Rutanen,E.M., Heikkinen,J., Halonen,K., Komi,J., Lammintausta,R., Ylikorkala,O., Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial, <i>Menopause</i> , 10, 433-439, 2003	Data not shown for outcome of interest (quality of life)
Saensak,S., Vutyavanich,T., Somboonporn,W., Srisurapanont,M., Relaxation for perimenopausal and postmenopausal symptoms, <i>Cochrane Database of Systematic Reviews</i> , 7, CD008582-, 2014	Individual studies checked for inclusion criteria and checked in STAR for interventions and outcomes of interest
Saletu,B., Sleep, vigilance and cognition in postmenopausal women: placebo-controlled studies with 2 mg estradiol valerate, with and without 3 mg dienogest, <i>Climacteric</i> , 6 Suppl 2, 37-45, 2003	Data in graphical format without accompanying numbers
Saletu,B., Brandstatter,N., Metka,M., Stamenkovic,M., Anderer,P., Semlitsch,H.V., Heytmanek,G., Huber,J., Grunberger,J., Linzmayer,L., Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression, <i>Psychopharmacology</i> , 122, 321-329, 1995	Not relevant to protocol
Saletu-Zyhlarz,G., Anderer,P., Gruber,G., Mandl,M., Gruber,D., Metka,M., Huber,J., Oettel,M., Graser,T., bu-Bakr,M.H., Gratzhofer,E., Saletu,B., Insomnia related to postmenopausal syndrome and hormone replacement therapy: sleep laboratory studies on baseline differences between patients and controls and double-blind, placebo-controlled investigations on the effects of a novel estrogen-	Not primary data

Study	Reason for exclusion
progestogen combination (Climodien, Lafamme) versus estrogen alone, Journal of Sleep Research, 12, 239-254, 2003	
Salmi,T., Punnonen,R., Clonidine in the treatment of menopausal symptoms, International Journal of Gynaecology and Obstetrics, 16, 422-426, 1979	Results not calculable due to composite score scales.
Samsioe,G., Dvorak,V., Genazzani,A.R., Hamann,B., Heikkinen,J., Mueck,A.O., Suzin,J., Kawakami,F.T., Ferreira,A., Sun,D., Arguinzon,M., One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women, Maturitas, 57, 171-181, 2007	Outcome not relevant to protocol
Sanchez,F.E., Urdinola,J.M., Onatra,W.H., Posso,H.V., Sanchez,J.A., Alwers,R.C., Clinical manifestations in menopause with modifications to hormone replacement therapy. Multicentre Clinical trial comparing mixed hormones (conjugated estrogens plus medroxyprogesterone vs. estradiol valerate plus cyproterone acetate, Revista Colombiana De Obstetricia y Ginecologia, 47, 263-272, 1996	Non-English language (Spanish)
Sandberg,M., Wijma,K., Wyon,Y., Nedstrand,E., Hammar,M., Effects of electro-acupuncture on psychological distress in postmenopausal women, Complementary Therapies in Medicine, 10, 161-169, 2002	Outcomes were combined rather than broken down (hostility, somatisation, interpersonal sensitivity, depression and anxiety)
Sarrel,P., Dobay,B., Wiita,B., Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses, Journal of Reproductive Medicine, 43, 847-856, 1998	Androgen and oestrogen combination therapy not of interest
Saure,A., Henriksson,L., Sternquist,M., Randomized comparison of a new estradiol-releasing vaginal ring versus estriol vaginal pessaries [5], American Journal of Obstetrics and Gynecology, 173, 670-671, 1995	Correspondence editorial
Saure,A., Hirvonen,E., Milsom,I., Christensen,A., Damber,M.G., A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms, Maturitas, 24, 111-118, 1996	Evaluated severity of climacteric symptoms
Saure,A., Planellas,J., Poulsen,H.K., Jaszczak,P., A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women, Maturitas, 34, 133-142, 2000	Results not calculable due to composite score scales.
Savolainen-Peltonen,H., Hautamaki,H., Tuomikoski,P., Ylikorkala,O., Mikkola,T.S., Health-related quality of life in women with or without hot flashes: a randomized placebo-controlled trial with hormone therapy, Menopause, 21, 732-739, 2014	Not a short term study (more than 16 weeks)
Sayyah,M., Feizy,F., Boostani,H., A preliminary randomized double-blind clinical trial on efficacy of estrogen after hysterectomy in postmenopausal women with major depression disorder, Minerva Psichiatrica, 51, 73-77, 2010	Interventions not of interest (fluoxetine plus placebo versus oestrogen plus fluoxetine)
Scambia,G., Mango,D., Signorelli,P.G., nselmi Angeli,R.A., Palena,C., Gallo,D., Bombardelli,E., Morazzoni,P., Riva,A., Mancuso,S., Clinical effects of a standardized soy extract in postmenopausal women: a pilot study, Menopause, 7, 105-111, 2000	No mean value and variation reported for outcome and interventions of interest
Scharf,M.B., Berkowitz,D.V., Reape,K.Z., Effects of synthetic conjugated estrogens A on sleep quality in postmenopausal women with nocturnal diaphoresis and/or hot flashes: a pilot study, Fertility and Sterility, 88, 654-656, 2007	Baseline values not reported and follow up less than 12 weeks
Scharf,M.B., McDannold,M.D., Stover,R., Zaretsky,N., Berkowitz,D.V., Effects of estrogen replacement therapy on rates of cyclic alternating patterns and hot-flush events during sleep in postmenopausal women: a pilot study, Clinical Therapeutics, 19, 304-311, 1997	Not a RCT
Schellenberg,R., Saller,R., Hess,L., Melzer,J., Zimmermann,C., Drewe,J., Zahner,C., Dose-dependent effects of the Cimicifuga racemosa extract Ze 450 in the treatment of climacteric complaints: A randomized, placebo-controlled study, Evidence-based Complementary and Alternative Medicine, 2012, 2012. Article Number, -, 2012	Outcome not relevant to protocol
Schiff,R., Bulpitt,C.J., Wesnes,K.A., Rajkumar,C., Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study, Psychoneuroendocrinology, 30, 309-315, 2005	Population of women aged 62 to 89 years old with mean age 71 therefore without menstrual symptoms.
Schindler,A.E., Heners,D., Pater,T., The treatment of the climacteric syndrome with a combination of low- dose clonidine and low-dose conjugated estrogens, Fortschritte der Medizin, 102, 1213-1216, 1984	Non-English language
Schneider,L.S., Small,G.W., Hamilton,S.H., Bystritsky,A., Nemeroff,C.B., Meyers,B.S., Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group, American Journal of Geriatric Psychiatry, 5, 97-106, 1997	Geriatrics study
Schult,T.M., Ensrud,K.E., Blackwell,T., Ettinger,B., Wallace,R., Tice,J.A., Effect of isoflavones on lipids and bone turnover markers in menopausal women, Maturitas, 48, 209-218, 2004	PICO not met - Outcomes of interest not reported
Schussler,P., Kluge,M., Yassouridis,A., Dresler,M., Held,K., Zihl,J., Steiger,A., Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women, Psychoneuroendocrinology, 33, 1124-1131, 2008	Study does not mention patients have menopause symptoms

Study	Reason for exclusion
Secreto,G., Chiechi,L.M., Amadori,A., Miceli,R., Venturelli,E., Valerio,T., Marubini,E., Soy isoflavones and melatonin for the relief of climacteric symptoms: a multicenter, double-blind, randomized study, <i>Maturitas</i> , 47, 11-20, 2004	Results not calculable due to composite score scales.
Seftel,A., Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: A randomized, placebo-controlled trial - Commentary, <i>Journal of Urology</i> , 175, 660-, 2006	Conference abstract
Sen,C., Morimoto,Y., Heak,S., Cooney,R.V., Franke,A.A., Maskarinec,G., Soy foods and urinary isoprostanol: results from a randomized study in premenopausal women, <i>Food and Function</i> , 3, 517-521, 2012	Secondary publication
Shams,T., Firwana,B., Habib,F., Alshahrani,A., Alnough,B., Murad,M.H., Ferwana,M., SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials, <i>Journal of General Internal Medicine</i> , 29, 204-213, 2014	Individual studies were checked for inclusion criteria and have been included in STAR, and protocol for interventions and outcomes of interest
Shams,T., Setia,M.S., Hemmings,R., McCusker,J., Sewitch,M., Ciampi,A., Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis. [56 refs], <i>Alternative Therapies in Health and Medicine</i> , 16, 36-44, 2010	Systematic review and meta-analysis
Shao,M., Huang,Y., Control study of mirtazapine combined with estrogen replacement therapy (HRT) and single HRT in treatment of menopause depression, <i>Chinese Journal of Health Psychology</i> , 13, 449-450, 2005	not in English
Sherwin,B.B., The impact of different doses of estrogen and progesterone on mood and sexual behavior in postmenopausal women, <i>Journal of Clinical Endocrinology and Metabolism</i> , 72, 336-343, 1991	Results reported on graph with no accompanying numbers
Sherwin,B.B., Gelfand,M.M., Sex steroids and affect in the surgical menopause: a double-blind, cross-over study, <i>Psychoneuroendocrinology</i> , 10, 325-335, 1985	Outcomes not relevant to protocol
Sherwin,B.B., Gelfand,M.M., A prospective one-year study of estrogen and progesterone in postmenopausal women: effects on clinical symptoms and lipoprotein lipids, <i>Obstetrics and Gynecology</i> , 73, 759-766, 1989	Data in graphs only
Sherwin,B.B., Gelfand,M.M., Effects of parenteral administration of estrogen and androgen on plasma hormone levels and hot flashes in the surgical menopause, <i>American Journal of Obstetrics and Gynecology</i> , 148, 552-557, 1984	Outcome not of interest to protocol
Sherwin,B.B., Gelfand,M.M., Brender,W., Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause, <i>Psychosomatic Medicine</i> , 47, 339-351, 1985	Results not calculable due to composite score scales.
Shifren,J.L., Braunstein,G.D., Simon,J.A., Casson,P.R., Buster,J.E., Redmond,G.P., Burki,R.E., Ginsburg,E.S., Rosen,R.C., Leiblum,S.R., Caramelli,K.E., Mazer,N.A., Transdermal testosterone treatment in women with impaired sexual function after oophorectomy, <i>New England Journal of Medicine</i> , 343, 682-688, 2000	Interventions not of interest (testosterone combined with oestrogen or placebo)
Shifren,J.L., Davis,S.R., Moreau,M., Waldbaum,A., Bouchard,C., Derogatis,L., Derzko,C., Bearson,P., Kakos,N., O'Neill,S., Levine,S., Wekselman,K., Buch,A., Rodenberg,C., Kroll,R., Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study.[Erratum appears in <i>Menopause</i> . 2007 Jan-Feb;14(1):157], <i>Menopause</i> , 13, 770-779, 2006	Outcome (satisfaction) not relevant to protocol
Shulman,L.P., Yankov,V., Uhl,K., Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials.[Erratum appears in <i>Menopause</i> . 2002 Sep-Oct;9(5):385], <i>Menopause</i> , 9, 195-207, 2002	Endometrial outcome only
Siddle,N.C., Fraser,D., Whitehead,M.I., Jesinger,D.K., Endacott,J., Prescott,P., Pryse-Davies,J., Endometrial, physical and psychological effects of postmenopausal oestrogen therapy with added dydrogesterone, <i>British Journal of Obstetrics and Gynaecology</i> , 97, 1101-1107, 1990	Does not report sample size per treatment group
Silva,B.H., Martinez,D., Wender,M.C., A randomized, controlled pilot trial of hormone therapy for menopausal insomnia, <i>Archives of Women's Mental Health</i> , 14, 505-508, 2011	Uses old PSQI global score (Buysse 1989)
Simon,J., Klaiber,E., Wiita,B., Bowen,A., Yang,H.M., Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women, <i>Menopause</i> , 6, 138-146, 1999	VMS reported graphically.
Simon,J.A., ESTRASORB Study Group., Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms, <i>Menopause</i> , 13, 222-231, 2006	Outcomes not relevant to protocol
Simon,J.A., Lin,V.H., Radovich,C., Bachmann,G.A., One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus, <i>Menopause</i> , 20, 418-427, 2013	An atrophy study
Simon,J.A., Liu,J.H., Speroff,L., Shumel,B.S., Symons,J.P., Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy, <i>American Journal of Obstetrics and Gynecology</i> , 188, 92-99, 2003	Evaluated the effects of HRT on the incidence and duration of vaginal bleeding.



Study	Reason for exclusion
Simon,J.A., Portman,D.J., Kaunitz,A.M., Mekonnen,H., Kazempour,K., Bhaskar,S., Lippman,J., Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials, <i>Menopause</i> , 20, 1027-1035, 2013	Incomplete data provided for vasomotor symptoms
Simunic,V., Banovic,I., Ciglar,S., Jeren,L., Pavicic,Baldani D., Sprem,M., Local estrogen treatment in patients with urogenital symptoms, <i>International Journal of Gynecology and Obstetrics</i> , 82, 187-197, 2003	Urogenital paper
Sites,C.K., L'Hommedieu,G.D., Toth,M.J., Brochu,M., Cooper,B.C., Fairhurst,P.A., The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: A randomized, double-blind, placebo-controlled trial, <i>Journal of Clinical Endocrinology and Metabolism</i> , 90, 2701-2707, 2005	No relevant data
Skarsgard,C., Berg,E., Ekblad,S., Wiklund,I., Hammar,M.L., Effects of estrogen therapy on well-being in postmenopausal women without vasomotor complaints, <i>Maturitas</i> , 36, 123-130, 2000	Population not relevant to protocol
Skrumsager,B.K., Kiehr,B., Pedersen,P.C., Gerrits,M., Watson,N., Bjarnason,K., Levormeloxifene: safety, pharmacodynamics and pharmacokinetics in healthy postmenopausal women following single and multiple doses of a new selective oestrogen receptor modulator, <i>British Journal of Clinical Pharmacology</i> , 53, 284-295, 2002	Outcomes of interest not reported
Soares,C.N., Escitalopram reduced hot flashes in non-depressed perimenopausal and postmenopausal women, <i>Evidence Based Medicine</i> , 16, 159-160, 2011	A commentary, not a study.
Soares,C.N., Joffe,H., Viguera,A.C., Petrillo,L., Rydzewski,M., Yehezkel,R., Somley,B., Cohen,L.S., Paroxetine versus placebo for women in midlife after hormone therapy discontinuation, <i>American Journal of Medicine</i> , 121, 159-162, 2008	Not a RCT
Soares,C.N., Poitras,J.R., Prouty,J., Alexander,A.B., Shifren,J.L., Cohen,L.S., Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms, <i>Journal of Clinical Psychiatry</i> , 64, 473-479, 2003	Intervention not of interest (citalopram plus progestogen and oestrogen)
Soares,C.N., Thase,M.E., Clayton,A., Guico-Pabia,C.J., Focht,K., Jiang,Q., Kornstein,S.G., Ninan,P.T., Kane,C.P., Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram, <i>CNS Drugs</i> , 25, 227-238, 2011	not a randomised controlled trial
Sonnendecker,E.W., Polakow,E.S., Effects of conjugated equine oestrogens with and without the addition of cyclical medrogestone on hot flushes, liver function, blood pressure and endocrinological indices, <i>South African Medical Journal, Suid-Afrikaanse Tydskrif Vir Geneeskunde</i> , 77, 281-285, 1990	outcome of interest is measured by hot flush scores--the study doesn't indicate how hot flush scores were measured
Sorensen,K.E., Dorup,I., Hermann,A.P., Mosekilde,L., Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function, <i>Circulation</i> , 97, 1234-1238, 1998	Endometrial outcomes
Spangler,L., Newton,K.M., Grothaus,L.C., Reed,S.D., Ehrlich,K., LaCroix,A.Z., The effects of black cohosh therapies on lipids, fibrinogen, glucose and insulin, <i>Maturitas</i> , 57, 195-204, 2007	No outcomes of interest reported
Speroff,L., Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms, <i>Obstetrics and Gynecology</i> , 102, 823-834, 2003	Study tests oestrogen alone on women with a uterus
Speroff,L., Eisenberg,E., Estradiol vaginal rings were an effective treatment for postmenopausal vasomotor symptoms, <i>Evidence-Based Obstetrics and Gynecology</i> , 6, 154-155, 2004	Abstract only
Speroff,L., Gass,M., Constantine,G., Olivier,S., Study 315 Investigators., Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial, <i>Obstetrics and Gynecology</i> , 111, 77-87, 2008	Outcome estimates not of interest. Used a severity score for hot flushes.
Speroff,L., Symons,J., Kempfert,N., Rowan,J., femhr,Study,I., The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhr) on the frequency and intensity of vasomotor symptoms, <i>Menopause</i> , 7, 383-390, 2000	data on outcome of interest presented in graphical format only
St,Germain A., Peterson,C.T., Robinson,J.G., Alekel,D.L., Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment, <i>Menopause</i> , 8, 17-26, 2001	Data in graphical format
Stadberg,E., Mattsson,L.A., Uvebrant,M., 17 beta-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy, <i>Maturitas</i> , 23, 31-39, 1996	Results not calculable due to graphical reporting.
Stanczyk,F.Z., Shoupe,D., Nunez,V., Ias-Gonzales,P., Vijod,M.A., Lobo,R.A., A randomized comparison of nonoral estradiol delivery in postmenopausal women, <i>American Journal of Obstetrics and Gynecology</i> , 159, 1540-1546, 1988	No outcomes relevant to protocol
Stearns,V., Beebe,K.L., Iyengar,M., Dube,E., Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial, <i>JAMA</i> , 289, 2827-2834, 2003	No variation per treatment group
Stearns,V., Isaacs,C., Rowland,J., Crawford,J., Ellis,M.J., Kramer,R., Lawrence,W., Hanfelt,J.J., Hayes,D.F., A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors, <i>Annals of Oncology</i> , 11, 17-22, 2000	Not an RCT
Stefanos,Z., Georgios,I., Panagiotis,P., Iordanis,N., Panagiotis,T., Georgios,G., Vasilios,L., Koutlaki,N., Marin,J., Sequential tibolone versus progestogen for premenopausal bleeding, <i>Gineco.ro</i> , 6, 37-40, 2010	Outcome = bleeding only

Study	Reason for exclusion
Steingold,K.A., Laufer,L., Chetkowski,R.J., DeFazio,J.D., Matt,D.W., Meldrum,D.R., Judd,H.L., Treatment of hot flashes with transdermal estradiol administration, Journal of Clinical Endocrinology and Metabolism, 61, 627-632, 1985	Outcome estimates cannot be extracted. Presented graphically.
Stomati,M., Bersi,C., Rubino,S., Palumbo,M., Comitini,G., Genazzani,A.D., Santuz,M., Petraglia,F., Genazzani,A.R., Neuroendocrine effects of different estradiol-progestogen regimens in postmenopausal women.[Erratum appears in Maturitas 1998 Jun 17;29(3):271 Note: Santre M [corrected to Santuz M]], Maturitas, 28, 127-135, 1997	Basal plasma outcome
Stovall,D.W., Utian,W.H., Gass,M.L., Qu,Y., Muram,D., Wong,M., Plouffe,L., Jr., The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety, Menopause, 14, 510-517, 2007	Results reported as n% with flushes, not VSM frequency.
Stovall,D.W., Utian,W.H., Gass,M.L.S., Qu,Y., Muram,D., Wong,M., Plouffe,L., The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety, Obstetrical and Gynecological Survey, 62, 591-593, 2007	Quantitative outcome estimates not reported.
Strickler,R., Stovall,D.W., Merritt,D., Shen,W., Wong,M., Silfen,S.L., Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial, Obstetrics and Gynecology, 96, 359-365, 2000	Women were asymptomatic
Studd,J., Pornel,B., Marton,I., Bringer,J., Varin,C., Tsouderos,Y., Christiansen,C., Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group.[Erratum appears in Lancet 1999 Aug 28;354(9180):780], Lancet, 353, 1574-1578, 1999	Only baseline results for hot flushes given.Estimates after treatment plotted graphically.Estimates in text not usable.
Studd,J.W., MacCarthy,K., Zamblera,D., Dain,M.P., Efficacy and safety of Menorest (50 mikrog/day) compared to Premarin 0.625 mg in the treatment of menopausal symptoms and the prevention of bone loss, in menopausal women. A single-center, comparative, randomized, double-blind, double-dummy study, Scandinavian Journal of Rheumatology - Supplement, 103, 89-90, 1996	Conference abstract
Studd,J.W., McCarthy,K., Zamblera,D., Burger,H.G., Silberberg,S., Wren,B., Dain,M.P., Le,Lann L., VandePol,C., Efficacy and tolerance of Menorest compared to Premarin in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study, Maturitas, 22, 105-114, 1995	duplicate of 255051
Studd,J.W.W., McCarthy,K., Zamblera,D., Burger,H.G., Silberberg,S., Wren,B., Dain,M.P., Le,L.L., VandePol,C., Efficacy and tolerance of Menorestregistered trade mark compared to Premarinregistered trade mark in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study, Maturitas, 22, 105-114, 1995	Intervention dosage and regiment reported in abstract contradicted those reported in the body
Studd,J.W.W., McCarthy,K., Zamblera,D., Dain,M.P., Le,LannL, A double-blind, double-dummy, comparative study of Menorest 50 versus Premarin 0.625 mg in the treatment of menopausal symptoms and the prevention of bone loss in patients with menopausal symptoms, Clinical Drug Investigation, 11, 205-213, 1996	Study tests oestrogen alone on women with a uterus
Sturdee,D.W., Van,DeWeijerP, Von,HolstT, Endometrial safety of a transdermal sequential estradiol-levonorgestrel combination, Climacteric, 5, 170-177, 2002	Outcome not relevant. Assessed the effect of HRT on the endometrium.
Sulak,P.J., Caubel,P., Lane,R., Efficacy and safety of a constant-estrogen, pulsed-progestogen regimen in hormone replacement therapy, International Journal of Fertility and Womens Medicine, 44, 286-296, 1999	VSM frequency outcome not reported
Sun,Z., Hao,Y., Zhang,M., Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials, Gynecologic and Obstetric Investigation, 75, 255-262, 2013	Meta-analysis of individual studies already excluded or included from the review
Sunay,D., Ozdiken,M., Arslan,H., Seven,A., Aral,Y., The effect of acupuncture on postmenopausal symptoms and reproductive hormones: a sham controlled clinical trial, Acupuncture in Medicine, 29, 27-31, 2011	Study does not focus on one of the 4 symptom areas but assesses menopausal symptoms in general (including somatic, psychological and urogenital) using the Menopause Rating Scale
Suvanto-Luukkonen,E., Koivunen,R., Sundstrom,H., Bloigu,R., Karjalainen,E., Haiva-Mallinen,L., Tapanainen,J.S., Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study, Menopause, 12, 18-26, 2005	data in graphical format only
Swanson,S.G., Drosman,S., Helmond,F.A., Stathopoulos,V.M., Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study, Menopause, 13, 917-925, 2006	Results reported in the abstract differ from the results section-the abstract reported average number of hot flashes, whereas the results section reported median number of hot flashes. Unclear if abstract results are mean or median as it is not stated
Symons,J., Kempfert,N., Speroff,L., Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. The FemHRT Study Investigators, Obstetrics and Gynecology, 96, 366-372, 2000	Bleeding outcome
Taavoni,S., Darsareh,F., Joolae,S., Haghani,H., The effect of aromatherapy massage on the psychological symptoms of postmenopausal Iranian women, Complementary Therapies in Medicine, 21, 158-163, 2013	Outcomes of interest not reported at endpoint
Taavoni,S., Ekbatani,N., Kashaniyan,M., Haghani,H., Effect of valerian on sleep quality in postmenopausal women: a randomized placebo-controlled clinical trial, Menopause, 18, 951-955, 2011	Uses old PSQI global score (Buysse 1989)

Study	Reason for exclusion
Taavoni,S., Nazem,Ekbatani N., Haghani,H., Valerian/lemon balm use for sleep disorders during menopause, <i>Complementary Therapies in Clinical Practice</i> , 19, 193-196, 2013	Wrong outcome
Tagliaferri,M., Creasman,J., Caygill,K.A., Olyae,A., Leitman,D., Cohen,I., Grady,D., Clinically meaningful efficacy of a non-estrogen agent: re-analysis of phase-2 data evaluating MF101, <i>Climacteric</i> , 15, 607-610, 2012	Outcome = treatment compliance
Tan,D., Haines,C.J., Limpaphayom,K.K., Holinka,C.F., Ausmanas,M.K., Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study, <i>Maturitas</i> , 52, 35-51, 2005	Results reported as graph
Tarim,E., Bagis,T., Kilicdag,E., Erkanli,S., Aslan,E., Kuscu,E., Moclobemide in the treatment of hot flashes in postmenopausal women, <i>Advances in Therapy</i> , 19, 258-265, 2002	intervention (Reversible inhibitor of monoamine oxidase type A) is not of interest
Tedeschi,C., Benvenuti,C., Research Group, Comparison of vaginal gel isoflavones versus no topical treatment in vaginal dystrophy: results of a preliminary prospective study, <i>Gynecological Endocrinology</i> , 28, 652-654, 2012	Outcomes not relevant
Tempfer,C.B., Bentz,E.K., Leodolter,S., Tscherne,G., Reuss,F., Cross,H.S., Huber,J.C., Phytoestrogens in clinical practice: a review of the literature. [82 refs], <i>Fertility and Sterility</i> , 87, 1243-1249, 2007	Literature review
Tempfer,CB., Froese,G., Heinze,G., Bentz, E., Hefler, LA, Huber, J.C., Side effects of phytoestrogens: a meta-analysis of randomized trials, <i>American Journal of Medicine</i> , 122, 939-946, 2009	Secondary data
Thomas,A.J., Ismail,R., Taylor-Swanson,L., Cray,L., Schnall,J.G., Mitchell,E.S., Woods,N.F., Effects of isoflavones and amino acid therapies for hot flashes and co-occurring symptoms during the menopausal transition and early postmenopause: a systematic review, <i>Maturitas</i> , 78, 263-276, 2014	Individual studies checked for inclusion criteria for interventions and outcomes of interest and checked in STAR
Thompson,CoonJ, Pittler,M.H., Ernst,E., Trifolium pratense isoflavones in the treatment of menopausal hot flushes: A systematic review and meta-analysis, <i>Phytomedicine</i> , 14, 153-159, 2007	Secondary data
Thomson,J., Double blind study on the effect of estrogen on sleep, anxiety and depression in perimenopausal women: preliminary results, <i>Proceedings of the Royal Society of Medicine</i> , 69, 829-830, 1976	Older version of article 227452
Toulis,K.A., Tzellos,T., Kouvelas,D., Goulis,D.G., Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. [44 refs], <i>Clinical Therapeutics</i> , 31, 221-235, 2009	Secondary data
Toulis,K.A., Tzellos,T.; Kouvelas,D., Goulis,D.G., Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis, <i>Clinical Therapeutics</i> , 31, 221-235, 2009	Secondary data
Travers,C., O'Neill,S.M., King,R., Battistutta,D., Khoo,S.K., Greene Climacteric Scale: norms in an Australian population in relation to age and menopausal status, <i>Climacteric</i> , 8, 56-62, 2005	No intervention
Tremblay,A., Sheeran,L., Aranda,S.K., Psychoeducational interventions to alleviate hot flashes: A systematic review, <i>Menopause</i> , 15, 193-202, 2008	Intervention not of interest to protocol
Tuomikoski,P., Ebert,P., Groop,P.H., Haapalahti,P., Hautamaki,H., Ronnback,M., Ylikorkala,O., Mikkola,T.S., Effect of hot flushes on vascular function: a randomized controlled trial, <i>Obstetrics and Gynecology</i> , 114, 777-785, 2009	Outcomes not relevant to protocol
Tuomikoski,P., Haapalahti,P., Sarna,S., Ylikorkala,O., Mikkola,T.S., Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy, <i>Annals of Medicine</i> , 42, 334-343, 2010	Outcome not relevant.Study compared the effect of HRT on ambulatory BP in post-menopausal women with or without severe hot flushes.
Tuomikoski,P., Mikkola,T.S., Tikkanen,M.J., Ylikorkala,O., Hot flushes and biochemical markers for cardiovascular disease: a randomized trial on hormone therapy, <i>Climacteric</i> , 13, 457-466, 2010	Outcome not relevant to protocol
Uesugi,S., Watanabe,S., Ishiwata,N., Uehara,M., Ouchi,K., Effects of isoflavone supplements on bone metabolic markers and climacteric symptoms in Japanese women, <i>Biofactors</i> , 22, 221-228, 2004	Outcome not relevant to protocol
Upmalis,D.H., Lobo,R., Bradley,L., Warren,M., Cone,F.L., Lamia,C.A., Erratum: Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: A multicenter, double-blind, randomized, placebo-controlled study ( <i>Menopause</i> (240)), <i>Menopause</i> , 7, 422-, 2000	Present corrected figures for study 255141
Ushiroyama,T., Ikeda,A., Sakuma,K., Ueki,M., Comparing the effects of estrogen and an herbal medicine on peripheral blood flow in post-menopausal women with hot flashes: hormone replacement therapy and gui-zhi-fu-ling-wan, a Kampo medicine, <i>American Journal of Chinese Medicine</i> , 33, 259-267, 2005	no relevant outcomes
Ushiroyama,T., Ikeda,A., Sakuma,K., Ueki,M., Chai-hu-gui-zhi-gan-jiang-tang regulates plasma interleukin-6 and soluble interleukin-6 receptor concentrations and improves depressed mood in climacteric women with insomnia, <i>American Journal of Chinese Medicine</i> , 33, 703-711, 2005	Interventions not of interest (tetracyclic antidepressant and SSRI combined with tranquilizer)
Utian,W., Leonard,T., Davis,A., Vega,R., Efficacy and safety study of a new synthetic 10-component, modified release conjugated estrogens (CE) tablet for treatment of vasomotor symptoms in postmenopausal women, <i>Fertility and Sterility</i> , Vol 78, S159, Abstract-129, 2002	Abstract

Study	Reason for exclusion
Utian,W.H., Gass,M.L., Pickar,J.H., Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women, <i>Menopause</i> , 11, 306-314, 2004	Secondary publication of 277491
Utian,W.H., Shoupe,D., Bachmann,G., Pinkerton,J.V., Pickar,J.H., Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate, <i>Fertility and Sterility</i> , 75, 1065-1079, 2001	VSM data presented in graphical format with no accompanying numbers
Uygur,D., Yesildaglar,N., Erkaya,S., Effect on sexual life--a comparison between tibolone and continuous combined conjugated equine estrogens and medroxyprogesterone acetate, <i>Gynecological Endocrinology</i> , 20, 209-212, 2005	Scoring was used for frequency of intercourse
Valiati,B., Capp,E., Edelweiss,M.I., de Freitas,F.M., Wender,M.C., Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium--a randomized controlled trial, <i>Maturitas</i> , 62, 81-84, 2009	Results = KI, endometrial and vaginal bleeding
van den Brink,H.R., van Everdingen,A.A., van Wijk,M.J., Jacobs,J.W., Bijlsma,J.W., Adjuvant oestrogen therapy does not improve disease activity in postmenopausal patients with rheumatoid arthritis, <i>Annals of the Rheumatic Diseases</i> , 52, 862-865, 1993	Outcome not relevant to protocol
van der Linden,M.C., Gerretsen,G., Brandhorst,M.S., Ooms,E.C., Kremer,C.M., Doesburg,W.H., The effect of estriol on the cytology of urethra and vagina in postmenopausal women with genito-urinary symptoms, <i>European Journal of Obstetrics, Gynecology, and Reproductive Biology</i> , 51, 29-33, 1993	PICO not met - Intervention given for less than 12 weeks. Outcome not of interest.
van der Sluijs,C.P., Bensoussan,A., Chang,S., Baber,R., A randomized placebo-controlled trial on the effectiveness of an herbal formula to alleviate menopausal vasomotor symptoms, <i>Menopause</i> , 16, 336-344, 2009	results Greene score, not frequency
Van Leusden,H.A., Albertyn,G., Verlaine,C., Van,Ruyambeke J., A comparative multicenter study of two transdermal estradiol replacement therapies in the treatment of postmenopausal symptoms, <i>International Journal of Fertility and Menopausal Studies</i> , 38, 210-218, 1993	Doesn't meet PICO-not all patients have hot flushes
Van,DeWeijerP, Long-term adherence to continuous combined HRT: Seven-year update on the Heikkinen study, <i>Journal of the British Menopause Society</i> , 9, 8-9, 2003	Outcome = compliance to treatment
van,Die,M.D., Bone,K.M., Burger,H.G., Reece,J.E., Teede,H.J., Effects of a combination of <i>Hypericum perforatum</i> and <i>Vitex agnus-castus</i> on PMS-like symptoms in late-perimenopausal women: findings from a subpopulation analysis, <i>Journal of Alternative and Complementary Medicine</i> , 15, 1045-1048, 2009	Secondary publication of 277916
van,Die,M.D., Bone,K.M., Burger,H.G., Teede,H.J., Are we drawing the right conclusions from randomised placebo-controlled trials? A post-hoc analysis of data from a randomised controlled trial, <i>BMC Medical Research Methodology</i> , 9, 41-, 2009	Secondary publication of 227916
Vartiainen,J., Wahlstrom,T., Nilsson,C.G., Effects and acceptability of a new 17 beta-oestradiol-releasing vaginal ring in the treatment of postmenopausal complaints, <i>Maturitas</i> , 17, 129-137, 1993	Local oestrogen for vagina
Veldhuis,J.D., Keenan,D.M., Iranmanesh,A., Mielke,K., Miles,J.M., Bowers,C.Y., Estradiol potentiates ghrelin-stimulated pulsatile growth hormone secretion in postmenopausal women, <i>Journal of Clinical Endocrinology and Metabolism</i> , 91, 3559-3565, 2006	PICO not met - Intervention (Transdermal estradiol) given for less than 12 weeks
Venzke,L., Calvert,J.F.,Jr., Gilbertson,B., A randomized trial of acupuncture for vasomotor symptoms in post-menopausal women, <i>Complementary Therapies in Medicine</i> , 18, 59-66, 2010	no frequency of hot flushes reported
Verhoeven,M.O., Teerlink,T., Kenemans,P., Vogelvang,T.E., van der Moeren,M.J., Research Group., Effects on asymmetric dimethylarginine of HMR 3339, a novel selective estrogen receptor modulator: a 12-week, randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women, <i>Menopause</i> , 14, 235-242, 2007	Outcome not relevant to protocol
Vestergaard,P., Hermann,A.P., Stilgren,L., Tofteng,C.L., Sorensen,O.H., Eiken,P., Nielsen,S.P., Mosekilde,L., Effects of 5 years of hormonal replacement therapy on menopausal symptoms and blood pressure-a randomised controlled study, <i>Maturitas</i> , 46, 123-132, 2003	PICO not met - not all women had symptoms
Vincent,A., Barton,D.L., Mandrekar,J.N., Cha,S.S., Zais,T., Wahner-Roedler,D.L., Keppler,M.A., Kreitzer,M.J., Loprinzi,C., Acupuncture for hot flashes: a randomized, sham-controlled clinical study, <i>Menopause</i> , 14, 45-52, 2007	hot flush score was reported, not frequency
Voipio,S.K., Komi,J., Kangas,L., Halonen,K., DeGregorio,M.W., Erkkola,R.U., Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women, <i>Maturitas</i> , 43, 207-214, 2002	Endometrial/vaginal outcomes
Volpe,A., Facchinetti,F., Grasso,A., Petraglia,F., Campanini,D., Genazzani,A.R., Benefits and risks of different hormonal replacement therapies in post-menopausal women, <i>Maturitas</i> , 8, 327-334, 1986	Results not calculable due to reporting on graph.
von,Holst T., Lang,E., Winkler,U., Keil,D., Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone, <i>Maturitas</i> , 43, 265-275, 2002	Outcome estimates reported not relevant

Study	Reason for exclusion
von, Holst T., Salbach, B., Efficacy of a new 7-day transdermal sequential estradiol/levonorgestrel patch in women, <i>Maturitas</i> , 41, 231-242, 2002	Relevant outcomes reported graphically
von, Schoultz E., Rutqvist, L.E., Stockholm Breast Cancer Study Group., Menopausal hormone therapy after breast cancer: the Stockholm randomized trial, <i>Journal of the National Cancer Institute</i> , 97, 533-535, 2005	PICO not met - women were asymptomatic. Outcome not relevant.
Voss, S., Quail, D., Dawson, A., Backstrom, T., Aguas, F., Erenus, M., The, H.S., Bonnar, J., De, Geyter C., Hunter, M., Nickelsen, T., Euralox Investigators Group., A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life, <i>BJOG: An International Journal of Obstetrics and Gynaecology</i> , 109, 874-885, 2002	Interventions (placebo plus treatment combined) not of interest
Waaseth, M., Nakling, M., Bakken, K., Grimsgaard, S., Use of dietary supplements and medication among postmenopausal women with vasomotor symptoms, <i>Climacteric</i> , 13, 585-593, 2010	Not a randomised controlled trial
Walker, E.M., Rodriguez, A.I., Kohn, B., Ball, R.M., Pegg, J., Pocock, J.R., Nunez, R., Peterson, E., Jakary, S., Levine, R.A., Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial, <i>Journal of Clinical Oncology</i> , 28, 634-640, 2010	Data presented in graphical format only
Wang, P.H., Horng, H.C., Cheng, M.H., Chao, H.T., Chao, K.C., Standard and low-dose hormone therapy for postmenopausal women--focus on the breast. [53 refs], <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 46, 127-134, 2007	narrative review
Warnock, J.K., Swanson, S.G., Borel, R.W., Zipfel, L.M., Brennan, J.J., ESTRATEST Clinical Study Group., Combined esterified estrogens and methyltestosterone versus esterified estrogens alone in the treatment of loss of sexual interest in surgically menopausal women, <i>Menopause</i> , 12, 374-384, 2005	Population and outcome not of interest.
Warren, M.P., Is megestrol acetate a suitable option for treatment of hot flashes in women with breast cancer?, <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 4, 650-651, 2008	Commentary
Watts, N.B., Notelovitz, M., Timmons, M.C., Addison, W.A., Wiita, B., Downey, L.J., Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. [Erratum appears in <i>Obstet Gynecol</i> 1995 May;85(5 Pt 1):668], <i>Obstetrics and Gynecology</i> , 85, 529-537, 1995	Outcome not relevant to protocol
Weisberg, E., Ayton, R., Darling, G., Farrell, E., Murkies, A., O'Neill, S., Kirkegard, Y., Fraser, I.S., Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet, <i>Climacteric</i> , 8, 83-92, 2005	This is an endometrial study
Welton, A.J., Vickers, M.R., Kim, J., Ford, D., Lawton, B.A., MacLennan, A.H., Meredith, S.K., Martin, J., Meade, T.W., Health-related quality of life after combined Hormone-Replacement therapy: Randomized controlled trial: Women's international study of long duration estrogen after the menopause, <i>Obstetrical and Gynecological Survey</i> , 64, 238-240, 2009	Commentary
Welton, A.J., Vickers, M.R., Kim, J., Ford, D., Lawton, B.A., MacLennan, A.H., Meredith, S.K., Martin, J., Meade, T.W., WISDOM team., Health related quality of life after combined hormone replacement therapy: randomised controlled trial, <i>BMJ</i> , 337, a1190-, 2008	Outcome not relevant to protocol
Welty, F.K., Lee, K.S., Lew, N.S., Nasca, M., Zhou, J.R., The association between soy nut consumption and decreased menopausal symptoms, <i>Journal of Women's Health</i> , 16, 361-369, 2007	Intervention (Dietary advice) not of interest
Wesel, S., Bourguignon, R.P., Bosuma, W.B., Veralipride versus conjugated oestrogens: a double-blind study in the management of menopausal hot flushes, <i>Current Medical Research and Opinion</i> , 8, 696-700, 1984	Treatment banned in E.U.
Westlund, Tam L., Parry, B.L., Does estrogen enhance the antidepressant effects of fluoxetine?, <i>Journal of Affective Disorders</i> , 77, 87-92, 2003	Population and outcomes not of interest
Whelan, A.M., Jurgens, T.M., Trinacty, M., Bioidentical progesterone cream for menopause-related vasomotor symptoms: is it effective?, <i>Annals of Pharmacotherapy</i> , 47, 112-116, 2013	Systematic review
White, W.B., Grady, D., Giudice, L.C., Berry, S.M., Zborowski, J., Snabes, M.C., A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder, <i>American Heart Journal</i> , 163, 27-32, 2012	Study protocol
Wihlbäck, A.C., Nyberg, S., Backstrom, T., Bixo, M., Sundstrom-Poromaa, I., Estradiol and the addition of progesterone increase the sensitivity to a neurosteroid in postmenopausal women, <i>Psychoneuroendocrinology</i> , 30, 38-50, 2005	PICO not met - Combination of interventions investigated. No outcomes of interest can be extracted
Wiklund, I., Holst, J., Karlberg, J., Mattsson, L.A., Samsioe, G., Sandin, K., Uvebrant, M., von, Schoultz B., A new methodological approach to the evaluation of quality of life in postmenopausal women, <i>Maturitas</i> , 14, 211-224, 1992	Not relevant to the protocol
Williamson-Hughes, P.S., Flickinger, B.D., Messina, M.J., Empie, M.W., Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published studies. [55 refs], <i>Menopause</i> , 13, 831-839, 2006	Not primary data
Winther, K., Rein, E., Hedman, C., Femal, a herbal remedy made from pollen extracts, reduces hot flushes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study, <i>Climacteric</i> , 8, 162-170, 2005	Data presented in graphical format

Study	Reason for exclusion
Witherby,S., Johnson,J., Demers,L., Mout,S., Littenberg,B., Maclean,C.D., Wood,M., Muss,H., Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study, <i>Oncologist</i> , 16, 424-431, 2011	Outcomes of interest.
Wolff,E.F., He,Y., Black,D.M., Brinton,E.A., Budoff,M.J., Cedars,M.I., Hodis,H.N., Lobo,R.A., Manson,J.E., Merriam,G.R., Miller,V.M., Naftolin,F., Pal,L., Santoro,N., Zhang,H., Harman,S.M., Taylor,H.S., Self-reported menopausal symptoms, coronary artery calcification, and carotid intima-media thickness in recently menopausal women screened for the Kronos early estrogen prevention study (KEEPS), <i>Fertility and Sterility</i> , 99, 1385-1391, 2013	Does not meet PICO
Wren,B.G., Brown,L.B., A double-blind trial with clonidine and a placebo to treat hot flushes, <i>Medical Journal of Australia</i> , 144, 369-370, 1986	No variation per treatment group
Wren,B.G., Champion,S.M., Willetts,K., Manga,R.Z., Eden,J.A., Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women, <i>Menopause</i> , 10, 13-18, 2003	Study examines more than one area (vasomotor, sexual function, psychological)
Wu,W.H., Lu,S.C., Wang,T.F., Jou,H.J., Wang,T.A., Effects of docosahexaenoic acid supplementation on blood lipids, estrogen metabolism, and in vivo oxidative stress in postmenopausal vegetarian women, <i>European Journal of Clinical Nutrition</i> , 60, 386-392, 2006	Not relevant to the protocol
Wuttke,W., Raus,K., Gorkow,C., Efficacy and tolerability of the Black cohosh ( <i>Actaea racemosa</i> ) ethanolic extract BNO 1055 on climacteric complaints: A double-blind, placebo- and conjugated estrogens-controlled study, <i>Maturitas</i> , 55, S83-S91, 2006	Secondary publication of 227583
Wuttke,W., Seidlova-Wuttke,D., Gorkow,C., The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers, <i>Maturitas</i> , 44 Suppl 1, S67-S77, 2003	Secondary publication of 227568
Wyeth, A Multicenter, Randomized, 8-Week Double-Blind Acute Phase Followed By a 6-Month Continuation Phase (Open-Label Or Double-Blind) Study to Evaluate the Efficacy, Safety, and Tolerability of DVS SR Versus Escitalopram in Postmenopausal Women With Major Depressive Disorder [NCT00406640], <i>ClinicalTrials.gov</i> [www.clinicaltrials.gov], 2006., -	PICO not met - Intervention (Desvenlafaxine) not of interest. Outcome estimates of interest not reported.
Wyrwich,K.W., Spratt,D.I., Gass,M., Yu,H., Bobula,J.D., Identifying meaningful differences in vasomotor symptoms among menopausal women, <i>Menopause</i> , 15, 698-705, 2008	PICO not met - Intervention (Desvenlafaxine) not of interest
Yalamanchili,V., Gallagher,J.C., Treatment with hormone therapy and calcitriol did not affect depression in older postmenopausal women: no interaction with estrogen and vitamin D receptor genotype polymorphisms, <i>Menopause</i> , 19, 697-703, 2012	This is a geriatric study
Yang,T.S., Wang,H.L., Chen,Y.J., Chang,S.P., Yuan,C.C., Effect of continuous administration of conjugated estrogen plus medroxyprogesterone acetate (Premelle) in postmenopausal women in Taiwan, <i>Journal of the Chinese Medical Association: JCMA</i> , 67, 336-343, 2004	Outcome not of interest (metabolic effects on lipids)
Yang,T.S., Wang,S.Y., Yang,Y.C., Su,C.H., Lee,F.K., Chen,S.C., Tseng,C.Y., Jou,H.J., Huang,J.P., Huang,K.E., Effects of standardized phytoestrogen on Taiwanese menopausal women, <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 51, 229-235, 2012	Scoring used for vasomotor symptoms
Yang,Z.D., Yu,J., Zhang,Q., Effects of raloxifene on cognition, mental health, sleep and sexual function in menopausal women: A systematic review of randomized controlled trials, <i>Maturitas</i> , 75, 341-348, 2013	Systematic review of individual studies that have been excluded from the review
Yasemin Karageyim,Karsidag A., Karsidag,C., Buyukbayrak,E.E., Kars,B., Pirimoglu,M., Unal,O., Effects of tibolone on depressive and anxiety symptoms in symptomatic postmenopausal women, <i>Dusunen adam</i> , 25, 135-139, 2012	Results incalculable due to KI reporting only
Yasui,T., Matsui,S., Yamamoto,S., Uemura,H., Tsuchiya,N., Noguchi,M., Yuzurihara,M., Kase,Y., Irahara,M., Effects of Japanese traditional medicines on circulating cytokine levels in women with hot flashes, <i>Menopause</i> , 18, 85-92, 2011	Outcome not of interest
Yasui,T., Uemura,H., Tezuka,M., Yamada,M., Irahara,M., Miura,M., Aono,T., Biological effects of hormone replacement therapy in relation to serum estradiol levels, <i>Hormone Research</i> , 56, 38-44, 2001	wrong result - KI score
Ye,Y.B., Wang,Z.L., Zhuo,S.Y., Lu,W., Liao,H.F., Verbruggen,M., Fang,S., Mai,H.Y., Chen,Y.M., Su,Y.X., Soy germ isoflavones improve menopausal symptoms but have no effect on blood lipids in early postmenopausal Chinese women: a randomized placebo-controlled trial, <i>Menopause</i> , 19, 791-798, 2012	Results not calculable due to scores reported on timeline graph.
Ylikorkala,O., Rozenberg,S., Efficacy and tolerability of fully transdermal hormone replacement in sequential or continuous therapy at two doses of progestogen in postmenopausal women, <i>Maturitas</i> , 37, 83-93, 2000	Outcome not relevant to protocol
Ylikorkala,O., Wahlstrom,T., Caubel,P., Lane,R., Intermittent progestogen administration as part of hormone replacement therapy: long-term comparison between estradiol 1 mg combined with intermittent norgestimate and estradiol 2 mg combined with constant norethisterone acetate, <i>Acta Obstetricia et Gynecologica Scandinavica</i> , 81, 654-660, 2002	Secondary publication of 227251
Yoles,I., Yogev,Y., Frenkel,Y., Hirsch,M., Nahum,R., Kaplan,B., Efficacy and safety of standard versus low-dose Femarelle (DT56a) for the treatment of menopausal symptoms, <i>Clinical and Experimental Obstetrics and Gynecology</i> , 31, 123-126, 2004	Outcome not relevant to protocol

Study	Reason for exclusion
Yu,H., Racketa,J., Chines,A.A., Mirkin,S., Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women, <i>Climacteric</i> , 16, 252-257, 2013	Results not calculable due to composite score scales.
Yuan,R., Peng,Q., Liao,Q., Li,H.X., Efficacy of hormone replacement plus antidepressant for anxiety and depression in patients with menopause syndrome, <i>Chinese Journal of Clinical Rehabilitation</i> , 10, 162-163, 2006	Foreign language study
Zheng,S., Wu,Y., Zhang,Z., Yang,X., Hui,Y., Zhang,Y., Chen,S., Deng,W., Liu,H., Ekangaki,A., Stocks,J., Harper,C., Liu,J., Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: A randomized clinical trial in Beijing, <i>Chinese Medical Journal</i> , 116, 1127-1133, 2003	Outcome not relevant to protocol
Zhou,J., Qu,F., Nan,R., Tang,D., The effect of chinese medicinal herbs in relieving menopausal symptoms in ovariectomized chinese women, <i>Explore: The Journal of Science and Healing</i> , 3, 478-484, 2007	Outcomes not relevant
Zhou,K., Jiang,J., Wu,J., Liu,Z., Electroacupuncture modulates reproductive hormone levels in patients with primary ovarian insufficiency: Results from a prospective observational study, <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013. Article Number, -, 2013	Women with POI only included, not naturally menopausal women.
Ziaei,S., Kazemnejad,A., Zareai,M., The effect of vitamin E on hot flashes in menopausal women, <i>Gynecologic and Obstetric Investigation</i> , 64, 204-207, 2007	Not a RCT
Zweifel,J.E., O'Brien,W.H., A meta-analysis of the effect of hormone replacement therapy upon depressed mood.[Erratum appears in <i>Psychoneuroendocrinology</i> 1997 Nov;22(8):655], <i>Psychoneuroendocrinology</i> , 22, 189-212, 1997	Secondary data

## G.4.1 Urogenital atrophy

### G.4.1.1 Short term treatment - clinical

Study	Reason for exclusion
Almendral,C., Casper,F., Distler,W., Frick,J., Herold,J., Huenges,P., Hussong,R., Methfessel,H.D., Muller,M., Petri,E., Retzke,U., Santellani,M., Weise,W., Wilhelm,H., Wortmann,M., Zimber,P., Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: A comparative and a placebo-controlled multicenter study, <i>International Urogynecology Journal and Pelvic Floor Dysfunction</i> , 10, 171-176, 1999	Secondary publication
Ayton,R.A., Darling,G.M., Murkies,A.L., Farrell,E.A., Weisberg,E., Selinus,I., Fraser,I.D., A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy, <i>British Journal of Obstetrics and Gynaecology</i> , 103, 351-358, 1996	Two local estrogen preparations were compared.
Bachmann,G., Bobula,J., Mirkin,S., Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy, <i>Climacteric</i> , 13, 132-140, 2010	PICO not met - No oestrogen alone group
Barentsen,R., van de Weijer,P.H., Schram,J.H., Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy, <i>European Journal of Obstetrics, Gynecology, and Reproductive Biology</i> , 71, 73-80, 1997	Compared two local estrogen preparations
Bateson,D.J., Weisberg,E., An open-label randomized trial to determine the most effective regimen of vaginal estrogen to reduce the prevalence of atrophic changes reported in postmenopausal cervical smears, <i>Menopause</i> , 16, 765-769, 2009	PICO not met - No placebo group
Bride,M.B.M., Shuster,L., Rhodes,D., Grossardt,B., Warndahl,R., Debra,B., Low dose vaginal estrogens for the treatment of vulvovaginal atrophy: A randomized, placebo-controlled trial evaluating effect of estriol, estradiol or placebo on vulvovaginal atrophy symptoms, <i>Journal of Sexual Medicine</i> , 11, 220-221, 2014	Abstract only
Buckler,Helen, Al-Azzawi,Farook, UK VR Multicentre Trial Group, The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women, <i>BJOG : an international journal of obstetrics and gynaecology</i> , 110, 753-759, 2003	Population and outcomes not relevant. Two estrogen preparations compared.
Capobianco,G., Donolo,E., Borghero,G., Dessole,F., Cherchi,P.L., Dessole,S., Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women, <i>Archives of Gynecology and Obstetrics</i> , 285, 397-403, 2012	PICO not met - No placebo group
Chen,J., Geng,L., Song,X., Li,H., Giordan,N., Liao,Q., Evaluation of the efficacy and safety of hyaluronic Acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial, <i>Journal of Sexual Medicine</i> , 10, 1575-1584, 2013	PICO not met - Population did not have urogenital atrophy and there was no placebo group
Constantine,G., Graham,S., Koltun,W.D., Kingsberg,S.A., Assessment of ospemifene or lubricants on clinical signs of VVA, <i>Journal of Sexual Medicine</i> , 11, 1033-1041, 2014	Summary of three studies: 226136, 254703, 319531
Constantine, G. D., Goldstein, S. R., Archer, D. F., Endometrial safety of ospemifene: results of the phase 2/3 clinical development program, <i>Menopause</i> , 22, 36-43, 2015	Review report, background reading

Study	Reason for exclusion
Cui,Y., Zong,H., Yan,H., Li,N., Zhang,Y., The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis, <i>Journal of Sexual Medicine</i> , 11, 487-497, 2014	Review
Dessole,S., Rubattu,G., Ambrosini,G., Gallo,O., Capobianco,G., Cherchi,P.L., Marci,R., Cosmi,E., Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women, <i>Menopause</i> , 11, 49-56, 2004	Duplicate
Dorr,M.B., Nelson,A.L., Mayer,P.R., Ranganath,R.P., Norris,P.M., Helzner,E.C., Preston,R.A., Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis, <i>Fertility and Sterility</i> , 94, 2365-2368, 2010	PICO not met - Interventions were not compared with placebo
Dugal,R., Hesla,K., Sordal,T., Aase,K.H., Lilleeidet,O., Wickstrom,E., Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy, <i>Acta Obstetrica et Gynecologica Scandinavica</i> , 79, 293-297, 2000	Two local estrogen preparations were compared.
Ekin,M., Yasar,L., Savan,K., Temur,M., Uhri,M., Gencer,I., Kivanc,E., The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial, <i>Archives of Gynecology and Obstetrics</i> , 283, 539-543, 2011	PICO not met - No placebo group
Eriksen,B., A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women, <i>American Journal of Obstetrics and Gynecology</i> , 180, 1072-1079, 1999	Population included postmenopausal women who had had >=3 urinary tract infections treated during the previous 12 months.
Eugster-Hausmann,M., Waitzinger,J., Lehnick,D., Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets, <i>Climacteric</i> , 13, 219-227, 2010	PICO not met - No placebo group
Felding,C., Mikkelsen,A.L., Clausen,H.V., Loft,A., Larsen,L.G., Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial, <i>Maturitas</i> , 15, 241-249, 1992	Population not relevant. Were postmenopausal women with genital prolapse scheduled for surgery.
Foidart,J.M., Vervliet,J., Buytaert,P., Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints, <i>Maturitas</i> , 13, 99-107, 1991	Outcomes was based on urogenital index which was calculated based on symptoms related atrophic vaginitis, urethral syndrome, degree of incontinence, and sex life
Freedman,M., Kaunitz,A.M., Reape,K.Z., Hait,H., Shu,H., Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy, <i>Menopause</i> , 16, 735-741, 2009	PICO not met - No oestrogen alone group
Gast,M.J., Freedman,M.A., Vieweg,A.J., De Melo,N.R., Girao,M.J., Zinaman,M.J., Dyspareunia Study Group., A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women, <i>Menopause</i> , 16, 247-256, 2009	PICO not met - Intervention (oral HRT combined with vaginal HRT) not of interest
Gennari,L., Merlotti,D., Valleggi,F., Nuti,R., Ospemifene use in postmenopausal women. [63 refs], <i>Expert Opinion on Investigational Drugs</i> , 18, 839-849, 2009	Review
Gordon,W.E., Hermann,H.W., Hunter,D.C., Treatment of atrophic vaginitis in postmenopausal women with micronized estradiol cream - a follow-up study, <i>Journal of the Kentucky Medical Association</i> , 77, 337-339, 1979	Extension study of a previous study
Jaisamran,U., Triwatanachai,S., Chaikittisilpa,S., Grob,P., Prasauskas,V., Taechakraichana,N., Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy, <i>Climacteric</i> , 16, 347-355, 2013	PICO not met - No oestrogen alone group
Kagan,R., Williams,R.S., Pan,K., Mirkin,S., Pickar,J.H., A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women, <i>Menopause</i> , 17, 281-289, 2010	PICO not met - No oestrogen alone group
Karoussos,K.E., Studer,S., Wyss,H.J., The treatment of atrophic vaginal conditions with Ortho-Gynest A pilot study, <i>Journal of International Medical Research</i> , 7, 569-572, 1979	Does not match review protocol
Karp,D., Jean-Michel,M., Peterson,T., Johnston,Y., Suci,G., Aguilar,V., Davila,G.W., Optimizing post-operative healing following vaginal reconstructive surgery: A triple arm randomized clinical trial of an estradiol-releasing vaginal ring, <i>Neurourology and Urodynamics</i> , 29, 887-888, 2010	PICO not met - Conference abstract of an included study 'Karp 2012'
Long,C.Y., Liu,C.M., Hsu,S.C., Wu,C.H., Wang,C.L., Tsai,E.M., A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women, <i>Menopause</i> , 13, 737-743, 2006	PICO not met - No placebo control group
Manonai,J., Theppisai,U., Suthutvoravut,S., Udomsubpayakul,U., Chittacharoen,A., The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study, <i>Journal of Obstetrics and Gynaecology Research</i> , 27, 255-260, 2001	Compared two local estrogen preparations
Marx,Phyllis, Schade,George, Wilbourn,Shelby, Blank,Stephen, Moyer,Dean L., Nett,Robert, Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis, <i>Maturitas</i> , 47, 47-54, 2004	Used oral estrogen preparation as intervention
Mazur,D., Vens-Cappell,B., Lohmann,K., Breckwoldt,M., Fractionated use of a 17beta estradiol cream for the treatment of vaginal atrophy in postmenopausal women. [German], <i>Geburtshilfe und Frauenheilkunde</i> , 65, 584-589, 2005	Article in German



Study	Reason for exclusion
Molander,U., Milsom,I., Ekelund,P., Mellstrom,D., Eriksson,O., Effect of oral oestriol on vaginal flora and cytology and urogenital symptoms in the post-menopause, <i>Maturitas</i> , 12, 113-120, 1990	Compared oral estrogen with placebo.
Nachtigall,L.E., Comparative study: Replens versus local estrogen in menopausal women, <i>Fertility and Sterility</i> , 61, 178-180, 1994	Used a vaginal health index to score outcomes of vaginal moisture, vaginal fluid volume, vaginal elasticity, and vagina mucosa
Nash,H.A., varez-Sanchez,F., Mishell,D.R.J., Fraser,I.S., Maruo,T., Harmon,T.M., Estradiol-delivering vaginal rings for hormone replacement therapy, <i>American Journal of Obstetrics and Gynecology</i> Am J Obstet Gynecol, 181, 1400-1406, 1999	Compared two local estrogen preparations.
Notelovitz,M., Funk,S., Nanavati,N., Mazzeo,M., Estradiol absorption from vaginal tablets in postmenopausal women, <i>Obstetrics and Gynecology</i> , 99, 556-562, 2002	Compared two local estrogen preparations
Palacios,S., Castelo-Branco,C., Cancelo,M.J., Vazquez,F., Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy, <i>Maturitas</i> , 50, 98-104, 2005	Systemic hormone therapy combined with local estrogen in the treatment arm
Parsons,A., Merritt,D., Rosen,A., Heath,H.,III, Siddhanti,S., Plouffe,L.,Jr., Study Groups on the Effects of Raloxifene HCl With Low-Dose Premarin Vaginal Cream., Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy, <i>Obstetrics and Gynecology</i> , 101, 346-352, 2003	Intervention not of interest to review question.
Portman,D., Simon,J., Goldstein,S., Safety and efficacy of ospemifene, a selective estrogen receptor modulator, for treatment of postmenopausal women with vulvovaginal atrophy, <i>Journal of Sexual Medicine</i> , Vol.9, pp.165, 2012., -, -32676	Abstract
Raghuandan,C., Agrawal,S., Dubey,P., Choudhury,M., Jain,A., A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women, <i>Journal of Sexual Medicine</i> , 7, 1284-1290, 2010	PICO not met: Study included women with a range of disorders including vaginal atrophy. Relevant outcomes of vaginal dryness and dyspareunia were combined and assessed using a urogenital score.
Rioux,J.E., Devlin,C., Gelfand,M.M., Steinberg,W.M., Hepburn,D.S., 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis, <i>Menopause</i> , 7, 156-161, 2000	Compared two local estrogen preparations
Simon,J., Nachtigall,L., Gut,R., Lang,E., Archer,D.F., Utian,W., Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet, <i>Obstetrics and Gynecology</i> , 112, 1053-1060, 2008	Duplicate
Simon,J., Portman,D., Mabey,R.G.,Jr., Ospemifene Study Group., Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women, <i>Maturitas</i> , 77, 274-281, 2014	Secondary publication of 319569
Simon,J.A., Lin,V.H., Radovich,C., Bachmann,G.A., One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus, <i>Menopause</i> , 20, 418-427, 2013	Duplicate
Simon,J.A., Lin,V.H., Radovich,C., Bachmann,G.A., Ospemifene Study Group., One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus, <i>Menopause</i> , 20, 418-427, 2013	For short term review question
Speroff,L., Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms, <i>Obstetrics and Gynecology</i> , 102, 823-834, 2003	Duplicate
Stute,P., Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief?, <i>Archives of Gynecology and Obstetrics</i> , 288, 1199-1201, 2013	Compared local estrogen with hyaluronic acid
Suckling,Jane A., Kennedy,Ray, Lethaby,Anne, Roberts,Helen, Local oestrogen for vaginal atrophy in postmenopausal women, <i>Cochrane Database of Systematic Reviews</i> , -, 2010	Review
Tan,Delfin, Haines,Christopher J., Limpaphayom,Khunying Kobchitt, Holinka,Christian F., Ausmanas,Militza K., Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study, <i>Maturitas</i> , 52, 35-51, 2005	Used oral estrogen preparation as intervention
Vartiainen,J., Wahlstrom,T., Nilsson,C.G., Effects and acceptability of a new 17 beta-oestradiol-releasing vaginal ring in the treatment of postmenopausal complaints, <i>Maturitas</i> , 17, 129-137, 1993	Population (postmenopausal women suffering from hot flashes) and outcomes not relevant to review protocol

#### G.4.1.2 Short term treatment – economic

Study	Reason for exclusion
Intrauterine device, <i>Obstetrics and Gynecology</i> , 105, 223-232, 2005	Not relevant intervention or population
Estrogen-progestin combinations for postmenopausal use, <i>Medical Letter on Drugs and Therapeutics</i> , 37, 53-54, 1995	not an economic evaluation
Albertazzi,P., Doren,M., Effects of menopause, <i>Contemporary Clinical Gynecology and Obstetrics</i> , 2, 195-204, 2002	Not an economic evaluation
Alsina,J., Benefits of hormone replacement therapy--overview and update. [103 refs], <i>International Journal of Fertility and Womens Medicine</i> , 42 Suppl 2, 329-346, 1997	Not an economic evaluation

Study	Reason for exclusion
Borud,E.K., Alraek,T., White,A., Fonnebo,V., Grimsgaard,S., The effect of TCM acupuncture on hot flushes among menopausal women (ACUFLASH) study: a study protocol of an ongoing multi-centre randomised controlled clinical trial, BMC Complementary and Alternative Medicine, Vol.7, pp.6, 2007., -, -32676	Not an economic evaluation
Brazier,J.E., Roberts,J., Platts,M., Zoellner,Y.F., Estimating a preference-based index for a menopause specific health quality of life questionnaire, Health and Quality of Life Outcomes, 3, 13-, 2005	Not an economic evaluation
Burkman,R.T., Managing the transition from oral contraceptives to hormone replacement therapy, American Journal of Managed Care, 7, S575-S579, 2001	Not an economic evaluation
Cheung,A.P., Wren,B.G., A cost-effectiveness analysis of hormone replacement therapy in the menopause, Medical Journal of Australia, 156, 312-316, 1992	Dated study focusing on fracture and myocardial infarction outcomes
Coyle,D., Cranney,A., Lee,K.M., Welch,V., Tugwell,P., Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation, Pharmacoeconomics, 19, 565-75, 2001	Does not assess treatments of interest
Daly,E., Gray,A., Barlow,D., McPherson,K., Roche,M., Vessey,M., Measuring the impact of menopausal symptoms on quality of life, BMJ, 307, 836-840, 1993	Not an economic evaluation
Daly,E., Roche,M., Barlow,D., Gray,A., McPherson,K., Vessey,M., HRT: An analysis of benefits, risks and costs, British Medical Bulletin, 48, 368-400, 1992	Incorrect timeframe as it is an economic evaluation of long-term HRT
Gambacciani,M., Ciaponi,M., Cappagli,B., Monteleone,P., Benussi,C., Bevilacqua,G., Genazzani,A.R., Effects of low-dose, continuous combined estradiol and norethisterone acetate on menopausal quality of life in early postmenopausal women, Maturitas, 44, 157-163, 2003	Not an economic evaluation
Genazzani,A.R., Nicolucci,A., Campagnoli,C., Crosignani,P., Nappi,C., Serra,G.B., Bottiglioni,E., Cianci,A., de,Aloysisio D., Donati,Sarti C., Gambacciani,M., Monteleone,P., Genazzani,A.D., Guaschino,S., Palumbo,G., Petraglia,F., Schonauer,S., Volpe,A., Di,Paolantonio T., Nagni,M., Tempesta,A., Coronel,G.A., Progetto Donna Qualita della Vita Working Group., Assessment of the QoL in Italian menopausal women: comparison between HRT users and non-users, Maturitas, 42, 267-280, 2002	Not an economic evaluation
Health Technology Advisory Committee., Postmenopausal hormone replacement, Minnesota: Health Technology Advisory Committee (HTAC), -, 2002	Not an economic evaluation
Karacam,Z., Seker,S.E., Factors associated with menopausal symptoms and their relationship with the quality of life among Turkish women, Maturitas, 58, 75-82, 2007	Not an economic evaluation
Kleinman,N.L., Rohrbacker,N.J., Bushmakina,A.G., Whiteley,J., Lynch,W.D., Shah,S.N., Direct and indirect costs of women diagnosed with menopause symptoms, Journal of Occupational and Environmental Medicine, 55, 465-470, 2013	Cost of illness study, not an economic evaluation
Nelson,H.D., Haney,E., Humphrey,L., Miller,J., Nedrow,A., Nicolaidis,C., Vesco,K., Walker,M., Bougatsos,C., Nygren,P., Management of menopause-related symptoms, Agency of Healthcare Research and Quality, US Department of Health and Human Services, -, 2005	Not an economic evaluation
NIHR,H.S.C., Ospemifene for vulvo-vaginal atrophy in postmenopausal women, National Institute for Health Research, -, 2013	Not an economic evaluation
Plumb,J.M., Guest,J.F., Economic impact of tibolone compared with continuous-combined hormone replacement therapy in the management of postmenopausal women with climacteric symptoms in the UK, Pharmacoeconomics, 18, 477-86, 2000	Cost-analysis only
Schousboe,J.T., Nyman,J.A., Kane,R.L., Ensrud,K.E., Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women, Annals of Internal Medicine, 142, 734-41, 2005	Study focused on intervention to prevent fractures
Sintonen,H., Johansson,S., Ohinmaa,A., Apajasalo,M., Kainulainen,P., Heikkinen,J., Measuring health-related quality of life in women on hormone replacement therapy, Expert Review of Pharmacoeconomics and Outcomes Research, 3, 351-361, 2003	Not an economic evaluation
Society of Obstetricians and Gynaecologists of Canada., SOGC clinical practice guidelines. The detection and management of vaginal atrophy. Number 145, May 2004, International Journal of Gynaecology and Obstetrics, 88, 222-228, 2005	Not an economic evaluation
Swedish Council on Technology Assessment in Health Care., Hormone replacement therapy, Report No. 159, -, 2002	Not an economic evaluation
Taipale,Kaisa, Leminen,Arto, Rasanen,Pirjo, Heikkila,Anne, Tapper,Anna Maija, Sintonen,Harri, Roine,Risto P., Costs and health-related quality of life effects of hysterectomy in patients with benign uterine disorders, Acta Obstetrica et Gynecologica ScandinavicaActa Obstet Gynecol Scand, 88, 1402-1410, 2009	Not directly related to menopause
Torgerson,D.J., Reid,D.M., The pharmacoeconomics of hormone replacement therapy, Pharmacoeconomics, 16, 9-16, 1999	Review article. Not an economic evaluation
Weinstein,M.C., Estrogen use in postmenopausal women: costs, risks, and benefits, New England Journal of Medicine, 303, 308-16, 1980	Analysis doesn't consider vasomotor symptoms
Whittington,R., Faulds,D., Hormone replacement therapy: I. A pharmacoeconomic appraisal of its therapeutic use in menopausal symptoms and urogenital estrogen deficiency. [108 refs][Erratum appears in Pharmacoeconomics 1995 Sep;8(3):244], Pharmacoeconomics, 5, 419-445, 1994	Not an economic evaluation

Study	Reason for exclusion
Williams-Frame,A., Carpenter,J.S., Costs of hormonal and nonhormonal prescription medications for hot flashes, <i>Women's health</i> , 5, 497-502, 2009	Cost analysis
Zethraeus,N., Willingness to pay for hormone replacement therapy, <i>Health EconomicsHealth Econ.</i> , 7, 31-38, 1998	WTP study. Not an economic evaluation
Zethraeus,N., Johannesson,M., Henriksson,P., Strand,R.T., The impact of hormone replacement therapy on quality of life and willingness to pay, <i>British Journal of Obstetrics and GynaecologyBr J Obstet Gynaecol</i> , 104, 1191-1195, 1997	WTP study. Not an economic evaluation
Zethraeus,N., Johannesson,M., Jonsson,B., A computer model to analyze the cost-effectiveness of hormone replacement therapy, <i>International Journal of Technology Assessment in Healthcare</i> , 15, 352-365, 1999	Population is asymptomatic women
Zolnierczuk-Kieliszek,D., Kulik,T.B., Pacian,A., Predictors of quality of life in peri- and postmenopausal Polish women living in Lublin Voivodeship, <i>Climacteric</i> , 14, 669-676, 2011	Not an economic evaluation

### G.4.1.3 Long term treatment

Study	Reason for exclusion
Al-Azzawi,F., Lees,B., Thompson,J., Stevenson,J.C., Bone mineral density in postmenopausal women treated with a vaginal ring delivering systemic doses of estradiol acetate, <i>Menopause</i> , 12, 331-339, 2005	PICO not met - Population did not have symptoms of urogenital atrophy at baseline. Outcomes also not relevant.
Almendral,C., Casper,F., Distler,W., Frick,J., Herold,J., Huenges,P., Hussong,R., Methfessel,H.D., Muller,M., Petri,E., Retzke,U., Santellani,M., Weise,W., Wilhelm,H., Wortmann,M., Zimber,P., Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: A comparative and a placebo-controlled multicenter study, <i>International Urogynecology Journal and Pelvic Floor Dysfunction</i> , 10, 171-176, 1999	PICO not met - Outcomes of interest not reported. Short-term review
Antoniou,G., Kalogirou,D., Karakitsos,P., Antoniou,D., Kalogirou,O., Giannikos,L., Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses, <i>Maturitas</i> , 26, 103-111, 1997	PICO not met - Intervention (estradiol-releasing vaginal ring combined with oral progesterone) not of interest
Bachmann,G., Bouchard,C., Hoppe,D., Ranganath,R., Altomare,C., Vieweg,A., Graepel,J., Helzner,E., Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally, <i>Menopause</i> , 16, 719-727, 2009	After the 12 week treatment with CE/placebo, all patients were followed by open-label treatment with CE cream for 40 weeks.
Bachmann,G., Lobo,R.A., Gut,R., Nachtigall,L., Notelovitz,M., Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial, <i>Obstetrics and Gynecology</i> , 111, 67-76, 2008	Short-term (12 weeks) which was switched to open-label with all receiving the same treatment.
Bachmann,G.A., Komi,J.O., Ospemifene Study Group., Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study, <i>Menopause</i> , 17, 480-486, 2010	Short-term review question
Bygdeman,M., Swahn,M.L., Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women, <i>Maturitas</i> , 23, 259-263, 1996	Short-term review
Cano,A., Estevez,J., Usandizaga,R., Gallo,J.L., Guinot,M., Delgado,J.L., Castellanos,E., Moral,E., Nieto,C., del Prado,J.M., Ferrer,J., The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study, <i>Menopause</i> , 19, 1130-1139, 2012	Short-term review
Cicinelli,E., de,Ziegler D., Alfonso,R., Nicoletti,R., Bellavia,M., Colafoglio,G., Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study, <i>Fertility and Sterility</i> , 83, 1859-1863, 2005	PICO not met - Intervention (transdermal estradiol gel combined with progesterone vaginal capsules) not of interest
Constantine,G., Graham,S., Koltun,W.D., Kingsberg,S.A., Assessment of ospemifene or lubricants on clinical signs of VVA, <i>Journal of Sexual Medicine</i> , 11, 1033-1041, 2014	Secondary publication of 226136, 254703, and 319531
Crandall,C., Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy. [35 refs], <i>Journal of Women's Health</i> , 11, 857-877, 2002	Systematic review
Eriksen,P.S., Rasmussen,H., Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study, <i>European Journal of Obstetrics, Gynecology, and Reproductive Biology</i> , 44, 137-144, 1992	Short-term review
Furness,Susan, Roberts,Helen, Marjoribanks,Jane, Lethaby,Anne, Hormone therapy in postmenopausal women and risk of endometrial hyperplasia, <i>Cochrane Database of Systematic Reviews</i> , -, 2012	Systematic review of combination hormone replacement therapy
Gerbaldo,D., Ferraiolo,A., Croce,S., Truini,M., Capitanio,G.L., Endometrial morphology after 12 months of vaginal oestriol therapy in post-menopausal women, <i>Maturitas</i> , 13, 269-274, 1991	Does not match review protocol
Gordon,W.E., Hermann,H.W., Hunter,D.C., Safety and efficacy of micronized estradiol vaginal cream, <i>Southern Medical Journal</i> , 72, 1252-1253, 1979	Short-term review question
Griesser,H., Skonietzki,S., Fischer,T., Fielder,K., Suesskind,M., Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled	Short-term review

Study	Reason for exclusion
trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol, <i>Maturitas</i> , 71, 360-368, 2012	
Henriksson,L., Stjernquist,M., Boquist,L., Cedergren,I., Selinus,I., A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging, <i>American Journal of Obstetrics and Gynecology</i> , 174, 85-92, 1996	Open label trial that compared to estrogen preparations.
Iosif,C.S., Effects of protracted administration of estriol on the lower genito urinary tract in postmenopausal women, <i>Archives of Gynecology and Obstetrics</i> , 251, 115-120, 1992	Does not match review protocol
Kalogirou,D., Antoniou,G., Karakitsos,P., Kalogirou,O., Antoniou,D., Giannikos,L., A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response, <i>International Journal of Fertility and Menopausal Studies</i> , 41, 522-527, 1996	PICO not met - Intervention (estradiol-releasing vaginal ring combined with oral progestogen) not of interest
Karoussos,K.E., Studer,S., Wyss,H.J., The treatment of atrophic vaginal conditions with Ortho-Gynest A pilot study, <i>Journal of International Medical Research</i> , 7, 569-572, 1979	Short-term review question
Karp,D.R., Jean-Michel,M., Johnston,Y., Suci,G., Aguilar,V.C., Davila,G.W., A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery, <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 18, 211-215, 2012	Short-term review
Keenan,N.L., Franks,A.L., Croft,J.B., Scholes,D., Murray,E.T., Vaginal estrogen creams: Use patterns among a cohort of women, <i>Journal of the American Geriatrics Society</i> , 47, 65-70, 1999	Outcomes not relevant to protocol.
Marjoribanks,Jane, Farquhar,Cindy, Roberts,Helen, Lethaby,Anne, Long term hormone therapy for perimenopausal and postmenopausal women, <i>Cochrane Database of Systematic Reviews</i> , -, 2012	Systematic review of different forms of hormone replacement therapy not including local oestrogen
Mettler,L., Olsen,P.G., Long-term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets, <i>Maturitas</i> , 14, 23-31, 1991	Compared two estrogen preparations.
Morch,L.S., Lokkegaard,E., Andreasen,A.H., Kruger-Kjaer,S., Lidegaard,O., Hormone therapy and ovarian cancer, <i>JAMA</i> , 302, 298-305, 2009	PICO not met - Unclear if local oestrogens use was long-term
Noe,G., Sitruk-Ware,R., Zegers-Hochschild,F., Variano,B., Montero,J.C., Arriagada,P., Li,A., Stanczyk,F.Z., Felix,J.C., Mishell,Jr, Croxatto,H.B., Endometrial effect of progesterone delivered by vaginal rings in estrogen-treated postmenopausal women, <i>Climacteric</i> , 13, 433-441, 2010	PICO not met - Intervention (estradiol combined with progesterone) not of interest
Portman,D., Palacios,S., Nappi,R.E., Mueck,A.O., Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: A randomised, placebo-controlled, phase III trial, <i>Maturitas</i> , 78, 91-98, 2014	For short term review question
Portman,D.J., Bachmann,G.A., Simon,J.A., Ospemifene Study Group., Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy, <i>Menopause</i> , 20, 623-630, 2013	For short term review question
Rutanen,E.M., Heikkinen,J., Halonen,K., Komi,J., Lammintausta,R., Ylikorkala,O., Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial, <i>Menopause</i> , 10, 433-439, 2003	Short-term review question
Simon,J., Nachtigall,L., Ulrich,L.G., Eugster-Hausmann,M., Gut,R., Endometrial safety of ultra-low-dose estradiol vaginal tablets, <i>Obstetrics and Gynecology</i> , 116, 876-883, 2010	Secondary publication of 227345
Sindberg,EriksenP, Rasmussen,H., Low-dose 17beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: A double-blind placebo controlled study, <i>European Journal of Obstetrics Gynecology and Reproductive Biology</i> , 44, 137-144, 1992	Short-term review question
Suhonen,S.P., Holmstrom,T., Allonen,H.O., Lahteenmaki,P., Intrauterine and subdermal progestogen administration in postmenopausal hormone replacement therapy, <i>Fertility and Sterility</i> , 63, 336-342, 1995	PICO not met - Intervention (oral estradiol combined with intrauterine levonorgestrel) not of interest
Suvanto-Luukkonen,E., Malinen,H., Sundstrom,H., Penttinen,J., Kauppila,A., Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone, <i>Acta Obstetrica et Gynecologica Scandinavica</i> , 77, 758-763, 1998	PICO not met - Intervention (percutaneous estradiol combined with intrauterine levonorgestrel or natural progesterone) not of interest
Ulrich,L.S., Naessen,T., Elia,D., Goldstein,J.A., Eugster-Hausmann,M., trial,investigators, Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy, <i>Climacteric</i> , 13, 228-237, 2010	Does not match review protocol
Voipio,S.K., Komi,J., Kangas,L., Halonen,K., DeGregorio,M.W., Erkkola,R.U., Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women, <i>Maturitas</i> , 43, 207-214, 2002	Short-term review question
Vooijs,G.P., Geurts,T.B., Review of the endometrial safety during intravaginal treatment with estriol. [50 refs], <i>European Journal of Obstetrics, Gynecology, and Reproductive Biology</i> , 62, 101-106, 1995	Literature review

Study	Reason for exclusion
Weisberg,E., Ayton,R., Darling,G., Farrell,E., Murkies,A., O'Neill,S., Kirkegard,Y., Fraser,I.S., Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet, <i>Climacteric</i> , 8, 83-92, 2005	Two estrogen preparations were compared.

## G.5 Review and referral

Study	Reason for exclusion
Andersen,L.F., Gram,J., Skouby,S.O., Jespersen,J., Effects of hormone replacement therapy on hemostatic cardiovascular risk factors, <i>American Journal of Obstetrics and Gynecology</i> , 180, 283-289, 1999	Setting in Denmark. No "clinical review" was examined, only reported that "blood samples" were collected after 0,6,and 12 months of observation.
Berning,B., Kuijk,C.V., Kuiper,J.W., Bennink,H.J., Kicovic,P.M., Fauser,B.C., Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study, <i>Bone</i> , 19, 395-399, 1996	Study setting in the Netherlands. No "clinical review" was assessed, just reported that bone density was assessed at 6-month intervals.
Duzenli,M.A., Ozdemir,K., Sokmen,A., Gezgin,K., Soylu,A., Celik,C., Altunkeser,B.B., Tokac,M., The effects of hormone replacement therapy on myocardial performance in early postmenopausal women, <i>Climacteric</i> , 13, 157-170, 2010	Study setting in Turkey.
Fenki,S., Fenki,V., Yilmazer,M., Serteser,M., Koken,T., Effects of short-term transdermal hormone replacement therapy on glycaemic control, lipid metabolism, C-reactive protein and proteinuria in postmenopausal women with type 2 diabetes or hypertension, <i>Human Reproduction</i> , 18, 866-870, 2003	Study carried out in Turkey.
Lindsay,R., Gallagher,J.C., Kleerekoper,M., Pickar,J.H., Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women, <i>JAMA</i> , 287, 2668-2676, 2002	Study setting in the US. No "clinical review" was assessed, just reported that bone mineral density was assessed every 6 months for 2 years.
Luyer,M.D.P., Khosla,S., Owen,W.G., Miller,V.M., Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women, <i>Journal of Clinical Endocrinology and Metabolism</i> , 86, 3629-3634, 2001	Study carried out in the US. Just reported that after 3-month blood sample was taken, no other details.
McNicholas,M.M., Heneghan,J.P., Milner,M.H., Tunney,T., Hourihane,J.B., MacErlaine,D.P., Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study, <i>AJR, American Journal of Roentgenology</i> . 163, 311-315, 1994	Setting in Ireland. No clinical review was examined. Only reported mammographic density changes were seen after only 4-month in one patient.
Parsey,K., Ellman,H., Rahman,M., Randomised, controlled comparison of transdermal estradiol with oral conjugated estrogens for the relief of hot flushes, <i>Clinical Drug Investigation</i> , 20, 207-214, 2000	Study setting in the US.
Stefanick,M.L., Anderson,G.L., Margolis,K.L., Hendrix,S.L., Rodabough,R.J., Paskett,E.D., Lane,D.S., Hubbell,F.A., Assaf,A.R., Sarto,G.E., Schenken,R.S., Yasmeen,S., Lessin,L., Chlebowski,R.T., Investigators,W.H.I., Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy, <i>JAMA</i> , 295, 1647-1657, 2006	US setting. No "clinical review" was examined, just reported 6-month intervals for clinical outcome assessment and annually for clinical visit. No information about clinical visit was reported.
Stevenson,J.C., Cust,M.P., Gangar,K.F., Hillard,T.C., Lees,B., Whitehead,M.I., Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women, <i>Lancet</i> , 336, 265-269, 1990	No "clinical review" was examined. The effect of transdermal vs oral HRT on bone density was examined. The study just reported increase was seen in transdermal group at 6-month and 12-month in the oral group.
Wattanakumtornkul,S., Chichareon,S., Geater,A., Suwan,K., Compliance with hormone replacement therapy at Songklanagarind Hospital, <i>Journal of Obstetrics and Gynaecology Research</i> , 29, 380-387, 2003	Study setting in Thailand.

## G.6 Starting and stopping HRT

Study	Reason for exclusion
Aslan,E., Bagis,T., Erkanli,S., Bulgan,Kilicdag E., Tarim,E., Asik,G., Comparison of cessation protocols of hormone replacement therapy on postmenopausal women: Immediate or tapered?, <i>Fertility and Sterility</i> , 80, S241, Abstract-363, 2003	Conference abstract - data subsequently published in Aslan 2006 (see included studies).
Buist,D.S., Anderson,M.L., Reed,S.D., iello Bowles,E.J., Fitzgibbons,E.D., Gandara,J.C., Seger,D., Newton,K.M., Short-term hormone therapy suspension and mammography recall: a randomized trial.[Summary for patients in <i>Ann Intern Med</i> . 2009 Jun 2;150(11):I28; PMID: 19487707], <i>Annals of Internal Medicine</i> , 150, 752-765, 2009	Intervention not relevant - women randomized to stopping or not stopping HRT before mammography.
Gill, S., Discontinuation of menopausal hormone therapy: What are the symptoms and how should they be managed?, <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2, 192-193, 2006	Synopsis of an early publication on experience after HRT discontinuation. No relevant comparison between tapered and abrupt discontinuation was made.

Study	Reason for exclusion
Haskell,S.G., Bean-Mayberry,B., Gordon,K., Discontinuing postmenopausal hormone therapy: an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms?, Menopause, 16, 494-499, 2009	Observational study asking women to self report their method of stopping and recurrence of symptoms.
Newton,K.M., Reed,S.D., Grothaus,L.C., La,CroixA, Nekhlyudov,L., Ehrlich,K., Ludman,E.J., Hormone therapy discontinuation: Physician practices after the Women's Health Initiative, Menopause, 17, 734-740, 2010	Not RCT - survey of physicians to identify current recommended practice for HRT discontinuation.
Pearce,J., Hawton,K., Blake,F., Barlow,D., Rees,M., Fagg,J., Keenan,J., Psychological effects of continuation versus discontinuation of hormone replacement therapy by estrogen implants: a placebo-controlled study, Journal of Psychosomatic Research, 42, 177-186, 1997	No comparison of methods of discontinuation - only compares women who discontinue treatment with those who continue.

## G.7 Long-term benefits and risks of HRT

### G.7.1 Venous thromboembolism

Study	Reason for exclusion
Oestrogen plus progestogen hormone replacement therapy increases venous thrombosis in postmenopausal women, Evidence-based Healthcare and Public Health, 9, 159-160, 2005	Summary of findings from WHI, no new data.
Anderson,G.L., Limacher,M., Assaf,A.R., Bassford,T., Beresford,S.A., Black,H., Bonds,D., Brunner,R., Brzyski,R., Caan,B., Chlebowski,R., Curb,D., Gass,M., Hays,J., Heiss,G., Hendrix,S., Howard,B.V., Hsia,J., Hubbell,A., Jackson,R., Johnson,K.C., Judd,H., Kotchen,J.M., Kuller,L., Lacroix,A.Z., Lane,D., Langer,R.D., Lasser,N., Lewis,C.E., Manson,J., Margolis,K., Ockene,J., O'Sullivan,M.J., Phillips,L., Prentice,R.L., Ritenbaugh,C., Robbins,J., Rossouw,J.E., Sarto,G., Stefanick,M.L., Van,Horn L., Wactawski-Wende,J., Wallace,R., Wassertheil-Smoller,S., Women's Health Initiative Steering Committee., Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial, JAMA, 291, 1701-1712, 2004	Secondary publication from WHI study. Relevant data included under Manson 2013.
Canonico, M., Plu-Bureau, G., O'Sullivan, M. J., Stefanick, M. L., Cochrane, B., Scarabin, P. Y., Manson, J. E., Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women's Health Initiative Hormone Therapy clinical trials, Menopause, 21, 214-20, 2014	WHI publication, relevant results (risk of VTE in relation to time since menopause) extracted and reported under Manson 2013.
Canonico,M., Oger,E., Conard,J., Meyer,G., Levesque,H., Trillot,N., Barrellier,M.T., Wahl,D., Emmerich,J., Scarabin,P.Y., Estrogen and Thromboembolism Risk (ESTHER) Study Group., Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study, Journal of Thrombosis and Haemostasis, 4, 1259-1265, 2006	Secondary publication of ESTHER study with no additional relevant data for the review.
Canonico,M., Plu-Bureau, Lowe,G.D., Scarabin,P.Y., Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. [23 refs], BMJ, 336, 1227-1231, 2008	Systematic review, no primary data.
Canonico,M., Plu-Bureau, O'Sullivan,M.J., Stefanick,M.L., Cochrane,B., Scarabin,P.Y., Manson,J.E., Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women's Health Initiative Hormone Therapy clinical trials, Menopause, 21, 214-220, 2014	Secondary publication of WHI data. No relevant outcomes for the review.
Cheung,A.M., Review: postmenopausal hormone therapy increases risk of stroke and venous thromboembolism but not coronary heart disease events, Evidence Based Medicine, 14, 18-, 2009	Commentary on published meta-analysis (Sare 2008). No additional data.
Clarke,S.C., Kelleher,J., Lloyd-Jones,H., Slack,M., Schofiel,P.M., A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study, BJOG: An International Journal of Obstetrics and Gynaecology, 109, 1056-1062, 2002	Mean age of participants > 65 years.
Collins,Peter, Flather,Marcus, Lees,Belinda, Mister,Rebecca, Proudler,Anthony J., Stevenson,John C., WHISP (Women's Hormone Intervention Secondary Prevention Study) Pilot Study Investigators, Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study, European heart journalEur Heart J, 27, 2046-2053, 2006	Mean age of participants > 65 years.
Curb,J.D., Prentice,R.L., Bray,P.F., Langer,R.D., Van,Horn L., Barnabei,V.M., Bloch,M.J., Cyr,M.G., Gass,M., Lepine,L., Rodabough,R.J., Sidney,S., Uwaifo,G.I., Rosendaal,F.R., Venous thrombosis and conjugated equine estrogen in women without a uterus, Archives of Internal Medicine, 166, 772-780, 2006	Secondary publication from WHI trial. Relevant data extracted and included under Manson 2013.
Cushman,M., Kuller,L.H., Prentice,R., Rodabough,R.J., Psaty,B.M., Stafford,R.S., Sidney,S., Rosendaal,F.R., Women's Health Initiative Investigators., Estrogen plus progestogen and risk of venous thrombosis, JAMA, 292, 1573-1580, 2004	Publication from WHI trial. Relevant data included under Manson 2012.
Devor,M., Barrett-Connor,E., Renvall,M., Feigal,Jr, Ramsdell,J., Estrogen replacement therapy and the risk of venous thrombosis, American Journal of Medicine, 92, 275-282, 1992	Mean age of participants > 65 years, and analysis only considers current use compared to no current use.
Douketis,J., Review: postmenopausal estrogen replacement therapy increases the risk for venous thromboembolism.[Erratum appears in ACP J Club. 2003 Feb 18;138(4):360.], ACP Journal Club, 137, 42-Oct, 2002	Commentary on systematic review (Miller 2002). No additional data.

Study	Reason for exclusion
Gangat,N., Wolanskyj,A.P., Schwager,S.M., Mesa,R.A., Tefferi,A., Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia, <i>Cancer</i> , 106, 2406-2411, 2006	Groups women taking oral contraceptive pill and women taking HRT together. No separate analysis for women taking HRT only.
Gerstman,B.B., Piper,J.M., Freiman,J.P., Tomita,D.K., Kennedy,D.L., Ferguson,W.J., Bennett,R.C., Oral contraceptive oestrogen and progestogen potencies and the incidence of deep venous thromboembolism, <i>International Journal of Epidemiology</i> , 19, 931-936, 1990	Includes oral contraceptive pill users only, not HRT users.
Grady,D., Wenger,N.K., Herrington,D., Khan,S., Furberg,C., Hunninghake,D., Vittinghoff,E., Hulley,S., Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestogen Replacement Study, <i>Annals of Internal Medicine</i> , 132, 689-696, 2000	Mean age of participants > 65 years.
Herrington,D.M., Reboussin,D.M., Brosnihan,K.B., Sharp,P.C., Shumaker,S.A., Snyder,T.E., Furberg,C.D., Kowalchuk,G.J., Stuckey,T.D., Rogers,W.J., Givens,D.H., Waters,D., Effects of estrogen replacement on the progression of coronary-artery atherosclerosis, <i>New England Journal of Medicine</i> , 343, 522-529, 2000	Mean age of participants > 65 years.
Herrington,D.M., Vittinghoff,E., Howard,T.D., Major,D.A., Owen,J., Reboussin,D.M., Bowden,D., Bittner,V., Simon,J.A., Grady,D., Hulley,S.B., Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease, <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> , 22, 1012-1017, 2002	Mean age of participants > 65 years.
Hulley,S., Furberg,C., Barrett-Connor,E., Cauley,J., Grady,D., Haskell,W., Knopp,R., Lowery,M., Satterfield,S., Schrott,H., Vittinghoff,E., Hunninghake,D., Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestogen Replacement Study follow-up (HERS II), <i>Journal of the American Medical Association</i> , 288, 58-66, 2002	Mean age of participants > 65 years.
Hulley,S., Furberg,C., Barrett-Connor,E., Cauley,J., Grady,D., Haskell,W., Knopp,R., Lowery,M., Satterfield,S., Schrott,H., Vittinghoff,E., Hunninghake,D., HERS Research Group., Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestogen Replacement Study follow-up (HERS II), <i>JAMA</i> , 288, 58-66, 2002	Mean age of participants > 65 years.
Hurbanek,J.G., Jaffer,A.K., Morra,N., Karafa,M., Brotman,D.J., Postmenopausal hormone replacement and venous thromboembolism following hip and knee arthroplasty, <i>Thrombosis and Haemostasis</i> , 92, 337-343, 2004	Median age of participants > 65, and study only compares current use of HRT to no current use (not ever use/past use).
Miller,J., Chan,B.K., Nelson,H.D., Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. [23 refs][Erratum appears in <i>Ann Intern Med</i> . 2003 Feb 18;138(4):360.], [Summary for patients in <i>Ann Intern Med</i> . 2002 May 7;136(9):142; PMID: 11992323], <i>Annals of Internal Medicine</i> , 136, 680-690, 2002	Systematic review - no primary data.
Nelson,H.D., Walker,M., Zakher,B., Mitchell,J., Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations, <i>Annals of Internal Medicine</i> , 157, 104-113, 2012	Systematic review, no primary data.
Oger,E., Scarabin,P.Y., Assessment of the risk for venous thromboembolism among users of hormone replacement therapy, <i>Drugs and Aging</i> , 14, 55-61, 1999	Narrative review article.
Olie,V., Canonico,M., Scarabin,P.Y., Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women, <i>Current Opinion in Hematology</i> , 17, 457-463, 2010	Narrative review article.
Olsson,H.L., Ingvar,C., Bladstrom,A., Hormone replacement therapy containing progestogens and given continuously increases breast carcinoma risk in Sweden, <i>Cancer</i> , 97, 1387-1392, 2003	Same cohort as
Prentice,R.L., Manson,J.E., Langer,R.D., Anderson,G.L., Pettinger,M., Jackson,R.D., Johnson,K.C., Kuller,L.H., Lane,D.S., Wactawski-Wende,J., Brzyski,R., Allison,M., Ockene,J., Sarto,G., Rossouw,J.E., Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause, <i>American Journal of Epidemiology</i> , 170, 12-23, 2009	Secondary publication of WHI data. No relevant outcomes for the review.
Renoux,C., Dell'Aniello,S., Suissa,S., Hormone replacement therapy and the risk of venous thromboembolism: a population-based study, <i>Journal of Thrombosis and Haemostasis</i> , 8, 979-986, 2010	Mean age of participants over 65 years (65.8 years) and only assesses current use of HRT compared to no current use.
Rosendaal,F.R., Vessey,M., Rumley,A., Daly,E., Woodward,M., Helmerhorst,F.M., Lowe,G.D.O., Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis, <i>British journal of haematologyBr J Haematol</i> , 116, 851-854, 2002	Secondary publication of data already included in Daly. No additional relevant outcomes to include.
Ross,R.K., Paganini-Hill,A., Gerkins,V.R., Mack,T.M., Pfeffer,R., Arthur,M., Henderson,B.E., A case-control study of menopausal estrogen therapy and breast cancer, <i>JAMA</i> , 243, 1635-1639, 1980	Risk estimates not reported. Age range not relevant to review question.
Rossouw,J.E., Anderson,G.L., Prentice,R.L., Lacroix,A.Z., Kooperberg,C., Stefanick,M.L., Jackson,R.D., Beresford,S.A., Howard,B.V., Johnson,K.C., Kotchen,J.M., Ockene,J., Writing Group for the Women's Health Initiative Investigators., Risks and benefits of estrogen plus progestogen in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial, <i>JAMA</i> , 288, 321-333, 2002	Secondary publication of WHI data. Updated data obtained from other publications.

Study	Reason for exclusion
Sare,G.M., Gray,L.J., Bath,P.M., Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. [40 refs], European Heart Journal, 29, 2031-2041, 2008	Meta-analysis - no primary data.
Scarabin,P.Y., Oger,E., Plu-Bureau, EStrogen and THromboEmbolism Risk Study Group., Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk, Lancet, 362, 428-432, 2003	Relevant data included in Canonico 2007 (updated analysis of same group of women with increased sample size).
Smith, N. L., Blondon, M., Wiggins, K. L., Harrington, L. B., van Hylckama Vlieg, A., Floyd, J. S., Hwang, M., Bis, J. C., McKnight, B., Rice, K. M., Lumley, T., Rosendaal, F. R., Heckbert, S. R., Psaty, B. M., Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens.[Erratum appears in JAMA Intern Med. 2014 Sep;174(9):1523], JAMA Internal Medicine, 174, 25-31, 2014	Case-control study
Smith,N.L., Heckbert,S.R., Lemaitre,R.N., Reiner,A.P., Lumley,T., Weiss,N.S., Larson,E.B., Rosendaal,F.R., Psaty,B.M., Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis, JAMA, 292, 1581-1587, 2004	Only compares current users of HRT to non-users, and mean age of participants was 68.5 years.
Smith,Nicholas L., Heckbert,Susan R., Lemaitre,Rozenn N., Reiner,Alexander P., Lumley,Thomas, Rosendaal,Frits R., Psaty,Bruce M., Conjugated equine estrogen, esterified estrogen, prothrombotic variants, and the risk of venous thrombosis in postmenopausal women, Arteriosclerosis, thrombosis, and vascular biologyArterioscler Thromb Vasc Biol, 26, 2807-2812, 2006	Mean age of participants > 65 years, and analysis only considers current use versus no current use.
Straczek,C., Oger,E., Yon de Jonage-Canonico MB, Plu-Bureau, Conard,J., Meyer,G., henc-Gelas,M., Levesque,H., Trillot,N., Barrellier,M.T., Wahl,D., Emmerich,J., Scarabin,P.Y., Estrogen and Thromboembolism Risk (ESTHER) Study Group., Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration, Circulation, 112, 3495-3500, 2005	Secondary publication of ESTHER study with no relevant additional data for the review.
Sweetland,S., Beral,V., Balkwill,A., Liu,B., Benson,V.S., Canonico,M., Green,J., Reeves,G.K., Million Women,Study Collaborators, Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study, Journal of Thrombosis and Haemostasis, 10, 2277-2286, 2012	Duplicate publication of the Million Women Study, same results have been reported under Benson 2012 included in the original review.
Waters,David D., Alderman,Edwin L., Hsia,Judith, Howard,Barbara V., Cobb,Frederick R., Rogers,William J., Ouyang,Pamela, Thompson,Paul, Tardif,Jean Claude, Higginson,Lyall, Bittner,Vera, Steffes,Michael, Gordon,David J., Proschan,Michael, Younes,Naji, Verter,Joel I., Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial, JAMA : the journal of the American Medical Association, 288, 2432-2440, 2002	Mean age of participants > 65 years.
Windler, E., Stute, P., Ortmann, O., Mueck, A. O., Is postmenopausal hormone replacement therapy suitable after a cardio- or cerebrovascular event?, Archives of Gynecology & Obstetrics, 291, 213-7, 2015	Review paper
Wu,O., Robertson,L., Langhorne,P., Twaddle,S., Lowe,G.D., Clark,P., Greaves,M., Walker,I.D., Brenkel,I., Regan,L., Greer,I.A., Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. [30 refs], Thrombosis and Haemostasis, 94, 17-25, 2005	Systematic review, no primary data.

## G.7.2 Cardiovascular disease

Study	Reason for exclusion
Do risks of hormone therapy persist after discontinuation?, Journal of Family Practice, 57, 366-, 2008	Comments on WHI findings.
Oestrogen increases the risk of stroke but has no effect on coronary heart disease in healthy post-menopausal women, Evidence-Based Healthcare and Public Health, 8, 308-309, 2004	Participants aged 50-79 years, no subgroup analysis was conducted.
Adam,S., Williams,V., Vessey,M.P., Cardiovascular disease and hormone replacement treatment: a pilot case-control study, British Medical Journal Clinical Research Ed., 282, 1277-1278, 1981	Case-control study, odds ratio not adjusted for any confounders.
Agrinier,N., Cournot,M., Dallongeville,J., Arveiler,D., Ducimetiere,P., Ruidavets,J.B., Ferrieres,J., Menopause and modifiable coronary heart disease risk factors: a population based study, Maturitas, 65, 237-243, 2010	Cross-sectional design
Alexandersen,P., Tanko,L.B., Bagger,Y.Z., Qin,G., Christiansen,C., The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women, Climacteric, 9, 108-118, 2006	Women aged 44-71 were included the study, no subgroup analysis by age was conducted.
Alpaslan,M., Shimokawa,H., Kuroiwa-Matsumoto,M., Harasawa,Y., Takeshita,A., Short-term estrogen administration ameliorates dobutamine-induced myocardial ischemia in postmenopausal women with coronary artery disease, Journal of the American College of Cardiology, 30, 1466-1471, 1997	Study of small sample size (n=8); and mean age of participants was 68 years.
Angeja,B.G., Shlipak,M.G., Go,A.S., Johnston,S.C., Frederick,P.D., Canto,J.G., Barron,H.V., Grady,D., National Registry of Myocardial Infarction, Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women, Journal of the American College of Cardiology, 38, 1297-1301, 2001	Participants aged 55-84 (mean: 71 years) were included, no subgroup analysis was conducted.



Study	Reason for exclusion
Arana,A., Varas,C., Gonzalez-Perez,A., Gutierrez,L., Bjerrum,L., Garcia Rodriguez,L.A., Hormone therapy and cerebrovascular events: a population-based nested case-control study, <i>Menopause</i> , 13, 730-736, 2006	Participants aged 50 and 69 years were included, no relevant subgroup analysis was conducted.
Arthur,H., HRT did not reduce coronary events in postmenopausal women with existing heart disease [commentary on Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/progestogen Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestogen for secondary prevention of coronary heart disease in postmenopausal women. <i>JAMA</i> 1998;280(7):605-13], <i>Evidence Based Nursing</i> , 2, 52, 1999-, 1999	Women aged 44-78 years were included, no relevant subgroup analysis was conducted.
Bingol,B., Gunenc,Z., Yilmaz,M., Biri,A., Tiras,B., Guner,H., Effects of hormone replacement therapy on glucose and lipid profiles and on cardiovascular risk parameters in postmenopausal women, <i>Archives of Gynecology and Obstetrics</i> , 281, 857-864, 2010	Single-centre clinical study, though no randomization reported.
Boardman, H. M., Hartley, L., Eisinga, A., Main, C., Roque i Figuls, M., Bonfill Cosp, X., Gabriel Sanchez, R., Knight, B., Hormone therapy for preventing cardiovascular disease in post-menopausal women [Review][Update of Cochrane Database Syst Rev. 2013;4:CD002229; PMID: 23633307], <i>Cochrane Database of Systematic Reviews</i> , 3, CD002229, 2015	The review had different inclusion criteria from ours in terms of population and outcomes of interest, therefore not all individual studies included in this review were considered in our systematic review.
Bray,P.F., Larson,J.C., Lacroix,A.Z., Manson,J., Limacher,M.C., Rossouw,J.E., Lasser,N.L., Lawson,W.E., Stefanick,M.L., Langer,R.D., Margolis,K.L., Women's Health Initiative Investigators., Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events, <i>American Journal of Cardiology</i> , 101, 1599-1605, 2008	Re-analysis of WHI data by baseline lipids and C-reactive level, all women aged 50-79 years were included.
Bretler,D.M., Hansen,P.R., Sorensen,R., Lindhardtsen,J., Ahlehoff,O., Andersson,C., Abildstrom,S.Z., Torp-Pedersen,C., Gislason,G.H., Discontinuation of hormone replacement therapy after myocardial infarction and short term risk of adverse cardiovascular events: nationwide cohort study, <i>BMJ</i> , 344, e1802-, 2012	Participants aged 40-79 years were included, no subgroup analysis was conducted.
Bushnell,C., Stroke Hormones and Outcomes in Women (SHOW) study: is the 'healthy-user effect' valid for women after stroke?, <i>Women's health</i> , 5, 485-496, 2009	Subjects were women aged 47-75 years, no subgroup analysis was conducted.
Cagnacci,A., Baldassari,F., Arangino,S., Alessandrini,C., Volpe,A., Administration of tibolone decreases 24 h heart rate but not blood pressure of post-menopausal women, <i>Maturitas</i> , 48, 155-160, 2004	Study of small sample size (n=30); and only 24-hour blood pressure change was examined.
Canonico, M., Plu-Bureau, G., O'Sullivan, M. J., Stefanick, M. L., Cochrane, B., Scarabin, P. Y., Manson, J. E., Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women's Health Initiative Hormone Therapy clinical trials, <i>Menopause</i> , 21, 214-20, 2014	WHI publication which mainly focused on VTE outcome.
Casanova,G., Spritzer,P.M., Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial, <i>Lipids in Health and Disease</i> , 11, 133-, 2012	The comparison was made between 17 $\beta$ estradiol 3mg/day group and 17 $\beta$ estradiol 1.5mg/day, wrong comparator.
Castelo-Branco,C., Blumel,J.E., Roncagliolo,M.E., Haya,J., Bolf,D., Binfa,L., Tacla,X., Colodron,M., Age, menopause and hormone replacement therapy influences on cardiovascular risk factors in a cohort of middle-aged Chilean women, <i>Maturitas</i> , 45, 205-212, 2003	Data can not be assessed as necessary information not presented (i.e. SD of mean change).
Cherry,N., Gilmour,K., Hannaford,P., Heagerty,A., Khan,M.A., Kitchener,H., McNamee,R., Elstein,M., Kay,C., Seif,M., Buckley,H., ESPRIT team., Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial, <i>Lancet</i> , 360, 2001-2008, 2002	Participants (current HRT users) aged 50-69 years were assessed, no subgroup analysis was conducted.
Chiu,C.L., Lujic,S., Thornton,C., O'Loughlin,A., Makris,A., Hennessy,A., Lind,J.M., Menopausal hormone therapy is associated with having high blood pressure in postmenopausal women: observational cohort study, <i>PLoS ONE [Electronic Resource]</i> , 7, e40260-, 2012	Cross-sectional study; high blood pressure rather than blood pressure change as the outcome.
Clarke,S.C., Kelleher,J., Lloyd-Jones,H., Slack,M., Schofiel,P.M., A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study, <i>BJOG: An International Journal of Obstetrics and Gynaecology</i> , 109, 1056-1062, 2002	Current HRT users with mean age of 67 $\pm$ 11.2 years were assessed. No subgroup analysis was conducted.
Colditz,G.A., Willett,W.C., Stampfer,M.J., Rosner,B., Speizer,F.E., Hennekens,C.H., Menopause and the risk of coronary heart disease in women, <i>New England Journal of Medicine</i> , 316, 1105-1110, 1987	The NHS publication, subgroup analysis was done by surgical vs. natural menopausal women, not of the Guideline Development Group's interest.
Conard,J., Basdevant,A., Thomas,J.L., Ochsenbein,E., Denis,C., Guyene,T.T., Degrelle,H., Cardiovascular risk factors and combined estrogen-progestogen replacement therapy: A placebo-controlled study with nomegestrol acetate and estradiol, <i>Fertility and Sterility</i> , 64, 957-962, 1995	Study of small sample size (n=38).
Criqui,M.H., Suarez,L., Barrett-Connor,E., McPhillips,J., Wingard,D.L., Garland,C., Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogeneous community, <i>American Journal of Epidemiology</i> , 128, 606-614, 1988	Women aged 50-79 years were included, no subgroup analysis was conducted.
Dallongeville,J., Marecaux,N., Isorez,D., Zylbergberg,G., Fruchart,J.C., Amouyel,P., Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women, <i>Atherosclerosis</i> , 118, 123-133, 1995	Cross-sectional design.

Study	Reason for exclusion
de Carvalho,M.N., Nobre,F., Mendes,M.C., Dos Reis,R.M., Ferriani,R.A., Silva de Sa,M.F., Low-dose transdermal hormone therapy does not interfere with the blood pressure of hypertensive menopausal women: a pilot study, Blood Pressure Monitoring, 13, 277-283, 2008	24-hour blood pressure change as the outcome.
de Lecinana,M.A., Egido,J.A., Fernandez,C., Martinez-Vila,E., Santos,S., Morales,A., Martinez,E., Pareja,A., varez-Sabin,J., Casado,I., PIVE Study Investigators of the Stroke Project of the Spanish Cerebrovascular Diseases Study Group., Risk of ischemic stroke and lifetime estrogen exposure, Neurology, 68, 33-38, 2007	Women aged 46-93 years (mean: 68.9) were included, no relevant subgroup analysis was conducted.
de Vries,C.S., Bromley,S.E., Farmer,R.D., Myocardial infarction risk and hormone replacement: differences between products, Maturitas, 53, 343-350, 2006	Subjects aged 40-74 years were included, past use with a duration of more than 5 years was examined but HRT initiation age can't be ascertained.
De,MeersmanR, Zion,A.S., Giardina,E.G.V., Weir,J.P., Lieberman,J.S., Downey,J.A., Estrogen replacement, vascular distensibility, and blood pressures in postmenopausal women, American Journal of Physiology - Heart and Circulatory Physiology, 274, H1539-H1544, 1998	Study of small sample size (n=26).
Falkeborn,M., Persson,I., Adami,H.O., Bergstrom,R., Eaker,E., Lithell,H., Mohsen,R., Naessen,T., The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement, British Journal of Obstetrics and Gynaecology, 99, 821-828, 1992	The risk of HRT use on MI was compared with the expected risk of MI in the general population, while participants in the general population were also exposed to HRT use, wrong comparator.
Falkeborn,M., Persson,I., Terent,A., Adami,H.O., Lithell,H., Bergstrom,R., Hormone replacement therapy and the risk of stroke. Follow-up of a population-based cohort in Sweden, Archives of Internal Medicine, 153, 1201-1209, 1993	Wrong comparator. Relative risk of incidence of stroke among HRT use women was compared with the expected by using standardized incidence ratios from the general population (not necessarily non-HRT users and not individual level data)
Ferrara,A., Quesenberry,C.P., Karter,A.J., Njoroge,C.W., Jacobson,A.S., Selby,J.V., Northern California Kaiser Permanente Diabetes Registry., Current use of unopposed estrogen and estrogen plus progestogen and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente Diabetes Registry, 1995-1998, Circulation, 107, 43-48, 2003	Subjects aged 50-70 years were included and only an overall risk estimate was reported.
Finucane,F.F., Madans,J.H., Bush,T.L., Wolf,P.H., Kleinman,J.C., Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort, Archives of Internal Medicine, 153, 73-79, 1993	Participants aged between 55 and 74 years. Just an overall relative risk compared with non HRT users was reported. No subgroup analysis was conducted.
Gami,A.S., Wright,R.S., Ballman,K.V., Kopecky,S.L., Hayes,S.N., Hormone replacement therapy and risk of acute myocardial infarction in postmenopausal women with diabetes mellitus, American Journal of Cardiology, 91, 1275-1277, 2003	Mean age of participants was 74(±10) years old, no subgroup analysis was conducted.
Grodstein,F., Manson,J.E., Stampfer,M.J., Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. a prospective, observational study, Annals of Internal Medicine, 135, 1-8, 2001	The cohort for this analysis of NHS data was limited to women who reported a previous MI at baseline in 1976 and on subsequent follow-ups since then. Age of participants ranged between 34 and 73.
Grodstein,F., Stampfer,M.J., Colditz,G.A., Willett,W.C., Manson,J.E., Joffe,M., Rosner,B., Fuchs,C., Hankinson,S.E., Hunter,D.J., Hennekens,C.H., Speizer,F.E., Postmenopausal hormone therapy and mortality, New England Journal of Medicine, 336, 1769-1775, 1997	The NHS study, data relating to CHD and stroke death extracted and reported under Grodstein 1996.
Grodstein,F., Stampfer,M.J., Falkeborn,M., Naessen,T., Persson,I., Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women, Epidemiology, 10, 476-480, 1999	Wrong comparator, low potency estrogen users rather than nonusers as the reference group.
Gu,H., Zhao,X., Zhao,X., Yang,Y., Lv,X., Risk of stroke in healthy postmenopausal women during and after hormone therapy: a meta-analysis, Menopause, 21, 1204-1210, 2014	Meta-analysis on stroke in relation to HRT use. Women of all ages were included, the analysis was not stratified by age.
Guthrie,J.R., Taffe,J.R., Lehert,P., Burger,H.G., Dennerstein,L., Association between hormonal changes at menopause and the risk of a coronary event: A longitudinal study, Menopause, 11, 315-322, 2004	The outcome is not CVD events but risk of CVD measured by a score system including age, cholesterol, smoking etc.
Heckbert,S.R., Kaplan,R.C., Weiss,N.S., Psaty,B.M., Lin,D., Furberg,C.D., Starr,J.R., Anderson,G.D., Lacroix,A.Z., Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy, Archives of Internal Medicine, 161, 1709-1713, 2001	Mean age of participants was 67.8 years, with those older than 70 years accounting for 40% in the sample. No relevant subgroup analysis was conducted.
Heckbert,S.R., Weiss,N.S., Koepsell,T.D., Lemaitre,R.N., Smith,N.L., Siscovick,D.S., Lin,D., Psaty,B.M., Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women, Archives of Internal Medicine, 157, 1330-1336, 1997	Participants aged between 30-79 (mean 69.9) years old, and just overall risk estimates reported.

Study	Reason for exclusion
Henderson,S.O., Haiman,C.A., Wilkens,L.R., Kolonel,L.N., Wan,P., Pike,M.C., Established risk factors account for most of the racial differences in cardiovascular disease mortality, PLoS one, 2, -, 2007	Women aged 45-75 were included, no subgroup analysis was conducted. Age of past use can't be ascertained.
Hendrix,S.L., Wassertheil-Smoller,S., Johnson,K.C., Howard,B.V., Kooperberg,C., Rossouw,J.E., Trevisan,M., Aragaki,A., Baird,A.E., Bray,P.F., Buring,J.E., Criqui,M.H., Herrington,D., Lynch,J.K., Rapp,S.R., Torner,J., Investigators,W.H.I., Effects of conjugated equine estrogen on stroke in the Women's Health Initiative, Circulation, 113, 2425-2434, 2006	WHI CEE trial publication, relevant data have been extracted under Anderson 2004.
Hippisley-Cox,J., Pringle,M., Crown,N., Coupland,C., A case-control study on the effect of hormone replacement therapy on ischaemic heart disease, British Journal of General Practice, 53, 191-196, 2003	Case-control study, mean age of subjects was 69. Past use of 6 months to 5 years was assessed but HRT initiation time can't be ascertained.
Huang,A.J., Sawaya,G.F., Vittinghoff,E., Lin,F., Grady,D., Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women, Menopause, 16, 639-643, 2009	Re-analysis of HERS data by hot flushes symptom at baseline. All participants aged 44-79 years were included, no analysis stratified by age was done.
Hulley,S., Grady,D., Bush,T., Furberg,C., Herrington,D., Riggs,B., Vittinghoff,E., Randomized trial of estrogen plus progestogen for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestogen Replacement Study (HERS) Research Group, JAMA, 280, 605-613, 1998	Participants aged 55-80 years were included at baseline, no subgroup analysis was performed.
Hunt,K., Vessey,M., McPherson,K., Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis, British Journal of Obstetrics and Gynaecology, 97, 1080-1086, 1990	Risk of HRT on CHD and stroke among patients attending menopause clinic was compared with "expected risk" calculated from a previous study where participants were also exposed to HRT use, wrong comparator.
Husak,L., Vaccarino,V., Veledar,E., Murrah,N., Wenger,N.K., Comparison of angiographic findings among postmenopausal women using unopposed estrogen, estrogen/progestogen combinations, and nonusers, American Journal of Cardiology, 93, 563-568, 2004	Mean age of participants > 65 years at baseline, no subgroup analysis was done.
Kaplan,R.C., Heckbert,S.R., Weiss,N.S., Wahl,P.W., Smith,N.L., Newton,K.M., Psaty,B.M., Postmenopausal estrogens and risk of myocardial infarction in diabetic women, Diabetes Care, 21, 1117-1121, 1998	Women aged 30-79 years were included (mean: 69.5), no subgroup analysis was conducted.
Karalis,I., Beevers,D.G., Beevers,M., Lip,G.Y.H., Hormone replacement therapy and arterial blood pressure in postmenopausal women with hypertension, Blood Pressure, 14, 38-44, 2005	Just the BP change of HRT group assessed before and after the intervention, no comparison group.
Khaw,K.T., Women, hormones and blood pressure. [16 refs], Canadian Journal of Cardiology, 12 Suppl D, 9D-12D, 1996	Discussion paper, no analysis carried out.
Kim,C., Golden,S.H., Kong,S., Nan,B., Mather,K.J., Barrett-Connor,E., Diabetes Prevention Program Research Group., Does hormone therapy affect blood pressure changes in the Diabetes Prevention Program?, Menopause, 21, 477-483, 2014	The study was "nested" in a diabetes prevention programme. All participants were overweight or obese, experiencing other treatment/intervention as well at the same time, e.g., metformin, intensive lifestyle change.
Kornhauser,C., Malacara,J.M., Garay,M.E., Perez-Luque,E.L., The effect of hormone replacement therapy on blood pressure and cardiovascular risk factors in menopausal women with moderate hypertension, Journal of Human Hypertension, 11, 405-411, 1997	Study of small size(n=29).
Kuh,D., Langenberg,C., Hardy,R., Kok,H., Cooper,R., Butterworth,S., Wadsworth,M.E., Cardiovascular risk at age 53 years in relation to the menopause transition and use of hormone replacement therapy: a prospective British birth cohort study, BJOG: An International Journal of Obstetrics and Gynaecology, 112, 476-485, 2005	Change of CVD risk profile from baseline rather than CVD event itself was assessed as the outcome.
Lemaitre,R.N., Heckbert,S.R., Psaty,B.M., Smith,N.L., Kaplan,R.C., Longstreth,W.T., Jr., Hormone replacement therapy and associated risk of stroke in postmenopausal women, Archives of Internal Medicine, 162, 1954-1960, 2002	Participants aged between 30 and 79 years were included. Past HRT use was examined but HRT initiation age can't be ascertained.
Lindenfeld,J., Ghali,J.K., Krause-Steinrauf,H.J., Khan,S., Adams,K., Goldman,S., Peberdy,M.A., Yancy,C., Thaneemit-Chen,S., Larsen,R.L., Young,J., Lowes,B., Rosenberg,Y.D., Investigators,B.E.S.T., Hormone replacement therapy is associated with improved survival in women with advanced heart failure, Journal of the American College of Cardiology, 42, 1238-1245, 2003	Participants aged 50-78 years (mean: 61.8±7.5) were included, no relevant subgroup analysis was carried out.
Lindenstrom,E., Boysen,G., Nyboe,J., Lifestyle factors and risk of cerebrovascular disease in women. The Copenhagen City Heart Study, Stroke, 24, 1468-1472, 1993	Participants aged 35-93 were included, no subgroup analysis was carried out.
Lip,G.Y., Beevers,M., Churchill,D., Beevers,D.G., Hormone replacement therapy and blood pressure in hypertensive women, Journal of Human Hypertension, 8, 491-494, 1994	Just before-and-after intervention difference on BP of the same HRT use group was assessed, no comparator.
Lloyd,G., McGing,E., Cooper,A., Patel,N., Lumb,P.J., Wierzbicki,A.S., Jackson,G., A randomised placebo controlled trial of the effects of tibolone on blood pressure	Study of small sample size (n=30).

Study	Reason for exclusion
and lipids in hypertensive women, <i>Journal of Human Hypertension</i> , 14, 99-104, 2000	
Lokkegaard,E., Jovanovic,Z., Heitmann,B.L., Keiding,N., Ottesen,B., Hundrup,Y.A., Obel,E.B., Pedersen,A.T., Increased risk of stroke in hypertensive women using hormone therapy: analyses based on the Danish Nurse Study, <i>Archives of Neurology</i> , 60, 1379-1384, 2003	Participants aged 45 and older than 80 years, no relevant subgroup analysis was conducted.
Longstreth,W.T., Nelson,L.M., Koepsell,T.D., van,Belle G., Subarachnoid hemorrhage and hormonal factors in women. A population-based case-control study, <i>Annals of Internal Medicine</i> , 121, 168-173, 1994	Women older than 18 years were included (mean: 57.4±16.9, age range not reported).
Lukes,A., Evolving issues in the clinical and managed care settings on the management of menopause following the women's health initiative, <i>Journal of Managed Care Pharmacy</i> , 14, S7-S13, 2008	Re-analysis and discussion of WHI, no data stratified by age, duration, or type reported.
Manson,J., Branch,H., The women's health initiative: the latest findings from long-term follow-up, <i>Women's health</i> , 10, 125-128, 2014	Interview of one of the WHI's leading authors on the latest findings from the study.
Mansur,A.D.P., Silva,T.C.B.F., Takada,J.Y., Avakian,S.D., Strunz,C.M.C., Cesar,L.A.M., Aldrighi,J.M., Ramires,J.A.F., Long-term prospective study of the influence of estrone levels on events in postmenopausal women with or at high risk for coronary artery disease, <i>The Scientific World Journal</i> , 2012, 2012. Article Number, -, 2012	Cross-sectional study.
Mares,P., Chevallier,T., Micheletti,M.C., Daures,J.P., Postruznik,D., De,Reilhac P., Coronary heart disease and HRT in France: MISSION study prospective phase results, <i>Gynecological Endocrinology</i> , 24, 696-700, 2008	RR not adjusted for any confounders.
Markovitz,J.H., Matthews,K.A., Wing,R.R., Kuller,L.H., Meilahn,E.N., Psychological, biological and health behavior predictors of blood pressure changes in middle-aged women, <i>Journal of Hypertension</i> , 9, 399-406, 1991	No comparison Group
McCubbin,J.A., Helfer,S.G., Switzer,F.S.,III, Price,T.M., Blood pressure control and hormone replacement therapy in postmenopausal women at risk for coronary heart disease, <i>American Heart Journal</i> , 143, 711-717, 2002	Subjects aged 43-70 years, no subgroup analysis by age was conducted.
Merz,C.N., Johnson,B.D., Berga,S.L., Braunstein,G.D., Azziz,R., Yang,Y., Reis,S.E., Bittner,V., Hodgson,T.K., Pepine,C.J., Sharaf,B.L., Sopko,G., Kelsey,S.F., Women's Ischemia Syndrome Evaluation Study Group., Total estrogen time and obstructive coronary disease in women: insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE), <i>Journal of Women's Health</i> , 18, 1315-1322, 2009	Subjects aged 36-85 years were included, no relevant subgroup analysis was conducted.
Merz,C.N.B., Olson,M.B., McClure,C., Yang,Y.C., Symons,J., Sopko,G., Kelsey,S.F., Handberg,E., Johnson,B.D., Cooper-DeHoff,R.M., Sharaf,B., Rogers,W.J., Pepine,C.J., A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: Results from the National Institutes of Health/National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE), <i>American Heart Journal</i> , 159, 987-987, 2010	Re-analysis of WHI data, all women aged 50-79 years were included.
Mhurchu,C.N., Anderson,C., Jamrozik,K., Hankey,G., Dunbabin,D., Australasian Cooperative Research on Subarachnoid Hemorrhage Study (ACROSS) Group., Hormonal factors and risk of aneurysmal subarachnoid hemorrhage: an international population-based, case-control study, <i>Stroke</i> , 32, 606-612, 2001	Women aged 16-94 (average: 58±17) years were included, no subgroup analysis was conducted.
Myrup,B., Jensen,G.F., McNair,P., Cardiovascular risk factors during estrogen-norethindrone and cholecalciferol treatment, <i>Archives of Internal Medicine</i> , 152, 2265-2268, 1992	Only health women of 70-year-old were included and examined.
Nachtigall,L.E., Nachtigall,R.H., Nachtigall,R.D., Beckman,E.M., Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems, <i>Obstetrics and Gynecology</i> , 54, 74-79, 1979	Participants were hospitalised patients with a mean age of 55 years, no age range reported nor subgroup analysis conducted.
Newton,K.M., LaCroix,A.Z., Heckbert,S.R., Abraham,L., McCulloch,D., Barlow,W., Estrogen therapy and risk of cardiovascular events among women with type 2 diabetes, <i>Diabetes Care</i> , 26, 2810-2816, 2003	Participants aged 45-80 years were included, no subgroup analysis was conducted.
Newton,K.M., LaCroix,A.Z., McKnight,B., Knopp,R.H., Siscovick,D.S., Heckbert,S.R., Weiss,N.S., Estrogen replacement therapy and prognosis after first myocardial infarction, <i>American Journal of Epidemiology</i> , 145, 269-277, 1997	Women aged up to 80 years were included; age of HRT initiation can't be ascertained although past use was assessed.
Nichols,H.B., Trentham-Dietz,A., Newcomb,P.A., Egan,K.M., Titus,L.J., Hampton,J.M., Visvanathan,K., Pre-diagnosis oophorectomy, estrogen therapy and mortality in a cohort of women diagnosed with breast cancer, <i>Breast Cancer Research</i> , 15, -, 2013	Women aged 50-79 years were included, no relevant subgroup analysis was conducted.
Nussmeier,N.A., Marino,M.R., Vaughn,W.K., Hormone replacement therapy is associated with improved survival in women undergoing coronary artery bypass grafting, <i>Journal of Thoracic and Cardiovascular Surgery</i> , 124, 1225-1229, 2002	Participants older than 55 years (mean: 68±7.8)were included, no subgroup analysis was conducted.
Nussmeier,N.A., Mora-Mangano,C., Fontes,M., Schwann,N.M., Mangano,D.T., Investigators of the Ischemia Education Foundation, Multicenter Study of Perioperative Ischemia Research Group., Hormone replacement therapy is safe in women undergoing coronary artery bypass grafting, <i>Texas Heart Institute Journal</i> , 32, 507-514, 2005	Current HRT users with a mean age of 63.1±8.6 years were assessed. HRT initiation age can't be ascertained.

Study	Reason for exclusion
O'Keefe, J.H., Jr., Kim, S.C., Hall, R.R., Cochran, V.C., Lawhorn, S.L., McCallister, B.D., Estrogen replacement therapy after coronary angioplasty in women, <i>Journal of the American College of Cardiology</i> , 29, 1-5, 1997	Mean age of the participants was 60±9 years, no subgroup analysis was conducted.
Osorio-Wender, M.C., Vitola, D., Spritzer, P.M., Percutaneous 17 beta-estradiol replacement therapy in hypertensive postmenopausal women, <i>Brazilian Journal of Medical and Biological Research</i> , 30, 1047-1053, 1997	Women aged 48-70 years were included, no subgroup analysis was conducted.
Paganini-Hill, A., Perez, Barreto M., Stroke risk in older men and women: aspirin, estrogen, exercise, vitamins, and other factors, <i>Journal of Gender-Specific Medicine</i> , 4, 18-28, 2001	Subjects aged 44-101, no subgroup analysis was conducted.
Paganini-Hill, A., Ross, R.K., Henderson, B.E., Postmenopausal oestrogen treatment and stroke: a prospective study, <i>BMJ</i> , 297, 519-522, 1988	Participants aged between 75 to 85 years were included. HRT initiation time can't be ascertained although HRT use with a duration of 8 years was examined.
Parsons, E., Newby, L.K., Bhapkar, M.V., Alexander, K.P., White, H.D., Shah, S.H., Bushnell, C.D., Califf, R.M., Symphony, and, Postmenopausal hormone use in women with acute coronary syndromes, <i>Journal of Women's Health</i> , 13, 863-871, 2004	Participants aged 54-68 years, no relevant sub-group analysis was conducted.
Petitti, D.B., Sidney, S., Quesenberry, C.P., Jr., Hormone replacement therapy and the risk of myocardial infarction in women with coronary risk factors, <i>Epidemiology</i> , 11, 603-606, 2000	Women aged 45-74 were included, no subgroup analysis was conducted.
Prentice, R.L., Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke, <i>Seminars in Reproductive Medicine</i> , 32, 419-425, 2014	Review and discussion paper of WHI. Results for women of all ages were re-visited and discussed.
Pripp, U., Hall, G., Csemiczky, G., Eksborg, S., Landgren, B.M., Schenck-Gustafsson, K., A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease, <i>Journal of Hypertension</i> , 17, 1379-1386, 1999	Women aged 44-75 years were included, no subgroup analysis was conducted.
Psaty, B.M., Heckbert, S.R., Atkins, D., Lemaitre, R., Koepsell, T.D., Wahl, P.W., Siscovick, D.S., Wagner, E.H., The risk of myocardial infarction associated with the combined use of estrogens and progestogens in postmenopausal women, <i>Archives of Internal Medicine</i> , 154, 1333-1339, 1994	Mean age of participants was 68 years, no age range reported, no subgroup analysis was conducted.
Psaty, B.M., Smith, N.L., Lemaitre, R.N., Vos, H.L., Heckbert, S.R., Lacroix, A.Z., Rosendaal, F.R., Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women, <i>JAMA</i> , 285, 906-913, 2001	Participants aged 30-79 years (mean: 68 years) were included, no relevant subgroup analysis was conducted.
Renoux, C., Dell'Aniello, S., Garbe, E., Suissa, S., Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study, <i>BMJ</i> , 340, c2519-, 2010	Participants aged 50-79 years were included, no subgroup analysis was conducted.
Renoux, C., Dell'Aniello, S., Garbe, E., Suissa, S., Hormone replacement therapy use and the risk of stroke, <i>Maturitas</i> , 61, 305-309, 2008	Risk of stroke in relation to HRT in current users aged between 50 and 79 years was assessed, no subgroup analysis was conducted.
Rexrode, K.M., Manson, J.E., Lee, I.M., Ridker, P.M., Sluss, P.M., Cook, N.R., Buring, J.E., Sex hormone levels and risk of cardiovascular events in postmenopausal women, <i>Circulation</i> , 108, 1688-1693, 2003	The study examined the effect of sex hormone levels such as SHBG on CVD, stratified by HRT use, no relevant information reported.
Rosenberg, S.H., Fausone, V., Clark, R., The role of estrogens as a risk factor for stroke in postmenopausal women, <i>Western Journal of Medicine</i> , 133, 292-296, 1980	Participants were current users of estrogen, inclusive of those aged between 50 and 80 years.
Ross, R.K., Paganini-Hill, A., Mack, T.M., Arthur, M., Henderson, B.E., Menopausal oestrogen therapy and protection from death from ischaemic heart disease, <i>Lancet</i> , 1, 858-860, 1981	Subjects were women under 80 years of age, no subgroup analysis was conducted.
Salpeter, S.R., Walsh, J.M., Greyber, E., Salpeter, E.E., Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. [Erratum appears in <i>J Gen Intern Med</i> . 2008 Oct;23(10):1728], <i>Journal of General Internal Medicine</i> , 21, 363-366, 2006	Meta-analysis rather than a systematic review. Individual studies checked and those that meet the review's inclusion criteria have been included.
Sanderson, J.E., Haines, C.J., Yeung, L., Yip, G.W.K., Tang, K., Yim, S.F., Jorgensen, L.N., Woo, J., Anti-ischemic action of estrogen-progestogen continuous combined hormone replacement therapy in postmenopausal women with established angina pectoris: A randomized, placebo-controlled, double-blind, parallel-group trial, <i>Journal of Cardiovascular Pharmacology</i> , 38, 372-383, 2001	Mean age of participants was 67.1 years, no subgroup analysis was conducted.
Schairer, C., Adami, H.O., Hoover, R., Persson, I., Cause-specific mortality in women receiving hormone replacement therapy, <i>Epidemiology</i> , 8, 59-65, 1997	The comparator group was the "general population" not exposed to HRT, where individual level data (exposure) was not available nor can be calculated.
Schneider, C., Jick, S.S., Meier, C.R., Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations, <i>Climacteric</i> , 12, 445-453, 2009	Participants aged between less than 50 years and more than 60 years, no subgroup analysis was conducted.
Scott, A.R., Dhindsa, P., Forsyth, J., Mansell, P., Kliofem Study Collaborative Group., Effect of hormone replacement therapy on cardiovascular risk factors in	This study is assessing risk factors for CVD in diabetic women taking HRT. Diabetes can be a major confounding

Study	Reason for exclusion
postmenopausal women with diabetes, Diabetes, Obesity and Metabolism, 6, 16-22, 2004	factor in assessing association between HRT and blood pressure.
Scuteri,A., Bos,A.J., Brant,L.J., Talbot,L., Lakatta,E.G., Fleg,J.L., Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women, Annals of Internal Medicine, 135, 229-238, 2001	Participants aged 21-96 years (mean: 64±10), no subgroup analysis was conducted.
Shakir,Y.A., Samsioe,G., Khatibi,E.A., Nyberg,P., Lidfeldt,J., Agardh,C.D., Nerbrand,C., Health hazards in middle-aged women with cardiovascular disease: A case-control study of swedish women. The Women's Health in the Lund Area (WHILA) study, Journal of Women's Health, 16, 406-414, 2007	HRT was not examined as a risk factor. It's the sex hormone profile in the HRT and non-HRT groups were reported and compared.
Shapiro,S., Pines,A., Menopausal hormone therapy and risk of hypertension, Climacteric, 15, 635-, 2012	Commentary.
Shetty,K.D., Vogt,W.B., Bhattacharya,J., Hormone replacement therapy and cardiovascular health in the United States, Medical Care, 47, 600-606, 2009	Women aged 40-79 years were included; and data were of population level.
Shlipak,M.G., Elmouchi,D.A., Herrington,D.M., Lin,F., Grady,D., Hlatky,M.A., Heart and Estrogen/progestogen Replacement Study Research Group., The incidence of unrecognized myocardial infarction in women with coronary heart disease, Annals of Internal Medicine, 134, 1043-1047, 2001	HERS, participants younger than 80 years were included, no subgroup analysis was conducted.
Shlipak,M.G., Simon,J.A., Vittinghoff,E., Lin,F., Barrett-Connor,E., Knopp,R.H., Levy,R.I., Hulley,S.B., Estrogen and progestogen, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause, JAMA, 283, 1845-1852, 2000	Participants aged < 80 years were included, no relevant subgroup analysis was performed.
Shufelt,C.L., Johnson,B.D., Berga,S.L., Braunstein,G.D., Reis,S.E., Bittner,V., Yang,Y., Pepine,C.J., Sharaf,B.L., Sopko,G., Kelsey,S.F., Merz,C.N., Women's Ischemia Syndrome Evaluation Study Group., Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation, Menopause, 18, 943-950, 2011	CVD risk profile by HRT initiation age > 55 years and < 55 years was reported, not the CVD event itself.
Shufelt,C.L., Merz,C.N., Prentice,R.L., Pettinger,M.B., Rossouw,J.E., Aroda,V.R., Kaunitz,A.M., Lakshminarayan,K., Martin,L.W., Phillips,L.S., Manson,J.E., Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study, Menopause, 21, 260-266, 2014	The WHI observational study, women aged 50-79 were examined.
Simon,J.A., Hsia,J., Cauley,J.A., Richards,C., Harris,F., Fong,J., Barrett-Connor,E., Hulley,S.B., Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestogen Replacement Study (HERS), Circulation, 103, 638-642, 2001	Risk of current HRT use on stroke was examined among women with a mean age of 67 years, no subgroup analysis was conducted.
Smith,N.L., Blondon,M., Wiggins,K.L., Harrington,L.B., van,Hylckama,V., Floyd,J.S., Hwang,M., Bis,J.C., McKnight,B., Rice,K.M., Lumley,T., Rosendaal,F.R., Heckbert,S.R., Psaty,B.M., Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens, JAMA Internal Medicine, 174, 25-31, 2014	Women aged 30-79 years were included, no subgroup analysis by age was done.
Smith,N.L., Blondon,M., Wiggins,K.L., Harrington,L.B., Van,HylckamaVliegA, Floyd,J.S., Hwang,M., Bis,J.C., McKnight,B., Rice,K.M., Lumley,T., Rosendaal,F.R., Heckbert,S.R., Psaty,B.M., Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens, JAMA Internal Medicine, 174, 25-31, 2014	Women aged 30-79 (mean: 65) years old were included, no subgroup analysis was conducted.
Sorensen,M.B., Rasmussen,V., Jensen,G., Ottesen,B., Temporal changes in clinic and ambulatory blood pressure during cyclic post-menopausal hormone replacement therapy, Journal of Hypertension, 18, 1387-1391, 2000	Small sampled study, n=16.
Speroff,L., Transdermal hormone therapy and the risk of stroke and venous thrombosis, Climacteric, 13, 429-432, 2010	Discussion paper, no primary data analysis.
Speroff,L., The Heart and Estrogen/progestogen Replacement Study (HERS), Maturitas, 31, 9-14, 1998	Discussion of HRES, hazard ratios for all participants aged 44-79 years were reported.
Steiner,A.Z., Hodis,H.N., Lobo,R.A., Shoupe,D., Xiang,M., Mack,W.J., Postmenopausal oral estrogen therapy and blood pressure in normotensive and hypertensive subjects: the Estrogen in the Prevention of Atherosclerosis Trial, Menopause, 12, 728-733, 2005	HRT's effect on blood pressure change by age group was only reported in graphs.
Stute,P., Is transdermal menopausal hormone therapy (MHT) associated with an increased cardiovascular risk?, Archives of Gynecology and Obstetrics, 290, 617-619, 2014	Discussion paper.
Tackett,A.H., Bailey,A.L., Foody,J.M., Miller,J.M., pperson-Hansen,C., Ohman,E.M., Hochman,J.S., Karnash,S.L., Califf,R.M., Topol,E.J., Moliterno,D.J., Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: insights from the GUSTO-III trial, American Heart Journal, 160, 678-684, 2010	Subjects aged 63-70 years, no subgroup analysis was conducted.
Tavani,A., Bertuzzi,M., Gallus,S., Negri,E., La,VecchiaC, Hormone replacement therapy and risk of nonfatal acute myocardial infarction in Italy, Journal of Clinical Epidemiology, 58, 747-750, 2005	Participants aged 45-75 years, no relevant subgroup analysis was conducted.
Thompson,S.G., Meade,T.W., Greenberg,G., The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women, Journal of Epidemiology and Community Health, 43, 173-178, 1989	Women aged 45-69 years were included, no subgroup analysis was conducted.

Study	Reason for exclusion
Varas-Lorenzo,C., Garcia-Rodriguez,L.A., Perez-Gutthann,S., Duque-Oliart,A., Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study, <i>Circulation</i> , 101, 2572-2578, 2000	Women aged 50-74 years were included, no relevant subgroup analysis was conducted.
Veerus,P., Fischer,K., Hakama,M., Hemminki,E., Trial,E.P.H.T., Results from a blind and a non-blind randomised trial run in parallel: experience from the Estonian Postmenopausal Hormone Therapy (EPHT) Trial, <i>BMC Medical Research Methodology</i> , 12, 44-, 2012	HRT users in blinded trial were compared with those in non-blinded trial, wrong comparator.
Veerus,P., Hovi,S.L., Fischer,K., Rahu,M., Hakama,M., Hemminki,E., Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757], <i>Maturitas</i> , 55, 162-173, 2006	Women aged 50-70 were included, no subgroup analysis was conducted.
Vickers,M.R., MacLennan,A.H., Lawton,B., Ford,D., Martin,J., Meredith,S.K., DeStavola,B.L., Rose,S., Dowell,A., Wilkes,H.C., Darbyshire,J.H., Meade,T.W., WISDOM group., Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women, <i>BMJ</i> , 335, 239-, 2007	Women aged 50-69 years old were included (with those > 65 years accounting for 40% of the population), no subgroup analysis was conducted.
Viscoli,C.M., Brass,L.M., Kernan,W.N., Sarrel,P.M., Suissa,S., Horwitz,R.I., A clinical trial of estrogen-replacement therapy after ischemic stroke, <i>New England Journal of Medicine</i> , 345, 1243-1249, 2001	Subjects aged 46-91 (mean 71) were included, no subgroup analysis was conducted.
Vittinghoff,E., Shlipak,M.G., Varosy,P.D., Furberg,C.D., Ireland,C.C., Khan,S.S., Blumenthal,R., Barrett-Connor,E., Hulley,S., Risk factors and secondary prevention in women with heart disease: The heart and estrogen/progestogen replacement study, <i>Annals of Internal Medicine</i> , 138, 81-89, 2003	HERS, participants younger than 80 years old were included, no subgroup analysis was conducted.
Wassertheil-Smoller,S., Hendrix,S.L., Limacher,M., Heiss,G., Kooperberg,C., Baird,A., Kotchen,T., Curb,J.D., Black,H., Rossouw,J.E., Aragaki,A., Safford,M., Stein,E., Laowattana,S., Mysiw,W.J., Investigators,W.H.I., Effect of estrogen plus progestogen on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial, <i>JAMA</i> , 289, 2673-2684, 2003	WHI publication on estrogen plus progestogen's effect on stroke, relevant data has been reported under Manson 2002.
Wassertheil-Smoller,S., Kaplan,R.C., Salazar,C.R., Stroke Findings in the Women's Health Initiative, <i>Seminars in Reproductive Medicine</i> , 32, 438-446, 2014	Paper on WHI findings across outcomes monitored. Relevant reports discussed have been examined in the original review.
White,W.B., Hanes,V., Chauhan,V., Pitt,B., Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension, <i>Hypertension</i> , 48, 246-253, 2006	Women aged 45-75 years were included, no sub-group analysis was conducted.
White,W.B., Pitt,B., Preston,R.A., Hanes,V., Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension, <i>Circulation</i> , 112, 1979-1984, 2005	Current HRT users aged 45-80 years were included in the trial, no subgroup analysis was conducted.
Wild,R.A., Wu,C., Curb,J.D., Martin,L.W., Phillips,L., Stefanick,M., Trevisan,M., Manson,J.E., Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials, <i>Menopause</i> , 20, 254-260, 2013	Re-analysis of WHI data by metabolic syndrome at baseline, participants aged 50-79 years were all included in the analysis.
Windler,E., Zyriax,B.C., Eidenmuller,B., Boeing,H., Hormone replacement therapy and risk for coronary heart disease. Data from the CORA-study--a case-control study on women with incident coronary heart disease, <i>Maturitas</i> , 57, 239-246, 2007	Participants aged between 60 and 70 or older (mean: 66±7.9). Time of past use or HRT initiation age can't be ascertained.
Wolf,P.H., Madans,J.H., Finucane,F.F., Higgins,M., Kleinman,J.C., Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort, <i>American Journal of Obstetrics and Gynecology</i> , 164, 489-494, 1991	Subjects of or older than 55 years of age were included (mean: 65), no subgroup analysis was conducted.
Ziaei,S., Vakilinia,T., Faghihzadeh,S., The effects of tibolone on risk factors of cardiovascular disease in menopausal women, <i>Iranian Journal of Medical Sciences</i> , 35, 281-286, 2010	WHI publication, just overall risk estimates for all participants aged 50-79 were reported.

### G.7.3 Development of type 2 diabetes

Study	Reason for exclusion
Chen,B.H., Brennan,K., Goto,A., Song,Y., Aziz,N., You,N.C., Wellons,M.F., Manson,J.E., White,D.L., Butch,A.W., Liu,S., Sex hormone-binding globulin and risk of clinical diabetes in American black, Hispanic, and Asian/Pacific Islander postmenopausal women, <i>Clinical Chemistry</i> , 58, 1457-1466, 2012	The study examined the risk of developing diabetes associated with sex hormone-binding globulin (SHBG), hormone therapy use was controlled for in the analysis model as a confounder.
De,Lauzon GuillainB, Fournier,A., Fabre,A., Simon,N., Mesrine,S., Boutron-Ruault,M.C., Balkau,B., Clavel-Chapelon,F., Menopausal hormone therapy and new-onset diabetes in the French E3N cohort, <i>Diabetologia</i> , 52, S243-, 2009	Only available in abstract.
Iannuzzi-Sucich,M., Prestwood,K.M., Kenny,A.M., Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women, <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 57, M772-M777, 2002	Was a prevalence study of sarcopenia.
Kim,C., Edelstein,S.L., Crandall,J.P., Dabelea,D., Kitabchi,A.E., Hamman,R.F., Montez,M.G., Perreault,L., Foulkes,M.A., Barrett-Connor,E., Diabetes Prevention Program Research Group., Menopause and risk of diabetes in the Diabetes Prevention Program, <i>Menopause</i> , 18, 857-868, 2011	Premenopausal women was compared with postmenopausal women using or not using HRT on the

Study	Reason for exclusion
	risk of developing T2DM, wrong comparator.
Monterrosa-Castro,A., Blumel,J.E., Portela-Buelvas,K., Mezones-Holguin,E., Baron,G., Bencosme,A., Benitez,Z., Bravo,L.M., Calle,A., Chedraui,P., Flores,D., Espinoza,M.T., Gomez,G., Hernandez-Bueno,J.A., Laribezcoa,F., Lima,S., Martino,M., Mostajo,D., Ojeda,E., Onatra,W., Sanchez,H., Navarro,D., Tserotas,K., Vallejo,M.S., Witis,S., Zuniga,M.C., Collaborative Group for Research of the Climacteric in Latin America (REDLINC), Type II diabetes mellitus and menopause: a multinational study, <i>Climacteric</i> , 16, 663-672, 2013	Cross-sectional study carried out among Hispanic women in 11 Latin American countries.
Pentti,K., Tuppurainen,M.T., Honkanen,R., Sandini,L., Kroger,H., Alhava,E., Saarikoski,S., Hormone therapy protects from diabetes: the Kuopio osteoporosis risk factor and prevention study, <i>European Journal of Endocrinology</i> , 160, 979-983, 2009	T1DM and T2DM were lumped together as the outcome, no separate analysis for T2DM only.
Rizzo, M. R., Leo, S., De Franciscis, P., Colacurci, N., Paolisso, G., Short-term effects of low-dose estrogen/drospirenone vs low-dose estrogen/dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome, <i>Age</i> , 36, 265-74, 2014	Outcomes did not match protocol
Salmen,T., Heikkinen,A.-M., Mahonen,A., Kroger,H., Komulainen,M., Saarikoski,S., Honkanen,R., Partanen,J., Maenpaa,P.H., Relation of estrogen receptor-alfa gene polymorphism and hormone replacement therapy to fall risk and muscle strenght in early postmenopausal women, <i>Annals of Medicine</i> , 34, 64-72, 2002	Outcomes not relevant.
Salpeter S R, Walsh J M, Ormiston T M, Greyber E, Buckley N S, Salpeter E E., Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women, <i>Diabetes Obesity and Metabolism</i> , 8, 538-554, 2006	Systematic review did not report type of diabetes, individual studies checked
Studer M, Briel M, Leimenstoll B, Glass T R, Bucher H C, Effect of different antilipidemic agents and diets on mortality: a systematic review, <i>Archives of Internal Medicine</i> , 165, 725-730, 2005	Systematic review, topic did not match protocol
van Genugten,R.E., Utzschneider,K.M., Tong,J., Gerchman,F., Zraika,S., Udayasankar,J., Boyko,E.J., Fujimoto,W.Y., Kahn,S.E., American Diabetes Association GENNID Study Group., Effects of sex and hormone replacement therapy use on the prevalence of isolated impaired fasting glucose and isolated impaired glucose tolerance in subjects with a family history of type 2 diabetes, <i>Diabetes</i> , 55, 3529-3535, 2006	The outcome examined was impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), which are known to increase the risk of developing diabetes. Subjects were limited to those with a family history of T2DM.

#### G.7.4 Management of type 2 diabetes – control of blood sugar

Study	Reason for exclusion
Andersson,B., Mattsson,L.A., The effect of transdermal estrogen replacement therapy on hyperandrogenicity and glucose homeostasis in postmenopausal women with NIDDM, <i>Acta Obstetricia et Gynecologica Scandinavica</i> , 78, 260-261, 1999	The study does not report a comparator group
Andersson,B., Mattsson,L.A., Hahn,L., Marin,P., Lapidus,L., Holm,G., Bengtsson,B.A., Bjorntorp,P., Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus, <i>Journal of Clinical Endocrinology and Metabolism</i> , 82, 638-643, 1997	Crossover study, within patient correlation not reported, data from different timepoints not reported
Araujo,D.A., Farias,M.L., Andrade,A.T., Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus, <i>Climacteric</i> , 5, 286-292, 2002	Comparator is not a placebo
Barrett-Connor,E., Ensrud,K.E., Harper,K., Mason,T.M., Sashegyi,A., Krueger,K.A., Anderson,P.W., Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes, <i>Clinical Therapeutics</i> , 25, 919-930, 2003	Insufficient data reported, dosage for FPG not reported for raloxifene, no HbA1c value reported for placebo/raloxifene at lower dose
Ching,H.L., Watts,G.F., Dhaliwal,S.S., Barrett,P.H., Stuckey,B.G., Vascular function of forearm microcirculation in postmenopausal women with type 2 diabetes: potential benefit of hormone replacement therapy?, <i>Climacteric</i> , 6, 31-37, 2003	Cross-sectional observational study, blood glucose and HbA1c reported at baseline only
Cornu,C., Mercier,C., Ffrench,P., Bully,C., Pugeat,M., Cousin,P., Riou,J.P., Bajart,L., Orgiazzi,J., Pomet-Nicot,C., Darsy,P., Boissel,J.P., Berthezene,F., Postmenopause hormone treatment in women with NIDDM or impaired glucose tolerance: the MEDIA randomized clinical trial, <i>Maturitas</i> , 37, 95-104, 2000	Treatment groups not clearly defined for HbA1c and blood glucose outcomes, and data not reported in text
Espeland,M.A., Hogan,P.E., Fineberg,S.E., Howard,G., Schrott,H., Waclawiw,M.A., Bush,T.L., Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestogen Interventions, <i>Diabetes Care</i> , 21, 1589-1595, 1998	Population not T2D
Grigoryan,O., Grodnitskaya,E., Andreeva,E., Shestakova,M., Melnichenko,G., Dedov,I., Contraception in perimenopausal women with diabetes mellitus, <i>Gynecological Endocrinology</i> , 22, 198-206, 2006	No indication of how perimenopausal women in the study were classified, no comparator group reported
Howard,B.V., Hsia,J., Ouyang,P., Van,Voorhees L., Lindsay,J., Silverman,A., Alderman,E.L., Tripputi,M., Waters,D.D., Postmenopausal hormone therapy is	Population not T2D



Study	Reason for exclusion
associated with atherosclerosis progression in women with abnormal glucose tolerance, <i>Circulation</i> , 110, 201-206, 2004	
Kanaya, A. M., Herrington, D., Vittinghoff, E., Lin, F., Grady, D., Bittner, V., Cauley, J. A., Barrett-Connor, E., Heart, Estrogen/progestogen Replacement, Study, Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestogen Replacement Study. A randomized, double-blind, placebo-controlled trial. [Summary for patients in <i>Ann Intern Med</i> . 2003 Jan 7;138(1):110; PMID: 12513063], <i>Annals of Internal Medicine</i> <i>Ann Intern Med</i> , 138, 1-9	Type of diabetes population not defined
Lamon-Fava, S., Herrington, D.M., Horvath, K.V., Schaefer, E.J., Asztalos, B.F., Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status, <i>Metabolism: clinical and experimental</i> , 59, 1794-1800, 2010	Outcomes reported were not of interest to review
Padwal R, Majumdar S R, Johnson J A, Varney J, McAlister F A, A systematic review of drug therapy to delay or prevent type 2 diabetes, <i>Diabetes Care</i> , 28, 736-744, 2005	Systematic review on risk of T2DM, and not impact of HRT on menopausal women who already have T2DM
Rizzo, M. R., Leo, S., De Franciscis, P., Colacurci, N., Paolisso, G., Short-term effects of low-dose estrogen/drospirenone vs low-dose estrogen/dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome, <i>Age</i> , 36, 265-74, 2014	Comparator or outcomes do not match the protocol
Samaras, K., Hayward, C.S., Sullivan, D., Kelly, R.P., Campbell, L.V., Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes: a prospective study, <i>Diabetes Care</i> , 22, 1401-1407, 1999	No washout period mentioned
Scott, A.R., Dhindsa, P., Forsyth, J., Mansell, P., Effect of hormone replacement therapy on cardiovascular risk factors in postmenopausal women with diabetes, <i>Diabetes, Obesity and Metabolism</i> , 6, 16-22, 2004	Outcome data was not reported for T2D
Thunell, L., Andersson, B., Glassell, M., Mattsson, L.A., The effect of continuous combined HRT on glucose homeostasis and plasma lipids. A placebo-controlled study in postmenopausal women with type 2 diabetes, <i>Maturitas</i> , 53, 430-438, 2006	Crossover study, does not report within patient correlation, and data from different timepoints not reported
Wiegatz, I., Starflinger, F., Tetzloff, W., Leifels-Fischer, B., Helmond, F.A., ricks-Tan, J.S., Kuhl, H., Effect of tibolone compared with sequential hormone replacement therapy on carbohydrate metabolism in postmenopausal women, <i>Maturitas</i> , 41, 133-141, 2002	Population not T2D
Xu, Y., Lin, J., Wang, S., Xiong, J., Zhu, Q., Combined estrogen replacement therapy on metabolic control in postmenopausal women with diabetes mellitus, <i>Kaohsiung Journal of Medical Sciences</i> , 30, 350-361, 2014	Systematic review, reported HbA1c and blood glucose outcomes as mixed population of T1D and T2D. Studies in meta-analyses were checked for inclusion in current review

## G.7.5 Breast cancer

Study	Reason for exclusion
Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. [Erratum appears in <i>Lancet</i> 1997 Nov 15;350(9089):1484], <i>Lancet</i> , 350, 1047-1059, 1997	Meta-analysis of individual participant data of studies already included in review
Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat, <i>Prescrire International</i> , 13, 106-109, 2004	Review
Al-Shaibani, H., Bu-Alayyan, S., Habiba, S., Sorkhou, E., Al-Shamali, N., Al-Qallaf, B., Risk factors of breast cancer in Kuwait: Case-control study, <i>Iranian Journal of Medical Sciences</i> , 31, 61-64, 2006	Population not relevant. Included premenopausal, perimenopausal and postmenopausal women.
Anderson, G.L., Limacher, M., Assaf, A.R., Bassford, T., Beresford, S.A., Black, H., Bonds, D., Brunner, R., Brzyski, R., Caan, B., Chlebowski, R., Curb, D., Gass, M., Hays, J., Heiss, G., Hendrix, S., Howard, B.V., Hsia, J., Hubbell, A., Jackson, R., Johnson, K.C., Judd, H., Kotchen, J.M., Kuller, L., Lacroix, A.Z., Lane, D., Langer, R.D., Lasser, N., Lewis, C.E., Manson, J., Margolis, K., Ockene, J., O'Sullivan, M.J., Phillips, L., Prentice, R.L., Ritenbaugh, C., Robbins, J., Rossouw, J.E., Sarto, G., Stefanick, M.L., Van, Horn L., Wactawski-Wende, J., Wallace, R., Wassertheil-Smoller, S., Women's Health Initiative Steering Committee., Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial, <i>JAMA</i> , 291, 1701-1712, 2004	Duplicate of 295534 which has already been extracted.
Antoine, C., Liebens, F., Carly, B., Pastijn, A., Rozenberg, S., Influence of HRT on prognostic factors for breast cancer: A systematic review after the Women's Health Initiative trial, <i>Human Reproduction</i> , 19, 741-756, 2004	Review
Bakken, K., Fournier, A., Lund, E., Waaseth, M., Dumeaux, V., Clavel-Chapelon, F., Fabre, A., Hemon, B., Rinaldi, S., Chajes, V., Slimani, N., Allen, N.E., Reeves, G.K., Bingham, S., Khaw, K.T., Olsen, A., Tjonneland, A., Rodriguez, L., Sanchez, M.J., Etzezarreta, P.A., Ardanaz, E., Tormo, M.J., Peeters, P.H., van Gils, C.H., Steffen, A., Schulz, M., Chang-Claude, J., Kaaks, R., Tumino, R., Gallo, V., Norat, T., Riboli, E., Panico, S., Masala, G., Gonzalez, C.A., Berrino, F., Menopausal hormone therapy	Secondary publication of 300918

Study	Reason for exclusion
and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition, <i>International Journal of Cancer</i> , 128, 144-156, 2011	
Beji,N.K., Reis,N., Risk factors for breast cancer in Turkish women: A hospital-based case-control study, <i>European Journal of Cancer Care</i> , 16, 178-184, 2007	Population not relevant to review question. Women were aged 28-72 years and included pre, peri and postmenopausal women.
Beral,V., Breast cancer and hormone-replacement therapy in the Million Women Study, <i>Lancet</i> , 362, 419-427, 2003	Data already entered using study id 300217
Beral,V., The Million Women Study: Design and characteristics of the study population, <i>Breast Cancer Research</i> , 1, 73-80, 1999	Study protocol paper.
Beral,V., Reeves,G., Bull,D., Green,J., Million Women, Study Collaborators, Breast cancer risk in relation to the interval between menopause and starting hormone therapy, <i>Journal of the National Cancer Institute</i> , 103, 296-305, 2011	Million women study cohort. Data extracted using study id 300217
Bergkvist,L., Adami,H.O., Persson,I., Hoover,R., Schairer,C., The risk of breast cancer after estrogen and estrogen-progestogen replacement, <i>New England Journal of Medicine</i> , 321, 293-297, 1989	Population included pre-menopausal women
Bitzer,J., Kenemans,P., Mueck,A.O., FSDeducation Group., Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy. [23 refs], <i>Maturitas</i> , 59, 209-218, 2008	Review
Bonds,D.E., Lasser,N., Qi,L., Brzyski,R., Caan,B., Heiss,G., Limacher,M.C., Liu,J.H., Mason,E., Oberman,A., O'Sullivan,M.J., Phillips,L.S., Prineas,R.J., Tinker,L., The effect of conjugated equine oestrogen on diabetes incidence: The Women's Health Initiative randomised trial, <i>Diabetologia</i> , 49, 459-468, 2006	Outcomes were incident diabetes
Brinton,L.A., Brogan,D.R., Coates,R.J., Swanson,C.A., Potischman,N., Stanford,J.L., Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy, <i>Menopause</i> , 5, 145-151, 1998	Population not relevant to review question. Population consisted of women 20-44 years who had been exposed to OCs and HRT.
Brinton,L.A., Richesson,D., Leitzmann,M.F., Gierach,G.L., Schatzkin,A., Mouw,T., Hollenbeck,A.R., Lacey,J.V., Jr., Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort, <i>Cancer Epidemiology, Biomarkers and Prevention</i> , 17, 3150-3160, 2008	Women were aged 50-71. Confidence intervals not reported.
Calle,E.E., Feigelson,H.S., Hildebrand,J.S., Teras,L.R., Thun,M.J., Rodriguez,C., Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype.[Erratum appears in <i>Cancer</i> . 2009 Apr 1;115(7):1587], <i>Cancer</i> , 115, 936-945, 2009	Reported HRs for breast cancer by hormone regimen and histologic subtypes of breast cancer
Calle,E.E., Feigelson,H.S., Hildebrand,J.S., Teras,L.R., Thun,M.J., Rodriguez,C., Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype, <i>Cancer</i> , 115, 936-945, 2009	Population aged 50-74 years.
Calvocoressi,L., Stowe,M.H., Carter,D., Claus,E.B., Postmenopausal hormone therapy and ductal carcinoma in situ: a population-based case-control study, <i>Cancer Epidemiology</i> , 36, 161-168, 2012	Population included those aged > 65 years.
Canonico,M., Fournier,A., Carcaillon,L., Olie,V., Plu-Bureau, Oger,E., Mesrine,S., Boutron-Ruault,M.C., Clavel-Chapelon,F., Scarabin,P.Y., Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study, <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> , 30, 340-345, 2010	Outcome not relevant
Catsburg,C., Gunter,M.J., Chen,C., Cote,M.L., Kabat,G.C., Nassir,R., Tinker,L., Wactawski-Wende,J., Page,D.L., Rohan,T.E., Insulin, estrogen, inflammatory markers, and risk of benign proliferative breast disease, <i>Cancer Research</i> , 74, 3248-3258, 2014	Evaluated endogenous estrogens.
Cerne,J.Z., Novakovic,S., Frkovic-Grazio,S., Pohar-Perme,M., Stegel,V., Gersak,K., Estrogen metabolism genotypes, use of long-term hormone replacement therapy and risk of postmenopausal breast cancer, <i>Oncology Reports</i> , 26, 479-485, 2011	Estimates for main outcomes not provided
Chen,C.L., Weiss,N.S., Newcomb,P., Barlow,W., White,E., Hormone replacement therapy in relation to breast cancer, <i>JAMA</i> , 287, 734-741, 2002	Population aged 50-74 years
Chen,F.P., Postmenopausal hormone therapy and risk of breast cancer. [57 refs], <i>Chang Gung Medical Journal</i> , 32, 140-147, 2009	Review
Chen,W., Petitti,D.B., Geiger,A.M., Mortality following development of breast cancer while using oestrogen or oestrogen plus progestogen: a computer record-linkage study, <i>British Journal of Cancer</i> , 93, 392-398, 2005	Explored survival after exposure to hormone therapy at or in the year prior to breast cancer diagnosis.
Chen,W.Y., Manson,J.E., Hankinson,S.E., Rosner,B., Holmes,M.D., Willett,W.C., Colditz,G.A., Unopposed estrogen therapy and the risk of invasive breast cancer, <i>Archives of Internal Medicine</i> , 166, 1027-1032, 2006	Part of the Nurses' Health Study Cohort
Chlebowski,R.T., Estrogen plus progestogen increased long-term risk for invasive breast cancer in postmenopausal women, <i>Annals of Internal Medicine</i> , 154, JC2-11, 2011	Commentary
Chlebowski,R.T., Anderson,G.L., Changing concepts: Menopausal hormone therapy and breast cancer, <i>Journal of the National Cancer Institute</i> , 104, 517-527, 2012	Review
Chlebowski,R.T., Hendrix,S.L., Langer,R.D., Stefanick,M.L., Gass,M., Lane,D., Rodabough,R.J., Gilligan,M.A., Cyr,M.G., Thomson,C.A., Khandekar,J., Petrovitch,H., McTiernan,A., Investigators,W.H.I., Influence of estrogen plus	Women aged 50-79 years. Estimates not reported for < 65 years.

Study	Reason for exclusion
progestogen on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial, JAMA, 289, 3243-3253, 2003	
Chlebowski,R.T., Manson,J.E., Anderson,G.L., Cauley,J.A., Aragaki,A.K., Stefanick,M.L., Lane,D.S., Johnson,K.C., Wactawski-Wende,J., Chen,C., Qi,L., Yasmeen,S., Newcomb,P.A., Prentice,R.L., Estrogen plus progestogen and breast cancer incidence and mortality in the Women's Health Initiative Observational Study, Journal of the National Cancer Institute, 105, 526-535, 2013	Participants were aged 50-79 years. Estimates not reported for age < 65 years.
Colditz,G.A., Hankinson,S.E., Hunter,D.J., Willett,W.C., Manson,J.E., Stampfer,M.J., Hennekens,C., Rosner,B., Speizer,F.E., The use of estrogens and progestogens and the risk of breast cancer in postmenopausal women, New England Journal of Medicine, 332, 1589-1593, 1995	Duplicate publication
Colditz,G.A., Stampfer,M.J., Willett,W.C., Hennekens,C.H., Rosner,B., Speizer,F.E., Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women.[Erratum appears in JAMA 1991 Apr 10;265(14):1828], JAMA, 264, 2648-2653, 1990	Data already extracted for NHS from 301487
Colditz,G.A., Stampfer,M.J., Willett,W.C., Hennekens,C.H., Rosner,B., Speizer,F.E., Prospect study of estrogen replacement therapy and risk of breast cancer in postmenopausal women, Journal of the American Medical Association, 264, 2648-2653, 1990	Duplicate of 301170
Collins,J.A., Blake,J.M., Crosignani,P.G., Breast cancer risk with postmenopausal hormonal treatment, Human Reproduction Update, 11, 545-560, 2005	Review paper
Cordina-Duverger,E., Truong,T., Anger,A., Sanchez,M., Arveux,P., Kerbrat,P., Guenel,P., Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France, PLoS ONE [Electronic Resource], 8, e78016-, 2013	Cases were aged 25-75 years and majority of participants started HRT after the 65 year age cutoff.
Corrao,G., Zambon,A., Conti,V., Nicotra,F., La,Vecchia C., Fornari,C., Cesana,G., Contiero,P., Tagliabue,G., Nappi,R.E., Merlino,L., Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation, Annals of Oncology, 19, 150-155, 2008	Age range not relevant to review question
Costagliola,D., Observation versus intervention in the evaluation of drugs: the story of hormone replacement therapy, Comptes Rendus Biologies, 330, 347-355, 2007	Review
Culhane,N.S., Estrogen plus progestogen may increase incidence of dementia, Journal of Family Practice, 52, 754-755, 2003	Outcome not relevant
Cummings,S.R., Duong,T., Kenyon,E., Cauley,J.A., Whitehead,M., Krueger,K.A., Serum estradiol level and risk of breast cancer during treatment with raloxifene, Journal of the American Medical Association, 287, 216-220, 2002	Intervention was not HRT.
Cummings,S.R., Eckert,S., Krueger,K.A., Grady,D., Powles,T.J., Cauley,J.A., Norton,L., Nickelsen,T., Bjarnason,N.H., Morrow,M., Lippman,M.E., Black,D., Glusman,J.E., Costa,A., Jordan,V.C., The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation, JAMA : the journal of the American Medical Association, 281, 2189-2197, 1999	Intervention not HRT.
Cushman,M., Kuller,L.H., Prentice,R., Rodabough,R.J., Psaty,B.M., Stafford,R.S., Sidney,S., Rosendaal,F.R., Women's Health Initiative Investigators., Estrogen plus progestogen and risk of venous thrombosis, JAMA, 292, 1573-1580, 2004	Outcome not relevant
Cuzick,J., Hormone replacement therapy and the risk of breast cancer. [26 refs], European Journal of Cancer, 44, 2344-2349, 2008	Review
de Lauzon-Guillain,B., Fournier,A., Fabre,A., Simon,N., Mesrine,S., Boutron-Ruault,M.C., Balkau,B., Clavel-Chapelon,F., Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Generale de l'Education Nationale (E3N) cohort, Diabetologia, 52, 2092-2100, 2009	Outcome not relevant
Devor,M., Barrett-Connor,E., Renvall,M., Feigal,Jr, Ramsdell,J., Estrogen replacement therapy and the risk of venous thrombosis, American Journal of Medicine, 92, 275-282, 1992	Outcome not relevant
Dupont,W.D., Page,D.L., Menopausal estrogen replacement therapy and breast cancer, Archives of Internal Medicine, 151, 67-72, 1991	Meta-analysis
Dupont,W.D., Page,D.L., Rogers,L.W., Parl,F.F., Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk, Cancer, 63, 948-957, 1989	Population and exposure not relevant to review question.
Espelund,M.A., Shumaker,S.A., Leng,I., Manson,J.E., Brown,C.M., LeBlanc,E.S., Vaughan,L., Robinson,J., Rapp,S.R., Goveas,J.S., Wactawski-Wende,J., Stefanick,M.L., Li,W., Resnick,S.M., WHIMSY Study Group., Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years, JAMA Internal Medicine, 173, 1429-1436, 2013	Outcome not relevant
Espelund,M.A., Tindle,H.A., Bushnell,C.A., Jaramillo,S.A., Kuller,L.H., Margolis,K.L., Mysiw,W.J., Maldjian,J.A., Melhem,E.R., Resnick,S.M., Women's Health Initiative Memory Study., Brain volumes, cognitive impairment, and conjugated equine estrogens, Journals of Gerontology Series A-Biological Sciences and Medical Sciences, 64, 1243-1250, 2009	Outcome not relevant
Ewertz,M., Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark, International Journal of Cancer, 42, 832-838, 1988	Population not relevant to review question. Consisted of pre, peri, and postmenopausal women.

Study	Reason for exclusion
Fernandez,E., Gallus,S., Bosetti,C., Franceschi,S., Negri,E., La,VecchiaC, Hormone replacement therapy and cancer risk: A systematic analysis from a network of case-control studies, International Journal of Cancer, 105, 408-412, 2003	Population aged 45-79 years
Fournier,A., Mesrine,S., Boutron-Ruault,M.C., Clavel-Chapelon,F., Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?, Journal of Clinical Oncology, 27, 5138-5143, 2009	Estimates only provided for the association of HRT and breast cancer risk according to timing of treatment initiation.
Fournier,A., Mesrine,S., Dossus,L., Boutron-Ruault,M.C., Clavel-Chapelon,F., Chabbert-Buffet,N., Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort, Breast Cancer Research and Treatment, 145, 535-543, 2014	Evaluated breast cancer outcomes after stopping treatment with HRT.
Franke, H.R., Vermes, I., Differential effects of progestogens on breast cancer cell lines, Maturitas, 46S1, S55-S58, 2003	Experimental research paper (in vitro breast cancer cell lines)
Galen,Buckwalter J., Crooks,V.C., Robins,S.B., Petitti,D.B., Hormone use and cognitive performance in women of advanced age, Journal of the American Geriatrics Society, 52, 182-186, 2004	Outcome not relevant
Gambrell,R.D., Oral contraceptives, postmenopausal oestrogen-progestagen use and breast cancer, Journal of Obstetrics and Gynaecology, 4, S121-S127, 1984	Population not relevant to review question. Population consisted of pre and postmenopausal on different types of OCs and HRT.
Gammon,M.D., Neugut,A.I., Santella,R.M., Teitelbaum,S.L., Britton,J.A., Terry,M.B., Eng,S.M., Wolff,M.S., Stellman,S.D., Kabat,G.C., Levin,B., Bradlow,H.L., Hatch,M., Beyea,J., Camann,D., Trent,M., Senie,R.T., Garbowski,G.C., Maffeo,C., Montalvan,P., Berkowitz,G.S., Kemeny,M., Citron,M., Schnabel,F., Schuss,A., Hajdu,S., Vinciguerra,V., Collman,G.W., Orams,G.I., The Long Island Breast Cancer Study Project: Description of a multi-institutional collaboration to identify environmental risk factors for breast cancer, Breast Cancer Research and Treatment, 74, 235-254, 2002	Population and intervention/exposure not relevant to review question.
Gapstur,S.M., Morrow,M., Sellers,T.A., Hormone replacement therapy and risk of breast cancer with a favorable histology: Results of the Iowa Women's Health Study, Journal of the American Medical Association, 281, 2091-2097, 2141, 1999	Outcomes were histological types of invasive breast cancer
Gaussoin,S.A., Espeland,M.A., Absher,J., Howard,B.V., Jones,B.M., Rapp,S.R., Ascertain dementia-related outcomes for deceased or proxy-dependent participants: an overview of the Women's Health Initiative Memory Study supplemental case ascertainment protocol, International Journal of Geriatric Psychiatry, 27, 205-214, 2012	Outcome not relevant
Gertig,D.M., Fletcher,A.S., English,D.R., Macinnis,R.J., Hopper,J.L., Giles,G.G., Hormone therapy and breast cancer: what factors modify the association?, Menopause, 13, 178-184, 2006	Age range not relevant to review question. Assessed histological subtypes of breast cancer.
Giersig,C., Progestogen and breast cancer. The missing pieces of a puzzle. [21 refs][Erratum appears in Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 Aug;51(8):946], Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 51, 782-786, 2008	Review
Gramling,R., Eaton,C.B., Rothman,K.J., Cabral,H., Silliman,R.A., Lash,T.L., Hormone replacement therapy, family history, and breast cancer risk among postmenopausal women, Epidemiology, 20, 752-756, 2009	Secondary publication of WHI
Greiser,C.M., Greiser,E.M., Doren,M., Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials, Human Reproduction Update, 11, 561-573, 2005	Systematic Review
Grimes,D.A., Lobo,R.A., Perspectives on the Women's Health Initiative trial of hormone replacement therapy. [86 refs], Obstetrics and Gynecology, 100, 1344-1353, 2002	Review
Hadjisavvas,A., Loizidou,M.A., Middleton,N., Michael,T., Papachristoforou,R., Kakouri,E., Daniel,M., Papadopoulos,P., Malas,S., Marcou,Y., Kyriacou,K., An investigation of breast cancer risk factors in Cyprus: A case control study, BMC Cancer, 10, 2010. Article Number, -, 2010	Population not relevant to review question. Population included all women.
Harman,S.M., Brinton,E.A., Clarkson,T., Heward,C.B., Hecht,H.S., Karas,R.H., Judelson,D.R., Naftolin,F., Is the WHI relevant to HRT started in the perimenopause?, Endocrine, 24, 195-202, 2004	Review
Harman,S.M., Naftolin,F., Brinton,E.A., Judelson,D.R., Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence, Annals of the New York Academy of Sciences, 1052, 43-56, 2005	Review
Harris,R.E., Namboodiri,K.K., Wynder,E.L., Breast cancer risk: effects of estrogen replacement therapy and body mass, Journal of the National Cancer Institute, 84, 1575-1582, 1992	Population not relevant. Consisted of women of all ages <30 to >80 years.
Heikkinen,J., Vaheri,R., Timonen,U., Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomised comparison of low and standard doses.[Erratum appears in J Br Menopause Soc. 2004 Dec;10(4):168], Journal of the British Menopause Society, 10, 95-102, 2004	Outcomes reported not to be related to intervention.
Heiss,G., Wallace,R., Anderson,G.L., Aragaki,A., Beresford,S.A.A., Brzyski,R., Chlebowski,R.T., Gass,M., Lacroix,A., Manson,J.E., Prentice,R.L., Rossouw,J., Stefanick,M.L., Health risks and benefits 3 years after stopping randomized	WHI trial.CEE MPA vs. placebo phase. Data already extracted for

Study	Reason for exclusion
treatment with estrogen and progestogen, JAMA - Journal of the American Medical Association, 299, 1036-1045, 2008	this. This report did not report data for women aged < 65 years.
Helzlsouer, K.J., Alberg, A.J., Bush, T.L., Longcope, C., Gordon, G.B., Comstock, G.W., A prospective study of endogenous hormones and breast cancer, Cancer Detection and Prevention, 18, 79-85, 1994	Intervention used endogenous hormones
Henderson, V.W., Benke, K.S., Green, R.C., Cupples, L.A., Farrer, L.A., MIRAGE Study Group., Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age, Journal of Neurology, Neurosurgery and Psychiatry, 76, 103-105, 2005	Outcome not relevant
Henderson, V.W., Paganini-Hill, A., Miller, B.L., Elble, R.J., Reyes, P.F., Shoupe, D., McCleary, C.A., Klein, R.A., Hake, A.M., Farlow, M.R., Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial, Neurology, 54, 295-301, 2000	Outcome not relevant
Herd, J.A., Gotto, A.M., Jr., Does post-menopausal hormone-replacement therapy increase risk for breast cancer? A perspective on the findings of the Nurses' Health Study, Pharmacological Research, 32, 331-333, 1995	Review
Herrington, D.M., Vittinghoff, E., Howard, T.D., Major, D.A., Owen, J., Reboussin, D.M., Bowden, D., Bittner, V., Simon, J.A., Grady, D., Hulley, S.B., Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease, Arteriosclerosis, Thrombosis and Vascular Biology, 22, 1012-1017, 2002	Outcome not relevant
Hogervorst, E., Boshuisen, M., Riedel, W., Willeken, C., Jolles, J., The effect of hormone replacement therapy on cognitive function in elderly women, Psychoneuroendocrinology, 24, 43-68, 1999	Outcome not relevant
Hogervorst, E., Boshuisen, M., Riedel, W., Willeken, C., Jolles, J., 1998 Curt P. Richter Award. The effect of hormone replacement therapy on cognitive function in elderly women, Psychoneuroendocrinology, 24, 43-68, 1999	Outcome not relevant
Hou, N., Hong, S., Wang, W., Olopade, O.I., Dignam, J.J., Huo, D., Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density, Journal of the National Cancer Institute, 105, 1365-1372, 2013	Prevalence study. Duration of HRT use unknown
Hulley, S., Furberg, C., Barrett-Connor, E., Cauley, J., Grady, D., Haskell, W., Knopp, R., Lowery, M., Satterfield, S., Schrott, H., Vittinghoff, E., Hunninghake, D., Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestogen Replacement Study follow-up (HERS II), Journal of the American Medical Association, 288, 58-66, 2002	Average age of participants at baseline was 67 years and had coronary heart disease at baseline.
Hulley, S., Furberg, C., Barrett-Connor, E., Cauley, J., Grady, D., Haskell, W., Knopp, R., Lowery, M., Satterfield, S., Schrott, H., Vittinghoff, E., Hunninghake, D., HERS Research Group., Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestogen Replacement Study follow-up (HERS II), JAMA, 288, 58-66, 2002	Average age at enrolment was 67 years. Had pre-existing coronary heart disease at enrolment.
Humphrey, L.L., AHRQ, Hormone replacement therapy and breast cancer, AHRQ Systematic Evidence Review No. 14, -, 2002	Systematic review
Hunt, K., Vessey, M., McPherson, K., Coleman, M., Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy, British Journal of Obstetrics and Gynaecology, 94, 620-635, 1987	Has an update which is studyid 229532
Hvidtfeldt, U.A., Lange, T., Andersen, I., Diderichsen, F., Keiding, N., Prescott, E., Sorensen, T.I., Tjonneland, A., Rod, N.H., Educational Differences in Postmenopausal Breast Cancer - Quantifying Indirect Effects through Health Behaviors, Body Mass Index and Reproductive Patterns, PLoS ONE [Electronic Resource], 8, e78690-, 2013	Population aged 50-70 years
James, R.E., Lukanova, A., Dossus, L., Becker, S., Rinaldi, S., Tjonneland, A., Olsen, A., Overvad, K., Mesrine, S., Engel, P., Clavel-Chapelon, F., Chang-Claude, J., Vrieling, A., Boeing, H., Schutze, M., Trichopoulou, A., Lagiou, P., Trichopoulos, D., Palli, D., Krogh, V., Panico, S., Tumino, R., Sacerdote, C., Rodriguez, L., Buckland, G., Sanchez, M.J., Amiano, P., Ardanaz, E., Bueno-de-Mesquita, B., Ros, M.M., van Gils, C.H., Peeters, P.H., Khaw, K.T., Wareham, N., Key, T.J., Allen, N.E., Romieu, I., Siddiq, A., Cox, D., Riboli, E., Kaaks, R., Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study, Cancer Prevention Research, 4, 1626-1635, 2011	Intervention/exposure not of relevance to review question.
Kang, J.H., Grodstein, F., Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline, Neurobiology of Aging, 33, 1129-1137, 2012	Outcome not relevant
Kaupilla, A., The use of oestrogens and progestogen and the risk of breast cancer in post-menopausal women. G.A. Colditz et al. N. Engl. J. Med. 1995; 332: 1589-93, Pharmacological Research, 32, 327-, 1995	Participants age not relevant to review.
Kerlikowske, K., Miglioretti, D.L., Ballard-Barbash, R., Weaver, D.L., Buist, D.S., Barlow, W.E., Cutter, G., Geller, B.M., Yankaskas, B., Taplin, S.H., Carney, P.A., Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population, Journal of Clinical Oncology, 21, 4314-4321, 2003	Participants aged 50-79 years
Kessenich, C.R., Oestrogen plus progestogen increased risk of breast cancer in postmenopausal women, Evidence-Based Nursing, 7, 16-, 2004	Part of the WHI trial which has already been extracted. Data was not reported for women aged < 65 years
King, J., Wynne, C.H., Assersohn, L., Jones, A., Hormone replacement therapy and women with premature menopause-a cancer survivorship issue, European Journal of Cancer, 47, 1623-1632, 2011	Review

Study	Reason for exclusion
La,Vecchia C., Menopause, hormone therapy and breast cancer risk, <i>European Journal of Cancer Prevention</i> , 12, 437-438, 2003	Review study
Laliberte,F., Dea,K., Duh,M.S., Kahler,K.H., Rolli,M., Lefebvre,P., Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy, <i>Menopause</i> , 18, 1052-1059, 2011	Outcome not relevant
Lee,S., Kolonel,L., Wilkens,L., Wan,P., Henderson,B., Pike,M., Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort, <i>International Journal of Cancer</i> , 118, 1285-1291, 2006	Population aged 45-75 years
Lee,S.A., Ross,R.K., Pike,M.C., An overview of menopausal oestrogen-progestogen hormone therapy and breast cancer risk, <i>British Journal of Cancer</i> , 92, 2049-2058, 2005	Review
Levi,F., Lucchini,F., Pasche,C., La,Vecchia C., Oral contraceptives, menopausal hormone replacement treatment and breast cancer risk, <i>European Journal of Cancer Prevention</i> , 5, 259-266, 1996	Population not relevant. Included premenopausal, perimenopausal and postmenopausal women
Li,C.I., Daling,J.R., Haugen,K.L., Tang,M.T.C., Porter,P.L., Malone,K.E., Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age, <i>Breast Cancer Research and Treatment</i> , 145, 481-489, 2014	Population aged 55-74 years
Li,C.I., Daling,J.R., Malone,K.E., Bernstein,L., Marchbanks,P.A., Liff,J.M., Strom,B.L., Simon,M.S., Press,M.F., McDonald,J.A., Ursin,G., Burkman,R.T., Deapen,D., Spirtas,R., Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer, <i>Cancer Epidemiology, Biomarkers and Prevention</i> , 15, 946-954, 2006	Outcomes were subtypes of histological cancers
Li,C.I., Malone,K.E., Porter,P.L., Lawton,T.J., Voigt,L.F., Cushing-Haugen,K.L., Lin,M.G., Yuan,X., Daling,J.R., Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas.[Erratum appears in <i>Cancer Epidemiol Biomarkers Prev.</i> 2009 Oct;18(10):2803], <i>Cancer Epidemiology, Biomarkers and Prevention</i> , 17, 43-50, 2008	Duplicate of 267567
Li,C.I., Malone,K.E., Porter,P.L., Lawton,T.J., Voigt,L.F., Cushing-Haugen,K.L., Ming,G.L., Yuan,X., Daling,J.R., Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas, <i>Cancer Epidemiology, Biomarkers and Prevention</i> , 17, 43-50, 2008	Assessed histological types of cancer
Li,C.I., Weiss,N.S., Stanford,J.L., Daling,J.R., Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women, <i>Cancer</i> , 88, 2570-2577, 2000	Included pre and perimenopausal women in analyses. Reported histologic types of breast carcinoma as outcomes
Li,R., Gilliland,F.D., Baumgartner,K., Samet,J., Hormone replacement therapy and breast carcinoma risk in Hispanic and non-Hispanic women, <i>Cancer</i> , 95, 960-968, 2002	Population aged 30-74 years
Lyytinen,H., Dyba,T., Pukkala,E., Ylikorkala,O., Do the dose or route of administration of norethisterone acetate as a part of hormone therapy play a role in risk of breast cancer: National-wide case-control study from Finland, <i>International Journal of Cancer</i> , 127, 185-189, 2010	Duplicate of 314676 which has already been extracted.
Lyytinen,H., Pukkala,E., Ylikorkala,O., Breast cancer risk in postmenopausal women using estradiol-progestogen therapy, <i>Obstetrics and Gynecology</i> , 113, 65-73, 2009	Population aged 50-85 years
Lyytinen,H., Pukkala,E., Ylikorkala,O., Breast cancer risk in postmenopausal women using estrogen-only therapy, <i>Obstetrics and Gynecology</i> , 108, 1354-1360, 2006	Outcome estimates not relevant.
Manson,J.E., Chlebowski,R.T., Stefanick,M.L., Aragaki,A.K., Rossouw,J.E., Prentice,R.L., Anderson,G., Howard,B.V., Thomson,C.A., LaCroix,A.Z., Wactawski-Wende,J., Jackson,R.D., Limacher,M., Margolis,K.L., Wassertheil-Smoller,S., Beresford,S.A., Cauley,J.A., Eaton,C.B., Gass,M., Hsia,J., Johnson,K.C., Kooperberg,C., Kuller,L.H., Lewis,C.E., Liu,S., Martin,L.W., Ockene,J.K., O'Sullivan,M.J., Powell,L.H., Simon,M.S., Van,Horn L., Vitollins,M.Z., Wallace,R.B., Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials, <i>JAMA</i> , 310, 1353-1368, 2013	Duplicate of the WHI
Manson,J.E., Rimm,E.B., Colditz,G.A., Willett,W.C., Nathan,D.M., Arky,R.A., Rosner,B., Hennekens,C.H., Speizer,F.E., Stampfer,M.J., A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus, <i>Annals of Epidemiology</i> , 2, 665-673, 1992	Outcome not relevant
McDonald,J.A., Weiss,N.S., Daling,J.R., Francis,A.M., Polissar,L., Menopausal estrogen use and the risk of breast cancer, <i>Breast Cancer Research and Treatment</i> , 7, 193-199, 1986	Age range and estimates reported not relevant to review
McPherson,K., Mant,R., Dose and duration of hormone use: understanding the effects of combined menopausal hormones on breast cancer better, 1976-2004. [20 refs], <i>Journal of Epidemiology and Community Health</i> , 59, 1078-1079, 2005	Review
McTiernan,A., Thomas,D.B., Johnson,L.K., Roseman,D., Risk factors for estrogen receptor-rich and estrogen receptor-poor breast cancers, <i>Journal of the National Cancer Institute</i> , 77, 849-854, 1986	Intervention/exposure not relevant to review question.
Munsell,M.F., Sprague,B.L., Berry,D.A., Chisholm,G., Trentham-Dietz,A., Body mass index and breast cancer risk according to postmenopausal estrogen-	Meta-analysis

Study	Reason for exclusion
progestogen use and hormone receptor status, <i>Epidemiologic Reviews</i> , 36, 114-136, 2014	
Nachtigall,L.E., Nachtigall,R.H., Nachtigall,R.D., Beckman,E.M., Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems, <i>Obstetrics and Gynecology</i> , 54, 74-79, 1979	Estimates not reported for Breast cancer. No cases of cancer reported in treated group.
Nachtigall,M.J., Smilen,S.W., Nachtigall,R.D., Nachtigall,R.H., Nachtigall,L.E., Incidence of breast cancer in a 22-year study of women receiving estrogen-progestogen replacement therapy, <i>Obstetrics and Gynecology</i> , 80, 827-830, 1992	Only post-intervention result of the RCT was reported. During the 12 years post-stopping phase, about 38% original placebo users switched to use HRT and were counted as HRT users in the analysis for the result reported.
Nanda,K., Bastian,LA, Schulz,K, Hormone replacement therapy and the risk of death from breast cancer: a systematic review (Structured abstract), <i>American Journal of Obstetrics and Gynecology</i> , 186, 325-224, 2002	Systematic review
Newcomb,P.A., Titus-Ernstoff,L., Egan,K.M., Trentham-Dietz,A., Baron,J.A., Storer,B.E., Willett,W.C., Stampfer,M.J., Postmenopausal estrogen and progestogen use in relation to breast cancer risk, <i>Cancer Epidemiology, Biomarkers and Prevention</i> , 11, 593-600, 2002	Included participants aged > 65 years
Newcomer,L.M., Newcomb,P.A., Potter,J.D., Yasui,Y., Trentham-Dietz,A., Storer,B.E., Longnecker,M.P., Baron,J.A., Daling,J.R., Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States), <i>Cancer Causes and Control</i> , 14, 225-233, 2003	Age range not relevant to review.
Nozaki,M., Koera,K., Nagata,H., Nakano,H., Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study, <i>Journal of Obstetrics and Gynaecology Research</i> , 30, 297-302, 2004	Age of population not relevant to review.
Olsson,H.L., Ingvar,C., Bladstrom,A., Hormone replacement therapy containing progestogens and given continuously increases breast carcinoma risk in Sweden, <i>Cancer</i> , 97, 1387-1392, 2003	Same cohort as 300056. Reported hazard ratios of breast cancer associated with type of HRT use
Onnis,A., Marchetti,M., Graziottin,A., Hormones and risk of breast cancer, <i>European Journal of Gynaecological Oncology</i> , 4, 13-17, 1983	Outcomes not relevant to review question.
Park,S.B., Shin,H.R., Lee,S.Y., A population-based cohort study of HRT use and breast cancer in Korea, <i>Asia-Pacific Journal of Public Health</i> , 24, 415-422, 2012	Age range not relevant to review
Pasco,J.A., Kotowicz,M.A., Henry,M.J., Sanders,K.M., Nicholson,G.C., Health outcomes associated with hormone therapy in australian women, <i>Current Drug Safety</i> , 4, 169-172, 2009	Population at start of HRT > 65 years
Persson,I., Thurfjell,E., Bergstrom,R., Holmberg,L., Hormone replacement therapy and the risk of breast cancer. Nested case- control study in a cohort of Swedish women attending mammography screening, <i>International Journal of Cancer</i> , 72, 758-761, 1997	Age range not relevant to review question
Persson,I., Thurfjell,E., Bergstrom,R., Holmberg,L., Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening, <i>International Journal of Cancer</i> , 72, 758-761, 1997	Population aged 40-74 years
Persson,I., Yuen,J., Bergkvist,L., Schairer,C., Cancer incidence and mortality in women receiving estrogen and estrogen-progestogen replacement therapy--long-term follow-up of a Swedish cohort, <i>International Journal of Cancer</i> , 67, 327-332, 1996	Duplicate publication
Persson,I., Yuen,J., Bergkvist,L., Schairer,C., Cancer incidence and mortality in women receiving estrogen and estrogen- progestogen replacement therapy - Long-term follow-up of a Swedish cohort, <i>International Journal of Cancer</i> , 67, 327-332, 1996	Reported standardised risk estimates
Petitti,D.B., Crooks,V.C., Chiu,V., Buckwalter,J.G., Chui,H.C., Incidence of dementia in long-term hormone users, <i>American Journal of Epidemiology</i> , 167, 692-700, 2008	Outcome not relevant
Pike,M.C., Kolonel,L.N., Henderson,B.E., Wilkens,L.R., Hankin,J.H., Feigelson,H.S., Wan,P.C., Stram,D.O., Nomura,A.M., Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites, <i>Cancer Epidemiology, Biomarkers and Prevention</i> , 11, 795-800, 2002	95% confidence intervals not reported.
Pike,M.C., Ross,R.K., Progestogens and menopause: epidemiological studies of risks of endometrial and breast cancer, <i>Steroids</i> , 65, 659-664, 2000	Estimates not reported for relevant outcomes.
Porch,J.V., Lee,I.M., Cook,N.R., Rexrode,K.M., Burin,J.E., Estrogen-progestogen replacement therapy and breast cancer risk: the Women's Health Study (United States), <i>Cancer Causes and Control</i> , 13, 847-854, 2002	Participants were part of the WHI observational cohort which included women aged > 65 years.
Prentice,R.L., Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke, <i>Seminars in Reproductive Medicine</i> , 32, 419-425, 2014	Review and discussion paper of WHI. Overall results for women of all ages were re-visited and discussed.
Prentice,R.L., Manson,J.E., Langer,R.D., Anderson,G.L., Pettinger,M., Jackson,R.D., Johnson,K.C., Kuller,L.H., Lane,D.S., Wactawski-Wende,J., Brzyski,R., Allison,M., Ockene,J., Sarto,G., Rossouw,J.E., Benefits and risks of	Age range not relevant

Study	Reason for exclusion
postmenopausal hormone therapy when it is initiated soon after menopause, American Journal of Epidemiology, 170, 12-23, 2009	
Pukkala,E., Tulenheimo-Silfvast,A., Leminen,A., Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997, Cancer Causes and Control, 12, 111-115, 2001	Outcome estimates not relevant. Age ranges not relevant.
Rebbeck,T.R., Friebel,T., Wagner,T., Lynch,H.T., Garber,J.E., Daly,M.B., Isaacs,C., Olopade,O.I., Neuhausen,S.L., van,t,V, Eeles,R., Evans,D.G., Tomlinson,G., Matloff,E., Narod,S.A., Eisen,A., Domchek,S., Armstrong,K., Weber,B.L., PROSE Study Group., Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group, Journal of Clinical Oncology, 23, 7804-7810, 2005	Non relevant exposure. Evaluated the effect of bilateral prophylactic oophorectomy on breast cancer risk.
Rebbeck,T.R., Troxel,A.B., Shatalova,E.G., Blanchard,R., Norman,S., Bunin,G., DeMichele,A., Schinnar,R., Berlin,J.A., Strom,B.L., Lack of effect modification between estrogen metabolism genotypes and combined hormone replacement therapy in postmenopausal breast cancer risk, Cancer Epidemiology Biomarkers and Prevention, 16, 1318-1320, 2007	Evaluated interaction between estrogen metabolism genotypes, HRT and breast cancer risk
Reeves,G.K., Beral,V., Green,J., Gathani,T., Bull,D., Million Women,Study Collaborators, Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis, Lancet Oncology, 7, 910-918, 2006	Further analyses of the million women study with histological types of breast cancer reported.
Reinier,K.S., Vacek,P.M., Geller,B.M., Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women, Breast Cancer Research and Treatment, 103, 343-348, 2007	Intervention/exposure not relevant to review.
Rice,M.M., Graves,A.B., McCurry,S.M., Gibbons,L.E., Bowen,J.D., McCormick,W.C., Larson,E.B., Postmenopausal estrogen and estrogen-progestogen use and 2-year rate of cognitive change in a cohort of older Japanese American women: The Kame Project, Archives of Internal Medicine, 160, 1641-1649, 2000	Outcome not related to review question
Ritte,R., Lukanova,A., Berrino,F., Dossus,L., Tjonneland,A., Olsen,A., Overvad,T.F., Overvad,K., Clavel-Chapelon,F., Fournier,A., Fagherazzi,G., Rohrmann,S., Teucher,B., Boeing,H., Aleksandrova,K., Trichopoulou,A., Lagiou,P., Trichopoulos,D., Palli,D., Sieri,S., Panico,S., Tumino,R., Vineis,P., Quiros,J.R., Buckland,G., Sanchez,M.J., Amiano,P., Chirlaque,M.D., Ardanaz,E., Sund,M., Lenner,P., Bueno-de-Mesquita,B., van Gils,C.H., Peeters,P.H., Krum-Hansen,S., Gram,I.T., Lund,E., Khaw,K.T., Wareham,N., Allen,N.E., Key,T.J., Romieu,I., Rinaldi,S., Siddiq,A., Cox,D., Riboli,E., Kaaks,R., Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study, Breast Cancer Research, 14, R76-, 2012	Evaluated HRT use and breast cancer risk by age and hormone receptor status
Rod,N.H., Hansen,A.M., Nielsen,J., Schnohr,P., Gronbaek,M., Low-risk factor profile, estrogen levels, and breast cancer risk among postmenopausal women, International Journal of Cancer, 124, 1935-1940, 2009	Exposure not relevant to review question.
Rohan,T.E., Negassa,A., Chlebowski,R.T., Habel,L., McTiernan,A., Ginsberg,M., Wassertheil-Smoller,S., Page,D.L., Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial.[Erratum appears in J Natl Cancer Inst. 2008 May 21;100(10):754], Journal of the National Cancer Institute, 100, 563-571, 2008	WHI trial. Outcome was benign proliferative breast disease.
Rosenberg,L., Palmer,J.R., Wise,L.A., dams-Campbell,L.L., A prospective study of female hormone use and breast cancer among black women, Archives of Internal Medicine, 166, 760-765, 2006	Population and intervention not relevant to review question.
Rosenberg,L.U., Einarsdottir,K., Friman,E.I., Wedren,S., Dickman,P.W., Hall,P., Magnusson,C., Risk factors for hormone receptor-defined breast cancer in postmenopausal women, Cancer Epidemiology, Biomarkers and Prevention, 15, 2482-2488, 2006	Evaluated estrogen receptor-defined breast cancers
Rosenberg,L.U., Granath,F., Dickman,P.W., Einarsdottir,K., Wedren,S., Persson,I., Hall,P., Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study, Breast Cancer Research, 10, R78-, 2008	Evaluated effects of HRT on tumour characteristics and breast-cancer specific survival
Rosenberg,L.U., Magnusson,C., Lindstrom,E., Wedren,S., Hall,P., Dickman,P.W., Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study, Breast Cancer Research, 8, R11-, 2006	Assessed histological subtypes of cancer
Ross,R.K., Paganini-Hill,A., Gerkins,V.R., Mack,T.M., Pfeiffer,R., Arthur,M., Henderson,B.E., A case-control study of menopausal estrogen therapy and breast cancer, JAMA, 243, 1635-1639, 1980	Did not report estimates for risk of breast cancer. Age range not relevant to review question.
Ross,R.K., Paganini-Hill,A., Wan,P.C., Pike,M.C., Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestogen, Journal of the National Cancer Institute, 92, 328-332, 2000	Age group not relevant. Confidence intervals not reported for risk estimates
Rossouw,J.E., Anderson,G.L., Prentice,R.L., Lacroix,A.Z., Kooperberg,C., Stefanick,M.L., Jackson,R.D., Beresford,S.A., Howard,B.V., Johnson,K.C., Kotchen,J.M., Ockene,J., Writing Group for the Women's Health Initiative Investigators., Risks and benefits of estrogen plus progestogen in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial, JAMA, 288, 321-333, 2002	Publication of WHI trial. Relevant results already extracted in another publication.
Rossouw,J.E., Anderson,G.L., Prentice,R.L., Lacroix,A.Z., Kooperberg,C., Stefanick,M.L., Jackson,R.D., Beresford,S.A.A., Howard,B.V., Johnson,K.C.,	WHI study. Population aged 50-79 years.



Study	Reason for exclusion
Kotchen,J.M., Ockene,J., Risks and benefits of estrogen plus progestogen in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial, Journal of the American Medical Association, 288, 321-333, 2002	
Ryan,J., Carriere,I., Scali,J., Ritchie,K., Ancelin,M.L., Life-time estrogen exposure and cognitive functioning in later life, Psychoneuroendocrinology, 34, 287-298, 2009	Outcome not relevant
Saeki,T., Sano,M., Komoike,Y., Sonoo,H., Honjyo,H., Ochiai,K., Kobayashi,T., Aogi,K., Sato,N., Sawai,S., Miyoshi,Y., Takeuchi,M., Takashima,S., No increase of breast cancer incidence in Japanese women who received hormone replacement therapy: overview of a case-control study of breast cancer risk in Japan.[Erratum appears in Int J Clin Oncol. 2008 Jun;13(3):279 Note: Miyoshi, Yoshio [corrected to Miyoshi, Yasuo]], International Journal of Clinical Oncology, 13, 8-11, 2008	This is a review article
Saether,S., Bakken,K., Lund,E., The risk of breast cancer linked to menopausal hormone therapy, Tidsskrift for Den Norske Laegeforening, 132, 1330-1334, 2012	In Norwegian
Sartwell,P.E., Arthes,F.G., Tonascia,J.A., Exogenous hormones, reproductive history, and breast cancer, Journal of the National Cancer Institute, 59, 1589-1592, 1977	Population aged 20-74 years
Schairer,C., Byrne,C., Keyl,P.M., Brinton,L.A., Sturgeon,S.R., Hoover,R.N., Menopausal estrogen and estrogen-progestogen replacement therapy and risk of breast cancer (United States), Cancer Causes and Control, 5, 491-500, 1994	Same cohort as 268450 which has more comprehensive information.
Schairer,C., Lubin,J., Troisi,R., Sturgeon,S., Brinton,L., Hoover,R., Menopausal estrogen and estrogen-progestogen replacement therapy and breast cancer risk, Journal of the American Medical Association, 283, 485-491, 2000	Study cohort part of study id 315166 cohort
Schonfeld,S.J., Pfeiffer,R.M., Lacey,J.V., Jr., Berrington de,Gonzalez A., Doody,M.M., Greenlee,R.T., Park,Y., Schairer,C., Schatzkin,A., Sigurdson,A.J., Hartge,P., Visvanathan,K., Hormone-related risk factors and postmenopausal breast cancer among nulliparous versus parous women: An aggregated study, American Journal of Epidemiology, 173, 509-517, 2011	Exposure not relevant. Evaluated joint effects of parity and HRT on breast cancer risk.
Sellers,T.A., Mink,P.J., Cerhan,J.R., Zheng,W., Anderson,K.E., Kushi,L.H., Folsom,A.R., The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer, Annals of Internal Medicine, 127, 973-980, 1997	Population aged 55-69 years
Seradour,B., Esteve,J., Heid,P., Jacquemier,J., Hormone replacement therapy and screening mammography: Analysis of the results in the Bouches du Rhone programme, Journal of Medical Screening, 6, 99-102, 1999	Aim was to determine the effectiveness of a screening programme for breast cancer where use of HRT is common
Sezer,H., Yilmaz,M., Gurler,H., Koyuncu,A., Breast cancer risk factors in Turkey: a hospital-based case-control study, Asian Pacific Journal of Cancer Prevention: Apjcp, 12, 2317-2322, 2011	Estimates not reported for the risk of breast cancer associated with use of HRT.
Shah,N.R., Borenstein,J., Dubois,R.W., Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. [43 refs], Menopause, 12, 668-678, 2005	Systematic review and meta-analysis
Shao,H., Breitner,J.C., Whitmer,R.A., Wang,J., Hayden,K., Wengreen,H., Corcoran,C., Tschanz,J., Norton,M., Munger,R., Welsh-Bohmer,K., Zandi,P.P., Cache,County,I., Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study, Neurology, 79, 1846-1852, 2012	Outcome not relevant
Shapiro,S., Risks of estrogen plus progestogen therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial, Climacteric, 6, 302-310, 2003	Sensitivity analysis of the findings for breast cancer in the WHI
Shumaker,S.A., Legault,C., Kuller,L., Rapp,S.R., Thal,L., Lane,D.S., Fillit,H., Stefanick,M.L., Hendrix,S.L., Lewis,C.E., Masaki,K., Coker,L.H., Women's Health Initiative Memory Study., Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study, JAMA, 291, 2947-2958, 2004	Outcome not relevant
Shumaker,S.A., Legault,C., Rapp,S.R., Thal,L., Wallace,R.B., Ockene,J.K., Hendrix,S.L., Jones,B.N.,III, Assaf,A.R., Jackson,R.D., Kotchen,J.M., Wassertheil-Smoller,S., Wactawski-Wende,J., WHIMS,investigators, Estrogen plus progestogen and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial, JAMA, 289, 2651-2662, 2003	Outcome not relevant
Sillero-Arenas,M., gado-Rodriguez,M., Rodigues-Canteras,R., Bueno-Cavanillas,A., Galvez-Vargas,R., Menopausal hormone replacement therapy and breast cancer: a meta-analysis, Obstetrics and Gynecology, 79, 286-294, 1992	Systematic review
Steinberg,K.K., Thacker,S.B., Smith,S.J., Stroup,D.F., Zack,M.M., Flanders,W.D., Berkelman,R.L., A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer, Journal of the American Medical Association, 265, 1985-1990, 1991	Review
Tavani,A., Braga,C., La,Vecchia C., Negri,E., Franceschi,S., Hormone replacement treatment and breast cancer risk: an age-specific analysis, Cancer Epidemiology, Biomarkers and Prevention, 6, 11-14, 1997	Population not relevant to review question. Population consisted of pre, peri, and postmenopausal women.
Thacker,H.L., Estrogen plus progestogen increased risk for breast cancer in postmenopausal women, ACP Journal Club, 139, 61-Dec, 2003	Commentary

Study	Reason for exclusion
Thomas,D.B., Persing,J.P., Hutchinson,W.B., Exogenous estrogens and other risk factors for breast cancer in women with benign breast diseases, Journal of the National Cancer Institute, 69, 1017-1025, 1982	Population not relevant to review question. Consisted of pre, peri, and postmenopausal women.
Thomas,H.V., Key,T.J., Allen,D.S., Moore,J.W., Dowsett,M., Fentiman,I.S., Wang,D.Y., A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey, British Journal of Cancer, 75, 1075-1079, 1997	Exposure was serum concentrations of oestradiol.
Toti,A., Agugiaro,S., Amadori,D., Buzzi,G., Bruzzi,P., Buiatti,E., Capelli,M.C., Ciatto,S., Delfino,E., Foti,E., Breast cancer risk factors in Italian women: a multicentric case-control study, Tumori, 72, 241-249, 1986	Population not relevant. Included women of all ages.
Vakil,D.V., Morgan,R.W., Halliday,M., Exogenous estrogens and development of breast and endometrial cancer, Cancer Detection and Prevention, 6, 415-424, 1983	Estimates were only reported for the reference populations.
Vassilopoulou-Sellin,R., Breast cancer and hormonal replacement therapy. [70 refs], Annals of the New York Academy of Sciences, 997, 341-350, 2003	Review paper.
Vassilopoulou-Sellin,R., Estrogen plus progestogen and breast cancer incidence and mortality in postmenopausal women, Breast Diseases, 22, 29-30, 2011	Secondary publication of WHI
Vickers,M.R., Martin,J., Meade,T.W., Arasaratnam,N., Collins,N., Furness,P., Ghali,M., Gordon,E., Huppert,F., Islam,Z., Knott,C., Meredith,S., Prince,M., Purdon,S., Richards,M., Taylor,L., Welton,A., Zhu,C.Q., Zuhrie,R., Dowell,A., Lawton,B., MacLennan,A., The Women's International Study of Long-duration Oestrogen after Menopause (WISDOM): A randomised controlled trial, BMC Women's Health, 7, 2007. Article Number, -, 2007	Duplicate of 230610
Waller,M., Moss,S., Watson,J., Moller,H., The effect of mammographic screening and hormone replacement therapy use on breast cancer incidence in England and Wales, Cancer Epidemiology, Biomarkers and Prevention, 16, 2257-2261, 2007	Used HRT prevalence to determine RRs.
Whitmer,R.A., Quesenberry,Jr, Zhou,J., Yaffe,K., Timing of hormone therapy and dementia: The critical window theory revisited, Annals of Neurology, 69, 163-169, 2011	Outcome not relevant
Wrensch,M., Chew,T., Farren,G., Barlow,J., Belli,F., Clarke,C., Erdmann,C.A., Lee,M., Moghadassi,M., Peskin-Mentzer,R., Quesenberry,Jr, Souders-Mason,V., Spence,L., Suzuki,M., Gould,M., Risk factors for breast cancer in a population with high incidence rates, Breast cancer research : BCR, 5, R88-102, 2003	Population not relevant to review question.
Wurtz,A.M., Tjonneland,A., Christensen,J., Dragsted,L.O., Aarestrup,J., Kyro,C., Overvad,K., Olsen,A., Serum estrogen and SHBG levels and breast cancer incidence among users and never users of hormone replacement therapy, Cancer Causes and Control, 23, 1711-1720, 2012	Exposure was serum levels of hormones
Yang,C.P., Daling,J.R., Band,P.R., Gallagher,R.P., White,E., Weiss,N.S., Noncontraceptive hormone use and risk of breast cancer, Cancer Causes and Control, 3, 475-479, 1992	Age range at HRT initiation not relevant to review
Yuen,J., Persson,I., Bergkvist,L., Hoover,R., Schairer,C., Adami,H.O., Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for 'healthy drug-user' effect, Cancer Causes and Control, 4, 369-374, 1993	Used oestrogen users as reference.
Zandi,P.P., Carlson,M.C., Plassman,B.L., Welsh-Bohmer,K.A., Mayer,L.S., Steffens,D.C., Breitner,J.C., Cache County Memory Study Investigators., Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study, JAMA, 288, 2123-2129, 2002	Outcome not relevant
Zhang,Y., Howard,B.V., Cowan,L.D., Yeh,J., Schaefer,C.F., Wild,R.A., Wang,W., Lee,E.T., The effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in american Indian postmenopausal women : the strong heart study, Diabetes Care, 25, 500-504, 2002	Outcome not relevant

## G.7.6 Osteoporosis

Study	Reason for exclusion
Estrogens given after the menopause protect against fractures, Nutrition Reviews, 38, 80-, 1980	Commentary on another study (Hutchinson 1979). No primary data.
No long-term benefit shown for bones after HRT, Journal of Family Practice, 53, 444-447, 2004	Brief summary of clinical trial results (evidence from NORA study).
Conjugated estrogens/bazedoxifene (Duavee) for menopausal symptoms and prevention of osteoporosis, Medical Letter on Drugs and Therapeutics, 56, 33-34, 2014	Outcomes did not match protocol
Abraham,L., Pinkerton,J.V., Messig,M., Ryan,K.A., Komm,B.S., Mirkin,S., Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene, Maturitas, 78, 212-218, 2014	Outcomes did not match protocol
Alabut,A.V., Salum,N.Y., Sikilinda,V.D., Algorithms of osteoporosis diagnostics, prevention and management in knee replacement, Sovremennyye Tehnologii v Medicine, 5, 64-68, 2013	Study design did not match protocol
Albrand,G., Munoz,F., Sornay-Rendu,E., Duboeuf,F., Delmas,P.D., Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study, Bone, 32, 78-85, 2003	Cohort study. Does not present adjusted odds ratio for fracture and HRT use. Only states that HRT was not an independent predictor after adjustment for all variables.

Study	Reason for exclusion
Alexandersen,P., Riis,B.J., Christiansen,C., Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study, <i>Journal of Clinical Endocrinology and Metabolism</i> , 84, 3013-3020, 1999	Study participants aged 60 to 70 years, with a mean age of 65.2 years.
Anderson,G.L., Limacher,M., Assaf,A.R., Thacker,H.L., Oestrogen therapy increased stroke risk and decreased hip fracture risk but did not affect coronary heart disease risk in postmenopausal women with prior hysterectomy, <i>Evidence-Based Medicine</i> , 9, 184-, 2004	Commentary on another clinical trial (WHI), no primary data.
Armstrong,A.L., Coupland,C.A.C., Pye,D.W., Wallace,W.A., A study of the effects of hormone replacement therapy (HRT) on bone density, strength and balance in post-menopausal women [Abstract], <i>Journal of Bone and Joint Surgery - British Volume</i> , Vol.76 Suppl 1, pp.42, 1994., -, -32676	Conference abstract only.
Bea,J.W., Zhao,Q., Cauley,J.A., LaCroix,A.Z., Bassford,T., Lewis,C.E., Jackson,R.D., Tylavsky,F.A., Chen,Z., Effect of hormone therapy on lean body mass, falls, and fractures: 6-year results from the Women's Health Initiative hormone trials, <i>Menopause</i> , 18, 44-52, 2011	No additional fracture data beyond other WHI publications.
Beckmann,M.W., Jap,D., Djahansouzi,S., Nestle-Kramling,C., Kuschel,B., Dall,P., Brumm,C., Bender,H.G., Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates, <i>Oncology</i> , 60, 199-206, 2001	Outcomes did not match protocol
Castelo-Branco,C., Davila,J., Perello,M.F., Peguero,A., Ros,C., Martinez-Serrano,M.J., Balasch,J., Long-term effect of hormone therapy on bone in early menopause: Vertebral fractures after 20 years, <i>Climacteric</i> , 17, 336-341, 2014	Unclear reporting of number of patients with fractures
Cauley,J.A., Black,D.M., Barrett-Connor,E., Harris,F., Shields,K., Applegate,W., Cummings,S.R., Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestogen Replacement Study (HERS), <i>American Journal of Medicine</i> , 110, 442-450, 2001	Mean age of participants 67 years.
Cauley,J.A., Seeley,D.G., Browner,W.S., Ensrud,K., Kuller,L.H., Lipschutz,R.C., Hulley,S.B., Estrogen replacement therapy and mortality among older women. The study of osteoporotic fractures, <i>Archives of Internal Medicine</i> , 157, 2181-2187, 1997	Outcome of all-cause mortality only - no fracture data or fracture-specific mortality data.
Cauley,J.A., Seeley,D.G., Ensrud,K., Ettinger,B., Black,D., Cummings,S.R., Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group, <i>Annals of Internal Medicine</i> , 122, 9-16, 1995	All women aged over 65 years.
Centre for Reviews and Dissemination., The effectiveness of bone density measurement and associated treatments for prevention of fractures: an international collaborative review (Structured abstract), <i>Database of Abstracts of Reviews of Effects</i> , -, 2014	Abstract and commentary for 1998 study
Centre for Reviews and Dissemination., A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis (Provisional abstract), <i>Database of Abstracts of Reviews of Effects</i> , -, 2014	This is an executive summary and did not contain results of systematic review
Centre for Reviews and Dissemination., Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials (Structured abstract), <i>Database of Abstracts of Reviews of Effects</i> , -, 2014	Abstract and commentary for 2001 paper
Centre for Reviews and Dissemination., Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials (Structured abstract), <i>Database of Abstracts of Reviews of Effects</i> , -, 2014	Abstract and commentary for 1999 paper
Centre for Reviews and Dissemination., Limited evidence for a protective effect of unopposed oestrogen therapy for osteoarthritis of the hip: a systematic review (Structured abstract), <i>Database of Abstracts of Reviews of Effects</i> , -, 2014	Abstract and commentary of 2009 paper
Centre for Reviews and Dissemination., Meta-analyses of therapies for postmenopausal osteoporosis - V: meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women (Provisional abstract), <i>Database of Abstracts of Reviews of Effects</i> , -, 2014	Abstract and commentary for 2002 paper, checked systematic review for individual studies
Centre for Reviews and Dissemination., Raloxifene for primary and secondary prevention of osteoporotic fractures in postmenopausal women: a systematic review of efficacy and safety evidence (Provisional abstract), <i>Database of Abstracts of Reviews of Effects</i> , -, 2014	Intervention/comparator did not match protocol
Centre for Reviews and Dissemination., The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women (Structured abstract), <i>Database of Abstracts of Reviews of Effects</i> , -, 2014	Interventions/comparator did not match protocol
Cheng,S., Sipila,S., Puolakka,H., Suominen,H., Effects of hormone replacement therapy and high impact physical exercise on bone/muscle ratio in postmenopausal women, <i>Osteoporosis International</i> , 11, 175-, 2000	Conference abstract only.
Cheng,S., Sipila,S., Taaffe,D.R., Puolakka,J., Suominen,H., Change in bone mass distribution induced by hormone replacement therapy and high-impact physical exercise in post-menopausal women, <i>Bone</i> , 31, 126-135, 2002	No overall assessment of BMD related to HRT, only considers change in bone mass distribution.
Cummings,S.R., Ettinger,B., Delmas,P.D., Kenemans,P., Stathopoulos,V., Verweij,P., Mol-Arts,M., Kloosterboer,L., Mosca,L., Christiansen,C., Bilezikian,J., Kerzberg,E.M., Johnson,S., Zanchetta,J., Grobbee,D.E., Seifert,W., Eastell,R.,	Mean age of participants 68.3 years.

Study	Reason for exclusion
LIFT, Trial, I, The effects of tibolone in older postmenopausal women, <i>New England Journal of Medicine</i> , 359, 697-708, 2008	
de Klerk B M, Schiphof D, Groeneveld F P, Koes B W, van Osch G J, van Meurs J B, Biermaâ€• Zeinstra S M, Limited evidence for a protective effect of unopposed oestrogen therapy for osteoarthritis of the hip: a systematic review, <i>Rheumatology</i> , 48, 104-112, 2009	Population did not match protocol
Doren, M., Nilsson, J.A., Johnell, O., Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis, <i>Human Reproduction</i> , 18, 1737-1746, 2003	Study did not report any data on fractures
Drakeley, A.J., Quenby, S., Longitudinal assessment of bone density with hormone replacement therapy, <i>British Journal of Hospital Medicine</i> , 57, 210-211, 1997	Clinical opinion article, no primary data.
Eichner S F, Lloyd K B, Timpe E M., Comparing therapies for postmenopausal osteoporosis prevention and treatment, <i>Pharmacotherapy</i> , 37, 711-724, 2003	Studies included in the systematic review were checked, included in review
Eiken, P., Nielsen, S.P., Kolthoff, N., Effects on bone mass after eight years of hormonal replacement therapy, <i>British Journal of Obstetrics and Gynaecology</i> , 104, 702-707, 1997	Study presents observational follow up for 6 years of women initially recruited to a 2 year RCT, therefore treated as cohort study. However, absolute fracture rates reported only, no adjustment for potential confounders.
Ettinger, B., Genant, H.K., Cann, C.E., Long-term estrogen replacement therapy prevents bone loss and fractures, <i>Annals of Internal Medicine</i> , 102, 319-324, 1985	Retrospective cohort study. Data presented are not adjusted for potential confounders.
Forsmo, S., Hvam, H.M., Rea, M.L., Lilleeng, S.E., Schei, B., Langhammer, A., Height loss, forearm bone density and bone loss in menopausal women: a 15-year prospective study. The Nord-Trondelag Health Study, Norway, <i>Osteoporosis International</i> , 18, 1261-1269, 2007	No assessment of HRT use.
Gallagher, J.C., Fowler, S.E., Detter, J.R., Sherman, S.S., Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss, <i>Journal of Clinical Endocrinology and Metabolism</i> , 86, 3618-3628, 2001	Study includes only women aged > 65.
Gallagher, J.C., Lindsay, R., Pan, K., Ryan, K.A., Mirkin, S., Chines, A.A., Bazedoxifene/conjugated estrogens: Effects on bone mineral density and bone turnover markers in a double-blind, randomized, placebo-and active-controlled phase 3 study, <i>Osteoporosis International</i> , 23, S63-S64, 2012	Conference abstract only.
Garnero, P., Tsouderos, Y., Marton, I., Pelissier, C., Varin, C., Delmas, P.D., Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women, <i>Journal of Clinical Endocrinology and Metabolism</i> , 84, 2390-2397, 1999	Intranasal estradiol - intervention not appropriate.
Greenspan, S.L., Resnick, N.M., Parker, R.A., Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial, <i>JAMA</i> , 289, 2525-2533, 2003	All women aged over 65 years.
Greenspan, S.L., Resnick, N.M., Parker, R.A., The effect of hormone replacement on physical performance in community-dwelling elderly women, <i>American Journal of Medicine</i> , 118, 1232-1239, 2005	Study includes only women aged > 65 years.
Grob, K.W., Stevermer, J.J., Does estrogen/progestogen therapy in postmenopausal women decrease their risk of fracture?, <i>Journal of Family Practice</i> , 50, 926-, 2001	Commentary and summary of HERS study. No primary data.
Grodstein, F., Stampfer, M.J., Falkeborn, M., Naessen, T., Persson, I., Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women, <i>Epidemiology</i> , 10, 476-480, 1999	Compares moderate dose to low dose oestrogens only, not to no use of HRT.
Hailey D, Sampietroâ€• Colom L, Marshall D, Rico R, Granados A, Asua J., The effectiveness of bone density measurement and associated treatments for prevention of fractures: an international collaborative review, <i>International Journal of Technology Assessment in Health Care</i> , 14, 237-254, 2014	Population did not match protocol
Herrington, D.M., Reboussin, D.M., Brosnihan, K.B., Sharp, P.C., Shumaker, S.A., Snyder, T.E., Furberg, C.D., Kowalchuk, G.J., Stuckey, T.D., Rogers, W.J., Givens, D.H., Waters, D., Effects of estrogen replacement on the progression of coronary-artery atherosclerosis, <i>New England Journal of Medicine</i> , 343, 522-529, 2000	Although study included women aged over 55 years, mean age of participants was 65.8 years.
Hulley, S., Furberg, C., Barrett-Connor, E., Cauley, J., Grady, D., Haskell, W., Knopp, R., Lowery, M., Satterfield, S., Schrott, H., Vittinghoff, E., Hunninghake, D., HERS Research Group., Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestogen Replacement Study follow-up (HERS II), <i>JAMA</i> , 288, 58-66, 2002	Participants in the study were aged 67 and over
Hutchinson, T.A., Polansky, S.M., Feinstein, A.R., Post-menopausal oestrogens protect against fractures of hip and distal radius. A case-control study, <i>Lancet</i> , 2, 705-709, 1979	Unable to separate data for hip or wrist fractures - only presented together.
Ishida, Y., Kawai, S., Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study, <i>American Journal of Medicine</i> , 117, 549-555, 2004	Although inclusion criteria states age 50 to 75, mean age of participants was 69 years.
Jensen, G.F., Christiansen, C., Transbol, I., Fracture frequency and bone preservation in postmenopausal women treated with estrogen, <i>Obstetrics and Gynecology</i> , 60, 493-496, 1982	Cohort study. Present absolute number of fractures in each group

Study	Reason for exclusion
	only, therefore unable to calculate appropriately adjusted relative risk.
Jensen,J., Christiansen,C., Rodbro,P., Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause, <i>New England Journal of Medicine</i> , 313, 973-975, 1985	Considers bone loss in relation to cigarette smoking only, not HRT use.
Karim,R., Dell,R.M., Greene,D.F., Mack,W.J., Gallagher,J.C., Hodis,H.N., Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization, <i>Menopause</i> , 18, 1172-1177, 2011	No comparison of no use of HRT with use, only considers discontinuing treatment with continuing treatment.
Kearns,A.E., Miyabara,Y., Miller,V.M., Effects of menopausal hormone therapy on bone mineral density and coronary artery calcification in early menopause, <i>Menopause</i> , 19, 1390-, 2012	Conference abstract only.
Kiel,D.P., Felson,D.T., Anderson,J.J., Wilson,P.W., Moskowitz,M.A., Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study, <i>New England Journal of Medicine</i> , 317, 1169-1174, 1987	Retrospective study
Komulainen,M., Tuppurainen,M.T., Kroger,H., Heikkinen,A.M., Puntila,E., Alhava,E., Honkanen,R., Saarikoski,S., Vitamin D and HRT: no benefit additional to that of HRT alone in prevention of bone loss in early postmenopausal women. A 2.5-year randomized placebo-controlled study, <i>Osteoporosis International</i> , 7, 126-132, 1997	No fracture data.
LaCroix,A.Z., Estrogen with and without progestogen: benefits and risks of short-term use. [17 refs], <i>American Journal of Medicine</i> , 118 Suppl 12B, 79-87, 2005	Narrative review.
Laster,A.J., Tanner,S.B., Duration of treatment in postmenopausal osteoporosis: how long to treat and what are the consequences of cessation of treatment?, <i>Rheumatic Diseases Clinics of North America</i> , 37, 323-336, 2011	Narrative review article.
Liao,E.Y., Luo,X.H., Deng,X.G., Wu,X.P., Liao,H.J., Wang,P.F., Mao,J.P., Zhu,X.P., Huang,G., Wei,Q.Y., The effect of low dose nylestriol-levonorgestrel replacement therapy on bone mineral density in women with postmenopausal osteoporosis, <i>Endocrine Research</i> , 29, 217-226, 2003	All participants with known osteoporosis.
Lindsay,R., Hart,D.M., Forrest,C., Baird,C., Prevention of spinal osteoporosis in oophorectomised women, <i>Lancet</i> , 2, 1151-1154, 1980	No report of randomisation during study, therefore cannot be certain that relative risk appropriately accounts for potential confounders.
Lindsay,R., Hart,D.M., Kraszewski,A., Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis, <i>British Medical Journal</i> , 280, 1207-1209, 1980	Case series of women treated with tibolone only, no comparator.
Lindsay,R., Tohme,J.F., Estrogen treatment of patients with established postmenopausal osteoporosis, <i>Obstetrics and Gynecology</i> , 76, 290-295, 1990	No fracture data in article. Although data were obtained in a meta-analysis (Torgerson and Bell-Syer 2001) they do not equate to the numbers of participants in the trial, therefore excluded due to uncertainty regarding data.
Liu,S.L., Lebrun,C.M., Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review. [104 refs], <i>British Journal of Sports Medicine</i> , 40, 11-24, 2006	Considers OCP only, not HRT.
Meema,S., Bunker,M.L., Meema,H.E., Preventive effect of estrogen on postmenopausal bone loss, <i>Archives of Internal Medicine</i> , 135, 1436-1440, 1975	No adjustment for potential confounders.
Melton,I.I.I.L., Khosla,S., Malkasian,G.D., Achenbach,S.J., Oberg,A.L., Riggs,B.L., Fracture Risk After Bilateral Oophorectomy in Elderly Women, <i>Journal of Bone and Mineral Research</i> , 18, 900-905, 2003	No assessment according to HRT use.
Meunier P J., Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials, <i>International Journal of Clinical Practice</i> , 53, 122-129, 1999	Systematic review included studies that are already included in the review. Individual studies checked.
Meyer,H.E., Lofthus,C.M., Sogaard,A.J., Falch,J.A., Change in the use of hormone replacement therapy and the incidence of fracture in Oslo, <i>Osteoporosis International</i> , 20, 827-830, 2009	Estimate fracture risk only, no primary data.
Michaelsson,K., Baron,J.A., Johnell,O., Persson,I., Ljunghall,S., Variation in the efficacy of hormone replacement therapy in the prevention of hip fracture. Swedish Hip Fracture Study Group, <i>Osteoporosis International</i> , 8, 540-546, 1998	Data only presented stratified by weight, height and BMI, no overall results.
Mulnard,R.A., Cotman,C.W., Kawas,C., van Dyck,C.H., Sano,M., Doody,R., Koss,E., Pfeiffer,E., Jin,S., Gamst,A., Grundman,M., Thomas,R., Thal,L.J., Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. <i>Alzheimer's Disease Cooperative Study</i> . [Erratum appears in <i>JAMA</i> 2000 Nov 22-29;284(20):2597], <i>JAMA</i> , 283, 1007-1015, 2000	Participants all aged > 60 years, with a mean age of 74 years.
Nachtigall,L.E., Nachtigall,R.H., Nachtigall,R.D., Beckman,E.M., Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis, <i>Obstetrics and Gynecology</i> , 53, 277-281, 1979	No description of any randomisation process, therefore cannot be certain that results appropriately account for differences between the two groups of women.
Naessen,T., Persson,I., Adami,H.O., Bergstrom,R., Bergkvist,L., Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study, <i>Annals of Internal Medicine</i> , 113, 95-103, 1990	No adjustment for potential confounders.

Study	Reason for exclusion
Nelson,H.D., Rizzo,J., Harris,E., Cauley,J., Ensrud,K., Bauer,D.C., Orwoll,E., Study of Osteoporotic Fractures Research Group., Osteoporosis and fractures in postmenopausal women using estrogen, Archives of Internal Medicine, 162, 2278-2284, 2002	All participants aged 65 years or older at the start of the study.
Nevitt,M.C., Cummings,S.R., Stone,K.L., Palermo,L., Black,D.M., Bauer,D.C., Genant,H.K., Hochberg,M.C., Ensrud,K.E., Hillier,T.A., Cauley,J.A., Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures, Journal of Bone and Mineral Research, 20, 131-140, 2005	Study only included women aged 65 years or older, and only considers current use of oestrogen.
Nguyen,T.V., Jones,G., Sambrook,P.N., White,C.P., Kelly,P.J., Eisman,J.A., Effects of estrogen exposure and reproductive factors on bone mineral density and osteoporotic fractures, Journal of Clinical Endocrinology and Metabolism, 80, 2709-2714, 1995	Cohort study, but absolute numbers of fractures given only, no adjustment for confounders.
Orr-Walker,B.J., Evans,M.C., Clearwater,J.M., Horne,A., Grey,A.B., Reid,I.R., Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women, Archives of Internal Medicine, 160, 2161-2166, 2000	Mean age of participants > 65 years.
Paganini-Hill,A., Ross,R.K., Gerkins,V.R., Henderson,B.E., Arthur,M., Mack,T.M., Menopausal estrogen therapy and hip fractures, Annals of Internal Medicine, 95, 28-31, 1981	No adjustment for potential confounders.
Papaioannou,A., Joseph,L., Ioannidis,G., Berger,C., Anastassiades,T., Brown,J.P., Hanley,D.A., Hopman,W., Josse,R.G., Kirkland,S., Murray,T.M., Olszynski,W.P., Pickard,L., Prior,J.C., Siminoski,K., Adachi,J.D., Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos), Osteoporosis International, 16, 568-578, 2005	Prospective cohort study. Assesses current use of HRT, but mean age of participants 66.6 years at baseline.
Parker,S.E., Troisi,R., Wise,L.A., Palmer,J.R., Titus-Ernstoff,L., Strohsnitter,W.C., Hatch,E.E., Menarche, menopause, years of menstruation, and the incidence of osteoporosis: the influence of prenatal exposure to diethylstilbestrol, Journal of Clinical Endocrinology and Metabolism, 99, 594-601, 2014	Study reports osteoporosis as outcome
Pasco,J.A., Kotowicz,M.A., Henry,M.J., Sanders,K.M., Seeman,E., Nicholson,G.C., Hormone therapy and risk of non-vertebral fracture: Geelong Osteoporosis Study, Osteoporosis International, 15, 434-438, 2004	Mean age of participants > 65 years, and only assesses current HRT use compared to fracture risk, rather than "ever" use, or past use.
Peeyananjarassri,K., Baber,R., Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. [80 refs], Climacteric, 8, 13-23, 2005	Non-systematic literature review.
Pfister,A.K., Welch,C.A., Emmett,M.K., Sheets,N.W., Risk factors predicting fractures in early postmenopausal women, The West Virginia medical journal, 109, 8-15, 2013	No adjustment for confounders. Reports p value only for use/non-use of HRT.
Pinheiro,M.M., Reis Neto,E.T., Machado,F.S., Omura,F., Yang,J.H., Szejnfeld,J., Szejnfeld,V.L., Risk factors for osteoporotic fractures and low bone density in pre and postmenopausal women, Revista de Saude Publica, 44, 479-485, 2010	No data presented on HRT use and fracture risk, only low BMD.
Recker,R.R., Davies,K.M., Dowd,R.M., Heaney,R.P., The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial, Annals of Internal Medicine, 130, 897-904, 1999	All participants aged over 65 years.
Ringe,J.D., Meiss,F., Prevention of early postmenopausal bone density loss by transdermal oestrogen replacement. <ORIGINAL> VERMEIDUNG FRUH-POSTMENOPAUSALER KNOCHENSUBSTANZVERLUSTE DURCH TRANSDERMALE OSTROGENSUBSTITUTION, DTSCH.MED.WOCHENSCHR, 118, 769-774, 1993	Non-English language (German).
Rymer,J., Robinson,J., Fogelman,I., Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women, Climacteric, 5, 390-398, 2002	Incidence of fractures only reported, not adjusted for confounders.
Rymer,J., Robinson,J., Fogelman,I., Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss, Osteoporosis International, 12, 478-483, 2001	Incidence of fractures only reported, not adjusted for confounders.
Salmen,T., Heikkinen,A.M., Mahonen,A., Kroger,H., Komulainen,M., Pallonen,H., Saarikoski,S., Honkanen,R., Maenpaa,P.H., Relation of aromatase gene polymorphism and hormone replacement therapy to serum estradiol levels, bone mineral density, and fracture risk in early postmenopausal women, Annals of Medicine, 35, 282-288, 2003	No assessment of correlation with HRT, only with aromatase gene polymorphism.
Spector,T.D., Brennan,P., Harris,P.A., Studd,J.W., Silman,A.J., Do current regimes of hormone replacement therapy protect against subsequent fractures?, Osteoporosis International, 2, 219-224, 1992	Cohort study but does not present data for adjusted relative risk (states that adjustment did not significantly alter result, but no data provided).
Stevenson,J.C., Lees,B., Bone conserving effects of oestrogen are dose-dependent for age and time since menopause, Osteoporosis International, 11, 25-, 2000	Fracture data included in Lees 2001.

Study	Reason for exclusion
Stevenson,J.C., Panay,N., Pexman-Fieth,C., Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety. [Erratum appears in Maturitas. 2013 Dec;76(4):388], Maturitas, 76, 10-21, 2013	Systematic review, individual studies checked for inclusion
Tengstrand,B., Oestrogen plus progestogen significantly improves bone mineral density and reduces risk of fracture, Evidence-Based Healthcare, 8, 102-104, 2004	Commentary on WHI trial, no primary data.
Torgerson D J, Bell S E, Syer S E, Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials, BMC Musculoskeletal Disorders, 2, 7, 2001	Individual studies checked, 5 studies already included in review
Torgerson,D.; Bell-Syer,S, Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials, Journal of the American Medical Association, , 2891-2897, 2001	Meta-analysis of RCTs - references checked and included where relevant.
Torgerson,D.J., Bell-Syer,S.E., Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. [45 refs], JAMA, 285, 2891-2897, 2001	Individual studies in systematic reviews checked for inclusion/exclusion
Tuppurainen,M., Honkanen,R., Kroger,H., Saarikoski,S., Alhava,E., Osteoporosis risk factors, gynaecological history and fractures in perimenopausal women--the results of the baseline postal enquiry of the Kuopio Osteoporosis Risk Factor and Prevention Study, Maturitas, 17, 89-100, 1993	Baseline data only from OSTPRE study.
Weiss,N.S., Ure,C.L., Ballard,J.H., Williams,A.R., Daling,J.R., Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen, New England Journal of Medicine, 303, 1195-1198, 1980	Study design did not match protocol
Wells,G., Tugwell,P., Shea,B., Guyatt,G., Peterson,J., Zytaruk,N., Robinson,V., Henry,D., O'Connell,D., Cranney,A., Adachi,J., Griffith,L., McGowan,J., Weaver,B., Willan,A., Rosen,C.J., Bilezikian,J.P., Black,D.M., Favus,M.J., Fitzpatrick,L.A., Kiel,D.P., Marcus,R., Orwoll,E.S., Schnitzer,T.J., V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women, Endocrine Reviews, 23, 529-539, 2002	Individual studies checked for inclusion/exclusion
Williams,A.R., Weiss,N.S., Ure,C.L., Ballard,J., Daling,J.R., Effect of weight, smoking, and estrogen use on the risk of hip and forearm fractures in postmenopausal women, Obstetrics and Gynecology, 60, 695-699, 1982	no overall assessment of oestrogen use and fracture risk, only for specific groups of women (smokers/obese etc.)
Ziller,M., Herwig,J., Ziller,V., Kauka,A., Kostev,K., Hadji,P., Effects of a low-dose oral estrogen only treatment on bone mineral density and quantitative ultrasonometry in postmenopausal women, Gynecological Endocrinology, 28, 1002-1005, 2012	All participants osteopenic or with known risk factors for osteoporosis.

## G.7.7 Dementia

Study	Reason for exclusion
Amended report from the NAMS Advisory Panel on postmenopausal hormone therapy, Menopause, 10, 6-12, 2003	Report
Hormone therapy with oestrogen or oestrogen plus progesterone does not reduce the risk of dementia or mild cognitive impairment in older postmenopausal women, Evidence-based Healthcare and Public Health, 8, 396-397, 2004	Only abstract available.
A decision tree for the use of estrogen replacement therapy or hormone replacement therapy in postmenopausal women: consensus opinion of The North American Menopause Society. [53 refs], Menopause, 7, 76-86, 2000	Conference proceedings, does not meet protocol requirement
Aidelsburger,P., Schauer,S., Grabein,K., Wasem,J., Alternative methods for the treatment of post-menopausal troubles, GMS Health Technology Assessment, 8, Doc03-, 2012	Outcome not of interest
Akhan,S.E., Gurel,T., Has,R., Iyibozkurt,A.C., Turfanda,A., Effects of long-term oral hormone replacement therapy on plasma nitric oxide and beta-endorphin levels in postmenopausal women, Gynecologic and Obstetric Investigation, 54, 196-200, 2002	Outcome measure not of interest, endorphin and nitric oxide levels
Akkayagorn,L., Tangwongchai,S., Worakul,P., Cognitive profiles, hormonal replacement therapy and related factors in Thai menopausal women, Asian Biomedicine, 3, 439-444, 2009	No comparator, wrong study design
Albertazzi,P., A review of non-hormonal options for the relief of menopausal symptoms, Treatments in Endocrinology, 5, 101-113, 2006	Does not report cognitive function
Al-Eassa,A.A., Al-Fadel,A.M., Al-Ajmi,M.A., Al-Najjar,A.A., Makboul,G.M., Elshazly,M., Knowledge and attitude of primary care doctors towards management of postmenopausal symptoms, Alexandria Journal of Medicine, 48, 167-173, 2012	Cross-sectional survey
Alhola,P., Polo-Kantola,P., Erkkola,R., Portin,R., Estrogen therapy and cognition: A 6-year single-blind follow-up study in postmenopausal women, Neurology, 67, 706-709, 2006	Not long-term use of HRT
Alhola,P., Tuomisto,H., Saarinen,R., Portin,R., Kalleinen,N., Polo-Kantola,P., Estrogen + progestogen therapy and cognition: a randomized placebo-controlled double-blind study, The journal of obstetrics and gynaecology research, 36, 796-802, 2010	Sample size <50
Almeida,O.P., Lautenschlager,N.T., Vasikaran,S., Leedman,P., Gelavis,A., Flicker,L., A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: Effect on mood, cognition and quality of life, Neurobiology of Aging, 27, 141-149, 2006	Participants age >70 years at enrolment

Study	Reason for exclusion
Aloysi,A., Van,DyK, Sano,M., Women's cognitive and affective health and neuropsychiatry, Mount Sinai Journal of Medicine, 73, 967-975, 2006	Review
Alves,DeMoraesS, Szklo,M., Knopman,D., Park,E., Prospective assessment of estrogen replacement therapy and cognitive functioning: Atherosclerosis Risk in Communities Study, American Journal of Epidemiology, 154, 733-739, 2001	Outcomes did not match protocol
Amin,Z., Gueorguieva,R., Cappiello,A., Czarkowski,K.A., Stiklus,S., Anderson,G.M., Naftolin,F., Epperson,C.N., Estradiol and tryptophan depletion interact to modulate cognition in menopausal women, Neuropsychopharmacology, 31, 2489-2497, 2006	Intervention not of interest, outcome not of interest, depression, ET vs tryptophan
Ammann,E.M., Pottala,J.V., Harris,W.S., Espeland,M.A., Wallace,R., Denburg,N.L., Carnahan,R.M., Robinson,J.G., -3 fatty acids and domain-specific cognitive aging: secondary analyses of data from WHISCA, Neurology, 81, 1484-1491, 2013	Intervention not of interest, omega 3 fatty acids
Amsterdam,J., Garcia-Espana,F., Fawcett,J., Quitkin,F., Reimherr,F., Rosenbaum,J., Beasley,C., Fluoxetine efficacy in menopausal women with and without estrogen replacement, Journal of Affective Disorders, 55, 11-17, 1999	Wrong intervention, outcomes stated in protocol not reported in study. Study reports antidepressant activity as outcome
Anderer,P., Saletu,B., Gruber,D., Linzmayer,L., Semlitsch,H.V., Saletu-Zyhlarz,G., Brandstatter,N., Metka,M., Huber,J., Age-related cognitive decline in the menopause: Effects of hormone replacement therapy on cognitive event-related potentials, Maturitas, 51, 254-269, 2005	Outcomes stated in protocol not reported in study
Anderer,P., Saletu,B., Saletu-Zyhlarz,G., Gruber,D., Metka,M., Huber,J., Pascual-Marqui,R.D., Brain regions activated during an auditory discrimination task in insomniac postmenopausal patients before and after hormone replacement therapy: low-resolution brain electromagnetic tomography applied to event-related potentials, Neuropsychobiology, 49, 134-153, 2004	Study not looking at cognitive function outcome or mortality
Anderer,P., Semlitsch,H.V., Saletu,B., Saletu-Zyhlarz,G., Gruber,D., Metka,M., Huber,J., Graser,T., Oettel,M., Effects of hormone replacement therapy on perceptual and cognitive event-related potentials in menopausal insomnia, Psychoneuroendocrinology, 28, 419-445, 2003	Wrong population, menopausal insomnia
Archer,J.S., Love-Geffen,T.E., Herbst-Damm,K.L., Swinney,D.A., Chang,J.R., Effect of estradiol versus estradiol and testosterone on brain-activation patterns in postmenopausal women, Menopause, 13, 528-537, 2006	Outcomes of dementia or mortality not reported
Arit,W., Dehydroepiandrosterone replacement therapy. [109 refs], Seminars in Reproductive Medicine, 22, 379-388, 2004	Dementia or mortality outcomes not reported, wrong study design
Asthana,S., Baker,L.D., Craft,S., Stanczyk,F.Z., Veith,R.C., Raskind,M.A., Plymate,S.R., High-dose estradiol improves cognition for women with AD: results of a randomized study, Neurology, 57, 605-612, 2001	Short term study of 8 weeks
Asthana,S., Craft,S., Baker,L.D., Raskind,M.A., Birnbaum,R.S., Lofgreen,C.P., Veith,R.C., Plymate,S.R., Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study, Psychoneuroendocrinology, 24, 657-677, 1999	Sample size <50
Asthana,S., Gleason,C.E., Wharton,W., Dowling,N.M., Carlsson,C.M., Brinton,E., Cedars,M., Lobo,R., Manson,J.E., Merriam,G., Miller,V.M., Neal-Perry,G., Santoro,N., Taylor,H., Black,D., Budoff,M., Hodis,H., Naftolin,F., Harman,S.M., The kronos early estrogen prevention study: Results of the cognitive & affective sub-study (KEEPS Cog), Menopause, 19, 1365-, 2012	Conference abstract
Atkins,D., Estrogen plus progestogen increased risk for stroke and probable dementia in postmenopausal women, ACP Journal Club, 139, 62-63, 2003	Information already included in another study
Backstrom,T., Symptoms related to the menopause and sex steroid treatments, Ciba Foundation Symposium, 191, 171-180, 1995	Literature review
Bagger,Y.Z., Tanko,L.B., Alexandersen,P., Qin,G., Christiansen,C., PERF Study Group., Early postmenopausal hormone therapy may prevent cognitive impairment later in life, Menopause, 12, 12-17, 2005	Outcomes did not match protocol
Baker,L.D., Asthana,S., Cholerton,B.A., Wilkinson,C.W., Plymate,S.R., Green,P.S., Merriam,G.R., Fishel,M.A., Watson,G.S., Cherrier,M.M., Kletke,M.L., Mehta,P.D., Craft,S., Cognitive response to estradiol in postmenopausal women is modified by high cortisol, Neurobiology of Aging, 33, 829-20, 2012	Study looked at estradiol and cortisol. Wrong outcome reported as biomarker
Baker,L.D., Sambamurti,K., Craft,S., Cherrier,M., Raskind,M.A., Stanczyk,F.Z., Plymate,S.R., Asthana,S., 17beta-estradiol reduces plasma Abeta40 for HRT-naive postmenopausal women with Alzheimer disease: a preliminary study, American Journal of Geriatric Psychiatry, 11, 239-244, 2003	Risk factor reported as outcome
Barrett-Connor,E., Kritz-Silverstein,D., Estrogen replacement therapy and cognitive function in older women, JAMA, 269, 2637-2641, 1993	Outcomes did not match protocol
Basaria,S., Wisniewski,A., Dupree,K., Bruno,T., Song,M.Y., Yao,F., Ojumu,A., John,M., Dobs,A.S., Effect of high-dose isoflavones on cognition, quality of life, androgens, and lipoprotein in post-menopausal women, Journal of Endocrinological Investigation, 32, 150-155, 2009	Wrong intervention, outcomes stated in protocol not in study
Bauer,M., Glenn,T., Pilhatsch,M., Pfennig,A., Whybrow,P.C., Gender differences in thyroid system function: relevance to bipolar disorder and its treatment, Bipolar Disorders, 16, 58-71, 2014	Wrong topic



Study	Reason for exclusion
Beardsworth,S.A., Purdie,D.W., Kearney,C.E., Selective oestrogen receptor modulation: An alternative to conventional oestrogen, <i>Current Obstetrics and Gynaecology</i> , 8, 96-101, 1998	Literature review
Bender,C.M., Sereika,S.M., Ryan,C.M., Brufsky,A.M., Puhalla,S., Berga,S.L., Hall,J.E., Does lifetime exposure to hormones predict pretreatment cognitive function in women before adjuvant therapy for breast cancer?, <i>Menopause</i> , 20, 922-929, 2013	Wrong population
Berent-Spillson,A., Persad,C.C., Love,T., Sowers,M., Randolph,J.F., Zubieta,J.K., Smith,Y.R., Hormonal environment affects cognition independent of age during the menopause transition, <i>Journal of Clinical Endocrinology and Metabolism</i> , 97, E1686-E1694, 2012	Wrong study design, cross-sectional
Berg,A.O., Allan,J.D., Frame,P., Homer,C.J., Johnson,M.S., Klein,J.D., Lieu,T.A., Orleans,C.T., Peipert,J.F., Pender,N.J., Siu,A.L., Teutsch,S.M., Westhoff,C., Woolf,S.H., Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: Recommendations and rationale, <i>Annals of Internal Medicine</i> , 137, 834-839, 2002	wrong study type
Biglia,N., Moggio,G., Peano,E., Sgandurra,P., Ponzzone,R., Nappi,R.E., Sismondi,P., Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight, <i>Journal of Sexual Medicine</i> , 7, 1891-1900, 2010	Wrong population and study type
Binder,E.F., Schechtman,K.B., Birge,S.J., Williams,D.B., Kohrt,W.M., Effects of hormone replacement therapy on cognitive performance in elderly women, <i>Maturitas</i> , 38, 137-146, 2001	Age of population above required age in protocol, study duration <1 year
Birge,S.J., The use of estrogen in older women, <i>Clinics in Geriatric Medicine</i> , 19, 617-627, 2003	Literature review
Birge,S.J., Is there a role for estrogen replacement therapy in the prevention and treatment of dementia?. [79 refs], <i>Journal of the American Geriatrics Society</i> , 44, 865-870, 1996	Literature review
Boccardi,M., Ghidoni,R., Govoni,S., Testa,C., Benussi,L., Bonetti,M., Binetti,G., Frisoni,G.B., Effects of hormone therapy on brain morphology of healthy postmenopausal women: a Voxel-based morphometry study, <i>Menopause</i> , 13, 584-591, 2006	Outcomes in protocol not reported in study
Bousman,C.A., Szoek,C., Chen,K., Dennerstein,L., Henderson,V.W., Everall,I.P., Oestrogen alpha-receptor variant and two-year memory decline in midlife Australian women, <i>Neuropsychobiology</i> , 66, 259-265, 2012	Study did not look at required intervention and did not report required outcomes of dementia or mortality
Brenner,D.E., Kukull,W.A., Stergachis,A., van,Belle G., Bowen,J.D., McCormick,W.C., Teri,L., Larson,E.B., Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study, <i>American Journal of Epidemiology</i> , 140, 262-267, 1994	Participants age >65 years at enrolment
Brinton,R.D., Nilsen,J., Breitner,J.C.S., Zandi,P.P., Yoon,B., Nyirjesy,I., Billingsley,F.S., Shumaker,S.A., Rapp,S.R., Espeland,M.A., Wallace,R.B., Hendrix,S.L., Henderson,V.W., Gass,M.L., Thal,L., Effects of estrogen plus progestogen on risk of dementia Shumaker SA, Legault C, Rapp SR et al Estrogen plus progestogen and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial <i>JAMA</i> 2003;289:2651-2662, <i>JAMA:Journal-of-the-American-Medical-Association</i> , 290, 1706-1708, 2003	Letter to editor
Brunner,R.L., Gass,M., Aragaki,A., Hays,J., Granek,I., Woods,N., Mason,E., Brzyski,R., Ockene,J., Assaf,A., LaCroix,A., Matthews,K., Wallace,R., Women's Health Initiative Investigators., Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial, <i>Archives of Internal Medicine</i> , 165, 1976-1986, 2005	Study did not report outcomes for dementia or mortality
Buckwalter,J.G., Crooks,V.C., Robins,S.B., Petitti,D.B., Hormone Use and Cognitive Performance in Women of Advanced Age, <i>Journal of the American Geriatrics Society</i> , 52, 182-186, 2004	Participants age >75 years at enrolment
Buhling,K.J., Von,StudnitzF, Jantke,A., Eulenburg,C., Mueck,A.O., Use of hormone therapy by female gynecologists and female partners of male gynecologists in Germany 8 years after the Women's Health Initiative study: Results of a survey, <i>Menopause</i> , 19, 1088-1091, 2012	Wrong study type, survey
Burkhardt,M.S., Foster,J.K., Laws,S.M., Baker,L.D., Craft,S., Gandy,S.E., Stuckey,B.G., Clarnette,R., Nolan,D., Hewson-Bower,B., Martins,R.N., Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon4, <i>Journal of Alzheimer's Disease</i> , 6, 221-228, 2004	No information on adjustment for covariates in analysis
Buyuk,E., Nejat,E., Neal-Perry,G., Determinants of female reproductive senescence: differential roles for the ovary and the neuroendocrine axis, <i>Seminars in Reproductive Medicine</i> , 28, 370-379, 2010	Literature review
Carlson,L.E., Sherwin,B.B., Relationships among cortisol (CRT), dehydroepiandrosterone-sulfate (DHEAS), and memory in a longitudinal study of healthy elderly men and women, <i>Neurobiology of Aging</i> , 20, 315-324, 1999	Age of population above 70. Upper age limit in protocol is 70
Carlson,M.C., Zandi,P.P., Plassman,B.L., Tschanz,J.T., Welsh-Bohmer,K.A., Steffens,D.C., Bastian,L.A., Mehta,K.M., Breitner,J.C., Cache County Study Group., Hormone replacement therapy and reduced cognitive decline in older women: the Cache County Study, <i>Neurology</i> , 57, 2210-2216, 2001	Only baseline information available

Study	Reason for exclusion
Casson,P.R., Carson,S.A., Androgen replacement therapy in women: Myths and realities, International Journal of Fertility and Menopausal Studies, 41, 412-422, 1996	Literature review
Castelo-Branco,C., Garcia-Fantini,M., Haya,J., Vascular reactivity and atheromatous plaques in post-menopausal women on tibolone treatment. Open prospective study with Doppler ultrasonography in internal carotid artery, Maturitas, 50, 259-265, 2005	Wrong topic
Cholerton,B., Gleason,C.E., Baker,L.D., Asthana,S., Estrogen and Alzheimer's disease: the story so far. [230 refs], Drugs and Aging, 19, 405-427, 2002	Literature review
Clark,M.S., Guthrie,J.R., Dennerstein,L., Hyperhomocysteinemia is associated with lower performance on memory tasks in post-menopausal women, Dementia and Geriatric Cognitive Disorders, 20, 57-62, 2005	HRT reported as confounder, not intervention
Cohen,D.P., Anti-osteoporotic medications: Traditional and nontraditional, Clinical Obstetrics and Gynecology, 46, 341-348, 2003	wrong study type
Coker,L.H., Espeland,M.A., Hogan,P.E., Resnick,S.M., Bryan,R.N., Robinson,J.G., Goveas,J.S., Davatzikos,C., Kuller,L.H., Williamson,J.D., Bushnell,C.D., Shumaker,S.A., WHIMS-MRI Study Group., Change in brain and lesion volumes after CEE therapies: the WHIMS-MRI studies, Neurology, 82, 427-434, 2014	Wrong outcomes
Coker,L.H., Espeland,M.A., Rapp,S.R., Legault,C., Resnick,S.M., Hogan,P., Gaussoin,S., Dailey,M., Shumaker,S.A., Postmenopausal hormone therapy and cognitive outcomes: the Women's Health Initiative Memory Study (WHIMS), Journal of Steroid Biochemistry and Molecular Biology, 118, 304-310, 2010	Background reading
Colenda,C.C., Legault,C., Rapp,S.R., DeBon,M.W., Hogan,P., Wallace,R., Hershey,L., Ockene,J., Whitmer,R., Phillips,L.S., Sarto,G.E., Psychiatric disorders and cognitive dysfunction among older, postmenopausal women: Results from the women's health initiative memory study, American Journal of Geriatric Psychiatry, 18, 177-186, 2010	Outcome not of interest, depression
Collins,B., Mackenzie,J., Stewart,A., Bielajew,C., Verma,S., Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study, Psycho-Oncology, 18, 811-821, 2009	Wrong population
Compton,J., van,AmelsvoortT, Murphy,D., Estrogen and the brain, Contemporary Clinical Gynecology and Obstetrics, 2, 5-12, 2002	Wrong study design
Constantine,G.D., Pickar,J.H., Estrogens in postmenopausal women: recent insights. [79 refs], Current Opinion in Pharmacology, 3, 626-634, 2003	Literature review
Cook,I.A., Morgan,M.L., Dunkin,J.J., David,S., Witte,E., Lufkin,R., Abrams,M., Rosenberg,S., Leuchter,A.F., Estrogen replacement therapy is associated with less progression of subclinical structural brain disease in normal elderly women: a pilot study, International Journal of Geriatric Psychiatry, 17, 610-618, 2002	Sample size <50
Coope,J., Hormonal and non-hormonal interventions for menopausal symptoms. [73 refs], Maturitas, 23, 159-168, 1996	Study does not report required outcomes stated in protocol
Cornwell,T., Cohick,W., Raskin,I., Dietary phytoestrogens and health. [188 refs], Phytochemistry, 65, 995-1016, 2004	Literature review
Cosma,M., Bailey,J., Miles,J.M., Bowers,C.Y., Veldhuis,J.D., Pituitary and/or peripheral estrogen-receptor alpha regulates follicle-stimulating hormone secretion, whereas central estrogenic pathways direct growth hormone and prolactin secretion in postmenopausal women, Journal of Clinical Endocrinology and Metabolism, 93, 951-958, 2008	Study does not report outcomes stated in protocol
Costa,M.M., Reus,V.I., Wolkowitz,O.M., Manfredi,F., Lieberman,M., Estrogen replacement therapy and cognitive decline in memory-impaired post-menopausal women, Biological Psychiatry, 46, 182-188, 1999	Participants were >65 years age at enrolment, no information provided about duration of HRT use
Craig,M.C., Should psychiatrists be prescribing oestrogen therapy to their female patients?, British Journal of Psychiatry, 202, 9-13, 2013	Literature review
Craig,M.C., Cutter,W.J., Wickham,H., van Amelsvoort,T.A., Rymer,J., Whitehead,M., Murphy,D.G., Effect of long-term estrogen therapy on dopaminergic responsivity in post-menopausal women--a preliminary study, Psychoneuroendocrinology, 29, 1309-1316, 2004	Study does not report outcomes stated in protocol
Craig,M.C., Daly,E.M., O'Gorman,R., Rymer,J., Lythgoe,D., Ng,G., Simmons,A., Maki,P.M., Murphy,D.G.M., Effects of acute ovarian hormone suppression on the human brain: An in vivo 1H MRS study, Psychoneuroendocrinology, 32, 1128-1132, 2007	Wrong topic
Craig,M.C., Maki,P.M., Murphy,D.G., The Women's Health Initiative Memory Study: findings and implications for treatment. [34 refs], Lancet Neurology, 4, 190-194, 2005	Subset of participants age >65 years at enrolment, no information about prior use
Craig,M.C., Murphy,D.G., Estrogen: effects on normal brain function and neuropsychiatric disorders. [67 refs], Climacteric, 10 Suppl 2, 97-104, 2007	Narrative review
Culhane,N.S., Estrogen plus progestogen may increase incidence of dementia, Journal of Family Practice, 52, 754-755, 2003	Participants >65 years at enrolment
Cutler,W.B., Genovese-Stone,E., Wellness in women after 40 years of age: The role of sex hormones and pheromones, Disease-a-Month, 44, 426-Month, 1998	Literature review
da,SilvaLaraL, Useche,B., Rosa,eSilvaJ, Ferriani,R.A., Reis,R.M., De,SaM, de,CarvalhoB, Carvalho,M.A.C.R., De,SaRosaESilvaA, Sexuality during the climacteric period, Maturitas, 62, 127-133, 2009	Literature review

Study	Reason for exclusion
Dang,H., Mack,W.J., Hodis,H., St.,JohnJ., Henderson,V.W., Rettberg,J., Brinton,R.D., Karim,R., Reproductive history correlates with late-life cognitive function in postmenopausal women, <i>Menopause</i> , 20, 1335-1336, 2013	Conference abstract
Davey,D.A., Menopause and HRT - Keeping perspective, <i>South African Medical Journal</i> , 94, 23-25, 2004	Literature review
Davis,S.R., Davison,S.L., Gavrilescu,M., Searle,K., Gogos,A., Rossell,S.L., Egan,G.F., Bell,R.J., Effects of testosterone on visuospatial function and verbal fluency in postmenopausal women: results from a functional magnetic resonance imaging pilot study, <i>Menopause</i> , 21, 410-414, 2014	Wrong intervention
Davis,S.R., Panjari,M., Stanczyk,F.Z., Clinical review: DHEA replacement for postmenopausal women, <i>Journal of Clinical Endocrinology and Metabolism</i> , 96, 1642-1653, 2011	Wrong study design, study looked at physiology
Davison,S.L., Bell,R.J., Gavrilescu,M., Searle,K., Maruff,P., Gogos,A., Rossell,S.L., Adams,J., Egan,G.F., Davis,S.R., Testosterone improves verbal learning and memory in postmenopausal women: Results from a pilot study, <i>Maturitas</i> , 70, 307-311, 2011	Wrong intervention
Davison,S.L., Bell,R.J., Robinson,P.J., Jane,F., Leech,J., Maruff,P., Egan,G.F., Davis,S.R., Continuous-combined oral estradiol/drospirenone has no detrimental effect on cognitive performance and improves estrogen deficiency symptoms in early postmenopausal women: a randomized placebo-controlled trial, <i>Menopause</i> , 20, 1020-1026, 2013	Sample size <50
DeGregorio,M.W., Taras,T.L., Hormone replacement therapy and breast cancer: revisiting the issues, <i>Journal of the American Pharmaceutical Association (Washington,D.C)</i> , 38, 738-744, 1998	Literature review
DeGrendele,H., O'Shaughnessy,J.A., Assessment of cognitive function in patients receiving adjuvant endocrine therapy, <i>Clinical Breast Cancer</i> , 4, 241-243, 2003	Intervention not of interest, tamoxifen, not HRT for dementia
Dent,S.F., Gaspo,R., Kissner,M., Pritchard,K.I., Aromatase inhibitor therapy: Toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer, <i>Breast Cancer Research and Treatment</i> , 126, 295-310, 2011	Wrong intervention
DeSancho,M.T., Dorff,T., Rand,J.H., Thrombophilia and the risk of thromboembolic events in women on oral contraceptives and hormone replacement therapy, <i>Blood Coagulation and Fibrinolysis</i> , 21, 534-538, 2010	Outcomes in study not of interest
Devi,G., Massimi,S., Schultz,S., Khosrowshahi,L., Laakso,U.K., A Double-Blind, Placebo-Controlled Trial of Donepezil for the Treatment of Menopause-Related Cognitive Loss, <i>Gender Medicine</i> , 4, 352-358, 2007	Sample size <50
Donangelo,I., Braunstein,G.D., Update on subclinical hyperthyroidism, <i>American Family Physician</i> , 83, 933-938, 2011	Wrong topic; review
Duff,S.J., Hampson,E., A beneficial effect of estrogen on working memory in postmenopausal women taking hormone replacement therapy, <i>Hormones and Behavior</i> , 38, 262-276, 2000	Cross-sectional study
Duffy,R., Wiseman,H., File,S.E., Improved cognitive function in postmenopausal women after 12 weeks of consumption of a soya extract containing isoflavones, <i>Pharmacology, Biochemistry and Behavior</i> , 75, 721-729, 2003	Wrong intervention. Participants not on HRT
Duka,T., Tasker,R., McGowan,J.F., The effects of 3-week estrogen hormone replacement on cognition in elderly healthy females, <i>Psychopharmacology</i> , 149, 129-139, 2000	Population not on HRT previously
Dumas,J., Hancur-Bucci,C., Naylor,M., Sites,C., Newhouse,P., Estradiol interacts with the cholinergic system to affect verbal memory in postmenopausal women: evidence for the critical period hypothesis, <i>Hormones and Behavior</i> , 53, 159-169, 2008	Study does not report dementia, and wrong intervention
Dumas,J., Hancur-Bucci,C., Naylor,M., Sites,C., Newhouse,P., Estrogen treatment effects on anticholinergic-induced cognitive dysfunction in normal postmenopausal women, <i>Neuropsychopharmacology</i> , 31, 2065-2078, 2006	Wrong intervention
Dumas,J.A., Albert,K.M., Naylor,M.R., Sites,C.K., Benkelfat,C., Newhouse,P.A., The effects of age and estrogen on stress responsivity in older women, <i>American Journal of Geriatric Psychiatry</i> , 20, 734-743, 2012	Study does not report outcomes stated in protocol
Dumas,J.A., Kutz,A.M., Naylor,M.R., Johnson,J.V., Newhouse,P.A., Estradiol treatment altered anticholinergic-related brain activation during working memory in postmenopausal women, <i>Neuroimage</i> , 60, 1394-1403, 2012	Wrong intervention
Dumas,J.A., Kutz,A.M., Naylor,M.R., Johnson,J.V., Newhouse,P.A., Increased memory load-related frontal activation after estradiol treatment in postmenopausal women, <i>Hormones and Behavior</i> , 58, 929-935, 2010	Population did not initiate HRT use prior to study
Dumas,J.A., McDonald,B.C., Saykin,A.J., McAllister,T.W., Hynes,M.L., West,J.D., Newhouse,P.A., Cholinergic modulation of hippocampal activity during episodic memory encoding in postmenopausal women: a pilot study, <i>Menopause</i> , 17, 852-859, 2010	Wrong intervention
Dumas,J.A., Saykin,A.J., McDonald,B.C., McAllister,T.W., Hynes,M.L., Newhouse,P.A., Nicotinic versus muscarinic blockade alters verbal working memory-related brain activity in older women, <i>American Journal of Geriatric Psychiatry</i> , 16, 272-282, 2008	Population not taking HRT prior to study, wrong interventions
Dunkin,J., Rasgon,N., Wagner-Steh,K., David,S., Altshuler,L., Rapkin,A., Reproductive events modify the effects of estrogen replacement therapy on	Sample size <50

Study	Reason for exclusion
cognition in healthy postmenopausal women, <i>Psychoneuroendocrinology</i> , 30, 284-296, 2005	
Dunkin,J., Rasgon,N., Zeller,M., Wagner-Steh,K., David,S., Altshuler,L., Rapkin,A., Estrogen replacement and cognition in postmenopausal women: Effect of years since menopause on response to treatment, <i>Drug Development Research</i> , 66, 150-159, 2005	Sample size <50 and trial time 10 weeks
Dunne,L., Seaton,T.L., Does hormone replacement therapy (HRT) improve cognitive function or either delay or prevent dementia in postmenopausal women?, <i>Journal of Family Practice</i> , 50, 547-, 2001	Conference abstract
Duzenli,M.A., Ozdemir,K., Sokmen,A., Gezinc,K., Soylu,A., Celik,C., Altunkeser,B.B., Tokac,M., The effects of hormone replacement therapy on myocardial performance in early postmenopausal women, <i>Climacteric</i> , 13, 157-170, 2010	Study does not report outcomes stated in protocol
Elfituri,A., Sherif,F., Elmahaishi,M., Chrystyn,H., Two hormone replacement therapy (HRT) regimens for middle-eastern postmenopausal women, <i>Maturitas</i> , 52, 52-59, 2005	Study does not report outcomes stated in protocol
Emmanuelle,E.K., Andreeva,V.A., Jeandel,C., Ferry,M., Hercberg,S., Galan,P., A healthy dietary pattern at midlife is associated with subsequent cognitive performance, <i>Journal of Nutrition</i> , 142, 909-915, 2012	Interventions not of interest
Epperson,C.N., Amin,Z., Ruparel,K., Gur,R., Loughead,J., Interactive effects of estrogen and serotonin on brain activation during working memory and affective processing in menopausal women, <i>Psychoneuroendocrinology</i> , 37, 372-382, 2012	Wrong outcome
Erickson,K.I., Colcombe,S.J., Elavsky,S., McAuley,E., Korol,D.L., Scalf,P.E., Kramer,A.F., Interactive effects of fitness and hormone treatment on brain health in postmenopausal women, <i>Neurobiology of Aging</i> , 28, 179-185, 2007	Wrong intervention
Erickson,K.I., Voss,M.W., Prakash,R.S., Chaddock,L., Kramer,A.F., A cross-sectional study of hormone treatment and hippocampal volume in postmenopausal women: evidence for a limited window of opportunity, <i>Neuropsychology</i> , 24, 68-76, 2010	Wrong study design
Espeland, M., Shumaker, S., Leng, I., Manson, J., Brown, C., Le Blanc, E., Vaughan, L., Robinson, J., Rapp, S., Goveas, J., Lane, D., Wactawski-Wende, J., Stefanick, M., Li, W., Resnick, S., Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50-54 years: Results from the women's health initiative memory study of younger women (whimsy), <i>Alzheimer's and Dementia</i> , 1), P529-P530, 2013	Conference abstract
Espeland,M., Shumaker,S., Leng,I., Manson,J., Brown,C., Le,BlancE, Vaughan,L., Robinson,J., Rapp,S., Goveas,J., Lane,D., Wactawski-Wende,J., Stefanick,M., Li,W., Resnick,S., Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50-54 years: Results from the women's health initiative memory study of younger women (whimsy), <i>Alzheimer's and Dementia</i> , 9, 529-530, 2013	Conference abstract
Espeland,M.A., Brunner,R.L., Hogan,P.E., Rapp,S.R., Coker,L.H., Legault,C., Granek,I., Resnick,S.M., Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: Results from the women's health initiative study of cognitive aging extension, <i>Journal of the American Geriatrics Society</i> , 58, 1263-1271, 2010	Participants age >65 years and prior use of HRT could not be determined
Espeland,M.A., Shumaker,S.A., Leng,I., Manson,J.E., Brown,C.M., LeBlanc,E.S., Vaughan,L., Robinson,J., Rapp,S.R., Goveas,J.S., Wactawski-Wende,J., Stefanick,M.L., Li,W., Resnick,S.M., WHIMSY Study Group., Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years, <i>JAMA Internal Medicine</i> , 173, 1429-1436, 2013	No data was reported for individual treatment groups
Espeland,M.A., Shumaker,S.A., Limacher,M., Rapp,S.R., Bevers,T.B., Barad,D.H., Coker,L.H., Gaussoin,S.A., Stefanick,M.L., Lane,D.S., Maki,P.M., Resnick,S.M., Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition, <i>Journal of Women's Health</i> , 19, 371-379, 2010	Intervention not of interest, tamoxifen, raloxifen, no details of HRT
Espeland,M.A., Tindle,H.A., Bushnell,C.A., Jaramillo,S.A., Kuller,L.H., Margolis,K.L., Mysiw,W.J., Maldjian,J.A., Melhem,E.R., Resnick,S.M., Women's Health Initiative Memory Study., Brain volumes, cognitive impairment, and conjugated equine estrogens, <i>Journals of Gerontology Series A-Biological Sciences and Medical Sciences</i> , 64, 1243-1250, 2009	Participants age >65 years at enrolment
Etnier,J.L., Sibley,B.L., Physical activity and hormone-replacement therapy: interactive effects on cognition?, <i>Journal of Aging and Physical Activity</i> , 12, 554-567, 2004	Physical activity not stated in protocol
Ettinger,B., Barrett-Connor,E., Hoq,L.A., Vader,J.P., Dubois,R.W., When is it appropriate to prescribe postmenopausal hormone therapy?. [14 refs], <i>Menopause</i> , 13, 404-410, 2006	Wrong study design
Fahlen,M., Wallberg,B., von,Schoultz E., Carlstrom,K., Svensson,G., Wilking,N., Brandberg,Y., Health-related quality of life during hormone therapy after breast cancer: a randomized trial, <i>Climacteric</i> , 14, 164-170, 2011	Wrong population, outcome not stated in protocol
Farrag,A.K., Khedr,E.M., bdel-Aleem,H., Rageh,T.A., Effect of surgical menopause on cognitive functions, <i>Dementia and Geriatric Cognitive Disorders</i> , 13, 193-198, 2002	Study did not look at HRT use.

Study	Reason for exclusion
File,S.E., Hartley,D.E., Elsabagh,S., Duffy,R., Wiseman,H., Cognitive improvement after 6 weeks of soy supplements in postmenopausal women is limited to frontal lobe function, <i>Menopause</i> , 12, 193-201, 2005	Wrong intervention, and population not taking HRT.
File,S.E., Jarrett,N., Fluck,E., Duffy,R., Casey,K., Wiseman,H., Eating soya improves human memory, <i>Psychopharmacology</i> , 157, 430-436, 2001	Wrong population, wrong intervention
Fillit,H., Future therapeutic developments of estrogen use, <i>Journal of Clinical Pharmacology</i> , 35, 25S-28S, 1995	Literature review
Fillit,H., Weinreb,H., Cholst,I., Luine,V., McEwen,B., Amador,R., Zabriskie,J., Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type, <i>Psychoneuroendocrinology</i> , 11, 337-345, 1986	Sample size <50
Finch,A., Evans,G., Narod,S.A., BRCA carriers, prophylactic salpingo-oophorectomy and menopause: Clinical management considerations and recommendations, <i>Women's health</i> , 8, 543-555, 2012	Wrong population, wrong study type
Fischer,B., Gleason,C., Asthana,S., Effects of hormone therapy on cognition and mood, <i>Fertility and Sterility</i> , 101, 898-904, 2014	Literature review
Fournier,L.R., Ryan Borchers,T.A., Robison,L.M., Wiediger,M., Park,J.S., Chew,B.P., McGuire,M.K., Sclar,D.A., Skaer,T.L., Beerman,K.A., The effects of soy milk and isoflavone supplements on cognitive performance in healthy, postmenopausal women, <i>Journal of Nutrition, Health and Aging</i> , 11, 155-164, 2007	Wrong intervention
Foy,M., Baudry,M., Thompson,R., Estrogen and hippocampal synaptic plasticity, <i>Neuron GLIA Biology</i> , 1, 327-338, 2004	Literature review
Freedman,R.R., Pathophysiology and treatment of menopausal hot flashes, <i>Seminars in Reproductive Medicine</i> , 23, 117-125, 2005	Wrong topic, study looking at hot flushes symptom
Fuh,J.L., Wang,S.J., Lee,S.J., Lu,S.R., Juang,K.D., A longitudinal study of cognition change during early menopausal transition in a rural community, <i>Maturitas</i> , 53, 447-453, 2006	Wrong study design, no comparator group
Galen,Buckwalter J., Crooks,V.C., Robins,S.B., Petitti,D.B., Hormone use and cognitive performance in women of advanced age, <i>Journal of the American Geriatrics Society</i> , 52, 182-186, 2004	Outcomes did not match protocol
Gaussoin,S.A., Espeland,M.A., Absher,J., Howard,B.V., Jones,B.M., Rapp,S.R., Ascertain dementia-related outcomes for deceased or proxy-dependent participants: an overview of the Women's Health Initiative Memory Study supplemental case ascertainment protocol, <i>International Journal of Geriatric Psychiatry</i> , 27, 205-214, 2012	Participants age>65 years at enrolment
Geller,S.E., Studee,L., Soy and red clover for mid-life and aging. [82 refs], <i>Climacteric</i> , 9, 245-263, 2006	Wrong intervention
Genazzani,A.R., Gambacciani,M., Hormone replacement therapy: The perspectives for the 21st century, <i>Maturitas</i> , 32, 11-17, 1999	Literature review
Ghezzi,A., Zaffaroni,M., Female-specific issues in multiple sclerosis, <i>Expert Review of Neurotherapeutics</i> , 8, 969-977, 2008	Wrong population, MS
Giacobini,E., Aging, Alzheimer's disease, and estrogen therapy. [14 refs], <i>Experimental Gerontology</i> , 33, 865-869, 1998	Literature review
Gianaros,P.J., Jennings,J.R., Sheu,L.K., Greer,P.J., Kuller,L.H., Matthews,K.A., Prospective reports of chronic life stress predict decreased grey matter volume in the hippocampus, <i>Neuroimage</i> , 35, 795-803, 2007	Literature review
Gleason,C., Wharton,W., Dowling,M., Brinton,E., Santoro,N., Neal-Perry,G., Taylor,H., Naftolin,F., Lobo,R., Merriam,G., Manson,J.E., Cedars,M., Miller,V.M., Black,D., Budoff,M., Hodis,H., Harman,S.M., Asthana,S., The kronos early estrogen prevention study-cognitive and affective sub-study (KEEPS-CA): Menopausal hormone therapy effects on mood, quality of life, and memory complaints, <i>Menopause</i> , 19, 1402-, 2012	Conference abstract
Gorenstein,C., Renno,J., Jr., Vieira Filho,A.H., Gianfaldoni,A., Goncalves,M.A., Halbe,H.W., Fernandes,C.E., Demetrio,F.N., Estrogen replacement therapy and cognitive functions in healthy postmenopausal women: a randomized trial, <i>Archives of Women's Mental Health</i> , 14, 367-373, 2011	Short term study, 6 months
Grady,D., Yaffe,K., Kristof,M., Lin,F., Richards,C., Barrett-Connor,E., Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestogen Replacement Study, <i>American Journal of Medicine</i> , 113, 543-548, 2002	Wrong population
Greendale,G.A., Huang,M.H., Wight,R.G., Seeman,T., Luetters,C., Avis,N.E., Johnston,J., Karlamangla,A.S., Effects of the menopause transition and hormone use on cognitive performance in midlife women, <i>Neurology</i> , 72, 1850-1857, 2009	Outcomes did not match protocol
Grigороva,M., Sherwin,B.B., Tulandi,T., Effects of treatment with leuprolide acetate depot on working memory and executive functions in young premenopausal women, <i>Psychoneuroendocrinology</i> , 31, 935-947, 2006	Wrong intervention
Grinspoon,S.K., Friedman,A.J., Miller,K.K., Lippman,J., Olson,W.H., Warren,M.P., Effects of a triphasic combination oral contraceptive containing norgestimate/ethinyl estradiol on biochemical markers of bone metabolism in young women with osteopenia secondary to hypothalamic amenorrhea, <i>Journal of Clinical Endocrinology and Metabolism</i> , 88, 3651-3656, 2003	Wrong outcomes reported
Grodstein,F., Chen,J., Pollen,D.A., Albert,M.S., Wilson,R.S., Folstein,M.F., Evans,D.A., Stampfer,M.J., Postmenopausal hormone therapy and cognitive function in healthy older women, <i>Journal of the American Geriatrics Society</i> , 48, 746-752, 2000	Outcomes did not match protocol

Study	Reason for exclusion
Guerriero,S., Paoletti,A.M., Ajossa,S., Vacca,A.M., Pilia,I., Orru',M., Perrone,G., Melis,G.B., Influence of vaginal danazol on uterine and brain perfusion during hormonal replacement therapy, <i>Menopause</i> , 8, 424-428, 2001	Wrong intervention
Gurney,E.P., Nachtigall,M.J., Nachtigall,L.E., Naftolin,F., The Women's Health Initiative trial and related studies: 10 years later: a clinician's view, <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 142, 4-11, 2014	Study did not report outcomes stated in protocol
Gurvich,C., Estrogen and cognition in women with schizophrenia, <i>Archives of Women's Mental Health</i> , 14, S116-S117, 2011	Conference abstract
Guvenal,T., Durna,A., Erden,O., Guvenal,F., Cetin,M., Cetin,A., Effects of different postmenopausal hormone therapy regimens on cerebral blood flow and cognitive functions, <i>Advances in Therapy</i> , 26, 805-811, 2009	Outcomes did not match protocol
Ha,D.M., Xu,J., Janowsky,J.S., Preliminary evidence that long-term estrogen use reduces white matter loss in aging, <i>Neurobiology of Aging</i> , 28, 1936-1940, 2007	Study did not report outcomes stated in protocol
Hachul,H., Bittencourt,L.R., Andersen,M.L., Haidar,M.A., Baracat,E.C., Tufik,S., Effects of hormone therapy with estrogen and/or progesterone on sleep pattern in postmenopausal women, <i>International Journal of Gynaecology and Obstetrics</i> , 103, 207-212, 2008	Wrong outcome reported in study
Hagenfeldt,K., Johansson,C., Johnell,O., Ljunggren,O., Moller,M., Morland,B., Osteoporosis - prevention, diagnosis and treatment (Structured abstract), <i>Health Technology Assessment Database</i> , -, 2014	Wrong population
Halbreich,U., Kahn,L.S., Selective oestrogen receptor modulators--current and future brain and behaviour applications. [97 refs], <i>Expert Opinion on Pharmacotherapy</i> , 1, 1385-1398, 2000	Literature review
Harman,S.M., Effects of oral conjugated estrogen or transdermal estradiol plus oral progesterone treatment on common carotid artery intima media thickness (CIMT) & coronary artery calcium (CAC) in menopausal women: Initial results from the kronos early estrogen prevention study (KEEPS), <i>Menopause</i> , 19, 1365-, 2012	Conference abstract
Harris,D., Hogan,P., Guassoian,S., Legault,C., Naughton,M., Robertson,J., Pleasants,D., Utilizing a web-based telephone call tracking system in the collection of cognitive data, <i>Clinical Trials</i> , 9, 531-, 2012	Conference abstract
Haskell,S.G., Richardson,E.D., Horwitz,R.I., The effect of estrogen replacement therapy on cognitive function in women: a critical review of the literature. [58 refs], <i>Journal of Clinical Epidemiology</i> , 50, 1249-1264, 1997	For background reading
HAYES, Inc., MammaPrint for prognosis of breast cancer recurrence (Structured abstract), <i>Health Technology Assessment Database</i> , -, 2014	wrong population
Hays,J., Ockene,J.K., Brunner,R.L., Kotchen,J.M., Manson,J.E., Patterson,R.E., Aragaki,A.K., Shumaker,S.A., Brzyski,R.G., LaCroix,A.Z., Granek,I.A., Valanis,B.G., Women's Health Initiative Investigators., Effects of estrogen plus progesterone on health-related quality of life, <i>New England Journal of Medicine</i> , 348, 1839-1854, 2003	Wrong outcome
Hebert,R., What's new in Nicotine & Tobacco Research?, <i>Nicotine and Tobacco Research</i> , 5, 1-6, 2003	wrong topic
Heinrich,A.B., Wolf,O.T., Investigating the effects of estradiol or estradiol/progesterone treatment on mood, depressive symptoms, menopausal symptoms and subjective sleep quality in older healthy hysterectomized women: a questionnaire study, <i>Neuropsychobiology</i> , 52, 17-23, 2005	Study does not report outcomes stated in protocol
Heitmann,C., Greiser,E., Doren,M., The impact of the Women's Health Initiative Randomized Controlled Trial 2002 on perceived risk communication and use of postmenopausal hormone therapy in Germany, <i>Menopause</i> , 12, 405-411, 2005	Wrong intervention
Henderson,V., Endocrine society 2010 scientific statement: Stroke risk and cognition, <i>Climacteric</i> , 14, 51-, 2011	Conference abstract
Henderson,V.W., Cognition and cognitive aging. [17 refs], <i>Climacteric</i> , 10 Suppl 2, 88-91, 2007	Literature review
Henderson,V.W., Estrogen replacement therapy for the prevention and treatment of Alzheimer's disease, <i>CNS Drugs</i> , 8, 343-351, 1997	Literature review
Henderson,V.W., Aging, estrogens, and episodic memory in women. [101 refs], <i>Cognitive and Behavioral Neurology</i> , 22, 205-214, 2009	Literature review
Henderson,V.W., The epidemiology of estrogen replacement therapy and Alzheimer's disease. [142 refs], <i>Neurology</i> , 48, S27-S35, 1997	Literature review
Henderson,V.W., Gonadal hormones and cognitive aging: a midlife perspective, <i>Women's health</i> , 7, 81-93, 2011	Literature review
Henderson,V.W., Paganini-Hill,A., Emanuel,C.K., Dunn,M.E., Buckwalter,J.G., Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects, <i>Archives of Neurology</i> , 51, 896-900, 1994	Retrospective study and no information on prior HRT use
Henderson,V.W., Paganini-Hill,A., Miller,B.L., Elble,R.J., Reyes,P.F., Shoupe,D., McCleary,C.A., Klein,R.A., Hake,A.M., Farlow,M.R., Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial, <i>Neurology</i> , 54, 295-301, 2000	Sample size <50
Henderson,V.W., Sherwin,B.B., Surgical versus natural menopause: cognitive issues. [60 refs], <i>Menopause</i> , 14, 572-579, 2007	Background reading
Herlitz,A., Thilers,P., Habib,R., Endogenous estrogen is not associated with cognitive performance before, during, or after menopause, <i>Menopause</i> , 14, 425-431, 2007	Intervention not reported in study

Study	Reason for exclusion
Hermann,M., Berger,P., Hormone replacement in the aging male?. [50 refs], <i>Experimental Gerontology</i> , 34, 923-933, 1999	Wrong population
Hermann,M., Berger,P., Hormone replacement in the aging male?, <i>Experimental Gerontology</i> , 34, 923-933, 1999	Literature review
Hermelink,K., Henschel,V., Untch,M., Bauerfeind,I., Lux,M.P., Munzel,K., Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study, <i>Cancer</i> , 113, 2431-2439, 2008	Wrong population
Heys,M., Jiang,C., Cheng,K.K., Zhang,W., Au Yeung,S.L., Lam,T.H., Leung,G.M., Schooling,C.M., Life long endogenous estrogen exposure and later adulthood cognitive function in a population of naturally postmenopausal women from Southern China: the Guangzhou Biobank Cohort Study, <i>Psychoneuroendocrinology</i> , 36, 864-873, 2011	Wrong study design, cross-sectional study
Hirshman,E., Merritt,P., Wang,C.C., Wiernan,M., Budescu,D.V., Kohrt,W., Templin,J.L., Bhasin,S., Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women, <i>Hormones and Behavior</i> , 45, 144-155, 2004	Wrong intervention
Hogervorst,E., Prevention of dementia with sex hormones: a focus on testosterone and cognition in women, <i>Minerva Medica</i> , 103, 353-359, 2012	Wrong intervention
Hogervorst,E., Bandelow,S., Sex steroids to maintain cognitive function in women after the menopause: a meta-analyses of treatment trials. [76 refs], <i>Maturitas</i> , 66, 56-71, 2010	Meta-analysis, wrong study design
Hogervorst,E., Bandelow,S., Moffat,S.D., Increasing testosterone levels and effects on cognitive functions in elderly men and women: A review, <i>Current Drug Targets: CNS and Neurological Disorders</i> , 4, 531-540, 2005	Wrong intervention
Hogervorst,E., Boshuisen,M., Riedel,W., Willeken,C., Jolles,J., 1998 Curt P. Richter Award. The effect of hormone replacement therapy on cognitive function in elderly women, <i>Psychoneuroendocrinology</i> , 24, 43-68, 1999	Sample size <50
Hogervorst,E., Boshuisen,M., Riedel,W., Willeken,C., Jolles,J., The effect of hormone replacement therapy on cognitive function in elderly women, <i>Psychoneuroendocrinology</i> , 24, 43-68, 1999	Duplicate of 300024
Hogervorst,E., Williams,J., Budge,M., Riedel,W., Jolles,J., The nature of the effect of female gonadal hormone replacement therapy on cognitive function in postmenopausal women: a meta-analysis, <i>Neuroscience</i> , 101, 485-512, 2000	Meta-analysis, wrong study design
Hogervorst,E., Yaffe,K., Richards,M., Huppert,F., Hormone replacement therapy for cognitive function in postmenopausal women. [52 refs][Update in Cochrane Database Syst Rev. 2008;(1):CD003122; PMID: 18254016], <i>Cochrane Database of Systematic Reviews</i> , CD003122-, 2002	Wrong study design
Hogervorst,E., Yaffe,K., Richards,M., Huppert,F., Hormone replacement therapy for cognitive function in postmenopausal women, <i>Cochrane database of systematic reviews (Online)</i> , 2002. Date of Publication, -, 2002	Systematic review, wrong study design
Hogervorst,E., Yaffe,K., Richards,M., Huppert,F., Hormone replacement therapy to maintain cognitive function in women with dementia. [49 refs][Update in Cochrane Database Syst Rev. 2009;(1):CD003799; PMID: 19160224], <i>Cochrane Database of Systematic Reviews</i> , CD003799-, 2002	Wrong study design
Hogervorst,E., Yaffe,K., Richards,M., Huppert,F., Hormone replacement therapy to maintain cognitive function in women with dementia, <i>Cochrane database of systematic reviews (Online)</i> , 2002. Date of Publication, -, 2002	Wrong study design
Hogue,C.W., Freedland,K., Hershey,T., Fucetola,R., Nassief,A., Barzilai,B., Thomas,B., Birge,S., Dixon,D., Schechtman,K.B., vila-Roman,V.G., Neurocognitive outcomes are not improved by 17beta-estradiol in postmenopausal women undergoing cardiac surgery, <i>Stroke; a journal of cerebral circulation</i> , 38, 2048-2054, 2007	Wrong intervention, main intervention was cardiac surgery
Hogue,C.W., Fucetola,R., Hershey,T., Nassief,A., Birge,S., vila-Roman,V.G., Barzilai,B., Thomas,B., Schechtman,K.B., Freedland,K., The role of postoperative neurocognitive dysfunction on quality of life for postmenopausal women 6 months after cardiac surgery, <i>Anesthesia and Analgesia</i> , 107, 21-28, 2008	Study did not report outcomes stated in protocol
Holinka,C.F., Design and conduct of clinical trials in hormone replacement therapy. [77 refs], <i>Annals of the New York Academy of Sciences</i> , 943, 89-108, 2001	Literature review
Hoskin,E.K., Tang,M.X., Manly,J.J., Mayeux,R., Elevated sex-hormone binding globulin in elderly women with Alzheimer's disease, <i>Neurobiology of Aging</i> , 25, 141-147, 2004	Wrong intervention
Howard,H., The early vs. late intervention trial with estradiol (ELITE), <i>Climacteric</i> , 14, 35-, 2011	Conference abstract
Hu,L., Yue,Y., Zuo,P.P., Jin,Z.Y., Feng,F., You,H., Li,M.L., Ge,Q.S., Evaluation of neuroprotective effects of long-term low dose hormone replacement therapy on postmenopausal women brain hippocampus using magnetic resonance scanner, <i>Chinese Medical Sciences Journal</i> , 21, 214-218, 2006	Wrong intervention
Hudson,T., Women's Health Update, <i>Alternative and Complementary Therapies</i> , 9, 264-267, 2003	Wrong study type, not enough information
Huerta-Ramos,E., Iniesta,R., Ochoa,S., Cobo,J., Miquel,E., Roca,M., Serrano-Blanco,A., Teba,F., Usall,J., Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial, <i>European Neuropsychopharmacology</i> , 24, 223-231, 2014	Wrong population

Study	Reason for exclusion
Huerta-Ramos,M.E., Usall,J., Iniesta,R., Cobo,J., Araya,S., Roca,M., Serrano-Blanco,A., Teba,F., Ochoa,S., Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: Neuropsychological effects, Archives of Women's Mental Health, 14, S160-, 2011	Conference abstract
Hunter,M., O'Dea,I., Cognitive appraisal of the menopause: The menopause representations questionnaire (MRQ), Psychology, Health and Medicine, 6, 65-76, 2001	Wrong study design
Ishii,M., Neurologic complications of nondiabetic endocrine disorders, CONTINUUM: Lifelong Learning in Neurology, 20, 560-579, 2014	Wrong population
Ishunina,T.A., Fischer,D.F., Swaab,D.F., Estrogen receptor alpha and its splice variants in the hippocampus in aging and Alzheimer's disease, Neurobiology of Aging, 28, 1670-1681, 2007	wrong study design
Jacobs,D.M., Tang,M.X., Stern,Y., Sano,M., Marder,K., Bell,K.L., Schofield,P., Dooneief,G., Gurland,B., Mayeux,R., Cognitive function in nondemented older women who took estrogen after menopause, Neurology, 50, 368-373, 1998	Outcomes did not match protocol
Jacobs,E.G., Kroenke,C., Lin,J., Epel,E.S., Kenna,H.A., Blackburn,E.H., Rasgon,N.L., Accelerated cell aging in female APOE-[epsilon]4 carriers: implications for hormone therapy use, PloS one, 8, e54713, 2013-, 2013	Outcomes reported in study not stated in protocol
Jefremov,V., Rakitin,A., Mahlapuu,R., Zilmer,K., Bogdanovic,N., Zilmer,M., Karelson,E., 17beta-Oestradiol stimulation of G-proteins in aged and Alzheimer's human brain: comparison with phytoestrogens, Journal of Neuroendocrinology, 20, 587-596, 2008	Wrong study design, research
Joffe,H., Hall,J.E., Gruber,S., Sarmiento,I.A., Cohen,L.S., Yurgelun-Todd,D., Martin,K.A., Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women, Menopause, 13, 411-422, 2006	Short term study, 12 weeks
Joffe,H., Soares,C.N., Cohen,L.S., Assessment and treatment of hot flushes and menopausal mood disturbance. [114 refs], Psychiatric Clinics of North America, 26, 563-580, 2003	Literature review
John,J.A.S., Henderson,V.W., Hodis,H.N., Kono,N., McCleary,C.A., Franke,A.A., Mack,W.J., Associations between urine excretion of isoflavonoids and cognition in postmenopausal women in the Women'S Isoflavone Soy Health clinical trial, Journal of the American Geriatrics Society, 62, 629-635, 2014	Wrong topic, urine excretion and cognitive change
Kaiser-Pagliarini,T.G., Hachul,H.C., Maciel,A.L., Yagihara,F.T., Garbuio,S.A., Freire,A.O., Tufik,S., Bittencourt,L.R.A., Acupuncture in Insomnia and its consequences in postmenopausalwomen, Sleep Medicine, 10, S18-, 2009	Conference abstract
Kang,J.H., Grodstein,F., Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline, Neurobiology of Aging, 33, 1129-1137, 2012	Outcomes did not match protocol
Kaufert,P., Boggs,P.P., Ettinger,B., Woods,N.F., Utian,W.H., Women and menopause: beliefs, attitudes, and behaviors. The North American Menopause Society 1997 Menopause Survey, Menopause, 5, 197-202, 1998	Wrong study design, survey
Kaweski,S., Anti-aging medicine: Part I. Hormone replacement therapy in women, Plastic and Reconstructive Surgery, 111, 935-938, 2003	Wrong study design
Kaya,E., Sahin,F.K., Koken,G., Kose,M., Cevrioglu,A.S., Acute effect of intranasal estrogen on cerebral and cerebellar perfusion in postmenopausal women, Maturitas, 59, 72-82, 2008	Outcomes in study not stated in protocol
Kenemans,P., van Unnik,G.A., Mijatovic,V., van der Mooren,M.J., Perspectives in hormone replacement therapy. [58 refs], Maturitas, 38 Suppl 1, S41-S48, 2001	Literature review
Kernan,W.N., Viscolti,C.M., Brass,L.M., Gill,T.M., Sarrel,P.M., Horwitz,R.I., Decline in physical performance among women with a recent transient ischemic attack or ischemic stroke: Opportunities for functional preservation. A report of the women's estrogen stroke trial, Stroke, 36, 630-634, 2005	Wrong topic
Kim,H., Xu,J., Su,Y., Xia,H., Li,L., Peterson,G., Murphy-Ullrich,J., Barnes,S., Actions of the soy phytoestrogen genistein in models of human chronic disease: potential involvement of transforming growth factor beta, Biochemical Society Transactions, 29, 216-222, 2001	Wrong intervention
King,R., Travers,C., O'Neill,S., Byrne,G., Khoo,S.K., The influence of postmenopausal hormone replacement therapy on cognitive functioning: results from an observational study, Journal of the British Menopause Society, 10, 103-107, 2004	Data in study unadjusted
Klaiber,E.L., Kobayashi,Y., Broverman,D.M., Hall,F., Plasma monoamine oxidase activity in regularly menstruating women and in amenorrheic women receiving cyclic treatment with estrogens and a progestogen, Journal of Clinical Endocrinology and Metabolism, 33, 630-638, 1971	Outcomes in study not stated in protocol
Ko,Y.H., Joe,S.H., Cho,W., Park,J.H., Lee,J.J., Jung,I.K., Kim,L., Kim,S.H., Effect of hormone replacement therapy on cognitive function in women with chronic schizophrenia, International Journal of Psychiatry in Clinical Practice, 10, 97-104, 2006	Wrong population
Kocoska-Maras,L., Radestad,A.F., Carlstrom,K., Backstrom,T., von,Schoultz B., Hirschberg,A.L., Cognitive function in association with sex hormones in postmenopausal women, Gynecological Endocrinology, 29, 59-62, 2013	Outcomes and comparators not of interest, endocrine protein and cognition
Kocoska-Maras,L., Zethraeus,N., Radestad,A.F., Ellingsen,T., von,Schoultz B., Johannesson,M., Hirschberg,A.L., A randomized trial of the effect of testosterone	4 week study, short term



Study	Reason for exclusion
and estrogen on verbal fluency, verbal memory, and spatial ability in healthy postmenopausal women, <i>Fertility and Sterility</i> , 95, 152-157, 2011	
Kok,H.S., Kuh,D., Cooper,R., van der Schouw,Y.T., Grobbee,D.E., Wadsworth,M.E., Richards,M., Cognitive function across the life course and the menopausal transition in a British birth cohort, <i>Menopause</i> , 13, 19-27, 2006	Outcomes did not match protocol
Kopernik,G., Shoham,Z., Tools for making correct decisions regarding hormone therapy. Part II. Organ response and clinical applications. [172 refs], <i>Fertility and Sterility</i> , 81, 1458-1477, 2004	Wrong study design
Kouri,E.M., Halbreich,U., Psychotropic effects of hormonal replacement therapy, <i>Drugs of Today</i> , 34, 251-257, 1998	Wrong study design
Kramer,J.H., Yaffe,K., Lengenfelder,J., Delis,D.C., Age and gender interactions on verbal memory performance, <i>Journal of the International Neuropsychological Society</i> , 9, 97-102, 2003	Wrong population
Kreatsoulas,C., Anand,S.S., Menopausal hormone therapy for the primary prevention of chronic conditions. U.S. Preventive Services Task Force recommendation statement, <i>Polskie Archiwum Medycyny Wewnetrznej</i> , 123, 112-117, 2013	Wrong study design
Kreijkamp-Kaspers,S., Kok,L., Grobbee,D.E., de Haan,E.H., Aleman,A., Lampe,J.W., van der Schouw,Y.T., Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial, <i>JAMA</i> , 292, 65-74, 2004	Wrong intervention
Krug,R., Born,J., Rasch,B., A 3-day estrogen treatment improves prefrontal cortex-dependent cognitive function in postmenopausal women, <i>Psychoneuroendocrinology</i> , 31, 965-975, 2006	Short term use of HRT
Kudchadkar,R., O'Regan,R.M., Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer, <i>Ca-A Cancer Journal for Clinicians</i> , 55, 145-163, 2005	Wrong population and intervention
Kulasingam,S., Moineddin,R., Lewis,J.E., Tierney,M.C., The validity of the Menopause Specific Quality of Life Questionnaire in older women, <i>Maturitas</i> , 60, 239-243, 2008	Wrong intervention
Kulkarni,J., Gurvich,C., Gilbert,H., Mehmedbegovic,F., Mu,L., Marston,N., Gavrilidis,E., de,Castella A., Hormone modulation: a novel therapeutic approach for women with severe mental illness, <i>Australian and New Zealand Journal of Psychiatry</i> , 42, 83-88, 2008	Wrong study design
Kulkarni,J., Roberts,K.A., Ong,V., Gavrilidis,E., Gurvich,C., De,CastellaA, Chaviaras,S., Damodaran,S., Hanna,B., Berk,M., Estrogen treatment for women with schizophrenia: Results from 2 placebo controlled trials, <i>Schizophrenia Bulletin</i> , 37, 312-, 2011	Conference abstract
Kuller,L.H., Hormone replacement therapy and coronary heart disease. A new debate. [93 refs], <i>Medical Clinics of North America</i> , 84, 181-198, 2000	Wrong outcome, coronary heart disease
Labrle,F., Role of intracrinology or peripheral sex steroid formation in women and men, <i>Revista Argentina de Endocrinologia y Metabolismo</i> , 49, 16-18, 2012	Conference abstract
Laine,K., Palovaara,S., Tapanainen,P., Manninen,P., Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy, <i>Clinical Pharmacology and Therapeutics</i> , 66, 602-608, 1999	Wrong outcome and study design
Lamberts,S.W., The endocrinology of gonadal involution: menopause and andropause. [32 refs], <i>Annales d Endocrinologie</i> , 64, 77-81, 2003	Literature review
Lamy,O., Krieg,M.A., Burckhardt,P., Wasserfallen,J.B., An economic analysis of hormone replacement therapy for the prevention of fracture in young postmenopausal women, <i>Expert Opinion on Pharmacotherapy</i> , 4, 1479-1488, 2003	Wrong study design, wrong population, economic evaluation
Langer,R.D., Manson,J.E., Allison,M.A., Have we come full circle or moved forward? the Women's Health Initiative 10 years on, <i>Climacteric</i> , 15, 206-212, 2012	Literature review
LeBlanc,E.S., Hormone therapy with oestrogen or oestrogen plus progesterone decreases cognitive function in older postmenopausal women, <i>Evidence-Based Healthcare and Public Health</i> , 8, 398-401, 2004	Commentary
LeBlanc,E.S., Neiss,M.B., Carello,P.E., Samuels,M.H., Janowsky,J.S., Hot flashes and estrogen therapy do not influence cognition in early menopausal women, <i>Menopause</i> , 14, 191-202, 2007	Sample size <50
Lee,G.J., Curiel,A.R., Miller,K.J., Amano,S., Gorsuch,R., Small,G.W., Language performance in postmenopausal women with and without hormone therapy and men, <i>Aging Health</i> , 8, 625-632, 2012	Study compared postmenopausal women with men of similar age
Lejbak,L., Vrbancic,M., Crossley,M., Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer, <i>Journal of Clinical and Experimental Neuropsychology: Official Journal of the International Neuropsychological Society</i> , 32, 836-846, 2010	Wrong population
Leon,R.L., Huber,J.D., Rosen,C.L., Potential age-dependent effects of estrogen on neural injury, <i>American Journal of Pathology</i> , 178, 2450-2460, 2011	Systematic review
Leong,S.L., Erickson,D.R., Pees,R.C., Hormone replacement therapy: the right choice for your patient?, <i>Journal of Family Practice</i> , 54, 428-436, 2005	Background reading
Lethaby,Anne, Marjoribanks,Jane, Kronenberg,Fredi, Roberts,Helen, Eden,John, Brown,Julie, Phytoestrogens for menopausal vasomotor symptoms, <i>Cochrane Database of Systematic Reviews</i> , -, 2013	Study looks at vasomotor symptoms, not dementia

Study	Reason for exclusion
Levine,A.J., Hewett,L., Estrogen replacement therapy and frontotemporal dementia, <i>Maturitas</i> , 45, 83-88, 2003	Mean age of current users was > 70 years
Lindamer,L.A., Buse,D.C., Lohr,J.B., Jeste,D.V., Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms?, <i>Biological Psychiatry</i> , 49, 47-51, 2001	Wrong population, schizophrenia
Linzmayr,L., Semlitsch,H.V., Saletu,B., Bock,G., Saletu-Zyhlarz,G., Zoghiami,A., Gruber,D., Metka,M., Huber,J., Oettel,M., Graser,T., Grunberger,J., Double-blind, placebo-controlled psychometric studies on the effects of a combined estrogen-progestogen regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients, <i>Arzneimittel-Forschung</i> , 51, 238-245, 2001	Wrong population, menopause and insomnia
Liu,J.H., Therapeutic effects of progestogens, androgens, and tibolone for menopausal symptoms. [38 refs], <i>American Journal of Medicine</i> , 118 Suppl 12B, 88-92, 2005	Wrong study design
Lobo,R.A., Views on recent trials and the future of hormonal therapy, <i>Clinical Obstetrics and Gynecology</i> , 47, 424-427, 2004	Literature review
Lokkegaard,E., Pedersen,A.T., Laursen,P., Loft,I.P., Larsen,S., Jorgensen,T., The influence of hormone replacement therapy on the aging-related change in cognitive performance. Analysis based on a Danish cohort study, <i>Maturitas</i> , 42, 209-218, 2002	No information on adjustment of covariates in analysis
LopezYarto,Maite, RodriguezMartin,Luis Jose, AlonsoCoello,Pablo, Dehydroepiandrosterone for postmenopausal women, <i>Cochrane Database of Systematic Reviews</i> , -, 2009	Protocol
Lord,C., Buss,C., Lupien,S.J., Pruessner,J.C., Hippocampal volumes are larger in postmenopausal women using estrogen therapy compared to past users, never users and men: a possible window of opportunity effect, <i>Neurobiology of Aging</i> , 29, 95-101, 2008	Study looking at hippocampal volumes
Losak,J., Kranz,G., Hahn,A., Sladky,R., Hofflich,A., Baldinger,P., Vanicek,T., Windischberger,C., Kasper,S., Lanzenberger,R., Long-term estradiol treatment induces changes in brain activation during cognitive task performance in fMRI, <i>European Neuropsychopharmacology</i> , 22, S193-, 2012	Conference abstract
Love,T., Smith,Y.R., Persad,C.C., Tkaczyk,A., Zubieta,J.K., Short-term hormone treatment modulates emotion response circuitry in postmenopausal women, <i>Fertility and Sterility</i> , 93, 1929-1937, 2010	Cross-over trial, reported outcome in study was emotion response
Low,L.F., Anstey,K.J., Jorm,A.F., Rodgers,B., Christensen,H., Reproductive period and cognitive function in a representative sample of naturally postmenopausal women aged 60-64 years, <i>Climacteric</i> , 8, 380-389, 2005	Wrong study design
Low,L.F., Anstey,K.J., Maller,J., Kumar,R., Wen,W., Lux,O., Salonikas,C., Naidoo,D., Sachdev,P., Hormone replacement therapy, brain volumes and white matter in postmenopausal women aged 60-64 years, <i>Neuroreport</i> , 17, 101-104, 2006	Wrong intervention, MRI
Lucas,R., Azevedo,A., Barros,H., Self-reported data on reproductive variables were reliable among postmenopausal women, <i>Journal of Clinical Epidemiology</i> , 61, 945-950, 2008	Wrong outcome, self-reported outcomes
Luetters,C., Huang,M.H., Seeman,T., Buckwalter,G., Meyer,P.M., Avis,N.E., Sternfeld,B., Johnston,J.M., Greendale,G.A., Menopause transition stage and endogenous estradiol and follicle-stimulating hormone levels are not related to cognitive performance: cross-sectional results from the study of women's health across the nation (SWAN), <i>Journal of Women's Health</i> , 16, 331-344, 2007	Wrong study design, cross-sectional study
MacLennan,A.H., The trials and tribulations of long-term postmenopausal hormone therapy, <i>Obstetrical and Gynecological Survey</i> , 59, 65-67, 2004	Literature review
MacLennan,A.H., Henderson,V.W., Paine,B.J., Mathias,J., Ramsay,E.N., Ryan,P., Stocks,N.P., Taylor,A.W., Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: The REMEMBER pilot study, <i>Menopause</i> , 13, 28-36, 2006	Outcomes did not match protocol
Maggio,M., Ceda,G.P., Lauretani,F., Bandinelli,S., Ruggiero,C., Guralnik,J.M., Jeffrey,MetterE, Ling,S.M., Paolisso,G., Valenti,G., Cappola,A.R., Ferrucci,L., Relationship between higher estradiol levels and 9-year mortality in older women, <i>Journal of the American Geriatrics Society</i> , 57, 1810-1815, 2009	This study follows women who are not on HRT and are age >65 years and serum oestradiol levels for 9 years
Magri,F., Gabellieri,E., Busconi,L., Guazzoni,V., Cravello,L., Valdes,V., Sorrentino,A.R., Chytiris,S., Ferrari,E., Cardiovascular, anthropometric and neurocognitive features of healthy postmenopausal women: effects of hormone replacement therapy, <i>Life Sciences</i> , 78, 2625-2632, 2006	Wrong study design
Maki,P., Hogervorst,E., The menopause and HRT. HRT and cognitive decline, <i>Best practice &amp; research</i> , 17, 105-122, 2003	Literature review
Maki,P.M., Hormone therapy and cognitive function: is there a critical period for benefit?. [42 refs], <i>Neuroscience</i> , 138, 1027-1030, 2006	Literature review
Maki,P.M., Minireview: effects of different HT formulations on cognition, <i>Endocrinology</i> , 153, 3564-3570, 2012	Literature review
Maki,P.M., The timing of estrogen therapy after ovariectomy--implications for neurocognitive function, <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 4, 494-495, 2008	Literature review
Maki,P.M., Dennerstein,L., Clark,M., Guthrie,J., LaMontagne,P., Fornelli,D., Little,D., Henderson,V.W., Resnick,S.M., Perimenopausal use of hormone therapy	Outcome in study not stated in protocol

Study	Reason for exclusion
is associated with enhanced memory and hippocampal function later in life, <i>Brain Research</i> , 1379, 232-243, 2011	
Maki,P.M., Dumas,J., Mechanisms of action of estrogen in the brain: insights from human neuroimaging and psychopharmacologic studies. [66 refs], <i>Seminars in Reproductive Medicine</i> , 27, 250-259, 2009	Literature review
Maki,P.M., Gast,M.J., Vieweg,A.J., Burriss,S.W., Yaffe,K., Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial, <i>Neurology</i> , 69, 1322-1330, 2007	Study duration 4 months, short term
Maki,P.M., Resnick,S.M., Effects of estrogen on patterns of brain activity at rest and during cognitive activity: a review of neuroimaging studies. [90 refs], <i>Neuroimage</i> , 14, 789-801, 2001	Literature review
Maki,P.M., Rubin,L.H., Fornelli,D., Drogos,L., Banuvar,S., Shulman,L.P., Geller,S.E., Effects of botanicals and combined hormone therapy on cognition in postmenopausal women, <i>Menopause</i> , 16, 1167-1177, 2009	Wrong intervention
Maki,P.M., Sundermann,E., Hormone therapy and cognitive function. [118 refs], <i>Human Reproduction Update</i> , 15, 667-681, 2009	Wrong study design
Maki,P.M., Freeman,E.W., Greendale,G.A., Henderson,V.W., Newhouse,P.A., Schmidt,P.J., Scott,N.F., Shively,C.A., Soares,C.N., Summary of the National Institute on Aging-sponsored conference on depressive symptoms and cognitive complaints in the menopausal transition, <i>Menopause</i> , 17, 815-822, 2010	Summary from conference
Manson,J.E., The kronos early estrogen prevention study (KEEPS): Rationale, design & baseline characteristics of the study population, <i>Menopause</i> , 19, 1365-, 2012	Conference abstract
Manson,J.E., Bassuk,S.S., Harman,S.M., Brinton,E.A., Cedars,M.I., Lobo,R., Merriam,G.R., Miller,V.M., Naftolin,F., Santoro,N., Postmenopausal hormone therapy: new questions and the case for new clinical trials, <i>Menopause</i> , 13, 139-147, 2006	Literature review
Manson,J.E., Chlebowski,R.T., Stefanick,M.L., Aragaki,A.K., Rossouw,J.E., Prentice,R.L., Anderson,G., Howard,B.V., Thomson,C.A., Lacroix,A.Z., Wactawski-Wende,J., Jackson,R.D., Limacher,M., Margolis,K.L., Wassertheil-Smoller,S., Beresford,S.A., Cauley,J.A., Eaton,C.B., Gass,M., Hsia,J., Johnson,K.C., Kooperberg,C., Kuller,L.H., Lewis,C.E., Liu,S., Martin,L.W., Ockene,J.K., O'Sullivan,M.J., Powell,L.H., Simon,M.S., Van,HornL., Vitamins,M.Z., Wallace,R.B., Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health initiative randomized trials, <i>JAMA - Journal of the American Medical Association</i> , 310, 1353-1368, 2013	For dementia, only overall risk of dementia for all included participants aged>65 years was assessed. No stratification by age for other outcomes
Marder,K., Tang,M.X., Alfaro,B., Mejia,H., Cote,L., Jacobs,D., Stern,Y., Sano,M., Mayeux,R., Postmenopausal estrogen use and Parkinson's disease with and without dementia, <i>Neurology</i> , 50, 1141-1143, 1998	No information on HRT duration of use and initiation of HRT
Marinho,R.M., Soares,J.M.,Jr., Santiago,R.C., Maganhin,C.C., Machado,F., de Miranda Cota,A.M., Baracat,E.C., Effects of estradiol on the cognitive function of postmenopausal women, <i>Maturitas</i> , 60, 230-234, 2008	Outcomes did not match protocol
Marjoribanks,J., Farquhar,C., Roberts,H., Lethaby,A., Long term hormone therapy for perimenopausal and postmenopausal women, <i>Cochrane database of systematic reviews (Online)</i> , 7, CD004143-, 2012	Systematic review
Markou,A., Duka,T., Prelevic,G.M., Estrogens and brain function, <i>Hormones (Athens, Greece)</i> , 4, 9-17, 2005	Literature review
Marks,R., Guertin,D., Postmenopausal osteoporosis and aerobic exercise: A review of the literature, <i>Current Rheumatology Reviews</i> , 2, 289-301, 2006	Literature review
Maruyama,H., Toji,H., Harrington,C.R., Sasaki,K., Izumi,Y., Ohnuma,T., Arai,H., Yasuda,M., Tanaka,C., Emson,P.C., Nakamura,S., Kawakami,H., Lack of an association of estrogen receptor alpha gene polymorphisms and transcriptional activity with Alzheimer disease, <i>Archives of Neurology</i> , 57, 236-240, 2000	Wrong outcome, gene transcriptional activity
Mazer,N.A., Testosterone deficiency in women: etiologies, diagnosis, and emerging treatments. [56 refs], <i>International Journal of Fertility and Womens Medicine</i> , 47, 77-86, 2002	Wrong topic, testosterone deficiency
Mazza,M., Bria,P., Taranto,C., Janiri,L., Mazza,S., Mood, hormones and quality of life. [27 refs], <i>Clinica Terapeutica</i> , 159, 105-109, 2008	Literature review
McLay,R.N., Maki,P.M., Lyketos,C.G., Nulliparity and late menopause are associated with decreased cognitive decline, <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 15, 161-167, 2003	Wrong topic
Merritt,P., Stangl,B., Hirshman,E., Verbalis,J., Administration of dehydroepiandrosterone (DHEA) increases serum levels of androgens and estrogens but does not enhance short-term memory in post-menopausal women, <i>Brain Research</i> , 1483, 54-62, 2012	Wrong intervention
Miller,E.H., Women and insomnia, <i>Clinical Cornerstone</i> , 6, S6-S18, 2004	Wrong population, insomnia
Miller,M.M., Franklin,K.B.J., Theoretical basis for the benefit of postmenopausal estrogen substitution, <i>Experimental Gerontology</i> , 34, 587-604, 1999	Literature review
Mitchell,E.S., Woods,N.F., Cognitive symptoms during the menopausal transition and early postmenopause, <i>Climacteric</i> , 14, 252-261, 2011	Wrong intervention
Mokbel,K., Focus on anastrozole and breast cancer. [17 refs], <i>Current Medical Research and Opinion</i> , 19, 683-688, 2003	Literature review
Moller,M.C., Bartfai,A.B., Radestad,A.F., Effects of testosterone and estrogen replacement on memory function, <i>Menopause</i> , 17, 983-989, 2010	Wrong intervention

Study	Reason for exclusion
Moller,M.C., Radestad,A.F., von,Schoultz B., Bartfai,A., Effect of estrogen and testosterone replacement therapy on cognitive fatigue, <i>Gynecological Endocrinology</i> , 29, 173-176, 2013	Study looking at cognitive fatigue
Molnar,G., Glaub,T., Such,A., Bazsane,K.Z., Pek,G., Csiky-Meszáros,M., Fulop,T., Ageing and problems in differential diagnosis of psychoorganic syndromes, <i>Archives of Gerontology and Geriatrics</i> , 16, 177-189, 1993	Wrong study design, diagnostic
Morales,L., Neven,P., Timmerman,D., Christiaens,M.R., Vergote,I., Van,Limbergen E., Carbonez,A., Van,Huffel S., Ameye,L., Paridaens,R., Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients, <i>Anti-Cancer Drugs</i> , 15, 753-760, 2004	Wrong population and intervention
Morgan,M.L., Rapkin,A.J., Biggio,G., Serra,M., Pisu,M.G., Rasgon,N., Neuroactive steroids after estrogen exposure in depressed postmenopausal women treated with sertraline and asymptomatic postmenopausal women, <i>Archives of Women's Mental Health</i> , 13, 91-98, 2010	Wrong population
Morse,C.A., Rice,K., Memory after menopause: preliminary considerations of hormone influence on cognitive functioning, <i>Archives of Women's Mental Health</i> , 8, 155-162, 2005	Literature review
Mortel,K.F., Meyer,J.S., Lack of postmenopausal estrogen replacement therapy and the risk of dementia, <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 7, 334-337, 1995	Participants age >65 years at enrolment, no information about prior HRT use and duration of HRT use and association with dementia
Mucowski,S.J., Shoupe,D., Dang,H., Henderson,V., Kono,N., Hodis,H.N., MacK,W.J., The effect of soy isoflavones on menopausal vasomotor flushing, <i>Fertility and Sterility</i> , 99, S35-, 2013	Conference abstract
Mulnard,R.A., Cotman,C.W., Kawas,C., van Dyck,C.H., Sano,M., Doody,R., Koss,E., Pfeiffer,E., Jin,S., Gamst,A., Grundman,M., Thomas,R., Thal,L.J., Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. <i>Alzheimer's Disease Cooperative Study</i> , <i>JAMA : the journal of the American Medical Association</i> , 283, 1007-1015, 2000	Participants mean age 74 years at enrolment
Naftolin,F., The kronos early estrogen prevention study (KEEPS), <i>Climacteric</i> , 14, 35-36, 2011	Conference abstract
Nagels,Helen E., Rishworth,Josephine R., Siristatidis,Charalambos S., Kroon,Ben, Androgens (dehydroepiandrosterone or testosterone) in women undergoing assisted reproduction, <i>Cochrane Database of Systematic Reviews</i> , -, 2012	Protocol
Naheed,Bushra, O'Brien,Michael Patrick, Uthman,Olaalekan A., O'Mahony,Fidelma, Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome, <i>Cochrane Database of Systematic Reviews</i> , -, 2013	Protocol
Natale,V., Albertazzi,P., Zini,M., Di,Micco R., Exploration of cyclical changes in memory and mood in postmenopausal women taking sequential combined oestrogen and progestogen preparations, <i>BJOG: An International Journal of Obstetrics and Gynaecology</i> , 108, 286-290, 2001	Sample size <50
Neele,S.J., Rombouts,S.A., Bierlaagh,M.A., Barkhof,F., Scheltens,P., Netelenbos,J.C., Raloxifene affects brain activation patterns in postmenopausal women during visual encoding, <i>Journal of Clinical Endocrinology and Metabolism</i> , 86, 1422-1424, 2001	Wrong study design, experimental
Nelson,H.D., Walker,M., Zakher,B., Mitchell,J., Menopausal hormone therapy for the primary prevention of chronic conditions: systematic review to update the 2002 and 2005 U.S. Preventive Services Task Force Recommendations (Structured abstract), <i>Health Technology Assessment Database</i> , -, 2014	Systematic review
Newhouse,P., Albert,K., Astur,R., Johnson,J., Naylor,M., Dumas,J., Tamoxifen improves cholinergically modulated cognitive performance in postmenopausal women, <i>Neuropsychopharmacology</i> , 38, 2632-2643, 2013	Outcomes in study not stated in protocol
Newhouse,P.A., Dumas,J., Wilkins,H., Coderre,E., Sites,C.K., Naylor,M., Benkelfat,C., Young,S.N., Estrogen treatment impairs cognitive performance after psychosocial stress and monoamine depletion in postmenopausal women, <i>Menopause</i> , 17, 860-873, 2010	Outcomes in study not stated in protocol
Nickelsen,T., Lufkin,E.G., Riggs,B.L., Cox,D.A., Crook,T.H., Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women, <i>Psychoneuroendocrinology</i> , 24, 115-128, 1999	Outcomes did not match protocol
Niemeier,J.P., Marwitz,J.H., Walker,W.C., Davis,L.C., Bushnik,T., Ripley,D.L., Ketchum,J.M., Are there cognitive and neurobehavioural correlates of hormonal neuroprotection for women after TBI?, <i>Neuropsychological Rehabilitation</i> , 23, 363-382, 2013	Wrong population, traumatic brain injury
Nilsson,S., Kuiper,G., Gustafsson,J.A., ERbeta: a novel estrogen receptor offers the potential for new drug development, <i>Trends in Endocrinology and Metabolism</i> , 9, 387-395, 1998	Literature review
Nitkowska,M., Czyzyk,M., Friedman,A., Reproductive life characteristics in females affected with Parkinson's disease and in healthy control subjects - a comparative study on Polish population, <i>Neurologia i Neurochirurgia Polska</i> , 48, 322-327, 2014	Outcomes did not match protocol
Norbury,R., Travis,M.J., Erlandsson,K., Waddington,W., Ell,P.J., Murphy,D.G., Estrogen therapy and brain muscarinic receptor density in healthy females: a SPET study, <i>Hormones and Behavior</i> , 51, 249-257, 2007	Wrong intervention

Study	Reason for exclusion
O'Brien,J., Jackson,J.W., Grodstein,F., Blacker,D., Weuve,J., Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer's disease, <i>Epidemiologic Reviews</i> , 36, 83-103, 2014	Background reading
O'Hara,R., Schroder,C.M., Bloss,C., Bailey,A.M., Alyeshmerni,A.M., Mumenthaler,M.S., Friedman,L.F., Yesavage,J.A., Hormone replacement therapy and longitudinal cognitive performance in postmenopausal women, <i>American Journal of Geriatric Psychiatry</i> , 13, 1107-1110, 2005	Outcomes did not match protocol
Olsen,L., Rasmussen,H.B., Hansen,T., Bagger,Y.Z., Tanko,L.B., Qin,G., Christiansen,C., Werge,T., Estrogen receptor alpha and risk for cognitive impairment in postmenopausal women, <i>Psychiatric Genetics</i> , 16, 85-88, 2006	Wrong study type, experimental
Othman,Z., Shafin,N., Zakaria,R., Hussain,N.H.N., Mohammad,W.M.Z.W., Improvement in immediate memory after 16 weeks of tualang honey (Agro Mas) supplement in healthy postmenopausal women, <i>Menopause</i> , 18, 1219-1224, 2011	Wrong intervention, tualang honey
Owens,C.T., Estrogen replacement therapy for Alzheimer disease in postmenopausal women. [22 refs], <i>Annals of Pharmacotherapy</i> , 36, 1273-1276, 2002	Sample size <50
Owens,J.F., Matthews,K.A., Everson,S.A., Cognitive function effects of suppressing ovarian hormones in young women, <i>Menopause</i> , 9, 227-235, 2002	Wrong population, young healthy women
Pae,C.U., Mandelli,L., Han,C., Ham,B.J., Masand,P.S., Patkar,A.A., Steffens,D.C., De,Ronchi D., Serretti,A., Thyroid hormones affect recovery from depression during antidepressant treatment, <i>Psychiatry and Clinical Neurosciences</i> , 63, 305-313, 2009	Wrong intervention
Pae,C.U., Mandelli,L., Han,C., Ham,B.J., Masand,P.S., Patkar,A.A., Steffens,D.C., De,Ronchi D., Serretti,A., Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women, <i>Neuroendocrinology Letters</i> , 29, 500-506, 2008	Wrong intervention, antidepressant treatments
Paganini-Hill,A., Henderson,V.W., Estrogen replacement therapy and risk of Alzheimer disease, <i>Archives of Internal Medicine</i> , 156, 2213-2217, 1996	The study did not report age of women at menopause or when HRT was initiated
Paganini-Hill,A., Henderson,V.W., The effects of hormone replacement therapy, lipoprotein cholesterol levels, and other factors on a clock drawing task in older women, <i>Journal of the American Geriatrics Society</i> , 44, 818-822, 1996	Wrong intervention and population
Palmer,J.L., Trotter,T., Joy,A.A., Carlson,L.E., Cognitive effects of Tamoxifen in pre-menopausal women with breast cancer compared to healthy controls, <i>Journal of Cancer Survivorship</i> , 2, 275-282, 2008	Wrong population, breast cancer
Pan,H.A., Wang,S.T., Chen,C.H., Pai,M.C., Wu,M.H., Huang,K.E., Flow resistance in carotid and middle cerebral arteries in postmenopausal women: a comparative study of tibolone and continuous combined hormone replacement therapy, <i>Climacteric</i> , 5, 259-265, 2002	Wrong outcome, vascular resistance and serum lipids
Pan,H.A., Wang,S.T., Pai,M.C., Chen,C.H., Wu,M.H., Huang,K.E., Cognitive function variations in postmenopausal women treated with continuous, combined HRT or tibolone: A comparison, <i>Journal of Reproductive Medicine for the Obstetrician and Gynecologist</i> , 48, 375-380, 2003	Short term study, 6 months
Pan,M., Li,Z., Yeung,V., Xu,R.J., Dietary supplementation of soy germ phytoestrogens or estradiol improves spatial memory performance and increases gene expression of BDNF, TrkB receptor and synaptic factors in ovariectomized rats, <i>Nutrition and Metabolism</i> , 7, 75-, 2010	Wrong intervention, soy germ phytoestrogens
Parry,B.L., Meliska,C.J., Martinez,L.F., Basavaraj,N., Zirpoli,G.G., Sorenson,D., Maurer,E.L., Lopez,A., Markova,K., Gamst,A., Wolfson,T., Hauger,R., Kripke,D.F., Menopause: neuroendocrine changes and hormone replacement therapy, <i>Journal of the American Medical Womens Association</i> , 59, 135-145, 2004	Wrong outcomes, neuroendocrine variation
Patel,B.N., Pang,D., Stern,Y., Silverman,W., Kline,J.K., Mayeux,R., Schupf,N., Obesity enhances verbal memory in postmenopausal women with Down syndrome, <i>Neurobiology of Aging</i> , 25, 159-166, 2004	Obesity risk factor as intervention
Pefanco,M.A., Kenny,A.M., Kaplan,R.F., Kuchel,G., Walsh,S., Kleppinger,A., Prestwood,K., The effect of 3-year treatment with 0.25 mg/day of micronized 17beta-estradiol on cognitive function in older postmenopausal women, <i>Journal of the American Geriatrics Society</i> , 55, 426-431, 2007	Participants age >70 years at enrolment
Peri,A., Serio,M., Estrogen receptor-mediated neuroprotection: The role of the Alzheimer's disease-related gene seladin-1, <i>Neuropsychiatric Disease and Treatment</i> , 4, 817-824, 2008	Wrong study design, gene activity
Peskind,E.R., Pharmacologic approaches to cognitive deficits in Alzheimer's disease. [46 refs], <i>Journal of Clinical Psychiatry</i> , 59 Suppl 9, 22-27, 1998	Literature review
Petitti,D.B., Buckwalter,J.G., Crooks,V.C., Chiu,V., Prevalence of dementia in users of hormone replacement therapy as defined by prescription data, <i>Journals of Gerontology Series A-Biological Sciences and Medical Sciences</i> , 57, M532-M538, 2002	Participants age >75 years at enrolment
Pharm,M.P.G.B., Dragomir,A., Pilon,D., Moride,Y., Perreault,S., Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication, <i>Pharmacoepidemiology and Drug Safety</i> , 16, 17-27, 2007	Outcome in study not stated in protocol

Study	Reason for exclusion
Phillips,K.A., Bernhard,J., Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. [84 refs], Journal of the National Cancer Institute, 95, 190-197, 2003	Literature review
Phillips,K.A., Ribbi,K., Fisher,R., Do aromatase inhibitors have adverse effects on cognitive function?, Breast Cancer Research, 13, 203-, 2011	Literature review
Phillips,K.A., Ribbi,K., Sun,Z., Stephens,A., Thompson,A., Harvey,V., Thurlimann,B., Cardoso,F., Coates,A.S., Bernhard,J., Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen in the breast international group (BIG) 1-98 trial, Asia-Pacific Journal of Clinical Oncology, 5, A67-, 2009	Conference abstract
Phillips,S.M., Sherwin,B.B., Effects of estrogen on memory function in surgically menopausal women, Psychoneuroendocrinology, 17, 485-495, 1992	Wrong population, benign disease
Pines,A., Sturdee,D.W., Birkhauser,M.H., de,Villiers T., Naftolin,F., Gompel,A., Farmer,R., Barlow,D., Tan,D., Maki,P., Lobo,R., Hodis,H., International Menopause Society., HRT in the early menopause: scientific evidence and common perceptions, Climacteric, 11, 267-272, 2008	Literature review
Pitkin,J., Rees,M.C.P., Gray,S., Lumsden,M.A., Marsden,J., Stevenson,J., Williamson,J., Managing the menopause: British Menopause Society Council consensus statement on hormone replacement therapy, Journal of the British Menopause Society, 11, 152-156, 2005	Wrong study design
Pitkin,J., Rees,M.C.P., Gray,S., Lumsden,M.A., Stevenson,J., Williamson,J., Managing the menopause British Menopause Society Council consensus statement on hormone replacement therapy, Journal of the British Menopause Society, 9, 129-131, 2003	Wrong study design, consensus statements
Polo-Kantola,P., Portin,R., Polo,O., Helenius,H., Irljala,K., Erkkola,R., The effect of short-term estrogen replacement therapy on cognition: a randomized, double-blind, cross-over trial in postmenopausal women, Obstetrics and Gynecology, 91, 459-466, 1998	Short term study
Pottala,J.V., Yaffe,K., Robinson,J.G., Espeland,M.A., Wallace,R., Harris,W.S., Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI study, Neurology, 82, 435-442, 2014	Wrong outcomes, total brain volume and hippocampal volume
Power,M.L., Schulkin,J., Rossouw,J.E., Evolving practice patterns and attitudes toward hormone therapy of obstetrician-gynecologists, Menopause, 14, 20-28, 2007	Literature review
Pritchard,K.I., Hormonal replacement therapy in breast cancer. [87 refs], Annals of Oncology, 13 Suppl 4, 73-80, 2002	Wrong population, breast cancer
Rachon,D., Mysliwska,J., Suchecka-Rachon,K., Wieckiewicz,J., Mysliwski,A., Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women, Journal of Endocrinology, 172, 387-395, 2002	Wrong outcome measure, IL-6 production
Rapp,S.R., Espeland,M.A., Manson,J.E., Resnick,S.M., Bryan,N.R., Smoller,S., Coker,L.H., Phillips,L.S., Stefanick,M.L., Sarto,G.E., Women's Health Initiative Memory Study., Educational attainment, MRI changes, and cognitive function in older postmenopausal women from the Women's Health Initiative Memory Study, International Journal of Psychiatry in Medicine, 46, 121-143, 2013	Wrong outcomes, total ischaemic lesion, brain volume
Rapp,S.R., Espeland,M.A., Shumaker,S.A., Henderson,V.W., Brunner,R.L., Manson,J.E., Gass,M.L., Stefanick,M.L., Lane,D.S., Hays,J., Johnson,K.C., Coker,L.H., Dailey,M., Bowen,D., WHIMS,Investigators, Effect of estrogen plus progestogen on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial, JAMA, 289, 2663-2672, 2003	Outcomes did not match protocol
Rapp,S.R., Legault,C., Henderson,V.W., Brunner,R.L., Masaki,K., Jones,B., Absher,J., Thal,L., Subtypes of mild cognitive impairment in older postmenopausal women: The women s health initiative memory study, Alzheimer Disease and Associated Disorders, 24, 248-255, 2010	Wrong study design
Rasgon,N.L., Kenna,H.A., Wroolie,T., Geist,C., Epel,E., Kroenke,C., Lin,J., Silverman,D., Differential effects of estrogen preparation on changes in regional cerebral metabolism in postmenopausal women, Neuropsychopharmacology, 36, S407-, 2011	Conference abstract
Rasgon,N.L., Kenna,H.A., Wroolie,T.E., Williams,K.E., DeMuth,B.N., Silverman,D.H., Insulin resistance and medial prefrontal gyrus metabolism in women receiving hormone therapy, Psychiatry Research, 223, 28-36, 2014	Wrong outcome, insulin resistance, medial prefrontal gyrus metabolism
Rasgon,N.L., Magnusson,C., Johansson,A.L., Pedersen,N.L., Elman,S., Gatz,M., Endogenous and exogenous hormone exposure and risk of cognitive impairment in Swedish twins: a preliminary study, Psychoneuroendocrinology, 30, 558-567, 2005	Wrong study design, cross-sectional
Rasgon,N.L., Small,G.W., Siddarth,P., Miller,K., Ercoli,L.M., Bookheimer,S.Y., Lavretsky,H., Huang,S.C., Barrio,J.R., Phelps,M.E., Estrogen use and brain metabolic change in older adults. A preliminary report, Psychiatry Research, 107, 11-18, 2001	Wrong study design, report
Raz,L., Estrogen and cerebrovascular regulation in menopause, Molecular and Cellular Endocrinology, 389, 22-30, 2014	Literature review
Reboussin,B.A., Greendale,G.A., Espeland,M.A., Effect of hormone replacement therapy on self-reported cognitive symptoms: results from the Postmenopausal Estrogen/Progestogen Interventions (PEPI) trial, Climacteric, 1, 172-179, 1998	Outcomes did not match protocol

Study	Reason for exclusion
Reed,M.J., Purohit,A., Woo,L.W., Newman,S.P., Potter,B.V., Steroid sulfatase: molecular biology, regulation, and inhibition. [318 refs], <i>Endocrine Reviews</i> , 26, 171-202, 2005	Wrong study design, biology
Rehman,H.U., Masson,E.A., Neuroendocrinology of female aging. [132 refs], <i>Gender Medicine</i> , 2, 41-56, 2005	Systematic review
Resnick,S.M., Coker,L.H., Maki,P.M., Rapp,S.R., Espeland,M.A., Shumaker,S.A., The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline, <i>Clinical Trials</i> , 1, 440-450, 2004	No information on HRT dementia
Resnick,S.M., Espeland,M.A., An,Y., Maki,P.M., Coker,L.H., Jackson,R., Stefanick,M.L., Wallace,R., Rapp,S.R., Women's Health Initiative Study of Cognitive Aging Investigators., Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy, <i>Journal of Clinical Endocrinology and Metabolism</i> , 94, 4152-4161, 2009	Duplicate
Resnick,S.M., Espeland,M.A., Jaramillo,S.A., Hirsch,C., Stefanick,M.L., Murray,A.M., Ockene,J., Davatzikos,C., Postmenopausal hormone therapy and regional brain volumes: The WHIMS-MRI Study, <i>Neurology</i> , 72, 135-142, 2009	Participants age >65 years at enrolment. Prior hormone use was controlled for in analyses.
Resnick,S.M., Maki,P.M., Effects of hormone replacement therapy on cognitive and brain aging. [57 refs], <i>Annals of the New York Academy of Sciences</i> , 949, 203-214, 2001	Literature review
Resnick,S.M., Maki,P.M., Rapp,S.R., Espeland,M.A., Brunner,R., Coker,L.H., Granek,I.A., Hogan,P., Ockene,J.K., Shumaker,S.A., Women's Health Initiative Study of Cognitive Aging Investigators., Effects of combination estrogen plus progestogen hormone treatment on cognition and affect, <i>Journal of Clinical Endocrinology and Metabolism</i> , 91, 1802-1810, 2006	Outcomes did not match protocol
Resnick,S.M., Metter,E.J., Zonderman,A.B., Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect?, <i>Neurology</i> , 49, 1491-1497, 1997	Outcome in study not stated in protocol
Ribi,K.E., Phillips,K.A., Sun,Z., Stephens,A., Thompson,A., Harvey,V., Thurlimann,B., Cardoso,F., Coates,A.S., Bernhard,J., Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial, <i>Journal of Clinical Oncology</i> , 27, 510-, 2009	Conference abstract
Rice,K., Morse,C., Measuring cognition in menopause research: A review of test use, <i>Climacteric</i> , 6, 2-22, 2003	Wrong study design, review
Rice,M.M., Graves,A.B., McCurry,S.M., Gibbons,L.E., Bowen,J.D., McCormick,W.C., Larson,E.B., Postmenopausal estrogen and estrogen-progestogen use and 2-year rate of cognitive change in a cohort of older Japanese American women: The Kame Project, <i>Archives of Internal Medicine</i> , 160, 1641-1649, 2000	Timing and duration of past use of HRT could not be determined from the study
Rice,M.M., Graves,A.B., McCurry,S.M., Larson,E.B., Estrogen replacement therapy and cognitive function in postmenopausal women without dementia. [53 refs], <i>American Journal of Medicine</i> , 103, 26S-35S, 1997	Literature review
Richards,M., Kuh,D., Hardy,R., Wadsworth,M., Lifetime cognitive function and timing of the natural menopause, <i>Neurology</i> , 53, 308-314, 1999	Intervention reported as outcome
Rigano,A., Rigano,M., Cancellieri,F., Pulle,C., Sexually and well-being in early menopause. Effect of transdermal estradiol therapy, <i>Panminerva Medica</i> , 43, 115-118, 2001	Outcomes reported in study not stated in protocol
Rigaud,A.S., Andre,G., Vellas,B., Touchon,J., Pere,J.J., French Study Group., No additional benefit of HRT on response to rivastigmine in menopausal women with AD, <i>Neurology</i> , 60, 148-149, 2003	Wrong intervention, revastigmine (used for dementia)
Roach,E.J., Rachel, Helmerhorst,Frans M., Lijfering,M., Willem, Algra,Ale, Dekkers,Olaf M., Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke, <i>Cochrane Database of Systematic Reviews</i> , -, 2014	Wrong outcomes, MI, and ischaemic stroke
Rocca, W.A., Bower, J.H., Maraganore, D.M., Ahlskog, J.E., Grossardt, B.R., de Andrade, M., Melton, L.J. 3 <sup>rd</sup> ., Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause, <i>Neurology</i> , 69, 11, 1074-1783, 2007	Study design did not match protocol criteria
Rocca,W.A., Grossardt,B.R., Shuster,L.T., Oophorectomy, menopause, estrogen, and cognitive aging: the timing hypothesis. [20 refs], <i>Neurodegenerative Diseases</i> , 7, 163-166, 2010	Wrong study design
Rocca,W.A., Grossardt,B.R., Shuster,L.T., Oophorectomy, estrogen, and dementia: a 2014 update, <i>Molecular and Cellular Endocrinology</i> , 389, 7-12, 2014	Systematic review
Rogines-Velo,M.P., Heberle,A.E., Joffe,H., Effect of medroxyprogesterone on depressive symptoms in depressed and nondepressed perimenopausal and postmenopausal women after discontinuation of transdermal estradiol therapy, <i>Menopause</i> , 19, 471-475, 2012	Wrong outcome, depressive symptoms
Rolnick,S.J., Kopher,R.A., DeFor,T.A., Kelley,M.E., Hormone use and patient concerns after the findings of the Women's Health Initiative, <i>Menopause</i> , 12, 399-404, 2005	Literature review
Rubin,L.H., Walega,D.R., Banuvar,S., Shulman,L., Maki,P., Reductions in objective vasomotor symptoms are positively associated with improvements in verbal learning: Findings from an RCT of stellate ganglion blockade for the treatment of vasomotor symptoms, <i>Menopause</i> , 20, 1350-1351, 2013	Conference abstract

Study	Reason for exclusion
Rudolph,I., Zimmermann,T., Kaminski,K., Jandova,K., Borovsky,B., Ahrendt,H.J., Golbs,S., Changes in psychic and somatic well-being and cognitive capabilities of peri- and postmenopausal women after the use of a hormone replacement drug containing estradiol valerate and levonorgestrel, <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 22, 51-56, 2000	Wrong study design, open-label post marketing surveillance study
Ruiz,A.D., Daniels,K.R., The effectiveness of sublingual and topical compounded bioidentical hormone replacement therapy in postmenopausal women: an observational cohort study, <i>International Journal of Pharmaceutical Compound</i> , 18, 70-77, 2014	Outcomes in study not stated in protocol
Ryan,J., Carriere,I., Scali,J., Dartigues,J.F., Tzourio,C., Poncet,M., Ritchie,K., Ancelin,M.L., Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study, <i>Neurology</i> , 73, 1729-1737, 2009	Mean age of participants initiating HRT was >70 years
Ryan,J., Scali,J., Carriere,I., Amieva,H., Rouaud,O., Berr,C., Ritchie,K., Ancelin,M.L., Impact of a premature menopause on cognitive function in later life, <i>BJOG: An International Journal of Obstetrics and Gynaecology</i> , 121, 1729-1739, 2014	The study does not report (unclear)the time point of HRT/no HRT use and cognitive decline
Saletu,B., Sleep, vigilance and cognition in postmenopausal women: placebo-controlled studies with 2 mg estradiol valerate, with and without 3 mg dienogest, <i>Climacteric</i> , 6 Suppl 2, 37-45, 2003	Wrong population, menopause and insomnia
Saletu,B., Brandstatter,N., Metka,M., Stamenkovic,M., Anderer,P., Semlitsch,H.V., Heytmanek,G., Huber,J., Grunberger,J., Linzmayer,L., Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression, <i>Psychopharmacology</i> , 122, 321-329, 1995	Wrong population, menopausal depression
Saletu,B., Brandstatter,N., Metka,M., Stamenkovic,M., Anderer,P., Semlitsch,H.V., Heytmanek,G., Huber,J., Grunberger,J., Linzmayer,L., Kurz,C., Decker,K., Binder,G., Knogler,W., Koll,B., Hormonal, syndromal and EEG mapping studies in menopausal syndrome patients with and without depression as compared with controls, <i>Maturitas</i> , 23, 91-105, 1996	Wrong population, depression
Sanjay,A., Gleason,C., Dowling,M., Wharton,W., Harman,M., Keeps cognitive & affective study: Effects of hormone therapy on cognition and mood in recently postmenopausal women, <i>Climacteric</i> , 17, 8-, 2014	Conference abstract
Sano,M., Jacobs,D., Andrews,H., Bell,K., Graff-Radford,N., Lucas,J., Rabins,P., Bolla,K., Tsai,W.Y., Cross,P., Andrews,K., Costa,R., Xiaodong,Luo, A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics, <i>Clinical Trials</i> , 5, 523-533, 2008	Background reading
Sarvari,M., Kallo,I., Hrabovszky,E., Solymosi,N., Liposits,Z., Ovariectomy and subsequent treatment with estrogen receptor agonists tune the innate immune system of the hippocampus in middle-aged female rats, <i>PLoS ONE [Electronic Resource]</i> , 9, e88540-, 2014	Experimental study
Scali,J., Ryan,J., Carriere,I., Dartigues,J.F., Tavernier,B., Ritchie,K., Ancelin,M.L., A prospective study of hormone therapy and depression in community-dwelling elderly women: the Three City Study, <i>Journal of Clinical Psychiatry</i> , 71, 1673-1679, 2010	Wrong outcome, depression
Scali,J., Ryan,J., Carriere,I., Ritchie,K., Ancelin,M.L., A prospective study of hormonal treatment and anxiety disorders in community-dwelling elderly women (the Esprit Study), <i>Journal of Affective Disorders</i> , 115, 274-279, 2009	Wrong outcome, anxiety disorders
Schiff,R., Bulpitt,C.J., Wesnes,K.A., Rajkumar,C., Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study, <i>Psychoneuroendocrinology</i> , 30, 309-315, 2005	Sample size <50
Schilder,C.M., Eggens,P.C., Seynaeve,C., Linn,S.C., Boogerd,W., Gundy,C.M., Beex,L.V., van Dam,F.S., Schagen,S.B., Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study, <i>Acta Oncologica</i> , 48, 76-85, 2009	Wrong study design
Schilder,C.M., Seynaeve,C., Beex,L.V., Boogerd,W., Linn,S.C., Gundy,C.M., Huizenga,H.M., Nortier,J.W., van,de,V, van Dam,F.S., Schagen,S.B., Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial, <i>Journal of Clinical Oncology</i> , 28, 1294-1300, 2010	Wrong population
Schmidt,J.W., Wollner,D., Curcio,J., Riedlinger,J., Kim,L.S., Hormone replacement therapy in menopausal women: Past problems and future possibilities, <i>Gynecological Endocrinology</i> , 22, 564-577, 2006	Literature review
Schmidt,P.J., Depression, the perimenopause, and estrogen therapy. [99 refs], <i>Annals of the New York Academy of Sciences</i> , 1052, 27-40, 2005	Literature review
Schmidt,R., Fazekas,F., Reinhart,B., Kapeller,P., Fazekas,G., Offenbacher,H., Eber,B., Schumacher,M., Freidl,W., Estrogen replacement therapy in older women: a neuropsychological and brain MRI study, <i>Journal of the American Geriatrics Society</i> , 44, 1307-1313, 1996	Wrong study design



Study	Reason for exclusion
Scott,E.L., Zhang,Q.G., Vadlamudi,R.K., Brann,D.W., Premature menopause and risk of neurological disease: basic mechanisms and clinical implications, <i>Molecular and Cellular Endocrinology</i> , 389, 2-6, 2014	Literature review
Shah,S., Bell,R.J., Davis,S.R., Homocysteine, estrogen and cognitive decline, <i>Climacteric</i> , 9, 77-87, 2006	Literature review
Shah,S., Bell,R.J., Savage,G., Goldstat,R., Papalia,M.A., Kulkarni,J., Donath,S., Davis,S.R., Testosterone aromatization and cognition in women: a randomized, placebo-controlled trial, <i>Menopause</i> , 13, 600-608, 2006	Wrong intervention, testosterone
Shaywitz,B.A., Shaywitz,S.E., Estrogen and Alzheimer disease plausible theory, negative clinical trial, <i>Journal of the American Medical Association</i> , 283, 1055-1056, 2000	No information on study
Shaywitz,S.E., Naftolin,F., Zelterman,D., Marchione,K.E., Holahan,J.M., Palter,S.F., Shaywitz,B.A., Better oral reading and short-term memory in midlife, postmenopausal women taking estrogen, <i>Menopause</i> , 10, 420-426, 2003	Sample size <50
Shaywitz,S.E., Shaywitz,B.A., Pugh,K.R., Fulbright,R.K., Skudlarski,P., Mencil,W.E., Constable,R.T., Naftolin,F., Palter,S.F., Marchione,K.E., Katz,L., Shankweiler,D.P., Fletcher,J.M., Lacadie,C., Keltz,M., Gore,J.C., Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks, <i>JAMA</i> , 281, 1197-1202, 1999	Study reported MRI imaging
Shepherd,J.E., Effects of estrogen on cognition mood, and degenerative brain diseases, <i>Journal of the American Pharmaceutical Association (Washington,D.C, 1996)</i> . 41, 221-228, 2001	Wrong study design
Sherwin,B.B., Estrogen and cognitive functioning in men with mild cognitive impairment, <i>Journal of Molecular Neuroscience</i> , 19, 219-223, 2002	Wrong population
Sherwin,B.B., Estrogen effects on cognition in menopausal women, <i>Neurology</i> , 48, S21-S26, 1997	Literature review
Sherwin,B.B., Can estrogen keep you smart? Evidence from clinical studies, <i>Journal of Psychiatry and Neuroscience</i> , 24, 315-321, 1999	Literature review
Sherwin,B.B., Estrogen and cognitive aging in women. [62 refs], <i>Neuroscience</i> , 138, 1021-1026, 2006	Literature review
Sherwin,B.B., Estrogen and cognitive functioning in women: Lessons we have learned, <i>Behavioral Neuroscience</i> , 126, 123-127, 2012	Literature review
Sherwin,B.B., Estrogen and memory in women: how can we reconcile the findings?. [36 refs], <i>Hormones and Behavior</i> , 47, 371-375, 2005	Literature review
Sherwin,B.B., Surgical menopause, estrogen, and cognitive function in women: what do the findings tell us?. [27 refs], <i>Annals of the New York Academy of Sciences</i> , 1052, 3-10, 2005	Literature review
Sherwin,B.B., Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women, <i>Psychoneuroendocrinology</i> , 13, 345-357, 1988	Wrong intervention/comparison
Sherwin,B.B., Hormones, mood, and cognitive functioning in postmenopausal women, <i>Obstetrics and Gynecology</i> , 87, 20S-26S, 1996	Literature review
Sherwin,B.B., Sex hormones and psychological functioning in postmenopausal women. [46 refs], <i>Experimental Gerontology</i> , 29, 423-430, 1994	Literature review
Sherwin,B.B., The clinical relevance of the relationship between estrogen and cognition in women, <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 106, 151-156, 2007	Literature review
Sherwin,B.B., The critical period hypothesis: can it explain discrepancies in the oestrogen-cognition literature?. [35 refs], <i>Journal of Neuroendocrinology</i> , 19, 77-81, 2007	literature review
Sherwin,B.B., Grigороva,M., Differential effects of estrogen and micronized progesterone or medroxyprogesterone acetate on cognition in postmenopausal women, <i>Fertility and Sterility</i> , 96, 399-403, 2011	Sample size <50
Sherwin,B.B., Henry,J.F., Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: a critical review. [244 refs], <i>Frontiers in Neuroendocrinology</i> , 29, 88-113, 2008	Literature review
Sherwin,B.B., McGill,J., Oestrogen plus progestogen doubles the risk of dementia in post-menopausal women, <i>Evidence-Based Mental Health</i> , 6, 111-, 2003	Commentary
Sherwin,B.B., Tulandi,T., "Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri, <i>Journal of Clinical Endocrinology and Metabolism</i> , 81, 2545-2549, 1996	Wrong population, women who have fibroids
Shilling,V., Jenkins,V., Fallowfield,L., Howell,A., The effects of oestrogens and anti-oestrogens on cognition, <i>Breast</i> , 10, 484-491, 2001	Literature review
Shulman,L.P., Yankov,V., Uhl,K., Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials.[Erratum appears in <i>Menopause</i> . 2002 Sep-Oct;9(5):385], <i>Menopause</i> , 9, 195-207, 2002	Outcomes in study not stated in protocol
Shumaker,S.A., Legault,C., Kuller,L., Rapp,S.R., Thal,L., Lane,D.S., Fillit,H., Stefanick,M.L., Hendrix,S.L., Lewis,C.E., Masaki,K., Coker,L.H., Women's Health Initiative Memory Study., Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study, <i>JAMA</i> , 291, 2947-2958, 2004	Sample size <50

Study	Reason for exclusion
Shumaker,S.A., Legault,C., Rapp,S.R., Thal,L., Wallace,R.B., Ockene,J.K., Hendrix,S.L., Jones,B.N.,III, Assaf,A.R., Jackson,R.D., Kotchen,J.M., Wassertheil-Smoller,S., Wactawski-Wende,J., WHIMS,investigators, Estrogen plus progestogen and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial, JAMA, 289, 2651-2662, 2003	Unclear about prior use of HRT
Simpkins,J.W., Perez,E., Wang,X., Yang,S., Wen,Y., Singh,M., The potential for estrogens in preventing Alzheimer's disease and vascular dementia, Therapeutic Advances in Neurological Disorders, 2, 31-49, 2009	Literature review
Simpkins,J.W., Yang,S.H., Wen,Y., Singh,M., Estrogens, progestogens, menopause and neurodegeneration: basic and clinical studies. [110 refs], Cellular and Molecular Life Sciences, 62, 271-280, 2005	Literature review
Simpson,E.R., Sources of estrogen and their importance. [40 refs], Journal of Steroid Biochemistry and Molecular Biology, 86, 225-230, 2003	Literature review
Simpson,E.R., Clyne,C., Rubin,G., Boon,W.C., Robertson,K., Britt,K., Speed,C., Jones,M., Aromatase--a brief overview. [144 refs], Annual Review of Physiology, 64, 93-127, 2002	Literature review
Simpson,E.R., Davis,S.R., Minireview: aromatase and the regulation of estrogen biosynthesis--some new perspectives. [55 refs], Endocrinology, 142, 4589-4594, 2001	Literature review
Sirtori,C.R., Risks and benefits of soy phytoestrogens in cardiovascular diseases, cancer, climacteric symptoms and osteoporosis. [166 refs], Drug Safety, 24, 665-682, 2001	Wrong intervention
Smith,C.A., McCleary,C.A., Murdock,G.A., Wilshire,T.W., Buckwalter,D.K., Bretsky,P., Marmol,L., Gorsuch,R.L., Buckwalter,J.G., Lifelong estrogen exposure and cognitive performance in elderly women, Brain and Cognition, 39, 203-218, 1999	Wrong study design, no comparator
Smith,Y.R., Love,T., Persad,C.C., Tkaczyk,A., Nichols,T.E., Zubieta,J.K., Impact of combined estradiol and norethindrone therapy on visuospatial working memory assessed by functional magnetic resonance imaging, Journal of Clinical Endocrinology and Metabolism, 91, 4476-4481, 2006	Wrong intervention/comparator
Smith,Y.R., Zubieta,J.K., Neuroimaging of aging and estrogen effects on central nervous system physiology. [108 refs], Fertility and Sterility, 76, 651-659, 2001	Literature review
Soares,C.N., Poitras,J.R., Prouty,J., Hormone treatment for mood disorders in women, Expert Review of Neurotherapeutics, 2, 25-34, 2002	Literature review
Sood,R., Faubion,S.S., Kuhle,C.L., Thielen,J.M., Shuster,L.T., Prescribing menopausal hormone therapy: an evidence-based approach, International Journal of Women's Health, 6, 47-57, 2014	Literature review
Spark,M.J., Willis,J., Systematic review of progesterone use by midlife and menopausal women, Maturitas, 72, 192-202, 2012	Literature review
Spence,J.D., Thornton,T., Muir,A.D., Westcott,N.D., The effect of flax seed cultivars with differing content of alpha-linolenic acid and lignans on responses to mental stress, Journal of the American College of Nutrition, 22, 494-501, 2003	wrong intervention
Speroff,L., The case for postmenopausal hormone therapy, Hospital Practice, 31, 75-86, 89, 1996	Literature review
Speroff,L., HT: A clinician demurs, Sexuality, Reproduction and Menopause, 1, 15-18, 2003	Wrong study design
Stein,D.G., The case for progesterone. [89 refs], Annals of the New York Academy of Sciences, 1052, 152-169, 2005	Literature review
Stevens,M.C., Clark,V.P., Prestwood,K.M., Low-dose estradiol alters brain activity, Psychiatry Research, 139, 199-217, 2005	Wrong outcome, fMRI
Stewart,A., Collins,B., Mackenzie,J., Tomiak,E., Verma,S., Bielajew,C., The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study, Psycho-Oncology, 17, 122-130, 2008	Wrong population, breast cancer
Studd,J., Panay,N., Hormones and depression in women, Climacteric, 7, 338-346, 2004	Literature review
Sullivan,Mitchell E., Fugate,Woods N., Midlife women's attributions about perceived memory changes: observations from the Seattle Midlife Women's Health Study, Journal of Womens Health and Gender-Based Medicine, 10, 351-362, 2001	Narrative analysis of a study
Szklo,M., Cerhan,J., ez-Roux,A.V., Chambless,L., Cooper,L., Folsom,A.R., Fried,L.P., Knopman,D., Nieto,F.J., Estrogen replacement therapy and cognitive functioning in the Atherosclerosis Risk in Communities (ARIC) study, American Journal of Epidemiology, 144, 1048-1057, 1996	Outcomes did not match protocol
Takamatsu,K., Ohta,H., Makita,K., Horiguchi,F., Nozawa,S., Effects of counseling on climacteric symptoms in Japanese postmenopausal women, Journal of Obstetrics and Gynaecology Research, 27, 133-140, 2001	wrong intervention
Tan,R.S., Pu,S.J., Culberson,J.W., Role of androgens in mild cognitive impairment and possible interventions during andropause, Medical Hypotheses, 62, 14-18, 2004	Literature review
Taxel,P., Stevens,M.C., Trahiotis,M., Zimmerman,J., Kaplan,R.F., The effect of short-term estradiol therapy on cognitive function in older men receiving hormonal suppression therapy for prostate cancer, Journal of the American Geriatrics Society, 52, 269-273, 2004	Wrong population, men

Study	Reason for exclusion
Thal,L.J., Thomas,R.G., Mulnard,R., Sano,M., Grundman,M., Schneider,L., Estrogen levels do not correlate with improvement in cognition, Archives of Neurology, 60, 209-212, 2003	No comparator group
Thiedke,C.C., Menopause, Clinics in Family Practice, 4, 985-1003, 2002	Literature review
Tierney,M.C., Oh,P., Moineddin,R., Greenblatt,E.M., Snow,W.G., Fisher,R.H., Iazzetta,J., Hyslop,P.S., MacLusky,N.J., A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women, Psychoneuroendocrinology, 34, 1065-1074, 2009	Outcomes did not match protocol
Tierney,M.C., Ryan,J., Ancelin,M.L., Moineddin,R., Rankin,S., Yao,C., Maclusky,N.J., Lifelong estrogen exposure and memory in older postmenopausal women, Journal of Alzheimer's Disease, 34, 601-608, 2013	No comparator group
Tivis,L.J., Ceballos,N.A., Chastain,G., Tivis,R.D., Alcohol and estrogen replacement therapy in postmenopausal women. Direct and mediated effects on cognitive component processes, Neuropsychobiology, 58, 104-110, 2008	Wrong intervention, alcohol
Tranah,G.J., Parimi,N., Blackwell,T., ncoli-Israel,S., Ensrud,K.E., Cauley,J.A., Redline,S., Lane,N., Paudel,M.L., Hillier,T.A., Yaffe,K., Cummings,S.R., Stone,K.L., Postmenopausal hormones and sleep quality in the elderly: a population based study, BMC Women's Health, 10, 15-, 2010	Wrong outcome, sleep quality
Tsolaki,M., Grammaticos,P., Karanasou,C., Balaris,V., Kapoukranidou,D., Kalpidis,I., Petsanis,K., Dedousi,E., Serum estradiol, progesterone, testosterone, FSH and LH levels in postmenopausal women with Alzheimer's dementia, Hellenic Journal of Nuclear Medicine, 8, 39-42, 2005	Outcomes in study not stated in protocol
Utian,W.H., Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. [54 refs], Health and Quality of Life Outcomes, 3, 47-, 2005	Literature review
Vassilopoulou-Sellin,R., Klein,M.J., Health care priorities for menopausal women with a history of breast cancer, Southern Medical Journal, 95, 1269-1275, 2002	Wrong topic, breast cancer
Vaughan,L., Espeland,M.A., Snively,B., Shumaker,S.A., Rapp,S.R., Shupe,J., Robinson,J.G., Sarto,G.E., Resnick,S.M., Women's Health Initiative Memory Study of Younger Women (WHIMS-), The rationale, design, and baseline characteristics of the Women's Health Initiative Memory Study of Younger Women (WHIMS-Y), Brain Research, 1514, 3-11, 2013	Study reported baseline information of population
Vearncombe,K.J., Pachana,N.A., Is cognitive functioning detrimentally affected after early, induced menopause?. [52 refs], Menopause, 16, 188-198, 2009	Literature review
Vickers,M.R., Martin,J., Meade,T.W., Arasaratnam,N., Collins,N., Furness,P., Ghali,M., Gordon,E., Huppert,F., Islam,Z., Knott,C., Meredith,S., Prince,M., Purdon,S., Richards,M., Taylor,L., Welton,A., Zhu,C.Q., Zuhrie,R., Dowell,A., Lawton,B., MacLennan,A., The Women's International Study of Long-duration Oestrogen after Menopause (WISDOM): A randomised controlled trial, BMC Women's Health, 7, 2007. Article Number, -, 2007	The study was prematurely stopped and outcomes of interest not reported in this publication
Viscoli,C.M., Brass,L.M., Kernan,W.N., Sarrel,P.M., Suissa,S., Horwitz,R.I., Estrogen therapy and risk of cognitive decline: results from the Women's Estrogen for Stroke Trial (WEST), American Journal of Obstetrics and Gynecology, 192, 387-393, 2005	Participants women with recent stroke or TIA
Vodermaier,A., Breast cancer treatment and cognitive function: The current state of evidence, underlying mechanisms and potential treatments, Women's health, 5, 503-516, 2009	Literature review
Vogelvang,T.E., Mijatovic,V., van der Mooren,M.J., Pinsdorf,U., von,Bergmann K., Netelenbos,J.C., Lutjohann,D., Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women, Maturitas, 50, 312-320, 2005	Outcomes in study not stated in protocol
Wagner,L.I., Gray,R.J., Sledge,G.W., Whelan,T.J., Hayes,D.F., Geyer,C.E., Dees,E.C., Cella,D., Sparano,J., Patient-reported cognitive impairments among women with breast cancer randomly assigned to hormonal therapy (HT) alone versus chemotherapy followed by hormonal therapy (C+HT): Results from the Trial Assigning Individualized Options for Treatment (TAILORx), Journal of Clinical Oncology, 30, -, 2012	Conference abstract
Waring,S.C., Rocca,W.A., Petersen,R.C., O'Brien,P.C., Tangalos,E.G., Kokmen,E., Postmenopausal estrogen replacement therapy and risk of AD: a population-based study, Neurology, 52, 965-970, 1999	Only age of participants with AD was reported (age range 57-96) but not for control group
Wassertheil-Smoller,S., Hendrix,S.L., Limacher,M., Shumaker,S.A., Legault,C., Rapp,S.R., Espeland,M.A., Atkins,D., Oestrogen plus progestogen increased risk of stroke and probable dementia in postmenopausal women, Evidence Based Medicine, 8, 170-171, 2003	Abstract and commentary
Weber,M., Mapstone,M., Memory complaints and memory performance in the menopausal transition, Menopause, 16, 694-700, 2009	No information whether participants on HRT
Wegesin,D.J., Stern,Y., Effects of hormone replacement therapy and aging on cognition: evidence for executive dysfunction, Aging Neuropsychology and Cognition, 14, 301-328, 2007	Outcomes did not match protocol
Wenger,N.K., HT and CVD prevention from myth to reality, Sexuality, Reproduction and Menopause, 1, 10-14, 2003	Literature review
Wharton,W., Baker,L.D., Gleason,C.E., Dowling,M., Barnet,J.H., Johnson,S., Carlsson,C., Craft,S., Asthana,S., Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer's disease:	Sample size <50

Study	Reason for exclusion
results of a randomized controlled trial, <i>Journal of Alzheimer's Disease</i> , 26, 495-505, 2011	
Wharton,W., Gleason,C.E., Miller,V.M., Asthana,S., Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS Cognitive and Affective sub study (KEEPS Cog), <i>Brain Research</i> , 1514, 12-17, 2013	Outcome in study not stated in protocol, atherosclerosis
White,J.P., Schilling,J.S., Postmenopausal hormone replacement: historical perspectives and current concerns. [64 refs], <i>Clinical Excellence for Nurse Practitioners</i> , 4, 277-285, 2000	Literature review
Whitmer,R.A., Haan,M.N., Miller,J.W., Yaffe,K., Hormone replacement therapy and cognitive performance: the role of homocysteine, <i>Journals of Gerontology Series A-Biological Sciences and Medical Sciences</i> , 58, 324-330, 2003	Participants age >65 years at enrolment, HRT examined for association between homocysteine and cognitive performance, not as a predictor.
Whitmer,R.A., Quesenberry,C.P., Zhou,J., Yaffe,K., Timing of hormone therapy and dementia: the critical window theory revisited, <i>Annals of Neurology</i> , 69, 163-169, 2011	Duplicate
Whooley,M.A., Grady,D., Cauley,J.A., Postmenopausal estrogen therapy and depressive symptoms in older women, <i>Journal of General Internal Medicine</i> , 15, 535-541, 2000	Wrong study design, cross-sectional
Wilbur,J., Miller,A.M., McDevitt,J., Wang,E., Miller,J., Menopausal status, moderate-intensity walking, and symptoms in midlife women, <i>Research and Theory for Nursing Practice</i> , 19, 163-180, 2005	Wrong intervention, exercise
Will,M.A., Randolph,J.F., The influence of reproductive hormones on brain function in the menopausal transition. [86 refs], <i>Minerva Ginecologica</i> , 61, 469-481, 2009	Literature review
Winkler,J.M., Fox,H.S., Transcriptome meta-analysis reveals a central role for sex steroids in the degeneration of hippocampal neurons in Alzheimer's disease, <i>BMC Systems Biology</i> , 7, 51-, 2013	Wrong study design, meta-analysis
Wisniewski,A.B., Nguyen,T.T., Dobs,A.S., Evaluation of high-dose estrogen and high-dose estrogen plus methyltestosterone treatment on cognitive task performance in postmenopausal women, <i>Hormone Research</i> , 58, 150-155, 2002	Wrong intervention
Witt,D.M., Lousberg,T.R., Controversies surrounding estrogen use in postmenopausal women. [55 refs], <i>Annals of Pharmacotherapy</i> , 31, 745-755, 1997	Literature review
Wnuk,A., Korol,D.L., Erickson,K.I., Estrogens, hormone therapy, and hippocampal volume in postmenopausal women, <i>Maturitas</i> , 73, 186-190, 2012	Literature review
Wolf,O.T., Kudielka,B.M., Hellhammer,D.H., Torber,S., McEwen,B.S., Kirschbaum,C., Two weeks of transdermal estradiol treatment in postmenopausal elderly women and its effect on memory and mood: verbal memory changes are associated with the treatment induced estradiol levels, <i>Psychoneuroendocrinology</i> , 24, 727-741, 1999	Short term study, 2 weeks
Woo,J., Lau,E., Ho,S.C., Cheng,F., Chan,C., Chan,A.S., Haines,C.J., Chan,T.Y., Li,M., Sham,A., Comparison of Pueraria lobata with hormone replacement therapy in treating the adverse health consequences of menopause, <i>Menopause</i> , 10, 352-361, 2003	Wrong intervention
Woolie,T.E., Kenna,H.A., Williams,K.E., Powers,B.N., Holcomb,M., Khaylis,A., Rasgon,N.L., Differences in verbal memory performance in postmenopausal women receiving hormone therapy: 17beta-estradiol versus conjugated equine estrogens, <i>American Journal of Geriatric Psychiatry</i> , 19, 792-802, 2011	Cross-sectional study
Woolie,T.E., Williams,K.E., Keller,J., Zappert,L.N., Shelton,S.D., Kenna,H.A., Reynolds,M.F., Rasgon,N.L., Mood and neuropsychological changes in women with midlife depression treated with escitalopram, <i>Journal of Clinical Psychopharmacology</i> , 26, 361-366, 2006	Wrong intervention, antidepressant
Yaffe,K., Estrogens, selective estrogen receptor modulators, and dementia: what is the evidence?. [58 refs], <i>Annals of the New York Academy of Sciences</i> , 949, 215-222, 2001	Literature review
Yaffe,K., Haan,M., Byers,A., Tangen,C., Kuller,L., Estrogen use, APOE, and cognitive decline: Evidence of gene-environment interaction, <i>Neurology</i> , 54, 1949-1953, 2000	Participants age >65 years at enrollment
Yaffe,K., Sawaya,G., Lieberburg,I., Grady,D., Estrogen therapy in postmenopausal women: effects on cognitive function and dementia, <i>JAMA</i> , 279, 688-695, 1998	Background reading
Yaffe,K., Vittinghoff,E., Ensrud,K.E., Johnson,K.C., Diem,S., Hanes,V., Grady,D., Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life, <i>Archives of Neurology</i> , 63, 945-950, 2006	Outcomes did not match protocol
Yaffe,Kristine, Vittinghoff,Eric, Ensrud,Kristine E., Johnson,Karen C., Diem,Susan, Hanes,Vladimir, Grady,Deborah, Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life, <i>Archives of neurologyArch Neurol</i> , 63, 945-950, 2006	Mean age of participants >65 years when HRT initiated
Yonker,J.E., Adolfsson,R., Eriksson,E., Hellstrand,M., Nilsson,L.G., Herlitz,A., Verified hormone therapy improves episodic memory performance in healthy postmenopausal women, <i>Aging Neuropsychology and Cognition</i> , 13, 291-307, 2006	Wrong study design, no comparator group
Yoon,B.K., Kim,D.K., Kang,Y., Kim,J.W., Shin,M.H., Na,D.L., Hormone replacement therapy in postmenopausal women with Alzheimer's disease: a randomized, prospective study, <i>Fertility and Sterility</i> , 79, 274-280, 2003	Short term study, intervention not of interest

Study	Reason for exclusion
Yue,Y., Hu,L., Tian,Q.J., Jiang,J.M., Dong,Y.L., Jin,Z.Y., Cheng,Y.H., Hong,X., Ge,Q.S., Zuo,P.P., Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes, <i>Acta Pharmacologica Sinica</i> , 28, 1129-1135, 2007	Outcomes in study not stated in protocol
Zandi,P.P., Carlson,M.C., Plassman,B.L., Welsh-Bohmer,K.A., Mayer,L.S., Steffens,D.C., Breitner,J.C., Cache County Memory Study Investigators., Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study, <i>JAMA</i> , 288, 2123-2129, 2002	Duplicate
Zickl,L., Francis,P., Fleming,G., Pagani,O., Walley,B., Price,K.N., Gelber,R.D., Regan,M.M., Soft and text: Trials of tamoxifen and exemestane with and without ovarian function suppression for premenopausal women with hormone receptor-positive early breast cancer, <i>Cancer Research</i> , 72, -, 2012	Conference abstract
Zwahr,M.D., Park,D.C., Shifren,K., Judgments about estrogen replacement therapy: the role of age, cognitive abilities, and beliefs, <i>Psychology and Aging</i> , 14, 179-191, 1999	Wrong study type, age, cognitive abilities and beliefs on use of ERT in women

## G.7.8 Loss of muscle mass (sarcopenia)

Study	Reason for exclusion
Anderson,G.L., Limacher,M., Assaf,A.R., Bassford,T., Beresford,S.A., Black,H., Bonds,D., Brunner,R., Brzyski,R., Caan,B., Chlebowski,R., Curb,D., Gass,M., Hays,J., Heiss,G., Hendrix,S., Howard,B.V., Hsia,J., Hubbell,A., Jackson,R., Johnson,K.C., Judd,H., Kotchen,J.M., Kuller,L., Lacroix,A.Z., Lane,D., Langer,R.D., Lasser,N., Lewis,C.E., Manson,J., Margolis,K., Ockene,J., O'Sullivan,M.J., Phillips,L., Prentice,R.L., Ritenbaugh,C., Robbins,J., Rossouw,J.E., Sarto,G., Stefanick,M.L., Van,Horn L., Wactawski-Wende,J., Wallace,R., Wassertheil-Smoller,S., Women's Health Initiative Steering Committee., Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial, <i>JAMA</i> , 291, 1701-1712, 2004	Outcomes not relevant
Bemben,D.A., Langdon,D.B., Relationship between estrogen use and musculoskeletal function in postmenopausal women, <i>Maturitas</i> , 42, 119-127, 2002	Does not match our review protocol
Bonds,D.E., Lasser,N., Qi,L., Brzyski,R., Caan,B., Heiss,G., Limacher,M.C., Liu,J.H., Mason,E., Oberman,A., O'Sullivan,M.J., Phillips,L.S., Prineas,R.J., Tinker,L., The effect of conjugated equine oestrogen on diabetes incidence: The Women's Health Initiative randomised trial, <i>Diabetologia</i> , 49, 459-468, 2006	Outcomes not relevant to review question
Canonico,M., Fournier,A., Carcaillon,L., Olie,V., Plu-Bureau, Oger,E., Mesrine,S., Boutron-Ruault,M.C., Clavel-Chapelon,F., Scarabin,P.Y., Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study, <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> , 30, 340-345, 2010	Outcomes not relevant to review question
Carville,S.F., Rutherford,O.M., Newham,D.J., Power output, isometric strength and steadiness in the leg muscles of pre- and postmenopausal women; the effects of hormone replacement therapy, <i>European Journal of Applied Physiology</i> , 96, 292-298, 2006	Does not match our review protocol
Culhane,N.S., Estrogen plus progestogen may increase incidence of dementia, <i>Journal of Family Practice</i> , 52, 754-755, 2003	Outcomes not relevant to review question
Cushman,M., Kuller,L.H., Prentice,R., Rodabough,R.J., Psaty,B.M., Stafford,R.S., Sidney,S., Rosendaal,F.R., Women's Health Initiative Investigators., Estrogen plus progestogen and risk of venous thrombosis, <i>JAMA</i> , 292, 1573-1580, 2004	Outcomes not relevant
de Lauzon-Guillain,B., Fournier,A., Fabre,A., Simon,N., Mesrine,S., Boutron-Ruault,M.C., Balkau,B., Clavel-Chapelon,F., Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Generale de l'Education Nationale (E3N) cohort, <i>Diabetologia</i> , 52, 2092-2100, 2009	Outcomes not related to this review question. Were incident diabetes outcomes
Devor,M., Barrett-Connor,E., Renvall,M., Feigal,Jr, Ramsdell,J., Estrogen replacement therapy and the risk of venous thrombosis, <i>American Journal of Medicine</i> , 92, 275-282, 1992	Outcomes not relevant
Espeland,M.A., Shumaker,S.A., Leng,I., Manson,J.E., Brown,C.M., LeBlanc,E.S., Vaughan,L., Robinson,J., Rapp,S.R., Goveas,J.S., Wactawski-Wende,J., Stefanick,M.L., Li,W., Resnick,S.M., WHIMSY Study Group., Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years, <i>JAMA Internal Medicine</i> , 173, 1429-1436, 2013	Outcomes not relevant
Espeland,M.A., Tindle,H.A., Bushnell,C.A., Jaramillo,S.A., Kuller,L.H., Margolis,K.L., Mysiw,W.J., Maldjian,J.A., Melhem,E.R., Resnick,S.M., Women's Health Initiative Memory Study., Brain volumes, cognitive impairment, and conjugated equine estrogens, <i>Journals of Gerontology Series A-Biological Sciences and Medical Sciences</i> , 64, 1243-1250, 2009	Outcomes not relevant
Galen,Buckwalter J., Crooks,V.C., Robins,S.B., Petitti,D.B., Hormone use and cognitive performance in women of advanced age, <i>Journal of the American Geriatrics Society</i> , 52, 182-186, 2004	Outcomes not relevant
Gaussoin,S.A., Espeland,M.A., Absher,J., Howard,B.V., Jones,B.M., Rapp,S.R., Ascertaining dementia-related outcomes for deceased or proxy-dependent participants: an overview of the Women's Health Initiative Memory Study	Outcomes not relevant

Study	Reason for exclusion
supplemental case ascertainment protocol, <i>International Journal of Geriatric Psychiatry</i> , 27, 205-214, 2012	
Greeves, J.P., Cable, N.T., Reilly, T., Kingsland, C., Changes in muscle strength in women following the menopause: a longitudinal assessment of the efficacy of hormone replacement therapy, <i>Clinical Science</i> , 97, 79-84, 1999	Does not match our review protocol
Hansen, R.D., Raja, C., Baber, R.J., Lieberman, D., Allen, B.J., Effects of 20-mg oestradiol implant therapy on bone mineral density, fat distribution and muscle mass in postmenopausal women, <i>Acta Diabetologica</i> , 40 Suppl 1, S191-S195, 2003	Does not match our review protocol
Heikkinen, J., Kyllonen, E., Kurttila-Matero, E., Wilen-Rosenqvist, G., Lankinen, K.S., Rita, H., Vaananen, H.K., HRT and exercise: effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestogen regimens in healthy postmenopausal women, <i>Maturitas</i> , 26, 139-149, 1997	Evaluated the effects of both HRT and exercise on bone density, muscle strength, and lipid metabolism
Henderson, V.W., Benke, K.S., Green, R.C., Cupples, L.A., Farrer, L.A., MIRAGE Study Group., Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age, <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 76, 103-105, 2005	Outcomes not relevant to review question.
Henderson, V.W., Paganini-Hill, A., Miller, B.L., Eble, R.J., Reyes, P.F., Shoupe, D., McCleary, C.A., Klein, R.A., Hake, A.M., Farlow, M.R., Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial, <i>Neurology</i> , 54, 295-301, 2000	Outcomes not relevant
Herrington, D.M., Vittinghoff, E., Howard, T.D., Major, D.A., Owen, J., Reboussin, D.M., Bowden, D., Bittner, V., Simon, J.A., Grady, D., Hulley, S.B., Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease, <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> , 22, 1012-1017, 2002	Outcomes not relevant
Hogervorst, E., Boshuisen, M., Riedel, W., Willeken, C., Jolles, J., 1998 Curt P. Richter Award. The effect of hormone replacement therapy on cognitive function in elderly women, <i>Psychoneuroendocrinology</i> , 24, 43-68, 1999	Outcome not relevant
Hogervorst, E., Boshuisen, M., Riedel, W., Willeken, C., Jolles, J., The effect of hormone replacement therapy on cognitive function in elderly women, <i>Psychoneuroendocrinology</i> , 24, 43-68, 1999	Outcomes not relevant to review
Hulley, S., Furberg, C., Barrett-Connor, E., Cauley, J., Grady, D., Haskell, W., Knopp, R., Lowery, M., Satterfield, S., Schrott, H., Vittinghoff, E., Hunnigake, D., Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestogen Replacement Study follow-up (HERS II), <i>Journal of the American Medical Association</i> , 288, 58-66, 2002	Outcomes not relevant to review question.
Iannuzzi-Sucich, M., Prestwood, K.M., Kenny, A.M., Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women, <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 57, M772-M777, 2002	Prevalence study of sarcopenia
Kang, J.H., Grodstein, F., Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline, <i>Neurobiology of Aging</i> , 33, 1129-1137, 2012	Outcomes not relevant to review question
Laliberte, F., Dea, K., Duh, M.S., Kahler, K.H., Rolli, M., Lefebvre, P., Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy, <i>Menopause</i> , 18, 1052-1059, 2011	Outcomes not relevant
Manson, J.E., Chlebowski, R.T., Stefanick, M.L., Aragaki, A.K., Rossouw, J.E., Prentice, R.L., Anderson, G., Howard, B.V., Thomson, C.A., Lacroix, A.Z., Wactawski-Wende, J., Jackson, R.D., Limacher, M., Margolis, K.L., Wassertheil-Smoller, S., Beresford, S.A., Cauley, J.A., Eaton, C.B., Gass, M., Hsia, J., Johnson, K.C., Kooperberg, C., Kuller, L.H., Lewis, C.E., Liu, S., Martin, L.W., Ockene, J.K., O'Sullivan, M.J., Powell, L.H., Simon, M.S., Van, Horn, L., Vitols, M.Z., Wallace, R.B., Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health initiative randomized trials, <i>JAMA - Journal of the American Medical Association</i> , 310, 1353-1368, 2013	Outcomes not relevant to review question.
Manson, J.E., Rimm, E.B., Colditz, G.A., Willett, W.C., Nathan, D.M., Arky, R.A., Rosner, B., Hennekens, C.H., Speizer, F.E., Stampfer, M.J., A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus, <i>Annals of Epidemiology</i> , 2, 665-673, 1992	Outcomes not relevant
Onambele, N.G., Skelton, D.A., Bruce, S.A., Woledge, R.C., Follow-up study of the benefits of hormone replacement therapy on isometric muscle strength of adductor pollicis in postmenopausal women, <i>Clinical Science</i> , 100, 421-422, 2001	Follow-up study of Skelton 1999
Perry, S.D., Bombardier, E., Radtke, A., Tiidus, P.M., Hormone replacement and strength training positively influence balance during gait in post-menopausal females: a pilot study, <i>Journal of Sports Science and Medicine</i> , 4, 372-381, 2005	Examined the effects of HRT combined with strength training on improving balance control and muscle strength.
Petitti, D.B., Crooks, V.C., Chiu, V., Buckwalter, J.G., Chui, H.C., Incidence of dementia in long-term hormone users, <i>American Journal of Epidemiology</i> , 167, 692-700, 2008	Outcomes not relevant
Preisinger, E., Alacamlioglu, Y., Saradeth, T., Resch, K.L., Holzer, G., Metka, M., Forearm bone density and grip strength in women after menopause, with and without estrogen replacement therapy, <i>Maturitas</i> , 21, 57-63, 1995	Does not match our review protocol

Study	Reason for exclusion
Prentice,R.L., Manson,J.E., Langer,R.D., Anderson,G.L., Pettinger,M., Jackson,R.D., Johnson,K.C., Kuller,L.H., Lane,D.S., Wactawski-Wende,J., Brzyski,R., Allison,M., Ockene,J., Sarto,G., Rossouw,J.E., Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause, <i>American Journal of Epidemiology</i> , 170, 12-23, 2009	Outcomes not relevant
Rice,M.M., Graves,A.B., McCurry,S.M., Gibbons,L.E., Bowen,J.D., McCormick,W.C., Larson,E.B., Postmenopausal estrogen and estrogen-progestogen use and 2-year rate of cognitive change in a cohort of older Japanese American women: The Kame Project, <i>Archives of Internal Medicine</i> , 160, 1641-1649, 2000	Outcomes not relevant to review question.
Ryan,J., Carriere,I., Scali,J., Ritchie,K., Ancelin,M.L., Life-time estrogen exposure and cognitive functioning in later life, <i>Psychoneuroendocrinology</i> , 34, 287-298, 2009	Outcomes not relevant
Salmen,T., Heikkinen,A.-M., Mahonen,A., Kroger,H., Komulainen,M., Saarikoski,S., Honkanen,R., Partanen,J., Maenpaa,P.H., Relation of estrogen receptor-alfa gene polymorphism and hormone replacement therapy to fall risk and muscle strenght in early postmenopausal women, <i>Annals of Medicine</i> , 34, 64-72, 2002	Outcomes not relevant
Shao,H., Breitner,J.C., Whitmer,R.A., Wang,J., Hayden,K., Wengreen,H., Corcoran,C., Tschanz,J., Norton,M., Munger,R., Welsh-Bohmer,K., Zandi,P.P., Cache,County,I, Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study, <i>Neurology</i> , 79, 1846-1852, 2012	Outcomes not relevant
Shumaker,S.A., Legault,C., Kuller,L., Rapp,S.R., Thal,L., Lane,D.S., Fillit,H., Stefanick,M.L., Hendrix,S.L., Lewis,C.E., Masaki,K., Coker,L.H., Women's Health Initiative Memory Study., Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study, <i>JAMA</i> , 291, 2947-2958, 2004	Outcomes not relevant
Shumaker,S.A., Legault,C., Rapp,S.R., Thal,L., Wallace,R.B., Ockene,J.K., Hendrix,S.L., Jones,B.N.,III, Assaf,A.R., Jackson,R.D., Kotchen,J.M., Wassertheil-Smoller,S., Wactawski-Wende,J., WHIMS,investigators, Estrogen plus progestogen and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial, <i>JAMA</i> , 289, 2651-2662, 2003	Outcomes not relevant
Whitmer,R.A., Quesenberry,Jr, Zhou,J., Yaffe,K., Timing of hormone therapy and dementia: The critical window theory revisited, <i>Annals of Neurology</i> , 69, 163-169, 2011	Outcomes not relevant to review question
Zandi,P.P., Carlson,M.C., Plassman,B.L., Welsh-Bohmer,K.A., Mayer,L.S., Steffens,D.C., Breitner,J.C., Cache County Memory Study Investigators., Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study, <i>JAMA</i> , 288, 2123-2129, 2002	Outcomes not relevant

## G.8 Premature ovarian insufficiency

### G.8.1 Diagnosis of premature ovarian insufficiency

Study	Reason for exclusion
Abe,N., Takeuchi,H., Kikuchi,I., Kinoshita,K., Effectiveness of microlaparoscopy in the diagnosis of premature ovarian failure, <i>Journal of Obstetrics and Gynaecology Research</i> , 32, 224-229, 2006	Only considers diagnosis of POI patients into those with any ovarian follicles and those with no follicles.
Abusief,M.E., Missmer,S.A., Ginsburg,E.S., Weeks,J.C., Partridge,A.H., Relationship between reproductive history, anthropometrics, lifestyle factors, and the likelihood of persistent chemotherapy-related amenorrhea in women with premenopausal breast cancer, <i>Fertility and Sterility</i> , 97, 154-159, 2012	Median age at diagnosis breast cancer was 43. Considers likelihood of remaining amenorrhoeic after chemotherapy in women with previous chemotherapy for breast cancer.
Amir,E., Freedman,O., Allen,L., Colgan,T., Clemons,M., Defining ovarian failure in amenorrhoeic young breast cancer patients, <i>Breast</i> , 19, 545-548, 2010	Narrative review article.
Arrigo,T., Bertelloni,S., Carcione,L., De,LucaF, De,SanctisC, Einaudi,S., Pirazzoli,P., Segni,M., Urso,L., Wasniewska,M., Characterization of early presentation idiopathic ovarian failure in girls and adolescents, <i>Journal of Pediatric Endocrinology and Metabolism</i> , 16, 835-842, 2003	No control group. Observational report of a cohort.
Ashrafi,M., Fallahian,M., Eshrati,B., Yazdi,R.S., The presence of anti thyroid and anti ovarian auto-antibodies in familial premature ovarian failure, <i>International Journal of Fertility and Sterility</i> , 1, 171-174, 2008	No tests of interest - only auto-antibodies.
Ates,S., Yesil,G., Sevket,O., Molla,T., Yildiz,S., Comparison of metabolic profile and abdominal fat distribution between karyotypically normal women with premature ovarian insufficiency and age matched controls, <i>Maturitas</i> , 79, 306-310, 2014	Case-control study design. Data needed for constructing the 2x2 table not available.
Barbakadze,L., Kristasashvili,J., Antimullerian hormone in cases of different reproductive pathologies, <i>Georgian Medical News</i> , 16-21, 2014	Data needed for constructing 2x2 table not available.
Blumenfeld,Z., Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers. [126 refs], <i>Molecular and Cellular Endocrinology</i> , 187, 93-105, 2002	Narrative review article.

Study	Reason for exclusion
Chao,K.C., Ho,C.H., Shyong,W.Y., Huang,C.Y., Tsai,S.C., Cheng,H.Y., Chou,L.C., Lin,C.H., Li,H.Y., Anti-Mullerian hormone serum level as a predictive marker of ovarian function in Taiwanese women, <i>Journal of the Chinese Medical Association</i> , 75, 70-74, 2012	Include 7 patients with POI or menopause. No analysis of POI patients independently.
Charpentier,A.M., Chong,A.L., Gingras-Hill,G., Ahmed,S., Cigsar,C., Gupta,A.A., Greenblatt,E., Hodgson,D.C., Anti-Mullerian hormone screening to assess ovarian reserve among female survivors of childhood cancer, <i>Journal of Cancer Survivorship</i> , 8, 548-554, 2014	Data needed for constructing 2x2 table not available.
Chiauszi,V.A., Bussmann,L., Calvo,J.C., Sundblad,V., Charreau,E.H., Circulating immunoglobulins that inhibit the binding of follicle-stimulating hormone to its receptor: a putative diagnostic role in resistant ovary syndrome?, <i>Clinical Endocrinology</i> , 61, 46-54, 2004	No outcomes of interest - assess levels of circulating immunoglobulins that inhibit FSH binding to its receptor. Also consider diagnosis of resistant ovary syndrome, rather than POI specifically.
Clowse,M.E., Harward,L., Criscione-Schreiber,L., Pisetsky,D., Copland,S., Anti-Mullerian hormone: a better marker of ovarian damage from cyclophosphamide, <i>Arthritis and Rheumatism</i> , 64, 1305-1310, 2012	Narrative review article.
Conway,G.S., Kaltsas,G., Patel,A., Davies,M.C., Jacobs,H.S., Characterization of idiopathic premature ovarian failure, <i>Fertility and Sterility</i> , 65, 337-341, 1996	Mean values of estrogen given - no data on sensitivity/specificity.
Cox,L., Liu,J.H., Primary ovarian insufficiency: An update, <i>International Journal of Women's Health</i> , 6, 235-243, 2014	Review paper.
Fenichel,P., Sosset,C., Barbarino-Monnier,P., Gobert,B., Hieronimus,S., Bene,M.C., Harter,M., Prevalence, specificity and significance of ovarian antibodies during spontaneous premature ovarian failure, <i>Human Reproduction</i> , 12, 2623-2628, 1997	No tests of interest - assesses ovarian antibodies only.
Ficicioglu,C., Yildirim,G., Attar,R., Akcin,O., Aygun,H.B., A preliminary study of POF: The correlation of triple CGG repeats on the FMR1 gene, AMH and Inhibin B as an ovarian reserve parameter, <i>Molecular Human Reproduction</i> , 24, i144-i145, 2009	Conference abstract only.
La,Marca A., Pati,M., Orvieto,R., Stabile,G., Carducci,Artenisio A., Volpe,A., Serum anti-mullerian hormone levels in women with secondary amenorrhoea, <i>Fertility and Sterility</i> , 85, 1547-1549, 2006	Results only reported in graph.
la,MarcaA, Brozzetti,A., Sighinolfi,G., Marzotti,S., Volpe,A., Falorni,A., Primary ovarian insufficiency: Autoimmune causes, <i>Current Opinion in Obstetrics and Gynecology</i> , 22, 277-282, 2010	Narrative review article.
Lamsal,M., Pokhrel,S., Mahato,R.V., Baral,N., Upreti,D., Sridhar,M.G., LH/FSH ratio: a better marker of secondary amenorrhoea in patients from eastern Nepal, <i>Nepal Medical College journal : NMCJ</i> , 9, 147-153, 2007	3 months amenorrhoea used to establish cases (diagnosing secondary amenorrhoea, rather than POI).
Li,H.W., Anderson,R.A., Yeung,W.S., Ho,P.C., Ng,E.H., Evaluation of serum antimullerian hormone and inhibin B concentrations in the differential diagnosis of secondary oligoamenorrhoea, <i>Fertility and Sterility</i> , 96, 774-779, 2011	Case-control study
Lie,Fong S., Lugtenburg,P.J., Schipper,I., Themmen,A.P., de Jong,F.H., Sonneveld,P., Laven,J.S., Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies, <i>Human Reproduction</i> , 23, 674-678, 2008	All treated patients developed POF - no analysis of value of markers in predicting POF.
Luborsky,J., Ovarian autoimmune disease and ovarian autoantibodies. [169 refs], <i>Journal of women's health and gender-based medicine</i> , 11, 585-599, 2002	Narrative review article.
Meduri,G., Massin,N., Guibourdenche,J., Bachelot,A., Fiori,O., Kuttann,F., Misrahi,M., Touraine,P., Serum anti-Mullerian hormone expression in women with premature ovarian failure, <i>Human Reproduction</i> , 22, 117-123, 2007	Control group only used for ovarian histology. No comparison for other outcomes.
Murray,A., Webb,J., MacSwiney,F., Shipley,E.L., Morton,N.E., Conway,G.S., Serum concentrations of follicle stimulating hormone may predict premature ovarian failure in FRAXA premutation women, <i>Human Reproduction</i> , 14, 1217-1218, 1999	Assessment of correlation between number of CGG repeats in FMR1 gene and FSH level only. Premenopausal women, not followed up to menopause.
Pacchiarotti,A., Frati,P., Milazzo,G.N., Catalano,A., Gentile,V., Moscarini,M., Evaluation of serum anti-Mullerian hormone levels to assess the ovarian reserve in women with severe endometriosis, <i>European Journal of Obstetrics, Gynecology, and Reproductive Biology</i> , 172, 62-64, 2014	Just average AMH level in each group was reported. Data needed for constructing 2x2 table not available.
Renata, K. P., Meden-Vrtovec, H., Novakovic, S., Rebolj Kodre, A., Comparison of serum concentrations of anti-mullerian hormone (AMH) and follicle stimulating hormone (FSH) with telomere length in premature ovarian insufficiency (POI), <i>Climacteric</i> , 17, 56, 2014	Conference abstract.
Roberts-Wilson,T.K., Spencer,J.B., Fantz,C.R., Using an algorithmic approach to secondary amenorrhoea: Avoiding diagnostic error, <i>Clinica Chimica Acta</i> , 423, 56-61, 2013	Narrative review article.
Sahmay,S., Usta,T.A., Ereli,T., Atakul,N., Aydogan,B., Elevated LH levels draw a stronger distinction than AMH in premature ovarian insufficiency, <i>Climacteric</i> , 17, 197-203, 2014	Data needed for constructing 2x2 table not available.
Siam,E.M., Office microlaparoscopy using augmented local anesthesia for assessment of primary ovarian insufficiency, <i>Journal of Gynecologic Surgery</i> , 28, 338-342, 2012	All participants had POI. Aim of study was to sub-classify these women.



Study	Reason for exclusion
Sklavos,M.M., Giri,N., Stratton,P., Alter,B.P., Pinto,L.A., Anti-Mullerian hormone deficiency in females with Fanconi anemia, Journal of Clinical Endocrinology and Metabolism, 99, 1608-1614, 2014	Data needed for constructing 2x2 table not available.
Spath,M.A., Feuth,T.B., Smits,A.P., Yntema,H.G., Braat,D.D., Thomas,C.M., van Kessel,A.G., Sherman,S.L., Allen,E.G., Predictors and risk model development for menopausal age in fragile X premutation carriers, Genetics in Medicine, 13, 643-650, 2011	No relevant tests - assess only CGG repeat size in FMR1 premutation carriers.
Sun,W., Stegmann,B.J., Henne,M., Catherino,W.H., Segars,J.H., A new approach to ovarian reserve testing, Fertility and Sterility, 90, 2196-2202, 2008	Narrative review article.Considers only women with diminished ovarian reserve, rather than women with POI.
Tehrani,F.R., Solaymani-Dodaran,M., Tohidi,M., Gohari,M.R., Azizi,F., Modeling age at menopause using serum concentration of anti-mullerian hormone, Journal of Clinical Endocrinology and Metabolism, 98, 729-735, 2013	No analysis of women with POI, only natural menopause. 46 women in the study went through the menopause at younger than 46, but no data on women under 40.
Tsigkou,A., Marzotti,S., Borges,L., Brozzetti,A., Reis,F., Candeloro,P., Luisa,Bacosi M., Bini,V., Petraglia,F., Falorni,A., High serum inhibin concentration discriminates autoimmune oophoritis from other forms of primary ovarian insufficiency, Journal of Clinical Endocrinology and Metabolism, 93, 1263-1269, 2008	Considers sensitivity and specificity of testing to distinguish autoimmune POI from other causes, rather than all forms of POI.
van Beek,R.D., van den Heuvel-Eibrink MM, Laven,J.S., de Jong,F.H., Themmen,A.P., Hakvoort-Cammel,F.G., van den,Bos C., van den,Berg H., Pieters,R., de Muinck Keizer-Schrama SM., Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood, Journal of Clinical Endocrinology and Metabolism, 92, 3869-3874, 2007	Only one woman included actually had POI. Analysis only of levels of AMH and inhibin in relation to different numbers of chemotherapy cycles.
van der Stege,J.G., Groen,H., van Zadelhoff,S.J., Lambalk,C.B., Braat,D.D., van Kasteren,Y.M., van Santbrink,E.J., Apperloo,M.J., Weijmar Schultz,W.C., Hoek,A., Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure, Menopause, 15, 23-31, 2008	No data suitable for 2x2 table to determine diagnostic accuracy.
Wallace,W.H., Kelsey,T.W., Ovarian reserve and reproductive age may be determined from measurement of ovarian volume by transvaginal sonography, Human Reproduction, 19, 1612-1617, 2004	Analysis for naturally menopausal women, not POI.
Zhang,K., Zeitlian,G., Adel,G., Santoro,N.F., Pal,L., Enhanced hypothalamic-pituitary sensitivity to estrogen in premenopausal women with diminished ovarian reserve compared with older perimenopausal controls, Menopause, 18, 880-885, 2011	No women with POI - only participants with subfertility.

## G.8.2 Management of premature ovarian insufficiency

Study	Reason for exclusion
Committee opinion no. 502: Primary ovarian insufficiency in the adolescent, Obstetrics and Gynecology, 118, 741-745, 2011	Narrative review.
Anasti,J.N., Premature ovarian failure: an update. [100 refs], Fertility and Sterility, 70, 1-15, 1998	Narrative review.
Athallah,Nat, Proctor,Michelle, Johnson,Neil, Oral versus injectable ovulation induction agents for unexplained subfertility, Cochrane Database of Systematic Reviews, -, 2009	Intervention/comparator and outcomes did not match protocol
Benâ€• Aharon I, Gafterâ€• Gvili A, Leibovici L, Stemmer SM, Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis, Breast Cancer Research and Treatment, 122, 803-811, 2010	Intervention, comparator and outcome did not match protocol
Binkowska,M., Debski,R., Paszkowski,T., Sendrakowska,M., Zgliczynski,W., Guidelines for menopausal hormone therapy:recommendations of the polish menopause and andropause society - State of knowledge as of December 2013Rekomendacjepolskiego towarzystwa menopauzy i andropauzy na temat hormonalnejterapii menopauzy - Stan wiedzy na grudzien 2013 roku, Przegląd Menopauzalny, 18, 1-12, 2014	Study design did not match protocol
Buijs,C., de Vries,E.G., Mourits,M.J., Willemse,P.H., The influence of endocrine treatments for breast cancer on health-related quality of life. [75 refs], Cancer Treatment Reviews, 34, 640-655, 2008	Intervention/comparator did not match protocol
Cartwright,B., Robinson,J., Rymer,J., Treatment of premature ovarian failure trial: Description of an ongoing clinical trial, Menopause International, 16, 18-22, 2010	Protocol for clinical trial - no data reported.
Cartwright,B., Robinson,J., Rymer,J., Treatment of premature ovarian failure trial: Description of an ongoing clinical trial, Menopause International, 16, 18-22, 2010	Protocol of ongoing trial
Castelo-Branco,C., Ros,C., Management of Turner's syndrome in adult life, Giornale Italiano di Ostetricia e Ginecologia, 34, 34-40, 2012	Narrative review
Centre for Reviews and Dissemination., Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis (Structured abstract), Database of Abstracts of Reviews of Effects, -, 2014	Intervention/comparator did not match protocol
Centre for Reviews and Dissemination., Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy (Structured abstract), Database of Abstracts of Reviews of Effects, -, 2014	Intervention did not match protocol

Study	Reason for exclusion
Crofton,P.M., Evans,N., Bath,L.E., Warner,P., Whitehead,T.J., Critchley,H.O., Kelnar,C.J., Wallace,W.H., Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover, <i>Clinical Endocrinology</i> , 73, 707-714, 2010	Secondary publication from trial reported in Langrish 2009. However, all data included in evidence table.
de,VriesE, Den,Tonkelaarl, Van,NoordP, Van,DerSchouwY, Te,VeldeE, Peeters,P.H.M., Oral contraceptive use in relation to age at menopause in the DOM cohort, <i>Human Reproduction</i> , 16, 1657-1662, 2001	Study did not report comparator group, outcomes did not match protocol
Gelbaya,T., Vitthala,S., Nardo,L., Seif,M., Optimizing hormone therapy for future reproductive performance in women with premature ovarian failure, <i>Gynecological Endocrinology</i> , 27, 1-7, 2011	Narrative review.
Gelbaya,Tarek A., Vitthala,Srisailesh, Nardo,Luciano G., Farquhar,Cindy, Seif,MW Mourad, Hormone therapy in women with premature ovarian failure, <i>Cochrane Database of Systematic Reviews</i> , -, 2010	Protocol for Cochrane review - final review not published.
Gonzalez,L., Witchel,S.F., The patient with Turner syndrome: Puberty and medical management concerns, <i>Fertility and Sterility</i> , 98, 780-786, 2012	Narrative review.
Gravholt,C.H., Poulsen,H.E., Ott,P., Christiansen,J.S., Vilstrup,H., Quantitative liver functions in Turner syndrome with and without hormone replacement therapy, <i>European Journal of Endocrinology</i> , 156, 679-686, 2007	Outcomes did not match protocol
Gravholt,C.H., Riis,A.L., Moller,N., Christiansen,J.S., Protein metabolism in Turner syndrome and the impact of hormone replacement therapy, <i>Clinical Endocrinology</i> , 67, 413-418, 2007	Outcomes did not match protocol
Haines,C., Lok,I., Kong,G., Ping,Cheung L., Law,C., Choy,D., Leung,P.C., Hormone replacement therapy versus oral contraception for prevention of osteoporosis in young hypoestrogenic women: A randomized controlled trial, <i>Menopause (New York, N.Y.)</i> , 20, 1338, CONFERENCE-	Conference abstract
Haines,C., Lok,I., Kong,G., Ping,CheungL, Law,C., Choy,D., Leung,P.C., Hormone replacement therapy versus oral contraception for prevention of osteoporosis in young hypoestrogenic women: A randomized controlled trial, <i>Menopause</i> , 20, 1338-, 2013	Conference abstract
Jospe,N., Orlowski,C.C., Furlanetto,R.W., Comparison of transdermal and oral estrogen therapy in girls with Turner's syndrome, <i>Journal of Pediatric Endocrinology</i> , 8, 111-116, 1995	The population and outcomes did not match protocol
Lami,T., Schulz-Lobmeyr,I., Obruca,A., Huber,J.C., Hartmann,B.W., Premature ovarian failure: etiology and prospects. [116 refs], <i>Gynecological Endocrinology</i> , 14, 292-302, 2000	Narrative review.
Lehmann-Willenbrock,E., Riedel,H.H., [Clinical and endocrinologic studies of the treatment of ovarian insufficiency manifestations following hysterectomy with intact adnexa], <i>Zentralblatt fur Gynakologie</i> , 110, 611-618, 1988	German language
Manson,J.E., Chlebowski,R.T., Stefanick,M.L., Aragaki,A.K., Rossouw,J.E., Prentice,R.L., Anderson,G., Howard,B.V., Thomson,C.A., Lacroix,A.Z., Wactawski-Wende,J., Jackson,R.D., Limacher,M., Margolis,K.L., Wassertheil-Smoller,S., Beresford,S.A., Cauley,J.A., Eaton,C.B., Gass,M., Hsia,J., Johnson,K.C., Kooperberg,C., Kuller,L.H., Lewis,C.E., Liu,S., Martin,L.W., Ockene,J.K., O'Sullivan,M., Powell,L.H., Simon,M.S., Van Horn,L., Vitolins,M.Z., Wallace,R.B., Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health initiative randomized trials, <i>Obstetrical and Gynecological Survey</i> , 69, 83-85, 2014	This was a report, intervention did not match protocol
Mittal,M., Kreatsa,M., Narvekar,N., Savvas,M., Hamoda,H., Fertility desires, choice of hormone replacement and the effect of length of time since menopause on bone density in women with premature ovarian insufficiency: a review of 223 consecutive new referrals to a tertiary centre, <i>Post reproductive health</i> , 20, 104-111, 2014	Study design did not match protocol
Mittal,M., Savvas,M., Narvekar,N., Panay,N., Hamoda,H., A cross-sectional national questionnaire survey assessing the clinical attitudes of members of the British Menopause Society to the management of women with premature ovarian insufficiency, <i>Post reproductive health</i> , 20, 90-97, 2014	Study design did not match protocol
Molina,J.R., Barton,D.L., Loprinzi,C.L., Chemotherapy-induced ovarian failure: Manifestations and management, <i>Drug Safety</i> , 28, 401-416, 2005	Narrative review
Naeraa,R.W., Nielsen,J., Kastrop,K.W., Growth hormone and 17 beta-oestradiol treatment of Turner girls--2-year results, <i>European Journal of Pediatrics</i> , 153, 72-77, 1994	Intervention, comparator and outcomes did not match protocol
Nelson H D, Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review, <i>JAMA</i> , 291, 1610-1620, 2004	Intervention/comparator did not match protocol
Nippita,T.A., Baber,R.J., Premature ovarian failure: A review, <i>Climacteric</i> , 10, 11-22, 2007	Narrative review only.
O'Donnell,R.L., Warner,P., Lee,R.J., Walker,J., Bath,L.E., Kelnar,C.J., Wallace,W.H., Critchley,H.O., Physiological sex steroid replacement in premature ovarian failure: randomized crossover trial of effect on uterine volume, endometrial thickness and blood flow, compared with a standard regimen, <i>Human Reproduction</i> , 27, 1130-1138, 2012	Secondary publication - data included in evidence table.
Panay,N., Management of premature ovarian failure, <i>Climacteric</i> , 14, 28-, 2011	Conference abstract.
Panay,N., Hamoda,H., Arya,R., Savvas,M., The 2013 British Menopause Society & Women's health concern recommendations on hormone replacement therapy, <i>Menopause International</i> , 19, 59-68, 2013	Narrative review

Study	Reason for exclusion
Smulders,Brechtje, van Oirschot,Sanne M., Farquhar,Cindy, Rombauts,Luk, Kremer,AM Jan, Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques, Cochrane Database of Systematic Reviews, -, 2010	Outcomes did not match protocol
Sowinska-Przepiera,E., ndrysiak-Mamos,E., Friebe,Z., Kapczuk,K., Pilarska,K., [The effect of primary lack of estrogens and the influence of the age at the beginning of estrogen therapy on bone mineral density in patients with Turner's syndrome], Endokrynologia Polska, 56, 145-153, 2005	Study not in English
Steele,S.J., Mason,B., Brett,A., Amenorrhoea after discontinuing combined oestrogen-progestogen oral contraceptives, British Medical Journal, 4, 343-345, 1973	Outcomes did not match protocol
Steingold,K.A., Matt,D.W., DeZiegler,D., Sealey,J.E., Fratkin,M., Reznikov,S., Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure, Journal of Clinical Endocrinology and Metabolism, 73, 275-280, 1991	Intervention not correct - compares oral to transdermal HRT preparations.
Takano,K., Ogawa,M., Tanaka,T., Tachibana,K., Fujita,K., Hizuka,N., Clinical trials of GH treatment in patients with Turner's syndrome in Japan - A consideration of final height, European Journal of Endocrinology, 137, 138-145, 1997	Outcomes did not match protocol
van Kasteren Y M, Schoemaker J, Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy, Human Reproduction Update, 5, 483-492, 1999	Systematic review did not match outcomes in protocol
Warren,M.P., Chua,A., Appropriate use of estrogen replacement therapy in adolescents and young adults with Turner syndrome and hypopituitarism in light of the Women's Health Initiative, Growth Hormone and Igf Research, 16, 98-102, 2006	Narrative review
Wemme,H., Pohlenz,J., Schonberger,W., Effect of oestrogen/gestagen replacement therapy on liver enzymes in patients with Ullrich-Turner syndrome, European Journal of Pediatrics, 154, 807-810, 1995	Intervention/comparator did not match protocol
Yahata,T., Kurabayashi,T., Kato,R., Yamamoto,Y., Fujimaki,T., Yasuda,M., Oda,K., Yoshizawa,H., Tanaka,K., [Effect of hormone replacement therapy on lipid metabolism in patients with premature ovarian failure and Turner's syndrome], Nihon Sanka Fujinka Gakkai zasshi, 46, 1197-1204, 1994	Japanese language

## **Appendix H: Evidence tables**

The evidence tables are presented in a separate document.

## **Appendix I: GRADE profiles**

The GRADE profiles are presented in a separate document.

## **Appendix J: Forest plots**

The forest plots are presented in a separate document.

## **Appendix K: Network meta-analysis of interventions in the pharmacological and non-pharmacological treatment of short term symptoms for women in menopause**

The network meta-analysis is presented in a separate document.

## **Appendix L: Health economics**

The health economics are presented in a separate document.



## **Appendix M: Absolute risk references**

The references for the calculations of absolute risk are presented in a separate document.